1	Responses	O
2	to	O
3	brainstem	O
4	of	O
5	nuclei	O
6	medialis	O
7	dorsalis	O
8	,	O
9	lateralis	O
10	posterior	O
11	were	O
12	of	O
13	considerably	O
14	longer	O
15	latency	O
16	.	O

1	Three	O
2	experiments	O
3	contrasted	O
4	the	O
5	effects	O
6	of	O
7	6	O
8	-	O
9	hydroxydopamine	O
10	-	O
11	induced	O
12	lesions	O
13	of	O
14	the	O
15	ventral	O
16	noradrenergic	O
17	and	O
18	dorsal	O
19	noradrenergic	O
20	projections	O
21	,	O
22	predominantly	O
23	to	O
24	hypothalamus	O
25	and	O
26	cortex	O
27	,	O
28	respectively	O
29	,	O
30	upon	O
31	body	O
32	weight	O
33	changes	O
34	and	O
35	food	O
36	-	O
37	related	O
38	behaviour	O
39	in	O
40	the	O
41	rat	O
42	.	O

1	An	O
2	increase	O
3	in	O
4	bone	O
5	mineral	O
6	density	O
7	at	O
8	the	O
9	spine	O
10	,	O
11	total	O
12	hip	O
13	,	O
14	and	O
15	total	O
16	body	O
17	has	O
18	been	O
19	reported	O
20	with	O
21	raloxifene	O
22	but	O
23	seems	O
24	to	O
25	be	O
26	less	O
27	than	O
28	that	O
29	seen	O
30	with	O
31	estrogen	O
32	or	O
33	alendronate	O
34	therapy	O
35	.	O

1	We	O
2	have	O
3	demonstrated	O
4	that	O
5	the	O
6	activity	O
7	of	O
8	ILK	O
9	is	O
10	constitutively	O
11	elevated	O
12	in	O
13	PTEN	O
14	mutant	O
15	cells	O
16	.	O

1	Replacement	B
2	variant	I
3	histone	I
4	genes	I
5	contain	O
6	intervening	O
7	sequences	O
8	.	O

1	Studies	O
2	using	O
3	HLA	B
4	-	I
5	DR	I
6	-	I
7	B7	I
8	-	I
9	1	I
10	-	I
11	LFA	I
12	-	I
13	3	O
14	triple	O
15	transfectants	O
16	showed	O
17	that	O
18	the	O
19	LFA	B
20	-	I
21	3	I
22	-	I
23	induced	O
24	NF	B
25	-	I
26	AT	O
27	DNA	O
28	binding	O
29	activity	O
30	was	O
31	negatively	O
32	regulated	O
33	by	O
34	B7	B
35	-	I
36	1	I
37	costimulation	I
38	.	O

1	Peroxydase	O
2	reaction	O
3	stains	O
4	were	O
5	negative	O
6	,	O
7	chloroacetate	B
8	esterase	I
9	were	O
10	strongly	O
11	positive	O
12	.	O

1	Moreover	O
2	,	O
3	in	O
4	transient	O
5	transfection	O
6	assays	O
7	,	O
8	PU	O
9	.	O
10	1	O
11	alone	O
12	activated	O
13	reporter	O
14	constructs	O
15	containing	O
16	the	O
17	JB	O
18	cis	O
19	-	O
20	element	O
21	,	O
22	and	O
23	the	O
24	activation	O
25	was	O
26	shown	O
27	to	O
28	be	O
29	dependent	O
30	on	O
31	a	O
32	glutamine	O
33	-	O
34	rich	O
35	sequence	O
36	in	O
37	the	O
38	amino	O
39	-	O
40	terminal	O
41	portion	O
42	of	O
43	PU	O
44	.	O
45	1	O
46	.	O

1	From	O
2	these	O
3	results	O
4	,	O
5	we	O
6	concluded	O
7	that	O
8	this	O
9	ORF	O
10	is	O
11	the	O
12	FRDS	O
13	gene	O
14	.	O

1	Microwave	O
2	hyperthermia	O
3	-	O
4	induced	O
5	blood	O
6	-	O
7	brain	O
8	barrier	O
9	alterations	O
10	.	O

1	Recent	O
2	studies	O
3	have	O
4	shown	O
5	the	O
6	rat	O
7	larynx	O
8	to	O
9	be	O
10	an	O
11	important	O
12	organ	O
13	in	O
14	the	O
15	evaluation	O
16	of	O
17	irritancy	O
18	of	O
19	inhaled	O
20	materials	O
21	.	O

1	Grossly	O
2	,	O
3	the	O
4	incidence	O
5	of	O
6	a	O
7	type	O
8	IIc	O
9	carcinoma	O
10	was	O
11	46	O
12	.	O
13	5	O
14	%	O
15	and	O
16	that	O
17	of	O
18	a	O
19	IIc	O
20	+	O
21	III	O
22	type	O
23	was	O
24	20	O
25	.	O
26	5	O
27	%,	O
28	respectively	O
29	.	O

1	The	O
2	provisional	O
3	reports	O
4	are	O
5	based	O
6	mainly	O
7	upon	O
8	macroscopic	O
9	findings	O
10	,	O
11	whereas	O
12	the	O
13	final	O
14	reports	O
15	include	O
16	the	O
17	information	O
18	provided	O
19	by	O
20	supplementary	O
21	investigations	O
22	such	O
23	as	O
24	microscopy	O
25	,	O
26	histochemistry	O
27	,	O
28	more	O
29	rarely	O
30	electron	O
31	microscopy	O
32	,	O
33	immunohistochemistry	O
34	and	O
35	/	O
36	or	O
37	microbiology	O
38	.	O

1	A	O
2	computed	O
3	tomographic	O
4	scan	O
5	obtained	O
6	after	O
7	EOE	O
8	-	O
9	13	O
10	infusion	O
11	accurately	O
12	showed	O
13	the	O
14	perfusion	O
15	pattern	O
16	of	O
17	the	O
18	implanted	O
19	catheter	O
20	.	O

1	After	O
2	overtraining	O
3	on	O
4	the	O
5	original	O
6	discrimination	O
7	,	O
8	the	O
9	controls	O
10	showed	O
11	the	O
12	normal	O
13	difficulty	O
14	in	O
15	learning	O
16	the	O
17	first	O
18	reversal	O
19	.	O

1	The	O
2	human	O
3	pathogenic	O
4	bacterium	O
5	group	O
6	A	O
7	Streptococcus	O
8	produces	O
9	an	O
10	extracellular	O
11	cysteine	O
12	protease	O
13	[	O
14	streptococcal	O
15	pyrogenic	O
16	exotoxin	O
17	B	O
18	(	O
19	SpeB	O
20	)]	O
21	that	O
22	is	O
23	a	O
24	critical	O
25	virulence	O
26	factor	O
27	for	O
28	invasive	O
29	disease	O
30	episodes	O
31	.	O

1	Comparison	O
2	of	O
3	1	O
4	.	O
5	5	O
6	Tesla	O
7	and	O
8	0	O
9	.	O
10	35	O
11	Tesla	O
12	field	O
13	strength	O
14	magnetic	O
15	resonance	O
16	imaging	O
17	scans	O
18	in	O
19	the	O
20	morphometric	O
21	evaluation	O
22	of	O
23	the	O
24	lumbar	O
25	intervertebral	O
26	foramina	O
27	.	O

1	Two	O
2	new	O
3	temperature	O
4	-	O
5	sensitive	O
6	alleles	O
7	of	O
8	SEC3	O
9	,	O
10	1	O
11	of	O
12	10	O
13	late	O
14	-	O
15	acting	O
16	SEC	O
17	genes	O
18	required	O
19	for	O
20	targeting	O
21	or	O
22	fusion	O
23	of	O
24	post	O
25	-	O
26	Golgi	O
27	secretory	O
28	vesicles	O
29	to	O
30	the	O
31	plasma	O
32	membrane	O
33	in	O
34	Saccharomyces	O
35	cerevisiae	O
36	,	O
37	were	O
38	isolated	O
39	in	O
40	a	O
41	screen	O
42	for	O
43	temperature	O
44	-	O
45	sensitive	O
46	secretory	O
47	mutants	O
48	that	O
49	are	O
50	synthetically	O
51	lethal	O
52	with	O
53	sec4	O
54	-	O
55	8	O
56	.	O

1	Immunoblotting	O
2	of	O
3	expressed	O
4	recombinant	O
5	proteins	O
6	with	O
7	the	O
8	monoclonal	O
9	08L	O
10	antibody	O
11	localized	O
12	the	O
13	08L	O
14	epitope	O
15	to	O
16	the	O
17	carboxyl	O
18	end	O
19	of	O
20	the	O
21	protein	O
22	.	O

1	The	O
2	lines	O
3	also	O
4	differed	O
5	in	O
6	postsynaptic	O
7	,	O
8	but	O
9	not	O
10	presynaptic	O
11	,	O
12	5	O
13	-	O
14	HT1A	O
15	receptors	O
16	.	O

1	Recombinant	B
2	erythropoietin	I
3	(	O
4	r	O
5	-	O
6	HuEPO	O
7	)	O
8	in	O
9	the	O
10	treatment	O
11	of	O
12	anemia	O
13	in	O
14	multiple	O
15	myeloma	O

1	Mature	O
2	tobacco	B
3	L12	I
4	protein	I
5	has	O
6	44	O
7	%	O
8	amino	O
9	acid	O
10	identity	O
11	with	O
12	ribosomal	B
13	protein	I
14	L7	I
15	/	I
16	L12	I
17	of	O
18	Escherichia	O
19	coli	O
20	.	O

1	In	O
2	addition	O
3	,	O
4	carp	O
5	JAK1	O
6	shows	O
7	higher	O
8	sequence	O
9	homology	O
10	to	O
11	mammalian	O
12	JAK1	O
13	in	O
14	both	O
15	the	O
16	kinase	O
17	-	O
18	like	O
19	(	O
20	JH2	O
21	)	O
22	and	O
23	kinase	O
24	(	O
25	JH1	O
26	)	O
27	domains	O
28	(	O
29	approximately	O
30	70	O
31	%	O
32	identity	O
33	).	O

1	Western	O
2	blotting	O
3	(	O
4	immunoblotting	O
5	)	O
6	with	O
7	an	O
8	antiserum	O
9	to	O
10	a	O
11	partial	O
12	SOD	B
13	expressed	O
14	in	O
15	Escherichia	O
16	coli	O
17	revealed	O
18	two	O
19	proteins	O
20	with	O
21	estimated	O
22	molecular	O
23	masses	O
24	of	O
25	19	O
26	and	O
27	29	O
28	kDa	O
29	.	O

1	As	O
2	an	O
3	alternative	O
4	approach	O
5	to	O
6	this	O
7	question	O
8	,	O
9	we	O
10	have	O
11	studied	O
12	the	O
13	effects	O
14	of	O
15	ectopically	O
16	expressed	O
17	SHIP	O
18	,	O
19	SHP	B
20	-	I
21	1	I
22	,	O
23	or	O
24	SHP	B
25	-	I
26	2	I
27	SH2	I
28	-	I
29	containing	I
30	decoy	I
31	proteins	I
32	on	O
33	Fc	B
34	gamma	I
35	RIIB1	O
36	signaling	O
37	.	O

1	Stress	B
2	-	I
3	activated	I
4	protein	I
5	kinase	I
6	1	I
7	(	O
8	SAPK1	O
9	),	O
10	also	O
11	called	O
12	c	B
13	-	I
14	Jun	I
15	N	I
16	-	I
17	terminal	I
18	kinase	I
19	(	O
20	JNK	B
21	),	O
22	becomes	O
23	activated	O
24	in	O
25	vivo	O
26	in	O
27	response	O
28	to	O
29	pro	O
30	-	O
31	inflammatory	O
32	cytokines	O
33	or	O
34	cellular	O
35	stresses	O
36	.	O

1	The	O
2	serum	O
3	concentration	O
4	of	O
5	iP	O
6	before	O
7	dialysis	O
8	(	O
9	HD	O
10	)	O
11	was	O
12	on	O
13	average	O
14	3	O
15	.	O
16	06	O
17	(+/-	O
18	0	O
19	.	O
20	81	O
21	)	O
22	mmol	O
23	/	O
24	l	O
25	and	O
26	D	O
27	was	O
28	on	O
29	average	O
30	55	O
31	.	O
32	6	O
33	(+/-	O
34	10	O
35	.	O
36	0	O
37	)	O
38	mmol	O
39	.	O

1	Surprisingly	O
2	,	O
3	Northern	O
4	(	O
5	RNA	O
6	)	O
7	blot	O
8	analysis	O
9	and	O
10	reverse	B
11	transcriptase	I
12	-	I
13	PCRs	O
14	performed	O
15	after	O
16	transfection	O
17	of	O
18	COS	O
19	-	O
20	7	O
21	or	O
22	HeLa	O
23	cells	O
24	with	O
25	these	O
26	viral	O
27	RNAs	O
28	revealed	O
29	that	O
30	Y88S	O
31	and	O
32	Y88L	O
33	RNAs	O
34	replicated	O
35	at	O
36	only	O
37	very	O
38	low	O
39	levels	O
40	.	O

1	Viable	O
2	flap	O
3	areas	O
4	were	O
5	established	O
6	following	O
7	vascular	O
8	pedicle	O
9	ligation	O
10	(	O
11	both	O
12	vessels	O
13	or	O
14	only	O
15	artery	O
16	or	O
17	vein	O
18	),	O
19	on	O
20	the	O
21	third	O
22	day	O
23	after	O
24	flap	O
25	replantation	O
26	in	O
27	both	O
28	island	O
29	and	O
30	free	O
31	flaps	O
32	.	O

1	Tissue	O
2	-	O
3	specific	O
4	expression	O
5	of	O
6	the	O
7	tmy	O
8	-	O
9	1	O
10	gene	O
11	was	O
12	determined	O
13	by	O
14	microinjection	O
15	of	O
16	a	O
17	promoter	O
18	/	O
19	lacZ	B
20	fusion	I
21	gene	I
22	and	O
23	with	O
24	immunohistochemistry	O
25	by	O
26	using	O
27	affinity	O
28	-	O
29	purified	O
30	tissue	O
31	-	O
32	specific	O
33	anti	O
34	-	O
35	tropomyosins	O
36	.	O

1	Weak	O
2	promoter	O
3	activity	O
4	was	O
5	observed	O
6	for	O
7	the	O
8	promoter	O
9	of	O
10	the	O
11	C1	O
12	and	O
13	C2	O
14	ORFs	O
15	(	O
16	C1	B
17	-	I
18	C2	I
19	gene	I
20	)	O
21	and	O
22	for	O
23	the	O
24	promoter	O
25	of	O
26	the	O
27	V1	O
28	ORF	O
29	.	O

1	The	O
2	skin	O
3	site	O
4	,	O
5	6	O
6	-	O
7	cm	O
8	-	O
9	distal	O
10	and	O
11	-	O
12	proximal	O
13	subcutaneous	O
14	segments	O
15	of	O
16	the	O
17	catheter	O
18	,	O
19	exudates	O
20	,	O
21	and	O
22	blood	O
23	were	O
24	cultured	O
25	.	O

1	We	O
2	propose	O
3	that	O
4	epigenetic	O
5	features	O
6	of	O
7	tissue	O
8	-	O
9	specific	O
10	control	O
11	and	O
12	of	O
13	the	O
14	control	O
15	of	O
16	allelic	O
17	expression	O
18	are	O
19	intricately	O
20	linked	O
21	.	O

1	The	O
2	micromethod	O
3	uses	O
4	microcuvettes	O
5	and	O
6	substitutes	O
7	ferrozine	O
8	for	O
9	the	O
10	bathophenanthroline	O
11	chromogen	O
12	of	O
13	the	O
14	ICSH	O
15	.	O

1	Thioredoxin	O
2	(	O
3	TR	O
4	)	O
5	is	O
6	a	O
7	small	O
8	ubiquitous	O
9	dithiol	B
10	-	I
11	reductase	I
12	enzyme	I
13	first	O
14	identified	O
15	in	O
16	bacteria	O
17	and	O
18	plants	O
19	.	O

1	This	O
2	is	O
3	consistent	O
4	with	O
5	a	O
6	model	O
7	proposing	O
8	that	O
9	SSV	O
10	was	O
11	generated	O
12	by	O
13	recombination	O
14	between	O
15	proviral	O
16	DNA	O
17	of	O
18	a	O
19	simian	O
20	sarcoma	O
21	associated	O
22	virus	O
23	and	O
24	proto	B
25	-	I
26	sis	I
27	and	O
28	that	O
29	introns	O
30	were	O
31	spliced	O
32	out	O
33	subsequently	O
34	from	O
35	a	O
36	fused	O
37	viral	B
38	-	I
39	sis	I
40	messenger	I
41	RNA	I
42	.	O

1	In	O
2	resting	O
3	3T3	O
4	cells	O
5	,	O
6	jun	B
7	-	I
8	D	I
9	is	O
10	expressed	O
11	at	O
12	a	O
13	higher	O
14	level	O
15	compared	O
16	to	O
17	c	B
18	-	I
19	jun	I
20	and	I
21	jun	I
22	-	I
23	B	I
24	,	O
25	and	O
26	its	O
27	transcription	O
28	is	O
29	stimulated	O
30	only	O
31	slightly	O
32	by	O
33	serum	O
34	growth	O
35	factors	O
36	.	O

1	Rinit	O
2	reflects	O
3	the	O
4	Newtonian	O
5	resistances	O
6	and	O
7	Rdiff	O
8	represents	O
9	the	O
10	viscoelastic	O
11	/	O
12	inhomogeneous	O
13	pressure	O
14	dissipations	O
15	in	O
16	the	O
17	system	O
18	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	AP	B
6	-	I
7	A	O
8	may	O
9	be	O
10	potentially	O
11	useful	O
12	in	O
13	the	O
14	management	O
15	of	O
16	heart	O
17	failure	O
18	.	O

1	Retinal	O
2	changes	O
3	in	O
4	pigmentary	O
5	retinopathy	O
6	in	O
7	children	O

1	Adaptation	O
2	of	O
3	taurocholate	O
4	transport	O
5	maximum	O
6	to	O
7	increased	O
8	secretory	O
9	load	O
10	in	O
11	the	O
12	rat	O
13	.	O

1	We	O
2	did	O
3	not	O
4	observe	O
5	any	O
6	changes	O
7	in	O
8	Bcl	B
9	-	I
10	2	I
11	or	O
12	Bcl	B
13	-	I
14	2	I
15	-	I
16	related	I
17	proteins	I
18	(	O
19	Bcl	B
20	-	I
21	x	O
22	,	O
23	Bax	O
24	,	O
25	and	O
26	Bad	O
27	)	O
28	in	O
29	control	O
30	or	O
31	KCREB	O
32	-	O
33	transfected	O
34	cells	O
35	before	O
36	or	O
37	after	O
38	treatment	O
39	with	O
40	Tg	O
41	.	O

1	Drosophila	O
2	UbcD1	O
3	encodes	O
4	a	O
5	highly	O
6	conserved	O
7	ubiquitin	B
8	-	I
9	conjugating	I
10	enzyme	I
11	involved	O
12	in	O
13	selective	O
14	protein	O
15	degradation	O
16	.	O

1	Postoperative	O
2	serum	O
3	ACTH	B
4	levels	O
5	were	O
6	normal	O
7	.	O

1	The	O
2	RMRI	O
3	was	O
4	tested	O
5	for	O
6	interrater	O
7	reliability	O
8	using	O
9	three	O
10	simulated	O
11	and	O
12	10	O
13	actual	O
14	patients	O
15	.	O

1	Following	O
2	the	O
3	observation	O
4	that	O
5	non	O
6	-	O
7	organ	O
8	-	O
9	specific	O
10	antibodies	O
11	are	O
12	related	O
13	with	O
14	pregnancy	O
15	loss	O
16	and	O
17	preeclampsia	O
18	,	O
19	the	O
20	role	O
21	of	O
22	organ	O
23	-	O
24	specific	O
25	antibodies	O
26	is	O
27	currently	O
28	being	O
29	extensively	O
30	investigated	O
31	.	O

1	Here	O
2	we	O
3	report	O
4	the	O
5	purification	O
6	of	O
7	this	O
8	larger	O
9	form	O
10	as	O
11	an	O
12	approximately	O
13	320	O
14	-	O
15	kDa	O
16	particle	O
17	that	O
18	contains	O
19	mRNP3	O
20	+	O
21	4	O
22	and	O
23	nine	O
24	additional	O
25	polypeptides	O
26	,	O
27	including	O
28	mRNA	O
29	-	O
30	binding	O
31	polypeptides	O
32	of	O
33	34	O
34	and	O
35	36	O
36	kDa	O
37	and	O
38	a	O
39	doublet	O
40	of	O
41	110	O
42	/	O
43	105	O
44	kDa	O
45	that	O
46	proved	O
47	to	O
48	be	O
49	nucleolin	O
50	.	O

1	Peripheral	O
2	visual	O
3	stimuli	O
4	and	O
5	monoaural	O
6	auditory	O
7	stimuli	O
8	were	O
9	used	O
10	as	O
11	targets	O
12	.	O

1	Specialist	O
2	in	O
3	family	O
4	practice	O
5	--	O
6	prototype	O
7	of	O
8	a	O
9	doctor	O
10	.	O

1	Radiolabelled	O
2	palmitate	O
3	was	O
4	not	O
5	incorporated	O
6	into	O
7	the	O
8	mutated	O
9	protein	O
10	,	O
11	showing	O
12	that	O
13	lipid	O
14	modification	O
15	occurs	O
16	at	O
17	the	O
18	Cys	O
19	-	O
20	22	O
21	residue	O
22	.	O

1	The	O
2	incompatibility	O
3	group	O
4	W	O
5	plasmid	O
6	pSa	O
7	suppresses	O
8	Agrobacterium	O
9	tumefaciens	O
10	oncogenicity	O
11	(	O
12	J	O
13	.	O

1	We	O
2	have	O
3	now	O
4	shown	O
5	that	O
6	in	O
7	vivo	O
8	phosphorylation	O
9	of	O
10	14	O
11	-	O
12	3	O
13	-	O
14	3	O
15	zeta	B
16	at	O
17	the	O
18	CKIalpha	O
19	site	O
20	(	O
21	Thr	O
22	-	O
23	233	O
24	)	O
25	negatively	O
26	regulates	O
27	its	O
28	binding	O
29	to	O
30	c	B
31	-	I
32	Raf	I
33	,	O
34	and	O
35	may	O
36	be	O
37	important	O
38	in	O
39	Raf	B
40	-	I
41	mediated	O
42	signal	O
43	transduction	O
44	.	O

1	Activation	O
2	of	O
3	alpha	B
4	4	I
5	beta	I
6	1	I
7	with	O
8	TS2	O
9	/	O
10	16	O
11	inhibited	O
12	the	O
13	cytoplasmic	O
14	protrusions	O
15	and	O
16	cell	O
17	migration	O
18	but	O
19	did	O
20	not	O
21	affect	O
22	the	O
23	pattern	O
24	of	O
25	phosphorylation	O
26	.	O

1	French	O
2	,	O
3	M	O
4	.	O

1	On	O
2	physical	O
3	examination	O
4	a	O
5	mild	O
6	symmetrical	O
7	polyarthritis	O
8	of	O
9	small	O
10	and	O
11	large	O
12	joints	O
13	was	O
14	seen	O
15	.	O

1	Serum	O
2	lipid	O
3	changes	O
4	during	O
5	pregnancy	O
6	due	O
7	to	O
8	oral	O
9	calcium	O
10	administration	O

1	Left	O
2	atrial	O
3	volumes	O
4	were	O
5	greater	O
6	in	O
7	old	O
8	compared	O
9	with	O
10	young	O
11	subjects	O
12	(	O
13	maximal	O
14	:	O
15	31	O
16	+/-	O
17	10	O
18	cm3	O
19	/	O
20	m2	O
21	vs	O
22	24	O
23	+/-	O
24	8	O
25	cm3	O
26	/	O
27	m2	O
28	,	O
29	p	O
30	=	O
31	0	O
32	.	O
33	02	O
34	;	O
35	at	O
36	onset	O
37	of	O
38	atrial	O
39	systole	O
40	:	O
41	23	O
42	+/-	O
43	8	O
44	cm3	O
45	/	O
46	m2	O
47	vs	O
48	15	O
49	+/-	O
50	5	O
51	cm3	O
52	/	O
53	m2	O
54	,	O
55	p	O
56	=	O
57	0	O
58	.	O
59	0002	O
60	;	O
61	minimal	O
62	:	O
63	13	O
64	+/-	O
65	5	O
66	cm3	O
67	/	O
68	m2	O
69	vs	O
70	9	O
71	+/-	O
72	4	O
73	cm3	O
74	/	O
75	m2	O
76	,	O
77	p	O
78	=	O
79	0	O
80	.	O
81	001	O
82	).	O

1	Until	O
2	such	O
3	investigations	O
4	are	O
5	performed	O
6	,	O
7	we	O
8	conclude	O
9	that	O
10	the	O
11	role	O
12	for	O
13	adjuvant	O
14	treatment	O
15	is	O
16	questionable	O
17	and	O
18	that	O
19	TME	O
20	surgery	O
21	is	O
22	preferred	O
23	as	O
24	the	O
25	treatment	O
26	option	O
27	for	O
28	Stage	O
29	T1	O
30	-	O
31	T3	O
32	rectal	O
33	cancers	O
34	.	O

1	RESULTS	O
2	:	O
3	Of	O
4	the	O
5	patients	O
6	with	O
7	IS	O
8	,	O
9	67	O
10	%	O
11	had	O
12	significantly	O
13	greater	O
14	values	O
15	of	O
16	directional	O
17	preponderance	O
18	on	O
19	the	O
20	OVAR	O
21	test	O
22	(	O
23	a	O
24	measure	O
25	of	O
26	otolith	O
27	system	O
28	imbalance	O
29	)	O
30	compared	O
31	with	O
32	control	O
33	subjects	O
34	.	O

1	Transcripts	O
2	for	O
3	both	O
4	ODV	O
5	-	O
6	E18	O
7	and	O
8	ODV	O
9	-	O
10	EC27	O
11	initiate	O
12	from	O
13	conserved	O
14	TAAG	O
15	motifs	O
16	,	O
17	and	O
18	transcripts	O
19	are	O
20	detected	O
21	from	O
22	16	O
23	through	O
24	72	O
25	hr	O
26	p	O
27	.	O
28	i	O
29	.	O

1	The	O
2	intranodal	O
3	mesothelial	O
4	cells	O
5	occupied	O
6	the	O
7	sinusoids	O
8	of	O
9	the	O
10	lymph	O
11	nodes	O
12	and	O
13	were	O
14	initially	O
15	suspected	O
16	of	O
17	being	O
18	metastatic	O
19	from	O
20	the	O
21	ovarian	O
22	tumor	O
23	in	O
24	each	O
25	case	O
26	.	O

1	Muscle	O
2	GSH	B
3	-	I
4	Px	I
5	activity	O
6	after	O
7	prolonged	O
8	exercise	O
9	,	O
10	training	O
11	,	O
12	and	O
13	selenium	O
14	supplementation	O
15	.	O

1	In	O
2	nucleus	O
3	ventralis	O
4	anterior	O
5	thalami	O
6	-	O
7	nucleus	O
8	ventralis	O
9	lateralis	O
10	thalami	O
11	neurons	O
12	with	O
13	an	O
14	inhibitory	O
15	input	O
16	from	O
17	nucleus	O
18	entopeduncularis	O
19	,	O
20	a	O
21	shortening	O
22	of	O
23	inhibition	O
24	from	O
25	17	O
26	.	O
27	5	O
28	+/-	O
29	3	O
30	.	O
31	6	O
32	to	O
33	9	O
34	.	O
35	1	O
36	+/-	O
37	1	O
38	.	O
39	8	O
40	ms	O
41	(	O
42	P	O
43	<	O
44	0	O
45	.	O
46	05	O
47	)	O
48	under	O
49	the	O
50	haloperidol	O
51	influence	O
52	was	O
53	evident	O
54	.	O

1	The	O
2	kinase	O
3	is	O
4	essential	O
5	in	O
6	vivo	O
7	for	O
8	normal	O
9	phosphorylation	O
10	of	O
11	the	O
12	CTD	O
13	and	O
14	for	O
15	normal	O
16	growth	O
17	and	O
18	differentiation	O
19	.	O

1	One	O
2	of	O
3	these	O
4	factors	O
5	,	O
6	IRF	B
7	-	I
8	2	I
9	,	O
10	was	O
11	initially	O
12	cloned	O
13	as	O
14	an	O
15	antagonistic	O
16	counterpart	O
17	to	O
18	IRF	B
19	-	I
20	1	I
21	with	O
22	oncogenic	O
23	potential	O
24	.	O

1	16	O
2	,	O
3	99	O
4	-	O
5	104	O
6	).	O

1	These	O
2	data	O
3	indicate	O
4	a	O
5	functional	O
6	role	O
7	for	O
8	U1	O
9	in	O
10	NRS	O
11	-	O
12	mediated	O
13	splicing	O
14	inhibition	O
15	.	O

1	Moreover	O
2	,	O
3	unlike	O
4	control	O
5	rats	O
6	operated	O
7	animals	O
8	did	O
9	not	O
10	show	O
11	aversion	O
12	to	O
13	the	O
14	highest	O
15	concentrations	O
16	of	O
17	saccharin	O
18	solutions	O
19	.	O

1	The	O
2	physical	O
3	linkage	O
4	of	O
5	the	O
6	FHR2	O
7	and	O
8	the	O
9	factor	O
10	H	O
11	genes	O
12	provides	O
13	additional	O
14	evidence	O
15	for	O
16	a	O
17	close	O
18	relatedness	O
19	of	O
20	complement	O
21	factor	O
22	H	O
23	and	O
24	the	O
25	factor	O
26	H	O
27	-	O
28	related	O
29	proteins	O
30	.	O

1	Its	O
2	early	O
3	lesions	O
4	were	O
5	characterized	O
6	by	O
7	angiomatosis	O
8	,	O
9	vasculopathy	O
10	,	O
11	and	O
12	proliferation	O
13	of	O
14	synoviocytes	O
15	and	O
16	fibroblasts	O
17	.	O

1	In	O
2	this	O
3	study	O
4	we	O
5	describe	O
6	that	O
7	platelet	B
8	-	I
9	derived	I
10	growth	I
11	factor	I
12	(	I
13	PDGF	I
14	),	O
15	12	O
16	-	O
17	O	O
18	-	O
19	tetradecanoyl	O
20	-	O
21	phorbol	O
22	-	O
23	acetate	O
24	(	O
25	TPA	O
26	),	O
27	and	O
28	forskolin	O
29	induced	O
30	CREB	B
31	(	I
32	cAMP	I
33	-	I
34	responsive	I
35	element	I
36	-	I
37	binding	I
38	protein	I
39	)	O
40	Ser	O
41	-	O
42	133	O
43	phosphorylation	O
44	with	O
45	comparable	O
46	magnitude	O
47	and	O
48	kinetics	O
49	in	O
50	NIH	O
51	3T3	O
52	cells	O
53	.	O

1	This	O
2	vector	O
3	transfected	O
4	into	O
5	the	O
6	yeast	O
7	Saccharomyces	O
8	cerevisiae	O
9	directs	O
10	expression	O
11	of	O
12	a	O
13	secreted	O
14	mature	O
15	protein	O
16	at	O
17	levels	O
18	up	O
19	to	O
20	200	O
21	mg	O
22	of	O
23	LAPP	O
24	/	O
25	liter	O
26	of	O
27	culture	O
28	medium	O
29	.	O

1	We	O
2	show	O
3	that	O
4	c	B
5	-	I
6	Fos	I
7	(	O
8	the	O
9	c	B
10	-	I
11	fos	I
12	protooncogene	I
13	product	I
14	),	O
15	which	O
16	is	O
17	an	O
18	intrinsically	O
19	unstable	O
20	nuclear	O
21	protein	O
22	,	O
23	is	O
24	metabolically	O
25	highly	O
26	stabilized	O
27	,	O
28	and	O
29	greatly	O
30	enhances	O
31	the	O
32	transforming	O
33	efficiency	O
34	of	O
35	NIH	O
36	3T3	O
37	cells	O
38	,	O
39	by	O
40	Mos	O
41	.	O

1	The	O
2	carcass	O
3	of	O
4	a	O
5	great	O
6	horned	O
7	owl	O
8	(	O
9	Bubo	O
10	virginianus	O
11	),	O
12	which	O
13	had	O
14	been	O
15	found	O
16	moribund	O
17	in	O
18	southern	O
19	Ontario	O
20	,	O
21	was	O
22	presented	O
23	for	O
24	necropsy	O
25	.	O

1	Cleidocranial	O
2	dysostosis	O

1	High	O
2	-	O
3	level	O
4	gains	O
5	(	O
6	HLGs	O
7	)	O
8	indicative	O
9	of	O
10	gene	O
11	amplifications	O
12	were	O
13	identified	O
14	at	O
15	11q13	O
16	in	O
17	two	O
18	cases	O
19	,	O
20	and	O
21	in	O
22	one	O
23	case	O
24	each	O
25	at	O
26	2q33	O
27	-	O
28	34	O
29	,	O
30	3q25	O
31	-	O
32	29	O
33	,	O
34	5p15	O
35	.	O
36	1	O
37	-	O
38	15	O
39	.	O
40	2	O
41	,	O
42	7q21	O
43	-	O
44	22	O
45	,	O
46	11p11	O
47	.	O
48	2	O
49	,	O
50	12p11	O
51	.	O
52	2	O
53	-	O
54	12	O
55	,	O
56	and	O
57	13q34	O
58	.	O

1	Analysis	O
2	of	O
3	promoter	O
4	and	O
5	androgen	O
6	regulatory	O
7	sequences	O
8	required	O
9	for	O
10	optimal	O
11	transcription	O
12	of	O
13	the	O
14	rat	B
15	androgen	I
16	-	I
17	binding	I
18	protein	I
19	gene	I
20	.	O

1	To	O
2	investigate	O
3	the	O
4	regulation	O
5	of	O
6	Spec	O
7	gene	O
8	activity	O
9	,	O
10	the	O
11	region	O
12	around	O
13	the	O
14	Spec1	O
15	transcriptional	O
16	initiation	O
17	site	O
18	was	O
19	analyzed	O
20	for	O
21	sites	O
22	of	O
23	protein	O
24	-	O
25	DNA	O
26	interaction	O
27	.	O

1	RESULTS	O
2	:	O
3	Soluble	O
4	CD23	O
5	levels	O
6	were	O
7	significantly	O
8	higher	O
9	in	O
10	women	O
11	with	O
12	endometriosis	O
13	before	O
14	treatment	O
15	than	O
16	in	O
17	ten	O
18	normal	O
19	controls	O
20	.	O

1	Retrospective	O
2	analyses	O
3	of	O
4	this	O
5	death	O
6	revealed	O
7	a	O
8	significant	O
9	decrease	O
10	of	O
11	the	O
12	left	O
13	ventricular	O
14	(	O
15	LV	O
16	)	O
17	end	O
18	-	O
19	diastolic	O
20	volume	O
21	index	O
22	(	O
23	EDVI	O
24	)	O
25	of	O
26	21	O
27	ml	O
28	/	O
29	m2	O
30	(	O
31	36	O
32	%	O
33	of	O
34	normal	O
35	).	O

1	Neuronal	O
2	signaling	O
3	properties	O
4	are	O
5	largely	O
6	determined	O
7	by	O
8	the	O
9	quantity	O
10	and	O
11	combination	O
12	of	O
13	ion	O
14	channels	O
15	expressed	O
16	.	O

1	In	O
2	contrast	O
3	to	O
4	this	O
5	mRNA	O
6	,	O
7	90	O
8	%	O
9	of	O
10	alpha	O
11	and	O
12	beta	B
13	actin	I
14	mRNAs	I
15	were	O
16	translated	O
17	in	O
18	both	O
19	myoblasts	O
20	and	O
21	myotubes	O
22	.	O

1	CONCLUSION	O
2	:	O
3	TNF	B
4	alpha	I
5	,	O
6	TGF	B
7	beta	I
8	,	O
9	PDGF	B
10	and	O
11	IL	B
12	-	I
13	1beta	I
14	increased	O
15	LDLr	O
16	gene	O
17	expression	O
18	by	O
19	increasing	O
20	sterol	O
21	-	O
22	independent	O
23	and	O
24	mitogenesis	O
25	-	O
26	independent	O
27	gene	O
28	transcription	O
29	.	O

1	After	O
2	base	O
3	-	O
4	line	O
5	CBF	O
6	was	O
7	established	O
8	,	O
9	hexamethonium	O
10	bromide	O
11	(	O
12	2	O
13	mg	O
14	/	O
15	kg	O
16	iv	O
17	),	O
18	ipratropium	O
19	bromide	O
20	(	O
21	0	O
22	.	O
23	5	O
24	microgram	O
25	/	O
26	kg	O
27	iv	O
28	),	O
29	indomethacin	O
30	(	O
31	2	O
32	mg	O
33	/	O
34	kg	O
35	iv	O
36	),	O
37	or	O
38	intravenous	O
39	0	O
40	.	O
41	9	O
42	%	O
43	saline	O
44	was	O
45	administered	O
46	.	O

1	In	O
2	two	O
3	experiments	O
4	,	O
5	neonatal	O
6	female	O
7	BALB	O
8	/	O
9	cCrgl	O
10	or	O
11	BALB	O
12	/	O
13	cfC3HCrgl	O
14	mice	O
15	were	O
16	given	O
17	subcutaneous	O
18	injections	O
19	of	O
20	5	O
21	micrograms	O
22	17	O
23	beta	O
24	-	O
25	estradiol	O
26	or	O
27	sesame	O
28	oil	O
29	for	O
30	the	O
31	first	O
32	3	O
33	days	O
34	of	O
35	life	O
36	and	O
37	were	O
38	ovariectomized	O
39	at	O
40	60	O
41	days	O
42	of	O
43	age	O
44	,	O
45	at	O
46	which	O
47	time	O
48	vaginal	O
49	concretions	O
50	(	O
51	Experiments	O
52	I	O
53	and	O
54	II	O
55	)	O
56	or	O
57	silica	O
58	(	O
59	Experiment	O
60	II	O
61	)	O
62	were	O
63	implanted	O
64	intravaginally	O
65	.	O

1	To	O
2	facilitate	O
3	the	O
4	investigation	O
5	of	O
6	parameters	O
7	that	O
8	govern	O
9	selective	O
10	export	O
11	in	O
12	adenovirus	O
13	-	O
14	infected	O
15	cells	O
16	,	O
17	we	O
18	constructed	O
19	a	O
20	marked	O
21	human	B
22	beta	I
23	-	I
24	actin	I
25	minigene	I
26	under	O
27	the	O
28	control	O
29	of	O
30	the	O
31	glucocorticoid	B
32	-	I
33	inducible	I
34	enhancer	I
35	-	I
36	promoter	I
37	of	O
38	mouse	O
39	mammary	O
40	tumor	O
41	virus	O
42	and	O
43	introduced	O
44	it	O
45	into	O
46	the	O
47	left	O
48	end	O
49	of	O
50	the	O
51	adenovirus	O
52	type	O
53	5	O
54	(	O
55	Ad5	O
56	)	O
57	genome	O
58	.	O

1	Unrecognized	O
2	amnionitis	O
3	and	O
4	prematurity	O
5	:	O
6	a	O
7	preliminary	O
8	report	O
9	.	O

1	In	O
2	similar	O
3	transient	O
4	transfection	O
5	experiments	O
6	in	O
7	HeLa	O
8	cells	O
9	,	O
10	overexpression	O
11	of	O
12	the	O
13	wt	O
14	human	O
15	retinoblastoma	B
16	susceptibility	I
17	gene	I
18	product	I
19	,	O
20	RB	O
21	,	O
22	was	O
23	found	O
24	to	O
25	repress	O
26	the	O
27	serum	O
28	-	O
29	induced	O
30	IL	B
31	-	I
32	6	O
33	(-	O
34	225	O
35	to	O
36	+	O
37	13	O
38	),	O
39	c	B
40	-	I
41	fos	I
42	(-	O
43	711	O
44	to	O
45	+	O
46	42	O
47	),	O
48	and	O
49	beta	B
50	-	I
51	actin	I
52	(-	O
53	3400	O
54	to	O
55	+	O
56	912	O
57	)	O
58	promoters	O
59	but	O
60	not	O
61	the	O
62	PRV	O
63	-	O
64	induced	O
65	IL	B
66	-	I
67	6	O
68	(-	O
69	110	O
70	to	O
71	+	O
72	13	O
73	)	O
74	or	O
75	the	O
76	serum	O
77	-	O
78	induced	O
79	MHC	B
80	(-	O
81	528	O
82	to	O
83	-	O
84	38	O
85	)	O
86	promoters	O
87	.	O

1	Terbutaline	O
2	;	O
3	a	O
4	beta2	B
5	-	I
6	adrenergic	I
7	agonist	O
8	,	O
9	and	O
10	aminophyllin	O
11	,	O
12	a	O
13	phosphodiesterase	O
14	inhibitor	O
15	,	O
16	were	O
17	given	O
18	separately	O
19	,	O
20	or	O
21	in	O
22	combination	O
23	,	O
24	to	O
25	rabbit	O
26	fetuses	O
27	on	O
28	the	O
29	28th	O
30	day	O
31	of	O
32	gestation	O
33	.	O

1	Current	O
2	status	O
3	of	O
4	telepathology	O
5	.	O

1	BCR	B
2	cross	O
3	-	O
4	linking	O
5	also	O
6	led	O
7	to	O
8	increased	O
9	MAPK	B
10	-	I
11	activated	I
12	protein	I
13	kinase	I
14	-	I
15	2	I
16	activity	O
17	,	O
18	an	O
19	enzyme	O
20	that	O
21	lies	O
22	immediately	O
23	downstream	O
24	from	O
25	p38	B
26	MAPK	I
27	;	O
28	MAPK	B
29	-	I
30	activated	I
31	protein	I
32	kinase	I
33	-	I
34	2	I
35	immune	O
36	complexes	O
37	phosphorylated	O
38	a	O
39	peptide	O
40	substrate	O
41	containing	O
42	the	O
43	CREB	B
44	serine	I
45	133	I
46	phosphoacceptor	I
47	motif	I
48	.	O

1	Human	O
2	PDK1	O
3	is	O
4	homologous	O
5	to	O
6	the	O
7	Drosophila	B
8	protein	I
9	kinase	I
10	DSTPK61	O
11	,	O
12	which	O
13	has	O
14	been	O
15	implicated	O
16	in	O
17	the	O
18	regulation	O
19	of	O
20	sex	O
21	differentiation	O
22	,	O
23	oogenesis	O
24	and	O
25	spermatogenesis	O
26	.	O

1	Endonuclease	O
2	III	O
3	(	O
4	Nth	O
5	)	O
6	of	O
7	Escherichia	O
8	coli	O
9	is	O
10	a	O
11	DNA	O
12	glycosylase	O
13	essential	O
14	for	O
15	the	O
16	removal	O
17	of	O
18	oxidised	O
19	pyrimidine	O
20	base	O
21	residues	O
22	from	O
23	DNA	O
24	.	O

1	DR1	O
2	molecules	O
3	purified	O
4	from	O
5	human	O
6	lymphoblastoid	O
7	cell	O
8	lines	O
9	could	O
10	specifically	O
11	bind	O
12	to	O
13	these	O
14	peptide	O
15	sequences	O
16	expressed	O
17	on	O
18	the	O
19	phage	O
20	surface	O
21	.	O

1	Patterns	O
2	of	O
3	connections	O
4	underlying	O
5	cross	O
6	-	O
7	modality	O
8	integration	O
9	were	O
10	studied	O
11	by	O
12	injecting	O
13	distinguishable	O
14	,	O
15	retrograde	O
16	tracers	O
17	(	O
18	Fluoro	O
19	-	O
20	Gold	O
21	and	O
22	diamidino	O
23	yellow	O
24	)	O
25	in	O
26	pairwise	O
27	manner	O
28	into	O
29	different	O
30	sensory	O
31	representations	O
32	(	O
33	visual	O
34	,	O
35	somatosensory	O
36	,	O
37	and	O
38	auditory	O
39	)	O
40	in	O
41	the	O
42	cerebral	O
43	cortex	O
44	of	O
45	the	O
46	rat	O
47	.	O

1	NF	B
2	-	I
3	HB	I
4	(	O
5	BSAP	O
6	)	O
7	is	O
8	a	O
9	repressor	O
10	of	O
11	the	O
12	murine	B
13	immunoglobulin	I
14	heavy	I
15	-	I
16	chain	I
17	3	I
18	'	I
19	alpha	I
20	enhancer	I
21	at	O
22	early	O
23	stages	O
24	of	O
25	B	O
26	-	O
27	cell	O
28	differentiation	O
29	.	O

1	However	O
2	,	O
3	ICK1	O
4	was	O
5	induced	O
6	by	O
7	ABA	O
8	,	O
9	and	O
10	along	O
11	with	O
12	ICK1	O
13	induction	O
14	there	O
15	was	O
16	a	O
17	decrease	O
18	in	O
19	Cdc2	B
20	-	I
21	like	I
22	histone	I
23	H1	I
24	kinase	I
25	activity	O
26	.	O

1	The	O
2	result	O
3	suggests	O
4	that	O
5	this	O
6	non	O
7	-	O
8	invasive	O
9	TTD	O
10	method	O
11	is	O
12	easily	O
13	available	O
14	and	O
15	useful	O
16	in	O
17	monitoring	O
18	the	O
19	intraoperative	O
20	cardiac	O
21	output	O
22	.	O

1	IE2	B
2	-	I
3	IE2	I
4	interactions	O
5	were	O
6	mapped	O
7	to	O
8	a	O
9	domain	O
10	containing	O
11	a	O
12	putative	O
13	helix	O
14	-	O
15	turn	O
16	-	O
17	helix	O
18	motif	O
19	located	O
20	near	O
21	the	O
22	C	O
23	terminus	O
24	of	O
25	IE2	B
26	,	O
27	between	O
28	amino	O
29	acids	O
30	456	O
31	and	O
32	539	O
33	.	O

1	The	O
2	fusion	O
3	proteins	O
4	were	O
5	tested	O
6	by	O
7	ELISA	O
8	for	O
9	reactivity	O
10	with	O
11	a	O
12	panel	O
13	of	O
14	human	O
15	anti	B
16	-	I
17	La	I
18	sera	O
19	in	O
20	order	O
21	to	O
22	define	O
23	the	O
24	nature	O
25	of	O
26	the	O
27	epitopes	O
28	.	O

1	Thus	O
2	E14	O
3	.	O
4	1TG3B1	O
5	is	O
6	a	O
7	useful	O
8	ES	O
9	cell	O
10	line	O
11	for	O
12	modifying	O
13	the	O
14	mouse	O
15	genome	O
16	using	O
17	the	O
18	HPRT	B
19	gene	I
20	as	O
21	a	O
22	selection	O
23	marker	O
24	and	O
25	for	O
26	transmission	O
27	at	O
28	a	O
29	high	O
30	frequency	O
31	into	O
32	the	O
33	mouse	O
34	germ	O
35	line	O
36	.	O

1	This	O
2	implies	O
3	that	O
4	the	O
5	groups	O
6	do	O
7	not	O
8	just	O
9	differ	O
10	along	O
11	one	O
12	dimension	O
13	,	O
14	but	O
15	along	O
16	three	O
17	dimensions	O
18	.	O

1	A	O
2	preliminary	O
3	study	O
4	on	O
5	pyogenic	O
6	arthritis	O
7	.	O

1	Evaluation	O
2	of	O
3	left	O
4	ventricular	O
5	function	O
6	using	O
7	gated	O
8	planar	O
9	myocardial	O
10	imaging	O
11	with	O
12	Tc	O
13	-	O
14	99m	O
15	-	O
16	MIBI	O

1	Studies	O
2	carried	O
3	out	O
4	with	O
5	the	O
6	Glossina	O
7	morsitans	O
8	colony	O
9	of	O
10	Lisbon	O
11	.	O

1	We	O
2	now	O
3	report	O
4	the	O
5	isolation	O
6	and	O
7	expression	O
8	of	O
9	cDNAs	O
10	encoding	O
11	PTF	O
12	gamma	O
13	and	O
14	PTF	O
15	delta	O
16	,	O
17	as	O
18	well	O
19	as	O
20	functional	O
21	studies	O
22	with	O
23	cognate	O
24	antibodies	O
25	that	O
26	recognize	O
27	the	O
28	native	O
29	PTF	O
30	complex	O
31	in	O
32	HeLa	O
33	extracts	O
34	.	O

1	Characterization	O
2	of	O
3	an	O
4	EcR	O
5	/	O
6	USP	O
7	heterodimer	O
8	target	O
9	site	O
10	that	O
11	mediates	O
12	ecdysone	O
13	responsiveness	O
14	of	O
15	the	O
16	Drosophila	B
17	Lsp	I
18	-	I
19	2	I
20	gene	I
21	.	O

1	Thalamotomy	O
2	aiming	O
3	at	O
4	the	O
5	CM	O
6	-	O
7	Pf	O
8	complex	O
9	and	O
10	using	O
11	stereotactic	O
12	gamma	O
13	irradiation	O
14	has	O
15	been	O
16	performed	O
17	in	O
18	a	O
19	series	O
20	of	O
21	52	O
22	patients	O
23	with	O
24	severe	O
25	pain	O
26	due	O
27	to	O
28	malignancy	O
29	.	O

1	Cell	O
2	factor	O
3	-	O
4	mediated	O
5	regulatory	O
6	interactions	O
7	are	O
8	involved	O
9	in	O
10	regulating	O
11	the	O
12	restricted	O
13	expression	O
14	of	O
15	the	O
16	HCMV	O
17	major	O
18	immediate	O
19	-	O
20	early	O
21	(	O
22	IE	B
23	)	I
24	gene	I
25	(	O
26	J	O
27	.	O

1	A	O
2	liquid	O
3	chromatographic	O
4	method	O
5	is	O
6	described	O
7	for	O
8	analysis	O
9	of	O
10	beta	O
11	-	O
12	carotene	O
13	in	O
14	medical	O
15	food	O
16	.	O

1	Interestingly	O
2	,	O
3	a	O
4	decreased	O
5	transcription	O
6	from	O
7	the	O
8	endogenous	O
9	c	B
10	-	I
11	Myb	I
12	promoter	I
13	was	O
14	observed	O
15	in	O
16	several	O
17	HTLV	O
18	-	O
19	I	O
20	transformed	O
21	T	O
22	-	O
23	cell	O
24	lines	O
25	.	O

1	Static	O
2	lung	O
3	function	O
4	in	O
5	puppies	O
6	after	O
7	pneumonectomy	O
8	.	O

1	Although	O
2	the	O
3	expression	O
4	of	O
5	the	O
6	4E	B
7	-	I
8	BP1	I
9	gene	I
10	alone	O
11	has	O
12	not	O
13	yet	O
14	been	O
15	accomplished	O
16	,	O
17	the	O
18	gene	O
19	was	O
20	expressed	O
21	in	O
22	Escherichia	O
23	coli	O
24	[	O
25	BL21	O
26	(	O
27	DE3	O
28	)]	O
29	as	O
30	a	O
31	fusion	O
32	gene	O
33	with	O
34	the	O
35	glutathione	B
36	-	I
37	S	I
38	-	I
39	transferase	I
40	(	O
41	GST	B
42	)	I
43	gene	I
44	using	O
45	a	O
46	prokaryotic	O
47	gene	O
48	fusion	O
49	vector	O
50	(	O
51	pGEX	O
52	-	O
53	4T	O
54	-	O
55	2	O
56	),	O
57	which	O
58	contains	O
59	a	O
60	gene	O
61	sequence	O
62	coding	O
63	the	O
64	cleavage	O
65	site	O
66	for	O
67	a	O
68	specific	O
69	protease	O
70	,	O
71	alpha	O
72	-	O
73	thrombin	B
74	.	O

1	Ligand	O
2	-	O
3	independent	O
4	activation	O
5	of	O
6	platelet	B
7	-	I
8	derived	I
9	growth	I
10	factor	I
11	receptor	I
12	is	O
13	a	O
14	necessary	O
15	intermediate	O
16	in	O
17	lysophosphatidic	O
18	,	O
19	acid	O
20	-	O
21	stimulated	O
22	mitogenic	O
23	activity	O
24	in	O
25	L	O
26	cells	O
27	.	O

1	Another	O
2	stem	O
3	-	O
4	loop	O
5	called	O
6	structure	O
7	III	O
8	near	O
9	the	O
10	3	O
11	'-	O
12	end	O
13	of	O
14	repY	O
15	sequesters	O
16	both	O
17	the	O
18	5	O
19	'-	O
20	rCGCC	O
21	-	O
22	3	O
23	'	O
24	sequence	O
25	and	O
26	the	O
27	repZ	O
28	ribosome	O
29	-	O
30	binding	O
31	site	O
32	.	O

1	These	O
2	results	O
3	provide	O
4	the	O
5	first	O
6	demonstration	O
7	that	O
8	an	O
9	SR	B
10	protein	I
11	can	O
12	influence	O
13	splicing	O
14	of	O
15	specific	O
16	pre	O
17	-	O
18	mRNAs	O
19	in	O
20	vivo	O
21	.	O

1	It	O
2	also	O
3	contains	O
4	a	O
5	picornaviral	O
6	3C	B
7	-	I
8	like	I
9	protease	I
10	domain	I
11	and	O
12	two	O
13	papain	B
14	-	I
15	like	I
16	protease	I
17	domains	I
18	.	O

1	Both	O
2	parents	O
3	are	O
4	clinically	O
5	normal	O
6	and	O
7	unrelated	O
8	.	O

1	The	O
2	characteristic	O
3	feature	O
4	of	O
5	liver	O
6	and	O
7	spleen	O
8	MP	O
9	function	O
10	in	O
11	patients	O
12	with	O
13	VHA	O
14	associated	O
15	with	O
16	HBsAg	O
17	carriership	O
18	consisted	O
19	in	O
20	the	O
21	lack	O
22	of	O
23	the	O
24	compensatory	O
25	reaction	O
26	on	O
27	the	O
28	part	O
29	of	O
30	spleen	O
31	MP	O
32	,	O
33	which	O
34	was	O
35	likely	O
36	to	O
37	be	O
38	connected	O
39	with	O
40	overstrain	O
41	of	O
42	long	O
43	standing	O
44	and	O
45	depletion	O
46	of	O
47	the	O
48	MP	O
49	system	O
50	due	O
51	to	O
52	permanent	O
53	antigenic	O
54	stimulation	O
55	of	O
56	HBsAg	O
57	.	O

1	We	O
2	have	O
3	used	O
4	mutation	O
5	-	O
6	directed	O
7	chemical	O
8	cross	O
9	-	O
10	linking	O
11	with	O
12	bis	O
13	(	O
14	sulfosuccinimidyl	O
15	)	O
16	suberate	O
17	(	O
18	BS3	O
19	)	O
20	to	O
21	investigate	O
22	the	O
23	architecture	O
24	of	O
25	the	O
26	gp41	O
27	oligomer	O
28	.	O

1	Clinical	O
2	aspects	O
3	and	O
4	therapy	O

1	Previous	O
2	investigators	O
3	have	O
4	suggested	O
5	that	O
6	subretinal	O
7	blood	O
8	damages	O
9	the	O
10	retina	O
11	in	O
12	part	O
13	because	O
14	of	O
15	its	O
16	solid	O
17	fibrin	B
18	meshwork	O
19	.	O

1	Stable	O
2	expression	O
3	of	O
4	truncated	O
5	inositol	O
6	1	O
7	,	O
8	4	O
9	,	O
10	5	O
11	-	O
12	trisphosphate	O
13	receptor	O
14	subunits	O
15	in	O
16	3T3	O
17	fibroblasts	O
18	.	O

1	Despite	O
2	significant	O
3	lethality	O
4	and	O
5	cardiovascular	O
6	dysfunction	O
7	,	O
8	in	O
9	the	O
10	septic	O
11	group	O
12	on	O
13	Days	O
14	1	O
15	and	O
16	2	O
17	,	O
18	septic	O
19	versus	O
20	control	O
21	animals	O
22	had	O
23	no	O
24	significant	O
25	differences	O
26	in	O
27	mean	O
28	metabolic	O
29	cart	O
30	measured	O
31	(	O
32	Vo2DIR	O
33	,	O
34	ml	O
35	/	O
36	kg	O
37	/	O
38	min	O
39	;	O
40	Day	O
41	1	O
42	:	O
43	11	O
44	.	O
45	9	O
46	versus	O
47	12	O
48	.	O
49	4	O
50	,	O
51	p	O
52	=	O
53	0	O
54	.	O
55	81	O
56	;	O
57	Day	O
58	2	O
59	:	O
60	14	O
61	.	O
62	2	O
63	versus	O
64	13	O
65	.	O
66	5	O
67	,	O
68	p	O
69	=	O
70	0	O
71	.	O
72	72	O
73	,	O
74	respectively	O
75	)	O
76	and	O
77	intravascular	O
78	catheter	O
79	calculated	O
80	(	O
81	Vo2INDIR	O
82	,	O
83	ml	O
84	/	O
85	kg	O
86	/	O
87	min	O
88	;	O
89	Day	O
90	1	O
91	:	O
92	11	O
93	.	O
94	2	O
95	versus	O
96	11	O
97	.	O
98	2	O
99	,	O
100	p	O
101	=	O
102	0	O
103	.	O
104	99	O
105	;	O
106	Day	O
107	2	O
108	:	O
109	12	O
110	.	O
111	8	O
112	versus	O
113	15	O
114	.	O
115	4	O
116	,	O
117	p	O
118	=	O
119	0	O
120	.	O
121	49	O
122	,	O
123	respectively	O
124	).	O

1	Neither	O
2	of	O
3	these	O
4	proteins	O
5	,	O
6	individually	O
7	or	O
8	as	O
9	a	O
10	pair	O
11	,	O
12	can	O
13	bind	O
14	the	O
15	alpha	B
16	-	I
17	globin	I
18	3	O
19	'	O
20	UTR	O
21	unless	O
22	they	O
23	are	O
24	complexed	O
25	with	O
26	the	O
27	remaining	O
28	non	O
29	-	O
30	poly	O
31	(	O
32	C	O
33	)	O
34	binding	O
35	proteins	O
36	of	O
37	the	O
38	alpha	O
39	-	O
40	complex	O
41	.	O

1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	phosphatidyl	O
7	inositol	O
8	4	O
9	,	O
10	5	O
11	bisphosphate	O
12	(	O
13	PIP2	O
14	)	O
15	hydrolysis	O
16	requires	O
17	direct	O
18	phosphorylation	O
19	at	O
20	tyrosine	O
21	residue	O
22	of	O
23	the	O
24	PLC	B
25	-	I
26	gamma1	I
27	isozyme	O
28	.	O

1	We	O
2	had	O
3	previously	O
4	analyzed	O
5	repair	O
6	rates	O
7	of	O
8	cyclobutane	O
9	pyrimidine	O
10	dimers	O
11	at	O
12	nucleotide	O
13	resolution	O
14	along	O
15	the	O
16	human	B
17	JUN	I
18	gene	I
19	in	O
20	normal	O
21	fibroblasts	O
22	and	O
23	found	O
24	very	O
25	efficient	O
26	repair	O
27	of	O
28	sequences	O
29	near	O
30	the	O
31	transcription	O
32	initiation	O
33	site	O
34	but	O
35	slow	O
36	repair	O
37	along	O
38	the	O
39	promoter	O
40	.	O

1	The	O
2	concomitant	O
3	interaction	O
4	of	O
5	mSTI1	O
6	with	O
7	hsp70	B
8	and	O
9	hsp90	O
10	at	O
11	its	O
12	N	O
13	-	O
14	and	O
15	C	O
16	-	O
17	termini	O
18	respectively	O
19	is	O
20	mediated	O
21	by	O
22	the	O
23	tetratricopeptide	O
24	repeat	O
25	(	O
26	TPR	O
27	)	O
28	motifs	O
29	in	O
30	these	O
31	regions	O
32	.	O

1	However	O
2	,	O
3	we	O
4	were	O
5	unable	O
6	to	O
7	identify	O
8	a	O
9	p4	O
10	molecule	O
11	.	O

1	Filter	O
2	and	O
3	cytocentrifuge	O
4	preparations	O
5	of	O
6	the	O
7	urine	O
8	were	O
9	studied	O
10	and	O
11	all	O
12	cases	O
13	displayed	O
14	numerous	O
15	scattered	O
16	aggregates	O
17	or	O
18	single	O
19	tumor	O
20	cells	O
21	in	O
22	an	O
23	inflammatory	O
24	background	O
25	.	O

1	Many	O
2	canonical	O
3	TATA	O
4	sequences	O
5	are	O
6	present	O
7	upstream	O
8	from	O
9	these	O
10	VZV	O
11	transcriptional	O
12	start	O
13	sites	O
14	but	O
15	,	O
16	apparently	O
17	,	O
18	are	O
19	not	O
20	used	O
21	.	O

1	A	O
2	cAMP	O
3	response	O
4	element	O
5	(	O
6	CRE	O
7	)	O
8	consensus	O
9	signal	O
10	was	O
11	identified	O
12	in	O
13	the	O
14	5	O
15	'-	O
16	noncoding	O
17	region	O
18	.	O
19	cAMP	O
20	regulates	O
21	the	O
22	expression	O
23	of	O
24	Kv1	O
25	.	O
26	5	O
27	gene	O
28	in	O
29	a	O
30	cell	O
31	-	O
32	specific	O
33	manner	O
34	.	O

1	NiCl	O
2	(	O
3	2	O
4	)-	O
5	induced	O
6	MCP	O
7	-	O
8	1	O
9	synthesis	O
10	required	O
11	activation	O
12	of	O
13	NF	B
14	-	I
15	kappaB	I
16	since	O
17	mutation	O
18	of	O
19	NF	B
20	-	I
21	kappaB	I
22	-	I
23	binding	I
24	sites	I
25	in	O
26	the	O
27	promoter	O
28	resulted	O
29	in	O
30	complete	O
31	loss	O
32	of	O
33	inducible	O
34	promoter	O
35	activity	O
36	.	O

1	In	O
2	the	O
3	first	O
4	part	O
5	of	O
6	our	O
7	study	O
8	,	O
9	the	O
10	highest	O
11	mutagenicity	O
12	was	O
13	revealed	O
14	by	O
15	TA98	O
16	strain	O
17	without	O
18	enzymatic	O
19	activation	O
20	,	O
21	suggesting	O
22	a	O
23	direct	O
24	-	O
25	acting	O
26	mutagenicity	O
27	prevalence	O
28	in	O
29	diesel	O
30	particulate	O
31	.	O

1	Of	O
2	115	O
3	hepatitis	O
4	B	O
5	patients	O
6	seen	O
7	at	O
8	12	O
9	months	O
10	,	O
11	6	O
12	%	O
13	had	O
14	chronic	O
15	hepatitis	O
16	Bs	O
17	antigenaemia	O
18	,	O
19	60	O
20	%	O
21	had	O
22	developed	O
23	anti	B
24	-	I
25	HBs	I
26	antibodies	I
27	,	O
28	and	O
29	7	O
30	.	O
31	3	O
32	%	O
33	still	O
34	had	O
35	abnormal	O
36	liver	O
37	function	O
38	.	O

1	RESULTS	O
2	:	O
3	Of	O
4	the	O
5	29	O
6	patients	O
7	who	O
8	received	O
9	concurrent	O
10	chemotherapy	O
11	and	O
12	G	B
13	-	I
14	CSF	I
15	,	O
16	ten	O
17	(	O
18	34	O
19	%;	O
20	95	O
21	%	O
22	confidence	O
23	interval	O
24	[	O
25	CI	O
26	],	O
27	17	O
28	.	O
29	9	O
30	to	O
31	54	O
32	.	O
33	3	O
34	%)	O
35	were	O
36	believed	O
37	to	O
38	have	O
39	clinically	O
40	significant	O
41	bleomycin	O
42	toxicity	O
43	.	O

1	To	O
2	the	O
3	problem	O
4	of	O
5	the	O
6	stimulation	O
7	of	O
8	the	O
9	growth	O
10	of	O
11	transplantable	O
12	tumors	O
13	of	O
14	animals	O
15	previously	O
16	treated	O
17	with	O
18	antineoplastic	O
19	antibiotics	O

1	An	O
2	experiment	O
3	on	O
4	the	O
5	return	O
6	-	O
7	of	O
8	-	O
9	fear	O
10	(	O
11	ROF	O
12	)	O
13	was	O
14	carried	O
15	out	O
16	on	O
17	40	O
18	snake	O
19	-	O
20	or	O
21	spider	O
22	-	O
23	phobic	O
24	subjects	O
25	in	O
26	order	O
27	to	O
28	determine	O
29	whether	O
30	an	O
31	arousing	O
32	event	O
33	that	O
34	occurs	O
35	shortly	O
36	before	O
37	retest	O
38	influences	O
39	the	O
40	magnitude	O
41	of	O
42	the	O
43	ROF	O
44	.	O

1	Nucleotide	O
2	sequence	O
3	and	O
4	transcriptional	O
5	analysis	O
6	of	O
7	the	O
8	DNA	O
9	polymerase	O
10	gene	O
11	of	O
12	Bombyx	O
13	mori	O
14	nuclear	O
15	polyhedrosis	O
16	virus	O
17	.	O

1	Furthermore	O
2	,	O
3	in	O
4	vivo	O
5	and	O
6	in	O
7	vitro	O
8	protein	O
9	-	O
10	protein	O
11	interaction	O
12	experiments	O
13	have	O
14	shown	O
15	that	O
16	SR33	O
17	protein	O
18	interacts	O
19	with	O
20	itself	O
21	and	O
22	with	O
23	SR45	O
24	protein	O
25	but	O
26	not	O
27	with	O
28	two	O
29	other	O
30	members	O
31	(	O
32	SRZ21	O
33	and	O
34	SRZ22	O
35	)	O
36	of	O
37	the	O
38	SR	B
39	family	I
40	that	O
41	are	O
42	known	O
43	to	O
44	interact	O
45	with	O
46	the	O
47	Arabidopsis	O
48	full	O
49	-	O
50	length	O
51	U	O
52	-	O
53	70K	O
54	only	O
55	.	O

1	In	O
2	accordance	O
3	with	O
4	clinical	O
5	improvement	O
6	we	O
7	found	O
8	a	O
9	decrease	O
10	of	O
11	laboratory	O
12	indicators	O
13	of	O
14	inflammation	O
15	(	O
16	C	O
17	-	O
18	reactive	O
19	protein	O
20	,	O
21	alpha	O
22	2	O
23	-	O
24	globuline	O
25	,	O
26	prostaglandin	O
27	E2	O
28	).	O

1	Additionally	O
2	,	O
3	the	O
4	enzyme	O
5	shows	O
6	activity	O
7	towards	O
8	triglycerides	O
9	such	O
10	as	O
11	olive	O
12	oil	O
13	and	O
14	tributyrin	O
15	and	O
16	towards	O
17	egg	O
18	-	O
19	yolk	O
20	emulsions	O
21	.	O

1	Existence	O
2	and	O
3	uniqueness	O
4	of	O
5	solutions	O
6	of	O
7	the	O
8	appropriate	O
9	boundary	O
10	value	O
11	problems	O
12	are	O
13	established	O
14	,	O
15	in	O
16	the	O
17	case	O
18	of	O
19	small	O
20	permeability	O
21	coefficients	O
22	and	O
23	transport	O
24	rates	O
25	,	O
26	or	O
27	large	O
28	diffusion	O
29	coefficients	O
30	and	O
31	small	O
32	resistance	O
33	to	O
34	flow	O
35	constants	O
36	.	O

1	Brain	O
2	scan	O
3	with	O
4	99mTc	O
5	-	O
6	labelled	O
7	macroaggregated	O
8	albumin	B
9	(	O
10	MAA	O
11	brain	O
12	scan	O
13	)	O
14	and	O
15	computed	O
16	tomography	O
17	studies	O
18	(	O
19	CT	O
20	)	O
21	were	O
22	performed	O
23	on	O
24	78	O
25	patients	O
26	with	O
27	intracranial	O
28	diseases	O
29	.	O

1	By	O
2	analyzing	O
3	the	O
4	RanGAP	O
5	activity	O
6	of	O
7	a	O
8	series	O
9	of	O
10	recombinantly	O
11	expressed	O
12	rna1p	O
13	mutant	O
14	derivatives	O
15	,	O
16	we	O
17	show	O
18	that	O
19	the	O
20	highly	O
21	acidic	O
22	sequence	O
23	in	O
24	the	O
25	C	O
26	-	O
27	terminal	O
28	domain	O
29	of	O
30	both	O
31	yeast	O
32	proteins	O
33	is	O
34	indispensable	O
35	for	O
36	activating	O
37	Ran	B
38	-	I
39	mediated	O
40	GTP	O
41	hydrolysis	O
42	.	O

1	Reye	O
2	'	O
3	s	O
4	syndrome	O
5	:	O
6	reports	O
7	of	O
8	7	O
9	cases	O
10	in	O
11	the	O
12	period	O
13	1982	O
14	-	O
15	1987	O

1	Heterogeneous	B
2	nuclear	I
3	ribonucleoprotein	I
4	(	I
5	hnRNP	I
6	)	I
7	core	I
8	protein	I
9	A1	I
10	is	O
11	a	O
12	major	O
13	component	O
14	of	O
15	mammalian	B
16	hnRNP	I
17	40	O
18	S	O
19	particles	O
20	.	O

1	This	O
2	study	O
3	demonstrates	O
4	secretion	O
5	of	O
6	bicarbonate	O
7	by	O
8	the	O
9	human	O
10	stomach	O
11	in	O
12	vivo	O
13	at	O
14	a	O
15	rate	O
16	equivalent	O
17	to	O
18	10	O
19	--	O
20	20	O
21	%	O
22	of	O
23	basal	O
24	acid	O
25	secretion	O
26	.	O

1	The	O
2	MMPI	O
3	-	O
4	A	O
5	(	O
6	Butcher	O
7	et	O
8	al	O
9	.,	O
10	1992	O
11	),	O
12	like	O
13	the	O
14	older	O
15	MMPI	O
16	(	O
17	Hathaway	O
18	&	O
19	McKinley	O
20	,	O
21	1983	O
22	),	O
23	distinguishes	O
24	between	O
25	anorexia	O
26	and	O
27	bulimia	O
28	.	O

1	The	O
2	site	O
3	of	O
4	autophosphorylation	O
5	is	O
6	Tyr397	O
7	which	O
8	corresponds	O
9	to	O
10	the	O
11	consensus	O
12	autophosphorylation	O
13	site	O
14	of	O
15	other	O
16	Src	B
17	family	I
18	tyrosine	I
19	kinases	I
20	.	O

1	Extraction	O
2	procedure	O
3	for	O
4	the	O
5	measurement	O
6	of	O
7	butyltin	O
8	compounds	O
9	in	O
10	biological	O
11	tissues	O
12	using	O
13	toluene	O
14	,	O
15	HBr	O
16	,	O
17	and	O
18	tropolone	O
19	.	O

1	The	O
2	yeast	O
3	MMS2	O
4	gene	O
5	was	O
6	cloned	O
7	by	O
8	its	O
9	ability	O
10	to	O
11	complement	O
12	the	O
13	methyl	O
14	methanesulfonate	O
15	sensitivity	O
16	of	O
17	the	O
18	mms2	O
19	-	O
20	1	O
21	mutant	O
22	and	O
23	was	O
24	later	O
25	shown	O
26	to	O
27	be	O
28	involved	O
29	in	O
30	DNA	O
31	post	O
32	-	O
33	replication	O
34	repair	O
35	.	O

1	Model	O
2	of	O
3	spatiotemporal	O
4	dynamics	O
5	of	O
6	stick	O
7	-	O
8	slip	O
9	motion	O
10	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	bradycardic	O
7	agents	O
8	alinidine	O
9	and	O
10	zatebradine	O
11	do	O
12	not	O
13	exert	O
14	antiarrhythmic	O
15	efficacy	O
16	against	O
17	SVT	O
18	induced	O
19	during	O
20	subacute	O
21	myocardial	O
22	infarction	O
23	in	O
24	conscious	O
25	dogs	O
26	.	O

1	Follow	O
2	-	O
3	up	O
4	controls	O
5	of	O
6	luteinizing	B
7	hormone	I
8	(	I
9	LH	I
10	),	O
11	follicle	B
12	stimulating	I
13	hormone	I
14	(	O
15	FSH	B
16	),	O
17	prolactin	B
18	(	O
19	HPRL	O
20	),	O
21	oestradiol	O
22	(	O
23	E2	O
24	),	O
25	progesterone	O
26	(	O
27	P	O
28	)	O
29	and	O
30	testosterone	O
31	(	O
32	T	O
33	)	O
34	in	O
35	the	O
36	catabolic	O
37	and	O
38	healing	O
39	phase	O
40	of	O
41	burn	O
42	disease	O
43	.	O

1	AgMNPV	O
2	and	O
3	Orgyia	O
4	pseudotsugata	O
5	MNPV	O
6	(	O
7	OpMNPV	O
8	)	O
9	are	O
10	similar	O
11	in	O
12	terms	O
13	of	O
14	promoter	O
15	structure	O
16	and	O
17	polyhedrin	O
18	primary	O
19	sequence	O
20	,	O
21	and	O
22	the	O
23	polyhedrin	B
24	gene	I
25	of	O
26	both	O
27	viruses	O
28	is	O
29	transcribed	O
30	in	O
31	the	O
32	anti	O
33	-	O
34	clockwise	O
35	direction	O
36	in	O
37	relation	O
38	to	O
39	their	O
40	physical	O
41	maps	O
42	.	O

1	However	O
2	,	O
3	it	O
4	remains	O
5	an	O
6	open	O
7	question	O
8	whether	O
9	vertebrate	O
10	Hox	B
11	genes	I
12	expressed	O
13	under	O
14	the	O
15	control	O
16	of	O
17	Drosophila	O
18	regulatory	O
19	sequences	O
20	can	O
21	substitute	O
22	the	O
23	function	O
24	of	O
25	Drosophila	B
26	Hox	I
27	genes	I
28	.	O

1	The	O
2	inflation	O
3	hub	O
4	of	O
5	the	O
6	probe	O
7	is	O
8	recreated	O
9	by	O
10	modifying	O
11	a	O
12	standard	O
13	USCI	O
14	Tuohy	O
15	-	O
16	Borst	O
17	Y	O
18	adaptor	O
19	and	O
20	attaching	O
21	this	O
22	to	O
23	the	O
24	transected	O
25	probe	O
26	hypotube	O
27	.	O

1	Deletion	O
2	studies	O
3	identified	O
4	a	O
5	distal	O
6	response	O
7	element	O
8	that	O
9	is	O
10	responsible	O
11	for	O
12	the	O
13	cytokine	O
14	response	O
15	and	O
16	has	O
17	properties	O
18	of	O
19	an	O
20	inducible	O
21	transcriptional	O
22	enhancer	O
23	.	O

1	The	O
2	Arabidopsis	O
3	FAD7	O
4	gene	O
5	encodes	O
6	a	O
7	chloroplast	O
8	omega	O
9	-	O
10	3	O
11	fatty	O
12	acid	O
13	desaturase	O
14	that	O
15	catalyzes	O
16	the	O
17	desaturation	O
18	of	O
19	lipid	O
20	-	O
21	linked	O
22	dienoic	O
23	fatty	O
24	acids	O
25	(	O
26	18	O
27	:	O
28	2	O
29	and	O
30	16	O
31	:	O
32	2	O
33	).	O

1	The	O
2	subjects	O
3	were	O
4	diagnosed	O
5	on	O
6	the	O
7	basis	O
8	of	O
9	DSM	O
10	-	O
11	IV	O
12	pathological	O
13	gambling	O
14	criteria	O
15	and	O
16	completed	O
17	the	O
18	Turkish	O
19	Version	O
20	of	O
21	South	O
22	Oaks	O
23	Gambling	O
24	Screen	O
25	(	O
26	SOGS	O
27	).	O

1	Sterol	O
2	-	O
3	mediated	O
4	suppression	O
5	of	O
6	cleavage	O
7	of	O
8	SREBP	B
9	-	I
10	1	I
11	was	O
12	found	O
13	to	O
14	be	O
15	dependent	O
16	on	O
17	the	O
18	extreme	O
19	COOH	O
20	-	O
21	terminal	O
22	region	O
23	(	O
24	residue	O
25	1034	O
26	to	O
27	the	O
28	COOH	O
29	terminus	O
30	),	O
31	which	O
32	exists	O
33	in	O
34	two	O
35	forms	O
36	as	O
37	a	O
38	result	O
39	of	O
40	alternative	O
41	splicing	O
42	.	O

1	Hyperthyroidism	O

1	An	O
2	immunologically	O
3	related	O
4	protein	O
5	was	O
6	detected	O
7	in	O
8	ribosome	O
9	and	O
10	membrane	O
11	fractions	O
12	of	O
13	mitochondria	O
14	from	O
15	Saccharomyces	O
16	cerevisiae	O
17	.	O

1	We	O
2	conclude	O
3	that	O
4	the	O
5	beta	O
6	-	O
7	adrenergic	O
8	agonist	O
9	,	O
10	isoproterenol	O
11	,	O
12	has	O
13	little	O
14	influence	O
15	on	O
16	vascular	O
17	capacitance	O
18	or	O
19	liver	O
20	volume	O
21	of	O
22	dogs	O
23	,	O
24	unless	O
25	the	O
26	hepatic	O
27	outflow	O
28	resistance	O
29	is	O
30	elevated	O
31	by	O
32	agents	O
33	such	O
34	as	O
35	histamine	O
36	.	O

1	Epstein	B
2	-	I
3	Barr	I
4	virus	I
5	nuclear	I
6	protein	I
7	2	I
8	(	I
9	EBNA2	I
10	)	O
11	binds	O
12	to	O
13	a	O
14	component	O
15	of	O
16	the	O
17	human	O
18	SNF	O
19	-	O
20	SWI	O
21	complex	O
22	,	O
23	hSNF5	O
24	/	O
25	Ini1	O
26	.	O

1	Abnormal	O
2	characteristics	O
3	and	O
4	verticillation	O
5	in	O
6	Platynothrus	O
7	peltifer	O

1	Hypothermia	O
2	After	O
3	Cardiac	O
4	Arrest	O
5	(	O
6	HACA	O
7	)	O
8	Study	O
9	Group	O
10	.	O

1	The	O
2	hepatocyte	B
3	nuclear	I
4	factor	I
5	-	I
6	3	O
7	(	O
8	HNF	B
9	-	I
10	3	I
11	)/	I
12	forkhead	I
13	(	O
14	fkh	O
15	)	O
16	proteins	O
17	consist	O
18	of	O
19	an	O
20	extensive	O
21	family	O
22	of	O
23	tissue	O
24	-	O
25	specific	O
26	and	O
27	developmental	O
28	gene	O
29	regulators	O
30	which	O
31	share	O
32	homology	O
33	within	O
34	the	O
35	winged	B
36	helix	I
37	DNA	O
38	binding	O
39	motif	O
40	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	combined	O
6	lesions	O
7	of	O
8	cholinergic	O
9	and	O
10	serotonergic	O
11	neurons	O
12	in	O
13	the	O
14	rat	O
15	brain	O
16	do	O
17	not	O
18	alter	O
19	olfactory	O
20	perception	O
21	or	O
22	olfactory	O
23	short	O
24	-	O
25	term	O
26	memory	O
27	.	O

1	Blood	O
2	sampling	O
3	procedures	O
4	were	O
5	videotaped	O
6	.	O

1	Fundamental	O
2	and	O
3	clinical	O
4	evaluation	O
5	of	O
6	equilibrium	O
7	dialysis	O
8	--	O
9	radioimmunoassay	O
10	system	O
11	for	O
12	measurement	O
13	of	O
14	serum	O
15	free	O
16	thyroxine	O

1	The	O
2	odds	O
3	ratio	O
4	for	O
5	CHD	O
6	was	O
7	1	O
8	.	O
9	21	O
10	(	O
11	95	O
12	%	O
13	confidence	O
14	interval	O
15	,	O
16	0	O
17	.	O
18	84	O
19	-	O
20	1	O
21	.	O
22	75	O
23	)	O
24	given	O
25	a	O
26	positive	O
27	serostatus	O
28	of	O
29	specific	O
30	IgG	B
31	antibodies	I
32	after	O
33	adjustment	O
34	for	O
35	covariates	O
36	.	O

1	MATERIALS	O
2	AND	O
3	METHODS	O
4	:	O
5	Coronal	O
6	3D	O
7	GRE	O
8	imaging	O
9	was	O
10	used	O
11	to	O
12	study	O
13	the	O
14	volar	O
15	,	O
16	middle	O
17	,	O
18	and	O
19	dorsal	O
20	portions	O
21	of	O
22	the	O
23	SLL	O
24	in	O
25	14	O
26	patients	O
27	with	O
28	an	O
29	arthroscopically	O
30	normal	O
31	SLL	O
32	and	O
33	in	O
34	five	O
35	cadaveric	O
36	wrists	O
37	that	O
38	had	O
39	a	O
40	normal	O
41	SLL	O
42	proved	O
43	with	O
44	dissection	O
45	.	O

1	RESULTS	O
2	:	O
3	In	O
4	an	O
5	18	O
6	moth	O
7	period	O
8	and	O
9	out	O
10	of	O
11	a	O
12	total	O
13	of	O
14	284	O
15	positive	O
16	blood	O
17	cultures	O
18	(	O
19	154	O
20	significant	O
21	isolations	O
22	)	O
23	14	O
24	episodes	O
25	of	O
26	bacteremia	O
27	by	O
28	M	O
29	.	O
30	tuberculosis	O
31	were	O
32	studied	O
33	in	O
34	12	O
35	prison	O
36	patients	O
37	coinfected	O
38	by	O
39	the	O
40	human	O
41	immunodeficiency	O
42	virus	O
43	with	O
44	associated	O
45	severe	O
46	immunosuppression	O
47	(	O
48	mean	O
49	of	O
50	CD4	B
51	=	O
52	0	O
53	.	O
54	068	O
55	x	O
56	10	O
57	(	O
58	9	O
59	)/	O
60	l	O
61	).	O

1	Mapping	O
2	features	O
3	of	O
4	HIV	B
5	-	I
6	1	I
7	integrase	I
8	near	O
9	selected	O
10	sites	O
11	on	O
12	viral	O
13	and	O
14	target	O
15	DNA	O
16	molecules	O
17	in	O
18	an	O
19	active	O
20	enzyme	O
21	-	O
22	DNA	O
23	complex	O
24	by	O
25	photo	O
26	-	O
27	cross	O
28	-	O
29	linking	O
30	.	O

1	The	O
2	management	O
3	of	O
4	the	O
5	"	O
6	chronic	O
7	"	O
8	patient	O
9	.	O

1	The	O
2	intracoronary	O
3	administration	O
4	of	O
5	both	O
6	drugs	O
7	markedly	O
8	reduced	O
9	the	O
10	incidence	O
11	of	O
12	VF	O
13	induced	O
14	by	O
15	the	O
16	release	O
17	of	O
18	a	O
19	40	O
20	-	O
21	min	O
22	coronary	O
23	artery	O
24	occlusion	O
25	.	O

1	Thus	O
2	the	O
3	present	O
4	data	O
5	also	O
6	suggest	O
7	that	O
8	BP	O
9	and	O
10	HR	O
11	measurements	O
12	are	O
13	influenced	O
14	not	O
15	only	O
16	by	O
17	state	O
18	-	O
19	dependent	O
20	factors	O
21	but	O
22	also	O
23	by	O
24	at	O
25	least	O
26	three	O
27	different	O
28	factors	O
29	that	O
30	are	O
31	each	O
32	independent	O
33	of	O
34	the	O
35	state	O
36	:	O
37	one	O
38	leads	O
39	to	O
40	BP	O
41	and	O
42	HR	O
43	values	O
44	that	O
45	are	O
46	influenced	O
47	by	O
48	the	O
49	cycle	O
50	the	O
51	animal	O
52	is	O
53	in	O
54	and	O
55	the	O
56	other	O
57	two	O
58	influence	O
59	,	O
60	respectively	O
61	,	O
62	the	O
63	ranking	O
64	of	O
65	the	O
66	individual	O
67	'	O
68	s	O
69	BP	O
70	and	O
71	HR	O
72	levels	O
73	within	O
74	the	O
75	population	O
76	.	O

1	Hemolytic	O
2	jaundice	O
3	due	O
4	to	O
5	G6PD	O
6	deficiency	O
7	causing	O
8	kernicterus	O
9	in	O
10	a	O
11	female	O
12	newborn	O
13	.	O

1	Its	O
2	cognate	O
3	binding	O
4	protein	O
5	,	O
6	REST	O
7	/	O
8	NRSF	O
9	,	O
10	is	O
11	an	O
12	essential	O
13	transcription	O
14	factor	O
15	;	O
16	its	O
17	null	O
18	mutations	O
19	result	O
20	in	O
21	embryonic	O
22	lethality	O
23	,	O
24	and	O
25	its	O
26	dominant	O
27	negative	O
28	mutants	O
29	produce	O
30	aberrant	O
31	expression	O
32	of	O
33	neuron	O
34	-	O
35	specific	O
36	genes	O
37	.	O

1	The	O
2	population	O
3	of	O
4	between	O
5	75	O
6	,	O
7	000	O
8	and	O
9	100	O
10	,	O
11	000	O
12	was	O
13	largely	O
14	unstable	O
15	,	O
16	and	O
17	cost	O
18	per	O
19	capita	O
20	was	O
21	$	O
22	0	O
23	.	O
24	95	O
25	to	O
26	$	O
27	1	O
28	.	O
29	21	O
30	.	O

1	N	O
2	.,	O
3	and	O
4	Fanning	O
5	,	O
6	E	O
7	.	O

1	Overexpression	O
2	of	O
3	CARP	O
4	in	O
5	cardiomyocytes	O
6	suppresses	O
7	cardiac	O
8	troponin	B
9	C	I
10	and	O
11	atrial	O
12	natriuretic	O
13	factor	O
14	transcription	O
15	.	O

1	This	O
2	motif	O
3	,	O
4	first	O
5	described	O
6	for	O
7	the	O
8	Drosophila	B
9	homeobox	I
10	activator	I
11	DEAF	I
12	-	I
13	1	I
14	,	O
15	identifies	O
16	an	O
17	emerging	O
18	group	O
19	of	O
20	metazoan	O
21	transcriptional	O
22	modulators	O
23	.	O

1	Three	O
2	chromosomal	O
3	crsA	O
4	mutations	O
5	,	O
6	crsA1	O
7	,	O
8	crsA4	O
9	,	O
10	and	O
11	crsA47	O
12	,	O
13	were	O
14	transferred	O
15	by	O
16	the	O
17	"	O
18	gene	O
19	conversion	O
20	"	O
21	process	O
22	to	O
23	B	O
24	.	O
25	subtilis	O
26	plasmid	O
27	pRPD11	O
28	,	O
29	which	O
30	consists	O
31	of	O
32	the	O
33	entire	O
34	wild	O
35	-	O
36	type	O
37	rpoD	O
38	coding	O
39	sequence	O
40	,	O
41	encoding	O
42	the	O
43	major	O
44	sigma	B
45	43	I
46	factor	I
47	of	O
48	B	O
49	.	O
50	subtilis	O
51	RNA	O
52	polymerase	O
53	,	O
54	and	O
55	pUB110	O
56	.	O

1	This	O
2	result	O
3	indicates	O
4	that	O
5	separate	O
6	complexes	O
7	exist	O
8	containing	O
9	ankyrin	O
10	and	O
11	fodrin	O
12	with	O
13	either	O
14	uvomorulin	O
15	or	O
16	Na	O
17	+,	O
18	K	O
19	+-	O
20	ATPase	O
21	.	O

1	A	O
2	subset	O
3	of	O
4	mutations	O
5	in	O
6	the	O
7	Psi	B
8	synthase	I
9	domain	I
10	impairs	I
11	association	O
12	of	O
13	the	O
14	altered	O
15	Cbf5p	B
16	proteins	I
17	with	O
18	selected	O
19	box	O
20	H	O
21	/	O
22	ACA	O
23	snoRNAs	O
24	,	O
25	suggesting	O
26	that	O
27	the	O
28	functional	O
29	catalytic	O
30	domain	O
31	is	O
32	essential	O
33	for	O
34	that	O
35	interaction	O
36	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	a	O
5	6	O
6	.	O
7	3	O
8	-	O
9	kbp	O
10	genomic	O
11	EcoRI	B
12	-	I
13	fragment	I
14	of	O
15	Alcaligenes	O
16	eutrophus	O
17	,	O
18	which	O
19	was	O
20	recently	O
21	identified	O
22	by	O
23	using	O
24	a	O
25	dihydrolipoamide	B
26	dehydrogenase	I
27	-	I
28	specific	O
29	DNA	O
30	probe	O
31	(	O
32	A	O
33	.	O

1	Consistent	O
2	with	O
3	a	O
4	possible	O
5	role	O
6	in	O
7	transcription	O
8	,	O
9	Paf1p	O
10	is	O
11	localized	O
12	to	O
13	the	O
14	nucleus	O
15	.	O

1	Ovulation	O
2	was	O
3	induced	O
4	in	O
5	8	O
6	(	O
7	56	O
8	.	O
9	7	O
10	%)	O
11	patients	O
12	who	O
13	conceived	O
14	.	O

1	These	O
2	findings	O
3	indicate	O
4	that	O
5	hypergastrinemia	O
6	induced	O
7	by	O
8	surgical	O
9	removal	O
10	of	O
11	acid	O
12	-	O
13	producing	O
14	mucosa	O
15	in	O
16	the	O
17	rat	O
18	has	O
19	the	O
20	same	O
21	effects	O
22	on	O
23	oxyntical	O
24	mucosal	O
25	HDC	O
26	activity	O
27	,	O
28	histamine	O
29	concentration	O
30	and	O
31	ECL	O
32	cell	O
33	density	O
34	as	O
35	hypergastrinemia	O
36	induced	O
37	by	O
38	continuous	O
39	gastrin	B
40	infusion	O
41	or	O
42	by	O
43	long	O
44	-	O
45	term	O
46	treatment	O
47	with	O
48	effective	O
49	antisecretagogues	O
50	.	O

1	Collectively	O
2	,	O
3	these	O
4	data	O
5	indicate	O
6	that	O
7	HIP	O
8	is	O
9	a	O
10	membrane	O
11	-	O
12	associated	O
13	HP	O
14	-	O
15	binding	O
16	protein	O
17	expressed	O
18	on	O
19	the	O
20	surface	O
21	of	O
22	normal	O
23	human	O
24	uterine	O
25	epithelia	O
26	and	O
27	uterine	O
28	epithelial	O
29	cell	O
30	lines	O
31	.	O

1	The	O
2	SUP44	O
3	suppressor	O
4	mutation	O
5	occurs	O
6	near	O
7	a	O
8	region	O
9	of	O
10	the	O
11	protein	O
12	that	O
13	corresponds	O
14	to	O
15	the	O
16	known	O
17	positions	O
18	of	O
19	alterations	O
20	in	O
21	E	O
22	.	O
23	coli	O
24	S5	O
25	ram	O
26	mutations	O
27	.	O

1	Transformed	O
2	cell	O
3	lines	O
4	expressing	O
5	solely	O
6	E1a	O
7	or	O
8	E1a	O
9	and	O
10	E1b	O
11	gene	O
12	products	O
13	derived	O
14	from	O
15	these	O
16	viruses	O
17	display	O
18	enhanced	O
19	anchorage	O
20	-	O
21	independent	O
22	growth	O
23	at	O
24	37	O
25	degrees	O
26	C	O
27	versus	O
28	32	O
29	degrees	O
30	C	O
31	and	O
32	display	O
33	a	O
34	cytoskeletal	O
35	architecture	O
36	resembling	O
37	untransformed	O
38	fibroblastic	O
39	CREF	O
40	cells	O
41	.	O

1	Human	O
2	neutrophil	O
3	response	O
4	to	O
5	short	O
6	-	O
7	term	O
8	exposure	O
9	to	O
10	F	O
11	-	O
12	75	O
13	cobalt	O
14	-	O
15	based	O
16	alloy	O
17	.	O

1	The	O
2	complement	O
3	C3a	O
4	anaphylatoxin	O
5	receptor	O
6	(	O
7	C3aR	O
8	)	O
9	is	O
10	a	O
11	seven	O
12	-	O
13	transmembrane	O
14	G	B
15	-	I
16	protein	I
17	coupled	I
18	chemoattractant	I
19	receptor	I
20	that	O
21	on	O
22	binding	O
23	the	O
24	C3a	O
25	peptide	O
26	ligand	O
27	mediates	O
28	numerous	O
29	cellular	O
30	responses	O
31	,	O
32	including	O
33	histamine	O
34	release	O
35	from	O
36	mast	O
37	cells	O
38	.	O
39	smooth	O
40	muscle	O
41	contraction	O
42	,	O
43	and	O
44	the	O
45	directed	O
46	migration	O
47	of	O
48	eosinophils	O
49	.	O

1	Her	O
2	serum	O
3	FT3	O
4	concentration	O
5	was	O
6	,	O
7	however	O
8	,	O
9	much	O
10	higher	O
11	than	O
12	the	O
13	ranges	O
14	in	O
15	normal	O
16	pregnancy	O
17	or	O
18	in	O
19	GTD	O
20	patients	O
21	without	O
22	clinical	O
23	hyperthyroidism	O
24	.	O

1	Phylogenetic	O
2	position	O
3	of	O
4	the	O
5	Phacotaceae	O
6	within	O
7	the	O
8	Chlamydophyceaeas	O
9	revealed	O
10	by	O
11	analysis	O
12	of	O
13	18S	O
14	rDNA	O
15	and	O
16	rbcL	O
17	sequences	O
18	.	O

1	In	O
2	supine	O
3	position	O
4	,	O
5	plasma	O
6	ANP	O
7	levels	O
8	ranged	O
9	from	O
10	12	O
11	pg	O
12	/	O
13	ml	O
14	to	O
15	51	O
16	.	O
17	5	O
18	pg	O
19	/	O
20	ml	O
21	,	O
22	with	O
23	an	O
24	average	O
25	level	O
26	of	O
27	35	O
28	.	O
29	3	O
30	+/-	O
31	11	O
32	.	O
33	5	O
34	pg	O
35	/	O
36	ml	O
37	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	decreased	O
6	class	O
7	I	O
8	enhancer	O
9	activity	O
10	in	O
11	Ad12	O
12	-	O
13	transformed	O
14	cells	O
15	may	O
16	,	O
17	at	O
18	least	O
19	in	O
20	part	O
21	,	O
22	be	O
23	due	O
24	to	O
25	the	O
26	higher	O
27	levels	O
28	of	O
29	an	O
30	enhancer	O
31	-	O
32	specific	O
33	factor	O
34	,	O
35	possibly	O
36	acting	O
37	as	O
38	a	O
39	repressor	O
40	.	O

1	Concomitant	O
2	chronic	O
3	lymphocytic	O
4	leukemia	O
5	,	O
6	acute	O
7	myeloid	O
8	leukemia	O
9	,	O
10	and	O
11	thrombosis	O
12	with	O
13	protein	O
14	C	O
15	deficiency	O
16	.	O

1	Yang	O
2	and	O
3	H	O
4	.	O

1	Chem	O
2	.	O

1	Purified	O
2	PLB	O
3	showed	O
4	optimal	O
5	lyase	O
6	activity	O
7	at	O
8	pH	O
9	10	O
10	.	O
11	0	O
12	.	O

1	The	O
2	transcriptional	O
3	unit	O
4	spans	O
5	a	O
6	chromosomal	O
7	region	O
8	of	O
9	about	O
10	55	O
11	kilobase	O
12	pairs	O
13	(	O
14	kbp	O
15	).	O

1	Hepatitis	O
2	B	O
3	surface	O
4	antigen	O
5	was	O
6	detected	O
7	in	O
8	2	O
9	patients	O
10	,	O
11	with	O
12	negative	O
13	hepatitis	O
14	C	O
15	virus	O
16	antibody	O
17	.	O

1	A	O
2	hydrodynamic	O
3	description	O
4	of	O
5	the	O
6	osmotic	O
7	reflection	O
8	coefficient	O
9	with	O
10	application	O
11	to	O
12	the	O
13	pore	O
14	theory	O
15	of	O
16	transcapillary	O
17	exchange	O
18	.	O

1	Finally	O
2	,	O
3	three	O
4	new	O
5	missense	O
6	mutations	O
7	,	O
8	E138V	O
9	,	O
10	R254G	O
11	,	O
12	and	O
13	P362R	O
14	,	O
15	were	O
16	identified	O
17	in	O
18	the	O
19	human	O
20	AC	O
21	gene	O
22	from	O
23	FD	O
24	patients	O
25	.	O

1	LysR	B
2	proteins	I
3	have	O
4	been	O
5	shown	O
6	to	O
7	regulate	O
8	urease	O
9	in	O
10	Klebsiella	O
11	aerogenes	O
12	(	O
13	NAC	O
14	),	O
15	and	O
16	catalase	O
17	in	O
18	Escherichia	O
19	coli	O
20	(	O
21	OxyR	O
22	),	O
23	which	O
24	offers	O
25	the	O
26	intracellular	O
27	bacterium	O
28	protection	O
29	from	O
30	phagolysosome	O
31	damage	O
32	.	O

1	Nuclear	B
2	protein	I
3	phosphatase	I
4	2A	I
5	dephosphorylates	I
6	protein	I
7	kinase	I
8	A	I
9	-	I
10	phosphorylated	O
11	CREB	B
12	and	O
13	regulates	O
14	CREB	B
15	transcriptional	O
16	stimulation	O
17	.	O

1	Endorphins	O
2	at	O
3	the	O
4	approach	O
5	of	O
6	death	O
7	.	O

1	The	O
2	RI	B
3	alpha	I
4	gene	I
5	is	O
6	composed	O
7	of	O
8	nine	O
9	coding	O
10	exons	O
11	of	O
12	varying	O
13	lengths	O
14	,	O
15	separated	O
16	by	O
17	introns	O
18	,	O
19	giving	O
20	the	O
21	gene	O
22	a	O
23	total	O
24	length	O
25	of	O
26	at	O
27	least	O
28	21	O
29	kb	O
30	.	O
31	our	O
32	recent	O
33	cloning	O
34	of	O
35	a	O
36	processed	O
37	RI	B
38	alpha	I
39	pseudogene	I
40	with	O
41	a	O
42	5	O
43	'-	O
44	noncoding	O
45	region	O
46	different	O
47	from	O
48	the	O
49	previously	O
50	reported	O
51	RI	B
52	alpha	I
53	complementary	O
54	RNA	O
55	indicated	O
56	that	O
57	the	O
58	RI	B
59	alpha	I
60	gene	I
61	may	O
62	have	O
63	multiple	O
64	leader	O
65	exons	O
66	giving	O
67	rise	O
68	to	O
69	alternately	O
70	spliced	O
71	messenger	O
72	RNAs	O
73	(	O
74	mRNAs	O
75	).	O

1	Supplementary	O
2	Phase	O
3	Contraste	O
4	RSE	O
5	("	O
6	Rapid	O
7	Sequential	O
8	Excitation	O
9	")	O
10	sequences	O
11	were	O
12	carried	O
13	out	O
14	in	O
15	29	O
16	patients	O
17	.	O

1	Diet	O
2	therapy	O
3	with	O
4	soy	O
5	proteins	O
6	for	O
7	chronic	O
8	stomach	O
9	ulcers	O

1	Later	O
2	in	O
3	development	O
4	,	O
5	Tbx6	O
6	expression	O
7	is	O
8	restricted	O
9	to	O
10	presomitic	O
11	,	O
12	paraxial	O
13	mesoderm	O
14	and	O
15	to	O
16	the	O
17	tail	O
18	bud	O
19	,	O
20	which	O
21	replaces	O
22	the	O
23	streak	O
24	as	O
25	the	O
26	source	O
27	of	O
28	mesoderm	O
29	.	O

1	Application	O
2	of	O
3	different	O
4	criteria	O
5	of	O
6	cure	O
7	revealed	O
8	that	O
9	19	O
10	patients	O
11	(	O
12	66	O
13	%)	O
14	had	O
15	basal	O
16	GH	B
17	levels	O
18	below	O
19	5	O
20	ng	O
21	/	O
22	ml	O
23	,	O
24	17	O
25	patients	O
26	(	O
27	59	O
28	%)	O
29	had	O
30	normal	O
31	somatomedin	B
32	-	I
33	C	I
34	values	O
35	,	O
36	16	O
37	patients	O
38	(	O
39	55	O
40	%)	O
41	had	O
42	complete	O
43	GH	B
44	suppression	O
45	(	O
46	less	O
47	than	O
48	1	O
49	ng	O
50	/	O
51	ml	O
52	)	O
53	during	O
54	OGTT	O
55	,	O
56	and	O
57	13	O
58	patients	O
59	(	O
60	45	O
61	%)	O
62	met	O
63	the	O
64	above	O
65	-	O
66	mentioned	O
67	criteria	O
68	with	O
69	disappearance	O
70	of	O
71	the	O
72	paradoxical	O
73	GH	B
74	response	O
75	to	O
76	TRH	B
77	/	I
78	GnRH	I
79	test	O
80	.	O

1	CONCLUSIONS	O
2	:	O
3	These	O
4	results	O
5	show	O
6	that	O
7	once	O
8	daily	O
9	oral	O
10	valganciclovir	O
11	can	O
12	produce	O
13	exposures	O
14	of	O
15	ganciclovir	O
16	(	O
17	AUC24	O
18	)	O
19	exceeding	O
20	those	O
21	attained	O
22	using	O
23	intravenous	O
24	ganciclovir	O
25	10	O
26	mg	O
27	/	O
28	kg	O
29	.	O

1	A	O
2	stretch	O
3	of	O
4	16	O
5	nucleotides	O
6	just	O
7	upstream	O
8	of	O
9	the	O
10	IL	B
11	-	I
12	4RE	O
13	contributed	O
14	to	O
15	IL	B
16	-	I
17	4	O
18	inducibility	O
19	and	O
20	formed	O
21	nucleoprotein	O
22	complexes	O
23	with	O
24	constitutive	O
25	factors	O
26	.	O

1	Dopamine	O
2	neurons	O
3	in	O
4	subjects	O
5	that	O
6	received	O
7	6	O
8	-	O
9	OHDA	O
10	were	O
11	protected	O
12	by	O
13	pre	O
14	-	O
15	treatment	O
16	with	O
17	GBR	O
18	-	O
19	12909	O
20	.	O

1	Human	O
2	AP	B
3	-	I
4	2rep	O
5	repressed	O
6	both	O
7	reporter	O
8	expression	O
9	from	O
10	a	O
11	transiently	O
12	transfected	O
13	AP	B
14	-	I
15	2alpha	I
16	promoter	I
17	and	O
18	the	O
19	endogenous	O
20	AP	B
21	-	I
22	2alpha	I
23	gene	I
24	and	O
25	inversely	O
26	was	O
27	negatively	O
28	regulated	O
29	by	O
30	AP	B
31	-	I
32	2alpha	I
33	.	O

1	In	O
2	the	O
3	unclipped	O
4	group	O
5	arterial	O
6	pressure	O
7	decreased	O
8	50	O
9	mmHg	O
10	to	O
11	normal	O
12	by	O
13	24	O
14	h	O
15	and	O
16	was	O
17	associated	O
18	with	O
19	increased	O
20	diuresis	O
21	and	O
22	a	O
23	small	O
24	decrease	O
25	in	O
26	blood	O
27	volume	O
28	(	O
29	9	O
30	.	O
31	8	O
32	%).	O

1	A	O
2	simple	O
3	analytical	O
4	method	O
5	for	O
6	l	O
7	-	O
8	menthol	O
9	by	O
10	high	O
11	-	O
12	performance	O
13	liquid	O
14	chromatography	O
15	with	O
16	a	O
17	polarized	O
18	photometric	O
19	detector	O
20	was	O
21	established	O
22	.	O

1	The	O
2	coefficient	O
3	of	O
4	determination	O
5	,	O
6	r2	O
7	,	O
8	of	O
9	the	O
10	other	O
11	scores	O
12	ranged	O
13	from	O
14	0	O
15	.	O
16	56	O
17	to	O
18	0	O
19	.	O
20	61	O
21	.	O

1	Each	O
2	trial	O
3	consisted	O
4	of	O
5	light	O
6	and	O
7	buzzer	O
8	for	O
9	five	O
10	seconds	O
11	as	O
12	conditioned	O
13	stimuli	O
14	and	O
15	electric	O
16	shock	O
17	for	O
18	five	O
19	seconds	O
20	as	O
21	an	O
22	unconditioned	O
23	stimulus	O
24	.	O

1	Electromobility	O
2	shift	O
3	and	O
4	cotransfection	O
5	assays	O
6	demonstrated	O
7	that	O
8	HNF1alpha	O
9	,	O
10	but	O
11	not	O
12	HNF4	O
13	,	O
14	bound	O
15	to	O
16	its	O
17	cognate	O
18	site	O
19	and	O
20	transactivated	O
21	G6Pase	O
22	gene	O
23	expression	O
24	.	O

1	Competitive	B
2	reverse	I
3	transcription	I
4	-	I
5	polymerase	I
6	chain	I
7	reaction	O
8	and	O
9	HPLC	O
10	analysis	O
11	showed	O
12	that	O
13	RUSH	O
14	-	O
15	1alpha	O
16	is	O
17	the	O
18	progesterone	O
19	-	O
20	dependent	O
21	splice	O
22	variant	O
23	.	O

1	Greek	O
2	classicism	O
3	in	O
4	living	O
5	structure	O
6	?	O
7	Some	O
8	deductive	O
9	pathways	O
10	in	O
11	animal	O
12	morphology	O
13	.	O

1	Neither	O
2	clone	O
3	encoded	O
4	the	O
5	cognate	O
6	endonuclease	O
7	.	O

1	The	O
2	effective	O
3	and	O
4	low	O
5	toxic	O
6	dose	O
7	schedules	O
8	of	O
9	KW	O
10	-	O
11	2083	O
12	should	O
13	be	O
14	investigated	O
15	further	O
16	.	O

1	The	O
2	sequence	O
3	of	O
4	four	O
5	clones	O
6	was	O
7	sufficient	O
8	to	O
9	construct	O
10	a	O
11	3018	O
12	-	O
13	bp	O
14	BAL	O
15	cDNA	O
16	structure	O
17	.	O

1	Inhibitor	O
2	-	O
3	1	O
4	(	O
5	I	O
6	-	O
7	1	O
8	)	O
9	and	O
10	inhibitor	O
11	-	O
12	2	O
13	(	O
14	I	O
15	-	O
16	2	O
17	)	O
18	selectively	O
19	inhibit	O
20	type	B
21	1	I
22	protein	I
23	serine	I
24	/	I
25	threonine	I
26	phosphatases	I
27	(	O
28	PP1	O
29	).	O

1	Atomic	O
2	absorption	O
3	spectrophotometry	O
4	applied	O
5	to	O
6	bacterially	O
7	expressed	O
8	E1A	B
9	proteins	I
10	revealed	O
11	that	O
12	the	O
13	289	O
14	-	O
15	amino	O
16	acid	O
17	protein	O
18	binds	O
19	one	O
20	zinc	O
21	ion	O
22	,	O
23	whereas	O
24	the	O
25	243	O
26	-	O
27	amino	O
28	acid	O
29	protein	O
30	binds	O
31	no	O
32	zinc	O
33	.	O

1	Biopsies	O
2	of	O
3	the	O
4	jejunal	O
5	mucosa	O
6	have	O
7	shown	O
8	abnormal	O
9	enzyme	O
10	activity	O
11	or	O
12	deficiencies	O
13	in	O
14	transport	O
15	mechanisms	O
16	.	O

1	Here	O
2	we	O
3	report	O
4	the	O
5	full	O
6	-	O
7	length	O
8	coding	O
9	cDNA	O
10	sequence	O
11	of	O
12	the	O
13	mouse	O
14	homologue	O
15	of	O
16	MPP3	O
17	.	O

1	Activation	O
2	of	O
3	PKA	B
4	by	O
5	8	O
6	-	O
7	bromo	O
8	-	O
9	cyclic	O
10	AMP	O
11	or	O
12	forskolin	O
13	,	O
14	and	O
15	inhibition	O
16	of	O
17	PKC	B
18	by	O
19	calphostin	O
20	C	O
21	,	O
22	resulted	O
23	in	O
24	a	O
25	significant	O
26	decrease	O
27	in	O
28	3TP	O
29	activity	O
30	as	O
31	well	O
32	as	O
33	in	O
34	vitro	O
35	ERK	B
36	kinase	I
37	activity	O
38	in	O
39	CRAC	O
40	.	O

1	The	O
2	sequences	O
3	following	O
4	the	O
5	X	O
6	.	O
7	borealis	O
8	oocyte	O
9	and	O
10	somatic	O
11	5S	O
12	genes	O
13	are	O
14	identical	O
15	in	O
16	12	O
17	of	O
18	the	O
19	first	O
20	14	O
21	residues	O
22	and	O
23	contain	O
24	two	O
25	or	O
26	more	O
27	T	O
28	clusters	O
29	,	O
30	as	O
31	does	O
32	the	O
33	corresponding	O
34	region	O
35	of	O
36	X	O
37	.	O
38	laevis	O
39	oocyte	O
40	5S	O
41	DNA	O
42	.	O

1	Visual	O
2	averaged	O
3	evoked	O
4	responses	O
5	and	O
6	platelet	O
7	monoamine	B
8	oxidase	I
9	in	O
10	patients	O
11	suffering	O
12	from	O
13	alcoholism	O
14	.	O

1	Quinone	O
2	-	O
3	binding	O
4	domain	O
5	and	O
6	amino	O
7	acid	O
8	residues	O
9	involved	O
10	in	O
11	quinone	O
12	binding	O
13	.	O

1	Amplification	O
2	and	O
3	overexpression	O
4	of	O
5	the	O
6	c	B
7	-	I
8	erbB	I
9	-	I
10	2	I
11	gene	I
12	in	O
13	21MT	O
14	-	O
15	2	O
16	and	O
17	21MT	O
18	-	O
19	1	O
20	human	O
21	breast	O
22	carcinoma	O
23	cells	O
24	results	O
25	in	O
26	progressively	O
27	elevated	O
28	levels	O
29	of	O
30	constitutively	O
31	tyrosine	O
32	-	O
33	phosphorylated	O
34	p185erbB	O
35	-	O
36	2	O
37	and	O
38	is	O
39	associated	O
40	with	O
41	progressive	O
42	insulin	B
43	-	I
44	like	I
45	growth	I
46	factor	I
47	(	I
48	IGF	I
49	)	O
50	and	O
51	combined	O
52	IGF	B
53	/	I
54	epidermal	I
55	growth	I
56	factor	I
57	(	O
58	EGF	B
59	)	O
60	independence	O
61	in	O
62	culture	O
63	.	O

1	Anti	B
2	-	I
3	NPROSP	I
4	-	I
5	C	I
6	also	O
7	exclusively	O
8	detected	O
9	time	O
10	-	O
11	dependent	O
12	appearances	O
13	of	O
14	5	O
15	-	O
16	10	O
17	-	O
18	kDa	O
19	proSP	O
20	-	O
21	C	O
22	forms	O
23	in	O
24	lamellar	O
25	bodies	O
26	and	O
27	homogenates	O
28	.	O

1	We	O
2	discuss	O
3	these	O
4	results	O
5	in	O
6	terms	O
7	of	O
8	the	O
9	influence	O
10	that	O
11	time	O
12	and	O
13	nutritional	O
14	constraints	O
15	have	O
16	on	O
17	odonate	O
18	development	O
19	patterns	O
20	and	O
21	fitness	O
22	.	O

1	Comparison	O
2	with	O
3	alkaline	B
4	phosphatases	I
5	and	O
6	5	O
7	-	O
8	nucleotidase	O
9	.	O

1	Thrombophlebitis	O
2	and	O
3	pulmonary	O
4	embolism	O
5	in	O
6	congenital	O
7	factor	O
8	XII	O
9	deficiency	O

1	Radionuclide	O
2	study	O
3	and	O
4	endomyocardial	O
5	biopsy	O
6	revealed	O
7	remarkable	O
8	degeneration	O
9	of	O
10	myocardium	O
11	.	O

1	We	O
2	propose	O
3	that	O
4	CTS1	O
5	and	O
6	CTS2	O
7	of	O
8	Ci	O
9	are	O
10	members	O
11	of	O
12	two	O
13	distinct	O
14	classes	O
15	of	O
16	fungal	O
17	chitinases	O
18	,	O
19	an	O
20	observation	O
21	not	O
22	previously	O
23	reported	O
24	for	O
25	a	O
26	single	O
27	fungus	O
28	.	O

1	The	O
2	role	O
3	of	O
4	transport	O
5	by	O
6	sea	O
7	ice	O
8	from	O
9	the	O
10	Kara	O
11	Sea	O
12	into	O
13	the	O
14	Arctic	O
15	Ocean	O
16	was	O
17	assessed	O
18	by	O
19	a	O
20	small	O
21	subgroup	O
22	at	O
23	GEOMAR	O
24	.	O

1	The	O
2	MMA	O
3	,	O
4	DMA	O
5	,	O
6	and	O
7	TMA	O
8	methyltransferases	O
9	are	O
10	not	O
11	homologs	O
12	;	O
13	however	O
14	,	O
15	like	O
16	the	O
17	MMA	B
18	methyltransferase	I
19	gene	I
20	,	O
21	the	O
22	genes	O
23	encoding	O
24	the	O
25	DMA	O
26	and	O
27	TMA	O
28	methyltransferases	O
29	each	O
30	contain	O
31	a	O
32	single	O
33	in	O
34	-	O
35	frame	O
36	amber	O
37	codon	O
38	.	O

1	CONCLUSION	O
2	:	O
3	Although	O
4	quantitative	O
5	and	O
6	qualitative	O
7	criteria	O
8	for	O
9	diagnosing	O
10	fatty	O
11	liver	O
12	on	O
13	helical	O
14	CT	O
15	can	O
16	be	O
17	determined	O
18	,	O
19	they	O
20	are	O
21	protocol	O
22	-	O
23	specific	O
24	.	O

1	Since	O
2	proteins	O
3	containing	O
4	TPR	O
5	elements	O
6	are	O
7	typically	O
8	involved	O
9	in	O
10	multiple	O
11	protein	O
12	-	O
13	protein	O
14	interactions	O
15	,	O
16	we	O
17	suggest	O
18	that	O
19	the	O
20	102kD	O
21	protein	O
22	interacts	O
23	within	O
24	the	O
25	tri	O
26	-	O
27	snRNP	O
28	with	O
29	both	O
30	the	O
31	U5	O
32	and	O
33	U4	B
34	/	I
35	U6	I
36	snRNPs	I
37	,	O
38	thus	O
39	bridging	O
40	the	O
41	two	O
42	particles	O
43	.	O

1	Marrow	O
2	dysplasia	O
3	is	O
4	a	O
5	major	O
6	characteristic	O
7	of	O
8	patients	O
9	with	O
10	myelodysplastic	O
11	syndrome	O
12	(	O
13	MDS	O
14	),	O
15	along	O
16	with	O
17	marrow	O
18	blastosis	O
19	,	O
20	cytopenia	O
21	and	O
22	cytogenetic	O
23	anomalies	O
24	.	O

1	In	O
2	addition	O
3	,	O
4	TRP1	O
5	RI	O
6	Circle	O
7	DNA	O
8	is	O
9	organized	O
10	into	O
11	nucleosomes	O
12	whose	O
13	size	O
14	and	O
15	spacing	O
16	are	O
17	indistinguishable	O
18	from	O
19	that	O
20	of	O
21	bulk	O
22	yeast	O
23	chromatin	O
24	.	O

1	For	O
2	the	O
3	present	O
4	work	O
5	we	O
6	used	O
7	water	O
8	saturated	O
9	with	O
10	a	O
11	50	O
12	/	O
13	50	O
14	mixture	O
15	of	O
16	H2	O
17	and	O
18	O2	O
19	gases	O
20	,	O
21	for	O
22	which	O
23	the	O
24	heat	O
25	defect	O
26	is	O
27	calculated	O
28	to	O
29	be	O
30	-	O
31	2	O
32	.	O
33	1	O
34	%.	O

1	However	O
2	,	O
3	despite	O
4	its	O
5	relationship	O
6	to	O
7	the	O
8	TR	O
9	,	O
10	Rev	B
11	-	I
12	Erb	O
13	bound	O
14	poorly	O
15	to	O
16	TR	B
17	binding	I
18	sites	I
19	.	O

1	Antibiotic	O
2	effect	O
3	of	O
4	the	O
5	mud	O
6	from	O
7	heviz	O

1	Three	O
2	ORFs	O
3	(	O
4	9765orfR002	O
5	,	O
6	9765orfR011	O
7	and	O
8	9765orfR013	O
9	)	O
10	were	O
11	found	O
12	to	O
13	be	O
14	homologous	O
15	with	O
16	Schizosaccharomyces	O
17	pombe	O
18	polyadenylate	O
19	binding	O
20	protein	O
21	,	O
22	Escherichia	O
23	coli	O
24	hypothetical	O
25	38	O
26	.	O
27	1	O
28	-	O
29	kDa	O
30	protein	O
31	in	O
32	the	O
33	BCR	O
34	5	O
35	'	O
36	region	O
37	,	O
38	and	O
39	transcription	O
40	regulatory	O
41	protein	O
42	Swi3	O
43	,	O
44	respectively	O
45	.	O

1	On	O
2	the	O
3	third	O
4	occasion	O
5	water	O
6	(	O
7	W	O
8	)	O
9	was	O
10	ingested	O
11	throughout	O
12	the	O
13	run	O
14	.	O

1	Fowlpox	O
2	virus	O
3	encodes	O
4	nonessential	O
5	homologs	O
6	of	O
7	cellular	O
8	alpha	O
9	-	O
10	SNAP	O
11	,	O
12	PC	B
13	-	I
14	1	I
15	,	O
16	and	O
17	an	O
18	orphan	O
19	human	O
20	homolog	O
21	of	O
22	a	O
23	secreted	O
24	nematode	O
25	protein	O
26	.	O

1	CONCLUSIONS	O
2	:	O
3	EBCT	O
4	technology	O
5	allows	O
6	minimally	O
7	invasive	O
8	evaluation	O
9	of	O
10	intramyocardial	O
11	microcirculatory	O
12	function	O
13	and	O
14	permits	O
15	assessment	O
16	of	O
17	microvascular	O
18	BV	O
19	distribution	O
20	in	O
21	different	O
22	functional	O
23	components	O
24	.	O

1	Next	O
2	,	O
3	to	O
4	identify	O
5	regions	O
6	of	O
7	the	O
8	promoter	O
9	involved	O
10	,	O
11	we	O
12	examined	O
13	a	O
14	series	O
15	of	O
16	tenascin	O
17	-	O
18	C	O
19	promoter	O
20	constructs	O
21	with	O
22	5	O
23	'	O
24	deletions	O
25	and	O
26	showed	O
27	that	O
28	denatured	B
29	collagen	I
30	-	I
31	dependent	I
32	promoter	I
33	activity	O
34	was	O
35	retained	O
36	by	O
37	a	O
38	122	O
39	-	O
40	base	O
41	pair	O
42	element	O
43	,	O
44	located	O
45	-	O
46	43	O
47	to	O
48	-	O
49	165	O
50	bp	O
51	upstream	O
52	of	O
53	the	O
54	RNA	O
55	start	O
56	site	O
57	.	O

1	The	O
2	yeast	O
3	silent	O
4	information	O
5	regulator	O
6	Sir4p	O
7	anchors	O
8	and	O
9	partitions	O
10	plasmids	O
11	.	O

1	The	O
2	PETCO2	O
3	measurement	O
4	during	O
5	precordial	O
6	compression	O
7	predicted	O
8	the	O
9	success	O
10	of	O
11	defibrillation	O
12	with	O
13	return	O
14	of	O
15	spontaneous	O
16	circulation	O
17	.	O

1	Northern	O
2	(	O
3	RNA	O
4	)	O
5	analysis	O
6	demonstrated	O
7	expression	O
8	of	O
9	human	O
10	PI	B
11	3	I
12	-	I
13	kinase	I
14	in	O
15	all	O
16	tissues	O
17	and	O
18	cell	O
19	lines	O
20	tested	O
21	.	O

1	From	O
2	our	O
3	ultrastructural	O
4	and	O
5	biochemical	O
6	studies	O
7	,	O
8	it	O
9	is	O
10	evident	O
11	that	O
12	Type	O
13	II	O
14	pneumocytes	O
15	are	O
16	an	O
17	early	O
18	target	O
19	of	O
20	radiation	O
21	and	O
22	the	O
23	release	O
24	of	O
25	surfactant	O
26	into	O
27	the	O
28	alveolus	O
29	shortly	O
30	after	O
31	exposure	O
32	persists	O
33	for	O
34	days	O
35	and	O
36	weeks	O
37	.	O

1	If	O
2	NCR	O
3	-	O
4	sensitive	O
5	gene	O
6	expression	O
7	occurs	O
8	exclusively	O
9	by	O
10	this	O
11	pathway	O
12	,	O
13	as	O
14	has	O
15	been	O
16	thought	O
17	to	O
18	be	O
19	the	O
20	case	O
21	,	O
22	then	O
23	the	O
24	NCR	O
25	sensitivity	O
26	of	O
27	a	O
28	gene	O
29	'	O
30	s	O
31	expression	O
32	should	O
33	be	O
34	abolished	O
35	by	O
36	a	O
37	ure2	O
38	delta	O
39	mutation	O
40	.	O

1	Circulating	O
2	oxytocin	O
3	in	O
4	male	O
5	guinea	O
6	pigs	O
7	affected	O
8	by	O
9	the	O
10	female	O
11	cohabitation	O
12	and	O
13	reproductive	O
14	condition	O
15	.	O

1	Interestingly	O
2	,	O
3	EGF	B
4	,	O
5	but	O
6	not	O
7	insulin	B
8	,	O
9	stimulated	O
10	tyrosine	O
11	phosphorylation	O
12	of	O
13	c	B
14	-	I
15	cbl	I
16	and	O
17	its	O
18	association	O
19	with	O
20	Crk	B
21	-	I
22	II	I
23	.	O

1	Although	O
2	most	O
3	SFV	O
4	genes	O
5	have	O
6	homologs	O
7	encoded	O
8	by	O
9	other	O
10	Chordopoxvirinae	O
11	,	O
12	the	O
13	SFV	O
14	genome	O
15	lacks	O
16	a	O
17	key	O
18	gene	O
19	required	O
20	for	O
21	the	O
22	production	O
23	of	O
24	extracellular	O
25	enveloped	O
26	virus	O
27	.	O

1	Identification	O
2	of	O
3	an	O
4	enhancer	O
5	and	O
6	an	O
7	alternative	O
8	promoter	O
9	in	O
10	the	O
11	first	O
12	intron	O
13	of	O
14	the	O
15	alpha	B
16	-	I
17	fetoprotein	I
18	gene	I
19	.	O

1	New	O
2	techniques	O
3	for	O
4	the	O
5	mass	O
6	spectrometry	O
7	of	O
8	natural	O
9	products	O
10	.	O

1	The	O
2	cis	O
3	-	O
4	acting	O
5	element	O
6	mediating	O
7	glucocorticoid	O
8	inducibility	O
9	of	O
10	the	O
11	chicken	B
12	glutamine	I
13	synthetase	I
14	gene	I
15	has	O
16	been	O
17	identified	O
18	.	O

1	Eight	O
2	rabbits	O
3	were	O
4	exposed	O
5	to	O
6	0	O
7	.	O
8	7	O
9	+/-	O
10	0	O
11	.	O
12	4	O
13	mg	O
14	/	O
15	m3	O
16	Co2	O
17	+	O
18	as	O
19	CoCl2	O
20	and	O
21	1	O
22	.	O
23	2	O
24	+/-	O
25	0	O
26	.	O
27	7	O
28	mg	O
29	/	O
30	m3	O
31	Cr3	O
32	+	O
33	as	O
34	Cr	O
35	(	O
36	NO3	O
37	)	O
38	3	O
39	(	O
40	group	O
41	Co	O
42	+	O
43	Cr	O
44	),	O
45	eight	O
46	to	O
47	0	O
48	.	O
49	6	O
50	+/-	O
51	0	O
52	.	O
53	5	O
54	mg	O
55	/	O
56	m3	O
57	Co2	O
58	+	O
59	(	O
60	group	O
61	Co	O
62	),	O
63	and	O
64	eight	O
65	to	O
66	filtered	O
67	air	O
68	(	O
69	control	O
70	group	O
71	),	O
72	for	O
73	4	O
74	months	O
75	,	O
76	5	O
77	days	O
78	/	O
79	week	O
80	,	O
81	and	O
82	6	O
83	hr	O
84	/	O
85	day	O
86	.	O

1	Our	O
2	data	O
3	,	O
4	combined	O
5	with	O
6	those	O
7	of	O
8	Hershey	O
9	and	O
10	co	O
11	-	O
12	workers	O
13	,	O
14	suggest	O
15	that	O
16	mammalian	O
17	eIF3	O
18	is	O
19	composed	O
20	of	O
21	at	O
22	least	O
23	10	O
24	subunits	O
25	:	O
26	p170	O
27	,	O
28	p116	O
29	(	O
30	hPrt1	O
31	),	O
32	p110	O
33	,	O
34	p66	O
35	,	O
36	p48	O
37	,	O
38	p47	O
39	,	O
40	p44	O
41	,	O
42	p40	O
43	,	O
44	p36	O
45	,	O
46	and	O
47	p35	O
48	.	O

1	Both	O
2	neural	O
3	and	O
4	hormonal	O
5	pathways	O
6	and	O
7	both	O
8	opiate	O
9	and	O
10	nonopiate	O
11	substances	O
12	play	O
13	roles	O
14	in	O
15	the	O
16	complex	O
17	modulation	O
18	of	O
19	pain	O
20	transmission	O
21	.	O

1	However	O
2	,	O
3	serial	O
4	passages	O
5	of	O
6	fetal	O
7	lamb	O
8	kidney	O
9	(	O
10	FLK	O
11	)	O
12	cells	O
13	,	O
14	which	O
15	are	O
16	sensitive	O
17	to	O
18	infection	O
19	with	O
20	BLV	O
21	,	O
22	after	O
23	transient	O
24	transfection	O
25	revealed	O
26	that	O
27	mutation	O
28	of	O
29	a	O
30	second	O
31	tyrosine	O
32	residue	O
33	in	O
34	the	O
35	N	O
36	-	O
37	terminal	O
38	motif	O
39	completely	O
40	prevented	O
41	the	O
42	propagation	O
43	of	O
44	the	O
45	virus	O
46	.	O

1	Insertional	O
2	inactivation	O
3	of	O
4	sms	O
5	led	O
6	to	O
7	increased	O
8	sensitivity	O
9	to	O
10	the	O
11	alkylating	O
12	agent	O
13	methylmethane	O
14	sulfonate	O
15	,	O
16	but	O
17	not	O
18	to	O
19	a	O
20	requirement	O
21	for	O
22	serine	O
23	or	O
24	other	O
25	metabolites	O
26	.	O

1	BACKGROUND	O
2	:	O
3	Hepatic	O
4	encephalopathy	O
5	is	O
6	a	O
7	neuropsychiatric	O
8	syndrome	O
9	associated	O
10	with	O
11	acute	O
12	liver	O
13	failure	O
14	,	O
15	chronic	O
16	parenchymal	O
17	liver	O
18	disease	O
19	or	O
20	portal	O
21	systemic	O
22	anastomosis	O
23	.	O

1	Transcriptional	O
2	regulation	O
3	of	O
4	the	O
5	yeast	O
6	PHO8	O
7	promoter	O
8	in	O
9	comparison	O
10	to	O
11	the	O
12	coregulated	O
13	PHO5	O
14	promoter	O
15	.	O

1	Two	O
2	distinct	O
3	Salmonella	O
4	fimbrins	O
5	,	O
6	AgfA	O
7	and	O
8	SefA	O
9	,	O
10	comprising	O
11	thin	O
12	aggregative	O
13	fimbriae	O
14	SEF17	O
15	and	O
16	SEF14	O
17	,	O
18	respectively	O
19	,	O
20	were	O
21	each	O
22	genetically	O
23	engineered	O
24	to	O
25	carry	O
26	PT3	O
27	,	O
28	an	O
29	alpha	O
30	-	O
31	helical	O
32	16	O
33	-	O
34	amino	O
35	acid	O
36	Leishmania	O
37	T	O
38	-	O
39	cell	O
40	epitope	O
41	derived	O
42	from	O
43	the	O
44	metalloprotease	O
45	gp63	O
46	.	O

1	By	O
2	contrast	O
3	,	O
4	mTRAP100	O
5	coprecipitates	O
6	in	O
7	vivo	O
8	with	O
9	another	O
10	component	O
11	of	O
12	the	O
13	TRAP	O
14	complex	O
15	(	O
16	TRAP220	O
17	),	O
18	which	O
19	directly	O
20	contacts	O
21	TR	O
22	and	O
23	the	O
24	vitamin	O
25	D	O
26	receptor	O
27	in	O
28	a	O
29	ligand	O
30	-	O
31	dependent	O
32	manner	O
33	.	O

1	Patients	O
2	with	O
3	Parkinson	O
4	'	O
5	s	O
6	disease	O
7	showed	O
8	a	O
9	relatively	O
10	high	O
11	incidence	O
12	to	O
13	psychoses	O
14	during	O
15	drug	O
16	treatment	O
17	(	O
18	51	O
19	.	O
20	47	O
21	%).	O

1	Truncation	O
2	variants	O
3	of	O
4	peptides	O
5	isolated	O
6	from	O
7	MHC	B
8	class	I
9	II	I
10	molecules	I
11	suggest	O
12	sequence	O
13	motifs	O
14	.	O

1	Necrosis	O
2	appears	O
3	6	O
4	h	O
5	after	O
6	TA	O
7	infusion	O
8	,	O
9	being	O
10	5	O
11	.	O
12	77	O
13	%	O
14	in	O
15	extent	O
16	after	O
17	12	O
18	h	O
19	,	O
20	14	O
21	.	O
22	9	O
23	%	O
24	after	O
25	24	O
26	h	O
27	and	O
28	animals	O
29	die	O
30	with	O
31	an	O
32	area	O
33	of	O
34	29	O
35	.	O
36	5	O
37	%	O
38	necrosis	O
39	.	O

1	Family	O
2	planning	O
3	continues	O
4	to	O
5	play	O
6	a	O
7	minor	O
8	role	O
9	,	O
10	and	O
11	only	O
12	25	O
13	.	O
14	3	O
15	per	O
16	cent	O
17	of	O
18	all	O
19	patients	O
20	reviewed	O
21	took	O
22	to	O
23	oral	O
24	contraceptives	O
25	for	O
26	shorter	O
27	or	O
28	longer	O
29	periods	O
30	of	O
31	time	O
32	.	O
33	-	O
34	The	O
35	percentages	O
36	of	O
37	primiparae	O
38	and	O
39	secundiparae	O
40	in	O
41	all	O
42	births	O
43	as	O
44	well	O
45	as	O
46	the	O
47	high	O
48	percentage	O
49	of	O
50	multigravidity	O
51	are	O
52	parameters	O
53	by	O
54	which	O
55	the	O
56	approach	O
57	to	O
58	reproduction	O
59	differs	O
60	substantively	O
61	from	O
62	behaviour	O
63	patterns	O
64	in	O
65	Europe	O
66	.	O

1	This	O
2	cluster	O
3	consisted	O
4	of	O
5	four	O
6	apparently	O
7	unrelated	O
8	ESTs	O
9	and	O
10	two	O
11	genes	O
12	,	O
13	pregnancy	O
14	-	O
15	associated	O
16	plasma	O
17	protein	O
18	-	O
19	A	O
20	(	O
21	PAPP	O
22	-	O
23	A	O
24	)	O
25	and	O
26	a	O
27	novel	O
28	gene	O
29	(	O
30	tentatively	O
31	named	O
32	EST	O
33	-	O
34	YD1	O
35	).	O

1	Skn	B
2	-	I
3	1a	I
4	lacking	O
5	the	O
6	C	O
7	-	O
8	terminal	O
9	region	O
10	completely	O
11	lost	O
12	transactivation	O
13	ability	O
14	,	O
15	irrespective	O
16	of	O
17	the	O
18	promoter	O
19	tested	O
20	,	O
21	and	O
22	was	O
23	able	O
24	to	O
25	block	O
26	transactivation	O
27	by	O
28	normal	O
29	Skn	B
30	-	I
31	1a	I
32	in	O
33	competition	O
34	assays	O
35	.	O

1	Respiratory	O
2	adaptation	O
3	to	O
4	chronic	O
5	hypoxia	O
6	in	O
7	newborn	O
8	rats	O
9	.	O

1	In	O
2	addition	O
3	,	O
4	marked	O
5	hypertension	O
6	accompanied	O
7	this	O
8	disorder	O
9	and	O
10	all	O
11	abnormalities	O
12	,	O
13	including	O
14	the	O
15	hypertension	O
16	,	O
17	responded	O
18	to	O
19	1	O
20	-	O
21	desamino	O
22	-	O
23	8	O
24	-	O
25	D	O
26	-	O
27	arginine	O
28	vasopressin	O
29	therapy	O
30	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	its	O
6	bZIP	O
7	structural	O
8	homology	O
9	,	O
10	meq	O
11	is	O
12	perhaps	O
13	the	O
14	only	O
15	member	O
16	of	O
17	the	O
18	jun	B
19	-	I
20	fos	I
21	gene	I
22	family	I
23	completely	O
24	viral	O
25	in	O
26	origin	O
27	.	O

1	Among	O
2	953	O
3	infants	O
4	in	O
5	22	O
6	neonatal	O
7	care	O
8	units	O
9	studied	O
10	,	O
11	23	O
12	%	O
13	(	O
14	median	O
15	value	O
16	,	O
17	range	O
18	0	O
19	-	O
20	78	O
21	)	O
22	were	O
23	found	O
24	to	O
25	be	O
26	faecally	O
27	colonized	O
28	with	O
29	one	O
30	of	O
31	21	O
32	distinct	O
33	nosocomial	O
34	strains	O
35	of	O
36	Escherichia	O
37	coli	O
38	,	O
39	Klebsiella	O
40	or	O
41	Enterobacter	O
42	spp	O
43	.	O

1	Molecular	O
2	and	O
3	genetic	O
4	analysis	O
5	of	O
6	the	O
7	yeast	O
8	early	O
9	meiotic	O
10	recombination	O
11	genes	O
12	REC102	O
13	and	O
14	REC107	O
15	/	O
16	MER2	O
17	.	O

1	Clin	O
2	.	O

1	Abdominal	O
2	tumors	O
3	in	O
4	childhood	O
5	.	O

1	RNAs	O
2	are	O
3	not	O
4	only	O
5	essential	O
6	components	O
7	of	O
8	both	O
9	ribosomal	O
10	subunits	O
11	but	O
12	also	O
13	transiently	O
14	interacting	O
15	factors	O
16	during	O
17	particle	O
18	formation	O
19	.	O

1	Botulinum	O
2	toxin	O
3	A	O
4	in	O
5	the	O
6	treatment	O
7	of	O
8	hemiplegic	O
9	spastic	O
10	foot	O
11	drop	O
12	--	O
13	clinical	O
14	and	O
15	functional	O
16	outcomes	O
17	.	O

1	In	O
2	the	O
3	present	O
4	experiments	O
5	,	O
6	we	O
7	investigate	O
8	the	O
9	role	O
10	played	O
11	by	O
12	the	O
13	temporal	O
14	pattern	O
15	of	O
16	neural	O
17	activity	O
18	during	O
19	the	O
20	ontogeny	O
21	of	O
22	frequency	O
23	tuning	O
24	in	O
25	the	O
26	mouse	O
27	central	O
28	auditory	O
29	system	O
30	.	O

1	In	O
2	contrast	O
3	to	O
4	T	O
5	cells	O
6	,	O
7	in	O
8	fibroblasts	O
9	PILOT	O
10	gene	O
11	expression	O
12	requires	O
13	only	O
14	one	O
15	signal	O
16	(	O
17	PMA	O
18	)	O
19	and	O
20	is	O
21	not	O
22	affected	O
23	by	O
24	CyA	O
25	.	O

1	The	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	calcium	O
7	antagonist	O
8	,	O
9	diltiazem	O
10	,	O
11	may	O
12	modify	O
13	the	O
14	effects	O
15	of	O
16	isoflurane	O
17	on	O
18	myocardial	O
19	function	O
20	.	O

1	N	O
2	-	O
3	Substituted	O
4	trimethylsilylcarbamates	O
5	were	O
6	tested	O
7	as	O
8	derivatizing	O
9	reagents	O
10	for	O
11	gas	O
12	chromatographic	O
13	analysis	O
14	.	O

1	BACKGROUND	O
2	:	O
3	Left	O
4	ventricular	O
5	hypertrophy	O
6	is	O
7	a	O
8	heterogeneous	O
9	disorder	O
10	with	O
11	distinct	O
12	morphologies	O
13	.	O

1	The	O
2	swa2	O
3	-	O
4	1	O
5	allele	O
6	recovered	O
7	from	O
8	the	O
9	original	O
10	screen	O
11	carries	O
12	a	O
13	point	O
14	mutation	O
15	in	O
16	its	O
17	tetratricopeptide	O
18	repeat	O
19	(	O
20	TPR	O
21	)	O
22	domain	O
23	,	O
24	a	O
25	motif	O
26	not	O
27	found	O
28	in	O
29	auxilin	O
30	but	O
31	known	O
32	in	O
33	other	O
34	proteins	O
35	to	O
36	mediate	O
37	interaction	O
38	with	O
39	heat	O
40	-	O
41	shock	O
42	proteins	O
43	.	O

1	Typical	O
2	and	O
3	atypical	O
4	clinical	O
5	features	O
6	of	O
7	this	O
8	lacrimal	O
9	sac	O
10	cyst	O
11	are	O
12	emphasized	O
13	.	O

1	Human	O
2	ZFM1	O
3	protein	O
4	is	O
5	a	O
6	transcriptional	O
7	repressor	O
8	that	O
9	interacts	O
10	with	O
11	the	O
12	transcription	O
13	activation	O
14	domain	O
15	of	O
16	stage	O
17	-	O
18	specific	O
19	activator	O
20	protein	O
21	.	O

1	The	O
2	effects	O
3	of	O
4	several	O
5	opioid	O
6	agonists	O
7	and	O
8	the	O
9	opioid	O
10	antagonist	O
11	naloxone	O
12	were	O
13	examined	O
14	in	O
15	rats	O
16	responding	O
17	under	O
18	a	O
19	fixed	O
20	-	O
21	consecutive	O
22	-	O
23	number	O
24	(	O
25	FCN	O
26	)	O
27	schedule	O
28	.	O

1	INTERVENTIONS	O
2	:	O
3	Study	O
4	patients	O
5	were	O
6	randomly	O
7	divided	O
8	into	O
9	four	O
10	parallel	O
11	groups	O
12	to	O
13	receive	O
14	either	O
15	terbinafine	O
16	250	O
17	mg	O
18	a	O
19	day	O
20	for	O
21	12	O
22	or	O
23	16	O
24	weeks	O
25	(	O
26	groups	O
27	T12	O
28	and	O
29	T16	O
30	)	O
31	or	O
32	itraconazole	O
33	400	O
34	mg	O
35	a	O
36	day	O
37	for	O
38	1	O
39	week	O
40	in	O
41	every	O
42	4	O
43	weeks	O
44	for	O
45	12	O
46	or	O
47	16	O
48	weeks	O
49	(	O
50	groups	O
51	I3	O
52	and	O
53	I4	O
54	).	O

1	Phd	O
2	antibody	O
3	-	O
4	immunoreactive	O
5	peptides	O
6	are	O
7	seen	O
8	in	O
9	light	O
10	-	O
11	adapted	O
12	mouse	O
13	retinal	O
14	cytosolic	O
15	and	O
16	nuclear	O
17	extracts	O
18	.	O

1	We	O
2	show	O
3	that	O
4	stabilization	O
5	of	O
6	the	O
7	hairpin	O
8	reduced	O
9	the	O
10	amount	O
11	of	O
12	tRNA	O
13	primer	O
14	that	O
15	is	O
16	annealed	O
17	to	O
18	the	O
19	PBS	O
20	.	O

1	HCV	O
2	infection	O
3	acquired	O
4	during	O
5	or	O
6	after	O
7	BMT	O
8	caused	O
9	only	O
10	mild	O
11	acute	O
12	hepatitis	O
13	C	O
14	,	O
15	which	O
16	progressed	O
17	to	O
18	chronic	O
19	hepatitis	O
20	C	O
21	in	O
22	one	O
23	patient	O
24	surviving	O
25	10	O
26	years	O
27	after	O
28	BMT	O
29	.	O

1	Plasma	O
2	was	O
3	tested	O
4	before	O
5	and	O
6	after	O
7	(	O
8	14	O
9	+/-	O
10	7	O
11	.	O
12	5	O
13	[	O
14	SD	O
15	]	O
16	days	O
17	)	O
18	surgery	O
19	for	O
20	IgG	B
21	antibodies	I
22	to	O
23	the	O
24	complex	O
25	of	O
26	heparin	O
27	/	O
28	platelet	O
29	factor	O
30	4	O
31	,	O
32	using	O
33	a	O
34	standardized	O
35	,	O
36	validated	O
37	enzyme	O
38	-	O
39	linked	O
40	immunosorbent	O
41	assay	O
42	(	O
43	ELISA	O
44	).	O

1	In	O
2	humans	O
3	,	O
4	four	O
5	AMP	O
6	deaminase	O
7	variants	O
8	,	O
9	termed	O
10	M	O
11	(	O
12	muscle	O
13	),	O
14	L	O
15	(	O
16	liver	O
17	),	O
18	E1	O
19	,	O
20	and	O
21	E2	O
22	(	O
23	erythrocyte	O
24	)	O
25	can	O
26	be	O
27	distinguished	O
28	by	O
29	a	O
30	variety	O
31	of	O
32	biochemical	O
33	and	O
34	immunological	O
35	criteria	O
36	.	O

1	Lysine	B
2	-	I
3	ketoglutarate	I
4	reductase	I
5	and	I
6	saccharopine	I
7	dehydrogenase	I
8	from	O
9	Arabidopsis	O
10	thaliana	O
11	:	O
12	nucleotide	O
13	sequence	O
14	and	O
15	characterization	O
16	.	O

1	Cheung	O
2	and	O
3	S	O
4	.	O

1	Radioligand	O
2	binding	O
3	was	O
4	indistinguishable	O
5	for	O
6	both	O
7	transiently	O
8	expressed	O
9	constructs	O
10	.	O

1	Organ	O
2	transplantation	O
3	in	O
4	Denmark	O
5	.	O

1	The	O
2	linear	O
3	plasmid	O
4	pCLU1	O
5	from	O
6	the	O
7	yeast	O
8	Kluyveromyces	O
9	lactis	O
10	normally	O
11	replicates	O
12	in	O
13	the	O
14	cytoplasm	O
15	,	O
16	with	O
17	the	O
18	aid	O
19	of	O
20	the	O
21	helper	O
22	linear	O
23	plasmid	O
24	pGKL2	O
25	,	O
26	using	O
27	terminal	O
28	protein	O
29	(	O
30	TP	O
31	)	O
32	as	O
33	a	O
34	primer	O
35	.	O

1	Differentiating	O
2	among	O
3	renal	O
4	stones	O
5	.	O

1	Examination	O
2	of	O
3	the	O
4	immediate	O
5	sequence	O
6	5	O
7	'	O
8	to	O
9	the	O
10	mRNA	O
11	start	O
12	site	O
13	reveals	O
14	no	O
15	TATA	O
16	box	O
17	and	O
18	multiple	O
19	known	O
20	enhancer	O
21	sequences	O
22	.	O

1	i	O
2	.	O

1	We	O
2	specially	O
3	devised	O
4	3	O
5	types	O
6	of	O
7	turbo	O
8	pumps	O
9	,	O
10	a	O
11	centrifugal	O
12	pump	O
13	(	O
14	CFP	O
15	),	O
16	a	O
17	mixed	O
18	flow	O
19	pump	O
20	(	O
21	MFP	O
22	),	O
23	and	O
24	an	O
25	axial	O
26	flow	O
27	pump	O
28	(	O
29	AFP	O
30	),	O
31	and	O
32	analyzed	O
33	their	O
34	in	O
35	vitro	O
36	performance	O
37	.	O

1	Pneumonia	O
2	in	O
3	children	O

1	Histological	O
2	slides	O
3	of	O
4	one	O
5	biopsy	O
6	of	O
7	each	O
8	patient	O
9	(	O
10	formalin	O
11	-	O
12	fixed	O
13	and	O
14	paraffin	O
15	-	O
16	embedded	O
17	)	O
18	were	O
19	stained	O
20	with	O
21	a	O
22	Modified	O
23	Giemsa	O
24	(	O
25	MG	O
26	),	O
27	the	O
28	Warthin	O
29	-	O
30	Starry	O
31	(	O
32	WS	O
33	),	O
34	and	O
35	an	O
36	immunohistochemical	O
37	method	O
38	(	O
39	IMM	O
40	)	O
41	using	O
42	purified	O
43	polyclonal	O
44	H	O
45	.	O
46	pylori	O
47	antiserum	O
48	(	O
49	DAKO	O
50	B471	O
51	).	O

1	Acute	O
2	decrease	O
3	in	O
4	body	O
5	temperature	O
6	(	O
7	TB	O
8	)	O
9	lowered	O
10	PaCO2	O
11	(	O
12	32	O
13	.	O
14	5	O
15	to	O
16	14	O
17	.	O
18	5	O
19	mmHg	O
20	)	O
21	and	O
22	[	O
23	HCO3	O
24	-]	O
25	a	O
26	(	O
27	24	O
28	.	O
29	20	O
30	mEq	O
31	/	O
32	L	O
33	to	O
34	17	O
35	.	O
36	56	O
37	mEq	O
38	/	O
39	L	O
40	),	O
41	increased	O
42	pHa	O
43	(	O
44	7	O
45	.	O
46	481	O
47	to	O
48	7	O
49	.	O
50	608	O
51	)	O
52	and	O
53	diminished	O
54	the	O
55	[	O
56	OH	O
57	-]/[	O
58	H	O
59	+]	O
60	ratio	O
61	,	O
62	but	O
63	had	O
64	no	O
65	significant	O
66	effect	O
67	on	O
68	[	O
69	SID	O
70	]	O
71	or	O
72	[	O
73	Atot	O
74	],	O
75	although	O
76	both	O
77	total	O
78	phosphorus	O
79	[	O
80	PT	O
81	]	O
82	and	O
83	inorganic	O
84	phosphate	O
85	[	O
86	Pi	O
87	]	O
88	increased	O
89	.	O

1	The	O
2	sample	O
3	includes	O
4	all	O
5	the	O
6	HIV	O
7	-	O
8	infected	O
9	-	O
10	patients	O
11	continuously	O
12	referred	O
13	to	O
14	the	O
15	Outpatient	O
16	Service	O
17	of	O
18	the	O
19	Infectious	O
20	Diseases	O
21	dept	O
22	.	O
23	of	O
24	Bologna	O
25	'	O
26	s	O
27	"	O
28	Ospedale	O
29	Maggiore	O
30	"	O
31	General	O
32	Hospital	O
33	during	O
34	some	O
35	five	O
36	days	O
37	(	O
38	19	O
39	-	O
40	23rd	O
41	,	O
42	July	O
43	1993	O
44	).	O

1	A	O
2	large	O
3	deletion	O
4	in	O
5	the	O
6	CTD	O
7	-	O
8	binding	O
9	motif	O
10	blocks	O
11	down	O
12	-	O
13	regulation	O
14	but	O
15	does	O
16	not	O
17	affect	O
18	the	O
19	essential	O
20	function	O
21	of	O
22	Nrd1	O
23	.	O

1	These	O
2	lesions	O
3	may	O
4	be	O
5	treated	O
6	by	O
7	propranolol	O
8	or	O
9	phentolamine	O
10	.	O

1	Occupational	O
2	asthma	O
3	and	O
4	rhinoconjunctivitis	O
5	from	O
6	inhalation	O
7	of	O
8	crystalline	O
9	bovine	O
10	serum	B
11	albumin	I
12	powder	I
13	.	O

1	Mechanism	O
2	of	O
3	enhancement	O
4	of	O
5	DNA	O
6	expression	O
7	consequent	O
8	to	O
9	cointernalization	O
10	of	O
11	a	O
12	replication	O
13	-	O
14	deficient	O
15	adenovirus	O
16	and	O
17	unmodified	O
18	plasmid	O
19	DNA	O
20	.	O

1	Six	O
2	distinct	O
3	Ets	B
4	mRNAs	I
5	were	O
6	identified	O
7	:	O
8	Ets2	O
9	,	O
10	Fli1	O
11	,	O
12	GABPalpha	O
13	,	O
14	SAP1	O
15	,	O
16	Elk1	O
17	,	O
18	and	O
19	PE1	O
20	.	O

1	These	O
2	observations	O
3	establish	O
4	that	O
5	RsmC	O
6	negatively	O
7	regulates	O
8	rsmB	O
9	transcription	O
10	but	O
11	positively	O
12	affects	O
13	RsmA	O
14	production	O
15	.	O

1	In	O
2	that	O
3	case	O
4	,	O
5	the	O
6	ratio	O
7	of	O
8	brush	O
9	abrasion	O
10	was	O
11	0	O
12	.	O
13	268	O
14	,	O
15	compressive	O
16	and	O
17	transverse	O
18	strength	O
19	,	O
20	124	O
21	.	O
22	3	O
23	and	O
24	86	O
25	.	O
26	3	O
27	MPa	O
28	respectively	O
29	,	O
30	hardness	O
31	,	O
32	43	O
33	.	O
34	2	O
35	Hk	O
36	,	O
37	water	O
38	absorption	O
39	14	O
40	.	O
41	2	O
42	micrograms	O
43	/	O
44	mm3	O
45	and	O
46	thermal	O
47	expansion	O
48	coefficient	O
49	,	O
50	47	O
51	.	O
52	4	O
53	x	O
54	10	O
55	(-	O
56	6	O
57	)/	O
58	degrees	O
59	C	O
60	.	O

1	In	O
2	situ	O
3	copper	O
4	-	O
5	phenanthroline	O
6	footprinting	O
7	of	O
8	individual	O
9	gel	O
10	shift	O
11	assembly	O
12	intermediates	O
13	shows	O
14	that	O
15	on	O
16	the	O
17	302	O
18	-	O
19	nucleotide	O
20	G4oric	O
21	,	O
22	the	O
23	first	O
24	two	O
25	SSB	O
26	tetramers	O
27	assemble	O
28	at	O
29	random	O
30	,	O
31	but	O
32	the	O
33	addition	O
34	of	O
35	more	O
36	SSB	O
37	tetramers	O
38	results	O
39	in	O
40	formation	O
41	of	O
42	a	O
43	unique	O
44	structure	O
45	.	O

1	Hippocampal	O
2	stimulation	O
3	overlapping	O
4	conditioned	O
5	stimulus	O
6	preexposure	O
7	produced	O
8	attenuation	O
9	of	O
10	latent	O
11	inhibition	O
12	,	O
13	as	O
14	did	O
15	stimulation	O
16	presented	O
17	during	O
18	conditioning	O
19	after	O
20	preexposure	O
21	.	O

1	The	O
2	authors	O
3	report	O
4	the	O
5	results	O
6	of	O
7	a	O
8	series	O
9	of	O
10	toxicological	O
11	tests	O
12	conducted	O
13	on	O
14	plastic	O
15	materials	O
16	(	O
17	polyethylene	O
18	)	O
19	activated	O
20	with	O
21	tetraphenylbutadiene	O
22	(	O
23	TPB	O
24	)	O
25	an	O
26	additive	O
27	recently	O
28	proposed	O
29	as	O
30	a	O
31	sensitizer	O
32	capable	O
33	of	O
34	photodegrading	O
35	plastic	O
36	materials	O
37	.	O

1	The	O
2	radiation	O
3	burden	O
4	associated	O
5	with	O
6	the	O
7	majority	O
8	of	O
9	examinations	O
10	in	O
11	nuclear	O
12	medicine	O
13	expressed	O
14	as	O
15	the	O
16	effective	O
17	dose	O
18	is	O
19	comparable	O
20	with	O
21	the	O
22	radiation	O
23	burden	O
24	of	O
25	radiodiagnostic	O
26	examinations	O
27	,	O
28	only	O
29	after	O
30	administration	O
31	of	O
32	preparations	O
33	with	O
34	131I	O
35	,	O
36	201Tl	O
37	,	O
38	67Ga	O
39	and	O
40	111In	O
41	it	O
42	is	O
43	markedly	O
44	higher	O
45	.	O

1	Drug	O
2	and	O
3	personnel	O
4	costs	O
5	were	O
6	reduced	O
7	when	O
8	batch	O
9	manufacturing	O
10	with	O
11	40	O
12	-	O
13	mL	O
14	multidose	O
15	vials	O
16	was	O
17	compared	O
18	with	O
19	extemporaneous	O
20	compounding	O
21	with	O
22	unit	O
23	-	O
24	dose	O
25	vials	O
26	.	O

1	In	O
2	17	O
3	patients	O
4	with	O
5	deletions	O
6	,	O
7	the	O
8	parental	O
9	origin	O
10	of	O
11	deletion	O
12	was	O
13	determined	O
14	.	O

1	The	O
2	apparent	O
3	Kd	O
4	of	O
5	the	O
6	MetRS	O
7	/	O
8	CAU	O
9	operator	O
10	complex	O
11	is	O
12	one	O
13	order	O
14	magnitude	O
15	higher	O
16	than	O
17	that	O
18	of	O
19	the	O
20	ThrRS	O
21	/	O
22	CGU	O
23	operator	O
24	complex	O
25	.	O

1	In	O
2	a	O
3	third	O
4	experiment	O
5	,	O
6	crossover	O
7	AM	O
8	between	O
9	dissimilar	O
10	textures	O
11	was	O
12	investigated	O
13	,	O
14	and	O
15	it	O
16	was	O
17	found	O
18	that	O
19	the	O
20	more	O
21	salient	O
22	textures	O
23	carried	O
24	the	O
25	AM	O
26	.	O

1	An	O
2	unexpected	O
3	finding	O
4	was	O
5	the	O
6	presence	O
7	at	O
8	position	O
9	-	O
10	403	O
11	to	O
12	-	O
13	385	O
14	of	O
15	a	O
16	putative	O
17	dioxin	O
18	responsive	O
19	element	O
20	,	O
21	a	O
22	sequence	O
23	found	O
24	to	O
25	be	O
26	responsible	O
27	for	O
28	the	O
29	induction	O
30	of	O
31	transcription	O
32	of	O
33	the	O
34	cytochrome	B
35	P450IA1	I
36	gene	I
37	(	O
38	CYPIA1	O
39	)	O
40	and	O
41	other	O
42	genes	O
43	involved	O
44	in	O
45	detoxification	O
46	/	O
47	activation	O
48	of	O
49	polycyclic	O
50	aromatic	O
51	hydrocarbons	O
52	.	O

1	Kodak	O
2	XV	O
3	-	O
4	2	O
5	film	O
6	is	O
7	wrapped	O
8	around	O
9	a	O
10	cylindrical	O
11	water	O
12	-	O
13	filled	O
14	phantom	O
15	and	O
16	the	O
17	dose	O
18	distribution	O
19	is	O
20	recorded	O
21	.	O

1	The	O
2	results	O
3	supported	O
4	the	O
5	therapeutic	O
6	principle	O
7	of	O
8	TCM	O
9	:	O
10	Treating	O
11	patients	O
12	according	O
13	to	O
14	their	O
15	pathophysiological	O
16	patterns	O
17	.	O

1	CONCLUSIONS	O
2	:	O
3	There	O
4	is	O
5	a	O
6	relation	O
7	in	O
8	the	O
9	topography	O
10	of	O
11	some	O
12	visual	O
13	field	O
14	areas	O
15	assessed	O
16	by	O
17	SWAP	O
18	and	O
19	the	O
20	inferotemporal	O
21	neuroretinal	O
22	rim	O
23	area	O
24	,	O
25	which	O
26	may	O
27	play	O
28	a	O
29	role	O
30	in	O
31	the	O
32	diagnosis	O
33	and	O
34	follow	O
35	-	O
36	up	O
37	of	O
38	suspected	O
39	glaucoma	O
40	.	O

1	The	O
2	GRE	O
3	at	O
4	nucleotide	O
5	7640	O
6	is	O
7	a	O
8	composite	O
9	GRE	O
10	(	O
11	cGRE	O
12	)	O
13	containing	O
14	an	O
15	overlapping	O
16	activator	O
17	protein	O
18	-	O
19	1	O
20	(	O
21	AP	B
22	-	I
23	1	I
24	)	O
25	motif	O
26	for	O
27	the	O
28	c	B
29	-	I
30	jun	I
31	homodimer	I
32	and	O
33	c	B
34	-	I
35	jun	I
36	/	I
37	c	I
38	-	I
39	fos	I
40	heterodimer	O
41	.	O

1	These	O
2	tumors	O
3	were	O
4	classified	O
5	into	O
6	three	O
7	broad	O
8	groups	O
9	:	O
10	I	O
11	,	O
12	cystadenoma	O
13	;	O
14	II	O
15	,	O
16	cystadenocarcinoma	O
17	;	O
18	and	O
19	III	O
20	,	O
21	adenocarcinoma	O
22	with	O
23	mucin	O
24	production	O
25	or	O
26	an	O
27	associated	O
28	cyst	O
29	.	O

1	To	O
2	assess	O
3	the	O
4	ability	O
5	of	O
6	the	O
7	atria	O
8	to	O
9	maintain	O
10	elevated	O
11	plasma	O
12	concentrations	O
13	of	O
14	atrial	O
15	natriuretic	O
16	peptide	O
17	(	O
18	ANP	O
19	),	O
20	the	O
21	temporal	O
22	changes	O
23	in	O
24	plasma	O
25	ANP	O
26	concentrations	O
27	were	O
28	studied	O
29	in	O
30	seven	O
31	chloralose	O
32	-	O
33	anaesthetized	O
34	dogs	O
35	during	O
36	4	O
37	h	O
38	of	O
39	sustained	O
40	rapid	O
41	cardiac	O
42	pacing	O
43	.	O

1	A	O
2	correlation	O
3	coefficient	O
4	was	O
5	used	O
6	for	O
7	assessing	O
8	the	O
9	similarity	O
10	of	O
11	each	O
12	map	O
13	pattern	O
14	with	O
15	the	O
16	normal	O
17	mean	O
18	IQRST	O
19	map	O
20	.	O

1	Acad	O
2	.	O

1	Eighty	O
2	patients	O
3	presenting	O
4	to	O
5	HGGM	O
6	with	O
7	non	O
8	-	O
9	Hodgkin	O
10	'	O
11	s	O
12	lymphomas	O
13	between	O
14	1962	O
15	and	O
16	1986	O
17	,	O
18	were	O
19	reviewed	O
20	.	O

1	Restarting	O
2	time	O
3	was	O
4	not	O
5	affected	O
6	by	O
7	magnesium	O
8	cardioplegia	O
9	.	O

1	The	O
2	HMG	B
3	CoA	I
4	reductase	I
5	inhibitors	O
6	are	O
7	the	O
8	most	O
9	effective	O
10	cholesterol	O
11	-	O
12	lowering	O
13	agents	O
14	currently	O
15	available	O
16	.	O

1	The	O
2	mean	O
3	day	O
4	of	O
5	diagnosis	O
6	of	O
7	periventricular	O
8	echodensities	O
9	was	O
10	3	O
11	+/-	O
12	2	O
13	days	O
14	(	O
15	range	O
16	1	O
17	-	O
18	11	O
19	days	O
20	),	O
21	and	O
22	of	O
23	cystic	O
24	PVL	O
25	21	O
26	+/-	O
27	8	O
28	days	O
29	(	O
30	range	O
31	2	O
32	-	O
33	47	O
34	days	O
35	).	O

1	These	O
2	results	O
3	provide	O
4	evidence	O
5	of	O
6	a	O
7	bypass	O
8	of	O
9	p53	B
10	-	I
11	induced	O
12	Waf1	B
13	/	I
14	Cip1	I
15	-	I
16	mediated	O
17	cell	O
18	cycle	O
19	regulatory	O
20	pathways	O
21	by	O
22	a	O
23	member	O
24	of	O
25	the	O
26	myb	B
27	oncogene	I
28	family	I
29	.	O

1	Patients	O
2	received	O
3	either	O
4	diltiazem	O
5	CD	O
6	180	O
7	mg	O
8	or	O
9	placebo	O
10	once	O
11	/	O
12	day	O
13	in	O
14	combination	O
15	with	O
16	existing	O
17	antianginal	O
18	therapy	O
19	.	O

1	Metformin	O
2	plasma	O
3	concentrations	O
4	remained	O
5	unchanged	O
6	except	O
7	for	O
8	patients	O
9	transferred	O
10	from	O
11	1	O
12	.	O
13	5	O
14	to	O
15	2	O
16	.	O
17	0	O
18	g	O
19	daily	O
20	to	O
21	850	O
22	mg	O
23	twice	O
24	daily	O
25	;	O
26	in	O
27	these	O
28	patients	O
29	plasma	O
30	concentrations	O
31	increased	O
32	from	O
33	1	O
34	.	O
35	83	O
36	+/-	O
37	0	O
38	.	O
39	87	O
40	to	O
41	2	O
42	.	O
43	50	O
44	+/-	O
45	0	O
46	.	O
47	89	O
48	micrograms	O
49	/	O
50	l	O
51	(	O
52	p	O
53	less	O
54	than	O
55	0	O
56	.	O
57	01	O
58	).	O

1	The	O
2	concentrations	O
3	of	O
4	apo	B
5	A	I
6	-	I
7	I	I
8	and	O
9	apo	B
10	A	I
11	-	I
12	II	I
13	of	O
14	abstainers	O
15	decreased	O
16	significantly	O
17	compared	O
18	with	O
19	the	O
20	corresponding	O
21	changes	O
22	in	O
23	controls	O
24	.	O

1	On	O
2	the	O
3	basis	O
4	of	O
5	the	O
6	mechanism	O
7	of	O
8	action	O
9	,	O
10	two	O
11	groups	O
12	of	O
13	inodilators	O
14	are	O
15	distinguished	O
16	,	O
17	the	O
18	phosphodiesterase	O
19	inhibitors	O
20	and	O
21	the	O
22	dopaminergic	O
23	agents	O
24	.	O

1	These	O
2	mutations	O
3	are	O
4	localized	O
5	in	O
6	the	O
7	same	O
8	region	O
9	where	O
10	the	O
11	HSV	O
12	transactivator	O
13	VP16	B
14	binds	O
15	,	O
16	but	O
17	did	O
18	not	O
19	coincide	O
20	with	O
21	the	O
22	VP16	B
23	contacts	O
24	.	O

1	When	O
2	cotransfected	O
3	in	O
4	fibroblasts	O
5	with	O
6	a	O
7	C	B
8	/	I
9	EBP	I
10	alpha	I
11	expression	O
12	vector	O
13	,	O
14	reporter	O
15	gene	O
16	expression	O
17	increased	O
18	3	O
19	-	O
20	fold	O
21	only	O
22	in	O
23	the	O
24	wild	O
25	-	O
26	type	O
27	constructs	O
28	.	O

1	UDP	B
2	-	I
3	GlcNAc	I
4	:	I
5	alpha	I
6	-	I
7	6	I
8	-	I
9	D	I
10	-	I
11	mannoside	I
12	beta	I
13	-	I
14	1	I
15	,	I
16	2	I
17	-	I
18	N	I
19	-	I
20	acetylglucosaminyltransferase	I
21	II	I
22	(	O
23	GnT	O
24	II	O
25	;	O
26	EC	O
27	2	O
28	.	O
29	4	O
30	.	O
31	1	O
32	.	O
33	143	O
34	)	O
35	is	O
36	essential	O
37	for	O
38	the	O
39	normal	O
40	assembly	O
41	of	O
42	complex	O
43	Asn	O
44	-	O
45	linked	O
46	glycans	O
47	.	O

1	The	O
2	induced	O
3	respiratory	O
4	burst	O
5	was	O
6	investigated	O
7	by	O
8	the	O
9	intracellular	O
10	oxidative	O
11	transformation	O
12	of	O
13	dihydrorhodamine	O
14	123	O
15	to	O
16	the	O
17	fluorescent	O
18	dye	O
19	rhodamine	O
20	123	O
21	via	O
22	flow	O
23	cytometry	O
24	.	O

1	During	O
2	the	O
3	past	O
4	decade	O
5	,	O
6	different	O
7	types	O
8	of	O
9	endogenous	O
10	retroviral	O
11	sequences	O
12	have	O
13	been	O
14	defined	O
15	in	O
16	the	O
17	human	O
18	genome	O
19	usually	O
20	by	O
21	low	O
22	stringency	O
23	hybridization	O
24	employing	O
25	DNA	O
26	probes	O
27	of	O
28	evolutionary	O
29	conserved	O
30	animal	O
31	retrovirus	O
32	genes	O
33	.	O

1	Furthermore	O
2	,	O
3	bone	O
4	marrow	O
5	-	O
6	derived	O
7	macrophages	O
8	from	O
9	LAT	O
10	-	O
11	deficient	O
12	mice	O
13	displayed	O
14	reduced	O
15	phagocytic	O
16	efficiency	O
17	in	O
18	comparison	O
19	to	O
20	the	O
21	macrophages	O
22	from	O
23	wild	O
24	-	O
25	type	O
26	mice	O
27	.	O

1	INTERVENTION	O
2	(	O
3	S	O
4	):	O
5	Twenty	O
6	-	O
7	six	O
8	hemostasis	O
9	parameters	O
10	evaluated	O
11	repeatedly	O
12	in	O
13	patients	O
14	undergoing	O
15	IVF	O
16	-	O
17	ET	O
18	.	O

1	For	O
2	228	O
3	of	O
4	425	O
5	deaths	O
6	(	O
7	54	O
8	%)	O
9	occurring	O
10	among	O
11	26	O
12	100	O
13	people	O
14	of	O
15	known	O
16	age	O
17	in	O
18	the	O
19	Malumfashi	O
20	area	O
21	of	O
22	northern	O
23	Nigeria	O
24	,	O
25	data	O
26	were	O
27	collected	O
28	on	O
29	symptoms	O
30	present	O
31	prior	O
32	to	O
33	death	O
34	.	O

1	Analysis	O
2	of	O
3	the	O
4	gag	B
5	and	O
6	rev	B
7	proteins	I
8	in	O
9	the	O
10	transfected	O
11	cells	O
12	demonstrated	O
13	that	O
14	these	O
15	proteins	O
16	were	O
17	not	O
18	detectable	O
19	in	O
20	cells	O
21	transfected	O
22	with	O
23	the	O
24	tat	B
25	mutants	I
26	but	O
27	could	O
28	be	O
29	readily	O
30	detected	O
31	when	O
32	the	O
33	mutations	O
34	were	O
35	complemented	O
36	in	O
37	trans	O
38	with	O
39	a	O
40	tat	B
41	expression	O
42	vector	O
43	.	O

1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	dopamine	O
6	receptor	O
7	stimulation	O
8	by	O
9	different	O
10	dopamine	O
11	agonists	O
12	produces	O
13	a	O
14	different	O
15	pattern	O
16	of	O
17	effects	O
18	on	O
19	the	O
20	characteristics	O
21	of	O
22	the	O
23	reaction	O
24	time	O
25	response	O
26	.	O

1	Comparative	O
2	study	O
3	of	O
4	the	O
5	differential	O
6	white	O
7	blood	O
8	cell	O
9	count	O
10	using	O
11	three	O
12	automated	O
13	analyzers	O
14	:	O
15	Coulter	O
16	STKS	O
17	,	O
18	Sysmex	O
19	NE	O
20	8000	O
21	and	O
22	Technicon	O
23	H	O
24	-	O
25	1	O
26	.	O

1	Uses	O
2	of	O
3	orthoclone	O
4	OKT3	O
5	for	O
6	prophylaxis	O
7	of	O
8	rejection	O
9	and	O
10	induction	O
11	in	O
12	initial	O
13	nonfunction	O
14	in	O
15	kidney	O
16	transplantation	O
17	.	O

1	In	O
2	vitro	O
3	transcription	O
4	extracts	O
5	from	O
6	ret1	O
7	-	O
8	1	O
9	cells	O
10	terminate	O
11	less	O
12	efficiently	O
13	at	O
14	weak	O
15	transcription	O
16	termination	O
17	signals	O
18	than	O
19	those	O
20	from	O
21	RET1	O
22	cells	O
23	,	O
24	using	O
25	a	O
26	variety	O
27	of	O
28	tRNA	O
29	templates	O
30	.	O

1	Since	O
2	the	O
3	regulation	O
4	of	O
5	SWI4	O
6	is	O
7	required	O
8	for	O
9	normal	O
10	cell	O
11	cycle	O
12	progression	O
13	,	O
14	we	O
15	have	O
16	characterized	O
17	cis	O
18	-	O
19	and	O
20	trans	O
21	-	O
22	acting	O
23	regulators	O
24	of	O
25	SWI4	O
26	transcription	O
27	.	O

1	However	O
2	,	O
3	bilateral	O
4	diffuse	O
5	pulmonary	O
6	infiltrations	O
7	developed	O
8	21	O
9	days	O
10	later	O
11	.	O

1	The	O
2	crystal	O
3	structure	O
4	of	O
5	the	O
6	VP16	B
7	core	O
8	has	O
9	been	O
10	determined	O
11	at	O
12	2	O
13	.	O
14	1	O
15	A	O
16	resolution	O
17	.	O

1	Our	O
2	results	O
3	demonstrate	O
4	the	O
5	importance	O
6	of	O
7	phosphate	O
8	and	O
9	calcium	O
10	in	O
11	influencing	O
12	the	O
13	secretion	O
14	of	O
15	PTH	O
16	and	O
17	CT	O
18	in	O
19	uremia	O
20	.	O

1	Catha	O
2	edulis	O
3	,	O
4	a	O
5	plant	O
6	that	O
7	has	O
8	amphetamine	O
9	effects	O
10	.	O

1	Sequencing	O
2	of	O
3	the	O
4	facB	O
5	gene	O
6	revealed	O
7	that	O
8	it	O
9	encodes	O
10	a	O
11	protein	O
12	that	O
13	contains	O
14	an	O
15	N	O
16	-	O
17	terminal	O
18	GAL4	B
19	-	I
20	like	I
21	Zn	O
22	(	O
23	II	O
24	)	O
25	2Cys6	O
26	(	O
27	or	O
28	C6	O
29	zinc	O
30	)	O
31	binuclear	O
32	cluster	O
33	for	O
34	DNA	O
35	binding	O
36	,	O
37	leucine	O
38	zipper	O
39	-	O
40	like	O
41	heptad	O
42	repeat	O
43	motifs	O
44	and	O
45	central	O
46	and	O
47	C	B
48	-	I
49	terminal	I
50	acidic	I
51	alpha	I
52	-	I
53	helical	O
54	regions	O
55	,	O
56	consistent	O
57	with	O
58	a	O
59	function	O
60	as	O
61	a	O
62	DNA	O
63	-	O
64	binding	O
65	transcriptional	O
66	activator	O
67	.	O

1	Since	O
2	the	O
3	morphology	O
4	of	O
5	the	O
6	lesions	O
7	can	O
8	mimic	O
9	that	O
10	of	O
11	other	O
12	cutaneous	O
13	disorders	O
14	,	O
15	Bowen	O
16	'	O
17	s	O
18	disease	O
19	is	O
20	often	O
21	not	O
22	recognized	O
23	initially	O
24	.	O

1	The	O
2	minimal	O
3	region	O
4	of	O
5	overlap	O
6	of	O
7	Langer	O
8	-	O
9	Giedion	O
10	syndrome	O
11	deletions	O
12	,	O
13	previously	O
14	identified	O
15	by	O
16	analysis	O
17	of	O
18	15	O
19	patients	O
20	,	O
21	was	O
22	placed	O
23	on	O
24	the	O
25	map	O
26	by	O
27	analysis	O
28	of	O
29	2	O
30	patients	O
31	whose	O
32	deletions	O
33	define	O
34	the	O
35	endpoints	O
36	.	O

1	Methods	O
2	of	O
3	clinical	O
4	and	O
5	experimental	O
6	algesimetry	O
7	are	O
8	described	O
9	that	O
10	have	O
11	been	O
12	used	O
13	to	O
14	evaluate	O
15	effects	O
16	of	O
17	peripherally	O
18	and	O
19	centrally	O
20	acting	O
21	analgesics	O
22	.	O

1	Mutants	O
2	lacking	O
3	the	O
4	3	O
5	'	O
6	stem	O
7	-	O
8	loop	O
9	exhibited	O
10	a	O
11	75	O
12	%	O
13	reduction	O
14	in	O
15	the	O
16	level	O
17	of	O
18	psaB	B
19	mRNA	I
20	.	O

1	The	O
2	protector	O
3	doubled	O
4	the	O
5	estimated	O
6	fall	O
7	distance	O
8	for	O
9	fracture	O
10	of	O
11	the	O
12	trochanter	O
13	.	O

1	Most	O
2	of	O
3	them	O
4	were	O
5	situated	O
6	at	O
7	Sylvius	O
8	fissure	O
9	(	O
10	13	O
11	cases	O
12	).	O

1	However	O
2	,	O
3	there	O
4	is	O
5	still	O
6	a	O
7	subset	O
8	of	O
9	tumors	O
10	that	O
11	displayed	O
12	no	O
13	changes	O
14	in	O
15	these	O
16	genes	O
17	.	O

1	We	O
2	have	O
3	isolated	O
4	and	O
5	characterized	O
6	the	O
7	GCD6	O
8	and	O
9	GCD7	O
10	genes	O
11	and	O
12	shown	O
13	that	O
14	their	O
15	products	O
16	are	O
17	required	O
18	to	O
19	repress	O
20	GCN4	B
21	translation	O
22	under	O
23	nonstarvation	O
24	conditions	O
25	.	O

1	Four	O
2	cases	O
3	of	O
4	synovial	O
5	chondromatosis	O
6	are	O
7	presented	O
8	.	O

1	During	O
2	the	O
3	aftermath	O
4	of	O
5	excitation	O
6	of	O
7	the	O
8	skin	O
9	sympathetic	O
10	nerve	O
11	by	O
12	mental	O
13	arithmetics	O
14	,	O
15	3	O
16	/	O
17	12	O
18	A	O
19	delta	O
20	units	O
21	were	O
22	turned	O
23	to	O
24	the	O
25	active	O
26	state	O
27	with	O
28	decreased	O
29	mechanical	O
30	threshold	O
31	.	O

1	EB	O
2	-	O
3	1	O
4	,	O
5	a	O
6	tyrosine	B
7	kinase	I
8	signal	I
9	transduction	I
10	gene	I
11	,	O
12	is	O
13	transcriptionally	O
14	activated	O
15	in	O
16	the	O
17	t	O
18	(	O
19	1	O
20	;	O
21	19	O
22	)	O
23	subset	O
24	of	O
25	pre	O
26	-	O
27	B	O
28	ALL	O
29	,	O
30	which	O
31	express	O
32	oncoprotein	O
33	E2a	O
34	-	O
35	Pbx1	O
36	.	O

1	Application	O
2	of	O
3	the	O
4	method	O
5	to	O
6	a	O
7	representative	O
8	set	O
9	of	O
10	50	O
11	known	O
12	genes	O
13	from	O
14	Arabidopsis	O
15	thaliana	O
16	showed	O
17	significant	O
18	improvement	O
19	in	O
20	prediction	O
21	accuracy	O
22	compared	O
23	to	O
24	previous	O
25	spliced	O
26	alignment	O
27	methods	O
28	.	O

1	The	O
2	effects	O
3	of	O
4	oral	O
5	vanadyl	O
6	sulfate	O
7	(	O
8	VOSO4	O
9	)	O
10	(	O
11	0	O
12	.	O
13	5	O
14	mg	O
15	/	O
16	kg	O
17	/	O
18	day	O
19	)	O
20	on	O
21	anthropometry	O
22	,	O
23	body	O
24	composition	O
25	,	O
26	and	O
27	performance	O
28	were	O
29	investigated	O
30	in	O
31	a	O
32	12	O
33	-	O
34	week	O
35	,	O
36	double	O
37	-	O
38	blind	O
39	,	O
40	placebo	O
41	-	O
42	controlled	O
43	trial	O
44	involving	O
45	weight	O
46	-	O
47	training	O
48	volunteers	O
49	.	O

1	Radiation	O
2	decreased	O
3	the	O
4	levels	O
5	of	O
6	T4	O
7	and	O
8	T3	O
9	6	O
10	h	O
11	and	O
12	72	O
13	h	O
14	in	O
15	group	O
16	C	O
17	,	O
18	in	O
19	group	O
20	A	O
21	at	O
22	72	O
23	h	O
24	,	O
25	in	O
26	group	O
27	B	O
28	at	O
29	24	O
30	h	O
31	postexposure	O
32	.	O

1	Whereas	O
2	cDNA	O
3	hybridization	O
4	to	O
5	genomic	O
6	DNA	O
7	blots	O
8	indicated	O
9	a	O
10	small	O
11	subfamily	O
12	of	O
13	G0S19	O
14	genes	O
15	,	O
16	simple	O
17	patterns	O
18	of	O
19	bands	O
20	indicated	O
21	that	O
22	most	O
23	cDNAs	O
24	,	O
25	including	O
26	G0S30	O
27	cDNA	O
28	,	O
29	corresponded	O
30	to	O
31	single	O
32	-	O
33	copy	O
34	genes	O
35	.	O

1	The	O
2	210	O
3	kDa	O
4	precursor	O
5	is	O
6	converted	O
7	slowly	O
8	(	O
9	t	O
10	1	O
11	/	O
12	2	O
13	=	O
14	2	O
15	h	O
16	)	O
17	by	O
18	proteolytic	O
19	processing	O
20	into	O
21	a	O
22	125	O
23	kDa	O
24	(	O
25	alpha	O
26	')	O
27	and	O
28	83	O
29	kDa	O
30	(	O
31	beta	O
32	')	O
33	species	O
34	.	O

1	A	O
2	pathway	O
3	for	O
4	regulation	O
5	of	O
6	B	O
7	lymphocyte	B
8	antigen	I
9	receptor	I
10	-	I
11	induced	O
12	calcium	O
13	flux	O
14	.	O

1	Compensative	O
2	justice	O
3	and	O
4	moral	O
5	investment	O
6	among	O
7	Japanese	O
8	,	O
9	Chinese	O
10	,	O
11	and	O
12	Koreans	O
13	.	O

1	However	O
2	,	O
3	calphostin	O
4	C	O
5	,	O
6	a	O
7	specific	O
8	inhibitor	O
9	of	O
10	PKC	B
11	,	O
12	abolished	O
13	the	O
14	TPA	O
15	-	O
16	induced	O
17	increase	O
18	in	O
19	CFI	O
20	mRNA	O
21	levels	O
22	.	O

1	This	O
2	concept	O
3	is	O
4	supported	O
5	by	O
6	the	O
7	identification	O
8	of	O
9	RH	O
10	-	O
11	like	O
12	genes	O
13	in	O
14	non	O
15	human	O
16	primates	O
17	.	O

1	Following	O
2	the	O
3	results	O
4	of	O
5	toxicological	O
6	experiments	O
7	in	O
8	the	O
9	target	O
10	animals	O
11	"	O
12	Toxicological	O
13	Drinking	O
14	Water	O
15	Standards	O
16	for	O
17	Animals	O
18	"	O
19	can	O
20	be	O
21	established	O
22	.	O

1	33	O
2	out	O
3	of	O
4	90	O
5	neurons	O
6	of	O
7	the	O
8	cat	O
9	medial	O
10	geniculate	O
11	body	O
12	revealed	O
13	the	O
14	selectivity	O
15	of	O
16	their	O
17	afterdischarges	O
18	to	O
19	movement	O
20	of	O
21	sound	O
22	when	O
23	velocity	O
24	of	O
25	the	O
26	movement	O
27	changed	O
28	from	O
29	30	O
30	to	O
31	180	O
32	deg	O
33	/	O
34	s	O
35	.	O

1	We	O
2	recommend	O
3	that	O
4	paracervical	O
5	block	O
6	with	O
7	lignocaine	O
8	should	O
9	be	O
10	used	O
11	in	O
12	conjunction	O
13	with	O
14	i	O
15	.	O
16	v	O
17	.	O
18	sedation	O
19	/	O
20	analgesia	O
21	during	O
22	egg	O
23	collection	O
24	performed	O
25	through	O
26	the	O
27	transvaginal	O
28	route	O
29	under	O
30	ultrasound	O
31	guidance	O
32	(	O
33	TUGOR	O
34	)	O
35	to	O
36	reduce	O
37	the	O
38	pain	O
39	of	O
40	the	O
41	procedure	O
42	.	O

1	Serum	O
2	ACTH	B
3	did	O
4	not	O
5	respond	O
6	to	O
7	insulin	B
8	and	O
9	metyrapone	O
10	.	O

1	We	O
2	conclude	O
3	that	O
4	for	O
5	mono	O
6	-	O
7	intronic	O
8	precursors	O
9	in	O
10	which	O
11	there	O
12	is	O
13	only	O
14	one	O
15	choice	O
16	of	O
17	splice	O
18	sites	O
19	,	O
20	most	O
21	of	O
22	the	O
23	exon	O
24	sequences	O
25	are	O
26	not	O
27	mechanistically	O
28	involved	O
29	in	O
30	the	O
31	splicing	O
32	process	O
33	.	O

1	Mutating	O
2	the	O
3	E	O
4	-	O
5	box	O
6	in	O
7	the	O
8	context	O
9	of	O
10	the	O
11	3	O
12	'-	O
13	flanking	O
14	region	O
15	confirmed	O
16	that	O
17	it	O
18	contributes	O
19	to	O
20	the	O
21	enhancement	O
22	of	O
23	transcriptional	O
24	activity	O
25	of	O
26	the	O
27	alpha1	O
28	(	O
29	I	O
30	)	O
31	collagen	B
32	gene	I
33	promoter	I
34	.	O

1	Parasitological	O
2	post	O
3	-	O
4	mortem	O
5	examination	O
6	of	O
7	all	O
8	seropositive	O
9	animals	O
10	showed	O
11	five	O
12	and	O
13	seven	O
14	false	O
15	-	O
16	positive	O
17	animals	O
18	when	O
19	E	O
20	/	O
21	S	O
22	and	O
23	CWE	O
24	antigens	O
25	were	O
26	used	O
27	,	O
28	respectively	O
29	.	O

1	Plasmids	O
2	were	O
3	constructed	O
4	with	O
5	the	O
6	mouse	O
7	promoter	O
8	region	O
9	linked	O
10	to	O
11	the	O
12	reporter	O
13	gene	O
14	chloramphenicol	B
15	acetyltransferase	I
16	(	O
17	CAT	B
18	),	O
19	and	O
20	transiently	O
21	and	O
22	stably	O
23	transfected	O
24	in	O
25	the	O
26	INS	O
27	-	O
28	1	O
29	cells	O
30	.	O

1	D3S1261	O
2	is	O
3	physically	O
4	located	O
5	at	O
6	or	O
7	near	O
8	the	O
9	MITF	O
10	locus	O
11	,	O
12	while	O
13	D3S2465	O
14	and	O
15	D3S1766	O
16	are	O
17	flanking	O
18	the	O
19	locus	O
20	at	O
21	about	O
22	17	O
23	.	O
24	5	O
25	cM	O
26	genetic	O
27	distance	O
28	each	O
29	side	O
30	.	O

1	In	O
2	this	O
3	study	O
4	we	O
5	examined	O
6	hepatic	O
7	stellate	O
8	cell	O
9	regulation	O
10	of	O
11	M6P	O
12	/	O
13	IGFIIR	O
14	expression	O
15	and	O
16	found	O
17	that	O
18	M6P	O
19	/	O
20	IGFIIR	O
21	mRNA	O
22	transcript	O
23	levels	O
24	increased	O
25	in	O
26	stellate	O
27	cells	O
28	from	O
29	rats	O
30	exposed	O
31	to	O
32	carbon	O
33	tetrachloride	O
34	(	O
35	CCl4	O
36	),	O
37	a	O
38	potent	O
39	fibrogenic	O
40	stimulant	O
41	.	O

1	An	O
2	analytic	O
3	method	O
4	for	O
5	comparative	O
6	parameter	O
7	weighting	O
8	in	O
9	magnetic	O
10	resonance	O
11	(	O
12	MR	O
13	)	O
14	imaging	O
15	has	O
16	been	O
17	developed	O
18	using	O
19	the	O
20	concept	O
21	of	O
22	"	O
23	fractional	O
24	sensitivity	O
25	."	O
26	This	O
27	new	O
28	approach	O
29	results	O
30	in	O
31	easily	O
32	calculated	O
33	indexes	O
34	for	O
35	T1	O
36	,	O
37	T2	O
38	,	O
39	and	O
40	hydrogen	O
41	weighting	O
42	.	O

1	The	O
2	treatment	O
3	of	O
4	hydronephrosis	O
5	in	O
6	children	O

1	This	O
2	fragment	O
3	contained	O
4	the	O
5	C	O
6	-	O
7	terminal	O
8	47	O
9	nucleotides	O
10	of	O
11	leuB	O
12	,	O
13	encoding	O
14	3	O
15	-	O
16	isopropylmalate	B
17	dehydrogenase	I
18	;	O
19	asd	O
20	,	O
21	encoding	O
22	aspartate	B
23	-	I
24	beta	I
25	-	I
26	semialdehyde	I
27	dehydrogenase	I
28	(	O
29	Asd	O
30	);	O
31	and	O
32	orfA	O
33	,	O
34	whose	O
35	product	O
36	showed	O
37	similarity	O
38	to	O
39	the	O
40	Asd	O
41	proteins	O
42	from	O
43	Vibrio	O
44	spp	O
45	.	O

1	Two	O
2	classes	O
3	of	O
4	Xanthomonas	O
5	pathogens	O
6	evading	O
7	Bs2	O
8	host	O
9	resistance	O
10	and	O
11	displaying	O
12	reduced	O
13	fitness	O
14	were	O
15	found	O
16	to	O
17	be	O
18	specifically	O
19	mutated	O
20	in	O
21	avrBs2	O
22	.	O

1	The	O
2	C	O
3	-	O
4	terminal	O
5	mutants	O
6	were	O
7	strongly	O
8	dominant	O
9	over	O
10	TraR	O
11	,	O
12	suggesting	O
13	that	O
14	they	O
15	can	O
16	form	O
17	heteromultimers	O
18	with	O
19	the	O
20	wild	O
21	-	O
22	type	O
23	activator	O
24	.	O

1	BiP670	O
2	retains	O
3	basal	O
4	and	O
5	Ca2	O
6	+	O
7	ionophore	O
8	A23187	O
9	-	O
10	inducible	O
11	activities	O
12	.	O

1	Varicella	O
2	-	O
3	zoster	O
4	virus	O
5	(	O
6	VZV	O
7	)	O
8	glycoprotein	O
9	gI	O
10	is	O
11	a	O
12	type	O
13	1	O
14	transmembrane	O
15	glycoprotein	O
16	which	O
17	is	O
18	one	O
19	component	O
20	of	O
21	the	O
22	heterodimeric	O
23	gE	O
24	:	O
25	gI	O
26	Fc	B
27	receptor	I
28	complex	I
29	.	O

1	We	O
2	enrolled	O
3	253	O
4	HIV	O
5	-	O
6	antibody	O
7	positive	O
8	heroin	O
9	addicts	O
10	without	O
11	HIV	O
12	-	O
13	related	O
14	disease	O
15	(	O
16	n	O
17	=	O
18	81	O
19	)	O
20	or	O
21	with	O
22	persistent	O
23	generalized	O
24	lymphadenopathy	O
25	(	O
26	n	O
27	=	O
28	172	O
29	)	O
30	in	O
31	a	O
32	prospective	O
33	study	O
34	to	O
35	evaluate	O
36	clinical	O
37	progression	O
38	to	O
39	AIDS	O
40	related	O
41	complex	O
42	(	O
43	ARC	O
44	)	O
45	or	O
46	AIDS	O
47	and	O
48	to	O
49	identify	O
50	factors	O
51	of	O
52	possible	O
53	prognostic	O
54	relevance	O
55	.	O

1	Recombinant	B
2	prenylcysteine	I
3	lyase	I
4	was	O
5	produced	O
6	in	O
7	a	O
8	baculovirus	O
9	-	O
10	Sf9	O
11	expression	O
12	system	O
13	.	O

1	The	O
2	somatoform	O
3	conundrum	O
4	:	O
5	a	O
6	question	O
7	of	O
8	nosological	O
9	valves	O
10	.	O

1	The	O
2	correct	O
3	termination	O
4	of	O
5	retroviral	O
6	transcripts	O
7	at	O
8	the	O
9	3	O
10	'	O
11	LTR	O
12	R	O
13	/	O
14	U5	O
15	junction	O
16	is	O
17	primarily	O
18	dependent	O
19	on	O
20	the	O
21	canonical	O
22	AAUAAA	O
23	polyadenylation	O
24	signal	O
25	,	O
26	so	O
27	we	O
28	have	O
29	analyzed	O
30	the	O
31	effect	O
32	of	O
33	mutating	O
34	the	O
35	polyadenylation	O
36	signal	O
37	sequences	O
38	on	O
39	the	O
40	properties	O
41	of	O
42	a	O
43	selectable	O
44	murine	O
45	retroviral	O
46	vector	O
47	.	O

1	Elimination	O
2	of	O
3	Haemophilus	O
4	influenzae	O
5	type	O
6	b	O
7	meningitis	O
8	after	O
9	introduction	O
10	of	O
11	vaccination	O

1	We	O
2	report	O
3	two	O
4	patients	O
5	receiving	O
6	maintenance	O
7	valproate	O
8	,	O
9	one	O
10	with	O
11	resolving	O
12	acute	O
13	hepatitis	O
14	C	O
15	and	O
16	the	O
17	other	O
18	with	O
19	chronic	O
20	persistent	O
21	hepatitis	O
22	C	O
23	,	O
24	with	O
25	incidental	O
26	microvesicular	O
27	steatosis	O
28	demonstrated	O
29	on	O
30	oil	O
31	-	O
32	red	O
33	O	O
34	stains	O
35	.	O

1	In	O
2	a	O
3	screen	O
4	for	O
5	genes	O
6	with	O
7	oncogenic	O
8	potential	O
9	expressed	O
10	by	O
11	the	O
12	murine	O
13	B6SUtA1	O
14	myeloid	O
15	progenitor	O
16	cell	O
17	line	O
18	,	O
19	we	O
20	isolated	O
21	a	O
22	2	O
23	.	O

1	The	O
2	upstream	O
3	promoter	O
4	is	O
5	located	O
6	within	O
7	the	O
8	coding	O
9	sequence	O
10	of	O
11	a	O
12	divergent	O
13	gene	O
14	expressing	O
15	a	O
16	protein	O
17	of	O
18	Mr	O
19	39	O
20	kDa	O
21	of	O
22	unknown	O
23	function	O
24	.	O

1	Molecular	O
2	cloning	O
3	and	O
4	expression	O
5	of	O
6	human	B
7	UDP	I
8	-	I
9	d	O
10	-	O
11	Xylose	O
12	:	O
13	proteoglycan	O
14	core	B
15	protein	I
16	beta	I
17	-	I
18	d	O
19	-	O
20	xylosyltransferase	O
21	and	O
22	its	O
23	first	O
24	isoform	O
25	XT	O
26	-	O
27	II	O
28	.	O

1	In	O
2	adult	O
3	tissues	O
4	,	O
5	it	O
6	was	O
7	less	O
8	restricted	O
9	,	O
10	indicating	O
11	that	O
12	RAFTK	O
13	expression	O
14	is	O
15	developmentally	O
16	up	O
17	-	O
18	regulated	O
19	.	O

1	In	O
2	Arabidopsis	O
3	,	O
4	the	O
5	induction	O
6	of	O
7	a	O
8	dehydration	O
9	-	O
10	responsive	O
11	gene	O
12	,	O
13	rd22	O
14	,	O
15	is	O
16	mediated	O
17	by	O
18	abscisic	O
19	acid	O
20	(	O
21	ABA	O
22	)	O
23	and	O
24	requires	O
25	protein	O
26	biosynthesis	O
27	for	O
28	ABA	O
29	-	O
30	dependent	O
31	gene	O
32	expression	O
33	.	O

1	Since	O
2	we	O
3	have	O
4	observed	O
5	effects	O
6	of	O
7	growth	O
8	factors	O
9	and	O
10	cAMP	O
11	as	O
12	well	O
13	as	O
14	estradiol	O
15	(	O
16	E2	O
17	)	O
18	on	O
19	regulation	O
20	of	O
21	expression	O
22	of	O
23	some	O
24	genes	O
25	stimulated	O
26	by	O
27	the	O
28	estrogen	O
29	receptor	O
30	(	O
31	ER	O
32	),	O
33	we	O
34	have	O
35	undertaken	O
36	studies	O
37	to	O
38	examine	O
39	directly	O
40	whether	O
41	activators	O
42	of	O
43	protein	O
44	kinases	O
45	can	O
46	modulate	O
47	transcriptional	O
48	activity	O
49	of	O
50	the	O
51	ER	O
52	.	O

1	Immediately	O
2	after	O
3	surgery	O
4	,	O
5	dialysate	O
6	PGE2	O
7	and	O
8	adenosine	O
9	concentrations	O
10	were	O
11	3	O
12	.	O
13	7	O
14	+/-	O
15	0	O
16	.	O
17	7	O
18	and	O
19	296	O
20	+/-	O
21	127	O
22	nM	O
23	,	O
24	respectively	O
25	.	O

1	We	O
2	find	O
3	that	O
4	BCL	B
5	-	I
6	6	I
7	POZ	I
8	domain	I
9	mutations	O
10	that	O
11	disrupt	O
12	the	O
13	interaction	O
14	with	O
15	N	O
16	-	O
17	CoR	O
18	and	O
19	SMRT	O
20	no	O
21	longer	O
22	repress	O
23	transcription	O
24	.	O

1	Although	O
2	IL	B
3	-	I
4	2	I
5	and	O
6	IFN	B
7	-	I
8	alpha	I
9	activated	I
10	STAT1	I
11	alpha	I
12	and	O
13	STAT5	O
14	,	O
15	IL	B
16	-	I
17	2	I
18	predominantly	I
19	activated	I
20	STAT5	I
21	,	O
22	while	O
23	IFN	B
24	-	I
25	alpha	I
26	predominantly	I
27	activated	I
28	STAT1	I
29	alpha	I
30	.	O

1	Manganese	O
2	ions	O
3	were	O
4	found	O
5	to	O
6	be	O
7	essential	O
8	for	O
9	autophosphorylation	O
10	of	O
11	BGLF4	O
12	,	O
13	and	O
14	magnesium	O
15	can	O
16	stimulate	O
17	the	O
18	activity	O
19	.	O

1	Disruption	O
2	mutations	O
3	have	O
4	been	O
5	constructed	O
6	in	O
7	the	O
8	SLK1	B
9	gene	I
10	.	O
11	slk1	O
12	null	O
13	mutants	O
14	cannot	O
15	grow	O
16	at	O
17	37	O
18	degrees	O
19	C	O
20	,	O
21	but	O
22	many	O
23	cells	O
24	can	O
25	grow	O
26	at	O
27	30	O
28	,	O
29	24	O
30	,	O
31	and	O
32	17	O
33	degrees	O
34	C	O
35	.	O

1	Catch	O
2	-	O
3	up	O
4	growth	O
5	was	O
6	observed	O
7	only	O
8	for	O
9	a	O
10	12	O
11	-	O
12	month	O
13	period	O
14	in	O
15	4	O
16	children	O
17	with	O
18	a	O
19	bone	O
20	age	O
21	of	O
22	7	O
23	to	O
24	8	O
25	years	O
26	.	O

1	As	O
2	retinoic	O
3	acid	O
4	and	O
5	thyroid	O
6	hormone	O
7	are	O
8	frequently	O
9	involved	O
10	in	O
11	developmental	O
12	regulatory	O
13	processes	O
14	,	O
15	it	O
16	is	O
17	possible	O
18	that	O
19	this	O
20	element	O
21	may	O
22	be	O
23	important	O
24	in	O
25	the	O
26	process	O
27	of	O
28	islet	O
29	cell	O
30	differentiation	O
31	.	O

1	A	O
2	controlled	O
3	trial	O
4	of	O
5	recombinant	O
6	human	B
7	granulocyte	I
8	-	I
9	macrophage	I
10	colony	I
11	-	I
12	stimulating	I
13	factor	I
14	after	O
15	total	O
16	body	O
17	irradiation	O
18	,	O
19	high	O
20	-	O
21	dose	O
22	chemotherapy	O
23	,	O
24	and	O
25	autologous	O
26	bone	O
27	marrow	O
28	transplantation	O
29	for	O
30	acute	O
31	lymphoblastic	O
32	leukemia	O
33	or	O
34	malignant	O
35	lymphoma	O
36	.	O

1	Genes	O
2	belonging	O
3	to	O
4	the	O
5	ras	B
6	superfamily	I
7	encode	O
8	low	O
9	-	O
10	molecular	O
11	-	O
12	weight	O
13	GTP	O
14	/	O
15	GDP	O
16	-	O
17	binding	O
18	proteins	O
19	that	O
20	are	O
21	highly	O
22	conserved	O
23	in	O
24	wide	O
25	variety	O
26	of	O
27	organisms	O
28	.	O

1	Proteolysis	O
2	of	O
3	Mbp1	O
4	and	O
5	Swi4	B
6	DNA	I
7	-	I
8	protein	I
9	complexes	I
10	has	O
11	revealed	O
12	the	O
13	extent	O
14	of	O
15	these	O
16	sequences	O
17	,	O
18	and	O
19	C	O
20	-	O
21	terminally	O
22	extended	O
23	molecules	O
24	with	O
25	substantially	O
26	enhanced	O
27	DNA	O
28	binding	O
29	activity	O
30	compared	O
31	to	O
32	the	O
33	core	O
34	domains	O
35	alone	O
36	have	O
37	been	O
38	produced	O
39	.	O

1	These	O
2	offspring	O
3	of	O
4	the	O
5	alpha	B
6	-	I
7	MSH	I
8	treated	O
9	mothers	O
10	were	O
11	less	O
12	sensitive	O
13	to	O
14	pain	O
15	and	O
16	as	O
17	adults	O
18	showed	O
19	a	O
20	reduced	O
21	analgesic	O
22	response	O
23	to	O
24	morphine	O
25	.	O

1	The	O
2	results	O
3	show	O
4	that	O
5	ROS	O
6	production	O
7	by	O
8	viable	O
9	spermatozoa	O
10	is	O
11	highly	O
12	correlated	O
13	with	O
14	the	O
15	concentration	O
16	of	O
17	PMN	B
18	elastase	I
19	and	O
20	the	O
21	number	O
22	of	O
23	both	O
24	peroxidase	B
25	-	I
26	positive	O
27	and	O
28	round	O
29	cells	O
30	.	O

1	Two	O
2	Pax2	O
3	/	O
4	5	O
5	/	O
6	8	O
7	-	O
8	binding	O
9	sites	O
10	in	O
11	Engrailed2	O
12	are	O
13	required	O
14	for	O
15	proper	O
16	initiation	O
17	of	O
18	endogenous	O
19	mid	O
20	-	O
21	hindbrain	O
22	expression	O
23	.	O

1	The	O
2	5	O
3	'	O
4	and	O
5	3	O
6	'	O
7	untranslated	O
8	sequences	O
9	contain	O
10	characteristic	O
11	sequences	O
12	that	O
13	are	O
14	involved	O
15	in	O
16	the	O
17	initiation	O
18	and	O
19	termination	O
20	of	O
21	transcription	O
22	,	O
23	including	O
24	two	O
25	possible	O
26	promoters	O
27	,	O
28	one	O
29	of	O
30	which	O
31	may	O
32	contain	O
33	two	O
34	overlapping	O
35	-	O
36	10	O
37	sequences	O
38	.	O

1	Angiotensin	B
2	converting	I
3	enzyme	I
4	inhibitors	O
5	enhance	O
6	the	O
7	antihypertensive	O
8	efficacy	O
9	of	O
10	diuretics	O
11	and	O
12	blunt	O
13	or	O
14	prevent	O
15	adverse	O
16	metabolic	O
17	effects	O
18	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	hypocitraturia	O
6	in	O
7	type	O
8	I	O
9	renal	O
10	tubular	O
11	acidosis	O
12	may	O
13	be	O
14	due	O
15	to	O
16	a	O
17	defect	O
18	in	O
19	proximal	O
20	tubule	O
21	function	O
22	.	O

1	IV	O
2	.	O

1	Although	O
2	p48	O
3	gene	O
4	induction	O
5	is	O
6	dependent	O
7	on	O
8	STAT1	B
9	and	O
10	JAK1	O
11	,	O
12	activated	O
13	STAT1	B
14	does	O
15	not	O
16	bind	O
17	to	O
18	GATE	O
19	.	O

1	To	O
2	quantify	O
3	any	O
4	mechanical	O
5	inhibitory	O
6	effect	O
7	of	O
8	nasal	O
9	intermittent	O
10	positive	O
11	pressure	O
12	ventilation	O
13	(	O
14	IPPV	O
15	)	O
16	on	O
17	inspiratory	O
18	activity	O
19	of	O
20	the	O
21	diaphragm	O
22	we	O
23	ventilated	O
24	five	O
25	conscious	O
26	relaxed	O
27	subjects	O
28	on	O
29	two	O
30	occasions	O
31	at	O
32	respiratory	O
33	rates	O
34	similar	O
35	to	O
36	quiet	O
37	breathing	O
38	(	O
39	QB	O
40	)	O
41	and	O
42	at	O
43	three	O
44	levels	O
45	of	O
46	applied	O
47	pressure	O
48	(	O
49	Pappl	O
50	)--	O
51	6	O
52	,	O
53	9	O
54	and	O
55	12	O
56	cmH2O	O
57	,	O
58	each	O
59	during	O
60	hypocapnia	O
61	(	O
62	P	O
63	(	O
64	CO2	O
65	)	O
66	allowed	O
67	to	O
68	decrease	O
69	)	O
70	and	O
71	eucapnia	O
72	(	O
73	CO2	O
74	added	O
75	to	O
76	inspired	O
77	gas	O
78	).	O

1	There	O
2	was	O
3	no	O
4	apparent	O
5	effect	O
6	of	O
7	growth	O
8	temperature	O
9	on	O
10	the	O
11	steady	O
12	-	O
13	state	O
14	levels	O
15	of	O
16	fad7	O
17	mRNA	O
18	in	O
19	wild	O
20	type	O
21	plants	O
22	.	O

1	Several	O
2	demographic	O
3	indices	O
4	of	O
5	isolated	O
6	populations	O
7	in	O
8	Uzbekistan	O

1	A	O
2	major	O
3	mechanism	O
4	whereby	O
5	steroid	B
6	hydroxylase	I
7	gene	I
8	transcription	O
9	is	O
10	regulated	O
11	in	O
12	the	O
13	adrenal	O
14	cortex	O
15	requires	O
16	the	O
17	pituitary	O
18	peptide	O
19	hormone	O
20	,	O
21	ACTH	B
22	,	O
23	which	O
24	acts	O
25	via	O
26	cAMP	O
27	.	O

1	KAR1	O
2	encodes	O
3	an	O
4	essential	O
5	component	O
6	of	O
7	the	O
8	yeast	O
9	spindle	O
10	pole	O
11	body	O
12	(	O
13	SPB	O
14	)	O
15	that	O
16	is	O
17	required	O
18	for	O
19	karyogamy	O
20	and	O
21	SPB	O
22	duplication	O
23	.	O

1	The	O
2	IL	B
3	-	I
4	8	I
5	receptor	I
6	is	O
7	a	O
8	seven	O
9	-	O
10	transmembrane	O
11	spanning	O
12	receptor	O
13	coupled	O
14	to	O
15	specific	O
16	heterotrimeric	B
17	G	I
18	proteins	I
19	including	O
20	Gi	O
21	and	O
22	G16	O
23	.	O

1	A	O
2	total	O
3	of	O
4	1459	O
5	men	O
6	aged	O
7	48	O
8	to	O
9	84	O
10	years	O
11	,	O
12	who	O
13	were	O
14	diagnosed	O
15	for	O
16	the	O
17	first	O
18	time	O
19	by	O
20	physicians	O
21	as	O
22	having	O
23	BPH	O
24	in	O
25	1994	O
26	and	O
27	who	O
28	had	O
29	not	O
30	received	O
31	treatment	O
32	,	O
33	participated	O
34	in	O
35	the	O
36	study	O
37	.	O

1	The	O
2	Tax	B
3	/	I
4	IKKgamma	I
5	interaction	O
6	serves	O
7	to	O
8	recruit	O
9	Tax	B
10	to	O
11	the	O
12	IKK	O
13	catalytic	O
14	subunits	O
15	,	O
16	IKKalpha	O
17	and	O
18	IKKbeta	O
19	,	O
20	and	O
21	this	O
22	recruitment	O
23	appears	O
24	to	O
25	be	O
26	an	O
27	essential	O
28	mechanism	O
29	by	O
30	which	O
31	Tax	B
32	stimulates	O
33	the	O
34	activity	O
35	of	O
36	IKK	O
37	.	O

1	UbiA	O
2	is	O
3	also	O
4	unique	O
5	among	O
6	known	O
7	polyubiquitin	O
8	genes	O
9	in	O
10	containing	O
11	four	O
12	cis	O
13	-	O
14	spliced	O
15	introns	O
16	within	O
17	its	O
18	coding	O
19	sequence	O
20	.	O

1	Although	O
2	the	O
3	molecular	O
4	mechanisms	O
5	involved	O
6	in	O
7	this	O
8	regulation	O
9	are	O
10	currently	O
11	being	O
12	elucidated	O
13	,	O
14	very	O
15	little	O
16	is	O
17	known	O
18	about	O
19	the	O
20	trans	O
21	-	O
22	acting	O
23	factors	O
24	that	O
25	allow	O
26	expression	O
27	of	O
28	the	O
29	nitrate	O
30	and	O
31	nitrite	B
32	reductase	I
33	genes	I
34	which	O
35	code	O
36	for	O
37	the	O
38	first	O
39	enzymes	O
40	in	O
41	the	O
42	pathway	O
43	.	O

1	Effects	O
2	of	O
3	a	O
4	new	O
5	antihypertensive	O
6	agent	O
7	,	O
8	SGB	O
9	-	O
10	1534	O
11	,	O
12	on	O
13	rat	O
14	platelet	O
15	aggregation	O
16	.	O

1	A	O
2	cytosolic	O
3	variant	O
4	of	O
5	the	O
6	protein	O
7	underwent	O
8	efficient	O
9	transphosphorylation	O
10	,	O
11	yet	O
12	failed	O
13	to	O
14	activate	O
15	appreciably	O
16	either	O
17	p70	B
18	(	O
19	S6k	O
20	)	O
21	or	O
22	MAP	B
23	kinase	I
24	following	O
25	treatment	O
26	with	O
27	FK1012	O
28	.	O

1	Linear	O
2	extrapolation	O
3	is	O
4	used	O
5	below	O
6	the	O
7	experimental	O
8	data	O
9	range	O
10	to	O
11	establish	O
12	an	O
13	upper	O
14	bound	O
15	on	O
16	carcinogenic	O
17	risk	O
18	at	O
19	low	O
20	doses	O
21	.	O

1	One	O
2	enigmatic	O
3	aspect	O
4	of	O
5	GATA	B
6	factor	I
7	expression	O
8	is	O
9	that	O
10	several	O
11	GATA	B
12	proteins	I
13	,	O
14	which	O
15	ostensibly	O
16	share	O
17	the	O
18	same	O
19	DNA	O
20	-	O
21	binding	O
22	site	O
23	specificity	O
24	,	O
25	are	O
26	coexpressed	O
27	in	O
28	erythroid	O
29	cells	O
30	.	O

1	We	O
2	emphasize	O
3	that	O
4	ANCA	O
5	-	O
6	associated	O
7	vasculitis	O
8	is	O
9	another	O
10	important	O
11	complication	O
12	of	O
13	RA	O
14	.	O

1	ORFA	O
2	and	O
3	ccdA	O
4	were	O
5	constitutively	O
6	cotranscribed	O
7	as	O
8	determined	O
9	by	O
10	primer	O
11	extension	O
12	analysis	O
13	.	O

1	Analysis	O
2	of	O
3	an	O
4	autopsy	O
5	population	O
6	.	O

1	Up	O
2	to	O
3	95	O
4	%	O
5	of	O
6	the	O
7	total	O
8	UV	O
9	exposure	O
10	received	O
11	is	O
12	in	O
13	the	O
14	UV	O
15	-	O
16	A	O
17	waveband	O
18	(	O
19	320	O
20	-	O
21	400	O
22	nm	O
23	).	O

1	The	O
2	lack	O
3	of	O
4	the	O
5	C2	O
6	domain	O
7	of	O
8	the	O
9	Ca	O
10	(	O
11	2	O
12	+)-	O
13	dependent	O
14	PKCs	O
15	and	O
16	the	O
17	presence	O
18	of	O
19	a	O
20	unique	O
21	NH2	O
22	-	O
23	terminal	O
24	sequence	O
25	with	O
26	a	O
27	potential	O
28	signal	O
29	peptide	O
30	and	O
31	a	O
32	transmembrane	O
33	domain	O
34	suggest	O
35	that	O
36	PKC	B
37	mu	I
38	is	O
39	a	O
40	novel	O
41	member	O
42	of	O
43	the	O
44	subgroup	O
45	of	O
46	atypical	O
47	PKCs	O
48	.	O

1	The	O
2	data	O
3	provide	O
4	strong	O
5	evidence	O
6	that	O
7	ThlA	O
8	is	O
9	involved	O
10	in	O
11	the	O
12	metabolism	O
13	of	O
14	both	O
15	acid	O
16	and	O
17	solvent	O
18	formation	O
19	,	O
20	whereas	O
21	the	O
22	physiological	O
23	function	O
24	of	O
25	ThlB	O
26	has	O
27	yet	O
28	to	O
29	be	O
30	elucidated	O
31	.	O

1	Our	O
2	results	O
3	,	O
4	when	O
5	combined	O
6	with	O
7	previously	O
8	published	O
9	in	O
10	vitro	O
11	results	O
12	,	O
13	support	O
14	a	O
15	direct	O
16	role	O
17	for	O
18	Prp44p	O
19	in	O
20	unwinding	O
21	of	O
22	the	O
23	U4	B
24	/	I
25	U6	I
26	helix	I
27	.	O

1	The	O
2	total	O
3	number	O
4	of	O
5	specimens	O
6	was	O
7	131	O
8	with	O
9	78	O
10	nonsmokers	O
11	and	O
12	53	O
13	smokers	O
14	.	O

1	The	O
2	protein	B
3	-	I
4	tyrosine	I
5	kinase	I
6	fer	O
7	associates	O
8	with	O
9	signaling	O
10	complexes	O
11	containing	O
12	insulin	B
13	receptor	I
14	substrate	I
15	-	I
16	1	I
17	and	O
18	phosphatidylinositol	B
19	3	I
20	-	I
21	kinase	I
22	.	O

1	Bacterial	O
2	recovery	O
3	of	O
4	SA	O
5	from	O
6	the	O
7	liver	O
8	/	O
9	spleen	O
10	and	O
11	the	O
12	cecal	O
13	tonsil	O
14	in	O
15	contact	O
16	poults	O
17	and	O
18	SG	O
19	from	O
20	contact	O
21	chicks	O
22	treated	O
23	with	O
24	ILK	O
25	was	O
26	dramatically	O
27	reduced	O
28	when	O
29	compared	O
30	to	O
31	non	O
32	-	O
33	treated	O
34	contact	O
35	poults	O
36	and	O
37	chicks	O
38	.	O

1	Taken	O
2	together	O
3	,	O
4	the	O
5	results	O
6	suggest	O
7	that	O
8	chlorphentermine	O
9	may	O
10	be	O
11	capable	O
12	of	O
13	producing	O
14	dual	O
15	stimulus	O
16	effects	O
17	in	O
18	animals	O
19	.	O

1	To	O
2	elucidate	O
3	the	O
4	regulatory	O
5	mechanism	O
6	of	O
7	human	O
8	AM	O
9	gene	O
10	expression	O
11	,	O
12	functional	O
13	elements	O
14	of	O
15	5	O
16	'-	O
17	flanking	O
18	region	O
19	of	O
20	AM	O
21	gene	O
22	were	O
23	studied	O
24	in	O
25	human	O
26	aortic	O
27	endothelial	O
28	cells	O
29	(	O
30	HAEC	O
31	).	O

1	Preflight	O
2	,	O
3	inflight	O
4	,	O
5	and	O
6	postflight	O
7	exercise	O
8	response	O
9	tests	O
10	were	O
11	conducted	O
12	on	O
13	the	O
14	astronauts	O
15	of	O
16	the	O
17	second	O
18	Skylab	O
19	mission	O
20	(	O
21	Skylab	O
22	3	O
23	)	O
24	as	O
25	part	O
26	of	O
27	an	O
28	evaluation	O
29	of	O
30	physiological	O
31	adaptation	O
32	to	O
33	long	O
34	-	O
35	term	O
36	weightlessness	O
37	.	O

1	Mg2	O
2	+	O
3	and	O
4	Mn2	O
5	+	O
6	compete	O
7	for	O
8	binding	O
9	sites	O
10	,	O
11	with	O
12	the	O
13	former	O
14	having	O
15	lower	O
16	affinity	O
17	.	O

1	Treatment	O
2	and	O
3	staining	O
4	of	O
5	smears	O
6	and	O
7	sections	O
8	for	O
9	detection	O
10	of	O
11	microorganisms	O

1	To	O
2	determine	O
3	whether	O
4	interaction	O
5	of	O
6	arsenite	O
7	with	O
8	the	O
9	hormone	O
10	-	O
11	binding	O
12	domain	O
13	results	O
14	in	O
15	receptor	O
16	activation	O
17	,	O
18	COS	O
19	-	O
20	1	O
21	cells	O
22	were	O
23	transiently	O
24	cotransfected	O
25	with	O
26	the	O
27	chimeric	B
28	receptors	I
29	GAL	I
30	-	I
31	ER	I
32	,	O
33	which	O
34	contains	O
35	the	O
36	hormone	O
37	-	O
38	binding	O
39	domain	O
40	of	O
41	ERalpha	O
42	and	O
43	the	O
44	DNA	O
45	-	O
46	binding	O
47	domain	O
48	of	O
49	the	O
50	transcription	O
51	factor	O
52	GAL4	B
53	,	O
54	and	O
55	a	O
56	GAL4	B
57	-	I
58	responsive	I
59	CAT	I
60	reporter	I
61	gene	I
62	.	O

1	Linearized	O
2	overall	O
3	infection	O
4	rates	O
5	(	O
6	events	O
7	/	O
8	100	O
9	patient	O
10	-	O
11	days	O
12	)	O
13	were	O
14	2	O
15	.	O
16	05	O
17	+/-	O
18	0	O
19	.	O
20	33	O
21	(	O
22	heart	O
23	-	O
24	lung	O
25	)	O
26	and	O
27	2	O
28	.	O
29	34	O
30	+/-	O
31	0	O
32	.	O
33	34	O
34	(	O
35	double	O
36	-	O
37	lung	O
38	;	O
39	P	O
40	=	O
41	NS	O
42	)	O
43	at	O
44	3	O
45	months	O
46	.	O

1	Eukaryotic	O
2	initiation	O
3	factor	O
4	3	O
5	(	O
6	eIF3	O
7	)	O
8	is	O
9	a	O
10	large	O
11	multisubunit	O
12	complex	O
13	that	O
14	stabilizes	O
15	the	O
16	ternary	O
17	complex	O
18	,	O
19	eIF2	O
20	x	O
21	GTP	O
22	x	O
23	tRNA	O
24	(	O
25	Met	O
26	)	O
27	i	O
28	and	O
29	promotes	O
30	mRNA	O
31	binding	O
32	to	O
33	the	O
34	40	O
35	S	O
36	ribosomal	O
37	subunit	O
38	.	O
39	eIF3	O
40	also	O
41	functions	O
42	as	O
43	a	O
44	ribosome	O
45	subunit	O
46	anti	O
47	-	O
48	association	O
49	factor	O
50	.	O

1	Roux	B
2	-	I
3	en	I
4	-	I
5	Y	I
6	gastroenterostomy	O
7	severely	O
8	disturbs	O
9	emptying	O
10	of	O
11	the	O
12	gallbladder	O
13	.	O

1	Toxicities	O
2	included	O
3	:	O
4	nausea	O
5	/	O
6	vomiting	O
7	(	O
8	69	O
9	%),	O
10	headache	O
11	(	O
12	25	O
13	%),	O
14	chills	O
15	(	O
16	69	O
17	%),	O
18	pain	O
19	at	O
20	tumor	O
21	sites	O
22	(	O
23	63	O
24	%),	O
25	hypotension	O
26	(	O
27	31	O
28	%),	O
29	and	O
30	hypertension	O
31	(	O
32	38	O
33	%).	O

1	In	O
2	the	O
3	past	O
4	,	O
5	immunology	O
6	in	O
7	Singapore	O
8	was	O
9	mainly	O
10	confined	O
11	to	O
12	serology	O
13	for	O
14	the	O
15	diagnosis	O
16	of	O
17	certain	O
18	infectious	O
19	diseases	O
20	.	O

1	In	O
2	order	O
3	to	O
4	determine	O
5	which	O
6	sequences	O
7	in	O
8	the	O
9	GATA	B
10	-	I
11	1	I
12	promoter	I
13	are	O
14	crucial	O
15	for	O
16	activation	O
17	by	O
18	the	O
19	ME26	O
20	viral	O
21	protein	O
22	,	O
23	we	O
24	made	O
25	deletions	O
26	of	O
27	the	O
28	promoter	O
29	,	O
30	cloned	O
31	them	O
32	into	O
33	a	O
34	luciferase	B
35	expression	O
36	vector	O
37	and	O
38	tested	O
39	their	O
40	activity	O
41	in	O
42	mouse	O
43	fibroblasts	O
44	,	O
45	which	O
46	do	O
47	not	O
48	express	O
49	GATA	B
50	-	I
51	1	I
52	.	O

1	We	O
2	examined	O
3	the	O
4	hypothesis	O
5	that	O
6	the	O
7	coronary	O
8	vasomotor	O
9	responses	O
10	to	O
11	etomidate	O
12	(	O
13	ETO	O
14	),	O
15	propofol	O
16	(	O
17	PRO	O
18	),	O
19	and	O
20	sodium	O
21	thiopental	O
22	(	O
23	STP	O
24	)	O
25	are	O
26	mediated	O
27	through	O
28	contrasting	O
29	effects	O
30	on	O
31	the	O
32	resting	O
33	nitric	B
34	oxide	I
35	(	O
36	NO	O
37	)-	O
38	dependent	O
39	vasodilator	O
40	tone	O
41	that	O
42	opposes	O
43	adrenergic	O
44	vasoconstrictor	O
45	activity	O
46	in	O
47	the	O
48	intact	O
49	dog	O
50	.	O

1	To	O
2	characterize	O
3	the	O
4	gene	O
5	products	O
6	,	O
7	the	O
8	cvaA	B
9	gene	I
10	was	O
11	subcloned	O
12	and	O
13	expressed	O
14	under	O
15	the	O
16	control	O
17	of	O
18	T7	B
19	RNA	I
20	polymerase	I
21	promoter	I
22	.	O

1	Adriamycin	O
2	:	O
3	comparison	O
4	of	O
5	a	O
6	5	O
7	-	O
8	week	O
9	schedule	O
10	with	O
11	a	O
12	3	O
13	-	O
14	week	O
15	schedule	O
16	in	O
17	the	O
18	treatment	O
19	of	O
20	breast	O
21	cancer	O
22	.	O

1	We	O
2	established	O
3	the	O
4	radiosensitive	O
5	cell	O
6	line	O
7	SX9	O
8	from	O
9	mammary	O
10	carcinoma	O
11	cell	O
12	line	O
13	FM3A	O
14	.	O

1	Poly	O
2	(	O
3	dT	O
4	)	O
5	and	O
6	denatured	O
7	calf	O
8	thymus	O
9	DNA	O
10	were	O
11	more	O
12	effective	O
13	than	O
14	were	O
15	other	O
16	polynucleotides	O
17	tested	O
18	in	O
19	promoting	O
20	accumulation	O
21	of	O
22	19	O
23	HDP	O
24	*;	O
25	(	O
26	dT	O
27	)	O
28	8	O
29	was	O
30	as	O
31	effective	O
32	as	O
33	were	O
34	longer	O
35	molecules	O
36	of	O
37	(	O
38	dT	O
39	)	O
40	n	O
41	,	O
42	but	O
43	(	O
44	dT	O
45	)	O
46	4	O
47	and	O
48	(	O
49	dT	O
50	)	O
51	6	O
52	were	O
53	much	O
54	less	O
55	effective	O
56	,	O
57	indicating	O
58	that	O
59	the	O
60	binding	O
61	site	O
62	involved	O
63	in	O
64	19	O
65	HDP	O
66	*	O
67	accumulation	O
68	covered	O
69	between	O
70	6	O
71	and	O
72	8	O
73	residues	O
74	of	O
75	(	O
76	dT	O
77	)	O
78	n	O
79	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	negative	O
7	inotropic	O
8	action	O
9	of	O
10	nicorandil	O
11	is	O
12	caused	O
13	by	O
14	inhibition	O
15	of	O
16	Ca	O
17	influx	O
18	and	O
19	intracellular	O
20	mobilization	O
21	of	O
22	Ca	O
23	.	O

1	Protein	B
2	phosphatases	I
3	play	O
4	a	O
5	critical	O
6	role	O
7	in	O
8	the	O
9	regulation	O
10	of	O
11	the	O
12	eukaryotic	O
13	cell	O
14	cycle	O
15	and	O
16	signal	O
17	transduction	O
18	.	O

1	Thus	O
2	,	O
3	the	O
4	CCAAT	O
5	box	O
6	also	O
7	has	O
8	tissue	O
9	-	O
10	specific	O
11	characteristics	O
12	that	O
13	assist	O
14	in	O
15	targeting	O
16	expression	O
17	of	O
18	the	O
19	alpha	B
20	-	I
21	subunit	I
22	gene	I
23	to	O
24	trophoblasts	O
25	.	O

1	Lauciello	O
2	describes	O
3	a	O
4	technique	O
5	for	O
6	the	O
7	placement	O
8	of	O
9	functionally	O
10	generated	O
11	amalgam	O
12	stops	O
13	as	O
14	restorations	O
15	within	O
16	mandibular	O
17	acrylic	O
18	teeth	O
19	.	O

1	The	O
2	etiology	O
3	,	O
4	pathology	O
5	,	O
6	brain	O
7	CT	O
8	scan	O
9	features	O
10	,	O
11	clinical	O
12	manifestations	O
13	and	O
14	treatment	O
15	of	O
16	these	O
17	accidents	O
18	were	O
19	discussed	O
20	.	O

1	Drugs	O
2	that	O
3	are	O
4	transformed	O
5	via	O
6	phase	O
7	II	O
8	reactions	O
9	usually	O
10	do	O
11	not	O
12	require	O
13	dosage	O
14	adjustment	O
15	.	O

1	Efficacy	O
2	of	O
3	a	O
4	three	O
5	-	O
6	versus	O
7	a	O
8	five	O
9	-	O
10	week	O
11	alcohol	O
12	treatment	O
13	program	O
14	.	O

1	Based	O
2	on	O
3	213	O
4	determinations	O
5	,	O
6	the	O
7	control	O
8	mean	O
9	serum	O
10	CPK	O
11	activity	O
12	was	O
13	262	O
14	+/-	O
15	113	O
16	I	O
17	.	O
18	U	O
19	./	O
20	liter	O
21	.	O

1	We	O
2	speculate	O
3	that	O
4	the	O
5	human	O
6	papillomavirus	O
7	late	O
8	mRNAs	O
9	,	O
10	produced	O
11	from	O
12	several	O
13	hundred	O
14	copies	O
15	of	O
16	the	O
17	virus	O
18	genome	O
19	present	O
20	in	O
21	infected	O
22	cells	O
23	,	O
24	compete	O
25	with	O
26	the	O
27	c	B
28	-	I
29	fos	I
30	mRNAs	I
31	for	O
32	destabilizing	O
33	cellular	O
34	factors	O
35	and	O
36	that	O
37	this	O
38	may	O
39	lead	O
40	to	O
41	elevated	O
42	Fos	B
43	protein	I
44	levels	O
45	in	O
46	human	O
47	papillomavirus	O
48	infected	O
49	cells	O
50	.	O

1	The	O
2	encoded	O
3	polypeptide	O
4	is	O
5	similar	O
6	in	O
7	sequence	O
8	to	O
9	the	O
10	ABA	O
11	-	O
12	1	O
13	allergen	O
14	of	O
15	Ascaris	O
16	,	O
17	the	O
18	gp15	O
19	/	O
20	400	O
21	'	O
22	ladder	O
23	'	O
24	protein	O
25	of	O
26	Brugia	O
27	malayi	O
28	,	O
29	Brugia	O
30	pahangi	O
31	and	O
32	Wuchereria	B
33	bancrofti	I
34	,	O
35	and	O
36	a	O
37	15	O
38	-	O
39	kDa	O
40	antigen	O
41	of	O
42	Dirofilaria	O
43	immitis	O
44	.	O

1	Molecule	O
2	(	O
3	s	O
4	)	O
5	secreted	O
6	by	O
7	neuronal	O
8	cultures	O
9	contribute	O
10	to	O
11	this	O
12	induction	O
13	of	O
14	GLT	O
15	-	O
16	1	O
17	,	O
18	but	O
19	little	O
20	is	O
21	known	O
22	about	O
23	the	O
24	signaling	O
25	pathways	O
26	mediating	O
27	this	O
28	regulation	O
29	.	O

1	Fourteen	O
2	patients	O
3	with	O
4	New	O
5	York	O
6	Heart	O
7	Association	O
8	class	O
9	II	O
10	congestive	O
11	heart	O
12	failure	O
13	were	O
14	enrolled	O
15	in	O
16	a	O
17	double	O
18	-	O
19	blind	O
20	,	O
21	cross	O
22	-	O
23	over	O
24	study	O
25	.	O

1	The	O
2	Cr	O
3	.	O
4	psbA	O
5	-	O
6	4	O
7	ORF	O
8	contains	O
9	an	O
10	H	O
11	-	O
12	N	O
13	-	O
14	H	O
15	motif	O
16	,	O
17	and	O
18	possibly	O
19	a	O
20	GIY	O
21	-	O
22	YIG	O
23	motif	O
24	.	O

1	Lyn	B
2	kinase	I
3	immunoprecipitated	O
4	from	O
5	lysates	O
6	of	O
7	irradiated	O
8	BCP	O
9	as	O
10	well	O
11	as	O
12	a	O
13	full	O
14	-	O
15	length	O
16	glutathione	B
17	S	I
18	-	I
19	transferase	I
20	(	O
21	GST	B
22	)-	I
23	Lyn	I
24	fusion	I
25	protein	I
26	-	I
27	phosphorylated	O
28	recombinant	O
29	human	O
30	p34cdc2	O
31	on	O
32	tyrosine	O
33	15	O
34	.	O

1	Managing	O
2	dysphagia	O
3	in	O
4	a	O
5	chronic	O
6	care	O
7	setting	O
8	:	O
9	an	O
10	introduction	O
11	.	O

1	Transient	O
2	transfection	O
3	experiments	O
4	revealed	O
5	that	O
6	Pax	B
7	-	I
8	8	I
9	isoforms	I
10	a	O
11	and	O
12	b	O
13	,	O
14	but	O
15	not	O
16	c	O
17	and	O
18	d	O
19	,	O
20	strongly	O
21	stimulate	O
22	transcription	O
23	from	O
24	a	O
25	promoter	O
26	containing	O
27	six	O
28	copies	O
29	of	O
30	a	O
31	paired	O
32	-	O
33	domain	O
34	recognition	O
35	sequence	O
36	.	O

1	Temafloxacin	O
2	400	O
3	mg	O
4	b	O
5	.	O
6	i	O
7	.	O
8	d	O
9	.	O
10	administered	O
11	orally	O
12	for	O
13	28	O
14	days	O
15	represents	O
16	a	O
17	safe	O
18	and	O
19	effective	O
20	treatment	O
21	for	O
22	chronic	O
23	bacterial	O
24	prostatitis	O
25	.	O

1	Pharmacologic	O
2	properties	O
3	of	O
4	serotonergic	O
5	agents	O
6	and	O
7	antidepressant	O
8	drugs	O
9	.	O

1	Expression	O
2	of	O
3	ME31B	O
4	cDNA	O
5	in	O
6	S	O
7	.	O
8	pombe	O
9	suppresses	O
10	the	O
11	ste13	O
12	mutation	O
13	.	O

1	Palindromic	O
2	rheumatism	O

1	An	O
2	intact	O
3	neurovascular	O
4	supply	O
5	is	O
6	essential	O
7	for	O
8	the	O
9	viability	O
10	of	O
11	a	O
12	muscle	O
13	flap	O
14	.	O

1	Expression	O
2	of	O
3	GlcNAc	B
4	-	I
5	TI	I
6	mRNA	I
7	in	O
8	tobacco	O
9	leaves	O
10	was	O
11	detected	O
12	using	O
13	RT	O
14	-	O
15	PCR	O
16	.	O

1	Defective	O
2	provirus	O
3	genomes	O
4	of	O
5	human	O
6	T	O
7	-	O
8	cell	O
9	leukemia	O
10	virus	O
11	type	O
12	I	O
13	are	O
14	frequently	O
15	detected	O
16	in	O
17	lymphocytes	O
18	from	O
19	infected	O
20	individuals	O
21	and	O
22	in	O
23	infected	O
24	cell	O
25	lines	O
26	.	O

1	M	O
2	.,	O
3	and	O
4	D	O
5	.	O

1	To	O
2	investigate	O
3	the	O
4	mechanisms	O
5	involved	O
6	in	O
7	the	O
8	transcriptional	O
9	control	O
10	of	O
11	retinoid	B
12	X	I
13	receptor	I
14	(	O
15	RXR	B
16	)	I
17	gene	I
18	expression	O
19	,	O
20	the	O
21	5	O
22	'-	O
23	flanking	O
24	region	O
25	of	O
26	the	O
27	human	O
28	RXRgamma2	O
29	isoform	O
30	was	O
31	characterized	O
32	.	O

1	Study	O
2	of	O
3	the	O
4	alterations	O
5	of	O
6	intestinal	O
7	absorption	O
8	,	O
9	by	O
10	means	O
11	of	O
12	I	O
13	-	O
14	131	O
15	-	O
16	triolein	O
17	,	O
18	in	O
19	the	O
20	whole	O
21	body	O
22	irradiated	O
23	rat	O

1	T7	O
2	transcription	O
3	could	O
4	be	O
5	manipulated	O
6	to	O
7	achieve	O
8	different	O
9	levels	O
10	of	O
11	constitutive	O
12	expression	O
13	,	O
14	through	O
15	the	O
16	use	O
17	of	O
18	promoter	O
19	mutations	O
20	.	O

1	Our	O
2	experiments	O
3	suggest	O
4	that	O
5	the	O
6	SCL	O
7	gene	O
8	can	O
9	be	O
10	a	O
11	target	O
12	for	O
13	the	O
14	erythroid	O
15	transcription	O
16	factor	O
17	GATA	B
18	-	I
19	1	I
20	and	O
21	that	O
22	the	O
23	SCL	B
24	gene	I
25	product	I
26	serves	O
27	as	O
28	a	O
29	positive	O
30	regulator	O
31	of	O
32	erythroid	O
33	differentiation	O
34	.	O

1	A	O
2	region	O
3	approximately	O
4	100	O
5	bp	O
6	upstream	O
7	from	O
8	the	O
9	transcription	O
10	start	O
11	point	O
12	of	O
13	virB	O
14	was	O
15	identified	O
16	as	O
17	being	O
18	necessary	O
19	for	O
20	full	O
21	activation	O
22	of	O
23	this	O
24	promoter	O
25	by	O
26	VirF	O
27	.	O

1	Calves	O
2	fed	O
3	MCT	O
4	-	O
5	milk	O
6	had	O
7	significantly	O
8	lower	O
9	blood	O
10	cholesterol	O
11	than	O
12	calves	O
13	fed	O
14	T	O
15	-	O
16	or	O
17	SBO	O
18	-	O
19	milk	O
20	.	O

1	Childhood	O
2	misbehavior	O
3	and	O
4	the	O
5	risk	O
6	of	O
7	injecting	O
8	drug	O
9	use	O
10	.	O

1	These	O
2	data	O
3	provide	O
4	evidence	O
5	that	O
6	the	O
7	2	O
8	.	O
9	0	O
10	-	O
11	kb	O
12	LAT	O
13	is	O
14	an	O
15	intron	O
16	of	O
17	the	O
18	mLAT	O
19	pre	O
20	-	O
21	mRNA	O
22	with	O
23	a	O
24	unique	O
25	branch	O
26	point	O
27	.	O

1	A	O
2	multi	O
3	-	O
4	centre	O
5	evaluation	O
6	of	O
7	the	O
8	card	O
9	indirect	O
10	agglutination	O
11	test	O
12	for	O
13	trypanosomiasis	O
14	(	O
15	TrypTect	O
16	CIATT	O
17	).	O

1	During	O
2	exercise	O
3	,	O
4	the	O
5	Pes	O
6	-	O
7	Ves	O
8	relation	O
9	was	O
10	shifted	O
11	toward	O
12	the	O
13	left	O
14	and	O
15	the	O
16	slope	O
17	[	O
18	end	O
19	-	O
20	systolic	O
21	elastance	O
22	(	O
23	Ees	O
24	)]	O
25	increased	O
26	from	O
27	7	O
28	.	O
29	7	O
30	+/-	O
31	2	O
32	.	O
33	8	O
34	to	O
35	12	O
36	.	O
37	7	O
38	+/-	O
39	4	O
40	.	O
41	2	O
42	(	O
43	SD	O
44	)	O
45	mmHg	O
46	/	O
47	ml	O
48	(	O
49	P	O
50	<	O
51	0	O
52	.	O
53	05	O
54	).	O

1	It	O
2	could	O
3	be	O
4	detected	O
5	exclusively	O
6	in	O
7	the	O
8	culture	O
9	medium	O
10	of	O
11	cDNA	O
12	-	O
13	transfected	O
14	COS	O
15	cells	O
16	.	O

1	Since	O
2	the	O
3	RINX	O
4	gene	O
5	is	O
6	likely	O
7	an	O
8	ortholog	O
9	of	O
10	the	O
11	goldfish	O
12	Vsx1	O
13	gene	O
14	,	O
15	it	O
16	has	O
17	been	O
18	named	O
19	VSX1	O
20	by	O
21	the	O
22	Human	O
23	Gene	O
24	Nomenclature	O
25	Committee	O
26	.	O

1	We	O
2	describe	O
3	a	O
4	novel	O
5	zinc	O
6	finger	O
7	protein	O
8	,	O
9	dsRBP	O
10	-	O
11	ZFa	O
12	,	O
13	isolated	O
14	by	O
15	screening	O
16	an	O
17	expression	O
18	library	O
19	with	O
20	dsRNA	O
21	.	O

1	Subretinal	O
2	fluid	O
3	was	O
4	punctured	O
5	on	O
6	the	O
7	poorer	O
8	eye	O
9	in	O
10	19	O
11	eyes	O
12	(	O
13	52	O
14	.	O
15	7	O
16	%)	O
17	and	O
18	on	O
19	the	O
20	better	O
21	eye	O
22	in	O
23	7	O
24	eyes	O
25	(	O
26	19	O
27	.	O
28	4	O
29	%).	O

1	Composites	O
2	as	O
3	restoration	O
4	materials	O

1	Five	O
2	-	O
3	year	O
4	prospective	O
5	study	O
6	of	O
7	peripheral	O
8	white	O
9	blood	O
10	cells	O
11	in	O
12	infectious	O
13	mononucleosis	O
14	.	O

1	CAL	O
2	gain	O
3	amounted	O
4	to	O
5	4	O
6	.	O
7	2	O
8	+/-	O
9	1	O
10	.	O
11	3	O
12	mm	O
13	,	O
14	60	O
15	%	O
16	of	O
17	the	O
18	defects	O
19	showing	O
20	CAL	O
21	gain	O
22	>	O
23	or	O
24	=	O
25	4	O
26	mm	O
27	.	O

1	In	O
2	a	O
3	model	O
4	of	O
5	the	O
6	ternary	O
7	complex	O
8	,	O
9	the	O
10	segment	O
11	of	O
12	NFAT	B
13	nearest	I
14	AP	I
15	-	I
16	1	I
17	is	O
18	the	O
19	Rel	B
20	insert	O
21	region	O
22	(	O
23	RIR	O
24	),	O
25	a	O
26	feature	O
27	that	O
28	is	O
29	notable	O
30	for	O
31	its	O
32	hypervariability	O
33	in	O
34	size	O
35	and	O
36	in	O
37	sequence	O
38	amongst	O
39	members	O
40	of	O
41	the	O
42	Rel	B
43	transcription	I
44	factor	I
45	family	I
46	.	O

1	Proctoscopy	O
2	and	O
3	roentgenographic	O
4	studies	O
5	may	O
6	be	O
7	an	O
8	important	O
9	part	O
10	of	O
11	evaluation	O
12	,	O
13	especially	O
14	in	O
15	patients	O
16	who	O
17	present	O
18	with	O
19	perianal	O
20	suppuration	O
21	,	O
22	masses	O
23	,	O
24	or	O
25	anal	O
26	fissures	O
27	.	O

1	Salzburg	O
2	,	O
3	9	O
4	-	O
5	12	O
6	September	O
7	1987	O
8	.	O

1	Analysis	O
2	of	O
3	several	O
4	Tat	B
5	mutants	I
6	indicated	O
7	that	O
8	both	O
9	the	O
10	cysteine	O
11	-	O
12	rich	O
13	and	O
14	the	O
15	core	O
16	domains	O
17	of	O
18	this	O
19	transactivator	O
20	are	O
21	necessary	O
22	and	O
23	sufficient	O
24	to	O
25	activate	O
26	transcription	O
27	when	O
28	TBP	B
29	is	O
30	overexpressed	O
31	.	O

1	Blood	O
2	levels	O
3	of	O
4	melatonin	O
5	,	O
6	serotonin	O
7	,	O
8	cortisol	O
9	,	O
10	and	O
11	prolactin	B
12	in	O
13	relation	O
14	to	O
15	the	O
16	circadian	O
17	rhythm	O
18	of	O
19	platelet	O
20	serotonin	O
21	uptake	O
22	.	O

1	Interestingly	O
2	,	O
3	virions	O
4	also	O
5	contained	O
6	smaller	O
7	proteins	O
8	that	O
9	reacted	O
10	with	O
11	antibodies	O
12	specific	O
13	for	O
14	the	O
15	accessory	O
16	proteins	O
17	as	O
18	well	O
19	as	O
20	SN	O
21	and	O
22	CAT	B
23	fusion	O
24	partners	O
25	.	O

1	Its	O
2	organization	O
3	and	O
4	regulation	O
5	indicate	O
6	that	O
7	the	O
8	S	O
9	.	O
10	pombe	O
11	URA1	O
12	gene	O
13	product	O
14	appears	O
15	very	O
16	similar	O
17	to	O
18	the	O
19	S	O
20	.	O
21	cerevisiae	O
22	URA2	B
23	gene	I
24	product	I
25	.	O

1	Some	O
2	reflexions	O
3	apropos	O
4	of	O
5	a	O
6	personal	O
7	statistical	O
8	study	O
9	of	O
10	513	O
11	arterial	O
12	embolisms	O

1	Commonly	O
2	used	O
3	stressors	O
4	are	O
5	mental	O
6	arithmetics	O
7	,	O
8	speech	O
9	tasks	O
10	,	O
11	the	O
12	Stroop	O
13	test	O
14	,	O
15	videogame	O
16	playing	O
17	,	O
18	films	O
19	or	O
20	videotapes	O
21	and	O
22	interviews	O
23	.	O

1	Courses	O
2	were	O
3	repeated	O
4	every	O
5	four	O
6	weeks	O
7	.	O

1	The	O
2	tumor	O
3	suppressor	O
4	and	O
5	transcriptional	O
6	factor	O
7	p53	B
8	is	O
9	a	O
10	phosphorylated	O
11	protein	O
12	.	O

1	In	O
2	patients	O
3	with	O
4	type	O
5	II	O
6	tumors	O
7	,	O
8	the	O
9	pattern	O
10	of	O
11	lymphatic	O
12	spread	O
13	was	O
14	primarily	O
15	directed	O
16	toward	O
17	the	O
18	paracardial	O
19	,	O
20	lesser	O
21	curvature	O
22	,	O
23	and	O
24	left	O
25	gastric	O
26	artery	O
27	nodes	O
28	;	O
29	esophagectomy	O
30	offered	O
31	no	O
32	survival	O
33	benefit	O
34	over	O
35	extended	O
36	gastrectomy	O
37	in	O
38	these	O
39	patients	O
40	.	O

1	The	O
2	original	O
3	technique	O
4	was	O
5	developed	O
6	in	O
7	the	O
8	1960	O
9	'	O
10	s	O
11	to	O
12	analyze	O
13	the	O
14	inner	O
15	ear	O
16	fluid	O
17	as	O
18	a	O
19	diagnostic	O
20	procedure	O
21	(	O
22	i	O
23	.	O
24	e	O
25	.,	O
26	diagnostic	O
27	labyrinthotomy	O
28	)	O
29	in	O
30	acoustic	O
31	neuroma	O
32	suspects	O
33	.	O

1	73	O
2	:	O
3	658	O
4	-	O
5	666	O
6	,	O
7	1999	O
8	).	O

1	51	O
2	.	O
3	9	O
4	%	O
5	(	O
6	P	O
7	=	O
8	0	O
9	.	O
10	0006	O
11	)	O
12	in	O
13	the	O
14	MMF	O
15	versus	O
16	the	O
17	AZA	O
18	groups	O
19	,	O
20	respectively	O
21	.	O

1	No	O
2	somatic	O
3	mutations	O
4	were	O
5	found	O
6	in	O
7	any	O
8	of	O
9	the	O
10	samples	O
11	,	O
12	suggesting	O
13	that	O
14	ING1	O
15	is	O
16	not	O
17	a	O
18	tumor	O
19	suppressor	O
20	gene	O
21	target	O
22	in	O
23	head	O
24	and	O
25	neck	O
26	cancer	O
27	.	O

1	Most	O
2	importantly	O
3	,	O
4	the	O
5	addition	O
6	of	O
7	purified	O
8	17S	O
9	U2	B
10	snRNPs	I
11	,	O
12	but	O
13	not	O
14	of	O
15	12S	B
16	U2	I
17	snRNPs	I
18	,	O
19	to	O
20	HeLa	O
21	splicing	O
22	extracts	O
23	in	O
24	which	O
25	the	O
26	endogeneous	O
27	U2	B
28	snRNPs	I
29	have	O
30	been	O
31	functionally	O
32	neutralized	O
33	with	O
34	anti	B
35	-	I
36	PRP9	I
37	antibodies	I
38	fully	O
39	restores	O
40	the	O
41	mRNA	O
42	-	O
43	splicing	O
44	activity	O
45	of	O
46	the	O
47	extracts	O
48	.	O

1	Magnetic	O
2	resonance	O
3	spectroscopy	O
4	(	O
5	MRS	O
6	)	O
7	and	O
8	imaging	O
9	(	O
10	MRI	O
11	)	O
12	are	O
13	now	O
14	well	O
15	established	O
16	techniques	O
17	for	O
18	the	O
19	study	O
20	of	O
21	cellular	O
22	metabolism	O
23	and	O
24	gross	O
25	structure	O
26	of	O
27	muscle	O
28	.	O

1	The	O
2	structure	O
3	of	O
4	the	O
5	enhancer	O
6	was	O
7	also	O
8	probed	O
9	by	O
10	inserting	O
11	a	O
12	pair	O
13	of	O
14	complementary	O
15	synthetic	O
16	oligodeoxynucleotides	O
17	which	O
18	represented	O
19	the	O
20	region	O
21	between	O
22	nt	O
23	positions	O
24	-	O
25	235	O
26	and	O
27	-	O
28	215	O
29	into	O
30	a	O
31	truncated	O
32	template	O
33	which	O
34	lacked	O
35	the	O
36	enhancer	O
37	.	O

1	The	O
2	grandfather	O
3	and	O
4	the	O
5	granddaughter	O
6	both	O
7	had	O
8	microtia	O
9	and	O
10	meatal	O
11	atresia	O
12	,	O
13	whereas	O
14	the	O
15	daughter	O
16	had	O
17	a	O
18	normal	O
19	outer	O
20	ear	O
21	except	O
22	for	O
23	a	O
24	narrow	O
25	meatus	O
26	and	O
27	auricular	O
28	appendages	O
29	.	O

1	A	O
2	distinct	O
3	staining	O
4	pattern	O
5	for	O
6	the	O
7	N	O
8	-	O
9	utrophin	O
10	was	O
11	not	O
12	detectable	O
13	,	O
14	although	O
15	it	O
16	was	O
17	expected	O
18	to	O
19	localise	O
20	at	O
21	the	O
22	actin	B
23	stress	O
24	fibers	O
25	.	O

1	The	O
2	effects	O
3	of	O
4	mean	O
5	luminance	O
6	were	O
7	also	O
8	measured	O
9	and	O
10	a	O
11	general	O
12	expression	O
13	that	O
14	would	O
15	take	O
16	them	O
17	into	O
18	account	O
19	was	O
20	derived	O
21	.	O

1	The	O
2	C	O
3	-	O
4	terminal	O
5	mature	O
6	region	O
7	is	O
8	highly	O
9	conserved	O
10	in	O
11	other	O
12	serine	O
13	carboxypeptidases	O
14	.	O

1	There	O
2	was	O
3	no	O
4	correlation	O
5	between	O
6	serum	O
7	LH	O
8	and	O
9	chronological	O
10	or	O
11	bone	O
12	age	O
13	in	O
14	this	O
15	age	O
16	group	O
17	,	O
18	which	O
19	suggests	O
20	that	O
21	the	O
22	correlation	O
23	found	O
24	is	O
25	not	O
26	due	O
27	to	O
28	age	O
29	-	O
30	related	O
31	parallel	O
32	phenomena	O
33	.	O

1	In	O
2	vitro	O
3	transcription	O
4	assays	O
5	demonstrate	O
6	that	O
7	the	O
8	TCA	O
9	-	O
10	cycle	O
11	intermediate	O
12	,	O
13	fumarate	O
14	,	O
15	directly	O
16	and	O
17	specifically	O
18	inhibits	O
19	the	O
20	formation	O
21	of	O
22	the	O
23	clcA	O
24	transcript	O
25	.	O

1	Object	O
2	relations	O
3	,	O
4	affect	O
5	management	O
6	,	O
7	and	O
8	psychic	O
9	structure	O
10	formation	O
11	.	O

1	T4	O
2	and	O
3	FT4I	O
4	followed	O
5	parallel	O
6	courses	O
7	in	O
8	both	O
9	groups	O
10	;	O
11	during	O
12	the	O
13	first	O
14	45	O
15	days	O
16	,	O
17	however	O
18	,	O
19	the	O
20	values	O
21	were	O
22	significantly	O
23	lower	O
24	in	O
25	premature	O
26	infants	O
27	under	O
28	34	O
29	weeks	O
30	'	O
31	EGA	O
32	than	O
33	in	O
34	term	O
35	infants	O
36	(	O
37	P	O
38	less	O
39	than	O
40	0	O
41	.	O
42	001	O
43	).	O

1	Pharmacokinetic	O
2	profile	O
3	of	O
4	clonazepam	O
5	in	O
6	rhesus	O
7	monkeys	O
8	.	O

1	A	O
2	specific	O
3	distal	O
4	promoter	O
5	controls	O
6	gamma	B
7	-	I
8	glutamyl	I
9	transpeptidase	I
10	gene	I
11	expression	O
12	in	O
13	undifferentiated	O
14	rat	O
15	transformed	O
16	liver	O
17	cells	O
18	.	O

1	To	O
2	begin	O
3	to	O
4	understand	O
5	this	O
6	role	O
7	,	O
8	we	O
9	overexpressed	O
10	ATF	B
11	-	I
12	2	I
13	in	O
14	a	O
15	human	O
16	cancer	O
17	cell	O
18	line	O
19	.	O

1	This	O
2	is	O
3	predicted	O
4	to	O
5	encode	O
6	a	O
7	315	O
8	-	O
9	residue	O
10	protein	O
11	containing	O
12	seven	O
13	hydrophobic	O
14	helical	O
15	regions	O
16	and	O
17	a	O
18	17	O
19	amino	O
20	acid	O
21	motif	O
22	characteristic	O
23	of	O
24	the	O
25	R7G	O
26	family	O
27	of	O
28	G	B
29	-	I
30	protein	I
31	coupled	I
32	membrane	I
33	-	I
34	bound	O
35	receptors	O
36	.	O

1	The	O
2	congenital	O
3	forms	O
4	(	O
5	7	O
6	cases	O
7	)	O
8	all	O
9	occurred	O
10	in	O
11	female	O
12	infants	O
13	and	O
14	involved	O
15	the	O
16	mucosa	O
17	overlying	O
18	either	O
19	the	O
20	anterior	O
21	ridge	O
22	of	O
23	the	O
24	maxilla	O
25	or	O
26	the	O
27	mandible	O
28	.	O

1	CONCLUSIONS	O
2	:	O
3	XCoe2	O
4	may	O
5	play	O
6	a	O
7	pivotal	O
8	role	O
9	in	O
10	the	O
11	transcriptional	O
12	cascade	O
13	that	O
14	specifies	O
15	primary	O
16	neurons	O
17	in	O
18	Xenopus	O
19	embryos	O
20	:	O
21	by	O
22	maintaining	O
23	Delta	O
24	-	O
25	Notch	B
26	signalling	O
27	,	O
28	XCoe2	O
29	stabilises	O
30	the	O
31	higher	O
32	neural	O
33	potential	O
34	of	O
35	selected	O
36	progenitor	O
37	cells	O
38	that	O
39	express	O
40	X	O
41	-	O
42	ngnr	O
43	-	O
44	1	O
45	,	O
46	ensuring	O
47	the	O
48	transition	O
49	between	O
50	neural	O
51	competence	O
52	and	O
53	irreversible	O
54	commitment	O
55	to	O
56	a	O
57	neural	O
58	fate	O
59	;	O
60	and	O
61	it	O
62	promotes	O
63	neuronal	O
64	differentiation	O
65	by	O
66	activating	O
67	XNeuroD	O
68	expression	O
69	,	O
70	directly	O
71	or	O
72	indirectly	O
73	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	results	O
6	suggest	O
7	that	O
8	silymarin	O
9	may	O
10	exert	O
11	a	O
12	strong	O
13	anticarcinogenic	O
14	effect	O
15	against	O
16	PCA	O
17	and	O
18	that	O
19	this	O
20	effect	O
21	is	O
22	likely	O
23	to	O
24	involve	O
25	impairment	O
26	of	O
27	erbB1	O
28	-	O
29	SHC	O
30	-	O
31	mediated	O
32	signaling	O
33	pathway	O
34	,	O
35	induction	O
36	of	O
37	CDKIs	O
38	,	O
39	and	O
40	a	O
41	resultant	O
42	G1	O
43	arrest	O
44	.	O

1	The	O
2	extraction	O
3	measurements	O
4	were	O
5	used	O
6	to	O
7	test	O
8	for	O
9	extracerebral	O
10	contamination	O
11	of	O
12	venous	O
13	outflow	O
14	.	O

1	Vascular	O
2	endothelial	O
3	cells	O
4	undergo	O
5	profound	O
6	changes	O
7	upon	O
8	cellular	O
9	activation	O
10	including	O
11	expression	O
12	of	O
13	a	O
14	spectrum	O
15	of	O
16	cell	O
17	activation	O
18	-	O
19	associated	O
20	genes	O
21	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	demonstrate	O
7	that	O
8	BOX	O
9	DNA	O
10	enhances	O
11	transcription	O
12	from	O
13	the	O
14	thymidine	B
15	kinase	I
16	(	O
17	TK	B
18	)	I
19	promoter	I
20	in	O
21	various	O
22	EC	O
23	cells	O
24	.	O

1	The	O
2	experimentally	O
3	mapped	O
4	regions	O
5	of	O
6	RPB5	O
7	involved	O
8	in	O
9	these	O
10	interactions	O
11	correspond	O
12	to	O
13	distinct	O
14	and	O
15	surface	O
16	-	O
17	exposed	O
18	alpha	O
19	-	O
20	helical	O
21	structures	O
22	.	O

1	Enzyme	O
2	I	O
3	of	O
4	the	O
5	phosphoenolpyruvate	O
6	:	O
7	sugar	O
8	phosphotransferase	O
9	system	O
10	.	O

1	Our	O
2	data	O
3	demonstrate	O
4	directly	O
5	that	O
6	Rpm1r	O
7	is	O
8	transcribed	O
9	with	O
10	its	O
11	substrates	O
12	,	O
13	tRNA	B
14	met	I
15	f	I
16	and	O
17	tRNAPro	O
18	,	O
19	from	O
20	a	O
21	promoter	O
22	located	O
23	upstream	O
24	of	O
25	the	O
26	tRNA	B
27	met	I
28	f	I
29	gene	I
30	and	O
31	suggest	O
32	that	O
33	a	O
34	portion	O
35	also	O
36	originates	O
37	from	O
38	a	O
39	second	O
40	promoter	O
41	,	O
42	located	O
43	between	O
44	the	O
45	tRNA	B
46	met	I
47	f	I
48	gene	I
49	and	O
50	RPM1	O
51	.	O

1	It	O
2	was	O
3	established	O
4	that	O
5	intrathecal	O
6	or	O
7	intraperitoneal	O
8	PTFL	O
9	,	O
10	elevated	O
11	the	O
12	nociceptive	O
13	threshold	O
14	for	O
15	mechanical	O
16	stimuli	O
17	in	O
18	the	O
19	formalin	O
20	test	O
21	in	O
22	rats	O
23	.	O

1	The	O
2	dying	O
3	tTG	O
4	-	O
5	transfected	O
6	cells	O
7	exhibit	O
8	both	O
9	cytoplasmic	O
10	and	O
11	nuclear	O
12	changes	O
13	characteristic	O
14	of	O
15	cells	O
16	undergoing	O
17	apoptosis	O
18	.	O

1	Although	O
2	human	O
3	infections	O
4	with	O
5	bacteraemia	O
6	due	O
7	to	O
8	Pasteurella	O
9	multocida	O
10	are	O
11	not	O
12	uncommon	O
13	,	O
14	endocarditis	O
15	associated	O
16	with	O
17	P	O
18	.	O
19	haemolytica	O
20	is	O
21	rare	O
22	.	O

1	Characterization	O
2	and	O
3	hormonal	O
4	regulation	O
5	of	O
6	the	O
7	promoter	O
8	of	O
9	the	O
10	rat	B
11	prostaglandin	I
12	endoperoxide	I
13	synthase	I
14	2	I
15	gene	I
16	in	O
17	granulosa	O
18	cells	O
19	.	O

1	However	O
2	,	O
3	in	O
4	a	O
5	new	O
6	experiment	O
7	in	O
8	which	O
9	the	O
10	deletion	O
11	task	O
12	was	O
13	presented	O
14	as	O
15	a	O
16	puppet	O
17	game	O
18	,	O
19	and	O
20	with	O
21	pretraining	O
22	and	O
23	selection	O
24	on	O
25	vowel	O
26	deletion	O
27	,	O
28	a	O
29	significantly	O
30	higher	O
31	level	O
32	of	O
33	success	O
34	was	O
35	achieved	O
36	by	O
37	the	O
38	children	O
39	working	O
40	with	O
41	the	O
42	CVCC	O
43	material	O
44	.	O

1	Effect	O
2	of	O
3	indomethacin	O
4	on	O
5	coronary	O
6	circulation	O
7	:	O
8	effect	O
9	on	O
10	ECG	O
11	tracing	O

1	Retrograde	O
2	filling	O
3	consists	O
4	in	O
5	sealing	O
6	endodontics	O
7	system	O
8	directly	O
9	at	O
10	the	O
11	apical	O
12	zone	O
13	after	O
14	surgical	O
15	approach	O
16	.	O

1	We	O
2	investigated	O
3	the	O
4	incidence	O
5	of	O
6	congenital	O
7	color	O
8	deficiency	O
9	among	O
10	Koreans	O
11	by	O
12	the	O
13	use	O
14	of	O
15	H	B
16	-	I
17	R	I
18	-	I
19	R	I
20	pseudoisochromatic	O
21	plates	O
22	.	O

1	The	O
2	analysis	O
3	of	O
4	the	O
5	structure	O
6	of	O
7	the	O
8	sleep	O
9	period	O
10	as	O
11	a	O
12	whole	O
13	reveals	O
14	that	O
15	with	O
16	increasing	O
17	of	O
18	the	O
19	age	O
20	the	O
21	delta	O
22	-	O
23	wave	O
24	stage	O
25	(	O
26	DS	O
27	)	O
28	of	O
29	the	O
30	QS	O
31	(	O
32	determined	O
33	by	O
34	defined	O
35	polygraphic	O
36	parameters	O
37	)	O
38	increases	O
39	,	O
40	while	O
41	the	O
42	paradoxical	O
43	phase	O
44	of	O
45	sleep	O
46	(	O
47	PS	O
48	)	O
49	decreases	O
50	,	O
51	this	O
52	change	O
53	being	O
54	more	O
55	pronounced	O
56	during	O
57	the	O
58	first	O
59	six	O
60	months	O
61	than	O
62	during	O
63	the	O
64	second	O
65	ones	O
66	of	O
67	the	O
68	first	O
69	year	O
70	of	O
71	the	O
72	life	O
73	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	the	O
5	polypeptide	O
6	component	O
7	of	O
8	the	O
9	Rel	B
10	-	I
11	related	I
12	human	O
13	p75	O
14	nucleoprotein	O
15	complex	O
16	has	O
17	revealed	O
18	its	O
19	identity	O
20	with	O
21	the	O
22	65	O
23	-	O
24	kDa	O
25	(	O
26	p65	B
27	)	O
28	subunit	O
29	of	O
30	NF	B
31	-	I
32	kappa	I
33	B	I
34	.	O

1	Biol	O
2	.	O

1	Mutation	O
2	of	O
3	the	O
4	central	O
5	Tyr497	O
6	to	O
7	Phe	O
8	blocks	O
9	the	O
10	tyrosine	O
11	phosphorylation	O
12	of	O
13	the	O
14	insulin	B
15	receptor	I
16	substrate	I
17	1	I
18	(	O
19	IRS1	O
20	)	O
21	and	O
22	diminishes	O
23	proliferation	O
24	in	O
25	response	O
26	to	O
27	IL	B
28	-	I
29	4	O
30	.	O

1	Risk	O
2	of	O
3	HTLV	O
4	infection	O
5	in	O
6	patients	O
7	on	O
8	haemodialysis	O
9	.	O

1	Retinoblastoma	O
2	:	O
3	a	O
4	study	O
5	of	O
6	natural	O
7	history	O
8	and	O
9	prognosis	O
10	of	O
11	268	O
12	cases	O
13	.	O

1	Furthermore	O
2	,	O
3	although	O
4	the	O
5	regional	O
6	distribution	O
7	of	O
8	lean	O
9	tissue	O
10	mass	O
11	in	O
12	the	O
13	trunk	O
14	and	O
15	legs	O
16	remained	O
17	fairly	O
18	constant	O
19	at	O
20	different	O
21	pubertal	O
22	stages	O
23	,	O
24	the	O
25	regional	O
26	distribution	O
27	of	O
28	fat	O
29	was	O
30	altered	O
31	significantly	O
32	,	O
33	becoming	O
34	more	O
35	central	O
36	and	O
37	less	O
38	peripheral	O
39	.	O

1	Positive	O
2	CRP	B
3	test	O
4	were	O
5	seen	O
6	.	O

1	The	O
2	aims	O
3	of	O
4	this	O
5	study	O
6	were	O
7	to	O
8	determine	O
9	and	O
10	rank	O
11	the	O
12	frequency	O
13	of	O
14	self	O
15	reported	O
16	visual	O
17	disability	O
18	in	O
19	daily	O
20	tasks	O
21	performed	O
22	by	O
23	glaucoma	O
24	patients	O
25	;	O
26	to	O
27	examine	O
28	the	O
29	interrelation	O
30	between	O
31	disabilities	O
32	using	O
33	factor	O
34	analysis	O
35	;	O
36	to	O
37	study	O
38	the	O
39	relation	O
40	between	O
41	perceived	O
42	visual	O
43	difficulty	O
44	and	O
45	a	O
46	measure	O
47	of	O
48	the	O
49	severity	O
50	of	O
51	visual	O
52	field	O
53	loss	O
54	;	O
55	to	O
56	develop	O
57	a	O
58	glaucoma	O
59	specific	O
60	subgroup	O
61	of	O
62	questions	O
63	;	O
64	and	O
65	examine	O
66	the	O
67	validity	O
68	and	O
69	reliability	O
70	of	O
71	this	O
72	subgroup	O
73	of	O
74	questions	O
75	.	O

1	The	O
2	primary	O
3	structure	O
4	of	O
5	a	O
6	2671	O
7	bp	O
8	DNA	O
9	fragment	O
10	between	O
11	the	O
12	pla	O
13	gene	O
14	(	O
15	encoding	O
16	plasminogen	B
17	activator	I
18	)	O
19	and	O
20	the	O
21	origin	O
22	of	O
23	replication	O
24	of	O
25	the	O
26	wild	O
27	-	O
28	type	O
29	Yersinia	O
30	pestis	O
31	plasmid	O
32	pYP358	O
33	was	O
34	determined	O
35	.	O

1	After	O
2	i	O
3	.	O
4	v	O
5	.	O

1	However	O
2	,	O
3	the	O
4	lens	O
5	dose	O
6	(	O
7	3	O
8	.	O
9	6	O
10	Gy	O
11	/	O
12	25	O
13	fractions	O
14	)	O
15	was	O
16	higher	O
17	compared	O
18	to	O
19	the	O
20	other	O
21	techniques	O
22	.	O

1	(	O
2	1992	O
3	)	O
4	J	O
5	.	O

1	Initial	O
2	estimates	O
3	indicate	O
4	that	O
5	27	O
6	,	O
7	193	O
8	people	O
9	are	O
10	either	O
11	in	O
12	receipt	O
13	of	O
14	or	O
15	in	O
16	need	O
17	of	O
18	mental	O
19	handicap	O
20	services	O
21	.	O

1	The	O
2	virus	O
3	-	O
4	associated	O
5	VAI	O
6	RNA	O
7	of	O
8	adenovirus	O
9	is	O
10	a	O
11	small	O
12	highly	O
13	structured	O
14	RNA	O
15	that	O
16	is	O
17	required	O
18	for	O
19	the	O
20	efficient	O
21	translation	O
22	of	O
23	cellular	O
24	and	O
25	viral	O
26	mRNAs	O
27	at	O
28	late	O
29	times	O
30	after	O
31	infection	O
32	.	O

1	Range	O
2	,	O
3	variations	O
4	and	O
5	neoplastic	O
6	potential	O
7	.	O

1	Heating	O
2	cells	O
3	to	O
4	43	O
5	degrees	O
6	C	O
7	decreased	O
8	the	O
9	amount	O
10	of	O
11	newly	O
12	synthesized	O
13	rRNA	O
14	to	O
15	less	O
16	than	O
17	5	O
18	%	O
19	of	O
20	the	O
21	control	O
22	level	O
23	and	O
24	led	O
25	to	O
26	greater	O
27	than	O
28	95	O
29	%	O
30	inhibition	O
31	of	O
32	transcription	O
33	termination	O
34	at	O
35	a	O
36	region	O
37	355	O
38	to	O
39	362	O
40	nucleotides	O
41	downstream	O
42	of	O
43	the	O
44	3	O
45	'	O
46	end	O
47	of	O
48	28S	B
49	rRNA	I
50	,	O
51	with	O
52	readthrough	O
53	continuing	O
54	into	O
55	the	O
56	next	O
57	transcription	O
58	unit	O
59	.	O

1	We	O
2	report	O
3	the	O
4	successful	O
5	use	O
6	of	O
7	electroconvulsive	O
8	therapy	O
9	for	O
10	treatment	O
11	of	O
12	severe	O
13	depression	O
14	in	O
15	a	O
16	young	O
17	man	O
18	with	O
19	adult	O
20	GM2	O
21	gangliosidosis	O
22	.	O

1	There	O
2	were	O
3	18	O
4	patients	O
5	with	O
6	Group	O
7	II	O
8	(	O
9	a	O
10	)	O
11	tumors	O
12	;	O
13	although	O
14	tumor	O
15	biopsy	O
16	was	O
17	attempted	O
18	on	O
19	eight	O
20	of	O
21	these	O
22	,	O
23	pathological	O
24	diagnosis	O
25	at	O
26	the	O
27	time	O
28	of	O
29	surgery	O
30	was	O
31	made	O
32	in	O
33	only	O
34	one	O
35	case	O
36	.	O

1	Activation	O
2	of	O
3	the	O
4	mitogen	B
5	activated	I
6	protein	I
7	(	I
8	MAP	I
9	)	I
10	kinase	I
11	is	O
12	a	O
13	primary	O
14	consequence	O
15	of	O
16	Ras	B
17	activation	O
18	and	O
19	plays	O
20	a	O
21	key	O
22	role	O
23	in	O
24	mediating	O
25	Ras	B
26	signal	O
27	transduction	O
28	.	O

1	CNS	O
2	effects	O
3	of	O
4	local	O
5	anesthetics	O
6	only	O
7	partially	O
8	dependent	O
9	on	O
10	biogenic	O
11	amine	O
12	mechanisms	O
13	.	O

1	Isolation	O
2	and	O
3	identification	O
4	of	O
5	genes	O
6	activating	O
7	UAS2	O
8	-	O
9	dependent	O
10	ADH2	O
11	expression	O
12	in	O
13	Saccharomyces	O
14	cerevisiae	O
15	.	O

1	Chronic	O
2	thyroiditis	O
3	as	O
4	a	O
5	risk	O
6	factor	O
7	of	O
8	B	O
9	-	O
10	cell	O
11	lymphoma	O
12	in	O
13	the	O
14	thyroid	O
15	gland	O
16	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	mitochondrial	O
6	presequences	O
7	interact	O
8	with	O
9	the	O
10	mt	B
11	-	I
12	hsp70	I
13	during	O
14	or	O
15	after	O
16	mitochondrial	O
17	protein	O
18	import	O
19	.	O

1	Clinical	O
2	value	O
3	of	O
4	the	O
5	estimation	O
6	of	O
7	growth	O
8	kinetics	O
9	of	O
10	primary	O
11	ovarian	O
12	cancer	O
13	recurrences	O
14	by	O
15	CA125	O
16	doubling	O
17	time	O

1	Derepression	O
2	of	O
3	gene	O
4	expression	O
5	mediated	O
6	by	O
7	the	O
8	5	O
9	'	O
10	upstream	O
11	region	O
12	of	O
13	the	O
14	isocitrate	B
15	lyase	I
16	gene	I
17	of	O
18	Candida	O
19	tropicalis	O
20	is	O
21	controlled	O
22	by	O
23	two	O
24	distinct	O
25	regulatory	O
26	pathways	O
27	in	O
28	Saccharomyces	O
29	cerevisiae	O
30	.	O

1	Deletion	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	NF	B
7	-	I
8	4FA	O
9	,	O
10	NF	B
11	-	I
12	4FB	I
13	,	O
14	and	O
15	AP	B
16	-	I
17	1	I
18	sequences	O
19	are	O
20	each	O
21	necessary	O
22	for	O
23	full	O
24	enhancer	O
25	activity	O
26	.	O

1	Optical	O
2	CD	O
3	,	O
4	and	O
5	spectral	O
6	and	O
7	activity	O
8	analyses	O
9	were	O
10	used	O
11	to	O
12	examine	O
13	reactivity	O
14	of	O
15	HO	O
16	isozymes	O
17	with	O
18	NO	O
19	species	O
20	produced	O
21	by	O
22	NO	O
23	donors	O
24	.	O

1	Intracellular	O
2	localization	O
3	studies	O
4	using	O
5	the	O
6	mDAP	O
7	-	O
8	3	O
9	/	O
10	EGFP	B
11	fusion	I
12	protein	I
13	,	O
14	cell	O
15	fractionation	O
16	and	O
17	protease	O
18	protection	O
19	experiments	O
20	localized	O
21	mDAP	O
22	-	O
23	3	O
24	to	O
25	the	O
26	mitochondrial	O
27	matrix	O
28	.	O

1	In	O
2	connective	O
3	tissue	O
4	,	O
5	cell	O
6	structure	O
7	contributes	O
8	to	O
9	type	O
10	I	O
11	collagen	B
12	expression	O
13	.	O

1	Organization	O
2	of	O
3	the	O
4	bovine	O
5	gene	O
6	encoding	O
7	the	O
8	endothelial	O
9	nitric	B
10	oxide	I
11	synthase	I
12	.	O

1	An	O
2	end	O
3	-	O
4	to	O
5	-	O
6	end	O
7	pancreaticojejunostomy	O
8	using	O
9	a	O
10	mechanical	O
11	purse	O
12	-	O
13	string	O
14	device	O
15	.	O

1	This	O
2	laser	O
3	provided	O
4	sufficient	O
5	power	O
6	in	O
7	an	O
8	amniotic	O
9	fluid	O
10	medium	O
11	to	O
12	occlude	O
13	placental	O
14	vessels	O
15	as	O
16	large	O
17	as	O
18	7	O
19	mm	O
20	in	O
21	diameter	O
22	within	O
23	6	O
24	seconds	O
25	at	O
26	a	O
27	power	O
28	density	O
29	of	O
30	2000	O
31	W	O
32	/	O
33	cm2	O
34	.	O

1	The	O
2	5	O
3	'	O
4	region	O
5	of	O
6	ADH5	O
7	contains	O
8	consensus	O
9	binding	O
10	sites	O
11	for	O
12	the	O
13	transcriptional	O
14	regulatory	O
15	proteins	O
16	,	O
17	Sp1	B
18	,	O
19	AP2	B
20	,	O
21	LF	B
22	-	I
23	A1	I
24	,	O
25	NF	B
26	-	I
27	1	I
28	,	O
29	NF	B
30	-	I
31	A2	I
32	,	O
33	and	O
34	NF	B
35	-	I
36	E1	O
37	.	O

1	ATP	O
2	by	O
3	itself	O
4	also	O
5	reduced	O
6	polypeptide	O
7	binding	O
8	to	O
9	Ssb1	O
10	/	O
11	2p	O
12	to	O
13	a	O
14	level	O
15	that	O
16	was	O
17	intermediate	O
18	between	O
19	that	O
20	observed	O
21	for	O
22	the	O
23	Ssa	O
24	Hsp70	O
25	proteins	O
26	tested	O
27	and	O
28	BiP	O
29	and	O
30	DnaK	O
31	.	O

1	Modification	O
2	by	O
3	this	O
4	latter	O
5	compound	O
6	was	O
7	so	O
8	extensive	O
9	that	O
10	the	O
11	amount	O
12	of	O
13	membrane	O
14	-	O
15	associated	O
16	N	O
17	-	O
18	myristoylated	O
19	protein	O
20	was	O
21	decreased	O
22	.	O

1	We	O
2	conclude	O
3	that	O
4	TA	O
5	caused	O
6	a	O
7	specific	O
8	decrease	O
9	in	O
10	AGD	O
11	on	O
12	GD	O
13	20	O
14	that	O
15	was	O
16	largely	O
17	reversed	O
18	by	O
19	PCD	O
20	23	O
21	.	O

1	Initial	O
2	results	O
3	indicate	O
4	that	O
5	this	O
6	23S	B
7	pre	I
8	-	I
9	rRNA	I
10	is	O
11	the	O
12	same	O
13	as	O
14	the	O
15	species	O
16	detected	O
17	on	O
18	depletion	O
19	of	O
20	the	O
21	small	B
22	nucleolar	I
23	RNA	I
24	-	I
25	associated	I
26	proteins	I
27	NOP1	I
28	and	O
29	GAR1	O
30	and	O
31	in	O
32	an	O
33	snr10	O
34	mutant	O
35	strain	O
36	.	O

1	The	O
2	finding	O
3	that	O
4	the	O
5	chimeric	O
6	TdT	B
7	::	I
8	Pol	I
9	beta	I
10	protein	I
11	possessed	I
12	significant	O
13	template	O
14	-	O
15	dependent	O
16	polymerase	O
17	activity	O
18	suggests	O
19	that	O
20	aa	O
21	1	O
22	-	O
23	60	O
24	of	O
25	Pol	B
26	beta	I
27	are	O
28	involved	O
29	in	O
30	template	O
31	utilization	O
32	during	O
33	the	O
34	polymerization	O
35	reaction	O
36	,	O
37	as	O
38	suggested	O
39	by	O
40	the	O
41	previous	O
42	finding	O
43	that	O
44	the	O
45	8	O
46	-	O
47	kDa	O
48	N	O
49	-	O
50	terminal	O
51	domain	O
52	of	O
53	Pol	B
54	beta	I
55	possesses	I
56	ssDNA	I
57	-	I
58	binding	I
59	activity	O
60	[	O
61	Kumar	O
62	et	O
63	al	O
64	.,	O
65	J	O
66	.	O

1	Tiaprofenic	O
2	acid	O
3	overdose	O
4	.	O

1	Similarly	O
2	,	O
3	supraventricular	O
4	tachycaydia	O
5	following	O
6	resuscitative	O
7	efforts	O
8	appeared	O
9	to	O
10	be	O
11	associated	O
12	with	O
13	a	O
14	negative	O
15	outcome	O
16	.	O

1	Arhythmacanthus	O
2	Yamaguti	O
3	,	O
4	1935	O
5	is	O
6	maintained	O
7	as	O
8	a	O
9	synonym	O
10	of	O
11	Heterosentis	O
12	because	O
13	the	O
14	distinction	O
15	between	O
16	two	O
17	and	O
18	three	O
19	hook	O
20	types	O
21	is	O
22	made	O
23	equivocal	O
24	when	O
25	the	O
26	transition	O
27	between	O
28	the	O
29	apical	O
30	and	O
31	subapical	O
32	hooks	O
33	is	O
34	gradual	O
35	.	O

1	Systemic	O
2	impact	O
3	of	O
4	risk	O
5	-	O
6	sharing	O
7	arrangements	O
8	.	O

1	The	O
2	sign	O
3	of	O
4	Leser	O
5	-	O
6	Trelat	O
7	:	O
8	does	O
9	it	O
10	exist	O
11	?	O
12	The	O
13	sign	O
14	of	O
15	Leser	O
16	-	O
17	Trelat	O
18	is	O
19	usually	O
20	regarded	O
21	as	O
22	a	O
23	reliable	O
24	cutaneous	O
25	marker	O
26	of	O
27	internal	O
28	malignancy	O
29	.	O

1	The	O
2	predicted	O
3	amino	O
4	acid	O
5	sequence	O
6	of	O
7	the	O
8	SAP	B
9	-	I
10	1	I
11	cDNA	I
12	showed	O
13	that	O
14	mature	O
15	SAP	B
16	-	I
17	1	I
18	consisted	O
19	of	O
20	1093	O
21	amino	O
22	acids	O
23	and	O
24	a	O
25	transmembrane	O
26	-	O
27	type	O
28	PTP	O
29	,	O
30	which	O
31	possessed	O
32	a	O
33	single	O
34	PTP	B
35	-	I
36	conserved	O
37	domain	O
38	in	O
39	the	O
40	cytoplasmic	O
41	region	O
42	.	O

1	Mutation	O
2	of	O
3	the	O
4	P450BM	O
5	-	O
6	3	O
7	Barbie	O
8	box	O
9	significantly	O
10	increased	O
11	the	O
12	expression	O
13	of	O
14	both	O
15	P450BM	O
16	-	O
17	3	O
18	and	O
19	Bm3P1	O
20	(	O
21	another	O
22	small	O
23	gene	O
24	located	O
25	upstream	O
26	of	O
27	the	O
28	P450BM	O
29	-	O
30	3	O
31	gene	O
32	that	O
33	encodes	O
34	a	O
35	second	O
36	putative	O
37	regulatory	O
38	protein	O
39	)	O
40	in	O
41	response	O
42	to	O
43	pentobarbital	O
44	induction	O
45	but	O
46	left	O
47	the	O
48	basal	O
49	levels	O
50	unaffected	O
51	.	O

1	The	O
2	protein	O
3	coding	O
4	region	O
5	,	O
6	1	O
7	,	O
8	696	O
9	bps	O
10	long	O
11	,	O
12	is	O
13	divided	O
14	by	O
15	an	O
16	intron	O
17	into	O
18	two	O
19	exons	O
20	.	O

1	Pol32Delta	O
2	strains	O
3	are	O
4	weak	O
5	antimutators	O
6	and	O
7	are	O
8	defective	O
9	for	O
10	damage	O
11	-	O
12	induced	O
13	mutagenesis	O
14	.	O

1	Thus	O
2	RV	O
3	O2	O
4	demand	O
5	fell	O
6	when	O
7	RC	O
8	O2	O
9	supply	O
10	was	O
11	reduced	O
12	,	O
13	although	O
14	a	O
15	flow	O
16	reserve	O
17	was	O
18	available	O
19	.	O

1	Closeup	O
2	:	O
3	a	O
4	resource	O
5	for	O
6	nurses	O
7	who	O
8	smoke	O
9	.	O

1	This	O
2	result	O
3	suggests	O
4	that	O
5	phosphorylation	O
6	of	O
7	Thr	O
8	14	O
9	and	O
10	/	O
11	or	O
12	Tyr	O
13	15	O
14	inhibits	O
15	p34cdc2	B
16	kinase	I
17	activity	O
18	,	O
19	in	O
20	line	O
21	with	O
22	the	O
23	location	O
24	of	O
25	these	O
26	residues	O
27	within	O
28	the	O
29	putative	O
30	ATP	O
31	binding	O
32	site	O
33	of	O
34	the	O
35	kinase	O
36	.	O

1	BACKGROUND	O
2	:	O
3	The	O
4	MAZE	O
5	-	O
6	III	O
7	is	O
8	the	O
9	surgical	O
10	treatment	O
11	of	O
12	choice	O
13	for	O
14	medically	O
15	refractory	O
16	atrial	O
17	fibrillation	O
18	.	O

1	In	O
2	Trial	O
3	1	O
4	,	O
5	eight	O
6	sows	O
7	were	O
8	allowed	O
9	to	O
10	farrow	O
11	naturally	O
12	(	O
13	d	O
14	114	O
15	,	O
16	NF	B
17	sows	O
18	)	O
19	and	O
20	eight	O
21	sows	O
22	were	O
23	induced	O
24	to	O
25	farrow	O
26	(	O
27	IF	O
28	sows	O
29	)	O
30	prematurely	O
31	by	O
32	injection	O
33	of	O
34	prostaglandin	O
35	F2	O
36	alpha	O
37	on	O
38	d	O
39	112	O
40	of	O
41	gestation	O
42	.	O

1	PNT	O
2	,	O
3	ADD	O
4	and	O
5	BSS	O
6	in	O
7	the	O
8	initial	O
9	stage	O
10	of	O
11	kindling	O
12	,	O
13	kindling	O
14	rate	O
15	for	O
16	the	O
17	stage	O
18	-	O
19	3	O
20	and	O
21	-	O
22	5	O
23	seizures	O
24	,	O
25	seizure	O
26	parameters	O
27	at	O
28	the	O
29	first	O
30	stage	O
31	-	O
32	3	O
33	and	O
34	-	O
35	5	O
36	were	O
37	recorded	O
38	and	O
39	compared	O
40	to	O
41	the	O
42	values	O
43	of	O
44	saline	O
45	-	O
46	treated	O
47	,	O
48	control	O
49	group	O
50	.	O

1	When	O
2	the	O
3	CO2	O
4	content	O
5	reached	O
6	9	O
7	Vol	O
8	%	O
9	the	O
10	animals	O
11	became	O
12	apathic	O
13	and	O
14	lost	O
15	body	O
16	weight	O
17	.	O

1	Investigation	O
2	on	O
3	the	O
4	exchange	O
5	of	O
6	Ca45	O
7	in	O
8	intact	O
9	and	O
10	burned	O
11	rats	O
12	by	O
13	the	O
14	kinetic	O
15	analysis	O
16	method	O

1	A	O
2	Chinese	O
3	(	O
4	HK	O
5	)	O
6	SF	O
7	-	O
8	36	O
9	survey	O
10	form	O
11	was	O
12	developed	O
13	by	O
14	an	O
15	iterative	O
16	translation	O
17	process	O
18	.	O

1	The	O
2	sequences	O
3	showed	O
4	extensive	O
5	homologies	O
6	with	O
7	squalene	B
8	synthase	I
9	genes	I
10	and	O
11	enzymes	O
12	from	O
13	a	O
14	number	O
15	of	O
16	other	O
17	organisms	O
18	and	O
19	extreme	O
20	amino	O
21	acid	O
22	conservation	O
23	within	O
24	the	O
25	binding	O
26	and	O
27	catalytic	O
28	domains	O
29	.	O

1	The	O
2	junctions	O
3	between	O
4	viral	O
5	and	O
6	cellular	O
7	sequences	O
8	were	O
9	determined	O
10	by	O
11	DNA	O
12	sequence	O
13	analysis	O
14	to	O
15	be	O
16	517	O
17	nucleotides	O
18	into	O
19	the	O
20	p30	O
21	sequence	O
22	and	O
23	1	O
24	,	O
25	920	O
26	nucleotides	O
27	into	O
28	the	O
29	polymerase	O
30	sequence	O
31	.	O

1	The	O
2	HGF	B
3	-	I
4	induced	O
5	cell	O
6	motility	O
7	was	O
8	mimicked	O
9	by	O
10	12	O
11	-	O
12	0	O
13	-	O
14	tetradecanoyl	O
15	-	O
16	phorbol	O
17	-	O
18	13	O
19	-	O
20	acetate	O
21	,	O
22	a	O
23	protein	B
24	kinase	I
25	C	I
26	-	I
27	activating	I
28	phorbol	O
29	ester	O
30	,	O
31	but	O
32	not	O
33	by	O
34	Ca2	O
35	+	O
36	ionophore	O
37	.	O

1	Effect	O
2	of	O
3	indomethacin	O
4	and	O
5	prostaglandin	O
6	F2	O
7	alpha	O
8	on	O
9	parturition	O
10	in	O
11	swine	O
12	.	O

1	VIII	O
2	in	O
3	doses	O
4	2	O
5	-	O
6	3	O
7	times	O
8	higher	O
9	than	O
10	usually	O
11	used	O
12	in	O
13	haemophiliacs	O
14	without	O
15	inhibitor	O
16	were	O
17	successful	O
18	.	O

1	This	O
2	review	O
3	seeks	O
4	to	O
5	summarize	O
6	the	O
7	disease	O
8	,	O
9	to	O
10	propose	O
11	pathways	O
12	of	O
13	carcinogenesis	O
14	and	O
15	to	O
16	suggest	O
17	ways	O
18	in	O
19	which	O
20	the	O
21	"	O
22	traditional	O
23	"	O
24	risk	O
25	factors	O
26	may	O
27	be	O
28	interpreted	O
29	on	O
30	the	O
31	basis	O
32	of	O
33	evolving	O
34	knowledge	O
35	.	O

1	The	O
2	results	O
3	imply	O
4	that	O
5	kindling	O
6	does	O
7	not	O
8	produce	O
9	its	O
10	facilitating	O
11	effect	O
12	on	O
13	acquisition	O
14	of	O
15	HPC	O
16	SS	O
17	by	O
18	removing	O
19	a	O
20	disruptive	O
21	effect	O
22	of	O
23	the	O
24	stimulation	O
25	.	O

1	Our	O
2	data	O
3	provide	O
4	a	O
5	biochemical	O
6	explanation	O
7	for	O
8	the	O
9	similarity	O
10	in	O
11	phenotype	O
12	between	O
13	A	O
14	-	O
15	T	O
16	and	O
17	NBS	O
18	.	O

1	The	O
2	temporal	O
3	and	O
4	static	O
5	plasma	O
6	concentration	O
7	-	O
8	effect	O
9	relationships	O
10	were	O
11	evaluated	O
12	by	O
13	pharmacodynamic	O
14	modeling	O
15	and	O
16	linear	O
17	regression	O
18	.	O

1	Despite	O
2	an	O
3	overall	O
4	survival	O
5	rate	O
6	of	O
7	43	O
8	%,	O
9	survival	O
10	to	O
11	discharge	O
12	varied	O
13	greatly	O
14	(	O
15	0	O
16	to	O
17	100	O
18	%)	O
19	among	O
20	the	O
21	24	O
22	diagnostic	O
23	groups	O
24	:	O
25	tumor	O
26	lysis	O
27	syndrome	O
28	and	O
29	systemic	O
30	lupus	O
31	erythematosus	O
32	(	O
33	3	O
34	/	O
35	3	O
36	patients	O
37	each	O
38	,	O
39	100	O
40	%),	O
41	hemolytic	O
42	uremic	O
43	syndrome	O
44	(	O
45	8	O
46	/	O
47	9	O
48	patients	O
49	,	O
50	89	O
51	%).	O

1	Only	O
2	two	O
3	patients	O
4	(	O
5	0	O
6	.	O
7	3	O
8	%)	O
9	had	O
10	a	O
11	CA	O
12	125	O
13	response	O
14	at	O
15	the	O
16	time	O
17	of	O
18	clinical	O
19	progression	O
20	.	O

1	Using	O
2	immunolocalization	O
3	,	O
4	we	O
5	observe	O
6	that	O
7	ACE3	O
8	,	O
9	a	O
10	440	O
11	-	O
12	bp	O
13	chorion	O
14	element	O
15	that	O
16	contains	O
17	information	O
18	sufficient	O
19	to	O
20	drive	O
21	amplification	O
22	,	O
23	directs	O
24	DmORC	O
25	localization	O
26	in	O
27	follicle	O
28	cells	O
29	.	O

1	METHODS	O
2	:	O
3	T2	O
4	*-	O
5	weighted	O
6	,	O
7	three	O
8	-	O
9	dimensional	O
10	gradient	O
11	-	O
12	echo	O
13	images	O
14	were	O
15	acquired	O
16	by	O
17	exploiting	O
18	the	O
19	magnetic	O
20	susceptibility	O
21	difference	O
22	between	O
23	oxygenated	O
24	and	O
25	deoxygenated	O
26	hemoglobin	B
27	in	O
28	the	O
29	vasculature	O
30	and	O
31	microvasculature	O
32	.	O

1	Fifty	O
2	-	O
3	eight	O
4	RMI	O
5	'	O
6	s	O
7	occurred	O
8	in	O
9	the	O
10	placebo	O
11	group	O
12	as	O
13	compared	O
14	to	O
15	only	O
16	twenty	O
17	in	O
18	the	O
19	AC	O
20	group	O
21	(	O
22	p	O
23	less	O
24	than	O
25	0	O
26	.	O
27	01	O
28	).	O

1	The	O
2	results	O
3	also	O
4	showed	O
5	that	O
6	although	O
7	oyster	O
8	shell	O
9	supplementation	O
10	generally	O
11	increased	O
12	alkaline	B
13	phosphatase	I
14	activity	O
15	,	O
16	bone	O
17	mineralization	O
18	was	O
19	relatively	O
20	uninfluenced	O
21	as	O
22	judged	O
23	by	O
24	the	O
25	low	O
26	coefficients	O
27	of	O
28	variation	O
29	(	O
30	CV	O
31	)	O
32	of	O
33	3	O
34	.	O
35	14	O
36	-	O
37	3	O
38	.	O
39	51	O
40	%	O
41	and	O
42	3	O
43	.	O
44	39	O
45	-	O
46	4	O
47	.	O
48	82	O
49	%	O
50	for	O
51	calcium	O
52	and	O
53	phosphorus	O
54	content	O
55	in	O
56	the	O
57	femur	O
58	and	O
59	tibia	O
60	respectively	O
61	.	O

1	The	O
2	4	O
3	degrees	O
4	stimuli	O
5	were	O
6	found	O
7	to	O
8	elicit	O
9	scalp	O
10	distributions	O
11	for	O
12	the	O
13	pattern	O
14	reversal	O
15	P100	O
16	and	O
17	the	O
18	pattern	O
19	onset	O
20	C1	O
21	consistent	O
22	with	O
23	striate	O
24	and	O
25	extrastriate	O
26	visual	O
27	cortical	O
28	origins	O
29	respectively	O
30	.	O

1	It	O
2	has	O
3	been	O
4	calculated	O
5	that	O
6	600	O
7	,	O
8	000	O
9	new	O
10	cases	O
11	of	O
12	lung	O
13	cancer	O
14	occur	O
15	worldwide	O
16	every	O
17	year	O
18	,	O
19	most	O
20	of	O
21	them	O
22	due	O
23	to	O
24	smoking	O
25	.	O

1	The	O
2	predicted	O
3	molecular	O
4	weight	O
5	of	O
6	the	O
7	polyprotein	O
8	encoded	O
9	by	O
10	ORF1	O
11	is	O
12	33	O
13	kilodaltons	O
14	(	O
15	kDa	O
16	).	O

1	Effects	O
2	of	O
3	nitrogen	O
4	(	O
5	PN2	O
6	:	O
7	5	O
8	and	O
9	14	O
10	MPa	O
11	)	O
12	and	O
13	helium	O
14	(	O
15	PHe	O
16	:	O
17	13	O
18	and	O
19	14	O
20	MPa	O
21	)	O
22	were	O
23	also	O
24	tested	O
25	.	O

1	Computer	O
2	software	O
3	assisted	O
4	ordering	O
5	(	O
6	CSAO	O
7	)	O
8	was	O
9	developed	O
10	to	O
11	integrate	O
12	PN	O
13	Ca	O
14	:	O
15	P	O
16	solubility	O
17	with	O
18	clinical	O
19	data	O
20	to	O
21	improve	O
22	parenteral	O
23	Ca	O
24	and	O
25	P	O
26	administration	O
27	.	O

1	Health	O
2	:	O
3	an	O
4	integrative	O
5	reticulum	O
6	.	O

1	The	O
2	second	O
3	patient	O
4	had	O
5	received	O
6	pituitary	O
7	-	O
8	derived	O
9	growth	O
10	hormone	O
11	for	O
12	treatment	O
13	of	O
14	growth	O
15	hormone	O
16	deficiency	O
17	,	O
18	secondary	O
19	to	O
20	a	O
21	third	O
22	ventricle	O
23	teratoma	O
24	,	O
25	exised	O
26	13	O
27	yr	O
28	earlier	O
29	.	O

1	A	O
2	single	O
3	exon	O
4	encodes	O
5	the	O
6	carboxyl	O
7	-	O
8	terminal	O
9	26	O
10	amino	O
11	acids	O
12	of	O
13	the	O
14	ssd	O
15	chain	O
16	and	O
17	the	O
18	3	O
19	'	O
20	untranslated	O
21	region	O
22	of	O
23	its	O
24	mRNA	O
25	,	O
26	ending	O
27	with	O
28	a	O
29	poly	O
30	(	O
31	A	O
32	)-	O
33	addition	O
34	site	O
35	.	O

1	Replacing	O
2	the	O
3	aspartic	O
4	acid	O
5	with	O
6	a	O
7	lysine	O
8	but	O
9	not	O
10	with	O
11	an	O
12	alanine	O
13	or	O
14	valine	O
15	residue	O
16	allowed	O
17	formation	O
18	of	O
19	disulfide	O
20	-	O
21	linked	O
22	dimers	O
23	.	O

1	(	O
2	i	O
3	)	O
4	Complete	O
5	Grb10	O
6	expression	O
7	from	O
8	cDNA	O
9	with	O
10	an	O
11	ecdysone	O
12	-	O
13	regulated	O
14	transient	O
15	expression	O
16	system	O
17	stimulated	O
18	PDGF	B
19	-	I
20	BB	I
21	-,	I
22	IGF	I
23	-	I
24	I	I
25	,	O
26	and	O
27	insulin	B
28	-	I
29	but	O
30	not	O
31	epidermal	B
32	growth	I
33	factor	I
34	(	O
35	EGF	B
36	)-	I
37	induced	O
38	DNA	O
39	synthesis	O
40	in	O
41	an	O
42	ecdysone	O
43	dose	O
44	-	O
45	responsive	O
46	fashion	O
47	.	O

1	This	O
2	suggests	O
3	that	O
4	alaproclate	O
5	acutely	O
6	increases	O
7	the	O
8	responsiveness	O
9	of	O
10	postsynaptic	B
11	muscarinic	I
12	and	I
13	alpha	I
14	1	I
15	adrenoceptors	I
16	.	O

1	Separate	O
2	experiments	O
3	measured	O
4	AIB	O
5	and	O
6	86RbCl	O
7	uptake	O
8	in	O
9	36B	O
10	-	O
11	10	O
12	cells	O
13	in	O
14	vitro	O
15	1	O
16	and	O
17	2	O
18	days	O
19	following	O
20	20	O
21	Gy	O
22	irradiation	O
23	to	O
24	assess	O
25	whether	O
26	this	O
27	radiation	O
28	dose	O
29	reduced	O
30	the	O
31	capacity	O
32	of	O
33	tumor	O
34	cells	O
35	to	O
36	trap	O
37	AIB	O
38	or	O
39	Rb	B
40	+.	O

1	Restriction	O
2	enzyme	O
3	mapping	O
4	and	O
5	Southern	O
6	analysis	O
7	indicated	O
8	further	O
9	that	O
10	the	O
11	human	B
12	MZF	I
13	-	I
14	1	I
15	gene	I
16	is	O
17	a	O
18	single	O
19	-	O
20	copy	O
21	gene	O
22	.	O

1	Glutathione	B
2	peroxidase	I
3	in	O
4	human	O
5	red	O
6	cells	O
7	in	O
8	health	O
9	and	O
10	disease	O
11	.	O

1	Hybridization	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	size	O
7	of	O
8	the	O
9	mRNA	O
10	is	O
11	about	O
12	1	O
13	.	O
14	4	O
15	kilobases	O
16	.	O

1	DNA	O
2	-	O
3	STAT	B
4	complexes	O
5	were	O
6	detected	O
7	in	O
8	all	O
9	Bcr	B
10	/	I
11	Abl	I
12	-	I
13	transformed	O
14	cell	O
15	lines	O
16	and	O
17	they	O
18	were	O
19	supershifted	O
20	by	O
21	antibodies	O
22	against	O
23	STAT1	B
24	and	O
25	STAT5	O
26	.	O

1	First	O
2	,	O
3	a	O
4	pet54	O
5	::	O
6	LEU2	O
7	cytoductant	O
8	bearing	O
9	the	O
10	'	O
11	short	O
12	'	O
13	mitochondrial	O
14	genome	O
15	that	O
16	lacks	O
17	both	O
18	COX1	O
19	introns	O
20	aI5	O
21	alpha	O
22	and	O
23	aI5	O
24	beta	O
25	is	O
26	defective	O
27	only	O
28	in	O
29	COX3	O
30	gene	O
31	expression	O
32	and	O
33	not	O
34	in	O
35	COX1	O
36	mRNA	O
37	splicing	O
38	or	O
39	mRNA	O
40	translation	O
41	.	O

1	Patients	O
2	with	O
3	an	O
4	enzymatic	O
5	activity	O
6	below	O
7	X	O
8	--	O
9	1	O
10	manifested	O
11	a	O
12	decrease	O
13	of	O
14	the	O
15	content	O
16	of	O
17	IgA	B
18	,	O
19	IgG	B
20	,	O
21	IgM	B
22	,	O
23	T	O
24	and	O
25	B	O
26	lymphocytes	O
27	,	O
28	and	O
29	of	O
30	phagocytic	O
31	activity	O
32	of	O
33	neutrophils	O
34	as	O
35	compared	O
36	to	O
37	patients	O
38	exhibiting	O
39	a	O
40	high	O
41	enzymatic	O
42	activity	O
43	.	O

1	With	O
2	exon	O
3	trapping	O
4	,	O
5	we	O
6	could	O
7	isolate	O
8	five	O
9	potential	O
10	exons	O
11	from	O
12	the	O
13	YAC	O
14	946E12	O
15	that	O
16	spans	O
17	the	O
18	region	O
19	,	O
20	four	O
21	of	O
22	which	O
23	could	O
24	be	O
25	placed	O
26	in	O
27	the	O
28	contig	O
29	in	O
30	the	O
31	vicinity	O
32	of	O
33	the	O
34	breakpoints	O
35	.	O

1	In	O
2	general	O
3	,	O
4	however	O
5	,	O
6	this	O
7	study	O
8	provided	O
9	little	O
10	evidence	O
11	of	O
12	any	O
13	effect	O
14	of	O
15	supplementation	O
16	to	O
17	athletic	O
18	performance	O
19	for	O
20	athletes	O
21	consuming	O
22	the	O
23	dietary	O
24	RDIs	O
25	.	O

1	DNase	B
2	I	I
3	footprint	O
4	analysis	O
5	identified	O
6	a	O
7	protected	O
8	region	O
9	from	O
10	-	O
11	37	O
12	to	O
13	-	O
14	53	O
15	.	O

1	Degenerate	O
2	primers	O
3	homologous	O
4	to	O
5	highly	O
6	conserved	O
7	regions	O
8	of	O
9	known	O
10	CYP3A	O
11	sequences	O
12	were	O
13	used	O
14	for	O
15	initial	O
16	RT	O
17	-	O
18	PCRs	O
19	.	O

1	Human	O
2	synovial	O
3	fluid	O
4	:	O
5	detection	O
6	of	O
7	a	O
8	new	O
9	component	O
10	.	O

1	Synthetic	O
2	ligands	O
3	have	O
4	been	O
5	identified	O
6	that	O
7	reset	O
8	and	O
9	amplify	O
10	the	O
11	cycle	O
12	of	O
13	pulsatile	O
14	GH	B
15	secretion	O
16	by	O
17	interacting	O
18	with	O
19	the	O
20	orphan	O
21	GH	B
22	-	I
23	secretagogue	I
24	receptor	I
25	(	I
26	GHS	I
27	-	I
28	R	I
29	).	O

1	Probable	O
2	progressive	O
3	multifocal	O
4	leukoencephalopathy	O
5	(	O
6	PML	O
7	)	O
8	was	O
9	diagnosed	O
10	on	O
11	the	O
12	basis	O
13	of	O
14	clinical	O
15	picture	O
16	and	O
17	magnetic	O
18	resonance	O
19	imaging	O
20	in	O
21	a	O
22	63	O
23	-	O
24	year	O
25	-	O
26	old	O
27	man	O
28	with	O
29	a	O
30	complete	O
31	remission	O
32	of	O
33	a	O
34	non	O
35	-	O
36	Hodgkin	O
37	'	O
38	s	O
39	lymphoma	O
40	.	O

1	We	O
2	studied	O
3	120	O
4	male	O
5	and	O
6	42	O
7	female	O
8	patients	O
9	with	O
10	early	O
11	CAD	O
12	who	O
13	were	O
14	unrelated	O
15	to	O
16	each	O
17	other	O
18	but	O
19	were	O
20	from	O
21	families	O
22	in	O
23	which	O
24	at	O
25	least	O
26	one	O
27	other	O
28	sibling	O
29	had	O
30	early	O
31	CAD	O
32	.	O

1	Recombinant	O
2	expression	O
3	of	O
4	a	O
5	chimeric	O
6	EGFR	B
7	/	I
8	ErbB	I
9	-	I
10	3	I
11	receptor	I
12	in	O
13	NIH	O
14	3T3	O
15	fibroblasts	O
16	allowed	O
17	us	O
18	to	O
19	investigate	O
20	cytoplasmic	O
21	events	O
22	associated	O
23	with	O
24	ErbB	B
25	-	I
26	3	O
27	signal	O
28	transduction	O
29	upon	O
30	ligand	O
31	activation	O
32	.	O

1	Initial	O
2	experience	O
3	with	O
4	the	O
5	new	O
6	technology	O
7	indicates	O
8	that	O
9	SieScape	O
10	is	O
11	an	O
12	alternative	O
13	to	O
14	other	O
15	methods	O
16	such	O
17	as	O
18	CT	O
19	and	O
20	MRI	O
21	.	O

1	The	O
2	RNase	B
3	MRP	I
4	RNA	I
5	gene	I
6	was	O
7	deleted	O
8	by	O
9	insertional	O
10	replacement	O
11	and	O
12	found	O
13	to	O
14	be	O
15	essential	O
16	for	O
17	cellular	O
18	viability	O
19	,	O
20	indicating	O
21	a	O
22	critical	O
23	nuclear	O
24	role	O
25	for	O
26	RNase	B
27	MRP	I
28	.	O

1	Additionally	O
2	,	O
3	observations	O
4	that	O
5	patients	O
6	with	O
7	mitral	O
8	versus	O
9	aortic	O
10	regurgitation	O
11	respond	O
12	differently	O
13	to	O
14	valve	O
15	replacement	O
16	suggest	O
17	that	O
18	differences	O
19	exist	O
20	preoperatively	O
21	between	O
22	these	O
23	two	O
24	types	O
25	of	O
26	volume	O
27	overload	O
28	.	O

1	Interestingly	O
2	,	O
3	Csx	O
4	/	O
5	Nkx2	O
6	.	O

1	High	O
2	trough	O
3	serum	O
4	TOB	O
5	concentrations	O
6	were	O
7	associated	O
8	with	O
9	death	O
10	and	O
11	very	O
12	low	O
13	levels	O
14	with	O
15	recovery	O
16	.	O

1	Conversely	O
2	,	O
3	E1A	B
4	binding	I
5	to	O
6	only	O
7	p300	B
8	/	I
9	CBP	I
10	results	O
11	in	O
12	an	O
13	increase	O
14	in	O
15	PARP	O
16	enzyme	O
17	activity	O
18	and	O
19	consequently	O
20	in	O
21	cell	O
22	death	O
23	susceptibility	O
24	to	O
25	irradiation	O
26	,	O
27	which	O
28	is	O
29	effectively	O
30	counteracted	O
31	by	O
32	the	O
33	PARP	O
34	chemical	O
35	inhibitor	O
36	3	O
37	-	O
38	aminobenzamide	O
39	.	O

1	The	O
2	'	O
3	field	O
4	of	O
5	stress	O
6	'	O
7	of	O
8	the	O
9	supervisory	O
10	nurse	O

1	The	O
2	5	O
3	'	O
4	flanking	O
5	region	O
6	contains	O
7	potential	O
8	binding	O
9	sites	O
10	for	O
11	TATA	O
12	-	O
13	binding	O
14	protein	O
15	,	O
16	Sp1	B
17	,	O
18	nuclear	O
19	factor	O
20	1	O
21	(	O
22	NF1	B
23	),	O
24	CAAT	B
25	-	I
26	box	I
27	binding	I
28	protein	I
29	(	I
30	C	I
31	/	I
32	EBP	I
33	),	O
34	hepatocyte	O
35	nuclear	O
36	factors	O
37	1	O
38	and	O
39	5	O
40	(	O
41	HNF1	O
42	,	O
43	HNF5	O
44	)	O
45	and	O
46	activator	O
47	proteins	O
48	1	O
49	and	O
50	2	O
51	(	O
52	AP1	B
53	,	O
54	AP2	B
55	).	O

1	Eukaryotic	O
2	translation	O
3	initiation	O
4	factor	O
5	4GI	O
6	is	O
7	a	O
8	cellular	O
9	target	O
10	for	O
11	NS1	B
12	protein	I
13	,	O
14	a	O
15	translational	O
16	activator	O
17	of	O
18	influenza	O
19	virus	O
20	.	O

1	Cattaneo	O
2	,	O
3	and	O
4	J	O
5	.	O

1	When	O
2	desipramine	O
3	was	O
4	injected	O
5	16	O
6	hrs	O
7	after	O
8	fluoxetine	O
9	injection	O
10	,	O
11	brain	O
12	levels	O
13	of	O
14	desipramine	O
15	were	O
16	no	O
17	longer	O
18	elevated	O
19	.	O

1	This	O
2	alternatively	O
3	spliced	O
4	transcript	O
5	contained	O
6	an	O
7	open	O
8	reading	O
9	frame	O
10	extending	O
11	from	O
12	the	O
13	upstream	O
14	J	O
15	alpha	O
16	11	O
17	-	O
18	2	O
19	region	O
20	to	O
21	82	O
22	nucleotides	O
23	downstream	O
24	of	O
25	the	O
26	beginning	O
27	of	O
28	the	O
29	TCR	B
30	C	I
31	alpha	I
32	region	O
33	,	O
34	and	O
35	potentially	O
36	encoded	O
37	a	O
38	36	O
39	amino	O
40	acid	O
41	polypeptide	O
42	.	O

1	Several	O
2	artifacts	O
3	occurred	O
4	that	O
5	interfered	O
6	with	O
7	visualization	O
8	of	O
9	the	O
10	diaphragm	O
11	.	O

1	Reporting	O
2	of	O
3	adverse	O
4	events	O
5	occurring	O
6	during	O
7	clinical	O
8	trials	O
9	of	O
10	investigational	O
11	drugs	O
12	is	O
13	a	O
14	complex	O
15	and	O
16	controversial	O
17	issue	O
18	.	O

1	U73	O
2	contains	O
3	C	O
4	,	O
5	D	O
6	and	O
7	D	O
8	'	O
9	boxes	O
10	and	O
11	a	O
12	12	O
13	-	O
14	nucleotide	O
15	antisense	O
16	complementarity	O
17	to	O
18	the	O
19	28S	B
20	ribosomal	I
21	RNA	I
22	.	O

1	Galphaq	O
2	,	O
3	Galpha12	O
4	,	O
5	and	O
6	Galpha13	O
7	,	O
8	but	O
9	not	O
10	Galphai	O
11	,	O
12	activate	O
13	SRF	B
14	through	O
15	RhoA	B
16	.	O

1	The	O
2	main	O
3	aim	O
4	of	O
5	the	O
6	contribution	O
7	,	O
8	which	O
9	opens	O
10	an	O
11	arena	O
12	for	O
13	discussion	O
14	on	O
15	the	O
16	Rivista	O
17	dell	O
18	'	O
19	Infermiere	O
20	is	O
21	to	O
22	critically	O
23	appraise	O
24	published	O
25	research	O
26	works	O
27	focusing	O
28	both	O
29	on	O
30	strengths	O
31	and	O
32	novelty	O
33	and	O
34	weaknesses	O
35	in	O
36	the	O
37	hypothesis	O
38	formulation	O
39	,	O
40	methods	O
41	and	O
42	instruments	O
43	used	O
44	,	O
45	discussion	O
46	of	O
47	results	O
48	.	O

1	There	O
2	were	O
3	3	O
4	/	O
5	32	O
6	(	O
7	9	O
8	.	O
9	4	O
10	per	O
11	cent	O
12	)	O
13	adverse	O
14	reactions	O
15	(	O
16	ADRs	O
17	),	O
18	and	O
19	one	O
20	case	O
21	each	O
22	of	O
23	nausea	O
24	,	O
25	dizziness	O
26	and	O
27	increased	O
28	menstrual	O
29	flow	O
30	.	O

1	Transcriptional	O
2	regulation	O
3	of	O
4	the	O
5	mouse	B
6	cytosolic	I
7	chaperonin	I
8	subunit	I
9	gene	I
10	Ccta	I
11	/	I
12	t	I
13	-	I
14	complex	I
15	polypeptide	I
16	1	I
17	by	O
18	selenocysteine	B
19	tRNA	I
20	gene	I
21	transcription	I
22	activating	I
23	factor	I
24	family	I
25	zinc	I
26	finger	I
27	proteins	I
28	.	O

1	Survival	O
2	of	O
3	111	O
4	Indium	O
5	-	O
6	labelled	O
7	autologous	O
8	platelets	O
9	was	O
10	studied	O
11	in	O
12	2	O
13	patients	O
14	after	O
15	correction	O
16	of	O
17	platelet	O
18	count	O
19	and	O
20	was	O
21	still	O
22	found	O
23	shortened	O
24	.	O

1	We	O
2	have	O
3	used	O
4	these	O
5	modified	O
6	assay	O
7	conditions	O
8	to	O
9	extend	O
10	studies	O
11	on	O
12	the	O
13	transposition	O
14	pathway	O
15	.	O

1	The	O
2	subjects	O
3	from	O
4	the	O
5	two	O
6	regions	O
7	with	O
8	a	O
9	higher	O
10	pollution	O
11	level	O
12	had	O
13	lower	O
14	FVC	O
15	and	O
16	FEV1	O
17	values	O
18	than	O
19	those	O
20	from	O
21	the	O
22	Viskovo	O
23	region	O
24	.	O

1	Here	O
2	,	O
3	we	O
4	show	O
5	that	O
6	the	O
7	zinc	O
8	finger	O
9	protein	O
10	Gis1	O
11	acts	O
12	as	O
13	a	O
14	dosage	O
15	-	O
16	dependent	O
17	suppressor	O
18	of	O
19	the	O
20	rim15Delta	O
21	defect	O
22	in	O
23	nutrient	O
24	limitation	O
25	-	O
26	induced	O
27	transcriptional	O
28	derepression	O
29	of	O
30	SSA3	O
31	.	O

1	We	O
2	have	O
3	elucidated	O
4	the	O
5	exon	O
6	-	O
7	intron	O
8	organization	O
9	of	O
10	the	O
11	entire	O
12	human	O
13	CD58	O
14	gene	O
15	,	O
16	including	O
17	approximately	O
18	2	O
19	.	O
20	5	O
21	kilobases	O
22	(	O
23	kb	O
24	)	O
25	of	O
26	5	O
27	'-	O
28	flanking	O
29	DNA	O
30	.	O

1	Southern	O
2	blot	O
3	analysis	O
4	of	O
5	endonuclease	O
6	-	O
7	digested	O
8	genomic	O
9	DNA	O
10	from	O
11	primary	O
12	chick	O
13	embryo	O
14	fibroblasts	O
15	(	O
16	CEF	O
17	)	O
18	suggested	O
19	that	O
20	MEK2	O
21	is	O
22	a	O
23	single	O
24	-	O
25	copy	O
26	gene	O
27	in	O
28	this	O
29	vertebrate	O
30	species	O
31	.	O

1	Cbf3	O
2	contains	O
3	three	O
4	proteins	O
5	,	O
6	Cbf3a	O
7	,	O
8	Cbf3b	O
9	and	O
10	Cbf3c	O
11	.	O

1	Plasma	O
2	levels	O
3	of	O
4	protein	O
5	C	O
6	,	O
7	protein	O
8	S	O
9	,	O
10	and	O
11	antithrombin	B
12	III	I
13	in	O
14	patients	O
15	with	O
16	subarachnoid	O
17	haemorrhage	O
18	.	O

1	Here	O
2	,	O
3	we	O
4	present	O
5	genetic	O
6	evidence	O
7	in	O
8	Saccharomyces	O
9	cerevisiae	O
10	for	O
11	a	O
12	functional	O
13	interaction	O
14	between	O
15	the	O
16	DEAH	O
17	protein	O
18	Prp16	O
19	,	O
20	and	O
21	the	O
22	U6	B
23	and	O
24	U2	B
25	spliceosomal	I
26	snRNAs	I
27	.	O

1	We	O
2	have	O
3	shown	O
4	previously	O
5	that	O
6	GH3	O
7	cells	O
8	transfected	O
9	with	O
10	the	O
11	rat	O
12	GnRH	B
13	receptor	I
14	cDNA	I
15	(	O
16	GGH3	O
17	-	O
18	1	O
19	'	O
20	cells	O
21	)	O
22	support	O
23	the	O
24	expression	O
25	of	O
26	a	O
27	cotransfected	O
28	fusion	O
29	gene	O
30	composed	O
31	of	O
32	797	O
33	base	O
34	pairs	O
35	of	O
36	rat	O
37	LHbeta	B
38	gene	I
39	5	O
40	'-	O
41	flanking	O
42	sequence	O
43	and	O
44	the	O
45	first	O
46	5	O
47	base	O
48	pairs	O
49	of	O
50	the	O
51	5	O
52	'-	O
53	untranslated	O
54	region	O
55	fused	O
56	to	O
57	a	O
58	luciferase	B
59	reporter	I
60	(-	O
61	797	O
62	/+	O
63	5LHbetaLUC	O
64	)	O
65	and	O
66	respond	O
67	to	O
68	a	O
69	GnRH	B
70	agonist	O
71	with	O
72	a	O
73	10	O
74	-	O
75	fold	O
76	stimulation	O
77	of	O
78	activity	O
79	.	O

1	Higher	O
2	CYP3A23	O
3	basal	O
4	activity	O
5	appears	O
6	to	O
7	be	O
8	due	O
9	to	O
10	an	O
11	E	O
12	-	O
13	box	O
14	in	O
15	3A23SiteA	O
16	that	O
17	interacts	O
18	with	O
19	USF1	O
20	,	O
21	a	O
22	ubiquitous	O
23	bHLH	B
24	/	I
25	leucine	I
26	zipper	I
27	transcription	I
28	factor	I
29	.	O

1	The	O
2	gene	O
3	encoding	O
4	TRP	O
5	-	O
6	2	O
7	maps	O
8	to	O
9	mouse	O
10	chromosome	O
11	14	O
12	,	O
13	in	O
14	the	O
15	region	O
16	of	O
17	the	O
18	coat	O
19	colour	O
20	mutation	O
21	slaty	O
22	.	O

1	First	O
2	,	O
3	two	O
4	MCTs	O
5	using	O
6	a	O
7	long	O
8	electrode	O
9	,	O
10	3	O
11	cm	O
12	in	O
13	size	O
14	,	O
15	were	O
16	performed	O
17	in	O
18	the	O
19	central	O
20	area	O
21	of	O
22	the	O
23	tumor	O
24	,	O
25	and	O
26	eight	O
27	MCTs	O
28	by	O
29	a	O
30	short	O
31	electrode	O
32	,	O
33	2	O
34	cm	O
35	in	O
36	size	O
37	,	O
38	were	O
39	done	O
40	in	O
41	the	O
42	peripheral	O
43	and	O
44	surrounding	O
45	area	O
46	of	O
47	the	O
48	tumor	O
49	.	O

1	The	O
2	transcription	O
3	initiation	O
4	site	O
5	was	O
6	determined	O
7	to	O
8	occur	O
9	66	O
10	bp	O
11	upstream	O
12	of	O
13	the	O
14	initiating	O
15	Met	O
16	.	O

1	This	O
2	study	O
3	was	O
4	designed	O
5	to	O
6	compare	O
7	the	O
8	efficacy	O
9	of	O
10	efegatran	O
11	plus	O
12	streptokinase	O
13	versus	O
14	heparin	O
15	plus	O
16	accelerated	O
17	tissue	B
18	plasminogen	I
19	activator	I
20	(	O
21	TPA	O
22	)	O
23	in	O
24	coronary	O
25	reperfusion	O
26	in	O
27	acute	O
28	MI	O
29	.	O

1	In	O
2	addition	O
3	,	O
4	all	O
5	three	O
6	Opa	O
7	proteins	O
8	of	O
9	C751	O
10	bind	O
11	equally	O
12	well	O
13	to	O
14	HeLa	O
15	cells	O
16	transfected	O
17	with	O
18	cDNA	O
19	encoding	O
20	the	O
21	carcinoembryonic	B
22	antigen	I
23	[	O
24	CEA	O
25	(	O
26	CD66e	O
27	)]	O
28	subgroup	O
29	of	O
30	the	O
31	CD66	O
32	family	O
33	,	O
34	but	O
35	show	O
36	distinct	O
37	tropism	O
38	for	O
39	CGM1	O
40	-	O
41	(	O
42	CD66d	O
43	)	O
44	and	O
45	NCA	O
46	(	O
47	CD66c	O
48	)-	O
49	expressing	O
50	cells	O
51	.	O

1	Naloxone	O
2	(	O
3	2	O
4	mg	O
5	/	O
6	kg	O
7	bolus	O
8	+	O
9	2	O
10	mg	O
11	X	O
12	kg	O
13	-	O
14	1	O
15	X	O
16	h	O
17	-	O
18	1	O
19	)	O
20	was	O
21	given	O
22	with	O
23	one	O
24	of	O
25	the	O
26	two	O
27	doses	O
28	of	O
29	the	O
30	lipopolysaccharide	O
31	.	O

1	The	O
2	relevance	O
3	of	O
4	these	O
5	elements	O
6	in	O
7	conferring	O
8	anaerobic	O
9	induction	O
10	of	O
11	gpc4	O
12	gene	O
13	expression	O
14	is	O
15	discussed	O
16	.	O

1	The	O
2	inhibition	O
3	of	O
4	focus	O
5	formation	O
6	observed	O
7	in	O
8	the	O
9	presence	O
10	of	O
11	C3G	O
12	was	O
13	not	O
14	due	O
15	to	O
16	toxic	O
17	effects	O
18	on	O
19	cell	O
20	viability	O
21	,	O
22	since	O
23	transfected	O
24	C3G	O
25	cells	O
26	exhibited	O
27	the	O
28	same	O
29	survival	O
30	and	O
31	growth	O
32	rates	O
33	as	O
34	untransfected	O
35	NIH3T3	O
36	cells	O
37	or	O
38	cells	O
39	transfected	O
40	with	O
41	plasmid	O
42	vector	O
43	alone	O
44	.	O

1	In	O
2	a	O
3	series	O
4	of	O
5	patients	O
6	with	O
7	neuroinfection	O
8	,	O
9	Lyme	O
10	disease	O
11	,	O
12	Guillain	O
13	Barre	O
14	syndrome	O
15	,	O
16	demyelinization	O
17	,	O
18	partial	O
19	or	O
20	generalized	O
21	,	O
22	epilepsy	O
23	,	O
24	we	O
25	have	O
26	investigated	O
27	antiphospholipid	O
28	antibodies	O
29	of	O
30	IgG	B
31	and	O
32	IgM	B
33	subtypes	O
34	,	O
35	together	O
36	with	O
37	anticoagulant	O
38	factors	O
39	,	O
40	member	O
41	of	O
42	thrombocytes	O
43	,	O
44	sedimentation	O
45	rate	O
46	of	O
47	erythrocytes	O
48	.	O

1	We	O
2	have	O
3	previously	O
4	reported	O
5	that	O
6	high	O
7	level	O
8	human	B
9	desmin	I
10	expression	O
11	depends	O
12	on	O
13	a	O
14	280	O
15	-	O
16	base	O
17	pair	O
18	muscle	O
19	-	O
20	specific	O
21	enhancer	O
22	which	O
23	can	O
24	function	O
25	not	O
26	only	O
27	in	O
28	myotubes	O
29	,	O
30	but	O
31	can	O
32	also	O
33	activate	O
34	gene	O
35	expression	O
36	in	O
37	myoblasts	O
38	.	O

1	Previously	O
2	,	O
3	we	O
4	reported	O
5	that	O
6	scanthrough	O
7	translation	O
8	,	O
9	where	O
10	the	O
11	initiating	O
12	AUG	O
13	of	O
14	a	O
15	primary	O
16	open	O
17	reading	O
18	frame	O
19	is	O
20	bypassed	O
21	,	O
22	is	O
23	most	O
24	likely	O
25	to	O
26	account	O
27	for	O
28	the	O
29	presentation	O
30	of	O
31	cryptic	O
32	epitopes	O
33	from	O
34	alternative	O
35	reading	O
36	frames	O
37	within	O
38	the	O
39	influenza	O
40	A	O
41	PR	O
42	/	O
43	8	O
44	/	O
45	34	O
46	nucleoprotein	O
47	gene	O
48	.	O

1	However	O
2	,	O
3	regional	O
4	MVO2	O
5	increased	O
6	to	O
7	about	O
8	the	O
9	same	O
10	extent	O
11	in	O
12	the	O
13	CFX	O
14	(	O
15	from	O
16	6	O
17	.	O
18	0	O
19	+/-	O
20	0	O
21	.	O
22	7	O
23	to	O
24	12	O
25	.	O
26	4	O
27	+/-	O
28	0	O
29	.	O
30	9	O
31	ml	O
32	O2	O
33	.	O
34	min	O
35	-	O
36	1	O
37	times	O
38	100	O
39	g	O
40	-	O
41	1	O
42	)	O
43	and	O
44	the	O
45	LAD	O
46	region	O
47	(	O
48	from	O
49	7	O
50	.	O
51	0	O
52	+/-	O
53	0	O
54	.	O
55	6	O
56	to	O
57	14	O
58	.	O
59	5	O
60	+/-	O
61	1	O
62	.	O
63	3	O
64	ml	O
65	O2	O
66	.	O
67	min	O
68	-	O
69	1	O
70	times	O
71	100	O
72	g	O
73	-	O
74	1	O
75	).	O

1	Additionally	O
2	,	O
3	deletion	O
4	analysis	O
5	of	O
6	the	O
7	UCP2	O
8	promoter	O
9	-	O
10	PLAP	O
11	constructs	O
12	indicated	O
13	that	O
14	the	O
15	minimal	O
16	region	O
17	exhibiting	O
18	the	O
19	promoter	O
20	activity	O
21	was	O
22	located	O
23	between	O
24	nt	O
25	-	O
26	33	O
27	and	O
28	+	O
29	100	O
30	,	O
31	and	O
32	that	O
33	a	O
34	strong	O
35	enhancer	O
36	was	O
37	present	O
38	within	O
39	601	O
40	bp	O
41	of	O
42	the	O
43	5	O
44	'-	O
45	promoter	O
46	region	O
47	.	O

1	PSI	B
2	-	I
3	G	I
4	and	I
5	PSI	I
6	-	I
7	K	O
8	probably	O
9	have	O
10	evolved	O
11	from	O
12	a	O
13	gene	O
14	duplication	O
15	of	O
16	an	O
17	ancestral	O
18	gene	O
19	.	O

1	Codon	O
2	optimization	O
3	for	O
4	high	O
5	-	O
6	level	O
7	expression	O
8	of	O
9	human	B
10	erythropoietin	I
11	(	O
12	EPO	B
13	)	O
14	in	O
15	mammalian	O
16	cells	O
17	.	O

1	Several	O
2	of	O
3	the	O
4	exon	O
5	boundaries	O
6	correspond	O
7	to	O
8	the	O
9	boundaries	O
10	of	O
11	functional	O
12	domains	O
13	in	O
14	the	O
15	p55	B
16	protein	I
17	.	O

1	While	O
2	all	O
3	deletions	O
4	within	O
5	the	O
6	sequence	O
7	coding	O
8	for	O
9	the	O
10	mature	O
11	tRNA	O
12	led	O
13	to	O
14	inactivity	O
15	of	O
16	the	O
17	mutated	O
18	genes	O
19	,	O
20	substitution	O
21	of	O
22	the	O
23	central	O
24	portion	O
25	by	O
26	concatenated	O
27	Hind	O
28	III	O
29	linkers	O
30	produced	O
31	gene	O
32	units	O
33	active	O
34	in	O
35	transcription	O
36	.	O

1	Because	O
2	L	O
3	-	O
4	plastin	O
5	expression	O
6	in	O
7	tissue	O
8	-	O
9	specifically	O
10	regulated	O
11	in	O
12	both	O
13	humans	O
14	and	O
15	rodents	O
16	,	O
17	it	O
18	is	O
19	likely	O
20	that	O
21	similar	O
22	mechanisms	O
23	regulate	O
24	L	B
25	-	I
26	plastin	I
27	gene	I
28	expression	O
29	in	O
30	human	O
31	and	O
32	rodent	O
33	cells	O
34	and	O
35	that	O
36	they	O
37	could	O
38	be	O
39	identified	O
40	by	O
41	comparing	O
42	the	O
43	function	O
44	and	O
45	nucleotide	O
46	sequences	O
47	of	O
48	the	O
49	human	O
50	and	O
51	murine	B
52	L	I
53	-	I
54	plastin	I
55	gene	I
56	promoters	I
57	.	O

1	RESULTS	O
2	:	O
3	The	O
4	binding	O
5	of	O
6	99mTc	O
7	d	O
8	,	O
9	1	O
10	-	O
11	HMPAO	O
12	to	O
13	human	O
14	placenta	O
15	ranged	O
16	from	O
17	2	O
18	.	O
19	95	O
20	%	O
21	+/-	O
22	1	O
23	.	O
24	5	O
25	%	O
26	to	O
27	5	O
28	.	O
29	82	O
30	%	O
31	+/-	O
32	0	O
33	.	O
34	3	O
35	%	O
36	per	O
37	1	O
38	ml	O
39	standard	O
40	solution	O
41	.	O

1	Initial	O
2	experience	O
3	with	O
4	a	O
5	serotonin	O
6	agonist	O
7	.	O

1	Three	O
2	subgenomes	O
3	also	O
4	comprised	O
5	15	O
6	to	O
7	75	O
8	nucleotides	O
9	derived	O
10	from	O
11	the	O
12	5	O
13	'	O
14	part	O
15	of	O
16	the	O
17	NS2	O
18	gene	O
19	.	O

1	The	O
2	60A	O
3	transcripts	O
4	and	O
5	protein	O
6	are	O
7	first	O
8	detected	O
9	at	O
10	the	O
11	onset	O
12	of	O
13	gastrulation	O
14	,	O
15	primarily	O
16	in	O
17	the	O
18	mesoderm	O
19	of	O
20	the	O
21	extending	O
22	germ	O
23	band	O
24	.	O

1	Wild	B
2	-	I
3	type	I
4	protein	I
5	bound	O
6	azido	O
7	-	O
8	ATP	O
9	well	O
10	,	O
11	but	O
12	mutants	O
13	with	O
14	substitutions	O
15	in	O
16	the	O
17	consensus	O
18	amino	O
19	acids	O
20	were	O
21	unable	O
22	to	O
23	bind	O
24	azido	O
25	-	O
26	ATP	O
27	.	O

1	Forty	O
2	4	O
3	-	O
4	month	O
5	old	O
6	SD	O
7	female	O
8	rats	O
9	were	O
10	randomly	O
11	divided	O
12	into	O
13	four	O
14	groups	O
15	,	O
16	namely	O
17	sham	O
18	operation	O
19	,	O
20	bilateral	O
21	ovariectomy	O
22	,	O
23	ovariectomy	O
24	plus	O
25	supplementary	O
26	ethinyl	O
27	estradiol	O
28	(	O
29	0	O
30	.	O
31	2	O
32	microgram	O
33	/	O
34	100	O
35	g	O
36	B	O
37	.	O

1	A	O
2	novel	O
3	cDNA	O
4	clone	O
5	termed	O
6	R2	O
7	was	O
8	isolated	O
9	by	O
10	subtractive	O
11	hybridization	O
12	of	O
13	a	O
14	cDNA	O
15	library	O
16	of	O
17	phytohemagglutinin	O
18	(	O
19	PHA	O
20	)/	O
21	phorbol	O
22	myristate	O
23	acetate	O
24	-	O
25	stimulated	O
26	Jurkat	O
27	cells	O
28	and	O
29	by	O
30	rescreening	O
31	a	O
32	cDNA	O
33	library	O
34	of	O
35	PHA	O
36	-	O
37	stimulated	O
38	peripheral	O
39	blood	O
40	lymphocytes	O
41	.	O

1	Intrapocket	O
2	chemotherapy	O
3	in	O
4	adult	O
5	periodontitis	O
6	using	O
7	a	O
8	new	O
9	controlled	O
10	-	O
11	release	O
12	insert	O
13	containing	O
14	ofloxacin	O
15	(	O
16	PT	O
17	-	O
18	01	O
19	).	O

1	The	O
2	distributed	O
3	current	O
4	density	O
5	J	O
6	is	O
7	calculated	O
8	within	O
9	the	O
10	volume	O
11	defined	O
12	by	O
13	the	O
14	motor	O
15	unit	O
16	.	O

1	A	O
2	surgical	O
3	technique	O
4	for	O
5	correcting	O
6	this	O
7	problem	O
8	is	O
9	described	O
10	.	O

1	Acad	O
2	.	O

1	We	O
2	report	O
3	here	O
4	that	O
5	out	O
6	of	O
7	the	O
8	major	O
9	pro	O
10	-	O
11	inflammatory	O
12	cytokines	O
13	examined	O
14	,	O
15	IL	B
16	-	I
17	1alpha	I
18	,	O
19	IL	B
20	-	I
21	1beta	I
22	,	O
23	TNF	B
24	-	I
25	alpha	I
26	and	O
27	IL	B
28	-	I
29	6	O
30	,	O
31	only	O
32	IL	B
33	-	I
34	6	O
35	was	O
36	generated	O
37	and	O
38	secreted	O
39	in	O
40	PKCeta	O
41	-	O
42	expressing	O
43	cells	O
44	without	O
45	any	O
46	additional	O
47	inducer	O
48	in	O
49	serum	O
50	-	O
51	supplemented	O
52	cultures	O
53	(	O
54	10	O
55	%	O
56	FCS	O
57	).	O

1	This	O
2	region	O
3	also	O
4	contains	O
5	a	O
6	gene	O
7	specifying	O
8	a	O
9	Leu	O
10	-	O
11	tRNA	O
12	precursor	O
13	and	O
14	a	O
15	remnant	O
16	of	O
17	a	O
18	tau	O
19	element	O
20	.	O

1	The	O
2	GALT	O
3	-	O
4	primed	O
5	calves	O
6	had	O
7	increased	O
8	serum	O
9	IgG	B
10	,	O
11	lavage	O
12	IgG	B
13	and	O
14	IgA	B
15	and	O
16	increased	O
17	LNA	O
18	titers	O
19	in	O
20	both	O
21	lavage	O
22	fluids	O
23	and	O
24	serum	O
25	following	O
26	the	O
27	SC	O
28	dose	O
29	of	O
30	killed	O
31	bacteria	O
32	.	O

1	There	O
2	were	O
3	no	O
4	interfering	O
5	peaks	O
6	in	O
7	the	O
8	quantitation	O
9	of	O
10	sulbactam	O
11	.	O

1	Tobacco	O
2	mosaic	O
3	virus	O
4	-	O
5	infected	O
6	tobacco	O
7	(	O
8	Nicotiana	O
9	tabacum	O
10	var	O
11	.	O

1	In	O
2	this	O
3	report	O
4	,	O
5	we	O
6	identify	O
7	and	O
8	characterize	O
9	two	O
10	overlapping	O
11	ELL	O
12	functional	O
13	domains	O
14	that	O
15	govern	O
16	its	O
17	interaction	O
18	with	O
19	RNA	B
20	polymerase	I
21	II	I
22	and	O
23	the	O
24	ternary	O
25	elongation	O
26	complex	O
27	.	O

1	Comparative	O
2	studies	O
3	of	O
4	the	O
5	antithrombin	B
6	III	I
7	level	O
8	and	O
9	plasminogen	B
10	activator	I
11	activity	O
12	in	O
13	patients	O
14	with	O
15	thrombophlebitis	O

1	The	O
2	amount	O
3	of	O
4	these	O
5	factors	O
6	was	O
7	reduced	O
8	in	O
9	GEO	O
10	cells	O
11	in	O
12	which	O
13	the	O
14	u	O
15	-	O
16	PAR	O
17	gene	O
18	is	O
19	only	O
20	weakly	O
21	transcriptionally	O
22	activated	O
23	.	O

1	Therefore	O
2	,	O
3	it	O
4	is	O
5	hoped	O
6	that	O
7	by	O
8	defining	O
9	the	O
10	transcriptional	O
11	control	O
12	of	O
13	the	O
14	L7	O
15	gene	O
16	insights	O
17	into	O
18	the	O
19	mechanisms	O
20	that	O
21	control	O
22	functional	O
23	fate	O
24	and	O
25	organization	O
26	in	O
27	the	O
28	nervous	O
29	system	O
30	can	O
31	be	O
32	gained	O
33	.	O

1	In	O
2	addition	O
3	,	O
4	a	O
5	comparison	O
6	of	O
7	the	O
8	hCHLR	O
9	gene	O
10	sequences	O
11	with	O
12	available	O
13	databases	O
14	indicates	O
15	that	O
16	a	O
17	large	O
18	portion	O
19	of	O
20	these	O
21	genes	O
22	,	O
23	including	O
24	exons	O
25	encoding	O
26	two	O
27	functional	O
28	domains	O
29	of	O
30	the	O
31	carboxyl	O
32	-	O
33	terminal	O
34	region	O
35	of	O
36	these	O
37	proteins	O
38	,	O
39	has	O
40	been	O
41	duplicated	O
42	as	O
43	part	O
44	of	O
45	a	O
46	larger	O
47	human	O
48	telomeric	O
49	repeat	O
50	sequence	O
51	found	O
52	on	O
53	many	O
54	human	O
55	chromosomes	O
56	.	O

1	A	O
2	new	O
3	vector	O
4	,	O
5	pHBK280	O
6	,	O
7	was	O
8	designed	O
9	to	O
10	facilitate	O
11	this	O
12	analysis	O
13	.	O

1	Type	O
2	2	O
3	genomes	O
4	containing	O
5	this	O
6	sequence	O
7	presumably	O
8	more	O
9	closely	O
10	reflect	O
11	the	O
12	structure	O
13	of	O
14	the	O
15	infectious	O
16	,	O
17	replication	O
18	-	O
19	competent	O
20	retrovirus	O
21	ancestors	O
22	of	O
23	the	O
24	HERV	O
25	-	O
26	K	O
27	family	O
28	than	O
29	do	O
30	type	O
31	1	O
32	genomes	O
33	that	O
34	lack	O
35	the	O
36	sequence	O
37	.	O

1	The	O
2	SSB	O
3	-	O
4	poly	O
5	(	O
6	dT	O
7	)	O
8	affinity	O
9	is	O
10	too	O
11	high	O
12	to	O
13	measure	O
14	in	O
15	buffers	O
16	containing	O
17	even	O
18	5	O
19	M	O
20	NaCl	O
21	;	O
22	however	O
23	,	O
24	in	O
25	1	O
26	.	O
27	8	O
28	-	O
29	2	O
30	.	O
31	5	O
32	M	O
33	NaBr	O
34	,	O
35	we	O
36	measure	O
37	alpha	O
38	log	O
39	Kobsd	O
40	/	O
41	alpha	O
42	log	O
43	[	O
44	NaBr	O
45	]	O
46	=	O
47	-	O
48	5	O
49	.	O
50	7	O
51	+/-	O
52	0	O
53	.	O
54	7	O
55	,	O
56	with	O
57	a	O
58	lower	O
59	value	O
60	of	O
61	omega	O
62	T	O
63	/	O
64	O	O
65	=	O
66	130	O
67	+/-	O
68	70	O
69	.	O

1	Finally	O
2	,	O
3	nonphotosynthetic	O
4	mutants	O
5	,	O
6	including	O
7	the	O
8	tscA	O
9	-	O
10	lacking	O
11	photosystem	O
12	I	O
13	mutant	O
14	,	O
15	H13	O
16	,	O
17	did	O
18	not	O
19	show	O
20	evidence	O
21	of	O
22	light	O
23	-	O
24	stimulated	O
25	RNA	O
26	processing	O
27	.	O

1	A	O
2	TATA	O
3	-	O
4	less	O
5	promoter	O
6	containing	O
7	binding	O
8	sites	O
9	for	O
10	ubiquitous	O
11	transcription	O
12	factors	O
13	mediates	O
14	cell	O
15	type	O
16	-	O
17	specific	O
18	regulation	O
19	of	O
20	the	O
21	gene	O
22	for	O
23	transcription	O
24	enhancer	O
25	factor	O
26	-	O
27	1	O
28	(	O
29	TEF	B
30	-	I
31	1	I
32	).	O

1	In	O
2	patients	O
3	,	O
4	the	O
5	effect	O
6	of	O
7	CCK	B
8	-	I
9	PZ	O
10	on	O
11	the	O
12	movement	O
13	of	O
14	the	O
15	terminal	O
16	part	O
17	of	O
18	the	O
19	bile	O
20	duct	O
21	was	O
22	measured	O
23	with	O
24	a	O
25	pressure	O
26	sensor	O
27	using	O
28	a	O
29	duodenofiberscope	O
30	.	O

1	Induction	O
2	of	O
3	the	O
4	urokinase	B
5	promoter	I
6	by	O
7	HGF	B
8	/	I
9	SF	I
10	via	O
11	the	O
12	Met	O
13	receptor	O
14	was	O
15	blocked	O
16	by	O
17	co	O
18	-	O
19	expression	O
20	of	O
21	a	O
22	dominant	O
23	-	O
24	negative	O
25	Grb2	B
26	and	O
27	Sos1	O
28	expression	O
29	construct	O
30	.	O

1	The	O
2	other	O
3	element	O
4	bound	O
5	RBP	B
6	-	I
7	J	I
8	kappa	I
9	with	O
10	low	O
11	affinity	O
12	.	O

1	The	O
2	case	O
3	for	O
4	neutrinos	O
5	from	O
6	SN	O
7	1987A	O
8	.	O

1	Working	O
2	session	O
3	report	O
4	:	O
5	in	O
6	vivo	O
7	-	O
8	in	O
9	vitro	O
10	screening	O
11	.	O

1	Information	O
2	about	O
3	immunologic	O
4	drug	O
5	interactions	O
6	is	O
7	needed	O
8	by	O
9	pharmacists	O
10	to	O
11	make	O
12	rational	O
13	drug	O
14	-	O
15	use	O
16	decisions	O
17	.	O

1	In	O
2	light	O
3	of	O
4	the	O
5	importance	O
6	of	O
7	GnRHR	O
8	,	O
9	the	O
10	molecular	O
11	mechanisms	O
12	underlying	O
13	the	O
14	transcriptional	O
15	regulation	O
16	of	O
17	the	O
18	human	B
19	GnRHR	I
20	(	O
21	hGnRHR	O
22	)	O
23	gene	O
24	become	O
25	a	O
26	key	O
27	issue	O
28	in	O
29	understanding	O
30	human	O
31	reproduction	O
32	.	O

1	Although	O
2	Micrococcus	O
3	luteus	O
4	UV	O
5	endonuclease	O
6	has	O
7	been	O
8	reported	O
9	to	O
10	be	O
11	an	O
12	18	O
13	-	O
14	kDa	O
15	enzyme	O
16	with	O
17	possible	O
18	homology	O
19	to	O
20	the	O
21	16	O
22	-	O
23	kDa	O
24	endonuclease	O
25	V	O
26	from	O
27	bacteriophage	O
28	T4	O
29	(	O
30	Gordon	O
31	,	O
32	L	O
33	.	O

1	Bimodal	O
2	cochlear	O
3	response	O
4	curves	O
5	in	O
6	rodents	O
7	.	O

1	Improvement	O
2	of	O
3	nursing	O
4	instruction	O
5	to	O
6	be	O
7	given	O
8	at	O
9	the	O
10	time	O
11	of	O
12	discharge	O
13	from	O
14	the	O
15	ward	O
16	for	O
17	premature	O
18	infants	O

1	Chem	O
2	.,	O
3	270	O
4	:	O
5	7117	O
6	-	O
7	7124	O
8	,	O
9	1995	O
10	;	O
11	and	O
12	MT	O
13	Hartsough	O
14	et	O
15	al	O
16	.,	O
17	J	O
18	.	O

1	Baseline	O
2	data	O
3	were	O
4	obtained	O
5	from	O
6	10	O
7	adults	O
8	.	O

1	These	O
2	articles	O
3	both	O
4	report	O
5	the	O
6	results	O
7	of	O
8	multi	O
9	-	O
10	institutional	O
11	,	O
12	randomized	O
13	,	O
14	phase	O
15	3	O
16	trials	O
17	for	O
18	the	O
19	treatment	O
20	of	O
21	patients	O
22	with	O
23	localized	O
24	(	O
25	T1	O
26	-	O
27	3	O
28	N0	O
29	-	O
30	1	O
31	M0	O
32	)	O
33	esophageal	O
34	squamous	O
35	cell	O
36	carcinoma	O
37	(	O
38	SCC	O
39	)	O
40	or	O
41	esophageal	O
42	adenocarcinoma	O
43	.	O

1	The	O
2	preferential	O
3	serum	O
4	IgA	B
5	response	O
6	observed	O
7	in	O
8	the	O
9	patient	O
10	population	O
11	suggests	O
12	that	O
13	bronchial	O
14	associated	O
15	lymphoid	O
16	tissue	O
17	in	O
18	the	O
19	diseased	O
20	lung	O
21	is	O
22	an	O
23	important	O
24	source	O
25	of	O
26	circulating	O
27	IgA	B
28	.	O

1	Because	O
2	of	O
3	concerns	O
4	regarding	O
5	blood	O
6	transfusion	O
7	-	O
8	related	O
9	communicable	O
10	disease	O
11	(	O
12	eg	O
13	,	O
14	acquired	O
15	immune	O
16	deficiency	O
17	syndrome	O
18	and	O
19	non	O
20	-	O
21	A	O
22	,	O
23	non	O
24	-	O
25	B	O
26	hepatitis	O
27	),	O
28	there	O
29	has	O
30	been	O
31	increasing	O
32	research	O
33	effort	O
34	into	O
35	postoperative	O
36	hemorrhage	O
37	related	O
38	to	O
39	cardiopulmonary	O
40	bypass	O
41	with	O
42	extracorporeal	O
43	circulation	O
44	.	O

1	Analysis	O
2	of	O
3	proteins	O
4	synthesized	O
5	by	O
6	plasmids	O
7	containing	O
8	deleted	O
9	forms	O
10	of	O
11	the	O
12	trfA	O
13	region	O
14	indicates	O
15	that	O
16	the	O
17	A2	O
18	protein	O
19	is	O
20	the	O
21	essential	O
22	trfA	O
23	-	O
24	encoded	O
25	replication	O
26	protein	O
27	of	O
28	plasmid	O
29	RK2	O
30	.	O

1	Studies	O
2	are	O
3	necessary	O
4	to	O
5	assess	O
6	the	O
7	source	O
8	of	O
9	contamination	O
10	and	O
11	potential	O
12	role	O
13	of	O
14	MRSA	O
15	-	O
16	contaminated	O
17	milk	O
18	in	O
19	the	O
20	transmission	O
21	of	O
22	MRSA	O
23	to	O
24	neonates	O
25	.	O

1	A	O
2	comparison	O
3	of	O
4	the	O
5	amino	O
6	acid	O
7	sequence	O
8	of	O
9	the	O
10	T	O
11	.	O
12	thermophilus	O
13	enzyme	O
14	with	O
15	that	O
16	of	O
17	the	O
18	Escherichia	O
19	coli	O
20	enzyme	O
21	showed	O
22	(	O
23	i	O
24	)	O
25	a	O
26	37	O
27	%	O
28	overall	O
29	similarity	O
30	;	O
31	(	O
32	ii	O
33	)	O
34	the	O
35	conservation	O
36	of	O
37	the	O
38	Ser	O
39	residue	O
40	,	O
41	which	O
42	is	O
43	known	O
44	to	O
45	be	O
46	phosphorylated	O
47	in	O
48	the	O
49	E	O
50	.	O
51	coli	O
52	enzyme	O
53	,	O
54	and	O
55	of	O
56	the	O
57	surrounding	O
58	sequence	O
59	;	O
60	and	O
61	(	O
62	iii	O
63	)	O
64	the	O
65	presence	O
66	of	O
67	141	O
68	extra	O
69	residues	O
70	at	O
71	the	O
72	C	O
73	terminus	O
74	of	O
75	the	O
76	T	O
77	.	O
78	thermophilus	O
79	enzyme	O
80	.	O

1	The	O
2	rad9	O
3	.	O
4	192	O
5	DNA	O
6	repair	O
7	mutant	O
8	from	O
9	the	O
10	fission	O
11	yeast	O
12	,	O
13	Schizosaccharomyces	O
14	pombe	O
15	,	O
16	is	O
17	sensitive	O
18	to	O
19	both	O
20	UV	O
21	and	O
22	ionising	O
23	radiation	O
24	.	O

1	The	O
2	UV	O
3	induction	O
4	of	O
5	c	B
6	-	I
7	jun	I
8	is	O
9	mediated	O
10	by	O
11	two	O
12	UV	O
13	response	O
14	elements	O
15	consisting	O
16	of	O
17	AP	B
18	-	I
19	1	I
20	-	I
21	like	I
22	sequences	O
23	within	O
24	its	O
25	5	O
26	'	O
27	control	O
28	region	O
29	.	O

1	Bipolarity	O
2	in	O
3	Jungian	O
4	type	O
5	theory	O
6	and	O
7	the	O
8	Myers	O
9	-	O
10	Briggs	O
11	Type	O
12	Indicator	O
13	.	O

1	I	O
2	.	O

1	Clinical	O
2	nutrition	O
3	of	O
4	adult	O
5	horses	O
6	.	O

1	Cooperative	O
2	dimerization	O
3	of	O
4	paired	O
5	class	O
6	homeo	O
7	domains	O
8	on	O
9	DNA	O
10	.	O

1	Factors	O
2	influencing	O
3	semen	O
4	characteristics	O
5	in	O
6	young	O
7	boars	O
8	reared	O
9	in	O
10	a	O
11	subtropical	O
12	environment	O
13	were	O
14	studied	O
15	.	O

1	A	O
2	recombinant	O
3	derivative	O
4	harboring	O
5	the	O
6	pMJ101	O
7	replication	O
8	region	O
9	proved	O
10	to	O
11	be	O
12	compatible	O
13	with	O
14	pJM1	O
15	,	O
16	a	O
17	plasmid	O
18	containing	O
19	the	O
20	iron	O
21	acquisition	O
22	system	O
23	required	O
24	for	O
25	the	O
26	virulence	O
27	of	O
28	V	O
29	.	O
30	anguillarum	O
31	775	O
32	,	O
33	another	O
34	important	O
35	pathogen	O
36	that	O
37	causes	O
38	vibriosis	O
39	.	O

1	For	O
2	example	O
3	,	O
4	introduction	O
5	of	O
6	immunogenic	O
7	and	O
8	purification	O
9	tag	O
10	sequences	O
11	into	O
12	the	O
13	C	O
14	-	O
15	terminal	O
16	coding	O
17	region	O
18	significantly	O
19	decreased	O
20	bop	O
21	gene	O
22	mRNA	O
23	and	O
24	protein	O
25	accumulation	O
26	.	O

1	We	O
2	postulate	O
3	that	O
4	CaM	B
5	binding	I
6	by	O
7	HIV	O
8	envelope	O
9	proteins	O
10	is	O
11	likely	O
12	to	O
13	exert	O
14	diverse	O
15	modulatory	O
16	effects	O
17	,	O
18	and	O
19	the	O
20	mechanism	O
21	for	O
22	HIV	O
23	-	O
24	induced	O
25	cytotoxicity	O
26	may	O
27	involve	O
28	,	O
29	in	O
30	part	O
31	,	O
32	inhibition	O
33	of	O
34	CaM	B
35	-	I
36	regulated	O
37	cellular	O
38	functions	O
39	.	O

1	Transfection	O
2	studies	O
3	also	O
4	showed	O
5	that	O
6	3	O
7	'-	O
8	deletion	O
9	of	O
10	sequences	O
11	downstream	O
12	of	O
13	the	O
14	transcriptional	O
15	start	O
16	site	O
17	(+	O
18	1	O
19	/+	O
20	47	O
21	)	O
22	markedly	O
23	reduced	O
24	OSM	O
25	-	O
26	fold	O
27	induction	O
28	.	O

1	Pharmacologic	O
2	doses	O
3	of	O
4	vitamin	O
5	B6	O
6	administered	O
7	to	O
8	lactating	O
9	women	O
10	have	O
11	been	O
12	reported	O
13	to	O
14	suppress	O
15	plasma	O
16	prolactin	B
17	.	O

1	Low	O
2	MAO	O
3	subjects	O
4	showed	O
5	a	O
6	pattern	O
7	of	O
8	higher	O
9	scores	O
10	in	O
11	KSP	O
12	Impulsiveness	O
13	,	O
14	EPQ	O
15	Neuroticism	O
16	,	O
17	and	O
18	KSP	O
19	Somatic	O
20	Anxiety	O
21	and	O
22	Irritability	O
23	and	O
24	lower	O
25	scores	O
26	in	O
27	KSP	O
28	Socialization	O
29	,	O
30	in	O
31	line	O
32	with	O
33	personality	O
34	profiles	O
35	found	O
36	in	O
37	alcoholics	O
38	,	O
39	psychopaths	O
40	,	O
41	and	O
42	suicide	O
43	attempters	O
44	who	O
45	also	O
46	tend	O
47	to	O
48	have	O
49	low	O
50	platelet	B
51	MAO	I
52	activity	O
53	.	O

1	The	O
2	cloning	O
3	of	O
4	PTR2	O
5	represents	O
6	the	O
7	first	O
8	example	O
9	of	O
10	the	O
11	molecular	O
12	genetic	O
13	characterization	O
14	of	O
15	a	O
16	eucaryotic	O
17	peptide	O
18	transport	O
19	gene	O
20	.	O

1	Either	O
2	two	O
3	or	O
4	more	O
5	different	O
6	sequences	O
7	can	O
8	promote	O
9	cleavage	O
10	,	O
11	or	O
12	a	O
13	single	O
14	element	O
15	exists	O
16	which	O
17	is	O
18	long	O
19	and	O
20	diffuse	O
21	.	O

1	We	O
2	report	O
3	here	O
4	on	O
5	the	O
6	molecular	O
7	nature	O
8	of	O
9	an	O
10	EMS	O
11	-	O
12	induced	O
13	mutant	O
14	,	O
15	mn1	O
16	-	O
17	89	O
18	,	O
19	a	O
20	leaky	O
21	semidominant	O
22	allele	O
23	of	O
24	the	O
25	Miniature1	O
26	(	O
27	Mn1	O
28	)	O
29	seed	O
30	locus	O
31	that	O
32	encodes	O
33	a	O
34	seed	O
35	-	O
36	specific	O
37	cell	O
38	wall	O
39	invertase	O
40	,	O
41	INCW2	O
42	.	O

1	One	O
2	group	O
3	(	O
4	n	O
5	=	O
6	9	O
7	)	O
8	was	O
9	premedicated	O
10	with	O
11	midazolam	O
12	,	O
13	0	O
14	.	O
15	1	O
16	mg	O
17	kg	O
18	-	O
19	1	O
20	,	O
21	and	O
22	atropine	O
23	0	O
24	.	O
25	2	O
26	-	O
27	0	O
28	.	O
29	4	O
30	mg	O
31	i	O
32	.	O
33	m	O
34	.	O

1	Recombinant	O
2	soluble	O
3	pMCP	O
4	that	O
5	lacked	O
6	transmembrane	O
7	and	O
8	cytoplasmic	O
9	domains	O
10	had	O
11	factor	O
12	I	O
13	cofactor	O
14	activity	O
15	in	O
16	C3b	O
17	cleavage	O
18	,	O
19	indicating	O
20	that	O
21	it	O
22	is	O
23	functionally	O
24	,	O
25	as	O
26	well	O
27	as	O
28	structurally	O
29	homologous	O
30	to	O
31	MCP	O
32	.	O

1	Transfection	O
2	of	O
3	increasing	O
4	amounts	O
5	of	O
6	delta5ERalpha	O
7	expression	O
8	vector	O
9	into	O
10	[	O
11	ERalpha	O
12	+]	O
13	OS	O
14	cells	O
15	resulted	O
16	in	O
17	potentiation	O
18	of	O
19	E2	O
20	-	O
21	stimulated	O
22	ERELuc	O
23	activity	O
24	in	O
25	a	O
26	synergistic	O
27	,	O
28	dose	O
29	-	O
30	dependent	O
31	manner	O
32	.	O

1	Comparison	O
2	with	O
3	the	O
4	sequence	O
5	databanks	O
6	show	O
7	that	O
8	Tactile	O
9	is	O
10	a	O
11	member	O
12	of	O
13	the	O
14	immunoglobulin	B
15	gene	I
16	superfamily	I
17	,	O
18	with	O
19	similarity	O
20	to	O
21	Drosophila	O
22	amalgam	O
23	,	O
24	the	O
25	melanoma	O
26	Ag	O
27	MUC	O
28	-	O
29	18	O
30	,	O
31	members	O
32	of	O
33	the	O
34	carcinoembryonic	B
35	Ag	I
36	family	I
37	,	O
38	the	O
39	poliovirus	O
40	receptor	O
41	,	O
42	and	O
43	the	O
44	neural	O
45	cell	O
46	adhesion	O
47	molecule	O
48	.	O

1	(	O
2	ii	O
3	)	O
4	ICP27	O
5	binds	O
6	preferentially	O
7	to	O
8	less	O
9	modified	O
10	forms	O
11	of	O
12	ICP4	B
13	,	O
14	a	O
15	protein	O
16	that	O
17	is	O
18	extensively	O
19	modified	O
20	posttranslationally	O
21	.	O

1	Following	O
2	the	O
3	injection	O
4	of	O
5	PGF2	O
6	alpha	O
7	,	O
8	heifers	O
9	were	O
10	observed	O
11	visually	O
12	for	O
13	signs	O
14	of	O
15	estrus	O
16	at	O
17	0730	O
18	and	O
19	1630	O
20	(	O
21	45	O
22	min	O
23	each	O
24	).	O

1	The	O
2	PAC	O
3	clone	O
4	with	O
5	an	O
6	insert	O
7	size	O
8	of	O
9	120kb	O
10	was	O
11	isolated	O
12	and	O
13	mapped	O
14	by	O
15	restriction	O
16	analysis	O
17	.	O

1	The	O
2	motor	O
3	unit	O
4	viewed	O
5	from	O
6	above	O
7	.	O

1	The	O
2	5	O
3	'	O
4	untranslated	O
5	and	O
6	coding	O
7	regions	O
8	are	O
9	contained	O
10	within	O
11	12	O
12	exons	O
13	,	O
14	with	O
15	the	O
16	translation	O
17	start	O
18	site	O
19	located	O
20	within	O
21	the	O
22	first	O
23	exon	O
24	.	O

1	When	O
2	expressed	O
3	in	O
4	COS	O
5	-	O
6	7	O
7	cells	O
8	,	O
9	MKP	B
10	-	I
11	4	O
12	blocks	O
13	activation	O
14	of	O
15	MAP	B
16	kinases	I
17	with	O
18	the	O
19	selectivity	O
20	ERK	B
21	>	O
22	p38	B
23	=	O
24	JNK	B
25	/	I
26	SAPK	I
27	.	O

1	Characteristics	O
2	of	O
3	lipase	B
4	activity	O
5	.	O

1	Ectopic	O
2	expression	O
3	of	O
4	Apo	O
5	-	O
6	3	O
7	in	O
8	HEK293	O
9	or	O
10	HeLa	O
11	cells	O
12	induced	O
13	marked	O
14	apoptosis	O
15	.	O

1	GAL4	B
2	-	I
3	VP16	I
4	-	I
5	mediated	O
6	antirepression	O
7	required	O
8	an	O
9	auxiliary	O
10	factor	O
11	,	O
12	denoted	O
13	as	O
14	a	O
15	co	O
16	-	O
17	antirepressor	O
18	,	O
19	which	O
20	was	O
21	partially	O
22	purified	O
23	from	O
24	Drosophila	O
25	embryos	O
26	.	O

1	No	O
2	TATA	O
3	box	O
4	was	O
5	found	O
6	in	O
7	the	O
8	putative	O
9	promoter	O
10	region	O
11	,	O
12	but	O
13	multiple	O
14	GC	O
15	boxes	O
16	were	O
17	found	O
18	around	O
19	the	O
20	cap	O
21	sites	O
22	,	O
23	supporting	O
24	the	O
25	previously	O
26	inferred	O
27	housekeeping	O
28	nature	O
29	of	O
30	CYP51	B
31	gene	I
32	and	O
33	the	O
34	existence	O
35	of	O
36	the	O
37	multiple	O
38	transcription	O
39	initiation	O
40	sites	O
41	.	O

1	Information	O
2	on	O
3	conserved	O
4	noncoding	O
5	sequences	O
6	will	O
7	help	O
8	in	O
9	studies	O
10	on	O
11	the	O
12	regulation	O
13	of	O
14	the	O
15	pro	B
16	alpha	I
17	1	I
18	(	I
19	II	I
20	)	I
21	collagen	I
22	gene	I
23	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	investigated	O
7	STAT	B
8	activation	O
9	in	O
10	a	O
11	panel	O
12	of	O
13	rodent	O
14	fibroblast	O
15	cell	O
16	lines	O
17	stably	O
18	transformed	O
19	by	O
20	diverse	O
21	viral	O
22	oncoproteins	O
23	.	O

1	Static	O
2	magnetic	O
3	fields	O
4	affect	O
5	the	O
6	diffusion	O
7	of	O
8	biological	O
9	particles	O
10	in	O
11	solutions	O
12	through	O
13	the	O
14	Lorentz	O
15	force	O
16	and	O
17	Maxwell	O
18	stress	O
19	.	O

1	The	O
2	degree	O
3	of	O
4	hypoperfusion	O
5	was	O
6	slightly	O
7	related	O
8	to	O
9	decrease	O
10	in	O
11	FEV1	O
12	.	O
13	0	O
14	%,	O
15	V25	O
16	and	O
17	PaO2	O
18	and	O
19	increase	O
20	in	O
21	circulating	O
22	blood	O
23	volume	O
24	and	O
25	peripheral	O
26	red	O
27	blood	O
28	cell	O
29	counts	O
30	.	O

1	Demonstration	O
2	of	O
3	fine	O
4	structure	O
5	of	O
6	the	O
7	guinea	O
8	pig	O
9	organ	O
10	of	O
11	Corti	O
12	after	O
13	electron	O
14	microscopic	O
15	silver	O
16	staining	O

1	By	O
2	stepwise	O
3	linear	O
4	multiple	O
5	regression	O
6	analysis	O
7	,	O
8	ionized	O
9	magnesium	O
10	was	O
11	significantly	O
12	related	O
13	to	O
14	cyclosporin	O
15	trough	O
16	level	O
17	and	O
18	total	O
19	cholesterol	O
20	but	O
21	not	O
22	to	O
23	serum	O
24	creatinine	O
25	,	O
26	time	O
27	after	O
28	transplant	O
29	or	O
30	the	O
31	dose	O
32	of	O
33	cyclosporin	O
34	.	O

1	After	O
2	infection	O
3	of	O
4	293	O
5	cells	O
6	(	O
7	which	O
8	provide	O
9	complementary	O
10	E1a	O
11	-	O
12	E1b	O
13	functions	O
14	),	O
15	both	O
16	viruses	O
17	directed	O
18	equal	O
19	amounts	O
20	of	O
21	P	O
22	/	O
23	C	O
24	-	O
25	specific	O
26	mRNA	O
27	transcription	O
28	.	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	intraarterial	O
6	neoadjuvant	O
7	chemotherapy	O
8	should	O
9	be	O
10	effective	O
11	on	O
12	advanced	O
13	cervical	O
14	cancer	O
15	.	O

1	During	O
2	the	O
3	observation	O
4	period	O
5	of	O
6	0	O
7	.	O
8	4	O
9	-	O
10	30	O
11	weeks	O
12	,	O
13	cardiac	O
14	white	O
15	spots	O
16	on	O
17	the	O
18	right	O
19	ventricle	O
20	of	O
21	BALB	O
22	/	O
23	c	O
24	mice	O
25	were	O
26	first	O
27	detected	O
28	at	O
29	three	O
30	weeks	O
31	(	O
32	6	O
33	of	O
34	20	O
35	mice	O
36	;	O
37	30	O
38	%),	O
39	and	O
40	the	O
41	maximal	O
42	incidence	O
43	of	O
44	cardiac	O
45	white	O
46	spots	O
47	was	O
48	obtained	O
49	at	O
50	nine	O
51	weeks	O
52	(	O
53	39	O
54	of	O
55	44	O
56	mice	O
57	;	O
58	88	O
59	%).	O

1	Cleavage	O
2	and	O
3	DNA	O
4	joining	O
5	reactions	O
6	,	O
7	carried	O
8	out	O
9	by	O
10	human	O
11	immunodeficiency	O
12	virus	O
13	type	O
14	1	O
15	(	O
16	HIV	O
17	-	O
18	1	O
19	)	O
20	integrase	O
21	,	O
22	are	O
23	necessary	O
24	to	O
25	effect	O
26	the	O
27	covalent	O
28	insertion	O
29	of	O
30	HIV	O
31	-	O
32	1	O
33	DNA	O
34	into	O
35	the	O
36	host	O
37	genome	O
38	.	O

1	Structure	O
2	and	O
3	regulation	O
4	of	O
5	a	O
6	nuclear	O
7	gene	O
8	in	O
9	Saccharomyces	O
10	cerevisiae	O
11	that	O
12	specifies	O
13	MRP13	O
14	,	O
15	a	O
16	protein	O
17	of	O
18	the	O
19	small	O
20	subunit	O
21	of	O
22	the	O
23	mitochondrial	O
24	ribosome	O
25	.	O

1	Thereafter	O
2	,	O
3	the	O
4	aggregation	O
5	rose	O
6	to	O
7	the	O
8	initial	O
9	100	O
10	%	O
11	value	O
12	4	O
13	h	O
14	after	O
15	drug	O
16	application	O
17	and	O
18	remained	O
19	at	O
20	this	O
21	level	O
22	during	O
23	the	O
24	observation	O
25	period	O
26	.(	O
27	ABSTRACT	O
28	TRUNCATED	O
29	AT	O
30	250	O
31	WORDS	O
32	)	O

1	Nucleotide	O
2	sequence	O
3	analysis	O
4	of	O
5	R	O
6	has	O
7	revealed	O
8	similarities	O
9	to	O
10	the	O
11	R1	O
12	plasmid	O
13	found	O
14	in	O
15	some	O
16	South	O
17	American	O
18	maize	O
19	races	O
20	with	O
21	RU	O
22	cytoplasm	O
23	,	O
24	to	O
25	the	O
26	M1	O
27	plasmid	O
28	found	O
29	in	O
30	one	O
31	source	O
32	of	O
33	Zea	O
34	luxurians	O
35	teosinte	O
36	,	O
37	to	O
38	the	O
39	atp9	B
40	mitochondrial	I
41	gene	I
42	and	O
43	its	O
44	3	O
45	'	O
46	flanking	O
47	sequence	O
48	,	O
49	and	O
50	also	O
51	to	O
52	a	O
53	region	O
54	3	O
55	'	O
56	to	O
57	the	O
58	orf221	O
59	gene	O
60	.	O

1	Nitric	O
2	oxide	O
3	inhalation	O
4	selectively	O
5	reduces	O
6	pulmonary	O
7	hypertension	O
8	in	O
9	porcine	O
10	endotoxin	O
11	shock	O
12	and	O
13	improves	O
14	arterial	O
15	oxygenation	O
16	and	O
17	pH	O
18	with	O
19	a	O
20	marked	O
21	attenuation	O
22	of	O
23	sympathetic	O
24	activation	O
25	.	O

1	This	O
2	mechanism	O
3	is	O
4	in	O
5	contrast	O
6	to	O
7	other	O
8	cases	O
9	of	O
10	splicing	O
11	regulation	O
12	by	O
13	PTB	O
14	,	O
15	in	O
16	which	O
17	the	O
18	protein	O
19	represses	O
20	the	O
21	splice	O
22	site	O
23	to	O
24	which	O
25	it	O
26	binds	O
27	.	O

1	Distinguishing	O
2	roles	O
3	of	O
4	the	O
5	membrane	O
6	-	O
7	cytoskeleton	O
8	and	O
9	cadherin	O
10	mediated	O
11	cell	O
12	-	O
13	cell	O
14	adhesion	O
15	in	O
16	generating	O
17	different	O
18	Na	O
19	+,	O
20	K	B
21	(+)-	I
22	ATPase	I
23	distributions	I
24	in	O
25	polarized	O
26	epithelia	O
27	.	O

1	The	O
2	immunosuppressant	O
3	FK506	O
4	inhibits	O
5	amino	O
6	acid	O
7	import	O
8	in	O
9	Saccharomyces	O
10	cerevisiae	O
11	.	O

1	Using	O
2	gel	O
3	retardation	O
4	assays	O
5	with	O
6	HepG2	O
7	nuclear	O
8	extract	O
9	,	O
10	we	O
11	demonstrated	O
12	the	O
13	presence	O
14	of	O
15	a	O
16	specific	O
17	protein	O
18	which	O
19	bound	O
20	to	O
21	the	O
22	NRE	O
23	fragment	O
24	.	O

1	Ischaemia	O
2	was	O
3	induced	O
4	by	O
5	a	O
6	low	O
7	flow	O
8	rate	O
9	of	O
10	0	O
11	.	O
12	8	O
13	mL	O
14	min	O
15	-	O
16	1	O
17	for	O
18	30	O
19	min	O
20	,	O
21	and	O
22	was	O
23	followed	O
24	by	O
25	a	O
26	40	O
27	-	O
28	minute	O
29	reperfusion	O
30	.	O

1	Optically	O
2	detected	O
3	librons	O
4	and	O
5	phonons	O
6	in	O
7	crystalline	O
8	C60	O
9	.	O

1	Comparison	O
2	of	O
3	transmembrane	O
4	and	O
5	cytoplasmic	O
6	domains	O
7	to	O
8	a	O
9	third	O
10	cell	O
11	-	O
12	surface	O
13	proteoglycan	O
14	,	O
15	48K5	O
16	from	O
17	human	O
18	lung	O
19	fibroblasts	O
20	(	O
21	Marynen	O
22	,	O
23	P	O
24	.,	O
25	Zhang	O
26	,	O
27	J	O
28	.,	O
29	Cassiman	O
30	,	O
31	J	O
32	.,	O
33	Vanden	O
34	Berghe	O
35	,	O
36	H	O
37	.,	O
38	and	O
39	David	O
40	,	O
41	C	O
42	.	O

1	The	O
2	limit	O
3	between	O
4	the	O
5	cecum	O
6	and	O
7	the	O
8	ascending	O
9	colon	O
10	was	O
11	externally	O
12	marked	O
13	by	O
14	the	O
15	sulcus	O
16	cecocolicus	O
17	dorsalis	O
18	and	O
19	ventralis	O
20	.	O

1	IFN	B
2	alpha	I
3	and	O
4	IFN	B
5	gamma	I
6	inducibility	O
7	is	O
8	mediated	O
9	by	O
10	a	O
11	single	O
12	element	O
13	:	O
14	a	O
15	high	O
16	affinity	O
17	,	O
18	nearly	O
19	palindromic	O
20	version	O
21	of	O
22	the	O
23	IFN	B
24	gamma	I
25	activation	O
26	site	O
27	(	O
28	GAS	O
29	).	O

1	Using	O
2	himA	O
3	mutants	O
4	,	O
5	we	O
6	confirmed	O
7	that	O
8	IHF	O
9	plays	O
10	a	O
11	role	O
12	in	O
13	the	O
14	molybdate	O
15	-	O
16	dependent	O
17	regulation	O
18	of	O
19	dmsA	O
20	-	O
21	lacZ	B
22	expression	O
23	in	O
24	vivo	O
25	.	O

1	Therefore	O
2	,	O
3	we	O
4	have	O
5	identified	O
6	a	O
7	cis	O
8	-	O
9	acting	O
10	element	O
11	,	O
12	the	O
13	E1	B
14	E	I
15	-	I
16	box	I
17	,	O
18	located	O
19	in	O
20	the	O
21	GAP	B
22	-	I
23	43	O
24	promoter	O
25	region	O
26	that	O
27	modulates	O
28	either	O
29	positively	O
30	or	O
31	negatively	O
32	the	O
33	expression	O
34	of	O
35	the	O
36	GAP	B
37	-	I
38	43	I
39	gene	I
40	depending	O
41	on	O
42	which	O
43	E	B
44	-	I
45	box	I
46	-	I
47	binding	I
48	proteins	I
49	occupy	O
50	this	O
51	site	O
52	.	O

1	Expression	O
2	of	O
3	the	O
4	human	O
5	papillomavirus	O
6	type	O
7	11	O
8	E5A	O
9	protein	O
10	from	O
11	the	O
12	E1E4	O
13	,	O
14	E5	O
15	transcript	O
16	.	O

1	EEA1	O
2	is	O
3	a	O
4	conserved	O
5	alpha	O
6	-	O
7	helical	O
8	peripheral	O
9	membrane	O
10	protein	O
11	flanked	O
12	by	O
13	cysteine	O
14	"	O
15	fingers	O
16	"	O
17	and	O
18	contains	O
19	a	O
20	calmodulin	B
21	-	I
22	binding	I
23	IQ	I
24	motif	I
25	.	O

1	Estrus	O
2	and	O
3	copulative	O
4	abilities	O
5	of	O
6	androgen	O
7	-	O
8	sterilized	O
9	rats	O

1	This	O
2	study	O
3	underlines	O
4	the	O
5	importance	O
6	of	O
7	terminal	O
8	SC5b	O
9	-	O
10	9	O
11	complement	O
12	complex	O
13	as	O
14	a	O
15	suitable	O
16	marker	O
17	in	O
18	the	O
19	evaluation	O
20	of	O
21	complement	O
22	activation	O
23	during	O
24	cardiopulmonary	O
25	bypass	O
26	.	O

1	1	O
2	.	O

1	Peptide	O
2	sequences	O
3	of	O
4	the	O
5	zinc	O
6	finger	O
7	protein	O
8	Ttk	O
9	and	O
10	the	O
11	transcription	O
12	factor	O
13	Adf	O
14	-	O
15	1	O
16	were	O
17	obtained	O
18	.	O

1	This	O
2	machinery	O
3	involves	O
4	a	O
5	secondary	O
6	structure	O
7	,	O
8	SECIS	O
9	element	O
10	,	O
11	in	O
12	the	O
13	selenoprotein	O
14	-	O
15	encoding	O
16	mRNA	O
17	,	O
18	directing	O
19	selenocysteine	O
20	insertion	O
21	at	O
22	the	O
23	position	O
24	of	O
25	an	O
26	opal	O
27	(	O
28	UGA	O
29	)	O
30	codon	O
31	,	O
32	normally	O
33	conferring	O
34	termination	O
35	of	O
36	translation	O
37	.	O

1	The	O
2	flow	O
3	rate	O
4	of	O
5	phosphate	O
6	buffered	O
7	saline	O
8	through	O
9	dermis	O
10	was	O
11	measured	O
12	as	O
13	a	O
14	function	O
15	of	O
16	applied	O
17	pressure	O
18	.	O

1	Infarct	O
2	regional	O
3	ejection	O
4	fraction	O
5	improved	O
6	by	O
7	10	O
8	.	O
9	1	O
10	+/-	O
11	2	O
12	.	O
13	1	O
14	%	O
15	between	O
16	early	O
17	and	O
18	late	O
19	studies	O
20	when	O
21	the	O
22	infarct	O
23	-	O
24	related	O
25	artery	O
26	was	O
27	patent	O
28	and	O
29	by	O
30	4	O
31	.	O
32	8	O
33	+/-	O
34	1	O
35	.	O
36	4	O
37	%	O
38	if	O
39	it	O
40	was	O
41	occluded	O
42	(	O
43	p	O
44	=	O
45	0	O
46	.	O
47	048	O
48	);	O
49	changes	O
50	in	O
51	global	O
52	and	O
53	noninfarct	O
54	regional	O
55	ejection	O
56	fraction	O
57	were	O
58	similar	O
59	irrespective	O
60	of	O
61	perfusion	O
62	status	O
63	.	O

1	Like	O
2	their	O
3	yeast	O
4	counterpart	O
5	,	O
6	the	O
7	mouse	B
8	GCN2	I
9	isoforms	I
10	contain	O
11	HisRS	O
12	-	O
13	related	O
14	sequences	O
15	juxtaposed	O
16	to	O
17	the	O
18	kinase	O
19	catalytic	O
20	domain	O
21	.	O

1	The	O
2	marker	O
3	orders	O
4	from	O
5	the	O
6	genetic	O
7	and	O
8	RH	O
9	maps	O
10	were	O
11	consistent	O
12	.	O

1	In	O
2	AcMNPV	O
3	-	O
4	infected	O
5	Sf9	O
6	cells	O
7	,	O
8	late	O
9	transcription	O
10	initiation	O
11	is	O
12	detected	O
13	from	O
14	only	O
15	two	O
16	upstream	O
17	TAAG	O
18	sites	O
19	and	O
20	not	O
21	from	O
22	three	O
23	downstream	O
24	TAAG	O
25	sites	O
26	.	O

1	How	O
2	do	O
3	graduates	O
4	of	O
5	different	O
6	types	O
7	of	O
8	programs	O
9	perform	O
10	on	O
11	state	O
12	boards	O
13	?	O

1	Splice	O
2	variations	O
3	in	O
4	genes	O
5	coding	O
6	for	O
7	the	O
8	transmembrane	O
9	FGF	B
10	receptor	I
11	(	I
12	FGFR	I
13	)	O
14	result	O
15	in	O
16	isoforms	O
17	that	O
18	vary	O
19	in	O
20	the	O
21	ectodomain	O
22	,	O
23	intracellular	O
24	juxtamembrane	O
25	domain	O
26	,	O
27	and	O
28	the	O
29	intracellular	O
30	kinase	O
31	domain	O
32	.	O

1	Herpes	O
2	virus	O
3	infection	O
4	was	O
5	characterized	O
6	by	O
7	inversion	O
8	of	O
9	the	O
10	T4	O
11	/	O
12	T8	O
13	ratio	O
14	below	O
15	1	O
16	.	O
17	0	O
18	(	O
19	sensitivity	O
20	90	O
21	%,	O
22	specificity	O
23	88	O
24	%),	O
25	caused	O
26	by	O
27	proliferation	O
28	of	O
29	the	O
30	T8	O
31	subpopulation	O
32	,	O
33	which	O
34	--	O
35	compared	O
36	with	O
37	the	O
38	findings	O
39	in	O
40	patients	O
41	with	O
42	rejection	O
43	crises	O
44	--	O
45	was	O
46	significantly	O
47	raised	O
48	(	O
49	P	O
50	less	O
51	than	O
52	0	O
53	.	O
54	001	O
55	).	O

1	During	O
2	the	O
3	following	O
4	9	O
5	1	O
6	/	O
7	2	O
8	years	O
9	three	O
10	sequential	O
11	liver	O
12	biopsies	O
13	were	O
14	performed	O
15	.	O

1	Mutagenesis	O
2	of	O
3	the	O
4	CDE	O
5	/	O
6	CHR	O
7	elements	O
8	and	O
9	Sp1	B
10	sites	I
11	in	O
12	this	O
13	region	O
14	,	O
15	alone	O
16	or	O
17	in	O
18	combination	O
19	,	O
20	reduced	O
21	transcriptional	O
22	activity	O
23	by	O
24	40	O
25	-	O
26	60	O
27	%	O
28	in	O
29	asynchronously	O
30	growing	O
31	cells	O
32	and	O
33	abolished	O
34	cell	O
35	cycle	O
36	periodicity	O
37	in	O
38	G2	O
39	-	O
40	M	O
41	-	O
42	synchronized	O
43	cells	O
44	.	O

1	The	O
2	critical	O
3	mutations	O
4	were	O
5	likely	O
6	to	O
7	have	O
8	been	O
9	multiple	O
10	and	O
11	dispersed	O
12	,	O
13	including	O
14	elongation	O
15	of	O
16	the	O
17	TM	O
18	and	O
19	Nef	O
20	coding	O
21	sequences	O
22	;	O
23	changes	O
24	in	O
25	RNA	O
26	splice	O
27	donor	O
28	and	O
29	acceptor	O
30	sites	O
31	,	O
32	TATA	O
33	box	O
34	sites	O
35	,	O
36	and	O
37	Sp1	B
38	sites	I
39	;	O
40	multiple	O
41	changes	O
42	in	O
43	the	O
44	V2	O
45	region	O
46	of	O
47	SU	O
48	,	O
49	including	O
50	a	O
51	consensus	O
52	neutralization	O
53	epitope	O
54	;	O
55	and	O
56	five	O
57	new	O
58	N	O
59	-	O
60	linked	O
61	glycosylation	O
62	sites	O
63	in	O
64	SU	O
65	.	O

1	A	O
2	poor	O
3	correlation	O
4	was	O
5	also	O
6	observed	O
7	between	O
8	PbB	O
9	and	O
10	ALAD	O
11	activity	O
12	of	O
13	the	O
14	stearate	O
15	workers	O
16	.	O

1	Together	O
2	,	O
3	these	O
4	data	O
5	suggest	O
6	that	O
7	the	O
8	carboxyl	O
9	terminus	O
10	of	O
11	CFTR	O
12	contains	O
13	a	O
14	tyrosine	O
15	-	O
16	based	O
17	internalization	O
18	signal	O
19	that	O
20	interacts	O
21	with	O
22	the	O
23	endocytic	O
24	adaptor	O
25	complex	O
26	AP	B
27	-	I
28	2	I
29	to	O
30	facilitate	O
31	efficient	O
32	entry	O
33	of	O
34	CFTR	O
35	into	O
36	clathrin	B
37	-	I
38	coated	I
39	vesicles	I
40	.	O

1	Serum	O
2	IgM	B
3	and	O
4	IgE	B
5	concentrations	O
6	,	O
7	allergen	O
8	-	O
9	specific	O
10	IgE	B
11	scores	O
12	,	O
13	and	O
14	the	O
15	tumor	O
16	E2R	O
17	status	O
18	were	O
19	combined	O
20	to	O
21	construct	O
22	a	O
23	three	O
24	-	O
25	level	O
26	risk	O
27	classification	O
28	that	O
29	was	O
30	more	O
31	prognostic	O
32	than	O
33	any	O
34	of	O
35	the	O
36	individual	O
37	components	O
38	.	O

1	A	O
2	stable	O
3	heterologous	O
4	cell	O
5	line	O
6	containing	O
7	the	O
8	mouse	O
9	TRH	B
10	receptor	I
11	was	O
12	constructed	O
13	by	O
14	transfection	O
15	of	O
16	nonexcitable	O
17	293	O
18	cells	O
19	,	O
20	which	O
21	lack	O
22	L	O
23	channel	O
24	activity	O
25	.	O

1	Complex	O
2	repetitive	O
3	discharges	O
4	were	O
5	observed	O
6	in	O
7	muscles	O
8	of	O
9	mdx	O
10	mice	O
11	but	O
12	no	O
13	complex	O
14	repetitive	O
15	discharges	O
16	or	O
17	other	O
18	abnormalities	O
19	were	O
20	observed	O
21	in	O
22	muscles	O
23	of	O
24	normal	O
25	control	O
26	mice	O
27	.	O

1	If	O
2	this	O
3	is	O
4	unavailable	O
5	,	O
6	then	O
7	Supramid	O
8	has	O
9	a	O
10	proven	O
11	record	O
12	for	O
13	good	O
14	tissue	O
15	compatibility	O
16	and	O
17	resistance	O
18	to	O
19	infection	O
20	.	O

1	GHB	O
2	,	O
3	2	O
4	CB	O
5	,	O
6	HMB	O
7	,	O
8	are	O
9	some	O
10	of	O
11	these	O
12	recent	O
13	substances	O
14	.	O

1	The	O
2	11	O
3	;	O
4	22	O
5	chromosomal	O
6	translocation	O
7	specifically	O
8	linked	O
9	to	O
10	Ewing	O
11	sarcoma	O
12	and	O
13	primitive	O
14	neuroectodermal	O
15	tumor	O
16	results	O
17	in	O
18	a	O
19	chimeric	O
20	molecule	O
21	fusing	O
22	the	O
23	amino	O
24	-	O
25	terminal	O
26	-	O
27	encoding	O
28	portion	O
29	of	O
30	the	O
31	EWS	B
32	gene	I
33	to	O
34	the	O
35	carboxyl	O
36	-	O
37	terminal	O
38	DNA	O
39	-	O
40	binding	O
41	domain	O
42	encoded	O
43	by	O
44	the	O
45	FLI1	B
46	gene	I
47	.	O

1	Virol	O
2	.	O

1	Oxygen	O
2	delivery	O
3	and	O
4	consumption	O
5	and	O
6	P50	O
7	in	O
8	patients	O
9	with	O
10	acute	O
11	myocardial	O
12	infarction	O
13	.	O

1	Intensification	O
2	of	O
3	human	O
4	myocardial	O
5	contractile	O
6	activity	O
7	as	O
8	affected	O
9	by	O
10	blood	O
11	serum	O

1	Molecular	O
2	characterization	O
3	of	O
4	the	O
5	50	O
6	-	O
7	and	O
8	57	O
9	-	O
10	kDa	O
11	subunits	O
12	of	O
13	the	O
14	bovine	O
15	vacuolar	O
16	proton	O
17	pump	O
18	.	O

1	Cyclin	B
2	D1	I
3	promoter	I
4	activity	O
5	was	O
6	stimulated	O
7	by	O
8	overexpression	O
9	of	O
10	mitogen	B
11	-	I
12	activated	I
13	protein	I
14	kinase	I
15	(	O
16	p41MAPK	O
17	)	O
18	or	O
19	c	B
20	-	I
21	Ets	I
22	-	I
23	2	I
24	through	O
25	the	O
26	proximal	O
27	22	O
28	base	O
29	pairs	O
30	.	O

1	Limb	O
2	allografts	O
3	in	O
4	rats	O
5	immunosuppressed	O
6	with	O
7	cyclosporin	O
8	A	O
9	.	O

1	Alanine	B
2	aminotransferase	I
3	(	O
4	ALT	O
5	)	O
6	levels	O
7	had	O
8	been	O
9	elevated	O
10	for	O
11	six	O
12	months	O
13	in	O
14	all	O
15	patients	O
16	and	O
17	hepatitis	O
18	B	O
19	viral	O
20	infection	O
21	was	O
22	replicative	O
23	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	have	O
7	cloned	O
8	the	O
9	5	O
10	'-	O
11	flanking	O
12	region	O
13	of	O
14	the	O
15	human	O
16	nidogen	O
17	gene	O
18	.	O

1	The	O
2	rates	O
3	of	O
4	total	O
5	energy	O
6	use	O
7	(	O
8	mean	O
9	+/-	O
10	SD	O
11	=	O
12	39	O
13	.	O
14	3	O
15	+/-	O
16	1	O
17	.	O
18	2	O
19	vs	O
20	35	O
21	.	O
22	7	O
23	+/-	O
24	1	O
25	.	O
26	3	O
27	kJ	O
28	X	O
29	min	O
30	-	O
31	1	O
32	;	O
33	P	O
34	less	O
35	than	O
36	0	O
37	.	O
38	05	O
39	)	O
40	were	O
41	significantly	O
42	higher	O
43	at	O
44	-	O
45	10	O
46	degrees	O
47	C	O
48	than	O
49	at	O
50	22	O
51	degrees	O
52	C	O
53	.	O

1	The	O
2	following	O
3	evidence	O
4	indicates	O
5	that	O
6	the	O
7	69	O
8	-	O
9	kD	O
10	protein	O
11	is	O
12	a	O
13	common	O
14	,	O
15	rather	O
16	than	O
17	a	O
18	U1	B
19	-	I
20	specific	O
21	,	O
22	protein	O
23	,	O
24	possibly	O
25	associating	O
26	with	O
27	the	O
28	snRNP	O
29	core	O
30	particles	O
31	by	O
32	protein	O
33	-	O
34	protein	O
35	interaction	O
36	.	O

1	Twenty	O
2	patients	O
3	aged	O
4	45	O
5	or	O
6	older	O
7	with	O
8	the	O
9	diagnosis	O
10	of	O
11	endogenous	O
12	depression	O
13	were	O
14	evaluated	O
15	in	O
16	terms	O
17	of	O
18	safety	O
19	and	O
20	efficacy	O
21	in	O
22	their	O
23	response	O
24	to	O
25	multiple	O
26	monitored	O
27	electroconvulsive	O
28	therapy	O
29	(	O
30	MMECT	O
31	)	O
32	versus	O
33	single	O
34	electroconvulsive	O
35	therapy	O
36	(	O
37	SECT	O
38	).	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	results	O
6	demonstrate	O
7	that	O
8	the	O
9	RP	O
10	,	O
11	like	O
12	the	O
13	20S	B
14	proteasome	I
15	,	O
16	is	O
17	functionally	O
18	and	O
19	structurally	O
20	conserved	O
21	among	O
22	eukaryotes	O
23	and	O
24	indicate	O
25	that	O
26	the	O
27	plant	O
28	RPT	O
29	subunits	O
30	,	O
31	like	O
32	their	O
33	yeast	O
34	counterparts	O
35	,	O
36	have	O
37	non	O
38	-	O
39	redundant	O
40	functions	O
41	.	O

1	In	O
2	a	O
3	previous	O
4	study	O
5	(	O
6	Brandl	O
7	,	O
8	C	O
9	.	O

1	THE	O
2	SCALING	O
3	OF	O
4	SONG	O
5	FREQUENCY	O
6	IN	O
7	CICADAS	O

1	CONCLUSIONS	O
2	:	O
3	Our	O
4	findings	O
5	suggest	O
6	that	O
7	pre	O
8	-	O
9	treatment	O
10	with	O
11	coenzyme	O
12	Q10	O
13	may	O
14	play	O
15	a	O
16	protective	O
17	role	O
18	during	O
19	routine	O
20	vascular	O
21	procedures	O
22	requiring	O
23	abdominal	O
24	aortic	O
25	cross	O
26	clamping	O
27	by	O
28	attenuating	O
29	the	O
30	degree	O
31	of	O
32	peroxidative	O
33	damage	O
34	.	O

1	Low	O
2	molecular	O
3	weight	O
4	heparins	O
5	have	O
6	stimulated	O
7	much	O
8	interest	O
9	because	O
10	of	O
11	their	O
12	supposedly	O
13	more	O
14	selective	O
15	action	O
16	on	O
17	Xa	O
18	factor	O
19	.	O

1	To	O
2	analyze	O
3	the	O
4	regulatory	O
5	activity	O
6	of	O
7	Gtx	O
8	,	O
9	we	O
10	first	O
11	identified	O
12	the	O
13	optimal	O
14	Gtx	B
15	-	I
16	binding	I
17	sequence	O
18	using	O
19	an	O
20	in	O
21	vitro	O
22	DNA	O
23	-	O
24	binding	O
25	assay	O
26	.	O

1	Levels	O
2	of	O
3	serum	O
4	IgE	B
5	were	O
6	measured	O
7	monthly	O
8	,	O
9	and	O
10	nasal	O
11	IgE	B
12	was	O
13	measured	O
14	at	O
15	the	O
16	height	O
17	and	O
18	end	O
19	of	O
20	the	O
21	season	O
22	.	O

1	Moreover	O
2	,	O
3	we	O
4	found	O
5	that	O
6	cyclin	B
7	E	I
8	,	O
9	in	O
10	contrast	O
11	to	O
12	cyclin	B
13	D1	I
14	,	O
15	was	O
16	required	O
17	for	O
18	the	O
19	G1	O
20	/	O
21	S	O
22	transition	O
23	even	O
24	in	O
25	cells	O
26	lacking	O
27	retinoblastoma	B
28	protein	I
29	function	O
30	.	O

1	The	O
2	central	O
3	globular	O
4	domain	O
5	is	O
6	highly	O
7	similar	O
8	to	O
9	those	O
10	regions	O
11	from	O
12	other	O
13	H1	O
14	molecules	O
15	,	O
16	and	O
17	the	O
18	carboxyl	O
19	-	O
20	terminal	O
21	domain	O
22	contains	O
23	a	O
24	repeating	O
25	hexapeptide	O
26	motif	O
27	,	O
28	variants	O
29	of	O
30	which	O
31	are	O
32	conserved	O
33	among	O
34	H1	O
35	molecules	O
36	.	O

1	The	O
2	cytogenetic	O
3	expression	O
4	of	O
5	the	O
6	folate	O
7	sensitive	O
8	fragile	O
9	site	O
10	,	O
11	FRAXE	O
12	,	O
13	is	O
14	due	O
15	to	O
16	the	O
17	expansion	O
18	of	O
19	a	O
20	GCC	O
21	repeat	O
22	in	O
23	proximal	O
24	Xq28	O
25	of	O
26	the	O
27	human	O
28	X	O
29	chromosome	O
30	and	O
31	is	O
32	associated	O
33	with	O
34	a	O
35	mild	O
36	form	O
37	of	O
38	mental	O
39	handicap	O
40	.	O

1	A	O
2	needs	O
3	assessment	O
4	of	O
5	these	O
6	families	O
7	was	O
8	also	O
9	done	O
10	.	O

1	In	O
2	the	O
3	former	O
4	instance	O
5	,	O
6	in	O
7	addition	O
8	to	O
9	serum	O
10	calcium	O
11	and	O
12	phosphorous	O
13	ion	O
14	concentrations	O
15	,	O
16	tissue	O
17	pH	O
18	,	O
19	blood	O
20	supply	O
21	,	O
22	hormones	O
23	,	O
24	i	O
25	.	O
26	e	O
27	.,	O
28	vitamin	O
29	D	O
30	,	O
31	vitamin	O
32	A	O
33	,	O
34	and	O
35	various	O
36	enzymes	O
37	(	O
38	e	O
39	.	O
40	g	O
41	.,	O
42	alkaline	B
43	phosphatase	I
44	and	O
45	pyrophosphatase	O
46	)	O
47	may	O
48	all	O
49	play	O
50	significant	O
51	,	O
52	ancillary	O
53	,	O
54	time	O
55	-	O
56	dependent	O
57	,	O
58	but	O
59	as	O
60	yet	O
61	undetermined	O
62	roles	O
63	.	O

1	VII	O
2	.	O

1	The	O
2	xylose	B
3	isomerase	I
4	-	I
5	encoding	I
6	gene	I
7	(	O
8	xylA	O
9	)	O
10	of	O
11	Clostridium	O
12	thermosaccharolyticum	O
13	:	O
14	cloning	O
15	,	O
16	sequencing	O
17	and	O
18	phylogeny	O
19	of	O
20	XylA	O
21	enzymes	O
22	.	O

1	No	O
2	changes	O
3	were	O
4	evident	O
5	in	O
6	the	O
7	FR	O
8	-	O
9	task	O
10	performance	O
11	of	O
12	controls	O
13	that	O
14	received	O
15	daily	O
16	saline	O
17	injections	O
18	.	O

1	We	O
2	show	O
3	that	O
4	the	O
5	en	O
6	stripes	O
7	expand	O
8	anteriorly	O
9	in	O
10	slp	O
11	mutant	O
12	embryos	O
13	and	O
14	that	O
15	slp	O
16	activity	O
17	is	O
18	an	O
19	absolute	O
20	requirement	O
21	for	O
22	maintenance	O
23	of	O
24	wg	O
25	expression	O
26	at	O
27	the	O
28	same	O
29	time	O
30	that	O
31	wg	O
32	transcription	O
33	is	O
34	dependent	O
35	on	O
36	hh	O
37	.	O

1	We	O
2	have	O
3	now	O
4	identified	O
5	,	O
6	after	O
7	21	O
8	serial	O
9	undiluted	O
10	passages	O
11	of	O
12	MHV	O
13	,	O
14	a	O
15	small	O
16	DI	O
17	RNA	O
18	,	O
19	DIssF	O
20	,	O
21	which	O
22	is	O
23	efficiently	O
24	packaged	O
25	into	O
26	virions	O
27	.	O

1	While	O
2	determination	O
3	of	O
4	the	O
5	protein	O
6	content	O
7	of	O
8	the	O
9	formulae	O
10	gave	O
11	no	O
12	valid	O
13	information	O
14	,	O
15	RAST	O
16	/	O
17	EAST	O
18	inhibition	O
19	was	O
20	highest	O
21	for	O
22	cow	O
23	'	O
24	s	O
25	milk	O
26	,	O
27	followed	O
28	by	O
29	the	O
30	partially	O
31	hydrolysed	O
32	whey	O
33	formula	O
34	,	O
35	partially	O
36	hydrolysed	O
37	whey	O
38	/	O
39	casein	B
40	formula	O
41	,	O
42	soy	O
43	/	O
44	pork	O
45	collagen	B
46	formula	O
47	,	O
48	and	O
49	the	O
50	amino	O
51	acid	O
52	formula	O
53	.	O

1	With	O
2	each	O
3	of	O
4	the	O
5	three	O
6	pairs	O
7	of	O
8	isolates	O
9	(	O
10	case	O
11	and	O
12	suspicious	O
13	case	O
14	),	O
15	identical	O
16	IS6110	O
17	banding	O
18	patterns	O
19	were	O
20	found	O
21	suggesting	O
22	identical	O
23	MTB	O
24	strains	O
25	.	O

1	This	O
2	organization	O
3	suggests	O
4	that	O
5	duplication	O
6	events	O
7	that	O
8	have	O
9	generated	O
10	the	O
11	primate	O
12	FUT3	O
13	-	O
14	FUT5	O
15	-	O
16	FUT6	O
17	cluster	O
18	might	O
19	have	O
20	occurred	O
21	through	O
22	a	O
23	long	O
24	-	O
25	interspersed	O
26	-	O
27	nuclear	O
28	-	O
29	element	O
30	-	O
31	based	O
32	mechanism	O
33	of	O
34	unequal	O
35	crossing	O
36	over	O
37	,	O
38	as	O
39	described	O
40	for	O
41	the	O
42	globin	B
43	cluster	I
44	.	O

1	In	O
2	addition	O
3	,	O
4	26	O
5	amino	O
6	acid	O
7	residues	O
8	,	O
9	K69	O
10	,	O
11	D88	O
12	,	O
13	E94	O
14	,	O
15	D134	O
16	,	O
17	R154	O
18	,	O
19	K169	O
20	,	O
21	H197	O
22	,	O
23	D233	O
24	,	O
25	G235	O
26	,	O
27	G236	O
28	,	O
29	G237	O
30	,	O
31	F238	O
32	,	O
33	E274	O
34	,	O
35	G276	O
36	,	O
37	R277	O
38	,	O
39	Y278	O
40	,	O
41	K294	O
42	,	O
43	Y323	O
44	,	O
45	Y331	O
46	,	O
47	D332	O
48	,	O
49	C360	O
50	,	O
51	D361	O
52	,	O
53	D364	O
54	,	O
55	G387	O
56	,	O
57	Y389	O
58	,	O
59	and	O
60	F397	O
61	(	O
62	mouse	O
63	ODC	O
64	numbering	O
65	),	O
66	all	O
67	of	O
68	which	O
69	are	O
70	implicated	O
71	in	O
72	the	O
73	formation	O
74	of	O
75	the	O
76	pyridoxal	O
77	phosphate	O
78	-	O
79	binding	O
80	domain	O
81	and	O
82	the	O
83	substrate	O
84	-	O
85	binding	O
86	domain	O
87	and	O
88	in	O
89	dimer	O
90	stabilization	O
91	with	O
92	the	O
93	eukaryotic	O
94	ODCs	O
95	,	O
96	were	O
97	also	O
98	conserved	O
99	in	O
100	S	O
101	.	O
102	ruminantium	O
103	LDC	O
104	.	O

1	This	O
2	report	O
3	presents	O
4	an	O
5	analysis	O
6	of	O
7	the	O
8	vocal	O
9	repertoire	O
10	of	O
11	howler	O
12	monkeys	O
13	(	O
14	Alouatta	O
15	palliata	O
16	)	O
17	observed	O
18	during	O
19	a	O
20	field	O
21	study	O
22	in	O
23	southwestern	O
24	Panama	O
25	.	O

1	Copper	O
2	and	O
3	ceruloplasmin	O
4	content	O
5	in	O
6	pregnant	O
7	women	O
8	and	O
9	in	O
10	women	O
11	with	O
12	certain	O
13	gynecological	O
14	diseases	O

1	Chronic	O
2	endotoxemia	O
3	appears	O
4	to	O
5	be	O
6	associated	O
7	with	O
8	an	O
9	elevated	O
10	pulmonary	O
11	microvascular	O
12	permeability	O
13	and	O
14	a	O
15	tendency	O
16	toward	O
17	a	O
18	hyperdynamic	O
19	circulation	O
20	but	O
21	with	O
22	an	O
23	appreciable	O
24	degree	O
25	of	O
26	refractoriness	O
27	associated	O
28	with	O
29	regional	O
30	hemodynamics	O
31	and	O
32	eicosanoid	O
33	biosynthesis	O
34	.	O

1	Assay	O
2	of	O
3	serum	O
4	immunoreactive	O
5	trypsin	B
6	in	O
7	dried	O
8	blood	O
9	spots	O
10	and	O
11	the	O
12	early	O
13	detection	O
14	of	O
15	cystic	O
16	fibrosis	O
17	.	O

1	Because	O
2	RNase	B
3	III	I
4	host	I
5	mutants	I
6	are	O
7	defective	O
8	in	O
9	sib	O
10	regulation	O
11	,	O
12	processing	O
13	of	O
14	the	O
15	PL	O
16	mRNA	O
17	at	O
18	sib	O
19	by	O
20	this	O
21	endoribonuclease	O
22	may	O
23	cause	O
24	int	B
25	mRNA	I
26	decay	O
27	and	O
28	decrease	O
29	int	O
30	synthesis	O
31	.	O

1	The	O
2	hypertension	O
3	with	O
4	elevated	O
5	PRA	O
6	,	O
7	however	O
8	,	O
9	was	O
10	resistant	O
11	to	O
12	the	O
13	angiotensin	B
14	II	I
15	(	O
16	AII	O
17	)	O
18	analog	O
19	[	O
20	Sar1	O
21	,	O
22	Ile8	O
23	]	O
24	ALL	O
25	.	O

1	Thus	O
2	,	O
3	SPECT	O
4	was	O
5	not	O
6	as	O
7	sensitive	O
8	as	O
9	PET	O
10	in	O
11	this	O
12	activation	O
13	task	O
14	.	O

1	The	O
2	results	O
3	showed	O
4	that	O
5	MIP	O
6	,	O
7	MMIF	O
8	,	O
9	FIC	O
10	,	O
11	Wimax	O
12	,	O
13	P0	O
14	.	O
15	1	O
16	and	O
17	minute	O
18	ventilation	O
19	(	O
20	Vr	O
21	)	O
22	were	O
23	significantly	O
24	increased	O
25	after	O
26	administration	O
27	of	O
28	methylphenidatum	O
29	and	O
30	aminophylline	O
31	.	O

1	The	O
2	electrocardiogram	O
3	.	O

1	The	O
2	first	O
3	symptoms	O
4	of	O
5	enzootic	O
6	calcinosis	O
7	were	O
8	noted	O
9	in	O
10	March	O
11	1998	O
12	,	O
13	when	O
14	some	O
15	of	O
16	the	O
17	cows	O
18	developed	O
19	locomotor	O
20	abnormalities	O
21	.	O

1	The	O
2	concentration	O
3	of	O
4	alpha	B
5	2	I
6	-	I
7	macroglobulin	I
8	,	I
9	alpha	I
10	1	I
11	-	I
12	antitrypsin	I
13	,	I
14	plasminogen	I
15	,	O
16	C3	B
17	-	I
18	complement	O
19	,	O
20	fibrinogen	B
21	degradation	O
22	products	O
23	(	O
24	FDP	O
25	)	O
26	and	O
27	fibrinolytic	O
28	activity	O
29	,	O
30	were	O
31	studied	O
32	in	O
33	the	O
34	aqueous	O
35	humour	O
36	and	O
37	serum	O
38	from	O
39	nine	O
40	patients	O
41	with	O
42	Fuchs	O
43	'	O
44	endothelial	O
45	dystrophy	O
46	,	O
47	17	O
48	patients	O
49	with	O
50	uncomplicated	O
51	senile	O
52	cataract	O
53	and	O
54	in	O
55	the	O
56	secondary	O
57	aqueous	O
58	from	O
59	six	O
60	cataract	O
61	patients	O
62	.	O

1	Since	O
2	the	O
3	integrated	O
4	13h00	O
5	-	O
6	16h00	O
7	plasma	O
8	cortisol	O
9	estimation	O
10	is	O
11	cheaper	O
12	and	O
13	simpler	O
14	than	O
15	the	O
16	mean	O
17	13h00	O
18	-	O
19	16h00	O
20	plasma	O
21	cortisol	O
22	estimation	O
23	,	O
24	we	O
25	recommend	O
26	it	O
27	as	O
28	an	O
29	adjunct	O
30	in	O
31	the	O
32	diagnosis	O
33	of	O
34	Cushing	O
35	'	O
36	s	O
37	syndrome	O
38	.	O

1	Sensory	O
2	kindling	O
3	:	O
4	implications	O
5	for	O
6	development	O
7	of	O
8	sensory	O
9	prostheses	O
10	.	O

1	Per	O
2	kg	O
3	FFM	O
4	SMR	O
5	was	O
6	almost	O
7	restored	O
8	to	O
9	baseline	O
10	values	O
11	for	O
12	the	O
13	EX	O
14	group	O
15	,	O
16	whereas	O
17	the	O
18	non	O
19	-	O
20	exercising	O
21	subjects	O
22	still	O
23	showed	O
24	depressed	O
25	values	O
26	(	O
27	EX	O
28	3	O
29	.	O
30	7	O
31	per	O
32	cent	O
33	and	O
34	D	O
35	+	O
36	DE	O
37	15	O
38	.	O
39	8	O
40	per	O
41	cent	O
42	lower	O
43	than	O
44	before	O
45	treatment	O
46	;	O
47	P	O
48	less	O
49	than	O
50	0	O
51	.	O
52	05	O
53	).	O

1	IL	B
2	-	I
3	12	O
4	production	O
5	was	O
6	correlated	O
7	with	O
8	C3a	O
9	concentration	O
10	measured	O
11	at	O
12	the	O
13	outlet	O
14	of	O
15	hemodialyzer	O
16	after	O
17	15	O
18	min	O
19	of	O
20	dialysis	O
21	(	O
22	r	O
23	=	O
24	0	O
25	.	O
26	69	O
27	,	O
28	P	O
29	<	O
30	0	O
31	.	O
32	01	O
33	).	O

1	Therefore	O
2	,	O
3	in	O
4	order	O
5	to	O
6	search	O
7	for	O
8	the	O
9	latent	O
10	genes	O
11	,	O
12	we	O
13	used	O
14	allotype	O
15	-	O
16	specific	O
17	oligonucleotides	O
18	for	O
19	b5	O
20	,	O
21	b6	O
22	and	O
23	b9	O
24	to	O
25	probe	O
26	DNAs	O
27	from	O
28	both	O
29	normal	O
30	and	O
31	T	O
32	.	O
33	brucei	O
34	-	O
35	infected	O
36	rabbits	O
37	by	O
38	Southern	O
39	blotting	O
40	.	O

1	The	O
2	criterion	O
3	was	O
4	reached	O
5	after	O
6	two	O
7	sessions	O
8	and	O
9	generalization	O
10	to	O
11	a	O
12	variety	O
13	of	O
14	pills	O
15	and	O
16	capsules	O
17	occurred	O
18	.	O

1	Activation	O
2	of	O
3	a	O
4	CRE	O
5	-	O
6	dependent	O
7	junB	B
8	promoter	I
9	/	I
10	chloramphenicol	I
11	acetyltransferase	I
12	(	O
13	CAT	B
14	)	I
15	reporter	I
16	gene	I
17	by	O
18	the	O
19	BCR	O
20	was	O
21	also	O
22	blocked	O
23	by	O
24	SB203580	O
25	.	O

1	Mutation	O
2	of	O
3	Enh4	O
4	,	O
5	an	O
6	essential	O
7	GT	B
8	-	I
9	IIC	I
10	-	I
11	like	I
12	enhanson	I
13	in	O
14	the	O
15	context	O
16	of	O
17	the	O
18	intact	O
19	enhancer	O
20	,	O
21	abolishes	O
22	silencer	O
23	activity	O
24	,	O
25	and	O
26	multimerized	O
27	GT	O
28	-	O
29	IIC	O
30	enhansons	O
31	mimic	O
32	the	O
33	intact	O
34	CSEn	O
35	enhancer	O
36	/	O
37	silencer	O
38	activities	O
39	in	O
40	BeWo	O
41	and	O
42	GC	O
43	cells	O
44	,	O
45	respectively	O
46	.	O

1	Finally	O
2	,	O
3	the	O
4	recovery	O
5	indexes	O
6	represented	O
7	by	O
8	the	O
9	times	O
10	required	O
11	for	O
12	T1	O
13	/	O
14	T0	O
15	and	O
16	T4	O
17	/	O
18	T1	O
19	to	O
20	rise	O
21	from	O
22	25	O
23	%	O
24	to	O
25	75	O
26	%	O
27	respectively	O
28	were	O
29	studied	O
30	.	O

1	Two	O
2	such	O
3	genes	O
4	,	O
5	designated	O
6	hsiggll150	O
7	and	O
8	hsiggll295	O
9	,	O
10	were	O
11	cloned	O
12	and	O
13	sequenced	O
14	from	O
15	genomic	O
16	DNA	O
17	.	O

1	We	O
2	conclude	O
3	that	O
4	administration	O
5	of	O
6	the	O
7	calcium	O
8	antagonist	O
9	Verapamil	O
10	is	O
11	of	O
12	no	O
13	additional	O
14	value	O
15	in	O
16	tocolytic	O
17	treatment	O
18	with	O
19	beta	O
20	-	O
21	mimetics	O
22	.	O

1	Our	O
2	mapping	O
3	results	O
4	did	O
5	not	O
6	suggest	O
7	involvement	O
8	of	O
9	this	O
10	gene	O
11	in	O
12	previously	O
13	mapped	O
14	genetic	O
15	disorders	O
16	or	O
17	in	O
18	known	O
19	neoplasia	O
20	-	O
21	associated	O
22	translocation	O
23	breakpoints	O
24	.	O

1	We	O
2	previously	O
3	showed	O
4	that	O
5	the	O
6	N	O
7	-	O
8	terminal	O
9	portion	O
10	common	O
11	to	O
12	various	O
13	chimeric	O
14	MLL	O
15	products	O
16	,	O
17	as	O
18	well	O
19	as	O
20	to	O
21	MLL	O
22	-	O
23	LTG9	O
24	and	O
25	MLL	O
26	-	O
27	LTG19	O
28	,	O
29	localizes	O
30	in	O
31	the	O
32	nuclei	O
33	,	O
34	and	O
35	therefore	O
36	suggested	O
37	that	O
38	it	O
39	might	O
40	play	O
41	an	O
42	important	O
43	role	O
44	in	O
45	leukemogenesis	O
46	.	O

1	Lys	O
2	(	O
3	193	O
4	)	O
5	and	O
6	Arg	O
7	(	O
8	194	O
9	),	O
10	located	O
11	at	O
12	the	O
13	COOH	O
14	-	O
15	terminal	O
16	end	O
17	of	O
18	HD	O
19	,	O
20	are	O
21	essential	O
22	for	O
23	dimerization	O
24	.	O

1	Colorectal	O
2	polyps	O
3	should	O
4	be	O
5	removed	O
6	endoscopically	O
7	whenever	O
8	possible	O
9	.	O

1	Apart	O
2	from	O
3	iron	O
4	regulation	O
5	,	O
6	sodA	O
7	expression	O
8	was	O
9	affected	O
10	by	O
11	changes	O
12	in	O
13	DNA	O
14	topology	O
15	induced	O
16	by	O
17	coumermycin	O
18	A	O
19	but	O
20	not	O
21	by	O
22	the	O
23	global	O
24	virulence	O
25	regulatory	O
26	Bvg	O
27	system	O
28	.	O

1	Intravenous	O
2	gamma	O
3	globulins	O

1	Consistent	O
2	with	O
3	the	O
4	hypothesis	O
5	that	O
6	it	O
7	acts	O
8	as	O
9	transcriptional	O
10	regulator	O
11	,	O
12	wild	B
13	-	I
14	type	I
15	p53	I
16	protein	I
17	binds	O
18	DNA	O
19	and	O
20	activates	O
21	transcription	O
22	of	O
23	several	O
24	promoters	O
25	.	O

1	Phosphoamino	O
2	acid	O
3	analysis	O
4	of	O
5	radiolabeled	O
6	ASGPR	O
7	subunits	O
8	identified	O
9	Ser	O
10	(	O
11	P	O
12	)	O
13	as	O
14	the	O
15	predominant	O
16	(	O
17	approximately	O
18	95	O
19	%)	O
20	and	O
21	Thr	O
22	(	O
23	P	O
24	)	O
25	as	O
26	a	O
27	minor	O
28	(	O
29	approximately	O
30	5	O
31	%)	O
32	phosphoamino	O
33	acid	O
34	in	O
35	each	O
36	polypeptide	O
37	and	O
38	confirmed	O
39	the	O
40	presence	O
41	of	O
42	Tyr	O
43	(	O
44	P	O
45	)	O
46	(	O
47	approximately	O
48	1	O
49	%)	O
50	in	O
51	RHL1	O
52	.	O

1	An	O
2	explanation	O
3	explored	O
4	for	O
5	this	O
6	lack	O
7	of	O
8	gene	O
9	expression	O
10	was	O
11	that	O
12	increased	O
13	levels	O
14	of	O
15	RAR	B
16	alpha	I
17	or	O
18	PML	O
19	might	O
20	suppress	O
21	APL	O
22	cell	O
23	growth	O
24	.	O

1	To	O
2	search	O
3	for	O
4	transcriptional	O
5	regulators	O
6	,	O
7	we	O
8	used	O
9	a	O
10	fragment	O
11	of	O
12	the	O
13	SpHE	B
14	promoter	I
15	containing	O
16	several	O
17	individual	O
18	elements	O
19	instead	O
20	of	O
21	the	O
22	conventional	O
23	bait	O
24	that	O
25	contains	O
26	a	O
27	multimerized	O
28	cis	O
29	element	O
30	.	O

1	The	O
2	role	O
3	of	O
4	daunorubicin	O
5	in	O
6	induction	O
7	therapy	O
8	for	O
9	adult	O
10	acute	O
11	myeloid	O
12	leukemia	O

1	CONCLUSIONS	O
2	:	O
3	Pretreatment	O
4	with	O
5	OCs	O
6	prior	O
7	to	O
8	pituitary	O
9	suppression	O
10	in	O
11	the	O
12	early	O
13	follicular	O
14	phase	O
15	decreases	O
16	ovarian	O
17	cyst	O
18	formation	O
19	,	O
20	without	O
21	an	O
22	apparent	O
23	effect	O
24	on	O
25	subsequent	O
26	follicular	O
27	recruitment	O
28	or	O
29	pregnancy	O
30	rates	O
31	.	O

1	The	O
2	Oct	B
3	and	O
4	HMG2	O
5	proteins	O
6	also	O
7	interact	O
8	in	O
9	vivo	O
10	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	fludarabine	O
6	is	O
7	a	O
8	highly	O
9	useful	O
10	agent	O
11	in	O
12	CLL	O
13	.	O

1	Through	O
2	transient	O
3	transfection	O
4	of	O
5	NIH3T3	O
6	fibroblast	O
7	cells	O
8	and	O
9	gel	O
10	mobility	O
11	shift	O
12	assays	O
13	,	O
14	the	O
15	functional	O
16	binding	O
17	site	O
18	was	O
19	localized	O
20	to	O
21	a	O
22	short	O
23	region	O
24	(-	O
25	318	O
26	to	O
27	-	O
28	303	O
29	bp	O
30	from	O
31	the	O
32	transcription	O
33	start	O
34	site	O
35	)	O
36	which	O
37	has	O
38	a	O
39	CTCCC	O
40	sequence	O
41	.	O

1	Ketamine	O
2	in	O
3	the	O
4	treatment	O
5	of	O
6	bronchospasm	O
7	during	O
8	mechanical	O
9	ventilation	O
10	.	O

1	Jkappa	O
2	DNA	O
3	-	O
4	binding	O
5	sites	O
6	were	O
7	not	O
8	required	O
9	for	O
10	this	O
11	activation	O
12	,	O
13	and	O
14	a	O
15	mutant	O
16	EBNA	B
17	-	I
18	3C	I
19	protein	I
20	unable	O
21	to	O
22	bind	O
23	Jkappa	O
24	activated	O
25	transcription	O
26	as	O
27	efficiently	O
28	as	O
29	wild	B
30	-	I
31	type	I
32	EBNA	I
33	-	I
34	3C	I
35	,	O
36	indicating	O
37	that	O
38	EBNA	B
39	-	I
40	3C	I
41	can	O
42	regulate	O
43	transcription	O
44	through	O
45	a	O
46	mechanism	O
47	that	O
48	is	O
49	independent	O
50	of	O
51	Jkappa	O
52	.	O

1	In	O
2	such	O
3	a	O
4	manner	O
5	,	O
6	activated	O
7	PKR	B
8	inhibits	O
9	cell	O
10	growth	O
11	and	O
12	induces	O
13	apoptosis	O
14	,	O
15	whereas	O
16	disruption	O
17	of	O
18	normal	O
19	PKR	B
20	signaling	O
21	results	O
22	in	O
23	unregulated	O
24	cell	O
25	growth	O
26	.	O

1	Two	O
2	specific	O
3	DNA	O
4	-	O
5	protein	O
6	complexes	O
7	were	O
8	identified	O
9	in	O
10	gel	O
11	retardation	O
12	assays	O
13	using	O
14	HeLa	O
15	cell	O
16	nuclear	O
17	extracts	O
18	and	O
19	an	O
20	oligonucleotide	O
21	probe	O
22	spanning	O
23	the	O
24	footprinted	O
25	region	O
26	.	O

1	We	O
2	have	O
3	recently	O
4	detected	O
5	high	O
6	levels	O
7	of	O
8	CKB	O
9	mRNA	O
10	in	O
11	HeLa	O
12	cells	O
13	and	O
14	,	O
15	in	O
16	this	O
17	study	O
18	,	O
19	have	O
20	tested	O
21	whether	O
22	this	O
23	may	O
24	be	O
25	due	O
26	to	O
27	the	O
28	extremely	O
29	low	O
30	amounts	O
31	of	O
32	p53	B
33	protein	I
34	present	O
35	in	O
36	HeLa	O
37	cells	O
38	.	O

1	Expression	O
2	of	O
3	this	O
4	cDNA	O
5	in	O
6	vitro	O
7	yields	O
8	a	O
9	peptide	O
10	which	O
11	comigrates	O
12	with	O
13	natural	O
14	eIF	B
15	-	I
16	2B	I
17	alpha	I
18	in	O
19	SDS	O
20	/	O
21	polyacrylamide	O
22	gels	O
23	.	O

1	Levels	O
2	of	O
3	TSG	O
4	-	O
5	14	O
6	protein	O
7	(	O
8	also	O
9	termed	O
10	PTX	O
11	-	O
12	3	O
13	)	O
14	become	O
15	elevated	O
16	in	O
17	the	O
18	serum	O
19	of	O
20	mice	O
21	and	O
22	humans	O
23	after	O
24	injection	O
25	with	O
26	bacterial	O
27	lipopolysaccharide	O
28	,	O
29	but	O
30	in	O
31	contrast	O
32	to	O
33	conventional	O
34	acute	O
35	phase	O
36	proteins	O
37	,	O
38	the	O
39	bulk	O
40	of	O
41	TSG	O
42	-	O
43	14	O
44	synthesis	O
45	in	O
46	the	O
47	intact	O
48	organism	O
49	occurs	O
50	outside	O
51	the	O
52	liver	O
53	.	O

1	The	O
2	epidemic	O
3	occurred	O
4	in	O
5	a	O
6	group	O
7	of	O
8	26	O
9	community	O
10	members	O
11	(	O
12	23	O
13	men	O
14	and	O
15	3	O
16	women	O
17	,	O
18	mean	O
19	age	O
20	,	O
21	28	O
22	.	O
23	9	O
24	--	O
25	3	O
26	years	O
27	)	O
28	living	O
29	and	O
30	working	O
31	together	O
32	,	O
33	who	O
34	underwent	O
35	acute	O
36	and	O
37	convalescent	O
38	serologic	O
39	tests	O
40	for	O
41	Mycoplasma	O
42	pneumoniae	O
43	,	O
44	Legionella	O
45	pneumophila	O
46	,	O
47	cytomegalovirus	O
48	,	O
49	adenovirus	O
50	,	O
51	Coxiella	O
52	burnetii	O
53	,	O
54	and	O
55	Chlamydia	O
56	pneumoniae	O
57	.	O

1	We	O
2	previously	O
3	showed	O
4	that	O
5	the	O
6	upstream	O
7	promoter	O
8	element	O
9	of	O
10	the	O
11	yeast	O
12	RP39A	O
13	gene	O
14	consists	O
15	of	O
16	these	O
17	identical	O
18	sequence	O
19	motifs	O
20	.	O

1	A	O
2	transformation	O
3	-	O
4	competent	O
5	mutant	O
6	,	O
7	like	O
8	the	O
9	wild	O
10	-	O
11	type	O
12	E5	O
13	protein	O
14	,	O
15	bound	O
16	the	O
17	receptor	O
18	and	O
19	induced	O
20	receptor	O
21	tyrosine	O
22	phosphorylation	O
23	and	O
24	down	O
25	-	O
26	regulation	O
27	.	O

1	The	O
2	use	O
3	of	O
4	an	O
5	appropriate	O
6	solution	O
7	of	O
8	methylene	O
9	blue	O
10	(	O
11	0	O
12	.	O
13	2	O
14	%	O
15	in	O
16	0	O
17	.	O
18	9	O
19	M	O
20	NaCl	O
21	for	O
22	15	O
23	min	O
24	)	O
25	permits	O
26	the	O
27	staining	O
28	of	O
29	premalignant	O
30	areas	O
31	and	O
32	CIS	O
33	,	O
34	and	O
35	their	O
36	early	O
37	diagnosis	O
38	.	O

1	A	O
2	.	O

1	The	O
2	genomic	O
3	structure	O
4	of	O
5	brk	O
6	consists	O
7	of	O
8	8	O
9	exons	O
10	,	O
11	whose	O
12	boundaries	O
13	are	O
14	distinct	O
15	from	O
16	other	O
17	non	B
18	-	I
19	receptor	I
20	PTK	I
21	family	I
22	members	O
23	,	O
24	again	O
25	indicating	O
26	a	O
27	structural	O
28	and	O
29	functional	O
30	divergence	O
31	.	O

1	Hierarchy	O
2	of	O
3	protein	O
4	tyrosine	O
5	kinases	O
6	in	O
7	interleukin	B
8	-	I
9	2	I
10	(	I
11	IL	I
12	-	I
13	2	I
14	)	O
15	signaling	O
16	:	O
17	activation	O
18	of	O
19	syk	O
20	depends	O
21	on	O
22	Jak3	O
23	;	O
24	however	O
25	,	O
26	neither	O
27	Syk	O
28	nor	O
29	Lck	O
30	is	O
31	required	O
32	for	O
33	IL	B
34	-	I
35	2	I
36	-	I
37	mediated	O
38	STAT	B
39	activation	O
40	.	O

1	MCh	O
2	infusion	O
3	caused	O
4	a	O
5	concentration	O
6	-	O
7	dependent	O
8	increase	O
9	in	O
10	airway	O
11	resistance	O
12	at	O
13	constant	O
14	QBA	O
15	.	O

1	Aedes	O
2	aegypti	O
3	(	O
4	L	O
5	.)	O
6	and	O
7	Aedes	O
8	albopictus	O
9	(	O
10	Skuse	O
11	)	O
12	in	O
13	Singapore	O
14	City	O
15	.	O

1	The	O
2	RS447	O
3	human	O
4	megasatellite	O
5	tandem	O
6	repetitive	O
7	sequence	O
8	encodes	O
9	a	O
10	novel	O
11	deubiquitinating	O
12	enzyme	O
13	with	O
14	a	O
15	functional	O
16	promoter	O
17	.	O

1	The	O
2	serum	O
3	levels	O
4	of	O
5	beta	O
6	-	O
7	human	B
8	chorionic	I
9	gonadotropin	I
10	(	O
11	HCG	O
12	)	O
13	and	O
14	placental	O
15	alkaline	B
16	phosphatase	I
17	(	O
18	PLAP	O
19	)	O
20	were	O
21	not	O
22	elevated	O
23	.	O

1	Exploratory	O
2	-	O
3	motor	O
4	task	O
5	to	O
6	evaluate	O
7	right	O
8	frontal	O
9	lobe	O
10	damage	O
11	.	O

1	Unfolding	O
2	can	O
3	be	O
4	described	O
5	by	O
6	a	O
7	two	O
8	-	O
9	state	O
10	process	O
11	since	O
12	a	O
13	ratio	O
14	of	O
15	delta	O
16	Hcalorimetric	O
17	to	O
18	delta	O
19	Hvan	O
20	'	O
21	t	O
22	Hoff	O
23	equals	O
24	0	O
25	.	O
26	96	O
27	.	O

1	The	O
2	SH2	B
3	-	I
4	containing	I
5	adapter	I
6	protein	I
7	GRB10	O
8	interacts	O
9	with	O
10	BCR	B
11	-	I
12	ABL	I
13	.	O

1	Such	O
2	transgenic	O
3	plants	O
4	should	O
5	enable	O
6	not	O
7	only	O
8	the	O
9	mutational	O
10	analysis	O
11	of	O
12	sequence	O
13	elements	O
14	within	O
15	the	O
16	replication	O
17	origin	O
18	region	O
19	,	O
20	but	O
21	also	O
22	the	O
23	construction	O
24	of	O
25	a	O
26	new	O
27	generation	O
28	of	O
29	vectors	O
30	for	O
31	gene	O
32	amplification	O
33	in	O
34	plants	O
35	,	O
36	based	O
37	on	O
38	a	O
39	minimal	O
40	virus	O
41	replicon	O
42	.	O

1	Six	O
2	patients	O
3	with	O
4	glomerulonephritis	O
5	in	O
6	association	O
7	with	O
8	a	O
9	ventriculovascular	O
10	shunt	O
11	were	O
12	treated	O
13	with	O
14	three	O
15	basic	O
16	modes	O
17	of	O
18	therapy	O
19	.	O

1	These	O
2	results	O
3	were	O
4	compared	O
5	with	O
6	those	O
7	obtained	O
8	in	O
9	-	O
10	D	O
11	mothers	O
12	and	O
13	pups	O
14	,	O
15	after	O
16	giving	O
17	the	O
18	mothers	O
19	an	O
20	oral	O
21	supplement	O
22	(	O
23	10	O
24	i	O
25	.	O
26	u	O
27	.	O
28	vitamin	O
29	D3	O
30	/	O
31	day	O
32	)	O
33	during	O
34	the	O
35	period	O
36	of	O
37	lactation	O
38	(	O
39	20	O
40	days	O
41	).	O

1	(	O
2	GUT	O
3	)	O
4	Sera	O
5	of	O
6	30	O
7	montoux	O
8	negative	O
9	healthy	O
10	adults	O
11	(	O
12	age	O
13	/	O
14	sex	O
15	matched	O
16	)	O
17	were	O
18	taken	O
19	as	O
20	control	O
21	by	O
22	detecting	O
23	IgG	B
24	anti	O
25	bodies	O
26	to	O
27	A60	B
28	antigen	I
29	.	O

1	CM	O
2	reduced	O
3	the	O
4	nuclear	O
5	binding	O
6	activity	O
7	of	O
8	transcription	O
9	factor	O
10	AP	B
11	-	I
12	1	I
13	.	O

1	The	O
2	Euglena	O
3	ribosomal	B
4	protein	I
5	gene	I
6	cluster	I
7	resembles	O
8	the	O
9	S	O
10	-	O
11	10	O
12	ribosomal	B
13	protein	I
14	operon	I
15	of	O
16	Escherichia	O
17	coli	O
18	in	O
19	gene	O
20	organization	O
21	and	O
22	follows	O
23	the	O
24	exact	O
25	linear	O
26	order	O
27	of	O
28	the	O
29	analogous	O
30	genes	O
31	in	O
32	the	O
33	tobacco	O
34	and	O
35	liverwort	O
36	chloroplast	O
37	genomes	O
38	.	O

1	Such	O
2	a	O
3	concept	O
4	is	O
5	crucial	O
6	to	O
7	our	O
8	understanding	O
9	of	O
10	the	O
11	pathology	O
12	of	O
13	ageing	O
14	in	O
15	general	O
16	.	O

1	Mean	O
2	weighted	O
3	skin	O
4	temperature	O
5	(	O
6	Tsk	O
7	)	O
8	was	O
9	lower	O
10	(	O
11	P	O
12	less	O
13	than	O
14	0	O
15	.	O
16	01	O
17	)	O
18	following	O
19	acclimation	O
20	than	O
21	before	O
22	,	O
23	and	O
24	acclimation	O
25	resulted	O
26	in	O
27	a	O
28	larger	O
29	(	O
30	P	O
31	less	O
32	than	O
33	0	O
34	.	O
35	02	O
36	)	O
37	Tre	O
38	-	O
39	to	O
40	-	O
41	Tsk	O
42	gradient	O
43	.	O

1	These	O
2	effects	O
3	were	O
4	abrogated	O
5	by	O
6	co	O
7	-	O
8	expression	O
9	of	O
10	kinase	O
11	-	O
12	deficient	O
13	PKC	B
14	zeta	I
15	and	O
16	inhibition	O
17	of	O
18	phosphatidylinositol	B
19	3	I
20	-	I
21	kinase	I
22	p85alpha	I
23	-	I
24	p110	I
25	by	O
26	wortmannin	O
27	,	O
28	LY294002	O
29	and	O
30	a	O
31	dominant	O
32	-	O
33	negative	O
34	mutant	O
35	of	O
36	p85alpha	O
37	.	O

1	Unexpectedly	O
2	,	O
3	all	O
4	ENK	O
5	-	O
6	specific	O
7	motifs	O
8	formed	O
9	specific	O
10	and	O
11	highly	O
12	abundant	O
13	protein	O
14	-	O
15	DNA	O
16	complexes	O
17	when	O
18	nuclear	O
19	extracts	O
20	from	O
21	the	O
22	human	O
23	tumor	O
24	cell	O
25	line	O
26	(	O
27	HeLa	O
28	),	O
29	which	O
30	does	O
31	not	O
32	express	O
33	ENK	O
34	,	O
35	were	O
36	used	O
37	.	O

1	Renal	O
2	and	O
3	extrarenal	O
4	arterial	O
5	fibromuscular	O
6	hyperplasia	O
7	with	O
8	hypertension	O
9	.	O

1	The	O
2	primary	O
3	pancreatic	O
4	insult	O
5	seemed	O
6	to	O
7	be	O
8	unaffected	O
9	by	O
10	the	O
11	treatment	O
12	,	O
13	because	O
14	neither	O
15	the	O
16	rise	O
17	in	O
18	plasma	O
19	lipase	B
20	nor	O
21	the	O
22	development	O
23	of	O
24	ascites	O
25	or	O
26	the	O
27	extension	O
28	of	O
29	the	O
30	pancreatic	O
31	necrosis	O
32	were	O
33	diminished	O
34	.	O

1	Insulin	B
2	-	I
3	regulated	O
4	events	O
5	,	O
6	however	O
7	,	O
8	occur	O
9	in	O
10	all	O
11	cells	O
12	.	O

1	We	O
2	infer	O
3	that	O
4	the	O
5	dominant	O
6	negative	O
7	inhibition	O
8	results	O
9	from	O
10	both	O
11	direct	O
12	proteolysis	O
13	of	O
14	the	O
15	beta	B
16	-	I
17	galactosidase	I
18	tetramer	I
19	by	O
20	the	O
21	fusion	O
22	subunit	O
23	and	O
24	detour	O
25	of	O
26	the	O
27	tetramer	O
28	to	O
29	the	O
30	lysosome	O
31	.	O

1	Two	O
2	points	O
3	are	O
4	indicated	O
5	:	O
6	first	O
7	,	O
8	the	O
9	photosensitized	O
10	damage	O
11	of	O
12	YHPD	O
13	is	O
14	interrelated	O
15	to	O
16	not	O
17	only	O
18	1O2	O
19	,	O
20	but	O
21	also	O
22	free	O
23	radicals	O
24	(	O
25	O2	O
26	-.	O
27	.	O
28	OH	O
29	and	O
30	YHPD	O
31	-.);	O
32	second	O
33	,	O
34	although	O
35	the	O
36	photosensitized	O
37	damage	O
38	of	O
39	YHPD	O
40	is	O
41	stronger	O
42	than	O
43	that	O
44	of	O
45	BHPD	O
46	,	O
47	yet	O
48	the	O
49	photosensitized	O
50	damage	O
51	is	O
52	negatively	O
53	correlated	O
54	to	O
55	the	O
56	yield	O
57	of	O
58	1O2	O
59	but	O
60	positively	O
61	correlated	O
62	to	O
63	those	O
64	of	O
65	O2	O
66	-.	O
67	and	O
68	OH	O
69	.	O

1	Effect	O
2	of	O
3	noise	O
4	on	O
5	CO	O
6	-	O
7	induced	O
8	increases	O
9	of	O
10	LAP	O
11	and	O
12	GPT	O
13	activity	O
14	in	O
15	the	O
16	plasma	O
17	of	O
18	rats	O

1	However	O
2	,	O
3	a	O
4	surprisingly	O
5	high	O
6	degree	O
7	of	O
8	conservation	O
9	of	O
10	intron	O
11	sequences	O
12	was	O
13	observed	O
14	between	O
15	both	O
16	species	O
17	.	O

1	The	O
2	strategy	O
3	has	O
4	been	O
5	used	O
6	to	O
7	determine	O
8	2	O
9	.	O
10	6	O
11	kilobases	O
12	of	O
13	nucleotide	O
14	sequence	O
15	in	O
16	the	O
17	Saccharomyces	O
18	cerevisiae	O
19	ADE	O
20	1	O
21	locus	O
22	.	O

1	A	O
2	safe	O
3	and	O
4	simple	O
5	system	O
6	for	O
7	the	O
8	detection	O
9	of	O
10	sudden	O
11	infant	O
12	death	O
13	syndrome	O
14	(	O
15	SIDS	O
16	)	O
17	is	O
18	proposed	O
19	.	O

1	Anatomy	O
2	of	O
3	the	O
4	uterine	O
5	artery	O
6	.	O

1	Interestingly	O
2	,	O
3	addition	O
4	of	O
5	purified	O
6	CBP	B
7	to	O
8	the	O
9	nuclear	O
10	extracts	O
11	of	O
12	T47D	O
13	cells	O
14	markedly	O
15	stimulated	O
16	progesterone	O
17	-	O
18	and	O
19	PR	O
20	-	O
21	dependent	O
22	transcription	O
23	from	O
24	a	O
25	nucleosome	O
26	-	O
27	free	O
28	,	O
29	progesterone	O
30	response	O
31	element	O
32	(	O
33	PRE	O
34	)-	O
35	linked	O
36	reporter	O
37	DNA	O
38	template	O
39	.	O

1	Other	O
2	assays	O
3	also	O
4	distinguished	O
5	the	O
6	processive	O
7	replication	O
8	of	O
9	pNeo	O
10	.	O
11	Myc	B
12	-	I
13	2	I
14	.	O
15	4	O
16	from	O
17	the	O
18	dispersive	O
19	labeling	O
20	of	O
21	control	O
22	plasmids	O
23	.	O

1	A	O
2	G22V	O
3	mutant	O
4	of	O
5	M	O
6	-	O
7	Ras	B
8	was	O
9	constitutively	O
10	active	O
11	and	O
12	its	O
13	expression	O
14	in	O
15	an	O
16	interleukin	B
17	-	I
18	3	I
19	(	I
20	IL	I
21	-	I
22	3	I
23	)-	I
24	dependent	I
25	mast	I
26	cell	O
27	/	O
28	megakaryocyte	O
29	cell	O
30	line	O
31	resulted	O
32	in	O
33	increased	O
34	survival	O
35	in	O
36	the	O
37	absence	O
38	of	O
39	IL	B
40	-	I
41	3	O
42	,	O
43	increased	O
44	growth	O
45	in	O
46	IL	B
47	-	I
48	4	O
49	,	O
50	and	O
51	,	O
52	at	O
53	high	O
54	expression	O
55	levels	O
56	,	O
57	in	O
58	factor	O
59	-	O
60	independent	O
61	growth	O
62	.	O

1	The	O
2	introduction	O
3	of	O
4	hARF4	O
5	to	O
6	the	O
7	cells	O
8	maintained	O
9	the	O
10	balance	O
11	between	O
12	cytosolic	O
13	and	O
14	membrane	O
15	-	O
16	associated	O
17	Sec7p	O
18	pools	O
19	.	O

1	Furthermore	O
2	,	O
3	formation	O
4	of	O
5	foci	O
6	of	O
7	transformed	O
8	RECs	O
9	by	O
10	the	O
11	c	B
12	-	I
13	jun	I
14	/	I
15	ras	I
16	combination	O
17	was	O
18	augmented	O
19	3	O
20	-	O
21	fold	O
22	by	O
23	the	O
24	tumor	O
25	promoter	O
26	phorbol	O
27	12	O
28	-	O
29	tetradecanoate	O
30	13	O
31	-	O
32	acetate	O
33	.	O

1	Because	O
2	the	O
3	CAP	O
4	measures	O
5	variables	O
6	predictive	O
7	of	O
8	abusive	O
9	behavior	O
10	,	O
11	a	O
12	substantial	O
13	relationship	O
14	was	O
15	expected	O
16	between	O
17	the	O
18	CAP	O
19	and	O
20	the	O
21	MHI	O
22	Loss	O
23	of	O
24	Behavioral	O
25	/	O
26	Emotional	O
27	Control	O
28	scale	O
29	.	O

1	Cytokine	O
2	-	O
3	induced	O
4	NF	B
5	-	I
6	kappa	I
7	B	I
8	DNA	O
9	binding	O
10	activity	O
11	,	O
12	RelA	O
13	nuclear	O
14	translocation	O
15	,	O
16	I	B
17	kappa	I
18	B	I
19	alpha	I
20	degradation	I
21	,	I
22	I	I
23	kappa	I
24	B	I
25	serine	I
26	32	O
27	phosphorylation	O
28	,	O
29	and	O
30	I	B
31	kappa	I
32	B	I
33	kinase	I
34	(	O
35	IKK	O
36	)	O
37	activity	O
38	were	O
39	blocked	O
40	by	O
41	curcumin	O
42	treatment	O
43	.	O

1	Five	O
2	of	O
3	these	O
4	eight	O
5	patients	O
6	in	O
7	group	O
8	II	O
9	also	O
10	received	O
11	8	O
12	-	O
13	in	O
14	-	O
15	1	O
16	chemotherapy	O
17	.	O

1	Histopathologic	O
2	response	O
3	of	O
4	gingival	O
5	tissues	O
6	to	O
7	hemodent	O
8	and	O
9	aluminum	O
10	chloride	O
11	solutions	O
12	as	O
13	tissue	O
14	displacement	O
15	materials	O
16	.	O

1	The	O
2	Ntl1	O
3	gene	O
4	is	O
5	present	O
6	as	O
7	a	O
8	unique	O
9	copy	O
10	in	O
11	the	O
12	diploid	O
13	N	O
14	.	O
15	plumbaginifolia	O
16	species	O
17	.	O

1	The	O
2	expression	O
3	of	O
4	this	O
5	clone	O
6	in	O
7	a	O
8	wee1	O
9	/	O
10	mik1	O
11	-	O
12	deficient	O
13	mutant	O
14	causes	O
15	an	O
16	elongated	O
17	cell	O
18	phenotype	O
19	under	O
20	non	O
21	-	O
22	permissive	O
23	growth	O
24	conditions	O
25	.	O

1	Muscular	O
2	pathology	O

1	Finally	O
2	,	O
3	using	O
4	in	O
5	vitro	O
6	binding	O
7	studies	O
8	,	O
9	we	O
10	showed	O
11	that	O
12	SREBP2	O
13	was	O
14	able	O
15	to	O
16	displace	O
17	ADD1	O
18	/	O
19	SREBP1	O
20	binding	O
21	from	O
22	the	O
23	sterol	O
24	regulatory	O
25	element	O
26	(	O
27	SRE	O
28	)	O
29	site	O
30	.	O

1	Deglycosylation	O
2	with	O
3	endoglycosidase	O
4	H	O
5	showed	O
6	that	O
7	the	O
8	mutant	O
9	receptors	O
10	had	O
11	mainly	O
12	high	O
13	-	O
14	mannose	B
15	oligosaccharide	I
16	chains	I
17	.	O

1	The	O
2	effect	O
3	of	O
4	the	O
5	Ca	O
6	entry	O
7	blocker	O
8	nitrendipine	O
9	,	O
10	the	O
11	antioxidant	O
12	superoxide	B
13	dismutase	I
14	(	O
15	SOD	B
16	),	O
17	and	O
18	a	O
19	combination	O
20	of	O
21	nitrendipine	O
22	and	O
23	superoxide	B
24	dismutase	I
25	on	O
26	postischemic	O
27	renal	O
28	function	O
29	was	O
30	studied	O
31	in	O
32	four	O
33	groups	O
34	(	O
35	n	O
36	=	O
37	24	O
38	)	O
39	of	O
40	rats	O
41	.	O

1	Substitution	O
2	of	O
3	either	O
4	Val33	O
5	(	O
6	by	O
7	Gly	O
8	)	O
9	or	O
10	Gly28	O
11	(	O
12	by	O
13	Ser	O
14	),	O
15	two	O
16	of	O
17	the	O
18	most	O
19	conserved	O
20	residues	O
21	in	O
22	all	O
23	protein	O
24	kinases	O
25	,	O
26	resulted	O
27	in	O
28	enzyme	O
29	with	O
30	marginally	O
31	detectable	O
32	activity	O
33	.	O

1	Strontium	O
2	-	O
3	90	O
4	was	O
5	inject	O
6	i	O
7	.	O
8	v	O
9	.	O
10	into	O
11	pregnant	O
12	rats	O
13	on	O
14	day	O
15	18	O
16	post	O
17	conception	O
18	(	O
19	p	O
20	.	O
21	c	O
22	.).	O

1	Tissue	O
2	-	O
3	specific	O
4	expression	O
5	of	O
6	the	O
7	diazepam	O
8	-	O
9	binding	O
10	inhibitor	O
11	in	O
12	Drosophila	O
13	melanogaster	O
14	:	O
15	cloning	O
16	,	O
17	structure	O
18	,	O
19	and	O
20	localization	O
21	of	O
22	the	O
23	gene	O
24	.	O

1	In	O
2	reconstitution	O
3	experiments	O
4	,	O
5	we	O
6	first	O
7	showed	O
8	that	O
9	expression	O
10	in	O
11	the	O
12	RAW	O
13	264	O
14	.	O
15	7	O
16	cell	O
17	line	O
18	of	O
19	C	B
20	-	I
21	terminal	I
22	Src	I
23	kinase	I
24	(	I
25	Csk	I
26	)	O
27	inhibited	O
28	and	O
29	that	O
30	of	O
31	a	O
32	membrane	O
33	-	O
34	anchored	O
35	,	O
36	gain	O
37	-	O
38	of	O
39	-	O
40	function	O
41	Csk	O
42	abolished	O
43	the	O
44	Fc	B
45	gamma	I
46	R	I
47	-	I
48	mediated	O
49	signaling	O
50	that	O
51	leads	O
52	to	O
53	phagocytosis	O
54	in	O
55	a	O
56	kinase	O
57	-	O
58	dependent	O
59	manner	O
60	.	O

1	Effect	O
2	of	O
3	biliary	O
4	obstruction	O
5	and	O
6	cholangitis	O
7	on	O
8	serum	O
9	SPan	O
10	-	O
11	1	O
12	level	O

1	We	O
2	report	O
3	an	O
4	example	O
5	of	O
6	an	O
7	MDV	O
8	-	O
9	transformed	O
10	T	O
11	-	O
12	lymphoblastoid	O
13	cell	O
14	line	O
15	(	O
16	T9	O
17	)	O
18	expressing	O
19	high	O
20	levels	O
21	of	O
22	a	O
23	truncated	O
24	C	B
25	-	I
26	MYB	I
27	protein	I
28	as	O
29	a	O
30	result	O
31	of	O
32	RAV	O
33	integration	O
34	within	O
35	one	O
36	c	B
37	-	I
38	myb	I
39	allele	I
40	.	O

1	These	O
2	intron	O
3	chimeras	O
4	show	O
5	that	O
6	peripheral	O
7	sequences	O
8	and	O
9	the	O
10	elements	O
11	that	O
12	define	O
13	the	O
14	splice	O
15	sites	O
16	are	O
17	adequate	O
18	for	O
19	self	O
20	-	O
21	splicing	O
22	activity	O
23	but	O
24	that	O
25	the	O
26	central	O
27	portions	O
28	containing	O
29	the	O
30	catalytic	O
31	cores	O
32	of	O
33	ai4	O
34	and	O
35	bi4	O
36	are	O
37	deficient	O
38	;	O
39	these	O
40	cores	O
41	are	O
42	the	O
43	likely	O
44	targets	O
45	of	O
46	the	O
47	splicing	O
48	proteins	O
49	.	O

1	This	O
2	motif	O
3	has	O
4	been	O
5	shown	O
6	to	O
7	mediate	O
8	protein	O
9	interactions	O
10	in	O
11	the	O
12	case	O
13	of	O
14	ankyrin	O
15	as	O
16	well	O
17	as	O
18	several	O
19	other	O
20	repeat	O
21	-	O
22	bearing	O
23	proteins	O
24	.	O

1	CONCLUSION	O
2	:	O
3	Local	O
4	control	O
5	was	O
6	highest	O
7	with	O
8	Preop	O
9	in	O
10	patients	O
11	presenting	O
12	primarily	O
13	with	O
14	gross	O
15	disease	O
16	,	O
17	and	O
18	with	O
19	Postop	O
20	in	O
21	patients	O
22	presenting	O
23	primarily	O
24	following	O
25	gross	O
26	total	O
27	excision	O
28	.	O

1	Handling	O
2	on	O
3	PND	O
4	9	O
5	did	O
6	not	O
7	result	O
8	in	O
9	elevated	O
10	CORT	O
11	levels	O
12	in	O
13	any	O
14	of	O
15	the	O
16	groups	O
17	.	O

1	The	O
2	oral	O
3	temperature	O
4	rose	O
5	and	O
6	the	O
7	serum	O
8	creatine	B
9	kinase	I
10	levels	O
11	fell	O
12	only	O
13	in	O
14	those	O
15	patients	O
16	who	O
17	were	O
18	actively	O
19	warmed	O
20	.	O

1	Invited	O
2	editorial	O
3	on	O
4	"	O
5	Acute	O
6	and	O
7	chronic	O
8	effects	O
9	of	O
10	exercise	O
11	on	O
12	leptin	O
13	levels	O
14	in	O
15	humans	O
16	".	O

1	The	O
2	term	O
3	osteomesopycnosis	O
4	is	O
5	proposed	O
6	for	O
7	a	O
8	sclerosing	O
9	bone	O
10	disease	O
11	with	O
12	dominant	O
13	inheritance	O
14	that	O
15	has	O
16	been	O
17	discovered	O
18	in	O
19	five	O
20	members	O
21	of	O
22	four	O
23	different	O
24	families	O
25	.	O

1	Reporter	O
2	gene	O
3	expression	O
4	analyses	O
5	indicate	O
6	that	O
7	both	O
8	WASP	O
9	promoters	O
10	show	O
11	high	O
12	levels	O
13	of	O
14	expression	O
15	in	O
16	different	O
17	hematopoietic	O
18	cell	O
19	lines	O
20	.	O

1	Although	O
2	previous	O
3	data	O
4	have	O
5	suggested	O
6	that	O
7	Rev	O
8	uses	O
9	the	O
10	same	O
11	export	O
12	pathway	O
13	as	O
14	uracil	O
15	-	O
16	rich	O
17	small	O
18	nuclear	O
19	RNAs	O
20	and	O
21	5S	B
22	ribosomal	I
23	RNA	I
24	,	O
25	the	O
26	CTE	O
27	seems	O
28	to	O
29	interact	O
30	with	O
31	evolutionarily	O
32	conserved	O
33	factors	O
34	that	O
35	are	O
36	essential	O
37	for	O
38	cellular	O
39	mRNA	O
40	export	O
41	.	O

1	The	O
2	decrease	O
3	of	O
4	TNF	B
5	receptors	I
6	by	O
7	IL	B
8	-	I
9	4	O
10	was	O
11	accompanied	O
12	by	O
13	down	O
14	-	O
15	regulation	O
16	of	O
17	TNF	B
18	-	I
19	induced	O
20	activities	O
21	,	O
22	including	O
23	cytotoxicity	O
24	,	O
25	caspase	O
26	-	O
27	3	O
28	activation	O
29	,	O
30	NF	B
31	-	I
32	kappaB	I
33	and	O
34	AP	B
35	-	I
36	1	I
37	activation	O
38	,	O
39	and	O
40	c	B
41	-	I
42	Jun	I
43	N	I
44	-	I
45	terminal	I
46	kinase	I
47	induction	O
48	.	O

1	Based	O
2	on	O
3	these	O
4	results	O
5	,	O
6	a	O
7	new	O
8	model	O
9	for	O
10	the	O
11	regulation	O
12	of	O
13	nif	O
14	/	O
15	fix	O
16	gene	O
17	expression	O
18	in	O
19	A	O
20	.	O
21	caulinodans	O
22	is	O
23	proposed	O
24	.	O

1	Emergency	O
2	treatment	O
3	of	O
4	facial	O
5	and	O
6	maxillary	O
7	/	O
8	mandibular	O
9	injuries	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	M	O
7	.	O
8	jannaschii	O
9	as	O
10	well	O
11	as	O
12	related	O
13	archaeal	B
14	20S	I
15	proteasomes	I
16	require	O
17	a	O
18	nucleotidase	O
19	complex	O
20	such	O
21	as	O
22	PAN	O
23	to	O
24	mediate	O
25	the	O
26	energy	O
27	-	O
28	dependent	O
29	hydrolysis	O
30	of	O
31	folded	O
32	-	O
33	substrate	O
34	proteins	O
35	and	O
36	that	O
37	the	O
38	N	O
39	-	O
40	terminal	O
41	73	O
42	amino	O
43	acid	O
44	residues	O
45	of	O
46	PAN	O
47	are	O
48	not	O
49	absolutely	O
50	required	O
51	for	O
52	this	O
53	reaction	O
54	.	O

1	Gastrointestinal	O
2	manifestations	O
3	of	O
4	systemic	O
5	sclerosis	O

1	In	O
2	contrast	O
3	,	O
4	both	O
5	C	O
6	-	O
7	Lys	O
8	and	O
9	C	O
10	-	O
11	Thr	O
12	retained	O
13	high	O
14	levels	O
15	of	O
16	kinase	O
17	activity	O
18	and	O
19	were	O
20	capable	O
21	of	O
22	responding	O
23	to	O
24	stimulation	O
25	.	O

1	Within	O
2	-	O
3	subject	O
4	BP	O
5	differences	O
6	between	O
7	fish	O
8	oil	O
9	and	O
10	corn	O
11	oil	O
12	treatment	O
13	were	O
14	similar	O
15	for	O
16	Dinamap	O
17	(	O
18	3	O
19	.	O
20	2	O
21	+/-	O
22	1	O
23	.	O
24	8	O
25	/	O
26	2	O
27	.	O
28	5	O
29	+/-	O
30	1	O
31	.	O
32	0	O
33	mm	O
34	Hg	O
35	)	O
36	and	O
37	for	O
38	24	O
39	-	O
40	h	O
41	ABP	O
42	(	O
43	2	O
44	.	O
45	5	O
46	+/-	O
47	1	O
48	.	O
49	0	O
50	/	O
51	2	O
52	.	O
53	3	O
54	+/-	O
55	0	O
56	.	O
57	8	O
58	mm	O
59	Hg	O
60	),	O
61	but	O
62	were	O
63	more	O
64	significant	O
65	with	O
66	the	O
67	latter	O
68	.	O

1	In	O
2	addition	O
3	,	O
4	this	O
5	kinase	O
6	is	O
7	well	O
8	conserved	O
9	evolutionarily	O
10	,	O
11	ubiquitously	O
12	expressed	O
13	,	O
14	and	O
15	its	O
16	genes	O
17	map	O
18	to	O
19	a	O
20	position	O
21	on	O
22	human	O
23	chromosome	O
24	1	O
25	frequently	O
26	deleted	O
27	in	O
28	the	O
29	late	O
30	stages	O
31	of	O
32	tumorigenesis	O
33	.	O

1	Thromboxane	O
2	B2	O
3	increased	O
4	(	O
5	97	O
6	+/-	O
7	105	O
8	versus	O
9	40	O
10	+/-	O
11	26	O
12	pg	O
13	/	O
14	ml	O
15	)	O
16	and	O
17	was	O
18	significantly	O
19	higher	O
20	during	O
21	heparin	O
22	free	O
23	hemodialysis	O
24	than	O
25	during	O
26	hemodialysis	O
27	with	O
28	heparin	O
29	(	O
30	p	O
31	=	O
32	0	O
33	.	O
34	01	O
35	,	O
36	Wilcoxon	O
37	matched	O
38	pairs	O
39	signed	O
40	rank	O
41	test	O
42	).	O

1	Pretreatment	O
2	of	O
3	cells	O
4	with	O
5	the	O
6	mitogen	B
7	-	I
8	activated	I
9	protein	I
10	-	I
11	extracellular	I
12	signal	I
13	-	I
14	regulated	I
15	kinase	I
16	kinase	I
17	(	O
18	MEK	B
19	)	O
20	inhibitor	O
21	U0126	O
22	inhibited	O
23	S6K2	O
24	activation	O
25	to	O
26	a	O
27	greater	O
28	extent	O
29	than	O
30	S6K1	O
31	.	O

1	Utilization	O
2	of	O
3	alternative	O
4	polyadenylation	O
5	signals	O
6	was	O
7	previously	O
8	shown	O
9	to	O
10	generate	O
11	two	O
12	sialophorin	O
13	mRNAs	O
14	of	O
15	1	O
16	.	O
17	9	O
18	and	O
19	4	O
20	.	O
21	3	O
22	kb	O
23	,	O
24	which	O
25	differ	O
26	in	O
27	the	O
28	length	O
29	of	O
30	their	O
31	3	O
32	'	O
33	untranslated	O
34	regions	O
35	.	O

1	The	O
2	mean	O
3	times	O
4	to	O
5	detection	O
6	of	O
7	all	O
8	mycobacteria	O
9	with	O
10	BACTEC	O
11	9000	O
12	MB	O
13	and	O
14	BACTEC	O
15	460	O
16	TB	O
17	were	O
18	similar	O
19	(	O
20	10	O
21	.	O
22	3	O
23	and	O
24	10	O
25	.	O
26	0	O
27	days	O
28	,	O
29	respectively	O
30	).	O

1	Slowed	O
2	lysosomal	O
3	enzyme	O
4	release	O
5	and	O
6	its	O
7	normalization	O
8	by	O
9	drugs	O
10	in	O
11	adjuvant	O
12	-	O
13	induced	O
14	polyarthritis	O
15	.	O

1	Comparison	O
2	of	O
3	three	O
4	different	O
5	preparations	O
6	of	O
7	disodium	O
8	cromoglycate	O
9	in	O
10	the	O
11	prevention	O
12	of	O
13	exercise	O
14	-	O
15	induced	O
16	bronchospasm	O
17	:	O
18	a	O
19	double	O
20	-	O
21	blind	O
22	study	O
23	.	O

1	Of	O
2	these	O
3	sites	O
4	,	O
5	PEA3	B
6	and	O
7	STAT	B
8	contributed	O
9	specifically	O
10	to	O
11	induction	O
12	by	O
13	v	B
14	-	I
15	src	I
16	,	O
17	whereas	O
18	the	O
19	remaining	O
20	elements	O
21	were	O
22	also	O
23	involved	O
24	in	O
25	induction	O
26	by	O
27	the	O
28	phorbol	O
29	ester	O
30	phorbol	O
31	myristate	O
32	acetate	O
33	(	O
34	PMA	O
35	).	O

1	However	O
2	,	O
3	overexpression	O
4	of	O
5	both	O
6	the	O
7	STE4	O
8	and	O
9	STE18	O
10	proteins	O
11	did	O
12	not	O
13	generate	O
14	a	O
15	stronger	O
16	pheromone	O
17	response	O
18	than	O
19	overexpression	O
20	of	O
21	STE4	O
22	in	O
23	the	O
24	presence	O
25	of	O
26	wild	O
27	-	O
28	type	O
29	levels	O
30	of	O
31	STE18	O
32	.	O

1	CSF	B
2	adenosine	I
3	deaminase	I
4	activity	O
5	(	O
6	ADA	O
7	)	O
8	was	O
9	measured	O
10	at	O
11	the	O
12	same	O
13	time	O
14	.	O

1	We	O
2	have	O
3	examined	O
4	the	O
5	role	O
6	of	O
7	two	O
8	recombination	O
9	-	O
10	and	O
11	repair	O
12	-	O
13	defective	O
14	mutations	O
15	,	O
16	rad1	O
17	and	O
18	rad52	O
19	,	O
20	on	O
21	direct	O
22	repeat	O
23	recombination	O
24	in	O
25	transcriptionally	O
26	active	O
27	and	O
28	inactive	O
29	sequences	O
30	.	O

1	We	O
2	also	O
3	mapped	O
4	a	O
5	3	O
6	'-	O
7	polyadenylation	O
8	site	O
9	504bp	O
10	downstream	O
11	of	O
12	the	O
13	TGA	O
14	stop	O
15	codon	O
16	,	O
17	consistent	O
18	with	O
19	the	O
20	2	O
21	.	O
22	5kb	O
23	transcript	O
24	size	O
25	.	O

1	BACKGROUND	O
2	:	O
3	In	O
4	the	O
5	ubiquitin	B
6	-	I
7	dependent	I
8	proteolysis	O
9	pathway	O
10	,	O
11	a	O
12	ubiquitin	B
13	ligase	I
14	(	O
15	E3	O
16	)	O
17	is	O
18	responsible	O
19	for	O
20	substrate	O
21	selectivity	O
22	and	O
23	timing	O
24	of	O
25	degradation	O
26	.	O

1	Histamine	O
2	metabolism	O
3	in	O
4	hemorrhagic	O
5	-	O
6	hypotensive	O
7	shock	O

1	The	O
2	micturition	O
3	pressure	O
4	was	O
5	significantly	O
6	decreased	O
7	only	O
8	after	O
9	injection	O
10	with	O
11	BUP	O
12	-	O
13	4	O
14	in	O
15	both	O
16	normal	O
17	and	O
18	obstructed	O
19	rats	O
20	.	O

1	Each	O
2	binding	O
3	site	O
4	,	O
5	however	O
6	,	O
7	was	O
8	different	O
9	in	O
10	its	O
11	preference	O
12	for	O
13	binding	O
14	partners	O
15	.	O

1	The	O
2	data	O
3	suggest	O
4	that	O
5	like	O
6	in	O
7	yeast	O
8	,	O
9	in	O
10	plants	O
11	a	O
12	certain	O
13	subfamily	O
14	of	O
15	UBC	O
16	is	O
17	specifically	O
18	involved	O
19	in	O
20	the	O
21	proteolytic	O
22	degradation	O
23	of	O
24	abnormal	O
25	proteins	O
26	as	O
27	result	O
28	of	O
29	stress	O
30	.	O

1	Water	O
2	content	O
3	and	O
4	equilibrium	O
5	water	O
6	partition	O
7	in	O
8	immature	O
9	cartilage	O
10	.	O

1	SUP46	O
2	is	O
3	implicated	O
4	in	O
5	translation	O
6	fidelity	O
7	and	O
8	encodes	O
9	the	O
10	ribosomal	B
11	protein	I
12	S13	I
13	.	O

1	In	O
2	PB	O
3	mice	O
4	,	O
5	there	O
6	was	O
7	only	O
8	a	O
9	small	O
10	deficit	O
11	in	O
12	the	O
13	number	O
14	of	O
15	the	O
16	hippocampal	O
17	pyramidal	O
18	neurons	O
19	compared	O
20	to	O
21	controls	O
22	(	O
23	15	O
24	%,	O
25	p	O
26	less	O
27	than	O
28	0	O
29	.	O
30	01	O
31	),	O
32	and	O
33	no	O
34	deficit	O
35	in	O
36	the	O
37	granule	O
38	cells	O
39	.	O

1	Acquired	O
2	bile	O
3	duct	O
4	blockage	O
5	:	O
6	entry	O
7	of	O
8	hepatobiliary	O
9	agent	O
10	into	O
11	an	O
12	intrahepatic	O
13	abscess	O
14	.	O

1	The	O
2	development	O
3	and	O
4	distribution	O
5	of	O
6	Trypanosoma	O
7	congolense	O
8	,	O
9	T	O
10	vivax	O
11	and	O
12	T	O
13	brucei	O
14	in	O
15	the	O
16	skin	O
17	of	O
18	goats	O
19	was	O
20	examined	O
21	after	O
22	the	O
23	animals	O
24	were	O
25	bitten	O
26	by	O
27	infected	O
28	Glossina	O
29	morsitans	O
30	centralis	O
31	.	O

1	A	O
2	neonatal	O
3	alloimmune	O
4	thrombocytopenia	O
5	with	O
6	an	O
7	HPA	O
8	-	O
9	3a	O
10	(	O
11	Baka	O
12	)	O
13	incompatibility	O
14	was	O
15	confirmed	O
16	.	O

1	CDDP	O
2	is	O
3	active	O
4	as	O
5	a	O
6	single	O
7	agent	O
8	in	O
9	non	O
10	-	O
11	Hodgkin	O
12	'	O
13	s	O
14	lymphoma	O
15	.	O

1	The	O
2	complete	O
3	cDNA	O
4	sequence	O
5	of	O
6	human	B
7	betaV	I
8	spectrin	I
9	is	O
10	available	O
11	from	O
12	GenBank	O
13	(	O
14	TM	O
15	)	O
16	as	O
17	accession	O
18	number	O
19	.	O

1	In	O
2	experiment	O
3	2	O
4	,	O
5	no	O
6	difference	O
7	in	O
8	gastric	O
9	emptying	O
10	of	O
11	40	O
12	%	O
13	peptone	O
14	or	O
15	25	O
16	%	O
17	glucose	O
18	was	O
19	found	O
20	between	O
21	rats	O
22	receiving	O
23	TPN	O
24	and	O
25	those	O
26	receiving	O
27	intragastric	O
28	nutrition	O
29	for	O
30	10	O
31	to	O
32	12	O
33	days	O
34	.	O

1	Hepatitis	O
2	B	O
3	vaccination	O
4	strategy	O
5	for	O
6	health	O
7	-	O
8	care	O
9	workers	O
10	in	O
11	a	O
12	country	O
13	of	O
14	intermediate	O
15	hepatitis	O
16	B	O
17	endemicity	O
18	.	O

1	However	O
2	,	O
3	the	O
4	mouse	O
5	has	O
6	previously	O
7	been	O
8	shown	O
9	to	O
10	possess	O
11	only	O
12	three	O
13	forms	O
14	of	O
15	ADH	O
16	.	O

1	The	O
2	responsive	O
3	region	O
4	of	O
5	the	O
6	alpha	O
7	2	O
8	(	O
9	V	O
10	)	O
11	collagen	B
12	gene	I
13	was	O
14	localized	O
15	to	O
16	a	O
17	fragment	O
18	including	O
19	100	O
20	bp	O
21	of	O
22	basal	O
23	promoter	O
24	and	O
25	150	O
26	bp	O
27	of	O
28	exon	O
29	1	O
30	sequences	O
31	,	O
32	which	O
33	contained	O
34	two	O
35	CRE	O
36	-	O
37	like	O
38	elements	O
39	.	O

1	Propagation	O
2	and	O
3	hormone	O
4	production	O
5	by	O
6	human	O
7	normal	O
8	and	O
9	malignant	O
10	trophoblast	O
11	in	O
12	rats	O
13	.	O

1	Magnetic	O
2	storm	O
3	indicators	O
4	could	O
5	be	O
6	used	O
7	in	O
8	medicine	O
9	,	O
10	in	O
11	geophysics	O
12	and	O
13	for	O
14	special	O
15	purposes	O
16	.	O

1	Aspirin	O
2	causes	O
3	peptic	O
4	ulcers	O
5	predominately	O
6	by	O
7	reducing	O
8	gastric	O
9	mucosal	O
10	cyclooxygenase	O
11	(	O
12	COX	O
13	)	O
14	activity	O
15	and	O
16	prostaglandin	O
17	synthesis	O
18	.	O

1	Ent	B
2	-	I
3	kaurene	I
4	synthase	I
5	from	O
6	the	O
7	fungus	O
8	Phaeosphaeria	O
9	sp	O
10	.	O

1	RESULTS	O
2	:	O
3	Transpulmonary	O
4	passage	O
5	of	O
6	contrast	O
7	occurred	O
8	in	O
9	sufficient	O
10	amounts	O
11	to	O
12	enhance	O
13	the	O
14	intensity	O
15	of	O
16	the	O
17	Doppler	O
18	signal	O
19	significantly	O
20	,	O
21	but	O
22	the	O
23	duration	O
24	of	O
25	this	O
26	effect	O
27	was	O
28	short	O
29	.	O

1	Multivariate	O
2	Cox	O
3	survival	O
4	analysis	O
5	identified	O
6	baseline	O
7	EF	O
8	<	O
9	or	O
10	=	O
11	30	O
12	%,	O
13	presence	O
14	of	O
15	significant	O
16	mitral	O
17	regurgitation	O
18	(>	O
19	2	O
20	+)	O
21	before	O
22	ablation	O
23	,	O
24	and	O
25	failure	O
26	to	O
27	exhibit	O
28	improved	O
29	cardiac	O
30	performance	O
31	by	O
32	1	O
33	month	O
34	after	O
35	ablation	O
36	as	O
37	the	O
38	only	O
39	independent	O
40	predictors	O
41	of	O
42	death	O
43	.	O

1	To	O
2	determine	O
3	whether	O
4	food	O
5	and	O
6	/	O
7	or	O
8	water	O
9	in	O
10	the	O
11	gastrointestinal	O
12	tract	O
13	affects	O
14	restitution	O
15	of	O
16	blood	O
17	volume	O
18	and	O
19	plasma	O
20	protein	O
21	after	O
22	hemorrhage	O
23	,	O
24	fed	O
25	and	O
26	24	O
27	-	O
28	h	O
29	-	O
30	fasted	O
31	awake	O
32	rats	O
33	received	O
34	a	O
35	20	O
36	ml	O
37	.	O
38	kg	O
39	-	O
40	1	O
41	x	O
42	3	O
43	min	O
44	-	O
45	1	O
46	hemorrhage	O
47	,	O
48	and	O
49	restitution	O
50	of	O
51	blood	O
52	volume	O
53	was	O
54	measured	O
55	by	O
56	Evans	O
57	blue	O
58	dye	O
59	and	O
60	dilution	O
61	of	O
62	hematocrit	O
63	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	utility	O
6	of	O
7	beta	B
8	2	I
9	transferrin	I
10	assay	O
11	in	O
12	the	O
13	diagnosis	O
14	of	O
15	cerebrospinal	O
16	fluid	O
17	otorrhea	O
18	is	O
19	presented	O
20	.	O

1	BCL6	O
2	encodes	O
3	a	O
4	POZ	O
5	/	O
6	Zn	O
7	finger	O
8	protein	O
9	,	O
10	a	O
11	structure	O
12	similar	O
13	to	O
14	that	O
15	of	O
16	many	O
17	Drosophila	O
18	developmental	O
19	regulators	O
20	and	O
21	to	O
22	another	O
23	protein	O
24	involved	O
25	in	O
26	a	O
27	human	O
28	hematopoietic	O
29	malignancy	O
30	,	O
31	PLZF	B
32	.	O

1	D	O
2	.	O

1	Hypoglycemic	O
2	and	O
3	antidiabetic	O
4	properties	O

1	The	O
2	Aie1	O
3	locus	O
4	was	O
5	mapped	O
6	to	O
7	mouse	O
8	chromosome	O
9	7A2	O
10	-	O
11	A3	O
12	by	O
13	fluorescent	O
14	in	O
15	situ	O
16	hybridization	O
17	.	O

1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	showed	O
6	that	O
7	two	O
8	adjacent	O
9	SP1	O
10	sites	O
11	proximal	O
12	to	O
13	exon	O
14	1	O
15	were	O
16	equally	O
17	important	O
18	in	O
19	sustaining	O
20	basal	O
21	promoter	O
22	activity	O
23	.	O

1	The	O
2	single	O
3	strandedness	O
4	is	O
5	manifested	O
6	as	O
7	a	O
8	terminal	O
9	extension	O
10	of	O
11	the	O
12	G	O
13	-	O
14	rich	O
15	strand	O
16	(	O
17	G	O
18	tails	O
19	)	O
20	that	O
21	can	O
22	occur	O
23	independently	O
24	of	O
25	telomerase	O
26	,	O
27	suggesting	O
28	that	O
29	cdc17	O
30	/	O
31	pol1	O
32	mutants	O
33	exhibit	O
34	defects	O
35	in	O
36	telomeric	O
37	lagging	O
38	-	O
39	strand	O
40	synthesis	O
41	.	O

1	This	O
2	,	O
3	together	O
4	with	O
5	the	O
6	data	O
7	obtained	O
8	with	O
9	haloperidol	O
10	,	O
11	suggests	O
12	that	O
13	a	O
14	minimal	O
15	increase	O
16	in	O
17	the	O
18	firing	O
19	rate	O
20	of	O
21	LC	O
22	cells	O
23	(+	O
24	140	O
25	%)	O
26	is	O
27	required	O
28	before	O
29	it	O
30	could	O
31	influence	O
32	the	O
33	turnover	O
34	of	O
35	NA	O
36	,	O
37	as	O
38	measured	O
39	by	O
40	DOPAC	O
41	changes	O
42	.	O

1	The	O
2	behavior	O
3	of	O
4	different	O
5	types	O
6	of	O
7	polytetrafluoroethylene	O
8	(	O
9	PTFE	O
10	)	O
11	prostheses	O
12	in	O
13	the	O
14	reparative	O
15	scarring	O
16	process	O
17	of	O
18	abdominal	O
19	wall	O
20	defects	O
21	.	O

1	A	O
2	region	O
3	of	O
4	the	O
5	deduced	O
6	protein	O
7	shares	O
8	extensive	O
9	homology	O
10	with	O
11	a	O
12	catalytic	O
13	region	O
14	of	O
15	Raf	B
16	kinases	I
17	,	O
18	a	O
19	feature	O
20	shared	O
21	only	O
22	with	O
23	TFIIE	O
24	among	O
25	transcription	O
26	factors	O
27	.	O

1	Nuclear	B
2	factor	I
3	III	I
4	(	O
5	NFIII	O
6	)	O
7	is	O
8	a	O
9	protein	O
10	from	O
11	HeLa	O
12	cells	O
13	that	O
14	stimulates	O
15	the	O
16	initiation	O
17	of	O
18	adenovirus	O
19	type	O
20	2	O
21	(	O
22	Ad2	O
23	)	O
24	DNA	O
25	replication	O
26	by	O
27	binding	O
28	to	O
29	a	O
30	specific	O
31	nucleotide	O
32	sequence	O
33	in	O
34	the	O
35	origin	O
36	,	O
37	adjacent	O
38	to	O
39	the	O
40	nuclear	B
41	factor	I
42	I	I
43	recognition	I
44	site	I
45	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	have	O
7	examined	O
8	the	O
9	regulation	O
10	of	O
11	B	B
12	-	I
13	Myb	I
14	activity	O
15	by	O
16	cyclin	B
17	-	I
18	Cdks	I
19	.	O

1	Yeast	B
2	U1	I
3	snRNP	I
4	is	O
5	considerably	O
6	more	O
7	complex	O
8	than	O
9	its	O
10	metazoan	O
11	counterpart	O
12	,	O
13	which	O
14	suggests	O
15	possible	O
16	differences	O
17	between	O
18	yeast	O
19	and	O
20	metazoa	O
21	in	O
22	early	O
23	splicing	O
24	events	O
25	.	O

1	We	O
2	show	O
3	that	O
4	other	O
5	cdc33	O
6	mutants	O
7	also	O
8	arrest	O
9	in	O
10	G1	O
11	.	O

1	The	O
2	US	O
3	National	O
4	Institute	O
5	on	O
6	Alcohol	O
7	Abuse	O
8	and	O
9	Alcoholism	O
10	(	O
11	NIAAA	O
12	)	O
13	recognizes	O
14	two	O
15	forms	O
16	of	O
17	problematic	O
18	drinking	O
19	:	O
20	'	O
21	willful	O
22	alcohol	O
23	abuse	O
24	',	O
25	a	O
26	behavioural	O
27	problem	O
28	,	O
29	and	O
30	'	O
31	alcohol	O
32	dependence	O
33	',	O
34	a	O
35	true	O
36	medical	O
37	disorder	O
38	,	O
39	which	O
40	includes	O
41	a	O
42	genetic	O
43	component	O
44	,	O
45	that	O
46	can	O
47	be	O
48	scientifically	O
49	understood	O
50	and	O
51	medically	O
52	treated	O
53	.	O

1	Here	O
2	,	O
3	we	O
4	describe	O
5	a	O
6	tyrosine	O
7	-	O
8	phosphorylated	O
9	nuclear	O
10	protein	O
11	,	O
12	YT521	O
13	-	O
14	B	O
15	,	O
16	and	O
17	show	O
18	that	O
19	it	O
20	interacts	O
21	with	O
22	the	O
23	nuclear	O
24	transcriptosomal	O
25	component	O
26	scaffold	O
27	attachment	O
28	factor	O
29	B	O
30	,	O
31	and	O
32	the	O
33	68	O
34	-	O
35	kDa	O
36	Src	B
37	substrate	O
38	associated	O
39	during	O
40	mitosis	O
41	,	O
42	Sam68	O
43	.	O

1	Receptors	O
2	for	O
3	interleukin	B
4	(	I
5	IL	I
6	)-	I
7	10	O
8	and	O
9	IL	B
10	-	I
11	6	I
12	-	I
13	type	I
14	cytokines	O
15	use	O
16	similar	O
17	signaling	O
18	mechanisms	O
19	for	O
20	inducing	O
21	transcription	O
22	through	O
23	IL	B
24	-	I
25	6	O
26	response	O
27	elements	O
28	.	O

1	The	O
2	therapeutic	O
3	action	O
4	of	O
5	cyclosporin	O
6	A	O
7	(	O
8	Sandimmun	O
9	):	O
10	its	O
11	application	O
12	in	O
13	rheumatoid	O
14	arthritis	O
15	.	O

1	Lithium	O
2	phthalocyanine	O
3	(	O
4	LiPc	O
5	)	O
6	is	O
7	a	O
8	prototype	O
9	of	O
10	another	O
11	generation	O
12	of	O
13	synthetic	O
14	,	O
15	metallic	O
16	-	O
17	organic	O
18	,	O
19	paramagnetic	O
20	crystallites	O
21	that	O
22	appear	O
23	very	O
24	useful	O
25	for	O
26	in	O
27	vitro	O
28	and	O
29	in	O
30	vivo	O
31	electron	O
32	paramagnetic	O
33	resonance	O
34	oximetry	O
35	.	O

1	Our	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	crucial	O
7	role	O
8	of	O
9	the	O
10	mutations	O
11	activating	O
12	v	B
13	-	I
14	erbA	I
15	as	O
16	an	O
17	oncogene	O
18	is	O
19	to	O
20	'	O
21	freeze	O
22	'	O
23	c	B
24	-	I
25	ErbA	O
26	/	O
27	TRalpha	O
28	in	O
29	its	O
30	non	O
31	-	O
32	liganded	O
33	,	O
34	repressive	O
35	conformation	O
36	and	O
37	to	O
38	facilitate	O
39	its	O
40	overexpression	O
41	.	O

1	In	O
2	vitro	O
3	studies	O
4	with	O
5	blood	O
6	cells	O
7	incubated	O
8	with	O
9	acetate	O
10	or	O
11	bicarbonate	O
12	ions	O
13	in	O
14	concentrations	O
15	,	O
16	which	O
17	are	O
18	observed	O
19	in	O
20	vivo	O
21	during	O
22	hemodialysis	O
23	,	O
24	suggest	O
25	that	O
26	probably	O
27	these	O
28	ions	O
29	do	O
30	not	O
31	directly	O
32	affect	O
33	superoxide	O
34	anions	O
35	generation	O
36	,	O
37	erythrocyte	O
38	SOD	B
39	-	I
40	1	I
41	and	O
42	catalase	O
43	activities	O
44	and	O
45	erythrocyte	O
46	membrane	O
47	lipid	O
48	peroxidation	O
49	.	O

1	A	O
2	triple	O
3	-	O
4	mutant	O
5	TBP	B
6	(	O
7	R231E	O
8	+	O
9	R235E	O
10	+	O
11	R239S	O
12	)	O
13	had	O
14	greatly	O
15	reduced	O
16	activity	O
17	for	O
18	yeast	O
19	U6	B
20	snRNA	I
21	gene	I
22	transcription	O
23	while	O
24	remaining	O
25	active	O
26	for	O
27	Pol	B
28	II	I
29	basal	O
30	transcription	O
31	.	O

1	Studies	O
2	have	O
3	substantiated	O
4	the	O
5	involvement	O
6	of	O
7	numerous	O
8	loci	O
9	on	O
10	certain	O
11	chromosomes	O
12	;	O
13	in	O
14	excess	O
15	of	O
16	10	O
17	chromosomes	O
18	are	O
19	thought	O
20	to	O
21	be	O
22	involved	O
23	.	O

1	In	O
2	the	O
3	diabetics	O
4	,	O
5	Ca2	O
6	+	O
7	infusions	O
8	induced	O
9	a	O
10	rise	O
11	of	O
12	plasma	O
13	Ca2	O
14	+	O
15	up	O
16	to	O
17	3	O
18	.	O
19	2	O
20	+/-	O
21	0	O
22	.	O
23	1	O
24	mmol	O
25	/	O
26	1	O
27	and	O
28	a	O
29	fall	O
30	of	O
31	circulating	O
32	glucagon	B
33	(-	O
34	26	O
35	.	O
36	4	O
37	+/-	O
38	5	O
39	.	O
40	7	O
41	%;	O
42	p	O
43	less	O
44	than	O
45	0	O
46	.	O
47	001	O
48	)	O
49	and	O
50	glucose	O
51	(-	O
52	23	O
53	.	O
54	3	O
55	+/-	O
56	3	O
57	.	O
58	6	O
59	%;	O
60	p	O
61	less	O
62	than	O
63	0	O
64	.	O
65	05	O
66	).	O

1	Since	O
2	CENP	O
3	-	O
4	B	O
5	gene	O
6	is	O
7	conserved	O
8	in	O
9	mammalian	O
10	species	O
11	and	O
12	CENP	O
13	-	O
14	B	O
15	boxes	O
16	are	O
17	found	O
18	also	O
19	in	O
20	mouse	O
21	centromere	O
22	satellite	O
23	DNA	O
24	(	O
25	minor	O
26	satellite	O
27	),	O
28	this	O
29	sequence	O
30	-	O
31	specific	O
32	DNA	O
33	-	O
34	protein	O
35	interaction	O
36	may	O
37	be	O
38	important	O
39	for	O
40	some	O
41	kind	O
42	of	O
43	common	O
44	centromere	O
45	function	O
46	.	O

1	Study	O
2	groups	O
3	were	O
4	control	O
5	,	O
6	and	O
7	those	O
8	treated	O
9	with	O
10	the	O
11	alpha1	B
12	-	I
13	adrenoceptor	I
14	-	I
15	subtype	I
16	blockers	O
17	WB4101	O
18	(	O
19	0	O
20	.	O
21	5	O
22	mg	O
23	/	O
24	kg	O
25	i	O
26	.	O
27	v	O
28	.)	O
29	or	O
30	chloroethylclonidine	O
31	(	O
32	1	O
33	.	O
34	9	O
35	mg	O
36	/	O
37	kg	O
38	i	O
39	.	O
40	v	O
41	.).	O

1	Thus	O
2	,	O
3	the	O
4	class	O
5	C	O
6	-	O
7	Vps	O
8	complex	O
9	directs	O
10	multiple	O
11	reactions	O
12	during	O
13	the	O
14	docking	O
15	and	O
16	fusion	O
17	of	O
18	vesicles	O
19	with	O
20	the	O
21	vacuole	O
22	,	O
23	each	O
24	of	O
25	which	O
26	contributes	O
27	to	O
28	the	O
29	overall	O
30	specificity	O
31	and	O
32	efficiency	O
33	of	O
34	this	O
35	transport	O
36	process	O
37	.	O

1	The	O
2	gene	O
3	pairs	O
4	psbB	O
5	-	O
6	psbT	O
7	and	O
8	psbH	O
9	-	O
10	psbN	O
11	are	O
12	cotranscribed	O
13	from	O
14	opposite	O
15	strands	O
16	.	O

1	METHODS	O
2	:	O
3	The	O
4	former	O
5	group	O
6	included	O
7	patients	O
8	who	O
9	had	O
10	been	O
11	treated	O
12	with	O
13	at	O
14	least	O
15	four	O
16	PGE1	O
17	alpha	O
18	-	O
19	ciclodestrina	O
20	,	O
21	short	O
22	-	O
23	term	O
24	treatment	O
25	cycles	O
26	per	O
27	year	O
28	while	O
29	the	O
30	latter	O
31	was	O
32	a	O
33	historical	O
34	reference	O
35	group	O
36	managed	O
37	without	O
38	prostaglandins	O
39	.	O

1	272	O
2	,	O
3	1904	O
4	].	O

1	Elimination	O
2	of	O
3	ETH1	O
4	in	O
5	apn1	O
6	strains	O
7	also	O
8	increased	O
9	spontaneous	O
10	mutation	O
11	rates	O
12	9	O
13	-	O
14	or	O
15	31	O
16	-	O
17	fold	O
18	compared	O
19	to	O
20	the	O
21	wild	O
22	type	O
23	as	O
24	determined	O
25	by	O
26	reversion	O
27	to	O
28	adenine	O
29	or	O
30	lysine	O
31	prototrophy	O
32	,	O
33	respectively	O
34	.	O

1	Three	O
2	classes	O
3	of	O
4	test	O
5	objects	O
6	were	O
7	considered	O
8	:	O
9	(	O
10	1	O
11	)	O
12	a	O
13	multicompartment	O
14	test	O
15	object	O
16	for	O
17	31P	O
18	MRS	O
19	measurements	O
20	performed	O
21	with	O
22	slice	O
23	-	O
24	selective	O
25	sequences	O
26	;	O
27	(	O
28	2	O
29	)	O
30	a	O
31	two	O
32	-	O
33	compartment	O
34	test	O
35	object	O
36	for	O
37	volume	O
38	-	O
39	selection	O
40	1H	O
41	MRS	O
42	;	O
43	and	O
44	(	O
45	3	O
46	)	O
47	two	O
48	-	O
49	compartment	O
50	test	O
51	objects	O
52	for	O
53	assessing	O
54	the	O
55	performance	O
56	of	O
57	experimental	O
58	systems	O
59	using	O
60	ISIS	O
61	as	O
62	volume	O
63	localization	O
64	sequence	O
65	in	O
66	31P	O
67	MRS	O
68	.	O

1	Pure	O
2	T1	O
3	and	O
4	dual	O
5	-	O
6	T1	O
7	images	O
8	were	O
9	visually	O
10	evaluated	O
11	for	O
12	image	O
13	quality	O
14	(	O
15	IQ	O
16	)	O
17	on	O
18	a	O
19	five	O
20	-	O
21	point	O
22	scale	O
23	(	O
24	0	O
25	=	O
26	unacceptable	O
27	to	O
28	4	O
29	=	O
30	excellent	O
31	).	O

1	Treatment	O
2	with	O
3	amphotericin	O
4	B	O
5	and	O
6	flucytosine	O
7	led	O
8	to	O
9	improvement	O
10	of	O
11	the	O
12	symptoms	O
13	but	O
14	did	O
15	not	O
16	eradicate	O
17	the	O
18	micro	O
19	-	O
20	organisms	O
21	from	O
22	the	O
23	cerebrospinal	O
24	fluid	O
25	(	O
26	CSF	O
27	).	O

1	Serial	O
2	measurements	O
3	of	O
4	total	O
5	serum	O
6	IgE	B
7	appears	O
8	to	O
9	be	O
10	a	O
11	useful	O
12	index	O
13	of	O
14	disease	O
15	activity	O
16	in	O
17	ABPA	O
18	.	O

1	Isolation	O
2	of	O
3	Proteus	O
4	vulgaris	O
5	MC	O
6	-	O
7	63	O
8	from	O
9	carcinoma	O
10	63	O
11	and	O
12	its	O
13	antitumor	O
14	effect	O
15	on	O
16	Crocker	O
17	sarcoma	O
18	180	O
19	and	O
20	Ehrlich	O
21	carcinoma	O
22	.	O

1	By	O
2	directly	O
3	interacting	O
4	with	O
5	both	O
6	Arfs	O
7	and	O
8	tyrosine	O
9	kinases	O
10	involved	O
11	in	O
12	regulating	O
13	cell	O
14	growth	O
15	and	O
16	cytoskeletal	O
17	organization	O
18	,	O
19	ASAP1	O
20	could	O
21	coordinate	O
22	membrane	O
23	remodeling	O
24	events	O
25	with	O
26	these	O
27	processes	O
28	.	O

1	The	O
2	encoded	O
3	sequence	O
4	revealed	O
5	a	O
6	typical	O
7	signal	O
8	peptide	O
9	,	O
10	a	O
11	predominantly	O
12	hydrophilic	O
13	707	O
14	amino	O
15	acid	O
16	residue	O
17	domain	O
18	with	O
19	8	O
20	N	O
21	-	O
22	glycosylation	O
23	sites	O
24	,	O
25	a	O
26	transmembrane	O
27	domain	O
28	,	O
29	and	O
30	a	O
31	C	O
32	-	O
33	terminal	O
34	domain	O
35	of	O
36	52	O
37	amino	O
38	acids	O
39	.	O

1	This	O
2	constitutes	O
3	evidence	O
4	for	O
5	an	O
6	in	O
7	vivo	O
8	role	O
9	of	O
10	SRC	B
11	-	I
12	1	I
13	in	O
14	dimerization	O
15	-	O
16	induced	O
17	activation	O
18	by	O
19	OR1	O
20	/	O
21	RXRalpha	O
22	.	O

1	Structure	O
2	and	O
3	expression	O
4	of	O
5	the	O
6	mouse	B
7	growth	I
8	hormone	I
9	receptor	I
10	/	I
11	growth	I
12	hormone	I
13	binding	I
14	protein	I
15	gene	I
16	.	O

1	IgE	B
2	levels	O
3	showed	O
4	higher	O
5	values	O
6	compared	O
7	to	O
8	normal	O
9	individuals	O
10	and	O
11	IgE	B
12	levels	O
13	were	O
14	higher	O
15	in	O
16	children	O
17	groups	O
18	than	O
19	in	O
20	adults	O
21	regardless	O
22	of	O
23	the	O
24	intensity	O
25	of	O
26	infection	O
27	.	O

1	The	O
2	transverse	O
3	magnetization	O
4	decays	O
5	mentioned	O
6	above	O
7	exhibited	O
8	two	O
9	components	O
10	,	O
11	a	O
12	T2	O
13	fast	O
14	(	O
15	T2f	O
16	)	O
17	and	O
18	a	O
19	T2	O
20	slow	O
21	(	O
22	T2s	O
23	)	O
24	component	O
25	.	O

1	Many	O
2	human	O
3	viruses	O
4	are	O
5	able	O
6	to	O
7	develop	O
8	suitable	O
9	strategies	O
10	for	O
11	modifying	O
12	apoptosis	O
13	in	O
14	virus	O
15	-	O
16	infected	O
17	cells	O
18	and	O
19	in	O
20	virus	O
21	-	O
22	primed	O
23	T	O
24	cells	O
25	.	O

1	Chemical	O
2	histologic	O
3	and	O
4	immunologic	O
5	responses	O
6	in	O
7	rats	O
8	to	O
9	CC1	O
10	-	O
11	4	O
12	by	O
13	different	O
14	routes	O
15	of	O
16	administration	O
17	.	O

1	Influence	O
2	of	O
3	oil	O
4	emulsions	O
5	and	O
6	diphenyl	O
7	on	O
8	post	O
9	-	O
10	harvest	O
11	physiconutritional	O
12	changes	O
13	in	O
14	Kagzi	O
15	limes	O
16	(	O
17	Citrus	O
18	aurantifolia	O
19	)	O
20	was	O
21	studied	O
22	.	O

1	IgM	B
2	and	O
3	IgG	B
4	anti	O
5	A	O
6	and	O
7	anti	B
8	B	I
9	antibody	I
10	status	O
11	of	O
12	100	O
13	antenatal	O
14	O	O
15	group	O
16	mothers	O
17	(	O
18	who	O
19	had	O
20	non	O
21	O	O
22	group	O
23	husbands	O
24	)	O
25	were	O
26	studied	O
27	.	O

1	INO2	O
2	,	O
3	a	O
4	regulatory	O
5	gene	O
6	in	O
7	yeast	O
8	phospholipid	O
9	biosynthesis	O
10	,	O
11	affects	O
12	nuclear	O
13	segregation	O
14	and	O
15	bud	O
16	pattern	O
17	formation	O
18	.	O

1	However	O
2	,	O
3	in	O
4	TF	B
5	-	I
6	1	I
7	cells	O
8	grown	O
9	on	O
10	GM	B
11	-	I
12	CSF	I
13	before	O
14	starvation	O
15	,	O
16	CREB	B
17	phosphorylation	O
18	was	O
19	observed	O
20	10	O
21	minutes	O
22	after	O
23	PIXY321	O
24	stimulation	O
25	.	O

1	It	O
2	corresponds	O
3	to	O
4	the	O
5	complete	O
6	mitochondrial	O
7	presequence	O
8	and	O
9	the	O
10	lipoyl	O
11	-	O
12	bearing	O
13	domain	O
14	that	O
15	are	O
16	encoded	O
17	by	O
18	exons	O
19	I	O
20	through	O
21	IV	O
22	of	O
23	the	O
24	functional	O
25	E2	B
26	gene	I
27	.	O

1	The	O
2	results	O
3	indicated	O
4	that	O
5	two	O
6	genes	O
7	(	O
8	citA	O
9	and	O
10	citB	O
11	)	O
12	have	O
13	separate	O
14	promoters	O
15	,	O
16	and	O
17	the	O
18	location	O
19	of	O
20	the	O
21	promoter	O
22	for	O
23	the	O
24	citB	B
25	gene	I
26	in	O
27	the	O
28	Tn3411	O
29	nucleotide	O
30	sequence	O
31	was	O
32	different	O
33	from	O
34	that	O
35	in	O
36	pMS185	O
37	.	O

1	The	O
2	target	O
3	contained	O
4	between	O
5	positions	O
6	-	O
7	403	O
8	and	O
9	-	O
10	125	O
11	acts	O
12	independently	O
13	of	O
14	orientation	O
15	,	O
16	in	O
17	different	O
18	cell	O
19	types	O
20	and	O
21	species	O
22	,	O
23	and	O
24	in	O
25	the	O
26	context	O
27	of	O
28	a	O
29	heterologous	O
30	promoter	O
31	.	O

1	The	O
2	potentially	O
3	SLE	O
4	-	O
5	inducing	O
6	drugs	O
7	are	O
8	reviewed	O
9	.	O

1	First	O
2	,	O
3	the	O
4	finding	O
5	of	O
6	a	O
7	monomeric	O
8	Alu	B
9	family	I
10	repeat	O
11	at	O
12	the	O
13	junction	O
14	between	O
15	nonhomology	O
16	block	O
17	I	O
18	and	O
19	homology	O
20	block	O
21	Y	O
22	of	O
23	the	O
24	alpha	B
25	2	I
26	gene	I
27	-	I
28	containing	O
29	unit	O
30	in	O
31	rhesus	O
32	macaque	O
33	suggests	O
34	that	O
35	the	O
36	dimeric	O
37	Alu	B
38	family	I
39	repeat	O
40	,	O
41	Alu	O
42	3	O
43	,	O
44	at	O
45	the	O
46	orthologous	O
47	position	O
48	in	O
49	human	O
50	was	O
51	generated	O
52	by	O
53	insertion	O
54	of	O
55	a	O
56	monomeric	O
57	Alu	B
58	family	I
59	repeat	O
60	into	O
61	the	O
62	3	O
63	'	O
64	end	O
65	of	O
66	another	O
67	preexisting	O
68	Alu	B
69	family	I
70	repeat	O
71	.	O

1	Posttranslational	O
2	regulation	O
3	of	O
4	Ty1	O
5	retrotransposition	O
6	by	O
7	mitogen	B
8	-	I
9	activated	I
10	protein	I
11	kinase	I
12	Fus3	I
13	.	O

1	Effects	O
2	of	O
3	posteroventral	O
4	pallidotomy	O
5	on	O
6	Parkinson	O
7	'	O
8	s	O
9	disease	O
10	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	axillo	O
6	-	O
7	axillary	O
8	by	O
9	-	O
10	pass	O
11	is	O
12	a	O
13	simple	O
14	solution	O
15	for	O
16	a	O
17	complex	O
18	haemodynamic	O
19	,	O
20	clinical	O
21	and	O
22	therapeutic	O
23	problem	O
24	.	O

1	The	O
2	survival	O
3	rate	O
4	at	O
5	forty	O
6	months	O
7	in	O
8	15	O
9	patients	O
10	with	O
11	N2	O
12	disease	O
13	who	O
14	underwent	O
15	R2b	O
16	operation	O
17	was	O
18	51	O
19	%.	O

1	Changes	O
2	following	O
3	periodontal	O
4	surgery	O
5	.	O

1	Effect	O
2	of	O
3	chronic	O
4	undernutrition	O
5	on	O
6	susceptibility	O
7	to	O
8	cold	O
9	stress	O
10	in	O
11	young	O
12	adult	O
13	and	O
14	aged	O
15	rats	O
16	.	O

1	A	O
2	total	O
3	of	O
4	281	O
5	patients	O
6	were	O
7	divided	O
8	into	O
9	groups	O
10	according	O
11	to	O
12	their	O
13	clinical	O
14	diagnosis	O
15	and	O
16	were	O
17	examined	O
18	using	O
19	capnography	O
20	,	O
21	spirometry	O
22	and	O
23	blood	O
24	-	O
25	gas	O
26	analysis	O
27	.	O

1	Ten	O
2	patients	O
3	with	O
4	advanced	O
5	,	O
6	diffuse	O
7	Hodgkin	O
8	'	O
9	s	O
10	and	O
11	non	O
12	-	O
13	Hodgkin	O
14	'	O
15	s	O
16	lymphomas	O
17	responding	O
18	poorly	O
19	to	O
20	the	O
21	most	O
22	widely	O
23	employed	O
24	primary	O
25	chemotherapy	O
26	regimens	O
27	were	O
28	treated	O
29	with	O
30	a	O
31	high	O
32	-	O
33	dose	O
34	chemotherapy	O
35	(	O
36	HDC	O
37	)	O
38	followed	O
39	by	O
40	rescue	O
41	with	O
42	non	O
43	-	O
44	frozen	O
45	autologous	O
46	bone	O
47	marrow	O
48	infusion	O
49	(	O
50	ABMT	O
51	).	O

1	Among	O
2	the	O
3	LE6	O
4	deletions	O
5	,	O
6	only	O
7	one	O
8	had	O
9	a	O
10	reduced	O
11	transformation	O
12	efficiency	O
13	,	O
14	while	O
15	seven	O
16	transformed	O
17	cells	O
18	at	O
19	least	O
20	as	O
21	efficiently	O
22	as	O
23	wild	O
24	-	O
25	type	O
26	LE6	O
27	.	O

1	We	O
2	concluded	O
3	that	O
4	activation	O
5	of	O
6	c	B
7	-	I
8	fosER	O
9	mediated	O
10	transcriptional	O
11	inhibition	O
12	of	O
13	p21	B
14	(	I
15	Cip1	I
16	/	I
17	WAF1	I
18	)	O
19	through	O
20	a	O
21	previously	O
22	uncharacterized	O
23	AP	B
24	-	I
25	1	I
26	site	I
27	,	O
28	revealing	O
29	an	O
30	important	O
31	role	O
32	for	O
33	c	B
34	-	I
35	fos	I
36	in	O
37	negative	O
38	control	O
39	of	O
40	cell	O
41	cycle	O
42	regulatory	O
43	genes	O
44	.	O

1	The	O
2	effect	O
3	of	O
4	feeding	O
5	patterns	O
6	on	O
7	fat	O
8	deposition	O
9	in	O
10	mice	O
11	.	O

1	Mutations	O
2	in	O
3	a	O
4	region	O
5	located	O
6	15	O
7	to	O
8	30	O
9	bp	O
10	downstream	O
11	from	O
12	the	O
13	major	O
14	transcription	O
15	start	O
16	site	O
17	that	O
18	shows	O
19	good	O
20	homology	O
21	to	O
22	a	O
23	sequence	O
24	in	O
25	the	O
26	first	O
27	exon	O
28	of	O
29	c	B
30	-	I
31	fos	I
32	implicated	O
33	as	O
34	a	O
35	negative	O
36	regulatory	O
37	element	O
38	resulted	O
39	in	O
40	a	O
41	significant	O
42	increase	O
43	in	O
44	basal	O
45	gene	O
46	expression	O
47	but	O
48	did	O
49	not	O
50	affect	O
51	regulation	O
52	.	O

1	TFEC	O
2	,	O
3	a	O
4	basic	B
5	helix	I
6	-	I
7	loop	I
8	-	I
9	helix	I
10	protein	I
11	,	O
12	forms	O
13	heterodimers	O
14	with	O
15	TFE3	O
16	and	O
17	inhibits	O
18	TFE3	O
19	-	O
20	dependent	O
21	transcription	O
22	activation	O
23	.	O

1	Here	O
2	we	O
3	report	O
4	the	O
5	cloning	O
6	,	O
7	expression	O
8	,	O
9	and	O
10	biochemical	O
11	characterization	O
12	of	O
13	the	O
14	32	O
15	-	O
16	kDa	O
17	subunit	O
18	of	O
19	human	O
20	(	O
21	h	O
22	)	O
23	TFIID	B
24	,	O
25	termed	O
26	hTAFII32	O
27	.	O

1	In	O
2	experiment	O
3	2	O
4	the	O
5	rats	O
6	had	O
7	free	O
8	access	O
9	to	O
10	two	O
11	bottles	O
12	,	O
13	one	O
14	of	O
15	which	O
16	contained	O
17	tap	O
18	water	O
19	,	O
20	and	O
21	the	O
22	other	O
23	contained	O
24	either	O
25	an	O
26	ethanol	O
27	(	O
28	6	O
29	%)	O
30	or	O
31	a	O
32	sucrose	O
33	(	O
34	5	O
35	%)	O
36	solution	O
37	.	O

1	The	O
2	12	O
3	,	O
4	000	O
5	MW	O
6	(	O
7	12K	O
8	)	O
9	IE	O
10	polypeptide	O
11	encoded	O
12	by	O
13	IEmRNA	O
14	-	O
15	5	O
16	is	O
17	translated	O
18	from	O
19	an	O
20	88	O
21	codon	O
22	open	O
23	reading	O
24	frame	O
25	,	O
26	leaving	O
27	a	O
28	1200	O
29	base	O
30	3	O
31	'	O
32	non	O
33	-	O
34	translated	O
35	region	O
36	.	O

1	Baseline	O
2	electrocorticography	O
3	over	O
4	the	O
5	surface	O
6	of	O
7	the	O
8	temporal	O
9	lobe	O
10	and	O
11	depth	O
12	electrode	O
13	recordings	O
14	in	O
15	the	O
16	amygdala	O
17	and	O
18	hippocampus	O
19	were	O
20	obtained	O
21	,	O
22	followed	O
23	by	O
24	10	O
25	min	O
26	of	O
27	recording	O
28	before	O
29	and	O
30	after	O
31	the	O
32	i	O
33	.	O
34	v	O
35	.	O
36	administration	O
37	of	O
38	both	O
39	alfentanil	O
40	50	O
41	microg	O
42	/	O
43	kg	O
44	and	O
45	fentanyl	O
46	10	O
47	microg	O
48	/	O
49	kg	O
50	.	O

1	Both	O
2	PPC	O
3	-	O
4	1	O
5	and	O
6	ALVA	O
7	-	O
8	31	O
9	cells	O
10	display	O
11	tumorigenesis	O
12	and	O
13	invasiveness	O
14	in	O
15	nude	O
16	mice	O
17	,	O
18	whereas	O
19	LNCap	O
20	cells	O
21	exhibit	O
22	a	O
23	less	O
24	malignant	O
25	phenotype	O
26	,	O
27	suggesting	O
28	a	O
29	correlation	O
30	between	O
31	CD44	B
32	variant	I
33	(	O
34	CD44v	O
35	)	O
36	expression	O
37	and	O
38	aggressive	O
39	prostate	O
40	tumor	O
41	behavior	O
42	.	O

1	CASE	O
2	REPORT	O
3	:	O
4	Referred	O
5	because	O
6	of	O
7	a	O
8	right	O
9	corneal	O
10	perforation	O
11	with	O
12	cellular	O
13	reaction	O
14	in	O
15	anterior	O
16	chamber	O
17	,	O
18	a	O
19	patient	O
20	was	O
21	sutured	O
22	and	O
23	treated	O
24	with	O
25	a	O
26	single	O
27	intravitreal	O
28	injection	O
29	of	O
30	0	O
31	.	O
32	2	O
33	ml	O
34	(	O
35	1	O
36	mg	O
37	)	O
38	Amikacin	O
39	and	O
40	0	O
41	.	O
42	2	O
43	ml	O
44	(	O
45	1	O
46	mg	O
47	)	O
48	Vancomycin	O
49	.	O

1	Aberrant	O
2	protein	O
3	phosphorylation	O
4	at	O
5	tyrosine	O
6	is	O
7	responsible	O
8	for	O
9	the	O
10	growth	O
11	-	O
12	inhibitory	O
13	action	O
14	of	O
15	pp60v	B
16	-	I
17	src	I
18	expressed	O
19	in	O
20	the	O
21	yeast	O
22	Saccharomyces	O
23	cerevisiae	O
24	.	O

1	Crossover	O
2	in	O
3	the	O
4	specific	O
5	heat	O
6	of	O
7	dilute	O
8	magnets	O
9	induced	O
10	by	O
11	critical	O
12	spin	O
13	-	O
14	wave	O
15	dynamics	O
16	.	O

1	The	O
2	growing	O
3	drug	O
4	problem	O
5	is	O
6	also	O
7	reflected	O
8	in	O
9	the	O
10	increasing	O
11	number	O
12	of	O
13	cases	O
14	of	O
15	hepatitis	O
16	B	O
17	and	O
18	of	O
19	drug	O
20	-	O
21	related	O
22	deaths	O
23	.	O

1	Immunochemical	O
2	studies	O
3	with	O
4	filarial	O
5	antigens	O
6	.	O

1	U24	O
2	has	O
3	two	O
4	separate	O
5	12	O
6	nt	O
7	long	O
8	complementarities	O
9	to	O
10	a	O
11	highly	O
12	conserved	O
13	tract	O
14	of	O
15	28S	B
16	rRNA	I
17	.	O

1	Botulinum	O
2	toxin	O
3	:	O
4	preferred	O
5	treatment	O
6	for	O
7	hemifacial	O
8	spasm	O
9	.	O

1	A	O
2	number	O
3	of	O
4	serological	O
5	tests	O
6	measuring	O
7	the	O
8	presence	O
9	of	O
10	Helicobacter	O
11	pylori	O
12	-	O
13	specific	O
14	serum	O
15	immunoglobulin	B
16	G	I
17	(	I
18	IgG	I
19	)	O
20	are	O
21	now	O
22	commercially	O
23	available	O
24	.	O

1	Cross	O
2	reactivity	O
3	in	O
4	theophylline	O
5	RIA	O
6	kit	O
7	decreased	O
8	.	O

1	Both	O
2	EWS	B
3	-	I
4	FLI	I
5	-	I
6	1	I
7	and	O
8	FLI	B
9	-	I
10	1	I
11	proteins	I
12	function	O
13	as	O
14	transcription	O
15	factors	O
16	that	O
17	bind	O
18	specifically	O
19	to	O
20	ets	B
21	sequences	O
22	(	O
23	the	O
24	ets	B
25	boxes	O
26	)	O
27	present	O
28	in	O
29	promoter	O
30	elements	O
31	.	O

1	No	O
2	recombination	O
3	signal	O
4	sequences	O
5	have	O
6	been	O
7	found	O
8	contiguous	O
9	to	O
10	the	O
11	recombination	O
12	point	O
13	.	O

1	Identification	O
2	of	O
3	eotaxin	O
4	-	O
5	3	O
6	will	O
7	further	O
8	promote	O
9	our	O
10	understanding	O
11	of	O
12	the	O
13	control	O
14	of	O
15	eosinophil	O
16	trafficking	O
17	and	O
18	other	O
19	CCR3	O
20	-	O
21	mediated	O
22	biological	O
23	phenomena	O
24	.	O

1	Periodic	O
2	breathing	O
3	and	O
4	apnea	O
5	in	O
6	preterm	O
7	infants	O
8	.	O

1	Calcifications	O
2	in	O
3	the	O
4	thoracic	O
5	aorta	O
6	at	O
7	the	O
8	level	O
9	of	O
10	the	O
11	11th	O
12	and	O
13	the	O
14	12th	O
15	thoracic	O
16	vertebrae	O
17	in	O
18	592	O
19	men	O
20	and	O
21	333	O
22	women	O
23	were	O
24	studied	O
25	using	O
26	computed	O
27	tomography	O
28	.	O

1	Private	O
2	hospital	O
3	accreditation	O
4	.	O

1	The	O
2	already	O
3	elevated	O
4	prolactin	B
5	levels	O
6	in	O
7	nursing	O
8	women	O
9	were	O
10	not	O
11	influenced	O
12	by	O
13	chronic	O
14	oestradiol	O
15	administration	O
16	.	O

1	We	O
2	show	O
3	that	O
4	in	O
5	contrast	O
6	to	O
7	SRC1	O
8	,	O
9	direct	O
10	binding	O
11	of	O
12	CBP	B
13	to	O
14	the	O
15	estrogen	O
16	receptor	O
17	is	O
18	weak	O
19	,	O
20	suggesting	O
21	that	O
22	SRC1	O
23	functions	O
24	primarily	O
25	as	O
26	an	O
27	adaptor	O
28	to	O
29	recruit	O
30	CBP	B
31	and	O
32	p300	B
33	.	O

1	Although	O
2	the	O
3	terminase	O
4	apparently	O
5	interacts	O
6	with	O
7	this	O
8	gp20	O
9	portal	O
10	peptide	O
11	,	O
12	polyclonal	O
13	antibody	O
14	against	O
15	the	O
16	portal	O
17	peptide	O
18	appears	O
19	unable	O
20	to	O
21	access	O
22	it	O
23	in	O
24	the	O
25	native	O
26	structure	O
27	,	O
28	suggesting	O
29	intimate	O
30	association	O
31	of	O
32	gp20	O
33	and	O
34	gp17	O
35	possibly	O
36	internalizes	O
37	terminase	O
38	regions	O
39	within	O
40	the	O
41	portal	O
42	in	O
43	the	O
44	packasome	O
45	complex	O
46	.	O

1	This	O
2	shows	O
3	that	O
4	the	O
5	characteristically	O
6	diffuse	O
7	banding	O
8	pattern	O
9	of	O
10	plant	O
11	nuclear	O
12	proteins	O
13	interacting	O
14	with	O
15	the	O
16	G	O
17	-	O
18	box	O
19	is	O
20	also	O
21	observed	O
22	in	O
23	a	O
24	binding	O
25	assay	O
26	using	O
27	only	O
28	one	O
29	recombinant	O
30	GBF	O
31	.	O

1	The	O
2	color	O
3	-	O
4	word	O
5	interference	O
6	effect	O
7	previously	O
8	reported	O
9	with	O
10	normal	O
11	populations	O
12	when	O
13	given	O
14	the	O
15	Stroop	O
16	test	O
17	was	O
18	demonstrated	O
19	for	O
20	this	O
21	retarded	O
22	sample	O
23	using	O
24	a	O
25	special	O
26	format	O
27	.	O

1	Genetic	O
2	alterations	O
3	in	O
4	elements	O
5	of	O
6	normal	O
7	signal	O
8	transduction	O
9	mechanisms	O
10	are	O
11	known	O
12	to	O
13	be	O
14	oncogenic	O
15	events	O
16	often	O
17	resulting	O
18	in	O
19	aberrant	O
20	activation	O
21	of	O
22	programs	O
23	of	O
24	gene	O
25	transcription	O
26	.	O

1	When	O
2	the	O
3	entire	O
4	diet	O
5	consisted	O
6	of	O
7	SBF	O
8	,	O
9	voluntary	O
10	feed	O
11	intake	O
12	was	O
13	reduced	O
14	,	O
15	indicating	O
16	that	O
17	SBF	O
18	should	O
19	not	O
20	be	O
21	fed	O
22	to	O
23	ponies	O
24	as	O
25	the	O
26	sole	O
27	dietary	O
28	ingredient	O
29	.	O

1	The	O
2	deduced	O
3	protein	O
4	sequence	O
5	is	O
6	characterized	O
7	by	O
8	a	O
9	putative	O
10	16	O
11	-	O
12	residue	O
13	amino	O
14	-	O
15	terminal	O
16	signal	O
17	peptide	O
18	that	O
19	is	O
20	cleaved	O
21	,	O
22	resulting	O
23	in	O
24	a	O
25	239	O
26	-	O
27	residue	O
28	polypeptide	O
29	.	O

1	In	O
2	contrast	O
3	,	O
4	similar	O
5	rates	O
6	of	O
7	B	O
8	.	O
9	sphaericus	O
10	products	O
11	,	O
12	ABG	O
13	-	O
14	6184	O
15	technical	O
16	powder	O
17	and	O
18	BSP	B
19	-	I
20	2	I
21	flowable	I
22	concentrate	I
23	,	O
24	produced	O
25	no	O
26	significant	O
27	reduction	O
28	.	O

1	Previous	O
2	studies	O
3	have	O
4	demonstrated	O
5	that	O
6	the	O
7	TATA	O
8	element	O
9	is	O
10	critical	O
11	for	O
12	basal	O
13	and	O
14	Tat	B
15	-	I
16	induced	O
17	HIV	B
18	-	I
19	1	I
20	gene	I
21	expression	O
22	.	O

1	Here	O
2	we	O
3	show	O
4	that	O
5	messenger	O
6	RNAs	O
7	encoding	O
8	trans	O
9	-	O
10	sialidases	O
11	containing	O
12	the	O
13	repeats	O
14	are	O
15	not	O
16	present	O
17	in	O
18	epimastigotes	O
19	but	O
20	are	O
21	abundant	O
22	in	O
23	trypomastigotes	O
24	.	O

1	Molecular	O
2	characterization	O
3	of	O
4	malignant	O
5	melanoma	O
6	of	O
7	soft	O
8	parts	O
9	or	O
10	soft	O
11	tissue	O
12	clear	O
13	cell	O
14	sarcoma	O
15	which	O
16	shares	O
17	t	O
18	(	O
19	12	O
20	;	O
21	22	O
22	)	O
23	chromosome	O
24	translocation	O
25	revealed	O
26	fusion	O
27	of	O
28	EWS	B
29	with	O
30	a	O
31	transcriptional	O
32	factor	O
33	gene	O
34	ATF	B
35	-	I
36	1	I
37	.	O

1	Expression	O
2	of	O
3	constitutively	O
4	active	O
5	MEK1	O
6	,	O
7	the	O
8	kinase	O
9	that	O
10	activates	O
11	ERKs	B
12	,	O
13	or	O
14	overexpression	O
15	of	O
16	ERK2	B
17	,	O
18	but	O
19	not	O
20	JNK1	B
21	,	O
22	inhibited	O
23	Stat3	B
24	activation	O
25	.	O

1	The	O
2	pharmacological	O
3	effects	O
4	of	O
5	the	O
6	novel	O
7	compound	O
8	WEB	O
9	1881	O
10	FU	O
11	(	O
12	4	O
13	-	O
14	amino	O
15	-	O
16	methyl	B
17	-	I
18	1	I
19	-	I
20	benzyl	I
21	-	I
22	pyrrolidine	I
23	-	I
24	2	I
25	-	I
26	one	O
27	-	O
28	fumarate	O
29	)	O
30	were	O
31	investigated	O
32	.	O

1	Heart	O
2	rate	O
3	(	O
4	HR	O
5	),	O
6	rectal	O
7	temperature	O
8	(	O
9	Tre	O
10	),	O
11	blood	O
12	pressure	O
13	,	O
14	temperature	O
15	and	O
16	relative	O
17	humidity	O
18	changes	O
19	inside	O
20	clothing	O
21	were	O
22	measured	O
23	on	O
24	18	O
25	professional	O
26	firemen	O
27	(	O
28	mean	O
29	age	O
30	29	O
31	.	O
32	4	O
33	+/-	O
34	7	O
35	.	O
36	4	O
37	yr	O
38	,	O
39	VO2	O
40	max	O
41	41	O
42	.	O
43	4	O
44	+	O
45	8	O
46	.	O
47	8	O
48	ml	O
49	kg	O
50	-	O
51	1	O
52	min	O
53	-	O
54	1	O
55	)	O
56	wearing	O
57	fire	O
58	fighter	O
59	'	O
60	s	O
61	uniforms	O
62	(	O
63	SU	O
64	)	O
65	or	O
66	aluminized	O
67	,	O
68	fire	O
69	resistant	O
70	,	O
71	impermeable	O
72	clothing	O
73	with	O
74	self	O
75	contained	O
76	breathing	O
77	apparatus	O
78	(	O
79	FE	O
80	).	O

1	A	O
2	malignant	O
3	true	O
4	teratoma	O
5	of	O
6	liver	O
7	in	O
8	childhood	O
9	.	O

1	Two	O
2	variant	O
3	PRP	O
4	-	O
5	precursor	O
6	alleles	O
7	occur	O
8	which	O
9	slightly	O
10	differ	O
11	in	O
12	the	O
13	number	O
14	of	O
15	repeats	O
16	in	O
17	domain	O
18	C	O
19	.	O

1	Application	O
2	of	O
3	the	O
4	2	O
5	-	O
6	deoxy	O
7	-	O
8	D	O
9	-	O
10	glucose	O
11	method	O
12	to	O
13	the	O
14	coupling	O
15	of	O
16	cerebral	O
17	metabolism	O
18	and	O
19	blood	O
20	flow	O
21	.	O

1	After	O
2	nitric	B
3	oxide	I
4	inhalation	O
5	,	O
6	the	O
7	results	O
8	showed	O
9	moderate	O
10	increases	O
11	in	O
12	PaO2	O
13	and	O
14	SaO2	O
15	(	O
16	P	O
17	>	O
18	0	O
19	.	O
20	05	O
21	)	O
22	and	O
23	a	O
24	significant	O
25	decrease	O
26	in	O
27	Qs	O
28	/	O
29	Q	O
30	tau	O
31	ratio	O
32	(	O
33	P	O
34	<	O
35	0	O
36	.	O
37	01	O
38	).	O

1	The	O
2	effect	O
3	of	O
4	independent	O
5	predictors	O
6	on	O
7	survival	O
8	was	O
9	examined	O
10	in	O
11	a	O
12	Cox	O
13	regression	O
14	model	O
15	with	O
16	adjustment	O
17	for	O
18	existing	O
19	illnesses	O
20	.	O

1	Strikingly	O
2	,	O
3	these	O
4	cells	O
5	contain	O
6	a	O
7	missense	O
8	mutation	O
9	of	O
10	the	O
11	p53	B
12	gene	I
13	at	O
14	codon	O
15	242	O
16	(	O
17	p53	B
18	(	O
19	242	O
20	)),	O
21	which	O
22	substitutes	O
23	alanine	O
24	for	O
25	glycine	O
26	.	O

1	Its	O
2	vasodilatory	O
3	,	O
4	anti	O
5	-	O
6	vasopressor	O
7	,	O
8	and	O
9	platelet	O
10	stabilizing	O
11	effects	O
12	could	O
13	be	O
14	expected	O
15	to	O
16	counteract	O
17	the	O
18	placental	O
19	ischemia	O
20	,	O
21	hypertension	O
22	and	O
23	excessive	O
24	coagulation	O
25	that	O
26	are	O
27	seen	O
28	in	O
29	pre	O
30	-	O
31	eclampsia	O
32	.	O

1	Sucrose	O
2	-	O
3	specific	O
4	regulation	O
5	of	O
6	scrB	O
7	was	O
8	also	O
9	lost	O
10	upon	O
11	deletion	O
12	of	O
13	4	O
14	bp	O
15	of	O
16	a	O
17	palindromic	O
18	sequence	O
19	(	O
20	OB	O
21	)	O
22	covering	O
23	positions	O
24	+	O
25	6	O
26	to	O
27	+	O
28	21	O
29	downstream	O
30	of	O
31	the	O
32	scrB	O
33	transcriptional	O
34	start	O
35	site	O
36	.	O

1	However	O
2	,	O
3	the	O
4	a1	O
5	isoform	O
6	is	O
7	expressed	O
8	most	O
9	heavily	O
10	in	O
11	brain	O
12	and	O
13	heart	O
14	,	O
15	a2	O
16	in	O
17	liver	O
18	and	O
19	kidney	O
20	,	O
21	and	O
22	a3	O
23	in	O
24	liver	O
25	,	O
26	lung	O
27	,	O
28	heart	O
29	,	O
30	brain	O
31	,	O
32	spleen	O
33	,	O
34	and	O
35	kidney	O
36	.	O

1	Further	O
2	observations	O
3	on	O
4	resorption	O
5	in	O
6	guinea	O
7	pigs	O
8	following	O
9	injections	O
10	of	O
11	trypan	O
12	blue	O
13	.	O

1	Expression	O
2	of	O
3	six	O
4	genes	O
5	,	O
6	ipaB	O
7	,	O
8	ipaC	O
9	,	O
10	invE	O
11	,	O
12	invG	O
13	,	O
14	invJ	O
15	,	O
16	and	O
17	invK	O
18	,	O
19	was	O
20	apparently	O
21	regulated	O
22	by	O
23	the	O
24	positive	O
25	regulator	O
26	virF	O
27	.	O

1	Auto	O
2	-	O
3	and	O
4	isotopy	O
5	of	O
6	the	O
7	conjunctiva	O

1	No	O
2	symptomatic	O
3	abnormality	O
4	has	O
5	been	O
6	noted	O
7	in	O
8	the	O
9	neonatal	O
10	period	O
11	except	O
12	periventricular	O
13	calcifications	O
14	.	O

1	Effect	O
2	of	O
3	triftazin	O
4	and	O
5	aminazin	O
6	on	O
7	hippocampal	O
8	bioelectric	O
9	activity	O

1	E2	O
2	treatments	O
3	elevated	O
4	hen	O
5	plasma	O
6	TG	O
7	7	O
8	.	O
9	2X	O
10	,	O
11	PL	O
12	5	O
13	.	O
14	1X	O
15	,	O
16	and	O
17	C	O
18	7	O
19	.	O
20	2X	O
21	;	O
22	and	O
23	pullet	O
24	plasma	O
25	TG	O
26	6	O
27	.	O
28	8X	O
29	,	O
30	PL	O
31	3	O
32	.	O
33	7X	O
34	,	O
35	and	O
36	C	O
37	2	O
38	.	O
39	5X	O
40	.	O

1	The	O
2	increase	O
3	in	O
4	amplitudes	O
5	of	O
6	the	O
7	b	O
8	-	O
9	wave	O
10	during	O
11	the	O
12	adaptation	O
13	period	O
14	was	O
15	more	O
16	prominent	O
17	in	O
18	lead	O
19	-	O
20	exposed	O
21	subjects	O
22	than	O
23	in	O
24	controls	O
25	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	phenotype	O
7	of	O
8	XLP	O
9	may	O
10	result	O
11	from	O
12	perturbed	O
13	signaling	O
14	not	O
15	only	O
16	through	O
17	SLAM	O
18	,	O
19	but	O
20	also	O
21	other	O
22	cell	O
23	surface	O
24	molecules	O
25	that	O
26	utilize	O
27	SAP	O
28	as	O
29	a	O
30	signaling	O
31	adaptor	O
32	protein	O
33	.	O

1	Enhancement	O
2	of	O
3	the	O
4	immune	O
5	response	O
6	by	O
7	aspecific	O
8	action	O
9	of	O
10	vaccine	O
11	additives	O
12	in	O
13	the	O
14	aerogenic	O
15	immunization	O
16	of	O
17	swine	O
18	against	O
19	swine	O
20	plague	O

1	Ca2	O
2	+	O
3	decreased	O
4	Zn2	O
5	+	O
6	binding	O
7	in	O
8	S100	B
9	beta	I
10	but	O
11	it	O
12	did	O
13	not	O
14	influence	O
15	binding	O
16	to	O
17	MRP14	O
18	,	O
19	suggesting	O
20	that	O
21	the	O
22	Zn2	O
23	+	O
24	binding	O
25	site	O
26	was	O
27	distinct	O
28	from	O
29	and	O
30	independent	O
31	of	O
32	the	O
33	two	O
34	Ca2	O
35	+	O
36	binding	O
37	domains	O
38	.	O

1	Clinical	O
2	research	O
3	of	O
4	non	O
5	-	O
6	A	O
7	,	O
8	non	O
9	-	O
10	B	O
11	post	O
12	-	O
13	transfusion	O
14	hepatitis	O

1	DNA	O
2	sequence	O
3	analysis	O
4	reveals	O
5	that	O
6	the	O
7	gene	O
8	encodes	O
9	a	O
10	protein	O
11	highly	O
12	homologous	O
13	to	O
14	rat	O
15	CRP1	O
16	.	O

1	Behaviorally	O
2	,	O
3	a	O
4	pain	O
5	-	O
6	tolerant	O
7	group	O
8	(	O
9	PT	O
10	=	O
11	29	O
12	Ss	O
13	)	O
14	tolerated	O
15	the	O
16	entire	O
17	3	O
18	-	O
19	min	O
20	test	O
21	(	O
22	means	O
23	=	O
24	180	O
25	+/-	O
26	0	O
27	sec	O
28	),	O
29	while	O
30	a	O
31	pain	O
32	-	O
33	sensitive	O
34	group	O
35	(	O
36	PS	O
37	=	O
38	13	O
39	Ss	O
40	)	O
41	averaged	O
42	only	O
43	50	O
44	.	O
45	31	O
46	+/-	O
47	20	O
48	.	O
49	81	O
50	sec	O
51	of	O
52	the	O
53	cold	O
54	-	O
55	pressor	O
56	test	O
57	(	O
58	t	O
59	=	O
60	16	O
61	.	O
62	75	O
63	,	O
64	P	O
65	less	O
66	than	O
67	0	O
68	.	O
69	0001	O
70	),	O
71	replicating	O
72	our	O
73	earlier	O
74	studies	O
75	.	O

1	Thus	O
2	,	O
3	the	O
4	consensus	O
5	sequences	O
6	for	O
7	phosphatase	O
8	regulation	O
9	are	O
10	5	O
11	'-	O
12	GCACGTGGG	O
13	-	O
14	3	O
15	'	O
16	and	O
17	5	O
18	'-	O
19	GCACGTTTT	O
20	-	O
21	3	O
22	'	O
23	which	O
24	differ	O
25	from	O
26	the	O
27	binding	O
28	sequences	O
29	for	O
30	the	O
31	Cpflp	O
32	protein	O
33	required	O
34	for	O
35	transcription	O
36	of	O
37	the	O
38	genes	O
39	in	O
40	methionine	O
41	biosynthesis	O
42	and	O
43	for	O
44	centromere	O
45	function	O
46	.	O

1	Utero	O
2	-	O
3	placental	O
4	blood	O
5	flow	O
6	and	O
7	the	O
8	effect	O
9	of	O
10	beta	B
11	2	I
12	-	I
13	adrenoceptor	I
14	stimulating	I
15	drugs	O
16	.	O

1	Carbon	O
2	catabolite	O
3	repression	O
4	of	O
5	the	O
6	gnt	O
7	operon	O
8	of	O
9	Bacillus	O
10	subtilis	O
11	is	O
12	mediated	O
13	by	O
14	the	O
15	catabolite	O
16	control	O
17	protein	O
18	CcpA	O
19	and	O
20	by	O
21	HPr	O
22	,	O
23	a	O
24	phosphocarrier	O
25	protein	O
26	of	O
27	the	O
28	phosphotransferase	O
29	system	O
30	.	O

1	Taken	O
2	together	O
3	,	O
4	our	O
5	results	O
6	indicate	O
7	that	O
8	the	O
9	FCR1	O
10	gene	O
11	behaves	O
12	as	O
13	a	O
14	negative	O
15	regulator	O
16	of	O
17	drug	O
18	resistance	O
19	in	O
20	C	O
21	.	O
22	albicans	O
23	and	O
24	constitute	O
25	the	O
26	first	O
27	evidence	O
28	that	O
29	FCZ	O
30	resistance	O
31	can	O
32	result	O
33	from	O
34	the	O
35	inactivation	O
36	of	O
37	a	O
38	regulatory	O
39	factor	O
40	such	O
41	as	O
42	Fcr1p	O
43	.	O

1	The	O
2	availability	O
3	of	O
4	cryoprecipitate	O
5	and	O
6	DDAVP	O
7	offers	O
8	an	O
9	alternative	O
10	and	O
11	effective	O
12	treatment	O
13	for	O
14	the	O
15	temporary	O
16	reversal	O
17	of	O
18	uremic	O
19	bleeding	O
20	in	O
21	patients	O
22	who	O
23	require	O
24	urgent	O
25	invasive	O
26	procedures	O
27	.	O

1	The	O
2	East	O
3	African	O
4	dik	O
5	-	O
6	dik	O
7	antelope	O
8	represents	O
9	a	O
10	miniature	O
11	model	O
12	ruminant	O
13	for	O
14	comparative	O
15	studies	O
16	.	O

1	Mobility	O
2	and	O
3	supershift	O
4	assays	O
5	demonstrated	O
6	that	O
7	upstream	O
8	stimulatory	O
9	factor	O
10	(	O
11	USF	B
12	)	O
13	and	O
14	Sp1	B
15	bind	O
16	to	O
17	the	O
18	former	O
19	elements	O
20	and	O
21	competition	O
22	experiments	O
23	confirmed	O
24	that	O
25	CREB	B
26	/	I
27	ATF	I
28	and	O
29	AP	B
30	-	I
31	1	I
32	bind	O
33	to	O
34	the	O
35	CRE	O
36	/	O
37	TRE	O
38	element	O
39	.	O

1	Spores	O
2	from	O
3	Rhizopus	O
4	stolonifer	O
5	were	O
6	suspended	O
7	in	O
8	distilled	O
9	water	O
10	(	O
11	1	O
12	x	O
13	10	O
14	(	O
15	6	O
16	)	O
17	spores	O
18	/	O
19	mL	O
20	)	O
21	and	O
22	used	O
23	as	O
24	starter	O
25	.	O

1	Synovial	O
2	cysts	O
3	of	O
4	the	O
5	hip	O
6	joint	O

1	Induction	O
2	was	O
3	reversed	O
4	by	O
5	coexpression	O
6	of	O
7	A	O
8	-	O
9	Fos	B
10	,	O
11	a	O
12	dominant	O
13	negative	O
14	to	O
15	AP	B
16	-	I
17	1	I
18	.	O

1	A	O
2	total	O
3	of	O
4	90	O
5	patients	O
6	were	O
7	randomly	O
8	allocated	O
9	either	O
10	to	O
11	an	O
12	MY	O
13	-	O
14	1	O
15	treated	O
16	or	O
17	an	O
18	untreated	O
19	group	O
20	.	O

1	In	O
2	a	O
3	gel	O
4	retardation	O
5	assay	O
6	using	O
7	HepG2	O
8	nuclear	O
9	extracts	O
10	,	O
11	the	O
12	5	O
13	'	O
14	flanking	O
15	sequence	O
16	from	O
17	-	O
18	74	O
19	to	O
20	-	O
21	46	O
22	showed	O
23	a	O
24	shifted	O
25	band	O
26	.	O

1	Because	O
2	the	O
3	biosynthetic	O
4	pathway	O
5	to	O
6	the	O
7	vacuole	O
8	intersects	O
9	with	O
10	the	O
11	endocytic	O
12	pathway	O
13	,	O
14	internalization	O
15	of	O
16	a	O
17	bulk	O
18	membrane	O
19	endocytic	O
20	marker	O
21	FM	O
22	4	O
23	-	O
24	64	O
25	was	O
26	assayed	O
27	in	O
28	the	O
29	sop	O
30	mutants	O
31	.	O

1	Northern	O
2	analyses	O
3	of	O
4	RNAs	O
5	from	O
6	mouse	O
7	tissues	O
8	and	O
9	cell	O
10	lines	O
11	indicated	O
12	that	O
13	p11	O
14	mRNA	O
15	levels	O
16	vary	O
17	widely	O
18	.	O

1	The	O
2	mutants	O
3	were	O
4	obtained	O
5	by	O
6	substitution	O
7	into	O
8	a	O
9	molecular	O
10	clone	O
11	of	O
12	M	O
13	-	O
14	MuLV	O
15	DNA	O
16	by	O
17	DNA	O
18	from	O
19	two	O
20	acutely	O
21	transforming	O
22	viruses	O
23	,	O
24	Ableson	O
25	MuLV	O
26	(	O
27	Ab	O
28	-	O
29	MuLV	O
30	)	O
31	and	O
32	Moloney	O
33	murine	O
34	sarcoma	O
35	virus	O
36	(	O
37	M	O
38	-	O
39	MSV	O
40	).	O

1	Stromelysin	O
2	-	O
3	1	O
4	,	O
5	matrix	O
6	metalloproteinase	B
7	-	I
8	3	I
9	(	I
10	MMP	I
11	-	I
12	3	O
13	),	O
14	is	O
15	an	O
16	important	O
17	endopeptidase	O
18	selectively	O
19	expressed	O
20	by	O
21	somatic	O
22	cells	O
23	in	O
24	organ	O
25	tissues	O
26	.	O

1	The	O
2	gene	O
3	(	O
4	ApxII	O
5	)	O
6	encoding	O
7	both	O
8	chloroplastic	O
9	ascorbate	B
10	peroxidase	I
11	isoenzymes	I
12	was	O
13	isolated	O
14	and	O
15	the	O
16	organization	O
17	of	O
18	the	O
19	gene	O
20	was	O
21	determined	O
22	.	O

1	These	O
2	cell	O
3	lines	O
4	displayed	O
5	methylation	O
6	of	O
7	the	O
8	CpG	O
9	island	O
10	surrounding	O
11	the	O
12	first	O
13	exon	O
14	of	O
15	p16INK4A	O
16	and	O
17	expressed	O
18	abundant	O
19	levels	O
20	of	O
21	a	O
22	nontranslated	O
23	mRNA	O
24	containing	O
25	an	O
26	alternative	O
27	first	O
28	exon	O
29	(	O
30	E1	B
31	beta	I
32	),	O
33	as	O
34	did	O
35	all	O
36	other	O
37	cell	O
38	lines	O
39	in	O
40	which	O
41	the	O
42	p16INK4A	O
43	locus	O
44	was	O
45	not	O
46	deleted	O
47	.	O

1	This	O
2	region	O
3	,	O
4	however	O
5	,	O
6	contains	O
7	a	O
8	CCAATC	O
9	box	O
10	in	O
11	the	O
12	reverse	O
13	complement	O
14	and	O
15	several	O
16	GC	O
17	boxes	O
18	that	O
19	are	O
20	recognition	O
21	sites	O
22	for	O
23	SP1	O
24	.	O

1	The	O
2	retrovesical	O
3	hydatid	O
4	cyst	O
5	is	O
6	a	O
7	very	O
8	rare	O
9	site	O
10	.	O

1	Three	O
2	mog	O
3	-	O
4	1	O
5	alleles	O
6	possess	O
7	premature	O
8	stop	O
9	codons	O
10	and	O
11	are	O
12	likely	O
13	to	O
14	be	O
15	null	O
16	alleles	O
17	,	O
18	and	O
19	one	O
20	is	O
21	a	O
22	missense	O
23	mutation	O
24	and	O
25	is	O
26	likely	O
27	to	O
28	retain	O
29	residual	O
30	activity	O
31	.	O
32	mog	O
33	-	O
34	1	O
35	mRNA	O
36	is	O
37	expressed	O
38	in	O
39	both	O
40	germ	O
41	line	O
42	and	O
43	somatic	O
44	tissues	O
45	and	O
46	appears	O
47	to	O
48	be	O
49	ubiquitous	O
50	.	O

1	Polysome	O
2	analysis	O
3	further	O
4	indicated	O
5	that	O
6	these	O
7	germ	O
8	cell	O
9	-	O
10	specific	O
11	Sp1	B
12	mRNAs	I
13	are	O
14	translated	O
15	,	O
16	albeit	O
17	with	O
18	a	O
19	lower	O
20	efficiency	O
21	than	O
22	the	O
23	somatic	O
24	transcript	O
25	.	O

1	The	O
2	dnaQ	O
3	-	O
4	lacZ	B
5	and	O
6	the	O
7	rnh	O
8	-	O
9	lacZ	B
10	fused	O
11	genes	O
12	were	O
13	constructed	O
14	and	O
15	hybrid	O
16	proteins	O
17	with	O
18	beta	B
19	-	I
20	galactosidase	I
21	activity	O
22	were	O
23	produced	O
24	.	O

1	The	O
2	reconstituted	O
3	RNA	O
4	polymerases	O
5	containing	O
6	the	O
7	mutant	O
8	alpha	O
9	subunits	O
10	were	O
11	examined	O
12	for	O
13	their	O
14	response	O
15	to	O
16	transcription	O
17	activation	O
18	by	O
19	cAMP	O
20	-	O
21	CRP	B
22	and	O
23	the	O
24	rrnBP1	O
25	UP	O
26	element	O
27	.	O

1	Both	O
2	TRE	O
3	-	O
4	like	O
5	elements	O
6	were	O
7	capable	O
8	of	O
9	binding	O
10	AP1	B
11	.	O

1	Differential	O
2	drawing	O
3	size	O
4	associated	O
5	with	O
6	unilateral	O
7	brain	O
8	damage	O
9	.	O

1	No	O
2	differences	O
3	in	O
4	total	O
5	cholesterol	O
6	levels	O
7	were	O
8	observed	O
9	between	O
10	mapuches	O
11	and	O
12	aymaras	O
13	.	O

1	J	O
2	.	O

1	Analysis	O
2	of	O
3	strains	O
4	harboring	O
5	an	O
6	mds1	O
7	null	O
8	mutation	O
9	demonstrates	O
10	that	O
11	MDS1	O
12	is	O
13	not	O
14	essential	O
15	during	O
16	normal	O
17	vegetative	O
18	growth	O
19	but	O
20	appears	O
21	to	O
22	be	O
23	required	O
24	for	O
25	meiosis	O
26	.	O

1	We	O
2	purified	O
3	both	O
4	proteins	O
5	from	O
6	human	O
7	platelet	O
8	membranes	O
9	using	O
10	DEAE	O
11	-	O
12	Sepharose	O
13	chromatography	O
14	followed	O
15	by	O
16	mAb	O
17	F11	O
18	affinity	O
19	chromatography	O
20	.	O

1	We	O
2	have	O
3	partially	O
4	sequenced	O
5	the	O
6	RAP74	B
7	protein	I
8	from	O
9	purified	O
10	HeLa	O
11	cells	O
12	,	O
13	cloned	O
14	its	O
15	complementary	O
16	DNA	O
17	and	O
18	shown	O
19	that	O
20	its	O
21	translation	O
22	product	O
23	can	O
24	interact	O
25	with	O
26	RAP30	O
27	in	O
28	vitro	O
29	as	O
30	well	O
31	as	O
32	in	O
33	vivo	O
34	.	O

1	Rheumatoid	O
2	factor	O
3	and	O
4	antinuclear	O
5	antibody	O
6	tests	O
7	were	O
8	frequently	O
9	positive	O
10	,	O
11	and	O
12	reactions	O
13	to	O
14	gold	O
15	therapy	O
16	were	O
17	more	O
18	frequent	O
19	than	O
20	in	O
21	other	O
22	rheumatoid	O
23	populations	O
24	.	O

1	RESULTS	O
2	:	O
3	The	O
4	standardised	O
5	mortality	O
6	ratio	O
7	(	O
8	SMR	O
9	)	O
10	for	O
11	all	O
12	malignant	O
13	neoplasms	O
14	was	O
15	94	O
16	(	O
17	95	O
18	%	O
19	CI	O
20	74	O
21	to	O
22	118	O
23	).	O

1	As	O
2	stands	O
3	shifted	O
4	in	O
5	dominance	O
6	from	O
7	pine	O
8	to	O
9	fir	O
10	with	O
11	age	O
12	,	O
13	subalpine	O
14	fir	O
15	appeared	O
16	to	O
17	maintain	O
18	gradually	O
19	increasing	O
20	rates	O
21	of	O
22	whole	O
23	-	O
24	forest	O
25	productivity	O
26	until	O
27	stands	O
28	were	O
29	approximately	O
30	400	O
31	years	O
32	old	O
33	.	O

1	RPS14	O
2	introns	O
3	3	O
4	and	O
5	4	O
6	both	O
7	contain	O
8	Alu	O
9	sequences	O
10	.	O

1	We	O
2	showed	O
3	that	O
4	Stat3	B
5	and	O
6	Stat3beta	O
7	were	O
8	affinity	O
9	purified	O
10	using	O
11	phosphopeptides	O
12	containing	O
13	Y704	O
14	and	O
15	Y744	O
16	but	O
17	not	O
18	by	O
19	nonphosphorylated	O
20	peptide	O
21	analogues	O
22	or	O
23	by	O
24	phosphopeptides	O
25	containing	O
26	Y729	O
27	and	O
28	Y764	O
29	.	O

1	However	O
2	,	O
3	there	O
4	was	O
5	a	O
6	difference	O
7	in	O
8	the	O
9	quality	O
10	of	O
11	immunity	O
12	:	O
13	fever	O
14	and	O
15	body	O
16	weight	O
17	loss	O
18	were	O
19	seen	O
20	in	O
21	hamsters	O
22	vaccinated	O
23	with	O
24	the	O
25	killed	O
26	-	O
27	toxoplasma	O
28	vaccine	O
29	after	O
30	they	O
31	were	O
32	challenge	O
33	exposed	O
34	with	O
35	T	O
36	-	O
37	1	O
38	strain	O
39	,	O
40	whereas	O
41	these	O
42	changes	O
43	were	O
44	rarely	O
45	seen	O
46	in	O
47	hamsters	O
48	given	O
49	the	O
50	live	O
51	-	O
52	toxoplasma	O
53	vaccine	O
54	and	O
55	then	O
56	challenge	O
57	exposed	O
58	with	O
59	RH	O
60	strain	O
61	.	O

1	The	O
2	C	O
3	-	O
4	terminal	O
5	region	O
6	of	O
7	the	O
8	150	O
9	-	O
10	kDa	O
11	protein	O
12	contains	O
13	an	O
14	NTP	B
15	-	I
16	binding	I
17	helicase	I
18	motif	I
19	and	O
20	the	O
21	readthrough	O
22	region	O
23	,	O
24	an	O
25	RNA	O
26	polymerase	O
27	motif	O
28	,	O
29	indicating	O
30	that	O
31	these	O
32	two	O
33	overlapping	O
34	proteins	O
35	may	O
36	form	O
37	an	O
38	RNA	O
39	replication	O
40	complex	O
41	similar	O
42	to	O
43	those	O
44	of	O
45	tobamo	O
46	-	O
47	and	O
48	tobraviruses	O
49	.	O

1	The	O
2	need	O
3	for	O
4	including	O
5	forensic	O
6	medical	O
7	expertise	O
8	in	O
9	the	O
10	list	O
11	of	O
12	urgent	O
13	criminal	O
14	investigative	O
15	actions	O

1	Southern	O
2	blot	O
3	hybridization	O
4	experiments	O
5	suggest	O
6	the	O
7	presence	O
8	of	O
9	one	O
10	copy	O
11	of	O
12	Atcys1	O
13	,	O
14	Athyp1	O
15	and	O
16	AKin10	O
17	per	O
18	haploid	O
19	genome	O
20	,	O
21	and	O
22	Northern	O
23	blot	O
24	analysis	O
25	demonstrates	O
26	that	O
27	the	O
28	three	O
29	genes	O
30	are	O
31	differentially	O
32	expressed	O
33	in	O
34	roots	O
35	,	O
36	shoots	O
37	and	O
38	leaves	O
39	.	O

1	Pigmentary	O
2	rhythms	O
3	as	O
4	indicators	O
5	of	O
6	neurosecretion	O
7	.	O

1	Insulin	B
2	-	I
3	like	I
4	growth	I
5	factor	I
6	II	I
7	(	O
8	IGFII	O
9	)	O
10	is	O
11	a	O
12	mitogenic	O
13	polypeptide	O
14	,	O
15	the	O
16	mRNAs	O
17	of	O
18	which	O
19	are	O
20	present	O
21	in	O
22	multiple	O
23	forms	O
24	,	O
25	despite	O
26	derivation	O
27	from	O
28	a	O
29	single	O
30	gene	O
31	.	O

1	Autoradiographic	O
2	localisation	O
3	of	O
4	its	O
5	cellular	O
6	distribution	O
7	in	O
8	the	O
9	kidney	O
10	.	O

1	This	O
2	phenomenon	O
3	may	O
4	be	O
5	regarded	O
6	as	O
7	a	O
8	variant	O
9	of	O
10	selective	O
11	individual	O
12	cell	O
13	death	O
14	,	O
15	currently	O
16	referred	O
17	to	O
18	as	O
19	apoptosis	O
20	,	O
21	which	O
22	has	O
23	not	O
24	been	O
25	previously	O
26	reported	O
27	in	O
28	a	O
29	case	O
30	of	O
31	embryonal	O
32	rhabdomyosarcoma	O
33	.	O

1	Four	O
2	forms	O
3	of	O
4	salmonellosis	O
5	were	O
6	recognised	O
7	in	O
8	feedlots	O
9	and	O
10	during	O
11	transport	O
12	by	O
13	sea	O
14	:	O
15	septicaemic	O
16	,	O
17	and	O
18	acute	O
19	,	O
20	subacute	O
21	and	O
22	chronic	O
23	enteric	O
24	.	O

1	The	O
2	importance	O
3	of	O
4	temporal	O
5	factors	O
6	on	O
7	the	O
8	presence	O
9	and	O
10	severity	O
11	of	O
12	ethanol	O
13	withdrawal	O
14	signs	O
15	in	O
16	the	O
17	rat	O
18	was	O
19	quantified	O
20	using	O
21	rating	O
22	scale	O
23	,	O
24	tremor	O
25	,	O
26	and	O
27	acoustic	O
28	startle	O
29	paradigms	O
30	.	O

1	Conclusion	O
2	:	O
3	inlet	O
4	type	O
5	VSD	O
6	and	O
7	perimembranous	O
8	type	O
9	TOF	O
10	have	O
11	anatomic	O
12	features	O
13	in	O
14	which	O
15	the	O
16	proximal	O
17	His	O
18	bundle	O
19	tends	O
20	to	O
21	be	O
22	jeopardized	O
23	by	O
24	suturing	O
25	for	O
26	VSD	O
27	closure	O
28	.	O

1	STK	O
2	/	O
3	RON	O
4	-	O
5	expressing	O
6	Ba	O
7	/	O
8	F3	O
9	pro	O
10	-	O
11	B	O
12	cells	O
13	(	O
14	BaF	O
15	/	O
16	STK	O
17	)	O
18	exhibited	O
19	MSP	O
20	-	O
21	dependent	O
22	growth	O
23	,	O
24	whereas	O
25	STK	O
26	/	O
27	RON	O
28	-	O
29	expressing	O
30	mouse	O
31	erythroleukaemia	O
32	cells	O
33	(	O
34	MEL	O
35	/	O
36	STK	O
37	)	O
38	displayed	O
39	MSP	O
40	-	O
41	induced	O
42	apoptosis	O
43	.	O

1	This	O
2	emphasizes	O
3	the	O
4	conclusion	O
5	that	O
6	CDF	O
7	-	O
8	1	O
9	is	O
10	not	O
11	an	O
12	E2F	B
13	family	I
14	member	O
15	and	O
16	points	O
17	to	O
18	profound	O
19	differences	O
20	in	O
21	the	O
22	cell	O
23	cycle	O
24	regulation	O
25	of	O
26	CDF	O
27	-	O
28	1	O
29	and	O
30	E2F	B
31	.	O

1	However	O
2	,	O
3	primary	O
4	transcripts	O
5	of	O
6	a	O
7	variant	O
8	tRNA	O
9	(	O
10	Val	O
11	)(	O
12	UAC	O
13	)	O
14	gene	O
15	are	O
16	processing	O
17	deficient	O
18	under	O
19	standard	O
20	growth	O
21	conditions	O
22	(	O
23	30	O
24	degrees	O
25	C	O
26	),	O
27	due	O
28	to	O
29	a	O
30	slightly	O
31	altered	O
32	5	O
33	'	O
34	flanking	O
35	region	O
36	.	O

1	Localization	O
2	of	O
3	67	O
4	exons	O
5	on	O
6	a	O
7	YAC	O
8	contig	O
9	spanning	O
10	1	O
11	.	O
12	5	O
13	Mb	O
14	around	O
15	the	O
16	multidrug	O
17	resistance	O
18	gene	O
19	region	O
20	of	O
21	human	O
22	chromosome	O
23	7q21	O
24	.	O
25	1	O
26	.	O

1	HEF1	B
2	,	O
3	p130	B
4	(	O
5	Cas	O
6	),	O
7	and	O
8	Efs	O
9	/	O
10	Sin	O
11	constitute	O
12	a	O
13	family	O
14	of	O
15	multidomain	O
16	docking	O
17	proteins	O
18	that	O
19	have	O
20	been	O
21	implicated	O
22	in	O
23	coordinating	O
24	the	O
25	regulation	O
26	of	O
27	cell	O
28	adhesion	O
29	.	O

1	Salazopyrine	O
2	desensitization	O

1	The	O
2	Fyn	B
3	NH2	O
4	terminus	O
5	was	O
6	necessary	O
7	but	O
8	not	O
9	sufficient	O
10	for	O
11	interaction	O
12	with	O
13	zeta	B
14	and	O
15	both	O
16	Fyn	B
17	kinase	I
18	and	O
19	SH2	B
20	domains	O
21	were	O
22	required	O
23	,	O
24	directing	O
25	phosphorylation	O
26	of	O
27	zeta	B
28	ITAM	I
29	tyrosines	I
30	and	O
31	binding	O
32	to	O
33	zeta	B
34	ITAM	O
35	phosphotyrosines	O
36	.	O

1	Among	O
2	booked	O
3	patients	O
4	the	O
5	maternal	O
6	mortality	O
7	rate	O
8	was	O
9	0	O
10	.	O
11	32	O
12	and	O
13	among	O
14	unbooked	O
15	patients	O
16	11	O
17	.	O
18	13	O
19	per	O
20	1000	O
21	deliveries	O
22	.	O

1	An	O
2	open	O
3	reading	O
4	frame	O
5	encoding	O
6	a	O
7	protein	O
8	which	O
9	shows	O
10	significant	O
11	similarity	O
12	to	O
13	invertases	O
14	and	O
15	resolvases	O
16	was	O
17	located	O
18	immediately	O
19	upstream	O
20	of	O
21	the	O
22	Pac25I	O
23	R	O
24	-	O
25	M	O
26	operon	O
27	.	O

1	The	O
2	rational	O
3	for	O
4	the	O
5	prophylactic	O
6	treatment	O
7	,	O
8	the	O
9	therapy	O
10	of	O
11	the	O
12	meningopathy	O
13	and	O
14	AIL	O
15	-	O
16	AIEOP	O
17	protocols	O
18	are	O
19	exposed	O
20	.	O

1	Negative	O
2	-	O
3	staining	O
4	,	O
5	refractile	O
6	mycobacteria	O
7	in	O
8	Romanowsky	O
9	-	O
10	stained	O
11	smears	O
12	.	O

1	Activation	O
2	of	O
3	the	O
4	SH2	B
5	-	I
6	containing	I
7	protein	I
8	tyrosine	I
9	phosphatase	I
10	,	O
11	SH	O
12	-	O
13	PTP2	O
14	,	O
15	by	O
16	phosphotyrosine	O
17	-	O
18	containing	O
19	peptides	O
20	derived	O
21	from	O
22	insulin	B
23	receptor	I
24	substrate	I
25	-	I
26	1	I
27	.	O

1	RUSH	B
2	-	I
3	1	I
4	beta	I
5	is	O
6	a	O
7	95	O
8	-	O
9	kDa	O
10	truncated	O
11	version	O
12	of	O
13	RUSH	B
14	-	I
15	1	I
16	alpha	I
17	that	O
18	results	O
19	from	O
20	alternative	O
21	splicing	O
22	of	O
23	a	O
24	57	O
25	-	O
26	bp	O
27	exon	O
28	as	O
29	confirmed	O
30	by	O
31	genomic	O
32	cloning	O
33	.	O

1	The	O
2	ubiquitously	O
3	expressed	O
4	hypoxia	B
5	-	I
6	inducible	I
7	factor	I
8	-	I
9	1	I
10	(	I
11	HIF	I
12	-	I
13	1	I
14	)	O
15	is	O
16	involved	O
17	in	O
18	expression	O
19	of	O
20	a	O
21	large	O
22	number	O
23	of	O
24	oxygen	O
25	-	O
26	regulated	O
27	genes	O
28	.	O

1	Increased	O
2	dietary	O
3	energy	O
4	decreased	O
5	PAB	O
6	and	O
7	the	O
8	use	O
9	of	O
10	added	O
11	dietary	O
12	CO	O
13	rather	O
14	than	O
15	PF	O
16	decreased	O
17	PSHL	O
18	in	O
19	broiler	O
20	breeders	O
21	between	O
22	26	O
23	and	O
24	47	O
25	wk	O
26	of	O
27	age	O
28	.	O

1	Enhancers	O
2	containing	O
3	disrupted	O
4	Ets	B
5	-	I
6	1	I
7	binding	I
8	sites	I
9	were	O
10	tested	O
11	in	O
12	transient	O
13	expression	O
14	assays	O
15	in	O
16	the	O
17	murine	O
18	T	O
19	-	O
20	cell	O
21	line	O
22	EL4	O
23	.	O
24	E1	O
25	;	O
26	alterations	O
27	in	O
28	the	O
29	LVb	O
30	element	O
31	affected	O
32	constitutive	O
33	enhancer	O
34	activity	O
35	,	O
36	while	O
37	mutation	O
38	of	O
39	either	O
40	the	O
41	LVb	O
42	or	O
43	LVc	O
44	element	O
45	disrupted	O
46	phorbol	O
47	ester	O
48	-	O
49	induced	O
50	enhancer	O
51	activity	O
52	.	O

1	The	O
2	association	O
3	of	O
4	p255	O
5	with	O
6	splicing	O
7	complexes	O
8	is	O
9	suggested	O
10	by	O
11	the	O
12	finding	O
13	that	O
14	mAb	O
15	CC3	O
16	can	O
17	inhibit	O
18	in	O
19	vitro	O
20	splicing	O
21	and	O
22	immunoprecipitate	O
23	pre	O
24	-	O
25	messenger	O
26	RNA	O
27	and	O
28	splicing	O
29	products	O
30	.	O

1	The	O
2	genetic	O
3	basis	O
4	for	O
5	the	O
6	expression	O
7	of	O
8	a	O
9	latent	O
10	VH	O
11	allotype	O
12	in	O
13	the	O
14	rabbit	O
15	was	O
16	investigated	O
17	.	O

1	Differential	O
2	regulation	O
3	of	O
4	the	O
5	alpha	B
6	/	I
7	beta	I
8	interferon	I
9	-	I
10	stimulated	I
11	Jak	I
12	/	I
13	Stat	I
14	pathway	O
15	by	O
16	the	O
17	SH2	B
18	domain	I
19	-	I
20	containing	I
21	tyrosine	I
22	phosphatase	I
23	SHPTP1	O
24	.	O

1	The	O
2	amplitudes	O
3	of	O
4	DPOAE	O
5	also	O
6	recovered	O
7	to	O
8	a	O
9	greater	O
10	extent	O
11	and	O
12	outer	O
13	hair	O
14	cell	O
15	losses	O
16	were	O
17	less	O
18	severe	O
19	in	O
20	the	O
21	R	O
22	-	O
23	PIA	O
24	-	O
25	treated	O
26	ears	O
27	.	O

1	For	O
2	patients	O
3	with	O
4	recurrent	O
5	or	O
6	metastatic	O
7	disease	O
8	,	O
9	the	O
10	data	O
11	suggest	O
12	that	O
13	I	O
14	-	O
15	131	O
16	MIBG	O
17	scintigraphy	O
18	is	O
19	the	O
20	examination	O
21	of	O
22	choice	O
23	.	O

1	One	O
2	complex	O
3	most	O
4	likely	O
5	contained	O
6	Sp1	B
7	,	O
8	and	O
9	another	O
10	complex	O
11	showed	O
12	S	O
13	-	O
14	phase	O
15	-	O
16	specific	O
17	binding	O
18	,	O
19	suggesting	O
20	a	O
21	direct	O
22	role	O
23	in	O
24	the	O
25	cell	O
26	-	O
27	cycle	O
28	-	O
29	dependent	O
30	R1	O
31	gene	O
32	expression	O
33	.	O

1	Exogenous	O
2	LHRH	O
3	is	O
4	also	O
5	known	O
6	to	O
7	facilitate	O
8	mating	O
9	behavior	O
10	in	O
11	several	O
12	species	O
13	.	O

1	The	O
2	role	O
3	of	O
4	protein	O
5	kinase	O
6	C	O
7	signaling	O
8	in	O
9	activated	O
10	DRA	O
11	transcription	O
12	.	O

1	Productive	O
2	growth	O
3	of	O
4	phage	O
5	P22	O
6	in	O
7	wild	B
8	-	I
9	type	I
10	Salmonella	I
11	typhimurium	I
12	correlates	O
13	with	O
14	the	O
15	presence	O
16	of	O
17	Abc2	O
18	,	O
19	but	O
20	is	O
21	independent	O
22	of	O
23	the	O
24	absolute	O
25	level	O
26	of	O
27	ATP	B
28	-	I
29	dependent	I
30	nuclease	I
31	activity	O
32	,	O
33	suggesting	O
34	a	O
35	qualitative	O
36	change	O
37	in	O
38	the	O
39	nature	O
40	of	O
41	Abc2	O
42	-	O
43	modified	O
44	RecBCD	O
45	nuclease	O
46	activity	O
47	relative	O
48	to	O
49	the	O
50	native	O
51	enzyme	O
52	.	O

1	Genetic	O
2	and	O
3	molecular	O
4	complexity	O
5	of	O
6	the	O
7	position	O
8	effect	O
9	variegation	O
10	modifier	O
11	mod	O
12	(	O
13	mdg4	O
14	)	O
15	in	O
16	Drosophila	O
17	.	O
18	mod	O
19	(	O
20	mdg4	O
21	),	O
22	also	O
23	known	O
24	as	O
25	E	O
26	(	O
27	var	O
28	)	O
29	3	O
30	-	O
31	93D	O
32	,	O
33	is	O
34	involved	O
35	in	O
36	a	O
37	variety	O
38	of	O
39	processes	O
40	,	O
41	such	O
42	as	O
43	gene	O
44	silencing	O
45	in	O
46	position	O
47	effect	O
48	variegation	O
49	(	O
50	PEV	O
51	),	O
52	the	O
53	control	O
54	of	O
55	gypsy	O
56	insulator	O
57	sequences	O
58	,	O
59	regulation	O
60	of	O
61	homeotic	B
62	gene	I
63	expression	O
64	,	O
65	and	O
66	programmed	O
67	cell	O
68	death	O
69	.	O

1	This	O
2	slope	O
3	was	O
4	further	O
5	significantly	O
6	decreased	O
7	at	O
8	5	O
9	min	O
10	ischemia	O
11	(-	O
12	26	O
13	.	O
14	5	O
15	+/-	O
16	8	O
17	.	O
18	8	O
19	microm	O
20	/	O
21	mmHg	O
22	)	O
23	but	O
24	returned	O
25	toward	O
26	control	O
27	values	O
28	in	O
29	short	O
30	-	O
31	term	O
32	hibernating	O
33	myocardium	O
34	at	O
35	90	O
36	min	O
37	ischemia	O
38	(-	O
39	17	O
40	.	O
41	2	O
42	+/-	O
43	6	O
44	.	O
45	6	O
46	microm	O
47	/	O
48	mmHg	O
49	).	O

1	These	O
2	mutants	O
3	all	O
4	failed	O
5	to	O
6	interact	O
7	with	O
8	the	O
9	TraR	O
10	fusion	O
11	in	O
12	the	O
13	two	O
14	-	O
15	hybrid	O
16	system	O
17	.	O

1	Pharmacokinetic	O
2	parameters	O
3	were	O
4	similar	O
5	to	O
6	values	O
7	given	O
8	in	O
9	the	O
10	literature	O
11	for	O
12	intravenous	O
13	(	O
14	IV	O
15	)	O
16	or	O
17	intraarterial	O
18	(	O
19	IA	O
20	)	O
21	bolus	O
22	MMC	O
23	injections	O
24	(	O
25	Tmax	O
26	=	O
27	7	O
28	.	O
29	0	O
30	min	O
31	following	O
32	the	O
33	beginning	O
34	of	O
35	MMC	O
36	infusion	O
37	,	O
38	Vss	O
39	=	O
40	0	O
41	.	O
42	57	O
43	1	O
44	/	O
45	kg	O
46	,	O
47	C1	O
48	=	O
49	8	O
50	.	O
51	9	O
52	ml	O
53	/	O
54	min	O
55	.	O
56	kg	O
57	,	O
58	T1	O
59	/	O
60	2	O
61	alpha	O
62	=	O
63	8	O
64	.	O
65	3	O
66	min	O
67	,	O
68	T1	O
69	/	O
70	2	O
71	beta	O
72	=	O
73	58	O
74	.	O
75	6	O
76	min	O
77	).	O

1	Gastrin	O
2	secretion	O
3	during	O
4	food	O
5	stimulation	O
6	in	O
7	digestive	O
8	system	O
9	diseases	O

1	Physical	O
2	analysis	O
3	maps	O
4	SAL6	O
5	to	O
6	chromosome	O
7	XVI	O
8	between	O
9	TPK2	O
10	and	O
11	spt14	O
12	.	O

1	Amikacin	O
2	was	O
3	the	O
4	most	O
5	stable	O
6	and	O
7	tobramycin	O
8	was	O
9	the	O
10	least	O
11	stable	O
12	aminoglycoside	O
13	under	O
14	the	O
15	conditions	O
16	tested	O
17	.	O

1	Deletion	O
2	or	O
3	inactivation	O
4	of	O
5	CRY1	O
6	leads	O
7	to	O
8	5	O
9	-	O
10	to	O
11	10	O
12	-	O
13	fold	O
14	-	O
15	increased	O
16	levels	O
17	of	O
18	CRY2	O
19	mRNA	O
20	.	O

1	This	O
2	reveals	O
3	a	O
4	new	O
5	test	O
6	for	O
7	short	O
8	saphenous	O
9	incompetence	O
10	and	O
11	shows	O
12	that	O
13	14	O
14	per	O
15	cent	O
16	of	O
17	varices	O
18	stem	O
19	from	O
20	a	O
21	saphenopopliteal	O
22	reflux	O
23	.	O

1	Although	O
2	both	O
3	transfected	O
4	cell	O
5	lines	O
6	contain	O
7	FGF	B
8	-	I
9	1	I
10	cell	O
11	surface	O
12	receptors	O
13	as	O
14	judged	O
15	by	O
16	crosslinking	O
17	studies	O
18	,	O
19	the	O
20	wild	O
21	-	O
22	type	O
23	transfectants	O
24	are	O
25	refractory	O
26	to	O
27	exogenous	O
28	FGF	B
29	-	I
30	1	I
31	,	O
32	whereas	O
33	the	O
34	mutant	O
35	transfectants	O
36	respond	O
37	normally	O
38	.(	O
39	ABSTRACT	O
40	TRUNCATED	O
41	AT	O
42	250	O
43	WORDS	O
44	)	O

1	HPLC	O
2	phosphopeptide	O
3	mapping	O
4	,	O
5	amino	O
6	acid	O
7	sequencing	O
8	,	O
9	and	O
10	site	O
11	-	O
12	directed	O
13	mutagenesis	O
14	determined	O
15	that	O
16	NCLK	O
17	phosphorylates	O
18	Ser	O
19	(	O
20	67	O
21	)	O
22	of	O
23	I	O
24	-	O
25	1	O
26	.	O

1	Conformational	O
2	studies	O
3	combining	O
4	secondary	O
5	structure	O
6	predictions	O
7	,	O
8	CD	O
9	and	O
10	NMR	O
11	spectroscopy	O
12	together	O
13	with	O
14	ELISA	O
15	assays	O
16	,	O
17	showed	O
18	that	O
19	the	O
20	greater	O
21	is	O
22	the	O
23	propensity	O
24	of	O
25	the	O
26	epitope	O
27	for	O
28	helix	O
29	formation	O
30	the	O
31	higher	O
32	is	O
33	the	O
34	recognition	O
35	by	O
36	anti	O
37	-	O
38	K159	O
39	.	O

1	Employing	O
2	this	O
3	sequence	O
4	information	O
5	from	O
6	c11	O
7	/	O
8	1	O
9	,	O
10	the	O
11	c11	O
12	/	O
13	1	O
14	-	O
15	specific	O
16	cDNA	O
17	was	O
18	generated	O
19	from	O
20	poly	O
21	(	O
22	A	O
23	)+	O
24	RNA	O
25	of	O
26	bovine	O
27	PMNLs	O
28	by	O
29	reverse	O
30	transcription	O
31	and	O
32	a	O
33	combination	O
34	of	O
35	polymerase	O
36	chain	O
37	reaction	O
38	(	O
39	PCR	O
40	)	O
41	methods	O
42	.	O

1	Metabolism	O
2	of	O
3	calcium	O
4	and	O
5	vitamin	O
6	D3	O
7	in	O
8	patients	O
9	with	O
10	acute	O
11	tubulointerstitial	O
12	nephritis	O
13	:	O
14	a	O
15	study	O
16	of	O
17	41	O
18	patients	O
19	with	O
20	nephropathia	O
21	epidemica	O
22	.	O

1	What	O
2	'	O
3	s	O
4	new	O
5	in	O
6	gynecologic	O
7	and	O
8	obstetrical	O
9	surgery	O
10	.	O

1	T2	O
2	cancers	O
3	should	O
4	not	O
5	be	O
6	excluded	O
7	from	O
8	the	O
9	benefit	O
10	of	O
11	preoperative	O
12	irradiation	O
13	.	O

1	The	O
2	results	O
3	confirm	O
4	that	O
5	a	O
6	single	O
7	base	O
8	change	O
9	in	O
10	the	O
11	branchpoint	O
12	consensus	O
13	sequence	O
14	of	O
15	an	O
16	intron	O
17	can	O
18	cause	O
19	human	O
20	disease	O
21	although	O
22	this	O
23	sequence	O
24	is	O
25	poorly	O
26	conserved	O
27	in	O
28	mammals	O
29	.	O

1	The	O
2	sequenced	O
3	genomic	O
4	region	O
5	thus	O
6	accounts	O
7	for	O
8	essentially	O
9	all	O
10	of	O
11	the	O
12	longest	O
13	known	O
14	transcript	O
15	(	O
16	4	O
17	.	O
18	5	O
19	kb	O
20	),	O
21	although	O
22	the	O
23	precise	O
24	ends	O
25	of	O
26	this	O
27	transcript	O
28	have	O
29	not	O
30	been	O
31	defined	O
32	.	O

1	Serine	O
2	528	O
3	is	O
4	phosphorylated	O
5	in	O
6	vivo	O
7	in	O
8	several	O
9	cell	O
10	lines	O
11	,	O
12	and	O
13	substitution	O
14	of	O
15	serine	O
16	528	O
17	to	O
18	alanine	O
19	(	O
20	S528A	O
21	)	O
22	resulted	O
23	in	O
24	an	O
25	increased	O
26	ability	O
27	of	O
28	Myb	B
29	to	O
30	transactivate	O
31	a	O
32	synthetic	O
33	promoter	O
34	containing	O
35	five	O
36	copies	O
37	of	O
38	the	O
39	mim	B
40	-	I
41	1A	I
42	Myb	I
43	-	I
44	responsive	I
45	element	I
46	and	O
47	a	O
48	minimal	O
49	herpes	B
50	tk	I
51	promoter	I
52	.	O

1	Yeast	O
2	mutants	O
3	assigned	O
4	to	O
5	the	O
6	pet	O
7	complementation	O
8	group	O
9	G104	O
10	were	O
11	found	O
12	to	O
13	lack	O
14	alpha	B
15	-	I
16	ketoglutarate	I
17	dehydrogenase	I
18	activity	O
19	as	O
20	a	O
21	result	O
22	of	O
23	mutations	O
24	in	O
25	the	O
26	dihydrolipoyl	O
27	transsuccinylase	O
28	(	O
29	KE2	O
30	)	O
31	component	O
32	of	O
33	the	O
34	complex	O
35	.	O

1	Changes	O
2	in	O
3	body	O
4	weight	O
5	and	O
6	agonistic	O
7	behavior	O
8	were	O
9	also	O
10	recorded	O
11	.	O

1	However	O
2	,	O
3	one	O
4	CAK	B
5	-	I
6	phosphorylated	O
7	phosphopeptide	O
8	comigrates	O
9	with	O
10	a	O
11	Cdc2	B
12	-	I
13	phosphorylated	O
14	phosphopeptide	O
15	previously	O
16	shown	O
17	to	O
18	be	O
19	mitosis	O
20	-	O
21	specific	O
22	,	O
23	suggesting	O
24	that	O
25	,	O
26	in	O
27	vitro	O
28	,	O
29	CAK	O
30	is	O
31	able	O
32	to	O
33	phosphorylate	O
34	at	O
35	least	O
36	one	O
37	site	O
38	that	O
39	is	O
40	also	O
41	phosphorylated	O
42	in	O
43	vivo	O
44	.	O

1	A	O
2	new	O
3	variant	O
4	of	O
5	the	O
6	EMG	O
7	-	O
8	BFB	O
9	method	O
10	(	O
11	multichannel	O
12	)	O
13	is	O
14	offered	O
15	which	O
16	has	O
17	made	O
18	it	O
19	possible	O
20	to	O
21	use	O
22	the	O
23	method	O
24	not	O
25	only	O
26	for	O
27	training	O
28	weakened	O
29	muscles	O
30	and	O
31	reducing	O
32	spasticity	O
33	in	O
34	their	O
35	antagonists	O
36	but	O
37	also	O
38	for	O
39	improving	O
40	motor	O
41	coordination	O
42	.	O

1	Motile	O
2	nocardoid	O
3	Actinomycetales	O
4	.	O

1	They	O
2	also	O
3	reported	O
4	that	O
5	E	O
6	mu	B
7	pim	I
8	-	I
9	1	I
10	transgenic	O
11	mice	O
12	show	O
13	greatly	O
14	accelerated	O
15	lymphoma	O
16	development	O
17	when	O
18	infected	O
19	with	O
20	wild	O
21	-	O
22	type	O
23	M	O
24	-	O
25	MuLV	O
26	at	O
27	birth	O
28	.	O

1	Serum	O
2	leptin	O
3	concentrations	O
4	in	O
5	women	O
6	during	O
7	gonadotropin	O
8	stimulation	O
9	cycles	O
10	.	O

1	Far	O
2	from	O
3	this	O
4	being	O
5	the	O
6	case	O
7	,	O
8	however	O
9	,	O
10	the	O
11	measurement	O
12	of	O
13	apo	O
14	B	O
15	has	O
16	met	O
17	every	O
18	reasonable	O
19	standard	O
20	of	O
21	laboratory	O
22	precision	O
23	and	O
24	reliability	O
25	to	O
26	allow	O
27	its	O
28	widespread	O
29	introduction	O
30	in	O
31	clinical	O
32	laboratories	O
33	.	O

1	There	O
2	was	O
3	a	O
4	close	O
5	correlation	O
6	between	O
7	plasma	O
8	clearance	O
9	of	O
10	NT	O
11	by	O
12	10	O
13	-	O
14	hydroxylation	O
15	and	O
16	the	O
17	D	O
18	metabolic	O
19	ratio	O
20	(	O
21	D	O
22	/	O
23	4	O
24	-	O
25	OH	O
26	-	O
27	D	O
28	in	O
29	urine	O
30	)	O
31	in	O
32	the	O
33	Ghanaians	O
34	(	O
35	rs	O
36	=	O
37	-	O
38	0	O
39	.	O
40	95	O
41	;	O
42	P	O
43	less	O
44	than	O
45	0	O
46	.	O
47	01	O
48	)	O
49	and	O
50	Swedes	O
51	(	O
52	rs	O
53	=	O
54	-	O
55	0	O
56	.	O
57	84	O
58	;	O
59	P	O
60	less	O
61	than	O
62	0	O
63	.	O
64	01	O
65	).	O

1	Optima	O
2	)	O
3	genomic	O
4	library	O
5	by	O
6	hybridizing	O
7	with	O
8	elicitor	O
9	-	O
10	induced	O
11	stilbene	B
12	synthase	I
13	cDNA	I
14	as	O
15	a	O
16	probe	O
17	.	O

1	The	O
2	other	O
3	patients	O
4	continued	O
5	the	O
6	trial	O
7	with	O
8	single	O
9	daily	O
10	doses	O
11	of	O
12	monotherapy	O
13	.	O

1	Although	O
2	stone	O
3	-	O
4	formers	O
5	were	O
6	not	O
7	found	O
8	to	O
9	display	O
10	any	O
11	features	O
12	of	O
13	magnesium	O
14	metabolism	O
15	that	O
16	were	O
17	different	O
18	from	O
19	those	O
20	in	O
21	the	O
22	control	O
23	group	O
24	,	O
25	their	O
26	lower	O
27	urinary	O
28	excretion	O
29	of	O
30	magnesium	O
31	in	O
32	relation	O
33	to	O
34	calcium	O
35	may	O
36	be	O
37	a	O
38	factor	O
39	in	O
40	their	O
41	increased	O
42	stone	O
43	-	O
44	forming	O
45	propensity	O
46	.	O

1	Regulation	O
2	of	O
3	irgA	O
4	by	O
5	iron	O
6	in	O
7	V	O
8	.	O
9	cholerae	O
10	occurs	O
11	at	O
12	the	O
13	transcriptional	O
14	level	O
15	,	O
16	and	O
17	there	O
18	is	O
19	an	O
20	interrupted	O
21	dyad	O
22	symmetric	O
23	sequence	O
24	in	O
25	the	O
26	vicinity	O
27	of	O
28	the	O
29	promoter	O
30	that	O
31	is	O
32	homologous	O
33	to	O
34	Fur	B
35	binding	I
36	sites	I
37	of	O
38	E	O
39	.	O
40	coli	O
41	.	O

1	Of	O
2	these	O
3	proteins	O
4	,	O
5	five	O
6	have	O
7	previously	O
8	been	O
9	shown	O
10	to	O
11	be	O
12	phosphorylated	O
13	during	O
14	mitosis	O
15	(	O
16	epithelial	O
17	-	O
18	microtubule	O
19	associated	O
20	protein	O
21	-	O
22	115	O
23	,	O
24	Oct91	O
25	,	O
26	Elongation	B
27	factor	I
28	1gamma	I
29	,	O
30	BRG1	O
31	and	O
32	Ribosomal	O
33	protein	O
34	L18A	O
35	),	O
36	five	O
37	are	O
38	related	O
39	to	O
40	proteins	O
41	postulated	O
42	to	O
43	have	O
44	roles	O
45	in	O
46	mitosis	O
47	(	O
48	epithelial	O
49	-	O
50	microtubule	O
51	associated	O
52	protein	O
53	-	O
54	115	O
55	,	O
56	Schizosaccharomyces	O
57	pombe	O
58	Cdc5	O
59	,	O
60	innercentrosome	O
61	protein	O
62	,	O
63	BRG1	O
64	and	O
65	the	O
66	RNA	B
67	helicase	I
68	WM6	I
69	),	O
70	and	O
71	nine	O
72	are	O
73	related	O
74	to	O
75	transcription	O
76	factors	O
77	(	O
78	BRG1	O
79	,	O
80	negative	O
81	co	B
82	-	I
83	factor	I
84	2alpha	I
85	,	O
86	Oct91	O
87	,	O
88	S	O
89	.	O
90	pombe	O
91	Cdc5	O
92	,	O
93	HoxD1	O
94	,	O
95	Sox3	O
96	,	O
97	Vent2	O
98	,	O
99	and	O
100	two	O
101	isoforms	O
102	of	O
103	Xbr1b	O
104	).	O

1	Slap	O
2	negatively	O
3	regulates	O
4	Src	B
5	mitogenic	O
6	function	O
7	but	O
8	does	O
9	not	O
10	revert	O
11	Src	B
12	-	I
13	induced	O
14	cell	O
15	morphology	O
16	changes	O
17	.	O

1	Both	O
2	HEF1	B
3	and	O
4	Cas	O
5	were	O
6	found	O
7	to	O
8	complex	O
9	with	O
10	the	O
11	related	O
12	adhesion	O
13	focal	B
14	tyrosine	I
15	kinase	I
16	(	O
17	RAFTK	O
18	),	O
19	and	O
20	when	O
21	tyrosine	O
22	phosphorylated	O
23	,	O
24	with	O
25	the	O
26	adapter	O
27	molecule	O
28	CrkL	O
29	.	O

1	Multiple	O
2	single	O
3	-	O
4	stranded	O
5	cis	O
6	elements	O
7	are	O
8	associated	O
9	with	O
10	activated	O
11	chromatin	O
12	of	O
13	the	O
14	human	O
15	c	B
16	-	I
17	myc	I
18	gene	I
19	in	O
20	vivo	O
21	.	O

1	The	O
2	incidence	O
3	of	O
4	early	O
5	neonatal	O
6	convulsions	O
7	for	O
8	inborn	O
9	babies	O
10	was	O
11	3	O
12	.	O
13	0	O
14	/	O
15	1000	O
16	live	O
17	births	O
18	.	O

1	We	O
2	recently	O
3	reported	O
4	the	O
5	molecular	O
6	cloning	O
7	of	O
8	a	O
9	PL	O
10	scramblase	O
11	of	O
12	human	O
13	(	O
14	HuPLSCR1	O
15	)	O
16	and	O
17	mouse	O
18	origin	O
19	,	O
20	respectively	O
21	.	O

1	Another	O
2	ORF	O
3	,	O
4	dda	O
5	.	O
6	2	O
7	located	O
8	between	O
9	modA	O
10	and	O
11	dda	O
12	,	O
13	shares	O
14	sequence	O
15	similarity	O
16	with	O
17	sigma70	O
18	,	O
19	and	O
20	we	O
21	call	O
22	it	O
23	srd	O
24	.	O

1	The	O
2	unique	O
3	nature	O
4	and	O
5	arrangement	O
6	of	O
7	the	O
8	ANT1	O
9	transcriptional	O
10	control	O
11	elements	O
12	may	O
13	account	O
14	for	O
15	this	O
16	differential	O
17	expression	O
18	.	O

1	Acute	O
2	feasibility	O
3	and	O
4	safety	O
5	of	O
6	a	O
7	smoking	O
8	reduction	O
9	strategy	O
10	for	O
11	smokers	O
12	with	O
13	schizophrenia	O
14	.	O

1	The	O
2	binding	O
3	of	O
4	transcription	O
5	factor	O
6	AP	B
7	-	I
8	1	I
9	and	O
10	vitamin	O
11	D	O
12	receptor	O
13	(	O
14	VDR	B
15	)	O
16	to	O
17	the	O
18	composite	O
19	AP	B
20	-	I
21	1	I
22	plus	O
23	vitamin	O
24	-	O
25	D	O
26	-	O
27	responsive	O
28	promoter	O
29	region	O
30	(	O
31	AP	B
32	-	I
33	1	I
34	+	I
35	VDRE	I
36	)	O
37	of	O
38	the	O
39	human	B
40	osteocalcin	I
41	gene	I
42	was	O
43	characterized	O
44	in	O
45	osteocalcin	O
46	-	O
47	producing	O
48	(	O
49	MG	O
50	-	O
51	63	O
52	)	O
53	and	O
54	non	O
55	-	O
56	producing	O
57	(	O
58	U2	B
59	-	I
60	Os	I
61	,	O
62	SaOs	O
63	-	O
64	2	O
65	)	O
66	human	O
67	osteosarcoma	O
68	cell	O
69	lines	O
70	.	O

1	This	O
2	indicates	O
3	that	O
4	the	O
5	mechanism	O
6	by	O
7	which	O
8	CX	O
9	blocks	O
10	rapid	O
11	degradation	O
12	of	O
13	tubulin	B
14	mRNA	I
15	in	O
16	vivo	O
17	is	O
18	not	O
19	simply	O
20	by	O
21	preventing	O
22	its	O
23	translation	O
24	and	O
25	suggests	O
26	the	O
27	involvement	O
28	of	O
29	an	O
30	altered	O
31	trans	O
32	-	O
33	factor	O
34	.	O

1	We	O
2	have	O
3	determined	O
4	the	O
5	nucleotide	O
6	(	O
7	nt	O
8	)	O
9	sequence	O
10	of	O
11	the	O
12	7	O
13	.	O
14	5	O
15	-	O
16	kb	O
17	COR	O
18	segment	O
19	that	O
20	encompasses	O
21	a	O
22	cluster	O
23	of	O
24	six	O
25	genes	O
26	(	O
27	CYC1	O
28	,	O
29	UTR1	O
30	,	O
31	UTR3	O
32	,	O
33	OSM1	O
34	,	O
35	tRNA	O
36	(	O
37	Gly	O
38	)	O
39	and	O
40	RAD7	O
41	)	O
42	located	O
43	on	O
44	chromosome	O
45	X	O
46	of	O
47	the	O
48	yeast	O
49	Saccharomyces	O
50	cerevisiae	O
51	.	O

1	Endotoxemia	O
2	induced	O
3	by	O
4	gram	O
5	-	O
6	negative	O
7	bacteria	O
8	leads	O
9	to	O
10	endotoxic	O
11	shock	O
12	pathogenetically	O
13	stemming	O
14	from	O
15	the	O
16	integral	O
17	component	O
18	of	O
19	the	O
20	bacterial	O
21	wall	O
22	--	O
23	lipid	O
24	A	O
25	.	O

1	In	O
2	contrast	O
3	,	O
4	mutations	O
5	affecting	O
6	the	O
7	other	O
8	two	O
9	Nim1p	O
10	-	O
11	related	O
12	kinases	O
13	in	O
14	S	O
15	.	O
16	cerevisiae	O
17	,	O
18	Hsl1p	O
19	and	O
20	Kcc4p	O
21	,	O
22	produce	O
23	no	O
24	detectable	O
25	effect	O
26	on	O
27	septin	O
28	organization	O
29	.	O

1	JPEG	O
2	53	O
3	,	O
4	resulting	O
5	in	O
6	a	O
7	compression	O
8	ratio	O
9	of	O
10	1	O
11	:	O
12	21	O
13	,	O
14	does	O
15	not	O
16	compromise	O
17	the	O
18	diagnostic	O
19	performance	O
20	in	O
21	general	O
22	.	O

1	Taxonomically	O
2	significant	O
3	colour	O
4	changes	O
5	in	O
6	Brevibacterium	O
7	linens	O
8	probably	O
9	associated	O
10	with	O
11	a	O
12	carotenoid	O
13	-	O
14	like	O
15	pigment	O
16	.	O

1	Twelve	O
2	genomic	O
3	fragments	O
4	containing	O
5	novel	O
6	response	O
7	elements	O
8	are	O
9	described	O
10	,	O
11	and	O
12	the	O
13	transcription	O
14	unit	O
15	associated	O
16	with	O
17	one	O
18	of	O
19	them	O
20	,	O
21	NN	O
22	-	O
23	84AG	O
24	,	O
25	was	O
26	characterized	O
27	in	O
28	detail	O
29	.	O

1	Using	O
2	a	O
3	polymerase	O
4	chain	O
5	reaction	O
6	-	O
7	based	O
8	approach	O
9	,	O
10	we	O
11	cloned	O
12	a	O
13	150	O
14	-	O
15	base	O
16	pair	O
17	fragment	O
18	of	O
19	a	O
20	new	O
21	sialymotif	O
22	from	O
23	human	O
24	placenta	O
25	mRNA	O
26	,	O
27	which	O
28	was	O
29	then	O
30	used	O
31	as	O
32	a	O
33	probe	O
34	to	O
35	clone	O
36	the	O
37	complete	O
38	coding	O
39	sequence	O
40	of	O
41	the	O
42	corresponding	O
43	gene	O
44	from	O
45	a	O
46	cDNA	O
47	library	O
48	.	O

1	Cryopreservation	O
2	straws	O
3	filled	O
4	with	O
5	media	O
6	plus	O
7	additive	O
8	are	O
9	emersed	O
10	below	O
11	the	O
12	surface	O
13	of	O
14	an	O
15	unprocessed	O
16	donor	O
17	ejaculate	O
18	.	O

1	It	O
2	is	O
3	exclusively	O
4	observed	O
5	in	O
6	smooth	O
7	muscle	O
8	cells	O
9	by	O
10	Northern	O
11	blotting	O
12	and	O
13	immunohistochemical	O
14	analysis	O
15	and	O
16	therefore	O
17	designated	O
18	"	O
19	smoothelin	O
20	."	O
21	A	O
22	human	O
23	smooth	O
24	muscle	O
25	cDNA	O
26	library	O
27	was	O
28	screened	O
29	with	O
30	the	O
31	monoclonal	O
32	antibody	O
33	R4A	O
34	,	O
35	and	O
36	a	O
37	full	O
38	-	O
39	size	O
40	cDNA	O
41	of	O
42	the	O
43	protein	O
44	was	O
45	selected	O
46	.	O

1	Data	O
2	from	O
3	the	O
4	V	O
5	-	O
6	HeFT	O
7	II	O
8	show	O
9	that	O
10	at	O
11	2	O
12	-	O
13	year	O
14	follow	O
15	-	O
16	up	O
17	,	O
18	a	O
19	progressive	O
20	rise	O
21	of	O
22	plasma	O
23	norepinephrine	O
24	was	O
25	observed	O
26	in	O
27	both	O
28	treatment	O
29	arms	O
30	,	O
31	suggesting	O
32	that	O
33	disease	O
34	progresses	O
35	despite	O
36	treatment	O
37	with	O
38	either	O
39	an	O
40	angiotensin	B
41	-	I
42	converting	I
43	enzyme	I
44	inhibitor	O
45	,	O
46	enalapril	O
47	,	O
48	or	O
49	vasodilator	O
50	therapy	O
51	with	O
52	hydralazine	O
53	/	O
54	isosorbide	O
55	dinitrate	O
56	.	O

1	SCFFWD1	O
2	may	O
3	be	O
4	critical	O
5	for	O
6	tumor	O
7	development	O
8	and	O
9	suppression	O
10	through	O
11	regulation	O
12	of	O
13	beta	B
14	-	I
15	catenin	I
16	protein	I
17	stability	O
18	.	O

1	But	O
2	the	O
3	application	O
4	solutions	O
5	of	O
6	instrument	O
7	disinfectants	O
8	should	O
9	not	O
10	be	O
11	used	O
12	longer	O
13	than	O
14	one	O
15	day	O
16	.	O

1	Based	O
2	on	O
3	these	O
4	data	O
5	,	O
6	we	O
7	conclude	O
8	that	O
9	transcription	O
10	of	O
11	prgX	O
12	is	O
13	initiated	O
14	from	O
15	the	O
16	Qa	O
17	promoter	O
18	in	O
19	prgQ	O
20	,	O
21	and	O
22	PrgX	O
23	autoregulates	O
24	its	O
25	transcription	O
26	either	O
27	by	O
28	mediating	O
29	transcriptional	O
30	readthrough	O
31	or	O
32	increasing	O
33	mRNA	O
34	stability	O
35	.	O

1	RESULTS	O
2	:	O
3	Patients	O
4	in	O
5	Group	O
6	A	O
7	had	O
8	a	O
9	higher	O
10	incidence	O
11	of	O
12	posterolateral	O
13	wall	O
14	motion	O
15	abnormalities	O
16	(	O
17	p	O
18	<	O
19	0	O
20	.	O
21	001	O
22	)	O
23	on	O
24	radionuclide	O
25	ventriculography	O
26	,	O
27	a	O
28	larger	O
29	infarct	O
30	area	O
31	(	O
32	as	O
33	evidenced	O
34	by	O
35	higher	O
36	peak	O
37	creatine	B
38	kinase	I
39	levels	O
40	)	O
41	(	O
42	p	O
43	<	O
44	0	O
45	.	O
46	02	O
47	)	O
48	and	O
49	a	O
50	lower	O
51	left	O
52	ventricular	O
53	ejection	O
54	fraction	O
55	(	O
56	LVEF	O
57	)	O
58	at	O
59	hospital	O
60	discharge	O
61	(	O
62	p	O
63	<	O
64	0	O
65	.	O
66	008	O
67	)	O
68	than	O
69	those	O
70	in	O
71	Group	O
72	B	O
73	.	O

1	The	O
2	prevalence	O
3	of	O
4	malnutrition	O
5	was	O
6	30	O
7	%	O
8	in	O
9	the	O
10	47	O
11	patients	O
12	without	O
13	CVD	O
14	and	O
15	was	O
16	significantly	O
17	higher	O
18	(	O
19	70	O
20	%,	O
21	P	O
22	<	O
23	0	O
24	.	O
25	001	O
26	)	O
27	in	O
28	the	O
29	70	O
30	patients	O
31	with	O
32	CVD	O
33	,	O
34	who	O
35	also	O
36	had	O
37	lower	O
38	tHcy	O
39	,	O
40	SAlb	O
41	,	O
42	plasma	O
43	IGF	B
44	-	I
45	1	I
46	,	O
47	serum	O
48	creatinine	O
49	(	O
50	SCr	O
51	),	O
52	and	O
53	blood	O
54	hemoglobin	B
55	.	O

1	Regions	O
2	of	O
3	the	O
4	translated	O
5	open	O
6	reading	O
7	frames	O
8	of	O
9	cobA	O
10	and	O
11	the	O
12	third	O
13	intron	O
14	of	O
15	the	O
16	cob	B
17	gene	I
18	in	O
19	yeast	O
20	show	O
21	high	O
22	amino	O
23	acid	O
24	homology	O
25	.	O

1	SNAC	O
2	or	O
3	PBS	O
4	was	O
5	infused	O
6	for	O
7	6	O
8	.	O
9	5	O
10	h	O
11	,	O
12	beginning	O
13	30	O
14	min	O
15	before	O
16	ischemia	O
17	and	O
18	continuing	O
19	throughout	O
20	the	O
21	duration	O
22	of	O
23	reperfusion	O
24	.	O

1	Here	O
2	,	O
3	we	O
4	propose	O
5	that	O
6	an	O
7	antagonistic	O
8	,	O
9	BMP	O
10	/	O
11	ALK2	O
12	/	O
13	Smad	B
14	-	I
15	mediated	O
16	signaling	O
17	pathway	O
18	is	O
19	active	O
20	on	O
21	the	O
22	right	O
23	side	O
24	of	O
25	the	O
26	Xenopus	O
27	embryo	O
28	.	O

1	Retroviral	O
2	replication	O
3	requires	O
4	that	O
5	a	O
6	portion	O
7	of	O
8	the	O
9	primary	O
10	transcripts	O
11	generated	O
12	from	O
13	proviral	O
14	DNA	O
15	be	O
16	spliced	O
17	to	O
18	serve	O
19	as	O
20	mRNA	O
21	for	O
22	the	O
23	envelope	O
24	protein	O
25	and	O
26	in	O
27	Rous	O
28	sarcoma	O
29	virus	O
30	as	O
31	src	B
32	mRNA	I
33	.	O

1	Reliability	O
2	of	O
3	cervical	O
4	range	O
5	of	O
6	motion	O
7	using	O
8	the	O
9	OSI	O
10	CA	O
11	6000	O
12	spine	O
13	motion	O
14	analyser	O
15	on	O
16	asymptomatic	O
17	and	O
18	symptomatic	O
19	subjects	O
20	.	O

1	The	O
2	efficacy	O
3	of	O
4	these	O
5	immunosuppressive	O
6	drugs	O
7	is	O
8	clinical	O
9	proven	O
10	.	O

1	Thus	O
2	,	O
3	the	O
4	presence	O
5	of	O
6	the	O
7	Cln2	O
8	PEST	O
9	domain	O
10	was	O
11	sufficient	O
12	to	O
13	destabilize	O
14	a	O
15	heterologous	O
16	protein	O
17	.	O

1	Recently	O
2	,	O
3	a	O
4	mutation	O
5	in	O
6	the	O
7	amino	O
8	-	O
9	terminus	O
10	of	O
11	IB1	O
12	was	O
13	associated	O
14	with	O
15	diabetes	O
16	.	O

1	A	O
2	drug	O
3	with	O
4	ISA	O
5	"	O
6	down	O
7	regulates	O
8	"	O
9	beta	O
10	receptors	O
11	;	O
12	thus	O
13	,	O
14	when	O
15	the	O
16	drug	O
17	is	O
18	withdrawn	O
19	there	O
20	is	O
21	no	O
22	post	O
23	-	O
24	beta	O
25	-	O
26	blocking	O
27	drug	O
28	hypersensitivity	O
29	in	O
30	contrast	O
31	to	O
32	agents	O
33	without	O
34	ISA	O
35	.	O

1	Stable	O
2	transfection	O
3	of	O
4	the	O
5	truncated	O
6	reduced	O
7	folate	O
8	carrier	O
9	cDNA	O
10	into	O
11	mouse	O
12	L1210	O
13	leukemia	O
14	cells	O
15	:	O
16	increased	O
17	folate	O
18	accumulation	O
19	,	O
20	decreased	O
21	their	O
22	leucovorin	O
23	and	O
24	folic	O
25	acid	O
26	growth	O
27	requirements	O
28	,	O
29	and	O
30	increased	O
31	their	O
32	sensitivity	O
33	to	O
34	methotrexate	O
35	.	O

1	Transactivation	O
2	of	O
3	the	O
4	HIV	B
5	-	I
6	1	I
7	LTR	I
8	by	O
9	T3R	B
10	alpha	I
11	and	O
12	several	O
13	receptor	O
14	mutants	O
15	revealed	O
16	that	O
17	the	O
18	50	O
19	-	O
20	amino	O
21	-	O
22	acid	O
23	N	O
24	-	O
25	terminal	O
26	A	O
27	/	O
28	B	O
29	region	O
30	of	O
31	T3R	B
32	alpha	I
33	,	O
34	known	O
35	to	O
36	interact	O
37	with	O
38	the	O
39	basal	O
40	transcription	O
41	factor	O
42	TFIIB	O
43	,	O
44	is	O
45	critical	O
46	for	O
47	activation	O
48	of	O
49	both	O
50	Tat	B
51	-	I
52	dependent	I
53	and	O
54	Tat	B
55	-	I
56	independent	O
57	responsive	O
58	sequences	O
59	of	O
60	the	O
61	LTR	O
62	.	O

1	The	O
2	presence	O
3	of	O
4	the	O
5	foreign	O
6	gene	O
7	was	O
8	confirmed	O
9	by	O
10	Southern	O
11	analysis	O
12	.	O

1	The	O
2	syndrome	O
3	of	O
4	resistance	O
5	to	O
6	thyroid	O
7	hormone	O
8	is	O
9	characterized	O
10	by	O
11	elevated	O
12	serum	O
13	free	O
14	thyroid	O
15	hormones	O
16	,	O
17	failure	O
18	to	O
19	suppress	O
20	pituitary	O
21	thyrotropin	O
22	secretion	O
23	,	O
24	and	O
25	variable	O
26	peripheral	O
27	refractoriness	O
28	to	O
29	hormone	O
30	action	O
31	.	O

1	Analysis	O
2	of	O
3	the	O
4	5	O
5	'	O
6	flanking	O
7	region	O
8	of	O
9	the	O
10	gene	O
11	also	O
12	revealed	O
13	the	O
14	presence	O
15	of	O
16	multiple	O
17	TATA	O
18	and	O
19	CAAT	O
20	sequences	O
21	.	O

1	The	O
2	ability	O
3	to	O
4	maintain	O
5	expression	O
6	of	O
7	FAS1	O
8	in	O
9	nmt1	O
10	-	O
11	451Dino2	O
12	Delta	O
13	cells	O
14	suggests	O
15	the	O
16	existence	O
17	of	O
18	another	O
19	transcription	O
20	factor	O
21	,	O
22	or	O
23	factors	O
24	,	O
25	whose	O
26	expression	O
27	/	O
28	activity	O
29	is	O
30	inversely	O
31	related	O
32	to	O
33	overall	O
34	levels	O
35	of	O
36	cellular	O
37	protein	O
38	N	O
39	-	O
40	myristoy	O
41	-	O
42	lation	O
43	.	O

1	Moreover	O
2	,	O
3	an	O
4	in	O
5	vitro	O
6	pull	O
7	-	O
8	down	O
9	assay	O
10	showed	O
11	that	O
12	Os	O
13	;	O
14	CycH	O
15	;	O
16	1	O
17	specifically	O
18	bound	O
19	to	O
20	R2	O
21	but	O
22	not	O
23	to	O
24	other	O
25	rice	O
26	CDKs	O
27	.	O

1	Theories	O
2	proffered	O
3	to	O
4	account	O
5	for	O
6	the	O
7	modality	O
8	shift	O
9	effect	O
10	are	O
11	critically	O
12	evaluated	O
13	.	O

1	Finally	O
2	,	O
3	we	O
4	demonstrate	O
5	that	O
6	C	B
7	/	I
8	EBP	I
9	alpha	I
10	can	O
11	also	O
12	active	O
13	the	O
14	GM	B
15	-	I
16	CSF	I
17	receptor	I
18	alpha	I
19	promoter	I
20	in	O
21	nonmyeloid	O
22	cells	O
23	.	O

1	CONCLUSIONS	O
2	:	O
3	These	O
4	findings	O
5	indicate	O
6	a	O
7	physical	O
8	barrier	O
9	of	O
10	oesophageal	O
11	surfactant	O
12	which	O
13	could	O
14	offer	O
15	some	O
16	degree	O
17	of	O
18	protection	O
19	against	O
20	gastro	O
21	-	O
22	oesophageal	O
23	reflux	O
24	but	O
25	one	O
26	which	O
27	is	O
28	particularly	O
29	prone	O
30	to	O
31	attack	O
32	by	O
33	bile	O
34	.	O

1	To	O
2	examine	O
3	the	O
4	possibility	O
5	that	O
6	LNNB	O
7	performance	O
8	of	O
9	the	O
10	schizophrenic	O
11	groups	O
12	may	O
13	have	O
14	been	O
15	related	O
16	to	O
17	neuroleptic	O
18	medication	O
19	,	O
20	analyses	O
21	were	O
22	completed	O
23	on	O
24	the	O
25	relationship	O
26	between	O
27	medication	O
28	levels	O
29	and	O
30	LNNB	O
31	scores	O
32	.	O

1	Regulated	O
2	activity	O
3	of	O
4	the	O
5	distal	O
6	promoter	O
7	-	O
8	like	O
9	element	O
10	of	O
11	the	O
12	human	B
13	corticotropin	I
14	-	I
15	releasing	I
16	hormone	I
17	gene	I
18	and	O
19	secondary	O
20	structural	O
21	features	O
22	of	O
23	its	O
24	corresponding	O
25	transcripts	O
26	.	O

1	Most	O
2	,	O
3	however	O
4	,	O
5	would	O
6	tell	O
7	the	O
8	spouse	O
9	the	O
10	full	O
11	truth	O
12	about	O
13	both	O
14	diagnosis	O
15	and	O
16	prognosis	O
17	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	the	O
6	plasma	O
7	prolactin	B
8	response	O
9	to	O
10	12	O
11	.	O
12	5	O
13	micrograms	O
14	i	O
15	.	O
16	v	O
17	.	O

1	Identification	O
2	of	O
3	mutations	O
4	in	O
5	the	O
6	coding	O
7	sequence	O
8	of	O
9	the	O
10	proto	B
11	-	I
12	oncogene	I
13	c	I
14	-	I
15	kit	I
16	in	O
17	a	O
18	human	O
19	mast	O
20	cell	O
21	leukemia	O
22	cell	O
23	line	O
24	causing	O
25	ligand	O
26	-	O
27	independent	O
28	activation	O
29	of	O
30	c	B
31	-	I
32	kit	I
33	product	I
34	.	O

1	ATF1	O
2	transcription	O
3	is	O
4	negatively	O
5	regulated	O
6	by	O
7	unsaturated	O
8	fatty	O
9	acids	O
10	and	O
11	oxygen	O
12	.	O

1	To	O
2	determine	O
3	if	O
4	the	O
5	NF	B
6	(	O
7	H	O
8	)	O
9	promoter	O
10	can	O
11	be	O
12	activated	O
13	in	O
14	a	O
15	tissue	O
16	specific	O
17	manner	O
18	during	O
19	development	O
20	transgenic	O
21	mice	O
22	containing	O
23	the	O
24	promoter	O
25	region	O
26	linked	O
27	to	O
28	a	O
29	beta	B
30	-	I
31	galactosidase	I
32	reporter	I
33	gene	I
34	were	O
35	generated	O
36	.	O

1	Fourteen	O
2	different	O
3	species	O
4	(	O
5	eight	O
6	Platyhelmintha	O
7	,	O
8	one	O
9	Nematoda	O
10	and	O
11	five	O
12	Crustacea	O
13	)	O
14	have	O
15	been	O
16	inventorized	O
17	.	O

1	In	O
2	situ	O
3	hybridization	O
4	analysis	O
5	in	O
6	adult	O
7	rat	O
8	tissue	O
9	reveals	O
10	good	O
11	correlation	O
12	with	O
13	this	O
14	pattern	O
15	and	O
16	indicates	O
17	that	O
18	drm	O
19	mRNA	O
20	is	O
21	most	O
22	highly	O
23	expressed	O
24	in	O
25	nondividing	O
26	and	O
27	terminally	O
28	differentiated	O
29	cells	O
30	,	O
31	such	O
32	as	O
33	neurons	O
34	,	O
35	type	O
36	1	O
37	lung	O
38	cells	O
39	,	O
40	and	O
41	goblet	O
42	cells	O
43	.	O

1	Mouse	B
2	growth	I
3	hormone	I
4	transcription	I
5	factor	I
6	Zn	I
7	-	I
8	16	O
9	:	O
10	unique	O
11	bipartite	O
12	structure	O
13	containing	O
14	tandemly	O
15	repeated	O
16	zinc	O
17	finger	O
18	domains	O
19	not	O
20	reported	O
21	in	O
22	rat	O
23	Zn	O
24	-	O
25	15	O
26	.	O

1	Direct	O
2	proof	O
3	that	O
4	the	O
5	heightened	O
6	renal	O
7	cellular	O
8	apoptosis	O
9	in	O
10	PKD	O
11	is	O
12	not	O
13	occurring	O
14	through	O
15	p53	B
16	was	O
17	obtained	O
18	by	O
19	successive	O
20	matings	O
21	between	O
22	SBM	O
23	and	O
24	p53	B
25	(-/-)	I
26	mice	O
27	.	O

1	Thus	O
2	,	O
3	the	O
4	B	O
5	-	O
6	S	O
7	mutant	O
8	does	O
9	not	O
10	mimic	O
11	efficiently	O
12	the	O
13	chloroplastic	O
14	GAPDHs	O
15	,	O
16	and	O
17	long	O
18	-	O
19	range	O
20	and	O
21	/	O
22	or	O
23	second	O
24	-	O
25	layer	O
26	effects	O
27	,	O
28	not	O
29	easily	O
30	predictable	O
31	from	O
32	visual	O
33	inspection	O
34	of	O
35	three	O
36	-	O
37	dimensional	O
38	structures	O
39	,	O
40	need	O
41	to	O
42	be	O
43	taken	O
44	into	O
45	account	O
46	for	O
47	designing	O
48	a	O
49	true	O
50	"	O
51	chloroplastic	O
52	-	O
53	like	O
54	"	O
55	mutant	O
56	of	O
57	cytosolic	O
58	GAPDH	O
59	.	O

1	No	O
2	post	O
3	-	O
4	operative	O
5	haemorrhages	O
6	from	O
7	the	O
8	prostheses	O
9	were	O
10	observed	O
11	.	O

1	However	O
2	,	O
3	a	O
4	10	O
5	--	O
6	15	O
7	%	O
8	lengthening	O
9	of	O
10	the	O
11	partial	O
12	thromboplastin	B
13	time	O
14	is	O
15	evident	O
16	after	O
17	24	O
18	hours	O
19	of	O
20	storage	O
21	.	O

1	Commercially	O
2	available	O
3	formulations	O
4	of	O
5	2	O
6	.	O
7	5	O
8	%	O
9	and	O
10	5	O
11	%	O
12	lambdacyhalothrin	O
13	can	O
14	be	O
15	diluted	O
16	either	O
17	with	O
18	water	O
19	for	O
20	ULV	O
21	cold	O
22	aerosol	O
23	space	O
24	-	O
25	spraying	O
26	or	O
27	with	O
28	diesel	O
29	/	O
30	kerosene	O
31	for	O
32	thermal	O
33	fogging	O
34	at	O
35	recommended	O
36	application	O
37	rates	O
38	of	O
39	0	O
40	.	O
41	5	O
42	-	O
43	1	O
44	g	O
45	ai	O
46	/	O
47	ha	O
48	for	O
49	mosquito	O
50	control	O
51	and	O
52	2	O
53	g	O
54	ai	O
55	/	O
56	ha	O
57	for	O
58	housefly	O
59	control	O
60	.	O

1	However	O
2	,	O
3	a	O
4	clear	O
5	difference	O
6	exists	O
7	between	O
8	myoblasts	O
9	and	O
10	10T1	O
11	/	O
12	2	O
13	cells	O
14	(	O
15	and	O
16	other	O
17	non	O
18	-	O
19	muscle	O
20	cell	O
21	types	O
22	)	O
23	in	O
24	the	O
25	chromatin	O
26	structure	O
27	of	O
28	the	O
29	chromosomal	O
30	myoD	B
31	core	I
32	enhancer	I
33	,	O
34	suggesting	O
35	that	O
36	the	O
37	myoD	B
38	enhancer	I
39	is	O
40	repressed	O
41	by	O
42	epigenetic	O
43	mechanisms	O
44	in	O
45	10T1	O
46	/	O
47	2	O
48	cells	O
49	.	O

1	Neonatal	O
2	Chagas	O
3	disease	O
4	:	O
5	laboratory	O
6	diagnosis	O
7	during	O
8	the	O
9	first	O
10	year	O
11	of	O
12	life	O

1	Isolation	O
2	of	O
3	a	O
4	novel	O
5	TP53	O
6	target	O
7	gene	O
8	from	O
9	a	O
10	colon	O
11	cancer	O
12	cell	O
13	line	O
14	carrying	O
15	a	O
16	highly	O
17	regulated	O
18	wild	B
19	-	I
20	type	I
21	TP53	I
22	expression	O
23	system	O
24	.	O

1	A	O
2	1	O
3	.	O
4	8	O
5	-	O
6	kb	O
7	cDNA	O
8	clone	O
9	(	O
10	designed	O
11	hKID	O
12	,	O
13	gene	O
14	symbol	O
15	AQP2L	O
16	)	O
17	with	O
18	homology	O
19	to	O
20	the	O
21	aquaporins	O
22	was	O
23	isolated	O
24	from	O
25	a	O
26	human	O
27	kidney	O
28	cDNA	O
29	library	O
30	.	O

1	They	O
2	include	O
3	genes	O
4	encoding	O
5	three	O
6	subunits	O
7	of	O
8	the	O
9	cytochrome	B
10	oxidase	I
11	(	O
12	cox1	O
13	to	O
14	3	O
15	),	O
16	apocytochrome	O
17	b	O
18	(	O
19	cob	O
20	),	O
21	seven	O
22	subunits	O
23	of	O
24	the	O
25	NADH	B
26	dehydrogenase	I
27	complex	I
28	(	O
29	nad1	O
30	to	O
31	6	O
32	,	O
33	nad4L	O
34	),	O
35	two	O
36	ATPase	O
37	subunits	O
38	(	O
39	atp6	O
40	and	O
41	atp9	O
42	),	O
43	three	O
44	ribosomal	O
45	RNAs	O
46	(	O
47	rrn5	O
48	,	O
49	srn	O
50	and	O
51	lrn	O
52	),	O
53	23	O
54	tRNAs	O
55	and	O
56	four	O
57	ribosomal	O
58	proteins	O
59	(	O
60	rps3	O
61	,	O
62	rps11	O
63	,	O
64	rps12	O
65	and	O
66	rpl16	O
67	).	O

1	Gene	O
2	constructs	O
3	consisting	O
4	of	O
5	human	B
6	growth	I
7	hormone	I
8	(	O
9	hGH	B
10	)	I
11	gene	I
12	driven	O
13	by	O
14	promoter	O
15	/	O
16	regulatory	O
17	sequence	O
18	of	O
19	mouse	O
20	metallothionein	O
21	(	O
22	mMT	O
23	),	O
24	viral	O
25	thymidine	B
26	kinase	I
27	(	O
28	vTK	O
29	),	O
30	rat	O
31	cholecystokinin	O
32	(	O
33	rCCK	O
34	),	O
35	or	O
36	chicken	B
37	beta	I
38	-	I
39	actin	I
40	(	O
41	cBA	O
42	)	O
43	gene	O
44	were	O
45	injected	O
46	into	O
47	the	O
48	cytoplasm	O
49	of	O
50	fertilized	O
51	medaka	O
52	eggs	O
53	via	O
54	the	O
55	micropyle	O
56	.	O

1	Labile	B
2	LTR	I
3	-	I
4	binding	I
5	proteins	I
6	appear	O
7	to	O
8	be	O
9	essential	O
10	for	O
11	c	B
12	-	I
13	myc	I
14	hyperexpression	O
15	,	O
16	since	O
17	both	O
18	LTR	O
19	-	O
20	enhanced	O
21	transcription	O
22	and	O
23	the	O
24	activities	O
25	of	O
26	LTR	O
27	-	O
28	binding	O
29	proteins	O
30	are	O
31	specifically	O
32	decreased	O
33	after	O
34	inhibition	O
35	of	O
36	protein	O
37	synthesis	O
38	(	O
39	A	O
40	.	O

1	Microstructure	O
2	and	O
3	conductivity	O
4	of	O
5	hierarchical	O
6	laminate	O
7	composites	O
8	.	O

1	Intracranial	O
2	arachnoid	O
3	cyst	O
4	of	O
5	the	O
6	middle	O
7	fossa	O
8	demonstrated	O
9	by	O
10	positive	O
11	99mTc	O
12	brainscintigraphy	O
13	.	O

1	Sinusoidal	O
2	oscillations	O
3	of	O
4	a	O
5	gas	O
6	dilution	O
7	indicator	O

1	Kidney	O
2	weight	O
3	and	O
4	kidney	O
5	-	O
6	to	O
7	-	O
8	body	O
9	weight	O
10	ratio	O
11	were	O
12	significantly	O
13	elevated	O
14	at	O
15	the	O
16	highest	O
17	dose	O
18	level	O
19	after	O
20	10	O
21	weeks	O
22	and	O
23	at	O
24	the	O
25	two	O
26	higher	O
27	dose	O
28	levels	O
29	after	O
30	15	O
31	weeks	O
32	of	O
33	exposure	O
34	.	O

1	To	O
2	characterize	O
3	this	O
4	effect	O
5	,	O
6	we	O
7	looked	O
8	for	O
9	targets	O
10	of	O
11	NS1	O
12	influenza	O
13	virus	O
14	protein	O
15	among	O
16	cellular	O
17	translation	O
18	factors	O
19	.	O

1	The	O
2	ARF	B
3	promoter	I
4	was	O
5	also	O
6	found	O
7	to	O
8	be	O
9	highly	O
10	responsive	O
11	to	O
12	E2F1	B
13	expression	O
14	,	O
15	in	O
16	keeping	O
17	with	O
18	previous	O
19	results	O
20	at	O
21	the	O
22	RNA	O
23	level	O
24	.	O

1	These	O
2	results	O
3	show	O
4	that	O
5	the	O
6	neonate	O
7	differs	O
8	from	O
9	the	O
10	adult	O
11	in	O
12	respect	O
13	of	O
14	both	O
15	the	O
16	nature	O
17	of	O
18	effects	O
19	of	O
20	the	O
21	drug	O
22	and	O
23	sensitivity	O
24	to	O
25	it	O
26	.	O

1	These	O
2	studies	O
3	indicate	O
4	that	O
5	the	O
6	acidimetric	O
7	test	O
8	was	O
9	less	O
10	sensitive	O
11	than	O
12	the	O
13	chromogenic	O
14	cephalosporin	O
15	substrates	O
16	and	O
17	that	O
18	nitrocefin	O
19	and	O
20	S1	O
21	could	O
22	be	O
23	used	O
24	to	O
25	screen	O
26	for	O
27	beta	B
28	-	I
29	lactamase	I
30	production	O
31	in	O
32	these	O
33	tested	O
34	species	O
35	.	O

1	The	O
2	observation	O
3	of	O
4	late	O
5	effects	O
6	after	O
7	irradiations	O
8	or	O
9	after	O
10	space	O
11	flights	O
12	show	O
13	the	O
14	difficulties	O
15	encountered	O
16	in	O
17	assessing	O
18	radiative	O
19	risks	O
20	during	O
21	long	O
22	duration	O
23	space	O
24	flights	O
25	.	O

1	All	O
2	groups	O
3	were	O
4	challenged	O
5	subsequently	O
6	with	O
7	naloxone	O
8	(	O
9	0	O
10	.	O
11	4	O
12	mg	O
13	/	O
14	kg	O
15	)	O
16	in	O
17	the	O
18	distinctive	O
19	environment	O
20	and	O
21	then	O
22	observed	O
23	for	O
24	signs	O
25	of	O
26	opiate	O
27	withdrawal	O
28	.	O

1	Expression	O
2	in	O
3	established	O
4	LCLs	O
5	,	O
6	occurring	O
7	irrespective	O
8	of	O
9	virus	O
10	producer	O
11	status	O
12	,	O
13	was	O
14	not	O
15	a	O
16	consequence	O
17	of	O
18	continued	O
19	in	O
20	vitro	O
21	passage	O
22	;	O
23	thus	O
24	,	O
25	appropriately	B
26	spliced	I
27	BamHI	I
28	-	I
29	A	I
30	transcripts	I
31	could	O
32	be	O
33	amplified	O
34	from	O
35	normal	O
36	B	O
37	cells	O
38	within	O
39	1	O
40	day	O
41	of	O
42	their	O
43	experimental	O
44	infection	O
45	in	O
46	vitro	O
47	,	O
48	along	O
49	with	O
50	BamHI	B
51	-	I
52	C	I
53	/	I
54	W	I
55	promoter	I
56	-	I
57	initiated	O
58	but	O
59	not	O
60	BamHI	B
61	-	I
62	F	I
63	promoter	I
64	-	I
65	initiated	O
66	mRNAs	O
67	.	O

1	Rare	O
2	neurogenic	O
3	tumor	O
4	with	O
5	metastasis	O
6	to	O
7	mouth	O
8	,	O
9	jaw	O
10	and	O
11	face	O
12	regions	O

1	Furthermore	O
2	,	O
3	the	O
4	negative	O
5	transcriptional	O
6	effect	O
7	of	O
8	COUP	B
9	-	I
10	TFs	O
11	is	O
12	dominant	O
13	over	O
14	the	O
15	activating	O
16	effect	O
17	of	O
18	the	O
19	Oct4	O
20	embryonic	O
21	stem	O
22	cell	O
23	-	O
24	specific	O
25	enhancer	O
26	.	O

1	The	O
2	cDNA	O
3	corresponding	O
4	to	O
5	the	O
6	FPS1	O
7	gene	O
8	was	O
9	isolated	O
10	by	O
11	functional	O
12	complementation	O
13	of	O
14	a	O
15	mutant	O
16	yeast	O
17	strain	O
18	defective	O
19	in	O
20	FPS	O
21	activity	O
22	(	O
23	Delourme	O
24	,	O
25	D	O
26	.,	O
27	Lacroute	O
28	,	O
29	F	O
30	.,	O
31	and	O
32	Karst	O
33	,	O
34	F	O
35	.	O

1	MBI	O
2	and	O
3	MMBI	O
4	showed	O
5	similar	O
6	Cmax	O
7	values	O
8	,	O
9	but	O
10	the	O
11	former	O
12	disappeared	O
13	slower	O
14	in	O
15	the	O
16	serum	O
17	than	O
18	the	O
19	latter	O
20	and	O
21	resulted	O
22	in	O
23	its	O
24	larger	O
25	AUC	O
26	values	O
27	.	O

1	The	O
2	RAT3	O
3	gene	O
4	encodes	O
5	an	O
6	1157	O
7	-	O
8	amino	O
9	acid	O
10	protein	O
11	without	O
12	similarity	O
13	to	O
14	other	O
15	known	O
16	proteins	O
17	.	O

1	The	O
2	films	O
3	were	O
4	analyzed	O
5	using	O
6	a	O
7	scanning	O
8	helium	O
9	-	O
10	neon	O
11	laser	O
12	densitometer	O
13	with	O
14	a	O
15	small	O
16	aperture	O
17	of	O
18	5	O
19	-	O
20	10	O
21	microns	O
22	.	O

1	The	O
2	Dax	O
3	-	O
4	1	O
5	gene	O
6	encodes	O
7	a	O
8	protein	O
9	that	O
10	is	O
11	structurally	O
12	related	O
13	to	O
14	members	O
15	of	O
16	the	O
17	orphan	B
18	nuclear	I
19	receptor	I
20	superfamily	I
21	.	O

1	METHODS	O
2	:	O
3	TBN	O
4	measurements	O
5	were	O
6	performed	O
7	in	O
8	31	O
9	female	O
10	outpatients	O
11	with	O
12	breast	O
13	carcinoma	O
14	who	O
15	were	O
16	undergoing	O
17	standard	O
18	cyclophosphamide	O
19	,	O
20	methotrexate	O
21	,	O
22	and	O
23	5	O
24	-	O
25	fluorouracil	O
26	(	O
27	CMF	O
28	)-	O
29	based	O
30	chemotherapy	O
31	(	O
32	median	O
33	age	O
34	,	O
35	48	O
36	years	O
37	;	O
38	range	O
39	,	O
40	26	O
41	-	O
42	77	O
43	years	O
44	).	O

1	Therefore	O
2	,	O
3	analogs	O
4	of	O
5	vitamin	O
6	D3	O
7	have	O
8	been	O
9	investigated	O
10	in	O
11	a	O
12	number	O
13	of	O
14	trials	O
15	showing	O
16	improvement	O
17	of	O
18	psoriasis	O
19	.	O

1	Furthermore	O
2	,	O
3	in	O
4	the	O
5	ischemia	O
6	/	O
7	angiotension	O
8	II	O
9	-	O
10	induced	O
11	AHF	O
12	model	O
13	,	O
14	NIC	O
15	decreased	O
16	left	O
17	ventricular	O
18	end	O
19	-	O
20	diastolic	O
21	pressure	O
22	(	O
23	LVEDP	O
24	).	O

1	The	O
2	influence	O
3	of	O
4	adrenergic	O
5	nerves	O
6	of	O
7	the	O
8	response	O
9	of	O
10	blood	O
11	vessels	O
12	in	O
13	the	O
14	rabbit	O
15	ear	O
16	to	O
17	2	O
18	--	O
19	phenylalanine	O
20	-	O
21	8	O
22	-	O
23	lysine	O
24	vasopressin	O
25	(	O
26	Octapressin	O
27	).	O

1	Neither	O
2	Ha	B
3	-	I
4	Ras	I
5	(	O
6	G12V	O
7	,	O
8	T35S	O
9	)	O
10	(	O
11	Ha	O
12	-	O
13	RasV12S35	O
14	),	O
15	which	O
16	activates	O
17	the	O
18	Rafl	O
19	signaling	O
20	pathway	O
21	,	O
22	nor	O
23	Ha	B
24	-	I
25	Ras	I
26	(	O
27	G12V	O
28	,	O
29	E37G	O
30	)	O
31	(	O
32	Ha	O
33	-	O
34	RasV12G37	O
35	),	O
36	which	O
37	stimulates	O
38	the	O
39	RalGDS	O
40	pathway	O
41	,	O
42	did	O
43	not	O
44	have	O
45	significant	O
46	effects	O
47	on	O
48	factor	O
49	-	O
50	withdrawal	O
51	apoptosis	O
52	of	O
53	myeloid	O
54	cells	O
55	.	O

1	Insert2	O
2	contains	O
3	repetitive	O
4	non	O
5	-	O
6	Ig	B
7	-	I
8	related	I
9	sequences	O
10	and	O
11	a	O
12	small	O
13	Ig	B
14	-	I
15	related	I
16	sequence	O
17	.	O

1	We	O
2	have	O
3	also	O
4	identified	O
5	a	O
6	functional	O
7	domain	O
8	in	O
9	the	O
10	ORF	O
11	50	O
12	protein	O
13	,	O
14	an	O
15	immediate	B
16	-	I
17	early	I
18	gene	I
19	product	I
20	that	O
21	is	O
22	mainly	O
23	encoded	O
24	by	O
25	ORF	O
26	50	O
27	.	O

1	Although	O
2	a	O
3	great	O
4	deal	O
5	is	O
6	understood	O
7	about	O
8	how	O
9	bHLH	O
10	factors	O
11	activate	O
12	gene	O
13	transcription	O
14	via	O
15	E	O
16	-	O
17	box	O
18	DNA	O
19	consensus	O
20	sequences	O
21	,	O
22	studies	O
23	of	O
24	bHLH	B
25	factor	I
26	function	O
27	in	O
28	higher	O
29	eukaryotes	O
30	often	O
31	have	O
32	been	O
33	hindered	O
34	by	O
35	the	O
36	presence	O
37	of	O
38	multiple	O
39	family	O
40	members	O
41	.	O

1	SUMMARY	O
2	OF	O
3	REVIEW	O
4	:	O
5	We	O
6	discuss	O
7	the	O
8	criteria	O
9	that	O
10	make	O
11	such	O
12	studies	O
13	comparable	O
14	,	O
15	drawing	O
16	on	O
17	the	O
18	experiences	O
19	of	O
20	recent	O
21	studies	O
22	performed	O
23	around	O
24	the	O
25	world	O
26	.	O

1	The	O
2	identification	O
3	of	O
4	viable	O
5	myocardium	O
6	with	O
7	both	O
8	99mTc	O
9	-	O
10	tetrofosmin	O
11	and	O
12	201Tl	O
13	can	O
14	be	O
15	greatly	O
16	enhanced	O
17	to	O
18	a	O
19	similar	O
20	degree	O
21	if	O
22	the	O
23	severity	O
24	of	O
25	reduction	O
26	in	O
27	activity	O
28	within	O
29	nonreversible	O
30	defects	O
31	is	O
32	considered	O
33	.	O

1	Among	O
2	these	O
3	360	O
4	ZFPs	O
5	,	O
6	a	O
7	novel	O
8	ZFP	O
9	cDNA	O
10	named	O
11	HFHZ	O
12	(	O
13	human	O
14	fetal	O
15	heart	O
16	ZFP	O
17	)	O
18	with	O
19	sequence	O
20	homology	O
21	to	O
22	a	O
23	Kruppel	B
24	-	I
25	associated	O
26	box	O
27	(	O
28	KRAB	B
29	)	O
30	was	O
31	identified	O
32	.	O

1	Doxorubicin	O
2	,	O
3	dacarbazine	O
4	,	O
5	vincristine	O
6	,	O
7	and	O
8	cyclophosphamide	O
9	in	O
10	the	O
11	treatment	O
12	of	O
13	advanced	O
14	gastrointestinal	O
15	leiomyosarcoma	O
16	.	O

1	The	O
2	ability	O
3	of	O
4	BCL	O
5	-	O
6	6	O
7	to	O
8	function	O
9	as	O
10	a	O
11	transcriptional	O
12	repressor	O
13	may	O
14	contribute	O
15	to	O
16	its	O
17	ability	O
18	to	O
19	transform	O
20	B	O
21	lymphocytes	O
22	in	O
23	diffuse	O
24	large	O
25	cell	O
26	lymphoma	O
27	.	O

1	4	O
2	)	O
3	PU	O
4	and	O
5	PD	O
6	lacked	O
7	the	O
8	canonical	O
9	TATA	O
10	or	O
11	CAAT	O
12	motifs	O
13	,	O
14	and	O
15	are	O
16	AT	O
17	-	O
18	rich	O
19	.	O

1	The	O
2	putative	O
3	immunity	O
4	protein	O
5	was	O
6	detected	O
7	among	O
8	the	O
9	[	O
10	35S	O
11	]	O
12	methionine	O
13	-	O
14	labelled	O
15	proteins	O
16	produced	O
17	by	O
18	minicells	O
19	carrying	O
20	cni	O
21	cloned	O
22	under	O
23	lac	B
24	promoter	I
25	control	O
26	,	O
27	and	O
28	when	O
29	the	O
30	gene	O
31	was	O
32	subcloned	O
33	into	O
34	expression	O
35	vectors	O
36	under	O
37	the	O
38	control	O
39	of	O
40	a	O
41	bacteriophage	O
42	T7	O
43	promoter	O
44	.	O

1	5	O
2	)	O
3	We	O
4	'	O
5	ve	O
6	noticed	O
7	that	O
8	the	O
9	mean	O
10	value	O
11	of	O
12	the	O
13	cost	O
14	for	O
15	episode	O
16	of	O
17	pnx	O
18	s	O
19	.	O
20	in	O
21	class	O
22	A	O
23	was	O
24	more	O
25	than	O
26	15	O
27	%	O
28	compared	O
29	to	O
30	class	O
31	B	O
32	and	O
33	the	O
34	cost	O
35	for	O
36	patient	O
37	in	O
38	class	O
39	A	O
40	was	O
41	nearly	O
42	double	O
43	than	O
44	in	O
45	class	O
46	B	O
47	.	O

1	Simian	O
2	parainfluenza	O
3	virus	O
4	5	O
5	(	O
6	SV5	O
7	)	O
8	is	O
9	a	O
10	prototype	O
11	of	O
12	the	O
13	Paramyxoviridae	O
14	family	O
15	of	O
16	nonsegmented	O
17	negative	O
18	-	O
19	sense	O
20	RNA	O
21	viruses	O
22	.	O

1	Since	O
2	1968	O
3	,	O
4	a	O
5	steep	O
6	decrease	O
7	in	O
8	the	O
9	number	O
10	of	O
11	strains	O
12	resistant	O
13	to	O
14	three	O
15	or	O
16	more	O
17	antibiotics	O
18	(	O
19	multiple	O
20	-	O
21	resistant	O
22	)	O
23	and	O
24	in	O
25	strains	O
26	of	O
27	the	O
28	83A	O
29	complex	O
30	was	O
31	noticed	O
32	.	O

1	D	O
2	.	O

1	Several	O
2	7SL	O
3	RNA	O
4	-	O
5	encoding	O
6	sequences	O
7	and	O
8	various	O
9	intergenic	O
10	spacers	O
11	were	O
12	amplified	O
13	from	O
14	the	O
15	individual	O
16	HindIII	O
17	fragments	O
18	of	O
19	about	O
20	1	O
21	.	O
22	3	O
23	and	O
24	2	O
25	.	O
26	8	O
27	kb	O
28	.	O

1	Multifunctional	B
2	protein	I
3	kinase	I
4	(	O
5	MFPK	O
6	)	O
7	phosphorylates	O
8	ATP	B
9	-	I
10	citrate	I
11	lyase	I
12	on	O
13	peptide	O
14	B	O
15	on	O
16	two	O
17	sites	O
18	,	O
19	BT	O
20	and	O
21	BS	O
22	,	O
23	on	O
24	threonine	O
25	and	O
26	serine	O
27	,	O
28	respectively	O
29	,	O
30	inhibitor	O
31	2	O
32	on	O
33	a	O
34	threonyl	O
35	residue	O
36	,	O
37	and	O
38	glycogen	B
39	synthase	I
40	at	O
41	sites	O
42	2	O
43	and	O
44	3	O
45	.	O

1	Component	O
2	P100	O
3	was	O
4	associated	O
5	with	O
6	a	O
7	frontal	O
8	negativity	O
9	of	O
10	similar	O
11	latency	O
12	favoring	O
13	the	O
14	hypothesis	O
15	of	O
16	a	O
17	dipolar	O
18	occipital	O
19	generator	O
20	.	O

1	When	O
2	blood	O
3	samples	O
4	of	O
5	patients	O
6	with	O
7	hyperbilirubinemia	O
8	were	O
9	analyzed	O
10	,	O
11	direct	O
12	measurement	O
13	of	O
14	ZPP	O
15	by	O
16	this	O
17	fluorimeter	O
18	yielded	O
19	significantly	O
20	higher	O
21	levels	O
22	than	O
23	did	O
24	an	O
25	alternate	O
26	extraction	O
27	method	O
28	.	O

1	To	O
2	define	O
3	the	O
4	mechanism	O
5	responsible	O
6	for	O
7	the	O
8	loss	O
9	of	O
10	transcription	O
11	elongation	O
12	blockage	O
13	and	O
14	resulting	O
15	c	B
16	-	I
17	myc	I
18	deregulation	I
19	in	O
20	Burkitt	O
21	'	O
22	s	O
23	lymphoma	O
24	,	O
25	we	O
26	analyzed	O
27	transcription	O
28	patterns	O
29	after	O
30	transfer	O
31	of	O
32	normal	O
33	and	O
34	Burkitt	O
35	'	O
36	s	O
37	lymphoma	O
38	c	B
39	-	I
40	myc	I
41	alleles	I
42	into	O
43	murine	O
44	cells	O
45	and	O
46	Xenopus	O
47	oocyte	O
48	germinal	O
49	vesicles	O
50	.	O

1	Stable	O
2	expression	O
3	of	O
4	the	O
5	chimeric	O
6	alpha	O
7	i	O
8	(	O
9	54	O
10	)/	O
11	s	O
12	polypeptide	O
13	in	O
14	Chinese	O
15	hamster	O
16	ovary	O
17	(	O
18	CHO	O
19	)	O
20	cells	O
21	constitutively	O
22	increased	O
23	both	O
24	cAMP	O
25	synthesis	O
26	and	O
27	cAMP	B
28	-	I
29	dependent	I
30	protein	I
31	kinase	I
32	activity	O
33	.	O

1	Prevention	O
2	of	O
3	acute	O
4	paraquat	O
5	toxicity	O
6	in	O
7	rats	O
8	by	O
9	superoxide	B
10	dismutase	I
11	.	O

1	We	O
2	have	O
3	initiated	O
4	studies	O
5	to	O
6	identify	O
7	candidate	O
8	signal	O
9	transducers	O
10	that	O
11	associate	O
12	with	O
13	the	O
14	cytosolic	O
15	domain	O
16	(	O
17	cd	O
18	)	O
19	of	O
20	the	O
21	IL	B
22	-	I
23	1R	I
24	.	O

1	CONCLUSION	O
2	:	O
3	The	O
4	probability	O
5	of	O
6	cardiopulmonary	O
7	complications	O
8	increases	O
9	significantly	O
10	when	O
11	patients	O
12	develop	O
13	class	O
14	1	O
15	HELLP	O
16	syndrome	O
17	.	O

1	The	O
2	human	O
3	insulin	B
4	-	I
5	like	I
6	growth	I
7	factor	I
8	II	I
9	(	I
10	IGF	I
11	-	I
12	II	I
13	)	I
14	gene	I
15	contains	O
16	four	O
17	promoters	O
18	(	O
19	P1	O
20	,	O
21	P2	O
22	,	O
23	P3	O
24	and	O
25	P4	O
26	).	O

1	Cytohesin	O
2	-	O
3	1	O
4	,	O
5	a	O
6	protein	O
7	abundant	O
8	in	O
9	cells	O
10	of	O
11	the	O
12	immune	O
13	system	O
14	,	O
15	has	O
16	been	O
17	proposed	O
18	to	O
19	be	O
20	a	O
21	human	O
22	homolog	O
23	of	O
24	the	O
25	Saccharomyces	B
26	cerevisiae	I
27	Sec7	I
28	gene	I
29	product	I
30	,	O
31	which	O
32	is	O
33	crucial	O
34	in	O
35	protein	O
36	transport	O
37	.	O

1	The	O
2	localization	O
3	of	O
4	ZAP	B
5	-	I
6	70	I
7	to	O
8	the	O
9	cell	O
10	cortex	O
11	is	O
12	,	O
13	therefore	O
14	,	O
15	regulated	O
16	by	O
17	the	O
18	activity	O
19	of	O
20	SRC	B
21	-	I
22	family	I
23	kinases	I
24	,	O
25	independently	O
26	of	O
27	their	O
28	ability	O
29	to	O
30	phosphorylate	O
31	immunoreceptor	O
32	tyrosine	O
33	-	O
34	based	O
35	activation	O
36	motifs	O
37	of	O
38	the	O
39	TCR	B
40	.	O

1	Insertion	O
2	of	O
3	short	O
4	oligonucleotides	O
5	encoding	O
6	the	O
7	basic	O
8	amino	O
9	acid	O
10	motifs	O
11	726	O
12	-	O
13	GRKRKSP	O
14	-	O
15	732	O
16	from	O
17	IE175	O
18	and	O
19	500	O
20	-	O
21	VRPRKRR	O
22	-	O
23	506	O
24	from	O
25	IE110	O
26	into	O
27	deleted	O
28	cytoplasmic	O
29	forms	O
30	of	O
31	the	O
32	two	O
33	proteins	O
34	restored	O
35	the	O
36	karyophilic	O
37	phenotype	O
38	and	O
39	confirmed	O
40	that	O
41	these	O
42	motifs	O
43	are	O
44	both	O
45	necessary	O
46	and	O
47	sufficient	O
48	for	O
49	proper	O
50	nuclear	O
51	localization	O
52	.	O

1	A	O
2	human	O
3	recombinant	O
4	cDNA	O
5	clone	O
6	that	O
7	encoded	O
8	253	O
9	amino	O
10	acids	O
11	residues	O
12	of	O
13	a	O
14	zinc	O
15	-	O
16	finger	O
17	protein	O
18	(	O
19	THZif	O
20	-	O
21	1	O
22	)	O
23	was	O
24	cloned	O
25	by	O
26	screening	O
27	a	O
28	cDNA	O
29	library	O
30	prepared	O
31	from	O
32	human	O
33	promyelocytic	O
34	leukemia	O
35	HL60	O
36	cells	O
37	with	O
38	synthetic	O
39	oligodeoxynucleotide	O
40	probes	O
41	that	O
42	corresponded	O
43	to	O
44	the	O
45	amino	O
46	acid	O
47	sequences	O
48	of	O
49	tryptic	O
50	peptides	O
51	derived	O
52	from	O
53	the	O
54	DNA	O
55	-	O
56	binding	O
57	protein	O
58	specific	O
59	for	O
60	the	O
61	nuclease	O
62	-	O
63	hypersensitive	O
64	element	O
65	(	O
66	NHE	O
67	)	O
68	of	O
69	the	O
70	human	O
71	c	B
72	-	I
73	myc	I
74	gene	I
75	.	O

1	The	O
2	workup	O
3	included	O
4	skin	O
5	tests	O
6	(	O
7	up	O
8	to	O
9	1	O
10	microgram	O
11	/	O
12	ml	O
13	,	O
14	Pharmacia	O
15	),	O
16	measurement	O
17	of	O
18	specific	O
19	serum	O
20	IgE	B
21	with	O
22	RAST	O
23	-	O
24	CAP	O
25	(	O
26	Pharmacia	O
27	),	O
28	and	O
29	CAST	O
30	with	O
31	three	O
32	concentrations	O
33	of	O
34	bee	O
35	(	O
36	Apis	O
37	mellifera	O
38	)	O
39	and	O
40	wasp	O
41	(	O
42	Vespula	O
43	spec	O
44	.)	O
45	venom	O
46	(	O
47	Aquagen	O
48	ALK	O
49	).	O

1	IMPLICATIONS	O
2	:	O
3	Given	O
4	the	O
5	small	O
6	size	O
7	of	O
8	this	O
9	study	O
10	and	O
11	the	O
12	inconsistency	O
13	of	O
14	results	O
15	among	O
16	the	O
17	few	O
18	prospective	O
19	studies	O
20	of	O
21	ovarian	O
22	cancer	O
23	conducted	O
24	to	O
25	test	O
26	these	O
27	associations	O
28	,	O
29	replications	O
30	of	O
31	these	O
32	findings	O
33	are	O
34	highly	O
35	desirable	O
36	.	O

1	The	O
2	opioid	O
3	antagonist	O
4	naltrexone	O
5	(	O
6	0	O
7	.	O
8	01	O
9	-	O
10	1	O
11	.	O
12	0	O
13	mg	O
14	/	O
15	kg	O
16	)	O
17	antagonized	O
18	the	O
19	discriminative	O
20	stimulus	O
21	effects	O
22	of	O
23	heroin	O
24	,	O
25	but	O
26	naltrexone	O
27	at	O
28	doses	O
29	up	O
30	to	O
31	10	O
32	mg	O
33	/	O
34	kg	O
35	had	O
36	no	O
37	effect	O
38	on	O
39	the	O
40	discriminative	O
41	stimulus	O
42	effects	O
43	of	O
44	cocaine	O
45	.	O

1	The	O
2	RAD18	O
3	gene	O
4	open	O
5	reading	O
6	frame	O
7	encodes	O
8	a	O
9	protein	O
10	of	O
11	487	O
12	amino	O
13	acids	O
14	,	O
15	with	O
16	a	O
17	calculated	O
18	molecular	O
19	weight	O
20	of	O
21	55	O
22	,	O
23	512	O
24	.	O

1	Three	O
2	missense	O
3	mutants	O
4	in	O
5	subunit	O
6	a	O
7	of	O
8	the	O
9	Escherichia	B
10	coli	I
11	F1F0	I
12	-	I
13	ATPase	I
14	were	O
15	isolated	O
16	and	O
17	characterized	O
18	after	O
19	hydroxylamine	O
20	mutagenesis	O
21	of	O
22	a	O
23	plasmid	O
24	carrying	O
25	the	O
26	uncB	O
27	(	O
28	subunit	O
29	a	O
30	)	O
31	gene	O
32	.	O

1	Letter	O
2	:	O
3	Aryl	B
4	hydrocarbon	I
5	hydroxylase	I
6	and	O
7	smoking	O
8	.	O

1	Initiation	O
2	of	O
3	translation	O
4	of	O
5	the	O
6	human	O
7	hepatitis	O
8	C	O
9	virus	O
10	(	O
11	HCV	O
12	)	O
13	RNA	O
14	genome	O
15	occurs	O
16	by	O
17	internal	O
18	ribosome	O
19	entry	O
20	into	O
21	the	O
22	5	O
23	'	O
24	noncoding	O
25	region	O
26	(	O
27	5	O
28	'	O
29	NCR	O
30	)	O
31	in	O
32	a	O
33	cap	O
34	-	O
35	independent	O
36	manner	O
37	.	O

1	S6K2	O
2	is	O
3	highly	O
4	homologous	O
5	to	O
6	S6K1	O
7	in	O
8	the	O
9	core	O
10	kinase	O
11	and	O
12	linker	O
13	regulatory	O
14	domains	O
15	but	O
16	differs	O
17	from	O
18	S6K1	O
19	in	O
20	the	O
21	N	O
22	-	O
23	and	O
24	C	O
25	-	O
26	terminal	O
27	regions	O
28	and	O
29	is	O
30	differently	O
31	localized	O
32	primarily	O
33	to	O
34	the	O
35	nucleus	O
36	because	O
37	of	O
38	a	O
39	C	O
40	-	O
41	terminal	O
42	nuclear	O
43	localization	O
44	signal	O
45	unique	O
46	to	O
47	S6K2	O
48	.	O

1	METHODS	O
2	:	O
3	Forty	O
4	-	O
5	nine	O
6	cases	O
7	with	O
8	intrahepatic	O
9	multiple	O
10	nodules	O
11	of	O
12	HCC	O
13	,	O
14	by	O
15	gross	O
16	examination	O
17	,	O
18	among	O
19	184	O
20	consecutive	O
21	resected	O
22	HCCs	O
23	were	O
24	examined	O
25	clinicopathologically	O
26	.	O

1	The	O
2	feed	O
3	given	O
4	to	O
5	young	O
6	broiler	O
7	chickens	O
8	was	O
9	contaminated	O
10	artificially	O
11	with	O
12	Salmonella	O
13	kedougou	O
14	,	O
15	a	O
16	serotype	O
17	associated	O
18	with	O
19	both	O
20	subclinical	O
21	infections	O
22	in	O
23	commercially	O
24	reared	O
25	chickens	O
26	and	O
27	food	O
28	poisoning	O
29	in	O
30	humans	O
31	.	O

1	Four	O
2	of	O
3	these	O
4	five	O
5	subjects	O
6	also	O
7	performed	O
8	mixed	O
9	sequences	O
10	under	O
11	conditional	O
12	control	O
13	of	O
14	the	O
15	words	O
16	(	O
17	e	O
18	.	O
19	g	O
20	.,	O
21	A1	B
22	----	I
23	B2	I
24	----	I
25	A3	I
26	----	I
27	B4	I
28	----	I
29	A5	I
30	and	O
31	its	O
32	reversal	O
33	),	O
34	verifying	O
35	that	O
36	the	O
37	stimuli	O
38	which	O
39	occupied	O
40	the	O
41	same	O
42	position	O
43	in	O
44	each	O
45	sequence	O
46	were	O
47	members	O
48	of	O
49	the	O
50	same	O
51	class	O
52	.	O

1	OKT3	O
2	prophylaxis	O
3	improves	O
4	long	O
5	-	O
6	term	O
7	renal	O
8	graft	O
9	survival	O
10	in	O
11	high	O
12	-	O
13	risk	O
14	patients	O
15	as	O
16	compared	O
17	to	O
18	cyclosporine	O
19	:	O
20	combined	O
21	results	O
22	from	O
23	the	O
24	prospective	O
25	,	O
26	randomized	O
27	Belgian	O
28	and	O
29	US	O
30	studies	O
31	.	O

1	The	O
2	activity	O
3	of	O
4	6	O
5	-	O
6	fluoroquinolones	O
7	and	O
8	their	O
9	nonfluorinated	O
10	derivatives	O
11	is	O
12	compared	O
13	in	O
14	general	O
15	.	O

1	The	O
2	artery	O
3	cuff	O
4	was	O
5	slightly	O
6	superior	O
7	to	O
8	the	O
9	fat	O
10	wrap	O
11	,	O
12	particularly	O
13	in	O
14	having	O
15	fewer	O
16	adhesions	O
17	and	O
18	a	O
19	better	O
20	histological	O
21	picture	O
22	.	O

1	The	O
2	isolation	O
3	of	O
4	this	O
5	gene	O
6	was	O
7	based	O
8	on	O
9	the	O
10	identification	O
11	of	O
12	the	O
13	Y	O
14	-	O
15	231	O
16	cosmid	O
17	that	O
18	contains	O
19	CpG	O
20	rich	O
21	sequences	O
22	(	O
23	HTF	O
24	islands	O
25	)	O
26	in	O
27	its	O
28	human	O
29	insert	O
30	.	O

1	One	O
2	hundred	O
3	fifty	O
4	patients	O
5	were	O
6	reviewed	O
7	at	O
8	1	O
9	year	O
10	after	O
11	arthroplasty	O
12	.	O

1	These	O
2	fusions	O
3	are	O
4	contained	O
5	on	O
6	plasmids	O
7	which	O
8	have	O
9	both	O
10	yeast	O
11	and	O
12	E	O
13	.	O
14	coli	O
15	replication	O
16	origins	O
17	and	O
18	selectable	O
19	markers	O
20	and	O
21	,	O
22	therefore	O
23	,	O
24	can	O
25	be	O
26	used	O
27	to	O
28	transform	O
29	either	O
30	yeast	O
31	or	O
32	E	O
33	.	O
34	coli	O
35	cells	O
36	.	O

1	Furthermore	O
2	,	O
3	we	O
4	have	O
5	identified	O
6	a	O
7	soluble	O
8	form	O
9	of	O
10	ERp57	O
11	/	O
12	GRP58	O
13	by	O
14	Western	O
15	blotting	O
16	and	O
17	biosynthetic	O
18	labeling	O
19	.	O

1	Primer	O
2	extension	O
3	experiments	O
4	revealed	O
5	a	O
6	strong	O
7	transcription	O
8	initiation	O
9	site	O
10	102	O
11	bp	O
12	upstream	O
13	of	O
14	the	O
15	translational	O
16	start	O
17	site	O
18	.	O

1	Therefore	O
2	,	O
3	the	O
4	impaired	O
5	floor	O
6	plate	O
7	development	O
8	in	O
9	oep	O
10	mutants	O
11	is	O
12	not	O
13	caused	O
14	by	O
15	the	O
16	absence	O
17	of	O
18	the	O
19	floor	O
20	plate	O
21	inducer	O
22	shh	O
23	.	O

1	We	O
2	recently	O
3	characterized	O
4	a	O
5	single	O
6	yeast	B
7	hnRNP	I
8	methyltransferase	I
9	(	O
10	HMT1	O
11	).	O

1	While	O
2	the	O
3	latter	O
4	corresponded	O
5	to	O
6	a	O
7	protein	O
8	of	O
9	824	O
10	amino	O
11	acids	O
12	,	O
13	an	O
14	upstream	O
15	open	O
16	reading	O
17	frame	O
18	(	O
19	uORF	O
20	)	O
21	within	O
22	the	O
23	5	O
24	'	O
25	leader	O
26	could	O
27	potentially	O
28	encode	O
29	a	O
30	54	O
31	amino	O
32	acid	O
33	peptide	O
34	.	O

1	High	O
2	radial	O
3	r	O
4	values	O
5	with	O
6	small	O
7	standard	O
8	deviations	O
9	were	O
10	observed	O
11	in	O
12	normal	O
13	LV	O
14	(	O
15	0	O
16	.	O
17	972	O
18	+/-	O
19	0	O
20	.	O
21	016	O
22	)	O
23	and	O
24	in	O
25	non	O
26	-	O
27	MI	O
28	regions	O
29	(	O
30	0	O
31	.	O
32	964	O
33	+/-	O
34	0	O
35	.	O
36	018	O
37	),	O
38	indicating	O
39	temporally	O
40	homogeneous	O
41	radial	O
42	shortening	O
43	.	O

1	Additional	O
2	studies	O
3	with	O
4	new	O
5	and	O
6	reprocessed	O
7	regenerated	O
8	cellulose	O
9	dialyzers	O
10	comparing	O
11	450	O
12	and	O
13	220	O
14	mL	O
15	/	O
16	min	O
17	blood	O
18	flow	O
19	rates	O
20	at	O
21	10	O
22	minutes	O
23	showed	O
24	no	O
25	change	O
26	in	O
27	BTG	O
28	.	O

1	The	O
2	persistence	O
3	of	O
4	members	O
5	of	O
6	the	O
7	prostigmatid	O
8	families	O
9	Tydeidae	O
10	,	O
11	Nanorchestidae	O
12	and	O
13	Tarsonemidae	O
14	in	O
15	the	O
16	moisture	O
17	-	O
18	deficient	O
19	90	O
20	%-	O
21	concentration	O
22	treatments	O
23	supports	O
24	previous	O
25	evidence	O
26	of	O
27	adaptations	O
28	to	O
29	low	O
30	-	O
31	water	O
32	-	O
33	content	O
34	habitats	O
35	.	O

1	There	O
2	was	O
3	no	O
4	further	O
5	increase	O
6	in	O
7	oxygen	O
8	consumption	O
9	when	O
10	these	O
11	subjects	O
12	breathed	O
13	with	O
14	inspiratory	O
15	pressures	O
16	above	O
17	SIP	O
18	.	O

1	Activation	O
2	of	O
3	c	B
4	-	I
5	fos	I
6	gene	I
7	expression	O
8	by	O
9	a	O
10	kinase	O
11	-	O
12	deficient	O
13	epidermal	B
14	growth	I
15	factor	I
16	receptor	I
17	.	O

1	Respiratory	O
2	interaction	O
3	after	O
4	spinal	O
5	anesthesia	O
6	and	O
7	sedation	O
8	with	O
9	midazolam	O
10	.	O

1	Ex	O
2	vivo	O
3	MAO	O
4	inhibition	O
5	data	O
6	indicated	O
7	DPGPEA	O
8	to	O
9	be	O
10	an	O
11	inhibitor	O
12	of	O
13	MAO	B
14	-	I
15	B	I
16	,	O
17	although	O
18	the	O
19	effect	O
20	was	O
21	much	O
22	weaker	O
23	than	O
24	seen	O
25	with	O
26	tranylcypromine	O
27	or	O
28	pargyline	O
29	.	O

1	Effects	O
2	of	O
3	single	O
4	and	O
5	combined	O
6	maltose	O
7	tetrapalmitate	O
8	immunotherapy	O
9	,	O
10	cyclophosphamide	O
11	chemotherapy	O
12	and	O
13	radiotherapy	O
14	on	O
15	ethyl	O
16	carbamate	O
17	accelerated	O
18	primary	O
19	lung	O
20	cancer	O
21	in	O
22	A	O
23	/	O
24	J	O
25	mice	O
26	.	O

1	The	O
2	Italian	O
3	Lung	O
4	Cancer	O
5	Task	O
6	Force	O
7	(	O
8	FONICAP	O
9	).	O

1	The	O
2	secondary	O
3	,	O
4	but	O
5	not	O
6	the	O
7	primary	O
8	,	O
9	antibody	O
10	responses	O
11	of	O
12	male	O
13	C57Bl	O
14	/	O
15	6	O
16	mice	O
17	were	O
18	higher	O
19	among	O
20	mice	O
21	housed	O
22	alone	O
23	compared	O
24	to	O
25	mice	O
26	housed	O
27	in	O
28	groups	O
29	;	O
30	differences	O
31	were	O
32	observed	O
33	for	O
34	both	O
35	IgM	B
36	and	O
37	IgG	B
38	anti	I
39	-	I
40	KLH	I
41	antibodies	I
42	.	O

1	A	O
2	36	O
3	-	O
4	kDa	O
5	protein	O
6	that	O
7	was	O
8	localized	O
9	to	O
10	the	O
11	membrane	O
12	fraction	O
13	was	O
14	detected	O
15	in	O
16	minicells	O
17	containing	O
18	plasmids	O
19	with	O
20	the	O
21	ftsN	O
22	gene	O
23	,	O
24	confirming	O
25	that	O
26	FtsN	O
27	was	O
28	a	O
29	membrane	O
30	protein	O
31	.	O

1	The	O
2	partial	O
3	sequence	O
4	of	O
5	the	O
6	62	O
7	-	O
8	kDa	O
9	nuclear	O
10	pore	O
11	glycoprotein	O
12	shows	O
13	little	O
14	similarity	O
15	to	O
16	other	O
17	characterized	O
18	proteins	O
19	and	O
20	elucidates	O
21	structural	O
22	features	O
23	of	O
24	a	O
25	member	O
26	of	O
27	the	O
28	family	O
29	of	O
30	nuclear	O
31	pore	O
32	glycoproteins	O
33	.	O

1	Changing	O
2	and	O
3	predicting	O
4	doses	O
5	of	O
6	Cs137	O
7	irradiation	O

1	The	O
2	availability	O
3	of	O
4	potent	O
5	regulatory	O
6	DNA	O
7	cassettes	O
8	harboring	O
9	the	O
10	murine	B
11	D1A	I
12	gene	I
13	promoter	I
14	could	O
15	aid	O
16	testing	O
17	the	O
18	neuronal	O
19	-	O
20	specific	O
21	expression	O
22	of	O
23	transgenes	O
24	in	O
25	vivo	O
26	.	O

1	Myelomatous	O
2	pleural	O
3	effusion	O
4	as	O
5	presentation	O
6	form	O
7	of	O
8	multiple	O
9	myeloma	O

1	Gene	O
2	silencing	O
3	associated	O
4	with	O
5	repeated	O
6	DNA	O
7	sequences	O
8	has	O
9	been	O
10	reported	O
11	for	O
12	many	O
13	eukaryotes	O
14	,	O
15	including	O
16	plants	O
17	.	O

1	In	O
2	order	O
3	to	O
4	decipher	O
5	the	O
6	pathway	O
7	that	O
8	leads	O
9	to	O
10	Hox	B
11	gene	I
12	induction	O
13	,	O
14	we	O
15	have	O
16	investigated	O
17	whether	O
18	a	O
19	Hox	B
20	gene	I
21	regulator	I
22	,	O
23	the	O
24	leucine	O
25	zipper	O
26	transcription	O
27	factor	O
28	MafB	O
29	/	O
30	Kr	O
31	,	O
32	is	O
33	itself	O
34	transcriptionally	O
35	regulated	O
36	by	O
37	the	O
38	environmental	O
39	signals	O
40	.	O

1	All	O
2	four	O
3	of	O
4	the	O
5	genes	O
6	have	O
7	a	O
8	similar	O
9	structure	O
10	,	O
11	with	O
12	the	O
13	receptor	O
14	protein	O
15	encoded	O
16	in	O
17	a	O
18	single	O
19	exon	O
20	.	O

1	Current	O
2	diagnostic	O
3	uses	O
4	of	O
5	computerized	O
6	tomography	O
7	in	O
8	clinical	O
9	medicine	O
10	.	O

1	Role	O
2	of	O
3	the	O
4	transcription	O
5	start	O
6	site	O
7	core	O
8	region	O
9	and	O
10	transcription	O
11	factor	O
12	YY1	B
13	in	O
14	Rous	O
15	sarcoma	O
16	virus	O
17	long	O
18	terminal	O
19	repeat	O
20	promoter	O
21	activity	O
22	.	O

1	Mutations	O
2	in	O
3	UPF1	O
4	lead	O
5	to	O
6	the	O
7	selective	O
8	stabilization	O
9	of	O
10	mRNAs	O
11	containing	O
12	early	O
13	nonsense	O
14	mutations	O
15	without	O
16	affecting	O
17	the	O
18	decay	O
19	rates	O
20	of	O
21	most	O
22	other	O
23	mRNAs	O
24	.	O

1	Muscle	O
2	action	O
3	potential	O
4	and	O
5	masticatory	O
6	rhythm	O
7	of	O
8	anterior	O
9	temporal	O
10	and	O
11	masseter	O
12	muscles	O
13	in	O
14	children	O
15	and	O
16	adults	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	contractile	O
6	action	O
7	of	O
8	arachidonic	O
9	acid	O
10	,	O
11	via	O
12	a	O
13	presumed	O
14	cyclooxygenase	B
15	product	I
16	that	O
17	mediated	O
18	the	O
19	contractions	O
20	caused	O
21	by	O
22	both	O
23	TF	O
24	and	O
25	EGF	B
26	,	O
27	was	O
28	not	O
29	blocked	O
30	by	O
31	any	O
32	of	O
33	the	O
34	signal	O
35	pathway	O
36	probe	O
37	inhibitors	O
38	.	O

1	The	O
2	strategies	O
3	by	O
4	which	O
5	hepatitis	O
6	B	O
7	and	O
8	hepatitis	O
9	D	O
10	can	O
11	be	O
12	diminished	O
13	and	O
14	eventually	O
15	eliminated	O
16	are	O
17	:	O
18	immunization	O
19	,	O
20	measures	O
21	to	O
22	prevent	O
23	exposure	O
24	to	O
25	infective	O
26	blood	O
27	or	O
28	blood	O
29	derivatives	O
30	and	O
31	education	O
32	(	O
33	in	O
34	particular	O
35	awareness	O
36	that	O
37	hepatitis	O
38	B	O
39	is	O
40	a	O
41	sexually	O
42	transmitted	O
43	disease	O
44	).	O

1	The	O
2	promoter	O
3	region	O
4	showed	O
5	no	O
6	consensus	O
7	TATA	O
8	box	O
9	but	O
10	it	O
11	contains	O
12	CCAAT	O
13	and	O
14	CreA	O
15	boxes	O
16	known	O
17	to	O
18	be	O
19	involved	O
20	in	O
21	both	O
22	stress	O
23	and	O
24	carbon	O
25	-	O
26	catabolite	O
27	regulation	O
28	of	O
29	fungal	O
30	promoters	O
31	.	O

1	The	O
2	variability	O
3	is	O
4	most	O
5	likely	O
6	a	O
7	result	O
8	of	O
9	alternative	O
10	splicing	O
11	of	O
12	exons	O
13	from	O
14	the	O
15	primary	O
16	elastin	B
17	transcripts	I
18	.	O

1	During	O
2	an	O
3	8	O
4	-	O
5	wk	O
6	follow	O
7	-	O
8	up	O
9	,	O
10	parasites	O
11	reappeared	O
12	in	O
13	10	O
14	patients	O
15	,	O
16	5	O
17	after	O
18	each	O
19	drug	O
20	,	O
21	between	O
22	1	O
23	and	O
24	7	O
25	wk	O
26	after	O
27	treatment	O
28	.	O

1	Utilizing	O
2	transient	O
3	transfection	O
4	studies	O
5	in	O
6	HepG2	O
7	cells	O
8	,	O
9	we	O
10	have	O
11	shown	O
12	that	O
13	deletion	O
14	of	O
15	the	O
16	factor	B
17	VIII	I
18	promoter	I
19	sequences	O
20	distal	O
21	to	O
22	nucleotide	O
23	-	O
24	44	O
25	results	O
26	in	O
27	a	O
28	significant	O
29	but	O
30	small	O
31	increase	O
32	in	O
33	promoter	O
34	activity	O
35	.	O

1	Spleen	O
2	weight	O
3	in	O
4	rats	O
5	during	O
6	tumour	O
7	growth	O
8	and	O
9	in	O
10	homograft	O
11	rejection	O
12	.	O

1	The	O
2	new	O
3	FIGO	O
4	definition	O
5	of	O
6	cervical	O
7	cancer	O
8	stage	O
9	IA	O
10	:	O
11	a	O
12	critique	O
13	.	O

1	Cut	O
2	-	O
3	off	O
4	levels	O
5	that	O
6	define	O
7	abnormality	O
8	are	O
9	rather	O
10	arbitrary	O
11	and	O
12	this	O
13	decreases	O
14	the	O
15	specificity	O
16	of	O
17	the	O
18	test	O
19	in	O
20	apparently	O
21	healthy	O
22	patients	O
23	.	O

1	Together	O
2	,	O
3	our	O
4	data	O
5	suggest	O
6	that	O
7	the	O
8	TR2	B
9	orphan	I
10	receptor	I
11	may	O
12	be	O
13	a	O
14	master	O
15	regulator	O
16	in	O
17	modulating	O
18	the	O
19	activation	O
20	of	O
21	two	O
22	key	O
23	HREs	O
24	,	O
25	RARE	B
26	beta	I
27	and	O
28	CRBPIIp	O
29	,	O
30	involved	O
31	in	O
32	the	O
33	retinoic	O
34	acid	O
35	signal	O
36	transduction	O
37	pathway	O
38	.	O

1	Examination	O
2	of	O
3	ANCA	O
4	is	O
5	not	O
6	only	O
7	a	O
8	significant	O
9	contribution	O
10	towards	O
11	a	O
12	more	O
13	accurate	O
14	diagnosis	O
15	of	O
16	renal	O
17	vasculitis	O
18	,	O
19	but	O
20	also	O
21	an	O
22	indicator	O
23	of	O
24	the	O
25	activity	O
26	of	O
27	the	O
28	disease	O
29	and	O
30	thus	O
31	of	O
32	the	O
33	effectiveness	O
34	of	O
35	immunosuppressive	O
36	treatment	O
37	.	O

1	Use	O
2	of	O
3	prostaglandin	O
4	F2	O
5	alpha	O
6	(	O
7	PGF2	O
8	alpha	O
9	)	O
10	in	O
11	cattle	O
12	breeding	O
13	.	O

1	Furthermore	O
2	,	O
3	plasma	O
4	fibrinogen	B
5	levels	O
6	increased	O
7	by	O
8	a	O
9	mean	O
10	of	O
11	17	O
12	.	O
13	6	O
14	%,	O
15	a	O
16	potentially	O
17	adverse	O
18	effect	O
19	of	O
20	gemfibrozil	O
21	that	O
22	has	O
23	not	O
24	been	O
25	previously	O
26	reported	O
27	.	O

1	The	O
2	ORs	O
3	of	O
4	GC	O
5	,	O
6	adjusted	O
7	for	O
8	age	O
9	and	O
10	sex	O
11	,	O
12	varied	O
13	from	O
14	17	O
15	.	O
16	1	O
17	,	O
18	for	O
19	those	O
20	with	O
21	baseline	O
22	diagnoses	O
23	of	O
24	superficial	O
25	intestinal	O
26	metaplasia	O
27	(	O
28	IM	O
29	),	O
30	to	O
31	29	O
32	.	O
33	3	O
34	,	O
35	for	O
36	those	O
37	with	O
38	deep	O
39	IM	O
40	or	O
41	mild	O
42	dysplasia	O
43	(	O
44	DYS	O
45	)	O
46	or	O
47	IM	O
48	with	O
49	glandular	O
50	atrophy	O
51	and	O
52	neck	O
53	hyperplasia	O
54	,	O
55	to	O
56	104	O
57	.	O
58	2	O
59	,	O
60	for	O
61	those	O
62	with	O
63	moderate	O
64	or	O
65	severe	O
66	DYS	O
67	,	O
68	as	O
69	compared	O
70	with	O
71	subjects	O
72	with	O
73	superficial	O
74	gastritis	O
75	(	O
76	SG	O
77	)	O
78	or	O
79	chronic	O
80	atrophic	O
81	gastritis	O
82	(	O
83	CAG	O
84	)	O
85	at	O
86	baseline	O
87	.	O

1	No	O
2	significant	O
3	correlation	O
4	was	O
5	found	O
6	between	O
7	LVM	O
8	or	O
9	wall	O
10	thickness	O
11	and	O
12	body	O
13	surface	O
14	area	O
15	,	O
16	age	O
17	,	O
18	blood	O
19	pressure	O
20	,	O
21	heart	O
22	rate	O
23	,	O
24	cardiac	O
25	output	O
26	,	O
27	total	O
28	peripheral	O
29	resistance	O
30	and	O
31	left	O
32	ventricular	O
33	systolic	O
34	wall	O
35	stress	O
36	,	O
37	whereas	O
38	CD25	O
39	was	O
40	correlated	O
41	with	O
42	urinary	O
43	catecholamines	O
44	only	O
45	in	O
46	hypertensive	O
47	patients	O
48	(	O
49	r	O
50	=	O
51	0	O
52	.	O
53	606	O
54	,	O
55	p	O
56	less	O
57	than	O
58	0	O
59	.	O
60	001	O
61	).	O

1	In	O
2	a	O
3	gntR	O
4	deletion	O
5	mutant	O
6	,	O
7	the	O
8	expression	O
9	of	O
10	a	O
11	chromosomal	O
12	gntT	O
13	::	O
14	lacZ	B
15	fusion	O
16	is	O
17	both	O
18	high	O
19	and	O
20	constitutive	O
21	,	O
22	confirming	O
23	that	O
24	GntR	O
25	is	O
26	the	O
27	negative	O
28	regulator	O
29	of	O
30	gntT	O
31	.	O

1	In	O
2	the	O
3	electrophoresis	O
4	mobility	O
5	shift	O
6	assay	O
7	using	O
8	nuclear	O
9	extracts	O
10	of	O
11	the	O
12	myogenic	O
13	cells	O
14	,	O
15	MyoD	B
16	and	O
17	myogenin	O
18	bound	O
19	to	O
20	the	O
21	right	O
22	E	O
23	-	O
24	box	O
25	in	O
26	the	O
27	enhancer	O
28	region	O
29	of	O
30	the	O
31	MCK	B
32	gene	I
33	even	O
34	in	O
35	the	O
36	presence	O
37	of	O
38	BMP	B
39	-	I
40	2	I
41	.	O

1	Similar	O
2	experiments	O
3	with	O
4	TR	O
5	support	O
6	the	O
7	high	O
8	affinity	O
9	of	O
10	RIP140	O
11	to	O
12	the	O
13	RXR	B
14	subunit	I
15	and	O
16	also	O
17	suggest	O
18	that	O
19	either	O
20	partner	O
21	in	O
22	the	O
23	TR	O
24	/	O
25	RXR	B
26	heterodimer	O
27	can	O
28	independently	O
29	respond	O
30	to	O
31	ligand	O
32	.	O

1	In	O
2	contrast	O
3	,	O
4	a	O
5	Maf	B
6	-	I
7	related	I
8	protein	I
9	,	O
10	Nrl	O
11	,	O
12	completely	O
13	mimicked	O
14	c	B
15	-	I
16	Maf	I
17	actions	O
18	.	O

1	The	O
2	DNA	O
3	sequence	O
4	adjacent	O
5	to	O
6	the	O
7	lacZ	B
8	gene	I
9	has	O
10	been	O
11	determined	O
12	for	O
13	91	O
14	vegetative	O
15	fusion	O
16	genes	O
17	whose	O
18	products	O
19	have	O
20	been	O
21	localized	O
22	and	O
23	for	O
24	43	O
25	meiotically	O
26	induced	O
27	fusions	O
28	.	O

1	Preimmune	O
2	IgG	B
3	,	O
4	anti	B
5	-	I
6	GalT	I
7	Fab	I
8	fragments	O
9	,	O
10	irrelevant	O
11	polymers	O
12	and	O
13	monomeric	O
14	N	O
15	-	O
16	acetylglucosamine	O
17	had	O
18	no	O
19	effect	O
20	.	O

1	This	O
2	philosophy	O
3	was	O
4	instituted	O
5	for	O
6	the	O
7	compound	O
8	RP	O
9	73401	O
10	,	O
11	a	O
12	specific	O
13	phosphodiesterase	O
14	IV	O
15	inhibitor	O
16	,	O
17	that	O
18	was	O
19	being	O
20	developed	O
21	simultaneously	O
22	for	O
23	delivery	O
24	by	O
25	both	O
26	oral	O
27	and	O
28	pulmonary	O
29	routes	O
30	of	O
31	administration	O
32	.	O

1	A	O
2	platelet	B
3	-	I
4	derived	I
5	growth	I
6	factor	I
7	receptor	I
8	(	I
9	PDGF	I
10	-	I
11	R	I
12	)	O
13	phosphopeptide	O
14	containing	O
15	Tyr	O
16	-	O
17	857	O
18	does	O
19	not	O
20	bind	O
21	appreciably	O
22	to	O
23	the	O
24	Src	B
25	SH2	I
26	domain	I
27	,	O
28	suggesting	O
29	it	O
30	is	O
31	not	O
32	the	O
33	PDGF	B
34	-	I
35	R	I
36	binding	I
37	site	I
38	for	O
39	Src	B
40	as	O
41	previously	O
42	reported	O
43	.	O

1	An	O
2	open	O
3	-	O
4	label	O
5	,	O
6	placebo	O
7	-	O
8	controlled	O
9	,	O
10	randomized	O
11	,	O
12	two	O
13	-	O
14	way	O
15	crossover	O
16	study	O
17	was	O
18	performed	O
19	in	O
20	12	O
21	healthy	O
22	volunteers	O
23	(	O
24	between	O
25	20	O
26	and	O
27	44	O
28	years	O
29	of	O
30	age	O
31	)	O
32	to	O
33	assess	O
34	the	O
35	effect	O
36	of	O
37	orlistat	O
38	,	O
39	a	O
40	gastrointestinal	O
41	lipase	B
42	inhibitor	O
43	that	O
44	reduces	O
45	dietary	O
46	fat	O
47	absorption	O
48	and	O
49	is	O
50	being	O
51	developed	O
52	for	O
53	weight	O
54	control	O
55	in	O
56	obesity	O
57	,	O
58	on	O
59	the	O
60	absorption	O
61	of	O
62	vitamins	O
63	A	O
64	and	O
65	E	O
66	.	O

1	In	O
2	Experiment	O
3	II	O
4	,	O
5	as	O
6	performing	O
7	moderate	O
8	supine	O
9	cycling	O
10	(	O
11	55	O
12	%	O
13	VO2	O
14	max	O
15	)	O
16	for	O
17	50	O
18	minutes	O
19	under	O
20	several	O
21	LBNP	O
22	conditions	O
23	in	O
24	5	O
25	sedentary	O
26	women	O
27	,	O
28	there	O
29	were	O
30	correspondingly	O
31	similar	O
32	changing	O
33	manners	O
34	of	O
35	the	O
36	cardiovascular	O
37	adjustments	O
38	to	O
39	each	O
40	of	O
41	the	O
42	phases	O
43	given	O
44	in	O
45	Experiment	O
46	I	O
47	.	O

1	Early	O
2	treatment	O
3	mechanics	O
4	of	O
5	the	O
6	Class	O
7	II	O
8	division	O
9	2	O
10	malocclusion	O
11	.	O

1	The	O
2	mouse	B
3	M	I
4	-	I
5	lysozyme	I
6	downstream	O
7	enhancer	O
8	has	O
9	been	O
10	previously	O
11	characterized	O
12	on	O
13	several	O
14	levels	O
15	of	O
16	gene	O
17	regulation	O
18	.	O

1	RESULTS	O
2	:	O
3	Plasma	O
4	AVP	O
5	responses	O
6	to	O
7	osmotic	O
8	stimulation	O
9	,	O
10	and	O
11	non	O
12	-	O
13	osmotic	O
14	inhibition	O
15	by	O
16	drinking	O
17	,	O
18	were	O
19	normal	O
20	in	O
21	patients	O
22	with	O
23	compulsive	O
24	water	O
25	drinking	O
26	.	O

1	The	O
2	3	O
3	'	O
4	terminus	O
5	of	O
6	the	O
7	genome	O
8	can	O
9	be	O
10	folded	O
11	into	O
12	a	O
13	tRNA	B
14	-	I
15	like	I
16	secondary	O
17	structure	O
18	that	O
19	has	O
20	a	O
21	valine	O
22	anticodon	O
23	;	O
24	the	O
25	tRNA	B
26	-	I
27	like	I
28	structure	O
29	lacks	O
30	a	O
31	pseudoknot	O
32	in	O
33	the	O
34	aminoacyl	O
35	stem	O
36	,	O
37	a	O
38	feature	O
39	common	O
40	to	O
41	both	O
42	genera	O
43	of	O
44	tetraviruses	O
45	.	O

1	Replacement	O
2	of	O
3	residues	O
4	in	O
5	positions	O
6	+	O
7	3	O
8	(	O
9	His128Asn	O
10	)	O
11	and	O
12	+	O
13	2	O
14	(	O
15	Gln155Lys	O
16	)	O
17	of	O
18	the	O
19	reading	O
20	helices	O
21	of	O
22	fingers	O
23	2	O
24	and	O
25	3	O
26	,	O
27	respectively	O
28	,	O
29	prevented	O
30	binding	O
31	.	O

1	The	O
2	ability	O
3	of	O
4	A20	O
5	to	O
6	block	O
7	NF	B
8	-	I
9	kappaB	I
10	activation	O
11	was	O
12	mapped	O
13	to	O
14	its	O
15	C	O
16	-	O
17	terminal	O
18	zinc	O
19	finger	O
20	domain	O
21	.	O

1	Two	O
2	patients	O
3	were	O
4	treated	O
5	successfully	O
6	with	O
7	a	O
8	combination	O
9	of	O
10	metronidazole	O
11	(	O
12	a	O
13	tissue	O
14	amoebicide	O
15	)	O
16	and	O
17	diloxanide	O
18	(	O
19	a	O
20	lumenal	O
21	amoebicide	O
22	).	O

1	The	O
2	serine	B
3	/	I
4	threonine	I
5	kinase	I
6	Raf	I
7	-	I
8	1	I
9	functions	O
10	downstream	O
11	of	O
12	Rats	O
13	in	O
14	a	O
15	signal	O
16	transduction	O
17	cascade	O
18	which	O
19	transmits	O
20	mitogenic	O
21	stimuli	O
22	from	O
23	the	O
24	plasma	O
25	membrane	O
26	to	O
27	the	O
28	nucleus	O
29	.	O

1	RESULTS	O
2	:	O
3	For	O
4	E1	O
5	,	O
6	itraconazole	O
7	plasma	O
8	drug	O
9	concentration	O
10	extrapolated	O
11	to	O
12	time	O
13	zero	O
14	(	O
15	IV	O
16	dose	O
17	)	O
18	was	O
19	5	O
20	.	O
21	2	O
22	+/-	O
23	1	O
24	.	O
25	4	O
26	micrograms	O
27	/	O
28	ml	O
29	,	O
30	and	O
31	mean	O
32	residence	O
33	time	O
34	(	O
35	MRT	O
36	)	O
37	was	O
38	37	O
39	+/-	O
40	16	O
41	hours	O
42	.	O

1	The	O
2	spleen	O
3	rate	O
4	of	O
5	about	O
6	600	O
7	villagers	O
8	of	O
9	RK	O
10	I	O
11	examined	O
12	was	O
13	54	O
14	.	O
15	3	O
16	%	O
17	and	O
18	the	O
19	parasite	O
20	rate	O
21	13	O
22	.	O
23	2	O
24	%	O
25	before	O
26	the	O
27	drug	O
28	intervention	O
29	.	O

1	No	O
2	significant	O
3	differences	O
4	existed	O
5	between	O
6	the	O
7	two	O
8	age	O
9	groups	O
10	in	O
11	baseline	O
12	characteristics	O
13	,	O
14	including	O
15	treatment	O
16	protocol	O
17	,	O
18	performance	O
19	status	O
20	,	O
21	and	O
22	serum	O
23	lactate	B
24	dehydrogenase	I
25	(	O
26	LDH	O
27	)	O
28	level	O
29	.	O

1	In	O
2	terms	O
3	of	O
4	sequence	O
5	repetitions	O
6	,	O
7	seven	O
8	tandemly	O
9	repeated	O
10	copies	O
11	of	O
12	the	O
13	hexanucleotide	O
14	ATTGTT	O
15	and	O
16	three	O
17	flanking	O
18	regions	O
19	of	O
20	dyad	O
21	symmetry	O
22	were	O
23	detected	O
24	,	O
25	all	O
26	in	O
27	ORF	O
28	T3C	O
29	.	O

1	Effects	O
2	of	O
3	temperature	O
4	and	O
5	moulting	O
6	cycle	O
7	on	O
8	melanin	O
9	synthesis	O
10	in	O
11	the	O
12	newt	O
13	,	O
14	Triturus	O
15	cristatus	O
16	.	O

1	Binding	O
2	affinities	O
3	of	O
4	different	O
5	nucleotide	O
6	mono	O
7	-,	O
8	di	O
9	-	O
10	and	O
11	triphosphates	O
12	and	O
13	non	O
14	-	O
15	hydrolyzable	O
16	analogs	O
17	indicate	O
18	that	O
19	the	O
20	beta	B
21	-	I
22	phosphate	I
23	moiety	I
24	is	O
25	required	O
26	for	O
27	substrate	O
28	binding	O
29	.	O

1	Review	O
2	:	O
3	deterioration	O
4	of	O
5	glucose	O
6	tolerance	O
7	with	O
8	age	O
9	:	O
10	the	O
11	role	O
12	of	O
13	insulin	B
14	resistance	O
15	.	O

1	With	O
2	chemical	O
3	shift	O
4	imaging	O
5	,	O
6	the	O
7	signal	O
8	intensity	O
9	decreased	O
10	on	O
11	the	O
12	out	O
13	-	O
14	of	O
15	-	O
16	phase	O
17	images	O
18	in	O
19	six	O
20	of	O
21	seven	O
22	(	O
23	86	O
24	%)	O
25	patients	O
26	with	O
27	APA	O
28	and	O
29	in	O
30	eight	O
31	of	O
32	nine	O
33	(	O
34	89	O
35	%)	O
36	patients	O
37	with	O
38	BAH	O
39	.	O

1	Modern	O
2	cancer	O
3	therapy	O
4	has	O
5	included	O
6	surgery	O
7	,	O
8	radiotherapy	O
9	,	O
10	chemotherapy	O
11	,	O
12	and	O
13	most	O
14	recently	O
15	,	O
16	immunotherapy	O
17	and	O
18	hyperthermia	O
19	.	O

1	Diacylglycerol	O
2	kinase	O
3	(	O
4	DGK	O
5	)	O
6	attenuates	O
7	levels	O
8	of	O
9	second	O
10	messenger	O
11	diacylglycerol	O
12	in	O
13	cells	O
14	and	O
15	produces	O
16	another	O
17	(	O
18	putative	O
19	)	O
20	messenger	O
21	,	O
22	phosphatidic	O
23	acid	O
24	.	O

1	Transplantation	O
2	of	O
3	kidneys	O
4	of	O
5	juvenile	O
6	donors	O
7	in	O
8	adult	O
9	recipients	O
10	.	O

1	Two	O
2	patients	O
3	with	O
4	recurrent	O
5	tumors	O
6	had	O
7	high	O
8	S	O
9	-	O
10	phase	O
11	fractions	O
12	both	O
13	on	O
14	the	O
15	first	O
16	resected	O
17	specimens	O
18	and	O
19	at	O
20	the	O
21	time	O
22	of	O
23	the	O
24	second	O
25	operation	O
26	.	O

1	Is	O
2	radical	O
3	trachelectomy	O
4	a	O
5	safe	O
6	alternative	O
7	to	O
8	radical	O
9	hysterectomy	O
10	for	O
11	patients	O
12	with	O
13	stage	O
14	IA	O
15	-	O
16	B	O
17	carcinoma	O
18	of	O
19	the	O
20	cervix	O
21	?	O
22	BACKGROUND	O
23	:	O
24	The	O
25	prognosis	O
26	associated	O
27	with	O
28	lymph	O
29	node	O
30	negative	O
31	,	O
32	early	O
33	stage	O
34	carcinoma	O
35	of	O
36	the	O
37	cervix	O
38	is	O
39	excellent	O
40	,	O
41	with	O
42	5	O
43	-	O
44	year	O
45	survival	O
46	rates	O
47	greater	O
48	than	O
49	90	O
50	%.	O

1	The	O
2	natural	O
3	history	O
4	of	O
5	these	O
6	lesions	O
7	,	O
8	locoregional	O
9	efficiency	O
10	of	O
11	the	O
12	different	O
13	treatments	O
14	used	O
15	,	O
16	the	O
17	part	O
18	played	O
19	by	O
20	chemotherapy	O
21	,	O
22	survival	O
23	,	O
24	causes	O
25	of	O
26	death	O
27	and	O
28	therapeutic	O
29	modalities	O
30	used	O
31	as	O
32	a	O
33	last	O
34	measure	O
35	,	O
36	have	O
37	been	O
38	analysed	O
39	.	O

1	Serum	B
2	creatine	I
3	kinase	I
4	(	O
5	SCK	O
6	)	O
7	was	O
8	measured	O
9	in	O
10	ten	O
11	subjects	O
12	in	O
13	the	O
14	laboratory	O
15	before	O
16	and	O
17	after	O
18	the	O
19	performance	O
20	of	O
21	bicycle	O
22	ergometry	O
23	and	O
24	a	O
25	lifting	O
26	task	O
27	.	O

1	Quantitative	O
2	predictions	O
3	are	O
4	confirmed	O
5	for	O
6	the	O
7	positive	O
8	responses	O
9	,	O
10	but	O
11	not	O
12	for	O
13	the	O
14	negatives	O
15	,	O
16	suggesting	O
17	that	O
18	the	O
19	SSTS	O
20	model	O
21	is	O
22	incorrect	O
23	.	O

1	Reactive	O
2	lymphoid	O
3	hyperplasia	O
4	was	O
5	found	O
6	in	O
7	15	O
8	cases	O
9	,	O
10	2	O
11	cases	O
12	had	O
13	angiofollicular	O
14	lymphoid	O
15	hyperplasia	O
16	or	O
17	Castleman	O
18	'	O
19	s	O
20	disease	O
21	,	O
22	atypical	O
23	lymphoid	O
24	hyperplasia	O
25	suggestive	O
26	of	O
27	malignant	O
28	lymphoma	O
29	was	O
30	observed	O
31	in	O
32	3	O
33	cases	O
34	,	O
35	and	O
36	malignant	O
37	lymphoma	O
38	was	O
39	diagnosed	O
40	in	O
41	the	O
42	remaining	O
43	4	O
44	cases	O
45	.	O

1	Epididymal	O
2	growth	O
3	was	O
4	retarded	O
5	in	O
6	animals	O
7	maintained	O
8	solely	O
9	on	O
10	chickpea	O
11	haulm	O
12	and	O
13	improved	O
14	with	O
15	supplementation	O
16	.	O

1	RNA	O
2	polymerase	O
3	bound	O
4	to	O
5	the	O
6	+	O
7	10A	O
8	promoter	O
9	partially	O
10	protects	O
11	a	O
12	20	O
13	base	O
14	-	O
15	pair	O
16	sequence	O
17	from	O
18	DNase	B
19	I	I
20	digestion	O
21	upstream	O
22	of	O
23	the	O
24	start	O
25	site	O
26	.	O

1	A	O
2	new	O
3	set	O
4	of	O
5	cDNA	O
6	clones	O
7	spanning	O
8	approximately	O
9	3	O
10	.	O
11	2	O
12	kb	O
13	was	O
14	isolated	O
15	from	O
16	a	O
17	lambda	O
18	-	O
19	ZAP	B
20	goose	O
21	liver	O
22	cDNA	O
23	library	O
24	using	O
25	the	O
26	5	O
27	'-	O
28	most	O
29	exon	O
30	-	O
31	containing	O
32	fragment	O
33	of	O
34	the	O
35	5	O
36	'-	O
37	most	O
38	genomic	O
39	DNA	O
40	clone	O
41	.	O

1	Serum	B
2	Fibrin	I
3	Degradation	I
4	Products	I
5	(	O
6	FDP	O
7	)	O
8	were	O
9	determined	O
10	in	O
11	50	O
12	oral	O
13	cancer	O
14	patients	O
15	and	O
16	50	O
17	normal	O
18	individuals	O
19	prior	O
20	to	O
21	any	O
22	kind	O
23	of	O
24	treatment	O
25	.	O

1	Furthermore	O
2	,	O
3	we	O
4	showed	O
5	that	O
6	the	O
7	IL	B
8	-	I
9	6	I
10	/	I
11	interferon	I
12	gamma	I
13	(	O
14	IFN	B
15	gamma	I
16	)	O
17	response	O
18	element	O
19	in	O
20	the	O
21	IRF	B
22	-	I
23	1	I
24	promoter	I
25	(	I
26	IR	I
27	/	I
28	IRF	I
29	-	I
30	1	I
31	),	O
32	which	O
33	contains	O
34	a	O
35	Stat	B
36	-	I
37	binding	I
38	site	I
39	and	O
40	an	O
41	adjacent	O
42	CRE	O
43	-	O
44	like	O
45	site	O
46	,	O
47	also	O
48	makes	O
49	IL	B
50	-	I
51	6	I
52	-	I
53	induced	O
54	binding	O
55	complexes	O
56	similar	O
57	to	O
58	JRE	B
59	-	I
60	IL6	I
61	-	I
62	BCs	O
63	.	O

1	Ficat	O
2	and	O
3	Bizou	O
4	'	O
5	s	O
6	condylar	O
7	depth	O
8	index	O
9	and	O
10	the	O
11	condylar	O
12	-	O
13	joint	O
14	surface	O
15	angle	O
16	of	O
17	Brattstrom	O
18	are	O
19	recommended	O
20	as	O
21	especially	O
22	suitable	O
23	methods	O
24	of	O
25	measurement	O
26	.	O

1	The	O
2	biochemical	O
3	and	O
4	molecular	O
5	spectrum	O
6	of	O
7	ornithine	O
8	transcarbamylase	O
9	deficiency	O
10	.	O

1	Horseradish	O
2	peroxidase	O
3	as	O
4	a	O
5	permeability	O
6	marker	O
7	in	O
8	injured	O
9	rat	O
10	caudal	O
11	and	O
12	iliac	O
13	arteries	O
14	.	O

1	Analysis	O
2	of	O
3	the	O
4	consensus	O
5	binding	O
6	sequence	O
7	and	O
8	the	O
9	DNA	O
10	-	O
11	binding	O
12	domain	O
13	of	O
14	ZF5	O
15	.	O

1	CONCLUSION	O
2	:	O
3	Intravenous	O
4	diazepam	O
5	administration	O
6	before	O
7	EGD	O
8	produces	O
9	a	O
10	significant	O
11	fall	O
12	in	O
13	SpO2	O
14	during	O
15	the	O
16	procedure	O
17	,	O
18	and	O
19	so	O
20	should	O
21	be	O
22	avoided	O
23	;	O
24	continuous	O
25	monitoring	O
26	of	O
27	SpO2	O
28	should	O
29	be	O
30	done	O
31	during	O
32	EGD	O
33	.	O

1	A	O
2	role	O
3	for	O
4	RalGDS	O
5	and	O
6	a	O
7	novel	O
8	Ras	B
9	effector	O
10	in	O
11	the	O
12	Ras	B
13	-	I
14	mediated	O
15	inhibition	O
16	of	O
17	skeletal	O
18	myogenesis	O
19	.	O

1	Cestode	O
2	invasion	O
3	in	O
4	irradiated	O
5	host	O
6	organism	O
7	increases	O
8	the	O
9	negative	O
10	effect	O
11	of	O
12	ionizing	O
13	radiation	O
14	on	O
15	the	O
16	hamster	O
17	immune	O
18	system	O
19	.	O

1	Computer	O
2	-	O
3	aided	O
4	"	O
5	FRAME	O
6	"	O
7	analysis	O
8	revealed	O
9	four	O
10	possible	O
11	open	O
12	reading	O
13	frames	O
14	(	O
15	ORFs	O
16	),	O
17	three	O
18	in	O
19	one	O
20	direction	O
21	and	O
22	one	O
23	in	O
24	the	O
25	opposite	O
26	direction	O
27	.	O

1	Data	O
2	from	O
3	119	O
4	men	O
5	and	O
6	40	O
7	women	O
8	undergoing	O
9	coronary	O
10	angiography	O
11	provide	O
12	an	O
13	opportunity	O
14	to	O
15	compare	O
16	these	O
17	associations	O
18	in	O
19	relation	O
20	to	O
21	a	O
22	direct	O
23	and	O
24	continuous	O
25	measure	O
26	of	O
27	atherosclerosis	O
28	while	O
29	controlling	O
30	for	O
31	age	O
32	,	O
33	sex	O
34	,	O
35	income	O
36	,	O
37	hypertension	O
38	,	O
39	serum	O
40	cholesterol	O
41	,	O
42	smoking	O
43	,	O
44	angina	O
45	,	O
46	diabetes	O
47	,	O
48	family	O
49	history	O
50	of	O
51	heart	O
52	disease	O
53	,	O
54	Type	O
55	A	O
56	behavior	O
57	pattern	O
58	,	O
59	and	O
60	hostility	O
61	.	O

1	Biliary	O
2	-	O
3	enteric	O
4	fistulas	O

1	The	O
2	factor	O
3	which	O
4	binds	O
5	to	O
6	the	O
7	TR	B
8	promoter	I
9	co	O
10	-	O
11	sedimented	O
12	with	O
13	SV40	O
14	chromosomes	O
15	extracted	O
16	late	O
17	in	O
18	infection	O
19	.	O

1	We	O
2	characterized	O
3	the	O
4	structure	O
5	of	O
6	this	O
7	leader	O
8	mRNA	O
9	by	O
10	using	O
11	the	O
12	program	O
13	Mfold	O
14	and	O
15	a	O
16	combination	O
17	of	O
18	nested	O
19	and	O
20	internal	O
21	deletions	O
22	transcriptionally	O
23	fused	O
24	to	O
25	a	O
26	promoterless	O
27	lac	B
28	operon	I
29	.	O

1	An	O
2	analysis	O
3	of	O
4	sequence	O
5	of	O
6	the	O
7	mutant	O
8	recN	O
9	gene	O
10	revealed	O
11	a	O
12	G	O
13	:	O
14	C	O
15	to	O
16	T	O
17	:	O
18	A	O
19	transversion	O
20	near	O
21	the	O
22	3	O
23	'	O
24	end	O
25	of	O
26	the	O
27	coding	O
28	region	O
29	.	O

1	Protein	O
2	electrophoresis	O
3	showed	O
4	decreased	O
5	albumin	B
6	levels	O
7	in	O
8	both	O
9	groups	O
10	,	O
11	with	O
12	lower	O
13	values	O
14	in	O
15	G2	O
16	.	O

1	Institution	O
2	of	O
3	both	O
4	intravenous	O
5	and	O
6	intracisternal	O
7	administration	O
8	of	O
9	amphotericin	O
10	B	O
11	and	O
12	possibly	O
13	concomitant	O
14	intravenous	O
15	administration	O
16	of	O
17	dexamethasone	O
18	may	O
19	be	O
20	warranted	O
21	in	O
22	situations	O
23	in	O
24	which	O
25	the	O
26	association	O
27	of	O
28	C	O
29	.	O
30	immitis	O
31	with	O
32	CNS	O
33	vasculitis	O
34	or	O
35	encephalitis	O
36	appears	O
37	likely	O
38	before	O
39	serologic	O
40	or	O
41	cultural	O
42	confirmation	O
43	of	O
44	C	O
45	.	O
46	immitis	O
47	infection	O
48	involving	O
49	the	O
50	CNS	O
51	is	O
52	available	O
53	.	O

1	Most	O
2	pituitary	B
3	hormone	I
4	-	I
5	coding	I
6	gene	I
7	promoters	I
8	are	O
9	activated	O
10	by	O
11	Ptx1	O
12	.	O

1	Immunologically	O
2	reactive	O
3	insulin	B
4	levels	O
5	were	O
6	determined	O
7	in	O
8	freely	O
9	-	O
10	moving	O
11	normal	O
12	rats	O
13	offered	O
14	three	O
15	different	O
16	test	O
17	-	O
18	meals	O
19	.	O

1	Interferon	B
2	-	I
3	alpha	I
4	may	O
5	exacerbate	O
6	cryoblobulinemia	O
7	-	O
8	related	O
9	ischemic	O
10	manifestations	O
11	:	O
12	an	O
13	adverse	O
14	effect	O
15	potentially	O
16	related	O
17	to	O
18	its	O
19	anti	B
20	-	I
21	angiogenic	I
22	activity	O
23	.	O

1	An	O
2	abundant	O
3	1	O
4	.	O
5	1	O
6	-	O
7	kb	O
8	virion	O
9	-	O
10	sense	O
11	polyadenylated	O
12	RNA	O
13	and	O
14	four	O
15	complementary	O
16	-	O
17	sense	O
18	polyadenylated	O
19	RNAs	O
20	of	O
21	1	O
22	.	O
23	7	O
24	,	O
25	1	O
26	.	O
27	5	O
28	,	O
29	1	O
30	.	O
31	3	O
32	,	O
33	and	O
34	0	O
35	.	O
36	7	O
37	kb	O
38	have	O
39	been	O
40	identified	O
41	by	O
42	northern	O
43	blot	O
44	hybridization	O
45	,	O
46	confirming	O
47	the	O
48	bidirectional	O
49	transcription	O
50	strategy	O
51	implied	O
52	by	O
53	the	O
54	arrangement	O
55	of	O
56	ORFs	O
57	.	O

1	Immunohistochemical	O
2	staining	O
3	was	O
4	positive	O
5	for	O
6	S	O
7	-	O
8	100	O
9	in	O
10	all	O
11	9	O
12	cases	O
13	stained	O
14	,	O
15	positive	O
16	for	O
17	HMB	O
18	-	O
19	45	O
20	in	O
21	9	O
22	(	O
23	90	O
24	%)	O
25	of	O
26	10	O
27	,	O
28	and	O
29	negative	O
30	for	O
31	cytokeratin	O
32	in	O
33	all	O
34	9	O
35	cases	O
36	in	O
37	which	O
38	myxoid	O
39	melanoma	O
40	remained	O
41	in	O
42	the	O
43	block	O
44	after	O
45	previous	O
46	sections	O
47	.	O

1	The	O
2	DNA	O
3	sequences	O
4	upstream	O
5	of	O
6	these	O
7	termini	O
8	exhibit	O
9	homology	O
10	to	O
11	plant	O
12	mitochondrial	O
13	-	O
14	processing	O
15	sites	O
16	,	O
17	therefore	O
18	the	O
19	proximal	O
20	5	O
21	'	O
22	ends	O
23	are	O
24	most	O
25	probably	O
26	generated	O
27	by	O
28	RNA	O
29	processing	O
30	.	O

1	Lack	O
2	of	O
3	cyclin	B
4	D	I
5	-	I
6	Cdk	I
7	complexes	I
8	in	O
9	Rb	B
10	-	I
11	negative	O
12	cells	O
13	correlates	O
14	with	O
15	high	O
16	levels	O
17	of	O
18	p16INK4	O
19	/	O
20	MTS1	O
21	tumour	B
22	suppressor	I
23	gene	I
24	product	I
25	.	O

1	The	O
2	second	O
3	group	O
4	of	O
5	homologous	O
6	elements	O
7	is	O
8	present	O
9	in	O
10	the	O
11	upstream	O
12	region	O
13	of	O
14	both	O
15	genes	O
16	.	O

1	Differential	O
2	association	O
3	of	O
4	products	O
5	of	O
6	alternative	O
7	transcripts	O
8	of	O
9	the	O
10	candidate	O
11	tumor	O
12	suppressor	O
13	ING1	O
14	with	O
15	the	O
16	mSin3	O
17	/	O
18	HDAC1	O
19	transcriptional	O
20	corepressor	O
21	complex	O
22	.	O

1	An	O
2	int6	O
3	deletion	O
4	(	O
5	int6Delta	O
6	)	O
7	mutant	O
8	was	O
9	viable	O
10	but	O
11	grew	O
12	slowly	O
13	in	O
14	minimal	O
15	medium	O
16	.	O

1	To	O
2	explore	O
3	the	O
4	functional	O
5	significance	O
6	of	O
7	these	O
8	subdomains	O
9	in	O
10	PRL	B
11	binding	I
12	and	O
13	signal	O
14	transduction	O
15	,	O
16	deletion	O
17	mutants	O
18	of	O
19	S1	O
20	or	O
21	/	O
22	and	O
23	S2	O
24	subdomains	O
25	were	O
26	constructed	O
27	.	O

1	Two	O
2	putative	O
3	Rev	B
4	proteins	I
5	with	O
6	apparent	O
7	molecular	O
8	masses	O
9	of	O
10	18	O
11	and	O
12	16	O
13	kDa	O
14	were	O
15	expressed	O
16	by	O
17	p2	O
18	/	O
19	2	O
20	and	O
21	p176	O
22	,	O
23	while	O
24	p20	O
25	expressed	O
26	only	O
27	a	O
28	16	O
29	-	O
30	kDa	O
31	species	O
32	.	O

1	We	O
2	have	O
3	studied	O
4	the	O
5	biokinetics	O
6	of	O
7	BLM	O
8	labeled	O
9	with	O
10	indium	O
11	-	O
12	111	O
13	(	O
14	In	O
15	-	O
16	111	O
17	).	O

1	Neuregulin	O
2	stimulates	O
3	ErbB2	O
4	,	O
5	ErbB3	O
6	,	O
7	and	O
8	ErbB4	O
9	,	O
10	members	O
11	of	O
12	the	O
13	ErbB	B
14	family	I
15	of	I
16	receptor	I
17	tyrosine	I
18	kinases	I
19	.	O

1	Pentazocine	O
2	analgesia	O
3	:	O
4	is	O
5	there	O
6	a	O
7	niche	O
8	for	O
9	Talwin	O
10	Nx	O
11	?	O
12	Pentazocine	O
13	can	O
14	be	O
15	a	O
16	useful	O
17	analgesic	O
18	agent	O
19	for	O
20	the	O
21	management	O
22	of	O
23	acute	O
24	dental	O
25	pain	O
26	.	O

1	Since	O
2	the	O
3	5	O
4	'-	O
5	flanking	O
6	region	O
7	of	O
8	this	O
9	gene	O
10	is	O
11	likely	O
12	involved	O
13	in	O
14	hormonal	O
15	regulation	O
16	of	O
17	its	O
18	expression	O
19	,	O
20	we	O
21	have	O
22	isolated	O
23	and	O
24	partially	O
25	characterized	O
26	an	O
27	avian	B
28	fatty	I
29	acid	I
30	synthase	I
31	gene	I
32	.	O

1	The	O
2	backbone	O
3	dynamics	O
4	of	O
5	residues	O
6	located	O
7	in	O
8	the	O
9	folded	O
10	part	O
11	of	O
12	CRP2	O
13	(	O
14	LIM2	O
15	)	O
16	R122A	O
17	have	O
18	been	O
19	characterized	O
20	by	O
21	proton	O
22	-	O
23	detected	O
24	(	O
25	15	O
26	)	O
27	N	O
28	NMR	O
29	spectroscopy	O
30	.	O

1	Mutations	O
2	that	O
3	alter	O
4	photoreceptor	O
5	cell	O
6	structure	O
7	and	O
8	development	O
9	were	O
10	isolated	O
11	that	O
12	fail	O
13	to	O
14	complement	O
15	these	O
16	deletions	O
17	.	O

1	The	O
2	treatment	O
3	group	O
4	also	O
5	showed	O
6	in	O
7	vivo	O
8	T	O
9	-	O
10	cell	O
11	activation	O
12	with	O
13	an	O
14	initial	O
15	lymphopenia	O
16	followed	O
17	by	O
18	a	O
19	rebound	O
20	lymphocytosis	O
21	and	O
22	upregulation	O
23	of	O
24	the	O
25	subset	O
26	markers	O
27	CD25	O
28	(	O
29	interleukin	B
30	2	I
31	receptor	I
32	)	O
33	and	O
34	CD45RO	O
35	(	O
36	T	O
37	-	O
38	memory	O
39	cells	O
40	).	O

1	W	O
2	.	O

1	In	O
2	spite	O
3	of	O
4	much	O
5	effort	O
6	,	O
7	no	O
8	one	O
9	has	O
10	succeeded	O
11	in	O
12	isolating	O
13	and	O
14	characterizing	O
15	the	O
16	enzyme	O
17	(	O
18	s	O
19	)	O
20	responsible	O
21	for	O
22	synthesis	O
23	of	O
24	cellulose	O
25	,	O
26	the	O
27	major	O
28	cell	O
29	wall	O
30	polymer	O
31	of	O
32	plants	O
33	.	O

1	Strontium	O
2	chloride	O
3	Sr	O
4	89	O
5	is	O
6	costly	O
7	,	O
8	but	O
9	preliminary	O
10	analysis	O
11	indicates	O
12	that	O
13	it	O
14	may	O
15	reduce	O
16	management	O
17	expenditures	O
18	overall	O
19	.(	O
20	ABSTRACT	O
21	TRUNCATED	O
22	AT	O
23	250	O
24	WORDS	O
25	)	O

1	Examination	O
2	of	O
3	nuclear	O
4	magnetic	O
5	resonance	O
6	(	O
7	NMR	O
8	)	O
9	spectra	O
10	of	O
11	a	O
12	series	O
13	of	O
14	N	O
15	-	O
16	terminally	O
17	truncated	O
18	MIP	B
19	-	I
20	1	I
21	beta	I
22	variants	I
23	reveals	O
24	that	O
25	these	O
26	proteins	O
27	possess	O
28	a	O
29	range	O
30	of	O
31	ability	O
32	to	O
33	dimerize	O
34	.	O

1	We	O
2	show	O
3	that	O
4	LexA	B
5	-	I
6	GAL4	I
7	and	O
8	LexA	B
9	-	I
10	Bicoid	I
11	fusion	I
12	proteins	I
13	are	O
14	both	O
15	dependent	O
16	on	O
17	SNF2	O
18	,	O
19	SNF5	O
20	,	O
21	and	O
22	SNF6	O
23	for	O
24	activation	O
25	of	O
26	target	O
27	genes	O
28	containing	O
29	one	O
30	or	O
31	multiple	O
32	lexA	O
33	operators	O
34	.	O

1	A	O
2	novel	O
3	phosphotyrosine	O
4	-	O
5	binding	O
6	domain	O
7	in	O
8	the	O
9	N	O
10	-	O
11	terminal	O
12	transforming	O
13	region	O
14	of	O
15	Cbl	B
16	interacts	O
17	directly	O
18	and	O
19	selectively	O
20	with	O
21	ZAP	B
22	-	I
23	70	I
24	in	O
25	T	O
26	cells	O
27	.	O

1	Hepatic	O
2	oxygen	O
3	supply	O
4	and	O
5	selected	O
6	blood	O
7	parameters	O
8	were	O
9	recorded	O
10	in	O
11	fasted	O
12	male	O
13	rates	O
14	given	O
15	20	O
16	--	O
17	30	O
18	mg	O
19	/	O
20	kg	O
21	Escherichia	O
22	coli	O
23	endotoxin	O
24	intraperitoneally	O
25	.	O

1	Aneurysmectomy	O
2	and	O
3	the	O
4	performance	O
5	of	O
6	CABG	O
7	were	O
8	not	O
9	significantly	O
10	associated	O
11	with	O
12	postoperative	O
13	ECG	O
14	changes	O
15	,	O
16	but	O
17	more	O
18	bypass	O
19	grafts	O
20	per	O
21	patient	O
22	grafted	O
23	appeared	O
24	in	O
25	the	O
26	group	O
27	with	O
28	postoperative	O
29	ECG	O
30	changes	O
31	,	O
32	suggesting	O
33	that	O
34	coronary	O
35	artery	O
36	disease	O
37	may	O
38	be	O
39	more	O
40	severe	O
41	in	O
42	that	O
43	group	O
44	.	O

1	These	O
2	results	O
3	suggest	O
4	KCC3	O
5	is	O
6	a	O
7	new	O
8	member	O
9	of	O
10	the	O
11	KCC	O
12	family	O
13	that	O
14	is	O
15	under	O
16	distinct	O
17	regulation	O
18	from	O
19	KCC1	O
20	.	O

1	Dorsal	O
2	root	O
3	ganglia	O
4	neuron	O
5	-	O
6	specific	O
7	promoter	O
8	activity	O
9	of	O
10	the	O
11	rabbit	B
12	beta	I
13	-	I
14	galactoside	I
15	alpha1	I
16	,	O
17	2	O
18	-	O
19	fucosyltransferase	O
20	gene	O
21	.	O

1	Jerseys	O
2	had	O
3	higher	O
4	hepatic	O
5	Cu	O
6	concentrations	O
7	than	O
8	did	O
9	Holsteins	O
10	on	O
11	d	O
12	60	O
13	(	O
14	346	O
15	vs	O
16	.	O

1	In	O
2	conclusion	O
3	,	O
4	marmoset	O
5	monkey	O
6	LHR	O
7	seems	O
8	to	O
9	lack	O
10	the	O
11	sequence	O
12	corresponding	O
13	to	O
14	exon	O
15	10	O
16	of	O
17	the	O
18	LHR	B
19	gene	I
20	in	O
21	other	O
22	mammalian	O
23	species	O
24	.	O

1	A	O
2	gapped	O
3	search	O
4	with	O
5	the	O
6	C	O
7	-	O
8	terminal	O
9	region	O
10	of	O
11	CDED	O
12	/	O
13	LIOR	O
14	revealed	O
15	a	O
16	36	O
17	-	O
18	41	O
19	%	O
20	similarity	O
21	to	O
22	several	O
23	proteins	O
24	related	O
25	to	O
26	signal	O
27	transduction	O
28	and	O
29	cell	O
30	replication	O
31	,	O
32	such	O
33	as	O
34	ORC1	O
35	and	O
36	KSR	O
37	.	O

1	When	O
2	phencyclidine	O
3	was	O
4	administered	O
5	alone	O
6	,	O
7	overall	O
8	response	O
9	rate	O
10	decreased	O
11	and	O
12	percent	O
13	errors	O
14	increased	O
15	with	O
16	increasing	O
17	doses	O
18	.	O

1	Isolation	O
2	of	O
3	cDNAs	O
4	encoding	O
5	gibbon	O
6	and	O
7	monkey	O
8	platelet	O
9	and	O
10	T	O
11	cell	O
12	activation	O
13	antigen	O
14	1	O
15	(	O
16	PTA1	O
17	).	O

1	Anti	B
2	-	I
3	anxiety	O
4	action	O
5	of	O
6	diazepam	O
7	after	O
8	intra	O
9	-	O
10	amygdaloid	O
11	application	O
12	in	O
13	the	O
14	rat	O
15	.	O

1	The	O
2	December	O
3	armed	O
4	revolt	O
5	in	O
6	Moscow	O
7	and	O
8	the	O
9	paramedical	O
10	personnel	O

1	Each	O
2	patient	O
3	had	O
4	measurable	O
5	LH	O
6	and	O
7	FSH	B
8	levels	O
9	,	O
10	with	O
11	pulsed	O
12	nocturnal	O
13	secretion	O
14	,	O
15	and	O
16	pubertal	O
17	LH	O
18	and	O
19	FSH	B
20	responses	O
21	to	O
22	LRH	O
23	.	O

1	Transcription	O
2	factor	O
3	recognition	O
4	surface	O
5	on	O
6	the	O
7	RNA	B
8	polymerase	I
9	alpha	I
10	subunit	I
11	is	O
12	involved	O
13	in	O
14	contact	O
15	with	O
16	the	O
17	DNA	O
18	enhancer	O
19	element	O
20	.	O

1	Insulin	B
2	-	I
3	like	I
4	growth	I
5	factor	I
6	1	I
7	(	I
8	IGF	I
9	-	I
10	1	I
11	)	O
12	in	O
13	burn	O
14	patients	O
15	.	O

1	The	O
2	participants	O
3	were	O
4	homosexual	O
5	men	O
6	in	O
7	hepatitis	O
8	B	O
9	vaccine	O
10	trials	O
11	in	O
12	Amsterdam	O
13	(	O
14	n	O
15	=	O
16	74	O
17	),	O
18	New	O
19	York	O
20	City	O
21	(	O
22	n	O
23	=	O
24	120	O
25	),	O
26	and	O
27	San	O
28	Francisco	O
29	(	O
30	n	O
31	=	O
32	168	O
33	).	O

1	The	O
2	pattern	O
3	of	O
4	RNase	B
5	E	I
6	digestion	O
7	of	O
8	finP305	O
9	RNA	O
10	differed	O
11	from	O
12	FinP	O
13	,	O
14	and	O
15	GST	B
16	-	I
17	FinO	I
18	did	O
19	not	O
20	protect	O
21	finP305	O
22	RNA	O
23	from	O
24	cleavage	O
25	in	O
26	vitro	O
27	.	O

1	This	O
2	element	O
3	was	O
4	used	O
5	to	O
6	screen	O
7	an	O
8	EMBL3	O
9	mouse	O
10	genomic	O
11	library	O
12	.	O

1	These	O
2	observations	O
3	lead	O
4	to	O
5	the	O
6	proposal	O
7	that	O
8	the	O
9	RNAP	B
10	II	I
11	CTD	O
12	might	O
13	be	O
14	an	O
15	in	O
16	vivo	O
17	target	O
18	for	O
19	the	O
20	activated	O
21	p42mapk	O
22	and	O
23	p44mapk	O
24	MAP	B
25	kinases	I
26	.	O

1	Concurrently	O
2	,	O
3	we	O
4	monitored	O
5	weather	O
6	conditions	O
7	and	O
8	used	O
9	time	O
10	-	O
11	activity	O
12	budget	O
13	data	O
14	of	O
15	free	O
16	-	O
17	living	O
18	birds	O
19	and	O
20	laboratory	O
21	data	O
22	on	O
23	resting	O
24	metabolic	O
25	rate	O
26	to	O
27	construct	O
28	time	O
29	-	O
30	activity	O
31	laboratory	O
32	(	O
33	TAL	O
34	)	O
35	estimates	O
36	of	O
37	daily	O
38	energy	O
39	expenditure	O
40	(	O
41	DEE	O
42	)	O
43	and	O
44	to	O
45	partition	O
46	the	O
47	verdins	O
48	'	O
49	energy	O
50	budget	O
51	into	O
52	thermoregulatory	O
53	,	O
54	activity	O
55	and	O
56	basal	O
57	components	O
58	.	O

1	Inefficacy	O
2	of	O
3	phosphine	O
4	fumigation	O
5	against	O
6	ticks	O
7	.	O

1	Using	O
2	Scheffe	O
3	'	O
4	s	O
5	procedure	O
6	as	O
7	an	O
8	illustration	O
9	,	O
10	comparisons	O
11	are	O
12	made	O
13	to	O
14	usual	O
15	sample	O
16	size	O
17	methods	O
18	that	O
19	incorrectly	O
20	ignore	O
21	the	O
22	stochastic	O
23	nature	O
24	of	O
25	S2p	O
26	.	O

1	Four	O
2	out	O
3	of	O
4	10	O
5	patients	O
6	showed	O
7	clinical	O
8	improvement	O
9	according	O
10	to	O
11	Ritchie	O
12	-	O
13	Index	O
14	,	O
15	pain	O
16	score	O
17	,	O
18	ESR	O
19	and	O
20	CRP	B
21	.	O

1	A	O
2	mixture	O
3	of	O
4	human	B
5	albumin	I
6	5	O
7	%	O
8	and	O
9	hydroxy	O
10	-	O
11	ethyl	O
12	-	O
13	starch	O
14	was	O
15	used	O
16	as	O
17	a	O
18	solution	O
19	for	O
20	dilution	O
21	.	O

1	Deletion	O
2	mutagenesis	O
3	demonstrated	O
4	that	O
5	these	O
6	two	O
7	elements	O
8	are	O
9	involved	O
10	in	O
11	the	O
12	positive	O
13	regulation	O
14	of	O
15	MLC	B
16	-	I
17	2	I
18	gene	I
19	transcription	O
20	.	O

1	Northern	O
2	blot	O
3	analysis	O
4	of	O
5	LeMT	O
6	(	O
7	A	O
8	)	O
9	and	O
10	LeMT	O
11	(	O
12	B	O
13	)	O
14	showed	O
15	that	O
16	transcripts	O
17	of	O
18	both	O
19	MT	B
20	-	I
21	like	I
22	genes	I
23	were	O
24	more	O
25	abundant	O
26	in	O
27	leaves	O
28	than	O
29	roots	O
30	in	O
31	tomato	O
32	plants	O
33	grown	O
34	without	O
35	addition	O
36	of	O
37	extra	O
38	metal	O
39	ions	O
40	,	O
41	a	O
42	characteristic	O
43	of	O
44	type	O
45	II	O
46	MTs	O
47	.	O

1	The	O
2	average	O
3	coefficients	O
4	of	O
5	correlation	O
6	were	O
7	0	O
8	.	O
9	9998	O
10	and	O
11	0	O
12	.	O
13	9993	O
14	for	O
15	the	O
16	QMF	O
17	and	O
18	the	O
19	QIT	O
20	system	O
21	,	O
22	respectively	O
23	.	O

1	National	O
2	abortion	O
3	laws	O
4	usually	O
5	do	O
6	not	O
7	allow	O
8	abortion	O
9	when	O
10	a	O
11	foetus	O
12	is	O
13	independently	O
14	viable	O
15	,	O
16	i	O
17	.	O
18	e	O
19	.	O
20	from	O
21	a	O
22	gestational	O
23	age	O
24	of	O
25	about	O
26	24	O
27	weeks	O
28	.	O

1	Sequences	O
2	required	O
3	for	O
4	interaction	O
5	of	O
6	mu2	O
7	and	O
8	CTLA	O
9	-	O
10	4	O
11	were	O
12	localized	O
13	to	O
14	residues	O
15	,	O
16	161TTGVY	O
17	in	O
18	CTLA	O
19	-	O
20	4	O
21	;	O
22	this	O
23	sequence	O
24	is	O
25	N	O
26	-	O
27	terminal	O
28	to	O
29	,	O
30	but	O
31	overlaps	O
32	with	O
33	,	O
34	a	O
35	previously	O
36	identified	O
37	SH2	B
38	binding	I
39	motif	I
40	,	O
41	165YVKM	O
42	,	O
43	involved	O
44	in	O
45	CTLA	O
46	-	O
47	4	O
48	signaling	O
49	.	O

1	Sequence	O
2	analysis	O
3	identified	O
4	some	O
5	of	O
6	these	O
7	cDNA	O
8	clones	O
9	as	O
10	Dlc	O
11	-	O
12	1	O
13	,	O
14	a	O
15	sequence	O
16	encoding	O
17	a	O
18	small	O
19	,	O
20	9	O
21	-	O
22	kDa	O
23	human	O
24	homolog	O
25	of	O
26	the	O
27	outer	B
28	-	I
29	arm	I
30	dynein	I
31	light	I
32	-	I
33	chain	I
34	protein	I
35	.	O

1	The	O
2	purified	O
3	recombinant	O
4	enzyme	O
5	catalyzed	O
6	specific	O
7	phosphoryl	O
8	transfer	O
9	from	O
10	ATP	O
11	to	O
12	UMP	O
13	and	O
14	CMP	O
15	.	O

1	Oxidative	O
2	degradation	O
3	of	O
4	adrenaline	O
5	solutions	O
6	:	O
7	study	O
8	of	O
9	the	O
10	intermediate	O
11	stages	O
12	and	O
13	their	O
14	analytic	O
15	value	O
16	for	O
17	the	O
18	control	O
19	of	O
20	this	O
21	solute	O

1	Consequently	O
2	,	O
3	it	O
4	is	O
5	not	O
6	known	O
7	how	O
8	knee	O
9	loading	O
10	changes	O
11	following	O
12	ACL	O
13	transection	O
14	,	O
15	and	O
16	how	O
17	it	O
18	contributes	O
19	to	O
20	cartilage	O
21	degeneration	O
22	.	O

1	During	O
2	treatment	O
3	,	O
4	the	O
5	phosphorylation	O
6	state	O
7	of	O
8	Rb	B
9	shifted	O
10	to	O
11	a	O
12	hypophosphorylated	O
13	form	O
14	.	O
15	mRNA	O
16	for	O
17	the	O
18	HPV	B
19	E6	I
20	/	I
21	E7	I
22	genes	I
23	decreased	O
24	;	O
25	however	O
26	,	O
27	significant	O
28	changes	O
29	in	O
30	the	O
31	E7	B
32	protein	I
33	were	O
34	not	O
35	observed	O
36	,	O
37	while	O
38	increased	O
39	levels	O
40	of	O
41	Rb	B
42	immunoprecipitated	O
43	with	O
44	anti	B
45	-	I
46	E7	I
47	antibodies	I
48	were	O
49	observed	O
50	.	O

1	Based	O
2	on	O
3	these	O
4	results	O
5	and	O
6	because	O
7	Cdc68	O
8	has	O
9	been	O
10	implicated	O
11	as	O
12	a	O
13	regulator	O
14	of	O
15	chromatin	O
16	structure	O
17	,	O
18	we	O
19	postulate	O
20	that	O
21	polymerase	O
22	alpha	O
23	may	O
24	interact	O
25	with	O
26	these	O
27	proteins	O
28	to	O
29	gain	O
30	access	O
31	to	O
32	its	O
33	template	O
34	or	O
35	to	O
36	origins	O
37	of	O
38	replication	O
39	in	O
40	vivo	O
41	.	O

1	Its	O
2	interaction	O
3	with	O
4	RFX5	O
5	and	O
6	RFXAP	O
7	is	O
8	essential	O
9	for	O
10	binding	O
11	of	O
12	the	O
13	RFX	O
14	complex	O
15	to	O
16	MHC	B
17	-	I
18	II	I
19	promoters	I
20	.	O

1	Exposure	O
2	of	O
3	peripheral	O
4	blood	O
5	T	O
6	cells	O
7	from	O
8	young	O
9	subjects	O
10	to	O
11	PHA	O
12	or	O
13	cross	O
14	-	O
15	linked	O
16	anti	B
17	-	I
18	CD3	I
19	monoclonal	I
20	antibodies	I
21	stimulated	O
22	rapid	O
23	increases	O
24	in	O
25	MAPK	O
26	and	O
27	MEK	B
28	enzymatic	O
29	activity	O
30	.	O

1	A	O
2	recently	O
3	described	O
4	protein	O
5	,	O
6	metaxin	O
7	1	O
8	,	O
9	serves	O
10	as	O
11	a	O
12	component	O
13	of	O
14	a	O
15	preprotein	O
16	import	O
17	complex	O
18	in	O
19	the	O
20	outer	O
21	membrane	O
22	of	O
23	the	O
24	mammalian	O
25	mitochondrion	O
26	.	O

1	For	O
2	functional	O
3	studies	O
4	,	O
5	two	O
6	promoter	O
7	regions	O
8	were	O
9	cloned	O
10	upstream	O
11	of	O
12	the	O
13	reporter	O
14	gene	O
15	,	O
16	chloramphenicol	B
17	acetyl	I
18	transferase	I
19	(	O
20	CAT	B
21	):	O
22	(	O
23	i	O
24	)	O
25	phbetaE	O
26	-	O
27	B	O
28	-	O
29	the	O
30	plasmid	O
31	that	O
32	contains	O
33	the	O
34	human	O
35	(	O
36	h	O
37	)	O
38	promoter	O
39	region	O
40	(-	O
41	2832	O
42	to	O
43	+	O
44	101	O
45	)	O
46	including	O
47	URE	O
48	,	O
49	and	O
50	(	O
51	ii	O
52	)	O
53	prhbetaE	O
54	-	O
55	B	O
56	-	O
57	the	O
58	plasmid	O
59	that	O
60	contains	O
61	the	O
62	rhesus	O
63	(	O
64	rh	O
65	)	O
66	promoter	O
67	region	O
68	excluding	O
69	URE	O
70	as	O
71	it	O
72	lacks	O
73	a	O
74	270	O
75	bp	O
76	region	O
77	of	O
78	the	O
79	hbetaAPP	O
80	promoter	O
81	(-	O
82	2435	O
83	to	O
84	-	O
85	2165	O
86	).	O

1	Gene	O
2	constructs	O
3	possessing	O
4	the	O
5	complete	O
6	tat	B
7	,	O
8	rev	O
9	(	O
10	tat	B
11	+	I
12	rev	I
13	+)	O
14	and	O
15	env	B
16	genes	I
17	were	O
18	transiently	O
19	expressed	O
20	in	O
21	COS	O
22	-	O
23	1	O
24	cells	O
25	as	O
26	precursor	O
27	SU	O
28	-	O
29	TM	O
30	(	O
31	gp160	O
32	),	O
33	SU	O
34	.	O
35	TM	O
36	(	O
37	gp120	O
38	x	O
39	41	O
40	),	O
41	and	O
42	nucleolar	O
43	rev	B
44	protein	I
45	.	O

1	The	O
2	importance	O
3	of	O
4	hepatitis	O
5	C	O
6	virus	O
7	(	O
8	HCV	O
9	)	O
10	infection	O
11	as	O
12	a	O
13	cause	O
14	of	O
15	chronic	O
16	liver	O
17	disease	O
18	has	O
19	become	O
20	clear	O
21	with	O
22	the	O
23	introduction	O
24	of	O
25	serologic	O
26	detection	O
27	methods	O
28	.	O

1	It	O
2	was	O
3	also	O
4	found	O
5	that	O
6	there	O
7	is	O
8	no	O
9	significant	O
10	difference	O
11	between	O
12	the	O
13	prevalence	O
14	of	O
15	nasal	O
16	carriage	O
17	of	O
18	S	O
19	.	O
20	aureus	O
21	amongst	O
22	the	O
23	hospital	O
24	staff	O
25	and	O
26	the	O
27	patients	O
28	.	O

1	One	O
2	complex	O
3	containing	O
4	a	O
5	70	O
6	D	O
7	protein	O
8	was	O
9	found	O
10	to	O
11	be	O
12	associated	O
13	specifically	O
14	with	O
15	transcriptionally	O
16	active	O
17	leukemia	O
18	cells	O
19	.	O

1	The	O
2	geometric	O
3	mean	O
4	hemagglutination	O
5	-	O
6	inhibition	O
7	antibody	O
8	titers	O
9	(	O
10	GMT	O
11	)	O
12	of	O
13	non	O
14	-	O
15	immunized	O
16	,	O
17	once	O
18	-	O
19	immunized	O
20	,	O
21	and	O
22	twice	O
23	-	O
24	immunized	O
25	chickens	O
26	were	O
27	compared	O
28	at	O
29	2	O
30	-	O
31	week	O
32	intervals	O
33	following	O
34	primary	O
35	immunization	O
36	,	O
37	secondary	O
38	immunization	O
39	,	O
40	and	O
41	challenge	O
42	.	O

1	Assuming	O
2	O2	O
3	consumption	O
4	of	O
5	the	O
6	isolated	O
7	skin	O
8	to	O
9	be	O
10	same	O
11	as	O
12	in	O
13	situ	O
14	,	O
15	calculations	O
16	showed	O
17	that	O
18	when	O
19	water	O
20	PO2	O
21	was	O
22	high	O
23	(	O
24	150	O
25	mm	O
26	Hg	O
27	),	O
28	about	O
29	40	O
30	%	O
31	of	O
32	total	O
33	cutaneous	O
34	O2	O
35	uptake	O
36	was	O
37	consumed	O
38	by	O
39	the	O
40	skin	O
41	.	O

1	Heat	B
2	-	I
3	labile	I
4	-	I
5	like	I
6	enterotoxin	I
7	(	O
8	LT	O
9	)	O
10	was	O
11	produced	O
12	by	O
13	26	O
14	of	O
15	42	O
16	stool	O
17	isolates	O
18	(	O
19	62	O
20	%),	O
21	while	O
22	only	O
23	1	O
24	of	O
25	the	O
26	42	O
27	isolates	O
28	(	O
29	2	O
30	%)	O
31	produced	O
32	enterotoxinlike	O
33	activity	O
34	in	O
35	suckling	O
36	mice	O
37	;	O
38	65	O
39	%	O
40	of	O
41	the	O
42	cytotoxin	O
43	-	O
44	producing	O
45	strains	O
46	also	O
47	produced	O
48	an	O
49	LT	B
50	-	I
51	like	I
52	material	O
53	.	O

1	Normal	O
2	baseline	O
3	(	O
4	day	O
5	-	O
6	8	O
7	)	O
8	PC	O
9	levels	O
10	(	O
11	86	O
12	and	O
13	89	O
14	%)	O
15	were	O
16	markedly	O
17	reduced	O
18	in	O
19	both	O
20	patients	O
21	at	O
22	the	O
23	time	O
24	of	O
25	VOD	O
26	manifestation	O
27	on	O
28	day	O
29	20	O
30	and	O
31	40	O
32	,	O
33	respectively	O
34	(	O
35	26	O
36	and	O
37	31	O
38	%).	O

1	Our	O
2	study	O
3	was	O
4	addressed	O
5	to	O
6	the	O
7	synthesis	O
8	of	O
9	some	O
10	derivatives	O
11	of	O
12	this	O
13	sequence	O
14	in	O
15	order	O
16	to	O
17	obtain	O
18	both	O
19	peptide	O
20	substrates	O
21	suitable	O
22	for	O
23	the	O
24	detection	O
25	of	O
26	the	O
27	Src	B
28	-	I
29	like	I
30	tyrosine	I
31	kinase	I
32	activity	O
33	and	O
34	active	O
35	site	O
36	-	O
37	directed	O
38	inhibitors	O
39	specific	O
40	for	O
41	this	O
42	class	O
43	of	O
44	enzymes	O
45	.	O

1	The	O
2	future	O
3	of	O
4	research	O
5	with	O
6	interferon	B
7	may	O
8	be	O
9	divided	O
10	into	O
11	three	O
12	areas	O
13	:	O
14	Efforts	O
15	must	O
16	be	O
17	made	O
18	to	O
19	determine	O
20	how	O
21	best	O
22	to	O
23	translate	O
24	the	O
25	in	O
26	vitro	O
27	synergy	O
28	into	O
29	clinically	O
30	meaningful	O
31	terms	O
32	;	O
33	in	O
34	order	O
35	to	O
36	exploit	O
37	the	O
38	fullest	O
39	potential	O
40	of	O
41	IFN	B
42	,	O
43	research	O
44	is	O
45	moving	O
46	toward	O
47	using	O
48	this	O
49	agent	O
50	earlier	O
51	in	O
52	disease	O
53	either	O
54	as	O
55	an	O
56	adjuvant	O
57	after	O
58	tumor	O
59	debulking	O
60	or	O
61	after	O
62	initial	O
63	diagnosis	O
64	;	O
65	the	O
66	medical	O
67	community	O
68	must	O
69	rethink	O
70	the	O
71	natural	O
72	history	O
73	of	O
74	some	O
75	diseases	O
76	,	O
77	because	O
78	the	O
79	fullest	O
80	potential	O
81	of	O
82	the	O
83	biologic	O
84	agents	O
85	will	O
86	most	O
87	likely	O
88	manifest	O
89	itself	O
90	when	O
91	these	O
92	agents	O
93	are	O
94	used	O
95	together	O
96	.	O

1	Fenoldopam	O
2	,	O
3	a	O
4	dopamine	O
5	receptor	O
6	agonist	O
7	,	O
8	has	O
9	been	O
10	shown	O
11	,	O
12	in	O
13	animal	O
14	experiments	O
15	,	O
16	to	O
17	improve	O
18	renal	O
19	perfusion	O
20	.	O

1	Most	O
2	patients	O
3	with	O
4	high	O
5	blood	O
6	pressure	O
7	(	O
8	BP	O
9	)	O
10	can	O
11	be	O
12	managed	O
13	by	O
14	using	O
15	one	O
16	of	O
17	4	O
18	classes	O
19	of	O
20	compounds	O
21	:	O
22	a	O
23	diuretic	O
24	,	O
25	beta	O
26	blocker	O
27	,	O
28	converting	O
29	enzyme	O
30	inhibitor	O
31	or	O
32	calcium	O
33	antagonist	O
34	.	O

1	A	O
2	case	O
3	of	O
4	AIDS	O
5	-	O
6	related	O
7	complex	O
8	(	O
9	ARC	O
10	/	O
11	LAS	O
12	)	O
13	in	O
14	a	O
15	health	O
16	worker	O

1	On	O
2	the	O
3	transport	O
4	of	O
5	mucus	O
6	and	O
7	its	O
8	rheologic	O
9	simulants	O
10	in	O
11	ciliated	O
12	systems	O
13	.	O

1	HeLa	O
2	and	O
3	Jurkat	O
4	cell	O
5	lines	O
6	carrying	O
7	the	O
8	nef	B
9	gene	I
10	linked	O
11	to	O
12	the	O
13	CMV	O
14	promoter	O
15	or	O
16	the	O
17	HIV	B
18	-	I
19	1	I
20	LTR	I
21	were	O
22	isolated	O
23	by	O
24	coselection	O
25	for	O
26	neomycin	O
27	resistance	O
28	.	O

1	Platelet	O
2	function	O
3	and	O
4	platelet	O
5	-	O
6	polymorphonuclear	O
7	-	O
8	neutrophil	O
9	interaction	O
10	in	O
11	patients	O
12	with	O
13	deficient	O
14	platelet	O
15	lipoxygenase	O
16	activity	O
17	.	O

1	Plastic	O
2	solution	O
3	of	O
4	elbow	O
5	joint	O
6	ankylosis	O
7	with	O
8	a	O
9	decorticated	O
10	cylindrical	O
11	flap	O

1	Shape	O
2	factor	O
3	correlated	O
4	well	O
5	with	O
6	hemodynamic	O
7	data	O
8	for	O
9	RV	O
10	/	O
11	LV	O
12	systolic	O
13	pressure	O
14	ratios	O
15	(	O
16	r	O
17	=	O
18	0	O
19	.	O
20	93	O
21	,	O
22	p	O
23	less	O
24	than	O
25	0	O
26	.	O
27	001	O
28	)	O
29	for	O
30	normalized	O
31	interventricular	O
32	pressure	O
33	differences	O
34	(	O
35	r	O
36	=	O
37	-	O
38	0	O
39	.	O
40	95	O
41	,	O
42	p	O
43	less	O
44	than	O
45	0	O
46	.	O
47	001	O
48	).	O

1	The	O
2	ED30	O
3	values	O
4	were	O
5	2	O
6	.	O
7	4	O
8	and	O
9	2	O
10	.	O
11	2	O
12	mg	O
13	/	O
14	kg	O
15	and	O
16	similar	O
17	to	O
18	the	O
19	respective	O
20	values	O
21	of	O
22	nifedipine	O
23	(	O
24	ED	O
25	30	O
26	:	O
27	2	O
28	.	O
29	4	O
30	,	O
31	2	O
32	.	O
33	1	O
34	mg	O
35	/	O
36	kg	O
37	).	O

1	We	O
2	have	O
3	found	O
4	that	O
5	PEA2	O
6	is	O
7	also	O
8	required	O
9	for	O
10	the	O
11	bipolar	O
12	budding	O
13	pattern	O
14	and	O
15	that	O
16	it	O
17	encodes	O
18	a	O
19	novel	O
20	protein	O
21	with	O
22	a	O
23	predicted	O
24	coiled	O
25	-	O
26	coil	O
27	domain	O
28	.	O

1	GRFI	O
2	bound	O
3	to	O
4	sequences	O
5	at	O
6	the	O
7	negative	O
8	regulatory	O
9	elements	O
10	(	O
11	silencers	O
12	)	O
13	of	O
14	the	O
15	silent	O
16	mating	O
17	type	O
18	loci	O
19	HML	O
20	E	O
21	and	O
22	HMR	O
23	E	O
24	and	O
25	to	O
26	the	O
27	upstream	O
28	activating	O
29	sequence	O
30	(	O
31	UAS	O
32	)	O
33	required	O
34	for	O
35	transcription	O
36	of	O
37	the	O
38	MAT	B
39	alpha	I
40	genes	I
41	.	O

1	It	O
2	is	O
3	suggested	O
4	that	O
5	a	O
6	raised	O
7	hydroxykynurenine	O
8	/	O
9	hydroxyanthranilic	O
10	acid	O
11	ratio	O
12	does	O
13	not	O
14	necessarily	O
15	indicate	O
16	vitamin	O
17	B6	O
18	deficiency	O
19	but	O
20	may	O
21	represent	O
22	a	O
23	nonspecific	O
24	response	O
25	of	O
26	tryptophan	O
27	metabolism	O
28	to	O
29	stress	O
30	.	O

1	Although	O
2	some	O
3	residues	O
4	are	O
5	found	O
6	reactive	O
7	toward	O
8	dimethylsulphate	O
9	and	O
10	kethoxal	O
11	in	O
12	regions	O
13	predicted	O
14	to	O
15	be	O
16	unpaired	O
17	by	O
18	the	O
19	phylogenetic	O
20	secondary	O
21	structure	O
22	model	O
23	of	O
24	4	O
25	.	O
26	5S	O
27	RNA	O
28	,	O
29	generally	O
30	the	O
31	reactivity	O
32	is	O
33	low	O
34	,	O
35	and	O
36	some	O
37	residues	O
38	in	O
39	internal	O
40	loops	O
41	are	O
42	not	O
43	reactive	O
44	at	O
45	all	O
46	.	O

1	A	O
2	late	O
3	diagnosis	O
4	of	O
5	retinoblastoma	O
6	is	O
7	an	O
8	unquestionable	O
9	fact	O
10	that	O
11	allows	O
12	its	O
13	growth	O
14	and	O
15	leads	O
16	to	O
17	a	O
18	deterioration	O
19	in	O
20	the	O
21	outlook	O
22	.	O

1	Treatment	O
2	of	O
3	ovarian	O
4	neoplasms	O

1	All	O
2	patients	O
3	had	O
4	abnormal	O
5	von	B
6	Willebrand	I
7	factor	I
8	(	O
9	vWF	O
10	)	O
11	fragmentation	O
12	as	O
13	reflected	O
14	by	O
15	decreased	O
16	high	O
17	molecular	O
18	weight	O
19	and	O
20	increased	O
21	low	O
22	molecular	O
23	weight	O
24	vWF	O
25	multimers	O
26	in	O
27	the	O
28	circulation	O
29	.	O

1	All	O
2	62	O
3	isolates	O
4	were	O
5	resistant	O
6	to	O
7	lincomycin	O
8	,	O
9	colistin	O
10	,	O
11	nystatin	O
12	,	O
13	amphotericin	O
14	B	O
15	,	O
16	trimethoprim	O
17	lactate	O
18	,	O
19	polymyxin	O
20	B	O
21	,	O
22	and	O
23	anisomycin	O
24	.	O

1	Mutations	O
2	at	O
3	three	O
4	sites	O
5	have	O
6	larger	O
7	effects	O
8	in	O
9	muscle	O
10	than	O
11	nonmuscle	O
12	cells	O
13	;	O
14	an	O
15	A	O
16	/	O
17	T	O
18	-	O
19	rich	O
20	site	O
21	mutation	O
22	has	O
23	a	O
24	pronounced	O
25	effect	O
26	in	O
27	both	O
28	striated	O
29	muscle	O
30	types	O
31	,	O
32	mutations	O
33	at	O
34	the	O
35	MEF1	O
36	(	O
37	Right	O
38	E	O
39	-	O
40	box	O
41	)	O
42	site	O
43	are	O
44	relatively	O
45	specific	O
46	to	O
47	expression	O
48	in	O
49	skeletal	O
50	muscle	O
51	,	O
52	and	O
53	mutations	O
54	at	O
55	the	O
56	CArG	O
57	site	O
58	are	O
59	relatively	O
60	specific	O
61	to	O
62	expression	O
63	in	O
64	cardiac	O
65	muscle	O
66	.	O

1	Significant	O
2	correlations	O
3	existed	O
4	between	O
5	FEV1	O
6	and	O
7	the	O
8	corresponding	O
9	values	O
10	of	O
11	Raw	O
12	,	O
13	MEF50	O
14	and	O
15	MEF25	O
16	,	O
17	although	O
18	there	O
19	were	O
20	considerable	O
21	individual	O
22	differences	O
23	between	O
24	test	O
25	results	O
26	.	O

1	In	O
2	particular	O
3	,	O
4	Western	O
5	,	O
6	supershift	O
7	,	O
8	and	O
9	promoter	O
10	deletion	O
11	analyses	O
12	suggested	O
13	a	O
14	role	O
15	for	O
16	CCAAT	B
17	/	I
18	enhancer	I
19	-	I
20	binding	I
21	protein	I
22	-	I
23	beta	I
24	(	I
25	C	I
26	/	I
27	EBP	I
28	-	I
29	beta	I
30	)	O
31	binding	O
32	site	O
33	between	O
34	-	O
35	2010	O
36	and	O
37	-	O
38	1954	O
39	in	O
40	regulating	O
41	transcription	O
42	of	O
43	collagenase	B
44	-	I
45	1	I
46	in	O
47	monocytic	O
48	cells	O
49	.	O

1	The	O
2	frequency	O
3	of	O
4	previous	O
5	transfusion	O
6	in	O
7	chronic	O
8	hepatitis	O
9	,	O
10	cirrhosis	O
11	and	O
12	hepatocellular	O
13	carcinoma	O
14	of	O
15	type	O
16	NANB	O
17	was	O
18	42	O
19	.	O
20	8	O
21	,	O
22	37	O
23	.	O
24	1	O
25	and	O
26	15	O
27	.	O
28	1	O
29	%,	O
30	respectively	O
31	,	O
32	whereas	O
33	the	O
34	incidence	O
35	of	O
36	early	O
37	posttransfusion	O
38	hepatitis	O
39	was	O
40	8	O
41	.	O
42	5	O
43	,	O
44	8	O
45	.	O
46	6	O
47	and	O
48	7	O
49	.	O
50	5	O
51	%,	O
52	respectively	O
53	.	O
54	in	O
55	chronic	O
56	liver	O
57	diseases	O
58	with	O
59	a	O
60	history	O
61	of	O
62	jaundice	O
63	and	O
64	/	O
65	or	O
66	hepatitis	O
67	,	O
68	previous	O
69	transfusions	O
70	are	O
71	more	O
72	frequently	O
73	associated	O
74	with	O
75	type	O
76	NANB	O
77	than	O
78	with	O
79	type	O
80	B	O
81	disease	O
82	.	O

1	Likewise	O
2	,	O
3	at	O
4	150	O
5	degrees	O
6	C	O
7	with	O
8	2	O
9	%	O
10	APS	O
11	the	O
12	surface	O
13	density	O
14	of	O
15	NH2	O
16	groups	O
17	reached	O
18	a	O
19	maximum	O
20	at	O
21	24	O
22	hr	O
23	and	O
24	remained	O
25	relatively	O
26	constant	O
27	up	O
28	to	O
29	96	O
30	hr	O
31	.	O

1	(	O
2	iii	O
3	)	O
4	In	O
5	these	O
6	cells	O
7	,	O
8	PKCbeta	O
9	plays	O
10	a	O
11	unique	O
12	Ras	B
13	-	I
14	independent	O
15	role	O
16	in	O
17	mediating	O
18	insulin	B
19	but	O
20	not	O
21	EGF	B
22	or	O
23	other	O
24	growth	O
25	factor	O
26	mitogenic	O
27	signals	O
28	.	O

1	Transcription	O
2	factors	O
3	containing	O
4	a	O
5	basic	B
6	helix	I
7	-	I
8	loop	I
9	-	I
10	helix	I
11	(	O
12	bHLH	O
13	)	O
14	motif	O
15	regulate	O
16	the	O
17	expression	O
18	of	O
19	tissue	O
20	-	O
21	specific	O
22	genes	O
23	in	O
24	a	O
25	number	O
26	of	O
27	mammalian	O
28	and	O
29	insect	O
30	systems	O
31	.	O

1	The	O
2	incidence	O
3	of	O
4	cardiac	O
5	death	O
6	(	O
7	one	O
8	per	O
9	group	O
10	),	O
11	Q	O
12	wave	O
13	MI	O
14	(	O
15	propofol	O
16	,	O
17	n	O
18	=	O
19	7	O
20	;	O
21	midazolam	O
22	,	O
23	n	O
24	=	O
25	3	O
26	;	O
27	P	O
28	=	O
29	0	O
30	.	O
31	27	O
32	),	O
33	or	O
34	non	O
35	Q	O
36	wave	O
37	MI	O
38	(	O
39	propofol	O
40	,	O
41	n	O
42	=	O
43	16	O
44	;	O
45	midazolam	O
46	,	O
47	n	O
48	=	O
49	18	O
50	;	O
51	P	O
52	=	O
53	0	O
54	.	O
55	81	O
56	)	O
57	did	O
58	not	O
59	differ	O
60	between	O
61	treatment	O
62	groups	O
63	.	O

1	Thus	O
2	,	O
3	hGRbeta	O
4	potentially	O
5	functions	O
6	as	O
7	a	O
8	dominant	O
9	negative	O
10	inhibitor	O
11	of	O
12	hGRalpha	O
13	activity	O
14	.	O

1	Female	O
2	but	O
3	not	O
4	male	O
5	mortalities	O
6	were	O
7	significantly	O
8	higher	O
9	for	O
10	cake	O
11	-	O
12	fed	O
13	rats	O
14	than	O
15	for	O
16	those	O
17	fed	O
18	diet	O
19	41B	O
20	.	O

1	We	O
2	did	O
3	not	O
4	detect	O
5	p50	B
6	in	O
7	association	O
8	with	O
9	native	O
10	glucocorticoid	B
11	receptor	I
12	in	O
13	L	O
14	cells	O
15	or	O
16	with	O
17	the	O
18	overexpressed	O
19	glucocorticoid	B
20	receptor	I
21	in	O
22	Chinese	O
23	hamster	O
24	ovary	O
25	cells	O
26	.	O

1	1	O
2	A	O
3	colonic	O
4	delivery	O
5	system	O
6	is	O
7	described	O
8	to	O
9	deliver	O
10	orally	O
11	ingested	O
12	drugs	O
13	to	O
14	the	O
15	colon	O
16	and	O
17	release	O
18	them	O
19	at	O
20	that	O
21	site	O
22	by	O
23	coating	O
24	with	O
25	an	O
26	acrylic	O
27	based	O
28	resin	O
29	(	O
30	Eudragit	O
31	S	O
32	).	O

1	Thus	O
2	,	O
3	blocks	O
4	in	O
5	the	O
6	RARalpha	O
7	-	O
8	specific	O
9	pathway	O
10	of	O
11	retinoid	O
12	-	O
13	induced	O
14	differentiation	O
15	may	O
16	be	O
17	bypassed	O
18	during	O
19	retinoid	O
20	induction	O
21	of	O
22	FR	B
23	-	I
24	beta	I
25	expression	O
26	.	O

1	There	O
2	was	O
3	a	O
4	weak	O
5	significant	O
6	correlation	O
7	between	O
8	TGF	B
9	beta	I
10	1	I
11	levels	O
12	and	O
13	normal	O
14	cell	O
15	radiosensitivity	O
16	(	O
17	lymphocyte	O
18	SF2	O
19	).	O

1	The	O
2	investigation	O
3	was	O
4	apt	O
5	at	O
6	studying	O
7	the	O
8	relationship	O
9	between	O
10	urinary	O
11	metabolites	O
12	of	O
13	serotonin	O
14	and	O
15	catecholamine	O
16	(	O
17	5	O
18	-	O
19	HIAA	O
20	and	O
21	VMA	O
22	),	O
23	T	O
24	-	O
25	cells	O
26	(	O
27	OKT3	O
28	+),	O
29	T	O
30	-	O
31	helper	O
32	(	O
33	OKT4	O
34	+),	O
35	T	O
36	-	O
37	suppressor	O
38	(	O
39	OKT8	O
40	+)	O
41	and	O
42	B	O
43	-	O
44	cells	O
45	(	O
46	EAC	O
47	-	O
48	rosette	O
49	forming	O
50	cells	O
51	)	O
52	in	O
53	normal	O
54	(	O
55	10	O
56	subjects	O
57	,	O
58	1	O
59	female	O
60	,	O
61	9	O
62	male	O
63	,	O
64	age	O
65	21	O
66	+/-	O
67	5	O
68	years	O
69	)	O
70	and	O
71	stress	O
72	administered	O
73	subjects	O
74	(	O
75	20	O
76	subjects	O
77	,	O
78	3	O
79	female	O
80	,	O
81	17	O
82	male	O
83	,	O
84	age	O
85	20	O
86	+/-	O
87	4	O
88	years	O
89	).	O

1	Molecular	O
2	cloning	O
3	and	O
4	expression	O
5	of	O
6	RPE65	O
7	,	O
8	a	O
9	novel	O
10	retinal	O
11	pigment	O
12	epithelium	O
13	-	O
14	specific	O
15	microsomal	O
16	protein	O
17	that	O
18	is	O
19	post	O
20	-	O
21	transcriptionally	O
22	regulated	O
23	in	O
24	vitro	O
25	.	O

1	The	O
2	most	O
3	common	O
4	types	O
5	of	O
6	malformations	O
7	were	O
8	eye	O
9	defects	O
10	and	O
11	open	O
12	coeloms	O
13	.	O

1	They	O
2	lack	O
3	a	O
4	predicted	O
5	single	O
6	stranded	O
7	(	O
8	ss	O
9	)	O
10	DNA	O
11	binding	O
12	motif	O
13	that	O
14	is	O
15	unique	O
16	the	O
17	large	O
18	terminase	B
19	proteins	I
20	in	O
21	T4	O
22	gp17	O
23	,	O
24	and	O
25	that	O
26	has	O
27	been	O
28	implicated	O
29	in	O
30	recognizing	O
31	ssDNA	O
32	regions	O
33	in	O
34	replicating	O
35	and	O
36	recombining	O
37	T4DNA	O
38	destined	O
39	to	O
40	be	O
41	packaged	O
42	.	O

1	The	O
2	exogenous	B
3	fos	I
4	gene	I
5	was	O
6	rapidly	O
7	induced	O
8	to	O
9	maximal	O
10	levels	O
11	within	O
12	1	O
13	-	O
14	2	O
15	hr	O
16	of	O
17	estrogen	O
18	addition	O
19	.	O

1	Selection	O
2	was	O
3	based	O
4	on	O
5	expression	O
6	of	O
7	an	O
8	integrated	O
9	DNA	O
10	fragment	O
11	containing	O
12	the	O
13	con	O
14	-	O
15	10	O
16	promoter	O
17	-	O
18	regulatory	O
19	region	O
20	followed	O
21	by	O
22	the	O
23	initial	O
24	segment	O
25	of	O
26	the	O
27	con	O
28	-	O
29	10	O
30	open	O
31	reading	O
32	frame	O
33	fused	O
34	in	O
35	frame	O
36	with	O
37	the	O
38	bacterial	B
39	hygromycin	I
40	B	I
41	phosphotransferase	I
42	structural	I
43	gene	I
44	(	O
45	con10	O
46	'-'	O
47	hph	O
48	).	O

1	Etiopathogenetic	O
2	and	O
3	therapeutic	O
4	problems	O
5	in	O
6	acute	O
7	orbital	O
8	inflammation	O

1	Depleted	O
2	and	O
3	enriched	O
4	U3O8	O
5	standard	O
6	reference	O
7	materials	O
8	were	O
9	used	O
10	to	O
11	calibrate	O
12	the	O
13	system	O
14	.	O

1	The	O
2	correcting	O
3	action	O
4	of	O
5	tropatepine	O
6	hydrochloride	O
7	upon	O
8	the	O
9	extrapyramidal	O
10	effects	O
11	induced	O
12	by	O
13	neuroleptics	O
14	has	O
15	been	O
16	studied	O
17	in	O
18	32	O
19	acute	O
20	psychotic	O
21	states	O
22	.	O

1	METHODS	O
2	:	O
3	The	O
4	most	O
5	distal	O
6	muscle	O
7	fibres	O
8	from	O
9	the	O
10	deep	O
11	and	O
12	superficial	O
13	finger	O
14	flexors	O
15	were	O
16	measured	O
17	relative	O
18	to	O
19	the	O
20	pisiform	O
21	bone	O
22	in	O
23	18	O
24	cadaveric	O
25	specimens	O
26	.	O

1	The	O
2	combination	O
3	of	O
4	Pitx2	O
5	and	O
6	another	O
7	homeodomain	B
8	protein	I
9	,	O
10	Pit	B
11	-	I
12	1	I
13	,	O
14	yielded	O
15	a	O
16	synergistic	O
17	55	O
18	-	O
19	fold	O
20	activation	O
21	of	O
22	the	O
23	prolactin	B
24	promoter	I
25	in	O
26	transfection	O
27	assays	O
28	.	O

1	CONCLUSION	O
2	:	O
3	Twice	O
4	daily	O
5	treatment	O
6	with	O
7	inhaled	O
8	fluticasone	O
9	propionate	O
10	50	O
11	micrograms	O
12	or	O
13	100	O
14	micrograms	O
15	was	O
16	significantly	O
17	more	O
18	effective	O
19	than	O
20	theophylline	O
21	in	O
22	the	O
23	treatment	O
24	of	O
25	mild	O
26	-	O
27	to	O
28	-	O
29	moderate	O
30	asthma	O
31	.	O

1	A	O
2	substantial	O
3	fraction	O
4	of	O
5	Cbl	B
6	was	O
7	constitutively	O
8	associated	O
9	with	O
10	Grb2	B
11	and	O
12	this	O
13	interaction	O
14	was	O
15	mediated	O
16	by	O
17	Grb2	B
18	SH3	I
19	domains	I
20	.	O

1	Role	O
2	of	O
3	superoxide	B
4	dismutase	I
5	in	O
6	cellular	O
7	oxidative	O
8	processes	O
9	and	O
10	method	O
11	of	O
12	its	O
13	determination	O
14	in	O
15	biological	O
16	materials	O

1	Selective	O
2	visual	O
3	attention	O
4	involves	O
5	dynamic	O
6	interplay	O
7	between	O
8	attentional	O
9	control	O
10	systems	O
11	and	O
12	sensory	O
13	brain	O
14	structures	O
15	.	O

1	The	O
2	proofreading	O
3	domain	O
4	of	O
5	Escherichia	B
6	coli	I
7	DNA	I
8	polymerase	I
9	I	I
10	and	O
11	other	O
12	DNA	O
13	and	O
14	/	O
15	or	O
16	RNA	O
17	exonuclease	O
18	domains	O
19	.	O

1	Senior	O
2	systems	O
3	--	O
4	45	O
5	;	O
6	Mental	O
7	health	O
8	and	O
9	illness	O
10	in	O
11	old	O
12	age	O
13	--	O
14	3	O
15	.	O

1	We	O
2	show	O
3	here	O
4	that	O
5	v	B
6	-	I
7	Rel	I
8	specifically	O
9	increased	O
10	expression	O
11	from	O
12	a	O
13	reporter	O
14	plasmid	O
15	containing	O
16	multiple	O
17	Sp1	B
18	binding	I
19	sites	I
20	approximately	O
21	sixfold	O
22	in	O
23	chicken	O
24	embryo	O
25	fibroblasts	O
26	(	O
27	CEFs	O
28	),	O
29	even	O
30	though	O
31	v	B
32	-	I
33	Rel	I
34	did	O
35	not	O
36	bind	O
37	directly	O
38	to	O
39	these	O
40	sites	O
41	.	O
42	v	B
43	-	I
44	Rel	I
45	also	O
46	increased	O
47	expression	O
48	from	O
49	a	O
50	reporter	O
51	plasmid	O
52	containing	O
53	a	O
54	human	O
55	immunodeficiency	O
56	virus	O
57	type	O
58	1	O
59	(	O
60	HIV	O
61	-	O
62	1	O
63	)	O
64	long	O
65	terminal	O
66	repeat	O
67	(	O
68	LTR	O
69	)	O
70	in	O
71	which	O
72	the	O
73	kappa	B
74	B	I
75	binding	I
76	sites	I
77	were	O
78	mutated	O
79	but	O
80	which	O
81	still	O
82	contained	O
83	intact	O
84	Sp1	B
85	binding	I
86	sites	I
87	.	O

1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	cells	O
7	containing	O
8	a	O
9	PTP1C	O
10	in	O
11	which	O
12	the	O
13	catalytic	O
14	site	O
15	had	O
16	been	O
17	inactivated	O
18	through	O
19	mutagenesis	O
20	,	O
21	stably	O
22	phosphorylated	O
23	the	O
24	phosphatase	O
25	.	O

1	The	O
2	pyrR	O
3	and	O
4	pyrP	O
5	genes	O
6	encoded	O
7	polypeptides	O
8	with	O
9	calculated	O
10	molecular	O
11	masses	O
12	of	O
13	19	O
14	.	O
15	9	O
16	and	O
17	45	O
18	.	O
19	2	O
20	kDa	O
21	,	O
22	respectively	O
23	.	O

1	Notably	O
2	,	O
3	SRF	B
4	has	O
5	been	O
6	found	O
7	to	O
8	be	O
9	a	O
10	key	O
11	regulator	O
12	of	O
13	members	O
14	of	O
15	a	O
16	class	O
17	of	O
18	cellular	O
19	response	O
20	genes	O
21	termed	O
22	immediate	O
23	-	O
24	early	O
25	genes	O
26	(	O
27	IEGs	O
28	),	O
29	many	O
30	of	O
31	which	O
32	are	O
33	believed	O
34	to	O
35	be	O
36	involved	O
37	in	O
38	regulating	O
39	cell	O
40	growth	O
41	and	O
42	differentiation	O
43	.	O

1	In	O
2	summary	O
3	,	O
4	the	O
5	efficacies	O
6	of	O
7	adjuvant	O
8	carboplatin	O
9	and	O
10	of	O
11	abdominal	O
12	radiotherapy	O
13	seem	O
14	to	O
15	be	O
16	identical	O
17	.	O

1	The	O
2	R	O
3	.	O
4	meliloti	O
5	nifH	B
6	promoter	I
7	but	O
8	not	O
9	the	O
10	K	O
11	.	O
12	pneumoniae	O
13	nifH	B
14	promoter	I
15	showed	O
16	sigma	B
17	54	I
18	-	I
19	dependent	I
20	methylation	O
21	protection	O
22	of	O
23	guanine	O
24	residues	O
25	at	O
26	-	O
27	14	O
28	,	O
29	-	O
30	25	O
31	and	O
32	-	O
33	26	O
34	,	O
35	the	O
36	most	O
37	conserved	O
38	nucleotides	O
39	characteristic	O
40	of	O
41	sigma	B
42	54	I
43	-	I
44	dependent	I
45	promoters	I
46	.	O

1	PKNbeta	O
2	had	O
3	high	O
4	sequence	O
5	homology	O
6	with	O
7	PKNalpha	O
8	,	O
9	originally	O
10	isolated	O
11	PKN	O
12	,	O
13	especially	O
14	in	O
15	the	O
16	repeats	O
17	of	O
18	charged	O
19	amino	O
20	acid	O
21	-	O
22	rich	O
23	region	O
24	with	O
25	leucine	O
26	-	O
27	zipper	O
28	like	O
29	sequences	O
30	(	O
31	CZ	O
32	region	O
33	/	O
34	HR1	O
35	),	O
36	in	O
37	the	O
38	carboxyl	O
39	-	O
40	terminal	O
41	catalytic	O
42	domain	O
43	,	O
44	and	O
45	in	O
46	approximately	O
47	130	O
48	amino	O
49	acid	O
50	stretch	O
51	(	O
52	D	O
53	region	O
54	/	O
55	HR2	O
56	),	O
57	located	O
58	between	O
59	CZ	O
60	region	O
61	/	O
62	HR1	O
63	and	O
64	the	O
65	catalytic	O
66	domain	O
67	.	O

1	The	O
2	majority	O
3	of	O
4	PI	B
5	kinase	I
6	activity	O
7	appeared	O
8	to	O
9	be	O
10	cbl	O
11	-	O
12	associated	O
13	after	O
14	PRL	B
15	stimulation	O
16	.	O

1	Cytoskeletal	O
2	polarization	O
3	of	O
4	T	O
5	cells	O
6	is	O
7	regulated	O
8	by	O
9	an	O
10	immunoreceptor	O
11	tyrosine	O
12	-	O
13	based	O
14	activation	O
15	motif	O
16	-	O
17	dependent	O
18	mechanism	O
19	.	O

1	Regulation	O
2	of	O
3	RhoA	B
4	is	O
5	required	O
6	to	O
7	maintain	O
8	adhesion	O
9	in	O
10	stationary	O
11	cells	O
12	,	O
13	but	O
14	is	O
15	also	O
16	critical	O
17	for	O
18	cell	O
19	spreading	O
20	and	O
21	migration	O
22	[	O
23	3	O
24	].	O

1	Also	O
2	discussed	O
3	is	O
4	the	O
5	possibility	O
6	of	O
7	a	O
8	combined	O
9	genetic	O
10	and	O
11	environmental	O
12	etiology	O
13	.	O

1	Thus	O
2	,	O
3	IRF	B
4	-	I
5	7	O
6	exhibits	O
7	functional	O
8	similarity	O
9	to	O
10	IRF	B
11	-	I
12	3	O
13	;	O
14	however	O
15	,	O
16	the	O
17	preferential	O
18	expression	O
19	of	O
20	IRF	B
21	-	I
22	7	O
23	in	O
24	lymphoid	O
25	cells	O
26	(	O
27	the	O
28	cell	O
29	type	O
30	that	O
31	expresses	O
32	IFNA	O
33	)	O
34	suggests	O
35	that	O
36	IRF	B
37	-	I
38	7	O
39	may	O
40	play	O
41	a	O
42	critical	O
43	role	O
44	in	O
45	regulating	O
46	the	O
47	IFNA	O
48	gene	O
49	expression	O
50	.	O

1	However	O
2	,	O
3	using	O
4	ATL	O
5	-	O
6	16T	O
7	nuclear	O
8	extract	O
9	,	O
10	we	O
11	demonstrated	O
12	that	O
13	GATA	B
14	-	I
15	4	O
16	is	O
17	the	O
18	only	O
19	GATA	B
20	-	I
21	binding	I
22	protein	I
23	that	O
24	forms	O
25	specific	O
26	DNA	O
27	-	O
28	protein	O
29	complex	O
30	with	O
31	the	O
32	-	O
33	70	O
34	GATA	B
35	site	I
36	.	O

1	Low	O
2	-	O
3	grade	O
4	gastric	O
5	MALT	O
6	lymphoma	O
7	and	O
8	helicobacter	O
9	heilmannii	O
10	(	O
11	Gastrospirillum	O
12	hominis	O

1	This	O
2	study	O
3	analyzed	O
4	whether	O
5	the	O
6	localization	O
7	of	O
8	an	O
9	accessory	O
10	pathway	O
11	could	O
12	be	O
13	predicted	O
14	by	O
15	using	O
16	the	O
17	polarity	O
18	of	O
19	the	O
20	QRS	O
21	complex	O
22	during	O
23	sinus	O
24	rhythm	O
25	on	O
26	the	O
27	surface	O
28	ECG	O
29	,	O
30	instead	O
31	of	O
32	the	O
33	delta	O
34	wave	O
35	polarity	O
36	as	O
37	used	O
38	in	O
39	many	O
40	reports	O
41	.	O

1	The	O
2	two	O
3	mouse	O
4	lines	O
5	carrying	O
6	the	O
7	unfragmented	O
8	Hnf3g	O
9	-	O
10	lacZ	B
11	YAC	O
12	showed	O
13	tissue	O
14	-	O
15	specific	O
16	,	O
17	copy	O
18	number	O
19	-	O
20	dependent	O
21	and	O
22	position	O
23	-	O
24	independent	O
25	expression	O
26	,	O
27	proving	O
28	that	O
29	170	O
30	kb	O
31	of	O
32	the	O
33	Hnf3g	O
34	locus	O
35	contain	O
36	all	O
37	elements	O
38	important	O
39	in	O
40	the	O
41	regulation	O
42	of	O
43	Hnf3g	O
44	.	O

1	However	O
2	,	O
3	when	O
4	domain	O
5	I	O
6	and	O
7	domain	O
8	II	O
9	were	O
10	linked	O
11	on	O
12	the	O
13	same	O
14	plasmid	O
15	,	O
16	high	O
17	levels	O
18	of	O
19	replication	O
20	were	O
21	observed	O
22	.	O

1	We	O
2	found	O
3	that	O
4	the	O
5	3	O
6	'-	O
7	end	O
8	-	O
9	adjacent	O
10	sequence	O
11	CA	O
12	(	O
13	N	O
14	)	O
15	3	O
16	-	O
17	10AGTNNAA	O
18	,	O
19	conserved	O
20	in	O
21	plant	O
22	Pol	B
23	II	I
24	-	I
25	specific	I
26	U	I
27	snRNA	I
28	genes	I
29	,	O
30	is	O
31	essential	O
32	for	O
33	the	O
34	3	O
35	'-	O
36	end	O
37	formation	O
38	of	O
39	U2	B
40	transcripts	I
41	and	O
42	,	O
43	similar	O
44	to	O
45	the	O
46	vertebrate	O
47	3	O
48	'	O
49	box	O
50	,	O
51	is	O
52	highly	O
53	tolerant	O
54	to	O
55	mutation	O
56	.	O

1	The	O
2	influenza	O
3	virus	O
4	NS1	B
5	protein	I
6	is	O
7	a	O
8	unique	O
9	posttranscriptional	O
10	regulator	O
11	that	O
12	has	O
13	two	O
14	activities	O
15	:	O
16	inhibition	O
17	of	O
18	the	O
19	nuclear	O
20	export	O
21	of	O
22	poly	O
23	A	O
24	-	O
25	containing	O
26	mRNAs	O
27	and	O
28	inhibition	O
29	of	O
30	pre	O
31	-	O
32	mRNA	O
33	splicing	O
34	.	O

1	Determination	O
2	of	O
3	an	O
4	RNA	O
5	structure	O
6	involved	O
7	in	O
8	splicing	O
9	inhibition	O
10	of	O
11	a	O
12	muscle	O
13	-	O
14	specific	O
15	exon	O
16	.	O

1	PAI	B
2	-	I
3	1	I
4	levels	O
5	increased	O
6	significantly	O
7	in	O
8	patients	O
9	who	O
10	received	O
11	iohexol	O
12	but	O
13	not	O
14	in	O
15	those	O
16	who	O
17	received	O
18	ioxaglate	O
19	.	O

1	In	O
2	controls	O
3	,	O
4	only	O
5	modest	O
6	differences	O
7	were	O
8	observed	O
9	.	O

1	Surprisingly	O
2	,	O
3	the	O
4	CSF1R	O
5	/	O
6	IRDelta960	O
7	was	O
8	as	O
9	effective	O
10	as	O
11	the	O
12	CSF1R	O
13	/	O
14	IR	O
15	in	O
16	mediating	O
17	CSF	B
18	-	I
19	1	I
20	protection	O
21	of	O
22	cells	O
23	from	O
24	staurosporine	O
25	-	O
26	induced	O
27	apoptosis	O
28	.	O

1	The	O
2	intercistronic	O
3	gene	O
4	junctions	O
5	of	O
6	vesicular	O
7	stomatitis	O
8	virus	O
9	(	O
10	VSV	O
11	)	O
12	contain	O
13	conserved	O
14	sequence	O
15	elements	O
16	that	O
17	are	O
18	important	O
19	for	O
20	polyadenylation	O
21	and	O
22	transcription	O
23	termination	O
24	of	O
25	upstream	O
26	transcript	O
27	as	O
28	well	O
29	as	O
30	reinitiation	O
31	of	O
32	transcription	O
33	of	O
34	downstream	O
35	transcript	O
36	.	O

1	B	B
2	cell	I
3	antigen	I
4	receptor	I
5	(	O
6	BCR	B
7	)-	I
8	mediated	O
9	formation	O
10	of	O
11	a	O
12	SHP	B
13	-	I
14	2	I
15	-	I
16	pp120	O
17	complex	O
18	and	O
19	its	O
20	inhibition	O
21	by	O
22	Fc	B
23	gamma	I
24	RIIB1	I
25	-	I
26	BCR	I
27	coligation	O
28	.	O

1	Although	O
2	YopH	O
3	is	O
4	a	O
5	highly	O
6	active	O
7	PTP	O
8	,	O
9	it	O
10	preferentially	O
11	targets	O
12	a	O
13	subset	O
14	of	O
15	tyrosine	O
16	-	O
17	phosphorylated	O
18	proteins	O
19	in	O
20	host	O
21	cells	O
22	,	O
23	including	O
24	p130Cas	O
25	.	O

1	In	O
2	E	O
3	.	O
4	coli	O
5	,	O
6	CheW	O
7	mediates	O
8	the	O
9	physical	O
10	coupling	O
11	of	O
12	the	O
13	receptors	O
14	to	O
15	the	O
16	kinase	O
17	CheA	O
18	.	O

1	CONCLUSION	O
2	:	O
3	These	O
4	findings	O
5	imply	O
6	that	O
7	eotaxin	O
8	either	O
9	is	O
10	mechanistically	O
11	involved	O
12	in	O
13	acute	O
14	asthma	O
15	or	O
16	serves	O
17	as	O
18	a	O
19	biomarker	O
20	for	O
21	activity	O
22	of	O
23	the	O
24	CCR3	O
25	receptor	O
26	ligand	O
27	system	O
28	,	O
29	which	O
30	is	O
31	functionally	O
32	linked	O
33	to	O
34	asthma	O
35	.	O

1	The	O
2	Drosophila	O
3	insulin	B
4	receptor	I
5	homolog	I
6	:	O
7	a	O
8	gene	O
9	essential	O
10	for	O
11	embryonic	O
12	development	O
13	encodes	O
14	two	O
15	receptor	O
16	isoforms	O
17	with	O
18	different	O
19	signaling	O
20	potential	O
21	.	O

1	Two	O
2	sterol	B
3	regulatory	I
4	element	I
5	-	I
6	like	I
7	sequences	O
8	mediate	O
9	up	O
10	-	O
11	regulation	O
12	of	O
13	caveolin	B
14	gene	I
15	transcription	O
16	in	O
17	response	O
18	to	O
19	low	O
20	density	O
21	lipoprotein	O
22	free	O
23	cholesterol	O
24	.	O

1	Our	O
2	data	O
3	therefore	O
4	indicate	O
5	that	O
6	it	O
7	is	O
8	possible	O
9	to	O
10	engineer	O
11	the	O
12	HA	B
13	envelope	I
14	glycoprotein	I
15	by	O
16	fusing	O
17	ligands	O
18	to	O
19	its	O
20	amino	O
21	-	O
22	terminal	O
23	end	O
24	without	O
25	affecting	O
26	its	O
27	fusion	O
28	activity	O
29	.	O

1	Localization	O
2	of	O
3	the	O
4	brachial	O
5	plexus	O
6	with	O
7	the	O
8	nerve	O
9	stimulator	O
10	is	O
11	equally	O
12	effective	O
13	at	O
14	the	O
15	interscalene	O
16	,	O
17	supraclavicular	O
18	,	O
19	and	O
20	axillary	O
21	sites	O
22	.	O

1	Characterization	O
2	of	O
3	the	O
4	microtubule	O
5	binding	O
6	domain	O
7	of	O
8	microtubule	B
9	actin	I
10	crosslinking	I
11	factor	I
12	(	O
13	MACF	O
14	):	O
15	identification	O
16	of	O
17	a	O
18	novel	O
19	group	O
20	of	O
21	microtubule	O
22	associated	O
23	proteins	O
24	.	O

1	The	O
2	problem	O
3	of	O
4	disablement	O
5	due	O
6	to	O
7	pulmonary	O
8	tuberculosis	O
9	,	O
10	on	O
11	the	O
12	basis	O
13	of	O
14	an	O
15	analysis	O
16	of	O
17	the	O
18	history	O
19	of	O
20	395	O
21	cases	O
22	as	O
23	observed	O
24	in	O
25	Gdansk	O
26	in	O
27	the	O
28	years	O
29	1946	O
30	-	O
31	1965	O

1	The	O
2	predicted	O
3	amino	O
4	acid	O
5	sequence	O
6	exhibited	O
7	70	O
8	%	O
9	identity	O
10	to	O
11	that	O
12	of	O
13	Bacillus	O
14	stearothermophilus	O
15	TyrTS	O
16	and	O
17	55	O
18	%	O
19	identity	O
20	to	O
21	that	O
22	of	O
23	E	O
24	.	O
25	coli	O
26	TyrTS	O
27	,	O
28	while	O
29	identity	O
30	to	O
31	a	O
32	second	O
33	cryptic	O
34	B	O
35	.	O
36	subtilis	O
37	TyrTS	O
38	gene	O
39	,	O
40	designated	O
41	tyrZ	O
42	,	O
43	was	O
44	only	O
45	27	O
46	%.	O

1	GlcNAc	O
2	-	O
3	and	O
4	GlcNAc2	O
5	-	O
6	PP	O
7	-	O
8	Dolichol	O
9	biosynthesis	O
10	could	O
11	be	O
12	shown	O
13	with	O
14	isolated	O
15	S	O
16	.	O
17	cerevisiae	O
18	membranes	O
19	from	O
20	cells	O
21	harboring	O
22	the	O
23	recombinant	O
24	plasmid	O
25	and	O
26	grown	O
27	on	O
28	glucose	O
29	thus	O
30	suppressing	O
31	transcription	O
32	of	O
33	the	O
34	endogenous	O
35	gene	O
36	.	O

1	Results	O
2	of	O
3	a	O
4	controlled	O
5	study	O

1	It	O
2	was	O
3	postulated	O
4	that	O
5	persistent	O
6	challenge	O
7	by	O
8	M	O
9	.	O
10	leprae	O
11	or	O
12	its	O
13	antigens	O
14	to	O
15	the	O
16	IgA	B
17	immunocytes	O
18	of	O
19	the	O
20	intestinal	O
21	epithelium	O
22	might	O
23	have	O
24	induced	O
25	tolerance	O
26	leading	O
27	to	O
28	IgA	B
29	deficiency	O
30	and	O
31	subsequent	O
32	subtotal	O
33	atrophy	O
34	of	O
35	the	O
36	intestinal	O
37	villi	O
38	in	O
39	the	O
40	patients	O
41	with	O
42	lepromatous	O
43	leprosy	O
44	.	O

1	The	O
2	in	O
3	vitro	O
4	relaxivity	O
5	of	O
6	the	O
7	complex	O
8	is	O
9	16	O
10	.	O
11	24	O
12	s	O
13	(-	O
14	1	O
15	)	O
16	mM	O
17	(-	O
18	1	O
19	).	O

1	In	O
2	addition	O
3	to	O
4	protein	O
5	binding	O
6	at	O
7	sequences	O
8	known	O
9	to	O
10	be	O
11	involved	O
12	in	O
13	the	O
14	regulation	O
15	of	O
16	transcription	O
17	,	O
18	genomic	O
19	footprinting	O
20	of	O
21	the	O
22	entire	O
23	promoter	O
24	region	O
25	also	O
26	showed	O
27	that	O
28	a	O
29	protein	O
30	factor	O
31	is	O
32	constitutively	O
33	bound	O
34	to	O
35	the	O
36	first	O
37	intron	O
38	of	O
39	the	O
40	rep3	O
41	gene	O
42	.	O

1	We	O
2	observed	O
3	that	O
4	dephosphorylation	O
5	severely	O
6	inhibits	O
7	the	O
8	DNA	O
9	-	O
10	binding	O
11	ability	O
12	of	O
13	C	B
14	/	I
15	EBP	I
16	-	I
17	delta	I
18	and	O
19	its	O
20	transactivating	O
21	potential	O
22	increases	O
23	in	O
24	the	O
25	presence	O
26	of	O
27	cellular	O
28	phosphatase	O
29	inhibitors	O
30	,	O
31	such	O
32	as	O
33	okadaic	O
34	acid	O
35	and	O
36	sodium	O
37	orthovanadate	O
38	.	O

1	This	O
2	study	O
3	determined	O
4	the	O
5	arthritogenic	O
6	potential	O
7	of	O
8	silicone	O
9	gel	O
10	by	O
11	either	O
12	mixing	O
13	it	O
14	with	O
15	bovine	B
16	collagen	I
17	II	I
18	(	O
19	BII	O
20	)	O
21	or	O
22	by	O
23	injecting	O
24	silicone	O
25	gel	O
26	alone	O
27	in	O
28	DA	O
29	rats	O
30	.	O

1	Patients	O
2	had	O
3	to	O
4	have	O
5	adequate	O
6	liver	O
7	,	O
8	renal	O
9	,	O
10	and	O
11	marrow	O
12	functions	O
13	.	O

1	Chaotic	O
2	electron	O
3	dynamics	O
4	around	O
5	a	O
6	single	O
7	elliptically	O
8	shaped	O
9	antidot	O
10	.	O

1	An	O
2	end	O
3	to	O
4	the	O
5	lottery	O
6	.	O

1	Radiogallium	O
2	imaging	O
3	is	O
4	thus	O
5	of	O
6	limited	O
7	use	O
8	in	O
9	evaluation	O
10	of	O
11	suspected	O
12	giant	O
13	cell	O
14	tumors	O
15	of	O
16	bone	O
17	.	O

1	The	O
2	rats	O
3	were	O
4	used	O
5	for	O
6	the	O
7	study	O
8	of	O
9	the	O
10	effects	O
11	of	O
12	sepsis	O
13	on	O
14	the	O
15	utilization	O
16	of	O
17	exogenous	O
18	fat	O
19	emulsion	O
20	.	O

1	The	O
2	atp	O
3	1	O
4	and	O
5	atp	O
6	2	O
7	types	O
8	of	O
9	cDNA	O
10	sequences	O
11	were	O
12	the	O
13	most	O
14	redundant	O
15	among	O
16	the	O
17	28	O
18	different	O
19	isoperoxidases	O
20	identified	O
21	among	O
22	about	O
23	200	O
24	peroxidase	O
25	encoding	O
26	ESTs	O
27	.	O

1	A	O
2	diagnosis	O
3	of	O
4	MS	O
5	was	O
6	made	O
7	based	O
8	on	O
9	subtle	O
10	neurologic	O
11	signs	O
12	,	O
13	spinal	O
14	fluid	O
15	gamma	B
16	globulin	I
17	elevations	O
18	,	O
19	and	O
20	abnormalities	O
21	in	O
22	neuropsychological	O
23	testing	O
24	.	O

1	Specifically	O
2	,	O
3	this	O
4	study	O
5	determined	O
6	the	O
7	influence	O
8	of	O
9	:	O
10	(	O
11	1	O
12	)	O
13	an	O
14	awareness	O
15	strategy	O
16	,	O
17	(	O
18	2	O
19	)	O
20	a	O
21	non	O
22	-	O
23	awareness	O
24	strategy	O
25	,	O
26	(	O
27	3	O
28	)	O
29	a	O
30	Five	O
31	-	O
32	Step	O
33	Approach	O
34	strategy	O
35	and	O
36	(	O
37	4	O
38	)	O
39	a	O
40	control	O
41	condition	O
42	.	O

1	Cotransfections	O
2	with	O
3	ATF	B
4	-	I
5	2	I
6	and	O
7	HNF	B
8	-	I
9	4	O
10	expression	O
11	plasmids	O
12	resulted	O
13	in	O
14	additive	O
15	transactivation	O
16	of	O
17	the	O
18	apoCIII	O
19	promoter	O
20	.	O

1	CASE	O
2	REPORT	O
3	:	O
4	We	O
5	observed	O
6	a	O
7	congenital	O
8	skin	O
9	defect	O
10	located	O
11	exclusively	O
12	on	O
13	the	O
14	trunk	O
15	.	O

1	Three	O
2	groups	O
3	of	O
4	patients	O
5	who	O
6	had	O
7	undergone	O
8	subtotal	O
9	thyroidectomy	O
10	for	O
11	Graves	O
12	'	O
13	s	O
14	disease	O
15	,	O
16	toxic	O
17	multinodular	O
18	goitre	O
19	,	O
20	or	O
21	euthyroid	O
22	multinodular	O
23	goitre	O
24	12	O
25	to	O
26	15	O
27	years	O
28	before	O
29	and	O
30	in	O
31	whom	O
32	a	O
33	normal	O
34	serum	O
35	thyroxine	O
36	(	O
37	T	O
38	-	O
39	4	O
40	)	O
41	level	O
42	was	O
43	found	O
44	were	O
45	each	O
46	divided	O
47	into	O
48	two	O
49	subgroups	O
50	on	O
51	the	O
52	basis	O
53	of	O
54	a	O
55	normal	O
56	or	O
57	a	O
58	raised	O
59	serum	O
60	thyrotrophin	O
61	concentration	O
62	.	O

1	y	O
2	.	O

1	It	O
2	then	O
3	merged	O
4	with	O
5	right	O
6	ventricular	O
7	wavefronts	O
8	ending	O
9	along	O
10	the	O
11	right	O
12	ventricular	O
13	anterior	O
14	atrioventricular	O
15	groove	O
16	and	O
17	outflow	O
18	tract	O
19	.	O

1	The	O
2	effects	O
3	of	O
4	contrast	O
5	media	O
6	on	O
7	coagulation	B
8	factor	I
9	XII	I
10	.	O

1	Autorosette	O
2	-	O
3	forming	O
4	cells	O
5	are	O
6	characterized	O
7	by	O
8	a	O
9	high	O
10	activity	O
11	of	O
12	alkaline	B
13	and	I
14	acid	I
15	phosphatases	I
16	and	O
17	low	O
18	NBT	O
19	-	O
20	test	O
21	values	O
22	.	O

1	Here	O
2	we	O
3	show	O
4	that	O
5	epidermal	B
6	growth	I
7	factor	I
8	or	O
9	platelet	B
10	-	I
11	derived	I
12	growth	I
13	factor	I
14	stimulation	O
15	of	O
16	intact	O
17	human	O
18	or	O
19	murine	O
20	cells	O
21	leads	O
22	to	O
23	phosphorylation	O
24	of	O
25	Nck	B
26	protein	I
27	on	O
28	tyrosine	O
29	,	O
30	serine	O
31	,	O
32	and	O
33	threonine	O
34	residues	O
35	.	O

1	Evaluation	O
2	of	O
3	human	O
4	and	O
5	bovine	O
6	modified	O
7	-	O
8	hemoglobin	B
9	solution	O
10	as	O
11	oxygen	O
12	-	O
13	carrying	O
14	fluid	O
15	for	O
16	blood	O
17	volume	O
18	replacement	O
19	.	O

1	The	O
2	CHARGE	O
3	association	O
4	is	O
5	a	O
6	collection	O
7	of	O
8	multisystem	O
9	congenital	O
10	anomalies	O
11	including	O
12	choanal	O
13	atresia	O
14	.	O

1	There	O
2	were	O
3	45	O
4	to	O
5	56	O
6	nt	O
7	differences	O
8	between	O
9	the	O
10	virulent	O
11	and	O
12	avirulent	O
13	groups	O
14	while	O
15	there	O
16	were	O
17	6	O
18	to	O
19	14	O
20	nt	O
21	differences	O
22	among	O
23	four	O
24	avirulent	O
25	strains	O
26	.	O

1	The	O
2	relative	O
3	risk	O
4	of	O
5	graft	O
6	loss	O
7	after	O
8	conversion	O
9	to	O
10	azathioprine	O
11	compared	O
12	with	O
13	graft	O
14	loss	O
15	after	O
16	conversion	O
17	to	O
18	azathioprine	O
19	compared	O
20	with	O
21	cyclosporin	O
22	maintenance	O
23	was	O
24	0	O
25	.	O
26	71	O
27	(	O
28	0	O
29	.	O
30	37	O
31	-	O
32	1	O
33	.	O
34	38	O
35	)	O
36	and	O
37	the	O
38	relative	O
39	risk	O
40	of	O
41	patient	O
42	death	O
43	was	O
44	0	O
45	.	O
46	57	O
47	(	O
48	0	O
49	.	O
50	23	O
51	-	O
52	1	O
53	.	O
54	41	O
55	).	O

1	The	O
2	structural	O
3	gene	O
4	for	O
5	hydrogenase	O
6	encodes	O
7	a	O
8	protein	O
9	product	O
10	of	O
11	molecular	O
12	mass	O
13	45820	O
14	Da	O
15	.	O

1	Expression	O
2	from	O
3	this	O
4	element	O
5	is	O
6	regulated	O
7	by	O
8	a	O
9	heteromeric	O
10	protein	O
11	complex	O
12	containing	O
13	ubiquitous	O
14	(	O
15	i	O
16	.	O
17	e	O
18	.	O
19	the	O
20	E2A	O
21	-	O
22	and	O
23	HEB	O
24	-	O
25	encoded	O
26	proteins	O
27	)	O
28	and	O
29	islet	O
30	-	O
31	enriched	O
32	members	O
33	of	O
34	the	O
35	bHLH	O
36	family	O
37	.	O

1	IL	B
2	-	I
3	1	I
4	and	O
5	TNF	B
6	increase	O
7	AND	O
8	-	O
9	34	O
10	transcript	O
11	levels	O
12	in	O
13	thymic	O
14	cortical	O
15	reticular	O
16	,	O
17	thymic	O
18	nurse	O
19	,	O
20	and	O
21	fibroblast	O
22	cell	O
23	lines	O
24	.	O

1	Competition	O
2	needs	O
3	to	O
4	be	O
5	better	O
6	studied	O
7	,	O
8	since	O
9	in	O
10	Central	O
11	America	O
12	and	O
13	Caribean	O
14	islands	O
15	this	O
16	kind	O
17	of	O
18	study	O
19	has	O
20	favored	O
21	the	O
22	biological	O
23	control	O
24	of	O
25	planorbid	O
26	species	O
27	.	O

1	A	O
2	fusion	O
3	protein	O
4	composed	O
5	of	O
6	beta	B
7	-	I
8	galactosidase	I
9	and	O
10	full	O
11	-	O
12	length	O
13	Ahr	O
14	translocates	O
15	from	O
16	the	O
17	cytoplasm	O
18	to	O
19	the	O
20	nucleus	O
21	in	O
22	a	O
23	ligand	O
24	-	O
25	dependent	O
26	manner	O
27	.	O

1	In	O
2	HeLa	O
3	cells	O
4	,	O
5	it	O
6	activated	O
7	transcription	O
8	from	O
9	the	O
10	herpes	B
11	simplex	I
12	virus	I
13	type	I
14	1	I
15	thymidine	I
16	kinase	I
17	promoter	I
18	linked	O
19	to	O
20	the	O
21	chloramphenicol	B
22	acetyltransferase	I
23	gene	I
24	when	O
25	located	O
26	in	O
27	inverted	O
28	orientation	O
29	upstream	O
30	of	O
31	the	O
32	thymidine	B
33	kinase	I
34	promoter	I
35	or	O
36	downstream	O
37	of	O
38	the	O
39	chloramphenicol	B
40	acetyltransferase	I
41	gene	I
42	coding	O
43	sequence	O
44	.	O

1	Some	O
2	studies	O
3	of	O
4	exercise	O
5	have	O
6	associated	O
7	beta	B
8	-	I
9	endorphin	I
10	release	O
11	with	O
12	increased	O
13	exertion	O
14	levels	O
15	,	O
16	but	O
17	other	O
18	evidence	O
19	suggests	O
20	that	O
21	acidosis	O
22	may	O
23	stimulate	O
24	the	O
25	release	O
26	of	O
27	beta	B
28	-	I
29	endorphin	I
30	.	O

1	SPP41	O
2	was	O
3	cloned	O
4	and	O
5	sequenced	O
6	and	O
7	found	O
8	to	O
9	be	O
10	essential	O
11	.	O
12	spp43	O
13	is	O
14	allelic	O
15	to	O
16	the	O
17	previously	O
18	identified	O
19	suppressor	O
20	srn1	O
21	,	O
22	which	O
23	encodes	O
24	a	O
25	negative	O
26	regulator	O
27	of	O
28	gene	O
29	expression	O
30	.	O

1	The	O
2	serum	O
3	levels	O
4	of	O
5	IgE	B
6	,	O
7	and	O
8	asIgE	O
9	and	O
10	IgG	B
11	-	I
12	4	O
13	against	O
14	14	O
15	common	O
16	food	O
17	allergens	O
18	were	O
19	determined	O
20	.	O

1	None	O
2	of	O
3	the	O
4	five	O
5	proprotein	O
6	processing	O
7	proteases	O
8	tested	O
9	were	O
10	capable	O
11	of	O
12	cleaving	O
13	human	O
14	pro	O
15	-	O
16	LPH	O
17	,	O
18	strongly	O
19	suggesting	O
20	that	O
21	they	O
22	are	O
23	not	O
24	involved	O
25	in	O
26	the	O
27	maturation	O
28	of	O
29	this	O
30	enzyme	O
31	.	O

1	The	O
2	present	O
3	results	O
4	demonstrate	O
5	that	O
6	rats	O
7	with	O
8	relatively	O
9	small	O
10	remnants	O
11	of	O
12	one	O
13	olfactory	O
14	bulb	O
15	can	O
16	perform	O
17	a	O
18	variety	O
19	of	O
20	odor	O
21	detection	O
22	and	O
23	discrimination	O
24	tasks	O
25	as	O
26	well	O
27	or	O
28	nearly	O
29	as	O
30	well	O
31	as	O
32	controls	O
33	.	O

1	These	O
2	studies	O
3	support	O
4	the	O
5	view	O
6	that	O
7	HMG	B
8	I	I
9	(	O
10	Y	O
11	)	O
12	is	O
13	an	O
14	important	O
15	cofactor	O
16	for	O
17	HLA	B
18	-	I
19	DRA	I
20	gene	I
21	activation	O
22	by	O
23	Oct	B
24	-	I
25	2A	I
26	and	O
27	provide	O
28	insights	O
29	into	O
30	its	O
31	mechanism	O
32	of	O
33	action	O
34	.	O

1	A	O
2	protein	O
3	lacking	O
4	the	O
5	SH2	B
6	and	O
7	RING	O
8	finger	O
9	domains	O
10	has	O
11	no	O
12	activity	O
13	,	O
14	but	O
15	a	O
16	chimeric	O
17	protein	O
18	with	O
19	the	O
20	SH2	B
21	and	O
22	RING	O
23	finger	O
24	domains	O
25	of	O
26	SLI	O
27	-	O
28	1	O
29	replaced	O
30	by	O
31	the	O
32	equivalent	O
33	domains	O
34	of	O
35	c	B
36	-	I
37	Cbl	I
38	has	O
39	activity	O
40	.	O

1	These	O
2	six	O
3	districts	O
4	have	O
5	an	O
6	area	O
7	of	O
8	34	O
9	,	O
10	000	O
11	km2	O
12	and	O
13	hold	O
14	a	O
15	population	O
16	of	O
17	30	O
18	million	O
19	.	O

1	Analysis	O
2	of	O
3	the	O
4	deduced	O
5	amino	O
6	acid	O
7	sequence	O
8	suggests	O
9	that	O
10	CHIP28	O
11	protein	O
12	contains	O
13	six	O
14	bilayer	O
15	-	O
16	spanning	O
17	domains	O
18	,	O
19	two	O
20	exofacial	O
21	potential	O
22	N	O
23	-	O
24	glycosylation	O
25	sites	O
26	,	O
27	and	O
28	intracellular	O
29	N	O
30	and	O
31	C	O
32	termini	O
33	.	O

1	An	O
2	RNA	B
3	-	I
4	binding	I
5	protein	I
6	gene	I
7	(	O
8	rbp1	O
9	)	O
10	from	O
11	Drosophila	O
12	melanogaster	O
13	,	O
14	encoding	O
15	an	O
16	RNA	O
17	recognition	O
18	motif	O
19	and	O
20	an	O
21	Arg	O
22	-	O
23	Ser	O
24	rich	O
25	(	O
26	RS	O
27	)	O
28	domain	O
29	,	O
30	has	O
31	been	O
32	characterized	O
33	.	O

1	Benefits	O
2	of	O
3	obtaining	O
4	board	O
5	certification	O
6	in	O
7	pharmacotherapy	O
8	.	O

1	Distribution	O
2	and	O
3	changing	O
4	morphological	O
5	course	O

1	Women	O
2	'	O
3	s	O
4	opportunities	O
5	for	O
6	paid	O
7	work	O
8	outside	O
9	the	O
10	home	O
11	are	O
12	constrained	O
13	by	O
14	their	O
15	role	O
16	as	O
17	primary	O
18	carer	O
19	within	O
20	the	O
21	family	O
22	,	O
23	writes	O
24	Trudy	O
25	Wynne	O
26	.	O

1	At	O
2	each	O
3	level	O
4	of	O
5	PaO2	O
6	we	O
7	obtained	O
8	simultaneous	O
9	measures	O
10	of	O
11	arterial	O
12	and	O
13	venous	O
14	blood	O
15	gases	O
16	,	O
17	venous	O
18	lactate	O
19	concentration	O
20	,	O
21	and	O
22	changes	O
23	in	O
24	the	O
25	relative	O
26	concentrations	O
27	of	O
28	inorganic	O
29	phosphate	O
30	,	O
31	phosphocreatine	O
32	,	O
33	and	O
34	ATP	O
35	measured	O
36	with	O
37	31P	O
38	magnetic	O
39	resonance	O
40	spectroscopy	O
41	.	O

1	Interferon	B
2	-	I
3	alpha	I
4	-	I
5	induced	O
6	gene	O
7	expression	O
8	:	O
9	evidence	O
10	for	O
11	a	O
12	selective	O
13	effect	O
14	of	O
15	ouabain	O
16	on	O
17	activation	O
18	of	O
19	the	O
20	ISGF3	O
21	transcription	O
22	complex	O
23	.	O

1	The	O
2	CANNTG	O
3	motifs	O
4	were	O
5	found	O
6	to	O
7	bind	O
8	MyoD	B
9	and	O
10	myogenin	B
11	fusion	I
12	proteins	I
13	and	O
14	to	O
15	interact	O
16	with	O
17	proteins	O
18	in	O
19	nuclear	O
20	extracts	O
21	from	O
22	cultured	O
23	myotubes	O
24	.	O

1	Internally	O
2	oriented	O
3	patients	O
4	'	O
5	scores	O
6	on	O
7	Rotter	O
8	'	O
9	s	O
10	Internal	O
11	-	O
12	External	O
13	Locus	O
14	of	O
15	Control	O
16	Scale	O
17	remained	O
18	the	O
19	same	O
20	over	O
21	treatment	O
22	but	O
23	those	O
24	of	O
25	externally	O
26	oriented	O
27	patients	O
28	shifted	O
29	toward	O
30	greater	O
31	internal	O
32	control	O
33	.	O

1	The	O
2	human	B
3	CD38	I
4	gene	I
5	consists	O
6	of	O
7	8	O
8	exons	O
9	that	O
10	extend	O
11	more	O
12	than	O
13	77	O
14	kb	O
15	on	O
16	the	O
17	human	O
18	genome	O
19	.	O

1	Recently	O
2	,	O
3	a	O
4	distantly	O
5	related	O
6	UmuC	O
7	-	O
8	homolog	O
9	,	O
10	DinB	O
11	,	O
12	has	O
13	also	O
14	been	O
15	identified	O
16	in	O
17	E	O
18	.	O
19	coli	O
20	.	O

1	The	O
2	most	O
3	common	O
4	characteristics	O
5	of	O
6	VRE	O
7	patients	O
8	were	O
9	recent	O
10	prior	O
11	vancomycin	O
12	use	O
13	,	O
14	recent	O
15	prior	O
16	susceptible	O
17	enterococcal	O
18	infection	O
19	,	O
20	coinfection	O
21	with	O
22	other	O
23	microbial	O
24	pathogens	O
25	,	O
26	and	O
27	concurrent	O
28	fungal	O
29	infection	O
30	.	O

1	Patterns	O
2	defined	O
3	by	O
4	combinations	O
5	of	O
6	normal	O
7	and	O
8	abnormal	O
9	laboratory	O
10	results	O
11	had	O
12	decreased	O
13	the	O
14	likelihood	O
15	of	O
16	PEM	O
17	from	O
18	an	O
19	all	O
20	-	O
21	2	O
22	to	O
23	all	O
24	-	O
25	0	O
26	pattern	O
27	.	O

1	To	O
2	identify	O
3	some	O
4	of	O
5	the	O
6	genes	O
7	expressed	O
8	in	O
9	LPS	O
10	-	O
11	activated	O
12	coelomocytes	O
13	,	O
14	we	O
15	sequenced	O
16	randomly	O
17	chosen	O
18	clones	O
19	from	O
20	a	O
21	directionally	O
22	constructed	O
23	cDNA	O
24	library	O
25	to	O
26	produce	O
27	a	O
28	set	O
29	of	O
30	expressed	O
31	sequence	O
32	tags	O
33	(	O
34	ESTs	O
35	).	O

1	Thyrotropin	B
2	-	I
3	releasing	I
4	hormone	I
5	-	I
6	induced	O
7	contraction	O
8	of	O
9	urethral	O
10	and	O
11	vaginal	O
12	muscle	O
13	.	O

1	The	O
2	development	O
3	and	O
4	histostructural	O
5	organization	O
6	of	O
7	intrahepatic	O
8	biliary	O
9	ducts	O
10	were	O
11	studied	O
12	on	O
13	a	O
14	human	O
15	embryofetal	O
16	material	O
17	6	O
18	to	O
19	32	O
20	weeks	O
21	old	O
22	.	O

1	The	O
2	human	O
3	purH	O
4	cDNA	O
5	is	O
6	1776	O
7	base	O
8	pairs	O
9	in	O
10	length	O
11	encoding	O
12	for	O
13	a	O
14	591	O
15	-	O
16	amino	O
17	acid	O
18	polypeptic	O
19	(	O
20	Mr	O
21	=	O
22	64	O
23	,	O
24	425	O
25	).	O

1	Fewer	O
2	recombination	O
3	events	O
4	are	O
5	detected	O
6	in	O
7	four	O
8	different	O
9	B	O
10	and	O
11	T	O
12	cell	O
13	lines	O
14	that	O
15	do	O
16	not	O
17	undergo	O
18	switch	O
19	recombination	O
20	of	O
21	their	O
22	endogenous	O
23	genes	O
24	.	O

1	In	O
2	a	O
3	group	O
4	of	O
5	13	O
6	patients	O
7	with	O
8	obliterative	O
9	arteriopathies	O
10	of	O
11	the	O
12	lower	O
13	limbs	O
14	the	O
15	plasma	O
16	levels	O
17	of	O
18	thrombomodulin	O
19	(	O
20	TM	O
21	),	O
22	betathromboglobulin	O
23	(	O
24	beta	O
25	-	O
26	TG	O
27	),	O
28	D	O
29	-	O
30	dimer	O
31	(	O
32	DD	O
33	)	O
34	and	O
35	plasminogen	B
36	activator	I
37	-	I
38	inhibitor	O
39	(	O
40	pAI	O
41	-	O
42	1	O
43	)	O
44	were	O
45	measured	O
46	,	O
47	and	O
48	compared	O
49	to	O
50	the	O
51	values	O
52	obtained	O
53	from	O
54	10	O
55	healthy	O
56	volunteers	O
57	.	O

1	We	O
2	have	O
3	isolated	O
4	cDNAs	O
5	for	O
6	a	O
7	gene	O
8	coding	O
9	for	O
10	a	O
11	G	B
12	protein	I
13	alpha	I
14	subunit	I
15	from	O
16	tomato	O
17	(	O
18	Lycopersicon	O
19	esculentum	O
20	,	O
21	cv	O
22	.	O

1	The	O
2	possibility	O
3	of	O
4	a	O
5	hereditary	O
6	disorder	O
7	leading	O
8	to	O
9	a	O
10	minor	O
11	defect	O
12	in	O
13	elastic	O
14	fibre	O
15	structure	O
16	which	O
17	could	O
18	be	O
19	responsible	O
20	for	O
21	the	O
22	spontaneous	O
23	lesions	O
24	is	O
25	discussed	O
26	.	O

1	With	O
2	steady	O
3	illumination	O
4	,	O
5	outer	O
6	retinal	O
7	(	O
8	photoreceptor	O
9	)	O
10	QO2	O
11	decreased	O
12	to	O
13	1	O
14	.	O
15	4	O
16	+/-	O
17	0	O
18	.	O
19	9	O
20	ml	O
21	O2	O
22	/(	O
23	100	O
24	g	O
25	.	O
26	min	O
27	),	O
28	but	O
29	inner	O
30	retinal	O
31	QO2	O
32	remained	O
33	unchanged	O
34	at	O
35	3	O
36	.	O
37	7	O
38	+/-	O
39	1	O
40	.	O
41	5	O
42	ml	O
43	O2	O
44	/(	O
45	100	O
46	g	O
47	.	O
48	min	O
49	)	O
50	(	O
51	5	O
52	cats	O
53	).	O

1	176	O
2	:	O
3	787	O
4	-	O
5	792	O
6	,	O
7	1992	O
8	;	O
9	M	O
10	.	O

1	Each	O
2	group	O
3	received	O
4	15	O
5	ml	O
6	/	O
7	kg	O
8	of	O
9	either	O
10	6	O
11	%	O
12	pentafraction	O
13	,	O
14	6	O
15	%	O
16	pentastarch	O
17	,	O
18	or	O
19	plasma	O
20	followed	O
21	two	O
22	hours	O
23	later	O
24	by	O
25	1	O
26	.	O
27	5	O
28	micrograms	O
29	/	O
30	kg	O
31	/	O
32	0	O
33	.	O
34	5	O
35	hr	O
36	E	O
37	.	O

1	Continued	O
2	absorption	O
3	of	O
4	amino	O
5	acids	O
6	by	O
7	the	O
8	NBB	O
9	carrier	O
10	(	O
11	for	O
12	neutral	O
13	amino	O
14	acids	O
15	),	O
16	the	O
17	Y	O
18	+	O
19	system	O
20	(	O
21	for	O
22	dibasic	O
23	amino	O
24	acids	O
25	),	O
26	and	O
27	the	O
28	PHE	O
29	carrier	O
30	were	O
31	operative	O
32	even	O
33	during	O
34	the	O
35	actively	O
36	purging	O
37	stage	O
38	of	O
39	watery	O
40	diarrhoea	O
41	due	O
42	to	O
43	cholera	O
44	.	O

1	Altogether	O
2	,	O
3	the	O
4	results	O
5	demonstrate	O
6	that	O
7	the	O
8	two	O
9	isoforms	O
10	elicit	O
11	similar	O
12	responses	O
13	in	O
14	vivo	O
15	despite	O
16	differences	O
17	in	O
18	their	O
19	regulation	O
20	.	O

1	The	O
2	effectiveness	O
3	of	O
4	NRT	O
5	appears	O
6	to	O
7	be	O
8	largely	O
9	independent	O
10	of	O
11	the	O
12	intensity	O
13	of	O
14	additional	O
15	support	O
16	provided	O
17	to	O
18	the	O
19	smoker	O
20	.	O

1	Using	O
2	5	O
3	ng	O
4	/	O
5	mL	O
6	as	O
7	the	O
8	cutoff	O
9	,	O
10	the	O
11	sensitivity	O
12	of	O
13	CEA	O
14	was	O
15	68	O
16	%.	O

1	A	O
2	newly	O
3	developed	O
4	broad	O
5	-	O
6	spectrum	O
7	fluoroquinolone	O
8	,	O
9	levofloxacin	O
10	(	O
11	LVFX	O
12	,	O
13	DR	O
14	-	O
15	3355	O
16	),	O
17	was	O
18	evaluated	O
19	in	O
20	vitro	O
21	and	O
22	in	O
23	vivo	O
24	in	O
25	comparison	O
26	with	O
27	ciprofloxacin	O
28	(	O
29	CPFX	O
30	),	O
31	ofloxacin	O
32	(	O
33	OFLX	O
34	)	O
35	and	O
36	norfloxacin	O
37	(	O
38	NFLX	O
39	).	O

1	Administration	O
2	of	O
3	dexamethasone	O
4	was	O
5	associated	O
6	with	O
7	progressive	O
8	rises	O
9	in	O
10	plasma	O
11	17	O
12	alpha	O
13	OH	O
14	progesterone	O
15	,	O
16	11	O
17	beta	O
18	-	O
19	desoxycortisol	O
20	,	O
21	DHEA	O
22	sulphate	O
23	,	O
24	androstenedione	O
25	and	O
26	testosterone	O
27	,	O
28	together	O
29	with	O
30	increased	O
31	urinary	O
32	excretion	O
33	of	O
34	androsterone	O
35	,	O
36	11	O
37	beta	O
38	OH	O
39	androsterone	O
40	,	O
41	etiocholanolone	O
42	,	O
43	DHEA	O
44	,	O
45	and	O
46	16	O
47	alpha	O
48	OH	O
49	DHEA	O
50	.	O

1	Studies	O
2	suggest	O
3	that	O
4	the	O
5	DGOR	O
6	without	O
7	acid	O
8	reflux	O
9	may	O
10	result	O
11	in	O
12	symptoms	O
13	but	O
14	unless	O
15	acid	O
16	reflux	O
17	is	O
18	present	O
19	simultaneously	O
20	,	O
21	it	O
22	does	O
23	not	O
24	cause	O
25	oesophagitis	O
26	.	O

1	Interestingly	O
2	,	O
3	internal	O
4	and	O
5	5	O
6	'	O
7	deletions	O
8	revealed	O
9	tha	O
10	the	O
11	distal	O
12	promoter	O
13	was	O
14	not	O
15	required	O
16	for	O
17	full	O
18	transcriptional	O
19	activity	O
20	and	O
21	that	O
22	the	O
23	first	O
24	631	O
25	base	O
26	pairs	O
27	of	O
28	WNT	B
29	-	I
30	5A	I
31	harbored	O
32	the	O
33	strongest	O
34	promoter	O
35	activity	O
36	.	O

1	Schooling	O
2	is	O
3	found	O
4	to	O
5	be	O
6	related	O
7	to	O
8	good	O
9	health	O
10	even	O
11	after	O
12	controlling	O
13	for	O
14	differences	O
15	in	O
16	observable	O
17	health	O
18	inputs	O
19	.	O

1	L3	O
2	-	O
3	L4	O
4	compressive	O
5	load	O
6	was	O
7	calculated	O
8	using	O
9	a	O
10	model	O
11	of	O
12	the	O
13	anatomy	O
14	of	O
15	the	O
16	trunk	O
17	musculoskeletal	O
18	system	O
19	.	O

1	In	O
2	co	O
3	-	O
4	transfection	O
5	studies	O
6	,	O
7	an	O
8	AP	B
9	-	I
10	2	I
11	but	O
12	not	O
13	an	O
14	Egr	B
15	-	I
16	1	I
17	expression	O
18	vector	O
19	activated	O
20	VPF	O
21	/	O
22	VEGF	B
23	transcription	O
24	,	O
25	thus	O
26	indicating	O
27	that	O
28	AP	B
29	-	I
30	2	I
31	protein	I
32	is	O
33	functionally	O
34	important	O
35	in	O
36	TGF	B
37	alpha	I
38	-	I
39	induced	O
40	VPF	O
41	/	O
42	VEGF	B
43	gene	I
44	expression	O
45	.	O

1	Neither	O
2	the	O
3	p42	O
4	/	O
5	44	O
6	nor	O
7	the	O
8	JNK	B
9	pathway	O
10	was	O
11	involved	O
12	in	O
13	the	O
14	action	O
15	of	O
16	IL	B
17	-	I
18	1beta	I
19	.	O

1	The	O
2	effect	O
3	of	O
4	diffusion	O
5	limitation	O
6	was	O
7	quantified	O
8	in	O
9	terms	O
10	of	O
11	the	O
12	ratio	O
13	O2	O
14	uptake	O
15	/	O
16	O2	O
17	requirement	O
18	(=	O
19	fraction	O
20	of	O
21	cross	O
22	-	O
23	sectional	O
24	area	O
25	supplied	O
26	with	O
27	O2	O
28	),	O
29	assuming	O
30	local	O
31	O2	O
32	requirement	O
33	per	O
34	unit	O
35	volume	O
36	to	O
37	be	O
38	constant	O
39	and	O
40	independent	O
41	of	O
42	PO2	O
43	at	O
44	PO2	O
45	greater	O
46	than	O
47	0	O
48	.	O

1	Repair	O
2	of	O
3	a	O
4	cosmetic	O
5	defect	O
6	of	O
7	the	O
8	lower	O
9	leg	O
10	with	O
11	a	O
12	myocutaneous	O
13	free	O
14	flap	O
15	.	O

1	ArgR	O
2	was	O
3	shown	O
4	to	O
5	be	O
6	a	O
7	dimer	O
8	of	O
9	two	O
10	equal	O
11	subunits	O
12	,	O
13	each	O
14	with	O
15	a	O
16	molecular	O
17	mass	O
18	of	O
19	37	O
20	,	O
21	000	O
22	Da	O
23	.	O

1	Collectively	O
2	,	O
3	these	O
4	results	O
5	suggest	O
6	that	O
7	components	O
8	of	O
9	the	O
10	protein	O
11	kinase	O
12	A	O
13	signaling	O
14	pathway	O
15	are	O
16	recruited	O
17	by	O
18	mIg	O
19	to	O
20	induce	O
21	junB	B
22	transcription	O
23	.	O

1	Atopic	O
2	allergy	O
3	and	O
4	other	O
5	hypersensitivities	O
6	.	O

1	Hence	O
2	,	O
3	the	O
4	uPA	B
5	promoter	I
6	contains	O
7	multiple	O
8	weak	O
9	cis	O
10	-	O
11	acting	O
12	elements	O
13	distributed	O
14	over	O
15	7	O
16	.	O
17	0	O
18	kb	O
19	5	O
20	'	O
21	to	O
22	the	O
23	translation	O
24	start	O
25	site	O
26	.	O

1	The	O
2	results	O
3	raise	O
4	the	O
5	possibility	O
6	that	O
7	pH	O
8	induced	O
9	post	O
10	-	O
11	translational	O
12	modifications	O
13	of	O
14	DdRPA	O
15	are	O
16	involved	O
17	in	O
18	events	O
19	that	O
20	halt	O
21	cell	O
22	proliferation	O
23	and	O
24	induce	O
25	differentiation	O
26	in	O
27	Dictyostelium	O
28	.	O

1	Pregnant	O
2	rats	O
3	were	O
4	exposed	O
5	to	O
6	one	O
7	of	O
8	the	O
9	following	O
10	:	O
11	(	O
12	1	O
13	)	O
14	10	O
15	%	O
16	O2	O
17	in	O
18	N2	O
19	or	O
20	100	O
21	%	O
22	O2	O
23	for	O
24	2	O
25	days	O
26	beginning	O
27	at	O
28	day	O
29	7	O
30	,	O
31	11	O
32	,	O
33	14	O
34	,	O
35	or	O
36	18	O
37	of	O
38	pregnancy	O
39	;	O
40	(	O
41	2	O
42	)	O
43	10	O
44	%	O
45	O2	O
46	in	O
47	N2	O
48	or	O
49	100	O
50	%	O
51	O2	O
52	for	O
53	10	O
54	h	O
55	/	O
56	day	O
57	beginning	O
58	at	O
59	day	O
60	7	O
61	;	O
62	or	O
63	(	O
64	3	O
65	)	O
66	14	O
67	-	O
68	11	O
69	%	O
70	O2	O
71	in	O
72	N2	O
73	continuously	O
74	beginning	O
75	at	O
76	day	O
77	14	O
78	till	O
79	day	O
80	21	O
81	when	O
82	they	O
83	were	O
84	sacrificed	O
85	.	O

1	A	O
2	secondary	O
3	phosphorylation	O
4	of	O
5	CREB341	O
6	at	O
7	Ser129	O
8	is	O
9	required	O
10	for	O
11	the	O
12	cAMP	O
13	-	O
14	mediated	O
15	control	O
16	of	O
17	gene	O
18	expression	O
19	.	O

1	Regulation	O
2	of	O
3	mitochondrial	O
4	single	O
5	-	O
6	stranded	O
7	DNA	O
8	-	O
9	binding	O
10	protein	O
11	gene	O
12	expression	O
13	links	O
14	nuclear	O
15	and	O
16	mitochondrial	O
17	DNA	O
18	replication	O
19	in	O
20	drosophila	O
21	.	O

1	OBJECTIVE	O
2	:	O
3	Although	O
4	the	O
5	preponderance	O
6	of	O
7	findings	O
8	offer	O
9	support	O
10	for	O
11	transient	O
12	(	O
13	where	O
14	is	O
15	it	O
16	?)	O
17	as	O
18	opposed	O
19	to	O
20	sustained	O
21	(	O
22	what	O
23	is	O
24	it	O
25	?)	O
26	deficit	O
27	,	O
28	a	O
29	need	O
30	remains	O
31	for	O
32	specific	O
33	depiction	O
34	of	O
35	the	O
36	deficit	O
37	.	O

1	Reverse	B
2	transcriptase	I
3	-	I
4	polymerase	I
5	chain	I
6	reaction	O
7	(	O
8	RT	O
9	-	O
10	PCR	O
11	)	O
12	was	O
13	performed	O
14	using	O
15	eyestalk	O
16	complementary	O
17	DNA	O
18	of	O
19	the	O
20	sand	O
21	shrimp	O
22	Metapenaeus	O
23	ensis	O
24	.	O

1	Conversely	O
2	,	O
3	activation	O
4	of	O
5	Oct	B
6	-	I
7	3	I
8	/	I
9	4	I
10	promoter	I
11	by	O
12	RAR	B
13	:	O
14	RXR	B
15	heterodimers	O
16	was	O
17	completely	O
18	abolished	O
19	by	O
20	EAR	O
21	-	O
22	3	O
23	/	O
24	COUP	B
25	-	I
26	TFI	I
27	and	O
28	by	O
29	ARP	B
30	-	I
31	1	I
32	/	I
33	COUP	I
34	-	I
35	TFII	I
36	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	residue	O
6	266	O
7	serves	O
8	as	O
9	a	O
10	"	O
11	protein	O
12	sensor	O
13	"	O
14	of	O
15	altered	O
16	minor	O
17	groove	O
18	interactions	O
19	and	O
20	identifies	O
21	which	O
22	base	O
23	pair	O
24	interactions	O
25	are	O
26	altered	O
27	by	O
28	these	O
29	lesions	O
30	.	O

1	The	O
2	heart	O
3	rate	O
4	,	O
5	respiratory	O
6	rate	O
7	,	O
8	arterial	O
9	O2	O
10	and	O
11	systemic	O
12	vascular	O
13	resistance	O
14	were	O
15	not	O
16	significantly	O
17	altered	O
18	.	O

1	The	O
2	Menopause	O
3	-	O
4	Rating	O
5	-	O
6	Scale	O
7	(	O
8	MRS	O
9	I	O
10	)	O
11	was	O
12	used	O
13	in	O
14	clinical	O
15	practice	O
16	since	O
17	1992	O
18	.	O

1	Gel	O
2	route	O
3	preparation	O
4	of	O
5	low	O
6	fusing	O
7	dental	O
8	porcelain	O
9	frit	O
10	.	O

1	The	O
2	relatively	O
3	high	O
4	level	O
5	transcription	O
6	from	O
7	this	O
8	gene	O
9	shows	O
10	that	O
11	the	O
12	polymorphic	O
13	chromosome	O
14	ends	O
15	of	O
16	P	O
17	.	O
18	falciparum	O
19	,	O
20	which	O
21	have	O
22	been	O
23	proposed	O
24	to	O
25	be	O
26	transcriptionally	O
27	silent	O
28	,	O
29	can	O
30	be	O
31	active	O
32	expression	O
33	sites	O
34	for	O
35	var	O
36	genes	O
37	.	O

1	A	O
2	comparison	O
3	of	O
4	the	O
5	nucleotide	O
6	and	O
7	deduced	O
8	amino	O
9	acid	O
10	sequences	O
11	of	O
12	the	O
13	core	O
14	regions	O
15	of	O
16	the	O
17	RNA	B
18	-	I
19	dependent	I
20	RNA	I
21	polymerase	I
22	domains	I
23	found	O
24	in	O
25	these	O
26	three	O
27	dsRNAs	O
28	suggested	O
29	that	O
30	these	O
31	dsRNAs	O
32	probably	O
33	evolved	O
34	independently	O
35	within	O
36	each	O
37	host	O
38	plant	O
39	from	O
40	a	O
41	common	O
42	ancestor	O
43	.	O

1	Binding	O
2	site	O
3	selection	O
4	using	O
5	in	O
6	vitro	O
7	-	O
8	synthesized	O
9	proteins	O
10	reveals	O
11	that	O
12	the	O
13	ROR	B
14	alpha	I
15	1	I
16	and	O
17	ROR	B
18	alpha	I
19	2	I
20	isoforms	I
21	bind	O
22	DNA	O
23	as	O
24	monomers	O
25	to	O
26	hormone	O
27	response	O
28	elements	O
29	composed	O
30	of	O
31	a	O
32	6	O
33	-	O
34	bp	O
35	AT	O
36	-	O
37	rich	O
38	sequence	O
39	preceding	O
40	a	O
41	half	O
42	-	O
43	site	O
44	core	O
45	motif	O
46	PuGGTCA	O
47	(	O
48	RORE	O
49	).	O

1	Together	O
2	,	O
3	these	O
4	data	O
5	identify	O
6	ERK2	B
7	as	O
8	a	O
9	specific	O
10	and	O
11	direct	O
12	target	O
13	of	O
14	HePTP	O
15	and	O
16	are	O
17	consistent	O
18	with	O
19	a	O
20	model	O
21	in	O
22	which	O
23	HePTP	O
24	negatively	O
25	regulates	O
26	ERK2	B
27	activity	O
28	as	O
29	part	O
30	of	O
31	a	O
32	feedback	O
33	mechanism	O
34	.	O

1	Protein	B
2	kinase	I
3	A	I
4	-	I
5	Ialpha	I
6	subunit	I
7	-	I
8	directed	O
9	antisense	O
10	inhibition	O
11	of	O
12	ovarian	O
13	cancer	O
14	cell	O
15	growth	O
16	:	O
17	crosstalk	O
18	with	O
19	tyrosine	B
20	kinase	I
21	signaling	O
22	pathway	O
23	.	O

1	A	O
2	deproteinization	O
3	procedure	O
4	was	O
5	coupled	O
6	with	O
7	a	O
8	reversed	O
9	-	O
10	phase	O
11	HPLC	O
12	separation	O
13	using	O
14	a	O
15	250x4	O
16	.	O
17	6	O
18	mm	O
19	I	O
20	.	O
21	D	O
22	.	O

1	Positron	O
2	emission	O
3	tomography	O
4	radioligands	O
5	for	O
6	dopamine	O
7	transporters	O
8	and	O
9	studies	O
10	in	O
11	human	O
12	and	O
13	nonhuman	O
14	primates	O
15	.	O

1	Upon	O
2	tyrosine	O
3	phosphorylation	O
4	at	O
5	the	O
6	ITIMs	O
7	,	O
8	these	O
9	molecules	O
10	recruit	O
11	SH2	B
12	domain	I
13	-	I
14	containing	I
15	phosphatases	I
16	such	O
17	as	O
18	SH2	B
19	-	I
20	containing	I
21	tyrosine	I
22	phosphatase	I
23	-	I
24	1	I
25	and	O
26	negatively	O
27	regulate	O
28	cell	O
29	activity	O
30	.	O

1	The	O
2	beta	O
3	chain	O
4	contains	O
5	five	O
6	potential	O
7	N	O
8	-	O
9	linked	O
10	glycosylation	O
11	sites	O
12	,	O
13	and	O
14	endoglycosidase	O
15	digestion	O
16	suggested	O
17	that	O
18	the	O
19	beta	O
20	chain	O
21	contained	O
22	multiple	O
23	complex	O
24	carbohydrate	O
25	side	O
26	chains	O
27	.	O

1	The	O
2	T	B
3	-	I
4	cyt	I
5	promoter	I
6	,	O
7	although	O
8	of	O
9	bacterial	O
10	origin	O
11	is	O
12	active	O
13	in	O
14	planta	O
15	and	O
16	the	O
17	30	O
18	bp	O
19	cyt	O
20	-	O
21	1	O
22	element	O
23	is	O
24	located	O
25	within	O
26	a	O
27	region	O
28	that	O
29	is	O
30	essential	O
31	for	O
32	T	O
33	-	O
34	cyt	O
35	promotor	O
36	activity	O
37	in	O
38	leaf	O
39	,	O
40	stem	O
41	and	O
42	root	O
43	cells	O
44	of	O
45	tobacco	O
46	plants	O
47	.	O

1	Haemodilution	O
2	in	O
3	cardiopulmonary	O
4	bypass	O
5	using	O
6	a	O
7	gelatine	O
8	derivative	O
9	for	O
10	priming	O
11	.	O

1	10	O
2	long	O
3	-	O
4	term	O
5	hemodialysis	O
6	patients	O
7	had	O
8	immediate	O
9	and	O
10	redistribution	O
11	thallium	O
12	-	O
13	201	O
14	myocardial	O
15	imaging	O
16	performed	O
17	after	O
18	a	O
19	course	O
20	of	O
21	hemodialysis	O
22	.	O

1	One	O
2	of	O
3	these	O
4	small	O
5	inteins	O
6	might	O
7	be	O
8	inactive	O
9	or	O
10	a	O
11	"	O
12	pseudo	O
13	intein	O
14	."	O
15	The	O
16	results	O
17	suggest	O
18	a	O
19	modular	O
20	architecture	O
21	for	O
22	inteins	O
23	,	O
24	clarify	O
25	their	O
26	origin	O
27	and	O
28	relationship	O
29	to	O
30	other	O
31	protein	O
32	families	O
33	,	O
34	and	O
35	extend	O
36	recent	O
37	experimental	O
38	findings	O
39	on	O
40	the	O
41	functional	O
42	roles	O
43	of	O
44	intein	O
45	N	O
46	,	O
47	C	O
48	,	O
49	and	O
50	EN	O
51	motifs	O
52	.	O

1	The	O
2	M	O
3	-	O
4	3	O
5	subtype	O
6	was	O
7	an	O
8	adverse	O
9	prognostic	O
10	factor	O
11	.	O

1	This	O
2	study	O
3	provides	O
4	a	O
5	direct	O
6	demonstration	O
7	of	O
8	a	O
9	role	O
10	for	O
11	G	O
12	betagamma	O
13	in	O
14	mediating	O
15	the	O
16	agonist	O
17	-	O
18	stimulated	O
19	translocation	O
20	of	O
21	GRK2	O
22	and	O
23	GRK3	O
24	in	O
25	an	O
26	intact	O
27	cellular	O
28	system	O
29	and	O
30	demonstrates	O
31	isoform	O
32	specificity	O
33	in	O
34	the	O
35	interaction	O
36	of	O
37	these	O
38	components	O
39	.	O

1	The	O
2	cleavage	O
3	of	O
4	Fak	O
5	by	O
6	caspases	O
7	may	O
8	thus	O
9	play	O
10	an	O
11	important	O
12	role	O
13	in	O
14	the	O
15	execution	O
16	of	O
17	the	O
18	suicide	O
19	program	O
20	by	O
21	disabling	O
22	the	O
23	anti	O
24	-	O
25	apoptotic	O
26	function	O
27	of	O
28	Fak	O
29	.	O

1	Five	O
2	different	O
3	subtypes	O
4	of	O
5	spondyloarthropathy	O
6	(	O
7	SpA	O
8	)	O
9	are	O
10	now	O
11	recognized	O
12	.	O

1	Moreover	O
2	,	O
3	the	O
4	major	O
5	site	O
6	of	O
7	transcriptional	O
8	initiation	O
9	,	O
10	which	O
11	was	O
12	localized	O
13	by	O
14	primer	O
15	extension	O
16	250	O
17	bp	O
18	upstream	O
19	of	O
20	the	O
21	5	O
22	'	O
23	end	O
24	of	O
25	the	O
26	Ets	B
27	-	I
28	1	I
29	cDNA	I
30	clone	O
31	,	O
32	was	O
33	shown	O
34	to	O
35	be	O
36	identical	O
37	in	O
38	normal	O
39	cells	O
40	and	O
41	tumors	O
42	carrying	O
43	a	O
44	provirus	O
45	in	O
46	the	O
47	Tpl	O
48	-	O
49	1	O
50	locus	O
51	.	O

1	ORFK10	O
2	.	O
3	5	O
4	encodes	O
5	a	O
6	protein	O
7	,	O
8	latency	O
9	-	O
10	associated	O
11	nuclear	O
12	antigen	O
13	2	O
14	(	O
15	LANA2	O
16	),	O
17	which	O
18	is	O
19	expressed	O
20	in	O
21	KSHV	O
22	-	O
23	infected	O
24	hematopoietic	O
25	tissues	O
26	,	O
27	including	O
28	PEL	O
29	and	O
30	CD	O
31	but	O
32	not	O
33	KS	O
34	lesions	O
35	.	O

1	The	O
2	percutaneous	O
3	absorption	O
4	of	O
5	clindamycin	O
6	was	O
7	studied	O
8	in	O
9	healthy	O
10	male	O
11	volunteers	O
12	,	O
13	comparing	O
14	two	O
15	investigative	O
16	clindamycin	O
17	(%	O
18	w	O
19	/	O
20	v	O
21	)/	O
22	tretinoin	O
23	(	O
24	0	O
25	.	O
26	025	O
27	%	O
28	w	O
29	/	O
30	v	O
31	)	O
32	gels	O
33	,	O
34	containing	O
35	clindamycin	O
36	phosphate	O
37	ester	O
38	and	O
39	clindamycin	O
40	HCl	O
41	,	O
42	respectively	O
43	,	O
44	relative	O
45	to	O
46	a	O
47	clindamycin	O
48	phosphate	O
49	lotion	O
50	(	O
51	1	O
52	%	O
53	clindamycin	O
54	;	O
55	Dalacin	O
56	T	O
57	).	O

1	Effects	O
2	of	O
3	aging	O
4	and	O
5	beta	B
6	-	I
7	adrenergic	I
8	-	I
9	blockade	O
10	on	O
11	standing	O
12	-	O
13	induced	O
14	QT	O
15	/	O
16	QS2	O
17	changes	O
18	.	O

1	This	O
2	is	O
3	the	O
4	first	O
5	report	O
6	that	O
7	an	O
8	in	O
9	vitro	O
10	-	O
11	synthesized	O
12	alphavirus	O
13	RNA	O
14	lacking	O
15	a	O
16	poly	O
17	(	O
18	A	O
19	)	O
20	tail	O
21	can	O
22	initiate	O
23	infection	O
24	and	O
25	produce	O
26	3	O
27	'	O
28	polyadenylated	O
29	viral	O
30	genome	O
31	in	O
32	vivo	O
33	.	O

1	Amino	O
2	acid	O
3	sequence	O
4	comparisons	O
5	of	O
6	the	O
7	E74A	O
8	protein	O
9	reveal	O
10	a	O
11	highly	O
12	conserved	O
13	C	O
14	-	O
15	terminal	O
16	region	O
17	that	O
18	is	O
19	rich	O
20	in	O
21	basic	O
22	amino	O
23	acid	O
24	residues	O
25	and	O
26	which	O
27	has	O
28	been	O
29	proposed	O
30	to	O
31	possess	O
32	sequence	O
33	-	O
34	specific	O
35	DNA	O
36	binding	O
37	activity	O
38	.	O

1	On	O
2	-	O
3	line	O
4	angioscopic	O
5	images	O
6	of	O
7	tissue	O
8	flaps	O
9	floating	O
10	in	O
11	the	O
12	lumen	O
13	,	O
14	recent	O
15	or	O
16	structured	O
17	thrombi	O
18	,	O
19	artery	O
20	wall	O
21	dissections	O
22	,	O
23	plaque	O
24	ruptures	O
25	,	O
26	deep	O
27	fissurations	O
28	and	O
29	sub	O
30	-	O
31	intimal	O
32	haemorrhages	O
33	demonstrate	O
34	,	O
35	in	O
36	live	O
37	colour	O
38	,	O
39	the	O
40	pathophysiological	O
41	mechanisms	O
42	of	O
43	coronary	O
44	artery	O
45	stenosis	O
46	.	O

1	As	O
2	in	O
3	Tb	O
4	,	O
5	U6	B
6	is	O
7	a	O
8	single	O
9	-	O
10	copy	O
11	gene	O
12	and	O
13	two	O
14	tRNA	O
15	genes	O
16	,	O
17	tRNAGln	O
18	and	O
19	tRNAIle	O
20	,	O
21	are	O
22	found	O
23	upstream	O
24	to	O
25	the	O
26	gene	O
27	.	O

1	We	O
2	isolated	O
3	a	O
4	ribosomal	O
5	protein	O
6	L18	O
7	by	O
8	interaction	O
9	with	O
10	PKR	B
11	.	O

1	A	O
2	constitutive	O
3	mutant	O
4	form	O
5	with	O
6	a	O
7	single	O
8	substitution	O
9	(	O
10	V88A	O
11	)	O
12	in	O
13	the	O
14	amino	O
15	-	O
16	terminal	O
17	(	O
18	response	O
19	regulator	O
20	)	O
21	region	O
22	was	O
23	used	O
24	.	O

1	Reverse	O
2	transcription	O
3	(	O
4	RT	O
5	)-	O
6	PCR	O
7	products	O
8	were	O
9	synthesized	O
10	with	O
11	two	O
12	degenerate	O
13	primers	O
14	derived	O
15	from	O
16	the	O
17	conserved	O
18	motifs	O
19	of	O
20	various	O
21	tyrosine	O
22	kinases	O
23	.	O

1	Subjects	O
2	with	O
3	a	O
4	short	O
5	postexposure	O
6	time	O
7	and	O
8	a	O
9	dioxin	O
10	burden	O
11	>	O
12	0	O
13	.	O
14	6	O
15	pg	O
16	/	O
17	m3	O
18	had	O
19	a	O
20	significantly	O
21	higher	O
22	risk	O
23	of	O
24	hypoergy	O
25	than	O
26	unexposed	O
27	subjects	O
28	(	O
29	hypoergy	O
30	I	O
31	:	O
32	OR	O
33	=	O
34	9	O
35	.	O
36	51	O
37	,	O
38	95	O
39	%	O
40	CI	O
41	=	O
42	1	O
43	.	O
44	96	O
45	-	O
46	42	O
47	.	O
48	02	O
49	;	O
50	hypoergy	O
51	II	O
52	:	O
53	OR	O
54	=	O
55	2	O
56	.	O
57	92	O
58	,	O
59	95	O
60	%	O
61	CI	O
62	=	O
63	1	O
64	.	O
65	14	O
66	-	O
67	7	O
68	.	O
69	5	O
70	).	O

1	Value	O
2	of	O
3	Normotest	O
4	and	O
5	antithrombin	B
6	3	O
7	in	O
8	the	O
9	assessment	O
10	of	O
11	liver	O
12	function	O
13	.	O

1	Studies	O
2	also	O
3	have	O
4	alluded	O
5	to	O
6	a	O
7	relationship	O
8	between	O
9	the	O
10	MSMR	O
11	cyst	O
12	and	O
13	certain	O
14	signs	O
15	or	O
16	symptoms	O
17	of	O
18	disease	O
19	.	O

1	Cerebrospinal	O
2	fluid	O
3	transferrin	B
4	II	I
5	studies	O
6	in	O
7	ischemic	O
8	disorders	O
9	of	O
10	the	O
11	central	O
12	nervous	O
13	system	O
14	.	O

1	In	O
2	the	O
3	absence	O
4	of	O
5	E1A243	O
6	,	O
7	YY1	B
8	represses	O
9	CRE	O
10	-	O
11	dependent	O
12	transcription	O
13	of	O
14	c	B
15	-	I
16	fos	I
17	by	O
18	physically	O
19	interacting	O
20	with	O
21	ATF	B
22	/	I
23	CREB	I
24	proteins	I
25	bound	O
26	to	O
27	the	O
28	-	O
29	67	O
30	CRE	O
31	.	O

1	In	O
2	a	O
3	similar	O
4	fashion	O
5	to	O
6	adipose	O
7	stromal	O
8	cells	O
9	,	O
10	serum	O
11	potentiated	O
12	the	O
13	response	O
14	to	O
15	dexamethasone	O
16	but	O
17	had	O
18	no	O
19	effect	O
20	on	O
21	phorbol	O
22	ester	O
23	-	O
24	stimulated	O
25	activity	O
26	.	O

1	DNA	O
2	sequence	O
3	analysis	O
4	has	O
5	confirmed	O
6	that	O
7	this	O
8	mutation	O
9	affects	O
10	the	O
11	C	O
12	-	O
13	terminal	O
14	region	O
15	of	O
16	the	O
17	alpha	O
18	subunit	O
19	,	O
20	changing	O
21	a	O
22	leucine	O
23	residue	O
24	at	O
25	position	O
26	290	O
27	to	O
28	a	O
29	histidine	O
30	(	O
31	rpoAL290H	O
32	).	O

1	Thus	O
2	,	O
3	unlike	O
4	other	O
5	proteins	O
6	reported	O
7	to	O
8	inhibit	O
9	SRF	B
10	activity	O
11	,	O
12	the	O
13	repressor	O
14	activity	O
15	associated	O
16	with	O
17	the	O
18	GC	O
19	-	O
20	rich	O
21	element	O
22	does	O
23	not	O
24	appear	O
25	to	O
26	function	O
27	through	O
28	direct	O
29	inhibition	O
30	of	O
31	SRF	B
32	binding	I
33	.	O

1	However	O
2	,	O
3	whether	O
4	or	O
5	not	O
6	nonsense	O
7	codon	O
8	recognition	O
9	within	O
10	TPI	O
11	transcripts	O
12	takes	O
13	place	O
14	prior	O
15	to	O
16	or	O
17	after	O
18	splicing	O
19	remained	O
20	unresolved	O
21	.	O

1	The	O
2	first	O
3	group	O
4	of	O
5	sequential	O
6	BMB	O
7	showed	O
8	a	O
9	significant	O
10	progress	O
11	to	O
12	myelofibrosis	O
13	in	O
14	so	O
15	-	O
16	called	O
17	"	O
18	Chronic	O
19	Megakaryocytic	O
20	-	O
21	Granulocytic	O
22	Myelosis	O
23	"--	O
24	CMGM	O
25	-,	O
26	which	O
27	corresponds	O
28	to	O
29	Agnogenic	O
30	Myeloid	O
31	Metaplasia	O
32	-	O
33	AMM	O
34	-	O
35	in	O
36	72	O
37	.	O
38	4	O
39	%	O
40	(	O
41	21	O
42	/	O
43	29	O
44	patients	O
45	),	O
46	as	O
47	well	O
48	as	O
49	in	O
50	CML	O
51	with	O
52	megakaryocytic	O
53	increase	O
54	-	O
55	CML	O
56	.	O
57	MI	O
58	-	O
59	in	O
60	39	O
61	.	O
62	2	O
63	%	O
64	(	O
65	20	O
66	/	O
67	51	O
68	).	O

1	Antithrombin	B
2	III	I
3	(	O
4	AT	O
5	III	O
6	)	O
7	is	O
8	a	O
9	plasma	O
10	protein	O
11	which	O
12	acts	O
13	as	O
14	the	O
15	principal	O
16	inhibitor	O
17	of	O
18	thrombin	B
19	and	O
20	is	O
21	a	O
22	major	O
23	modulator	O
24	of	O
25	intravascular	O
26	coagulation	O
27	.	O

1	The	O
2	therapeutic	O
3	use	O
4	of	O
5	botulinum	B
6	toxin	I
7	(	O
8	Botox	O
9	)	O
10	is	O
11	increasing	O
12	in	O
13	popularity	O
14	.	O

1	This	O
2	compound	O
3	is	O
4	the	O
5	main	O
6	bioactive	O
7	metabolite	O
8	of	O
9	trimebutine	O
10	II	O
11	(	O
12	Debridat	O
13	,	O
14	CAS	O
15	39133	O
16	-	O
17	31	O
18	-	O
19	8	O
20	),	O
21	an	O
22	antispasmodic	O
23	widely	O
24	used	O
25	for	O
26	intestinal	O
27	diseases	O
28	since	O
29	1969	O
30	.	O

1	The	O
2	carboxyl	O
3	-	O
4	terminal	O
5	CCCC	O
6	module	O
7	is	O
8	structurally	O
9	related	O
10	to	O
11	the	O
12	DNA	O
13	-	O
14	binding	O
15	domain	O
16	of	O
17	the	O
18	erythroid	O
19	transcription	O
20	factor	O
21	GATA	B
22	-	I
23	1	I
24	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	essential	O
5	IncP	O
6	alpha	O
7	plasmid	O
8	transfer	O
9	genes	O
10	traF	O
11	and	O
12	traG	O
13	and	O
14	involvement	O
15	of	O
16	traF	O
17	in	O
18	phage	O
19	sensitivity	O
20	.	O

1	SRF	B
2	-	I
3	deficient	O
4	embryos	O
5	(	O
6	Srf	O
7	-/-)	O
8	have	O
9	a	O
10	severe	O
11	gastrulation	O
12	defect	O
13	and	O
14	do	O
15	not	O
16	develop	O
17	to	O
18	term	O
19	.	O

1	The	O
2	disturbance	O
3	of	O
4	pulmonary	O
5	gas	O
6	exchange	O
7	,	O
8	as	O
9	revealed	O
10	by	O
11	the	O
12	high	O
13	value	O
14	of	O
15	AaDO2	O
16	,	O
17	existed	O
18	without	O
19	left	O
20	ventricular	O
21	dysfunction	O
22	,	O
23	and	O
24	AaDO2	O
25	had	O
26	no	O
27	significant	O
28	relationship	O
29	with	O
30	any	O
31	of	O
32	the	O
33	hemodynamic	O
34	parameters	O
35	including	O
36	the	O
37	difference	O
38	between	O
39	plasma	O
40	colloid	O
41	osmotic	O
42	pressure	O
43	and	O
44	PCW	O
45	.	O

1	Tyrosine	B
2	kinase	I
3	oncogenes	I
4	abrogate	I
5	interleukin	I
6	-	I
7	3	O
8	dependence	O
9	of	O
10	murine	O
11	myeloid	O
12	cells	O
13	through	O
14	signaling	O
15	pathways	O
16	involving	O
17	c	B
18	-	I
19	myc	I
20	:	O
21	conditional	O
22	regulation	O
23	of	O
24	c	B
25	-	I
26	myc	I
27	transcription	O
28	by	O
29	temperature	O
30	-	O
31	sensitive	O
32	v	B
33	-	I
34	abl	I
35	.	O

1	The	O
2	known	O
3	B1	O
4	-	O
5	deficiency	O
6	reaches	O
7	excessive	O
8	high	O
9	values	O
10	with	O
11	light	O
12	exercise	O
13	.	O

1	During	O
2	the	O
3	last	O
4	6	O
5	months	O
6	of	O
7	the	O
8	study	O
9	a	O
10	striking	O
11	change	O
12	in	O
13	epidemiology	O
14	concerning	O
15	hepatitis	O
16	A	O
17	was	O
18	seen	O
19	,	O
20	apparently	O
21	caused	O
22	by	O
23	a	O
24	steep	O
25	increase	O
26	in	O
27	the	O
28	incidence	O
29	of	O
30	this	O
31	type	O
32	of	O
33	hepatitis	O
34	among	O
35	drug	O
36	addicts	O
37	.	O

1	The	O
2	overall	O
3	prevalence	O
4	of	O
5	psoriasis	O
6	was	O
7	4	O
8	.	O
9	79	O
10	%	O
11	in	O
12	men	O
13	and	O
14	4	O
15	.	O
16	85	O
17	%	O
18	in	O
19	women	O
20	.	O

1	ULKs	O
2	and	O
3	UNC	B
4	-	I
5	51	O
6	share	O
7	a	O
8	typical	O
9	domain	O
10	structure	O
11	of	O
12	an	O
13	amino	O
14	-	O
15	terminal	O
16	kinase	O
17	domain	O
18	,	O
19	a	O
20	central	O
21	proline	O
22	/	O
23	serine	O
24	rich	O
25	(	O
26	PS	O
27	)	O
28	domain	O
29	,	O
30	and	O
31	a	O
32	carboxy	O
33	-	O
34	terminal	O
35	(	O
36	C	O
37	)	O
38	domain	O
39	.	O

1	Based	O
2	on	O
3	our	O
4	observations	O
5	,	O
6	we	O
7	propose	O
8	a	O
9	model	O
10	whereby	O
11	inactive	O
12	precursor	O
13	molecules	O
14	produced	O
15	from	O
16	the	O
17	PEP4	B
18	gene	I
19	self	O
20	-	O
21	activate	O
22	within	O
23	the	O
24	yeast	O
25	vacuole	O
26	and	O
27	subsequently	O
28	activate	O
29	other	O
30	vacuolar	B
31	hydrolases	I
32	.	O

1	The	O
2	enzymatic	O
3	response	O
4	of	O
5	neutrophils	O
6	and	O
7	monocytes	O
8	was	O
9	similar	O
10	although	O
11	the	O
12	magnitude	O
13	of	O
14	the	O
15	NADPH	B
16	oxidase	I
17	activity	O
18	was	O
19	significantly	O
20	higher	O
21	in	O
22	neutrophils	O
23	than	O
24	in	O
25	monocytes	O
26	.	O

1	Implications	O
2	of	O
3	this	O
4	observation	O
5	for	O
6	pediatrics	O
7	are	O
8	discussed	O
9	.	O

1	Despite	O
2	this	O
3	DNA	O
4	binding	O
5	activity	O
6	,	O
7	AP	B
8	-	I
9	1	I
10	reporter	I
11	activity	O
12	was	O
13	suppressed	O
14	in	O
15	these	O
16	cells	O
17	.	O

1	Papers	O
2	of	O
3	the	O
4	Society	O
5	for	O
6	Clinical	O
7	Vascular	O
8	Surgery	O
9	.	O

1	Histochemistry	O
2	and	O
3	electron	O
4	microscopy	O
5	of	O
6	acute	O
7	liver	O
8	lesions	O
9	induced	O
10	by	O
11	Aflatoxin	O
12	B1	O
13	in	O
14	ducklings	O
15	.	O

1	SETTING	O
2	--	O
3	Women	O
4	,	O
5	Infants	O
6	,	O
7	and	O
8	Children	O
9	clinics	O
10	in	O
11	Minneapolis	O
12	,	O
13	Minn	O
14	.	O

1	C	O
2	.	O

1	It	O
2	has	O
3	been	O
4	established	O
5	that	O
6	preoperative	O
7	irradiation	O
8	in	O
9	the	O
10	form	O
11	of	O
12	the	O
13	fractionation	O
14	of	O
15	a	O
16	single	O
17	focal	O
18	dose	O
19	of	O
20	6	O
21	Gy	O
22	every	O
23	other	O
24	day	O
25	,	O
26	the	O
27	summary	O
28	dose	O
29	of	O
30	24	O
31	Gy	O
32	within	O
33	8	O
34	-	O
35	10	O
36	days	O
37	followed	O
38	by	O
39	surgery	O
40	1	O
41	-	O
42	3	O
43	days	O
44	after	O
45	irradiation	O
46	does	O
47	not	O
48	either	O
49	complicate	O
50	its	O
51	performance	O
52	or	O
53	the	O
54	course	O
55	of	O
56	the	O
57	postoperative	O
58	period	O
59	,	O
60	and	O
61	by	O
62	the	O
63	short	O
64	-	O
65	and	O
66	long	O
67	-	O
68	term	O
69	results	O
70	it	O
71	is	O
72	no	O
73	worse	O
74	than	O
75	the	O
76	routine	O
77	dose	O
78	fractionation	O
79	.	O

1	Further	O
2	analysis	O
3	of	O
4	AP	B
5	-	I
6	1	I
7	DNA	O
8	binding	O
9	activities	O
10	in	O
11	7	O
12	-	O
13	to	O
14	14	O
15	-	O
16	day	O
17	culture	O
18	activated	O
19	HSCs	O
20	led	O
21	to	O
22	the	O
23	discovery	O
24	of	O
25	high	O
26	mobility	O
27	AP	B
28	-	I
29	1	I
30	complexes	I
31	(	I
32	HMAP	I
33	-	I
34	1	I
35	).	O

1	Specific	O
2	binding	O
3	was	O
4	not	O
5	observed	O
6	with	O
7	either	O
8	the	O
9	orthologous	O
10	rat	O
11	or	O
12	mouse	O
13	fragments	O
14	using	O
15	human	O
16	or	O
17	rodent	O
18	extracts	O
19	.	O

1	We	O
2	now	O
3	show	O
4	that	O
5	gp200	O
6	-	O
7	MR6	O
8	ligation	O
9	can	O
10	also	O
11	mimic	O
12	IL	B
13	-	I
14	4	O
15	and	O
16	have	O
17	an	O
18	anti	B
19	-	I
20	proliferative	I
21	pro	I
22	-	I
23	maturational	O
24	influence	O
25	within	O
26	the	O
27	immune	O
28	system	O
29	,	O
30	causing	O
31	up	O
32	-	O
33	regulation	O
34	of	O
35	co	O
36	-	O
37	stimulatory	O
38	molecules	O
39	on	O
40	B	O
41	lymphocytes	O
42	.	O

1	The	O
2	results	O
3	suggest	O
4	that	O
5	,	O
6	although	O
7	both	O
8	the	O
9	N	O
10	-	O
11	and	O
12	C	O
13	-	O
14	terminal	O
15	regions	O
16	of	O
17	talin	O
18	bind	O
19	actin	B
20	,	O
21	the	O
22	properties	O
23	of	O
24	these	O
25	two	O
26	regions	O
27	of	O
28	the	O
29	protein	O
30	are	O
31	distinct	O
32	.	O

1	Mutational	O
2	analysis	O
3	of	O
4	chromosomal	O
5	segment	O
6	64AB	O
7	,	O
8	a	O
9	region	O
10	containing	O
11	the	O
12	glutamic	B
13	acid	I
14	decarboxylase	I
15	gene	I
16	.	O

1	One	O
2	group	O
3	of	O
4	six	O
5	cDNA	O
6	clones	O
7	was	O
8	derived	O
9	from	O
10	a	O
11	2	O
12	.	O
13	9	O
14	-	O
15	kilobase	O
16	early	O
17	transcript	O
18	encoded	O
19	by	O
20	the	O
21	IR2	O
22	repeat	O
23	element	O
24	and	O
25	showed	O
26	restriction	O
27	site	O
28	polymorphism	O
29	for	O
30	the	O
31	enzyme	O
32	SmaI	O
33	.	O

1	The	O
2	bovine	B
3	papillomavirus	I
4	E2	I
5	protein	I
6	can	O
7	inhibit	O
8	the	O
9	proliferation	O
10	of	O
11	HT	O
12	-	O
13	3	O
14	cells	O
15	,	O
16	a	O
17	p53	B
18	-	I
19	negative	O
20	cervical	O
21	carcinoma	O
22	cell	O
23	line	O
24	containing	O
25	integrated	O
26	human	O
27	papillomavirus	O
28	type	O
29	30	O
30	DNA	O
31	.	O

1	When	O
2	tested	O
3	with	O
4	wild	O
5	-	O
6	type	O
7	(	O
8	DBA	O
9	/	O
10	2	O
11	)	O
12	p16	O
13	,	O
14	both	O
15	A134C	O
16	and	O
17	G232A	O
18	BALB	O
19	/	O
20	c	B
21	-	I
22	specific	O
23	variants	O
24	of	O
25	p16	O
26	were	O
27	inefficient	O
28	in	O
29	their	O
30	ability	O
31	to	O
32	inhibit	O
33	the	O
34	activity	O
35	of	O
36	cyclin	B
37	D2	I
38	/	I
39	CDK4	I
40	in	O
41	kinase	O
42	assays	O
43	with	O
44	retinoblastoma	B
45	protein	I
46	,	O
47	suggesting	O
48	this	O
49	defective	O
50	,	O
51	inherited	O
52	allele	O
53	plays	O
54	an	O
55	important	O
56	role	O
57	in	O
58	the	O
59	genetic	O
60	susceptibility	O
61	of	O
62	BALB	O
63	/	O
64	c	O
65	mice	O
66	for	O
67	plasmacytoma	O
68	induction	O
69	and	O
70	that	O
71	p16	O
72	(	O
73	INK4a	O
74	)	O
75	is	O
76	a	O
77	strong	O
78	candidate	O
79	for	O
80	the	O
81	Pctr1	B
82	locus	I
83	.	O

1	Is	O
2	nisoldipine	O
3	capable	O
4	of	O
5	reducing	O
6	left	O
7	ventricular	O
8	preload	O
9	?	O
10	In	O
11	ten	O
12	anesthetized	O
13	pigs	O
14	,	O
15	nisoldipine	O
16	(	O
17	2	O
18	-	O
19	4	O
20	micrograms	O
21	X	O
22	kg	O
23	-	O
24	1	O
25	X	O
26	min	O
27	-	O
28	1	O
29	),	O
30	a	O
31	calcium	O
32	channel	O
33	blocker	O
34	structurally	O
35	related	O
36	to	O
37	nifedipine	O
38	,	O
39	reduced	O
40	left	O
41	ventricular	O
42	systolic	O
43	pressure	O
44	(	O
45	40	O
46	%)	O
47	and	O
48	systemic	O
49	vascular	O
50	resistance	O
51	(	O
52	35	O
53	%),	O
54	whereas	O
55	maxLVdP	O
56	/	O
57	dt	O
58	decreased	O
59	by	O
60	20	O
61	%	O
62	and	O
63	cardiac	O
64	output	O
65	was	O
66	unchanged	O
67	.	O

1	Binding	O
2	specificity	O
3	and	O
4	modulation	O
5	of	O
6	the	O
7	ApoA	O
8	-	O
9	I	O
10	promoter	O
11	activity	O
12	by	O
13	homo	O
14	-	O
15	and	O
16	heterodimers	O
17	of	O
18	nuclear	O
19	receptors	O
20	.	O

1	Amikacin	O
2	concentrations	O
3	in	O
4	serum	O
5	and	O
6	blister	O
7	fluid	O
8	in	O
9	healthy	O
10	volunteers	O
11	and	O
12	in	O
13	patients	O
14	with	O
15	renal	O
16	impairment	O
17	.	O

1	New	O
2	and	O
3	successful	O
4	steps	O
5	have	O
6	been	O
7	made	O
8	in	O
9	immunodiagnostics	O
10	,	O
11	immunotherapy	O
12	,	O
13	and	O
14	immunoprophylaxis	O
15	of	O
16	immunologically	O
17	conditioned	O
18	infertility	O
19	.	O

1	Two	O
2	of	O
3	the	O
4	three	O
5	groups	O
6	were	O
7	administered	O
8	dauricine	O
9	,	O
10	as	O
11	a	O
12	new	O
13	calcium	O
14	channel	O
15	blocker	O
16	,	O
17	and	O
18	verapamil	O
19	,	O
20	as	O
21	a	O
22	generally	O
23	recognized	O
24	calcium	O
25	channel	O
26	blocker	O
27	,	O
28	respectively	O
29	,	O
30	from	O
31	15	O
32	minutes	O
33	pre	O
34	-	O
35	bypass	O
36	to	O
37	the	O
38	end	O
39	of	O
40	the	O
41	bypass	O
42	procedure	O
43	(	O
44	a	O
45	period	O
46	of	O
47	95	O
48	minutes	O
49	).	O

1	Further	O
2	,	O
3	intracerebroventricular	O
4	injections	O
5	of	O
6	KA	O
7	resulted	O
8	in	O
9	the	O
10	substantial	O
11	loss	O
12	of	O
13	pyramidal	O
14	cells	O
15	in	O
16	the	O
17	whole	O
18	CA3	O
19	field	O
20	of	O
21	the	O
22	hippocampus	O
23	.	O

1	In	O
2	contrast	O
3	,	O
4	COUP	B
5	-	I
6	TF	I
7	alone	O
8	had	O
9	no	O
10	effect	O
11	on	O
12	repCRS2	O
13	-	O
14	dependent	O
15	reporter	O
16	gene	O
17	activity	O
18	.	O

1	In	O
2	patients	O
3	who	O
4	had	O
5	received	O
6	no	O
7	previous	O
8	drug	O
9	treatment	O
10	,	O
11	log	O
12	baseline	O
13	plasma	O
14	renin	B
15	activity	O
16	and	O
17	change	O
18	in	O
19	mean	O
20	blood	O
21	pressure	O
22	after	O
23	SQ	O
24	20881	O
25	correlated	O
26	significantly	O
27	(	O
28	r	O
29	=	O
30	0	O
31	.	O
32	651	O
33	,	O
34	P	O
35	less	O
36	than	O
37	0	O
38	.	O
39	05	O
40	).	O

1	Endocytosis	O
2	and	O
3	lysosomal	O
4	targeting	O
5	of	O
6	epidermal	B
7	growth	I
8	factor	I
9	receptors	I
10	are	O
11	mediated	O
12	by	O
13	distinct	O
14	sequences	O
15	independent	O
16	of	O
17	the	O
18	tyrosine	B
19	kinase	I
20	domain	I
21	.	O

1	Increasing	O
2	the	O
3	extracellular	O
4	calcium	O
5	concentration	O
6	enhanced	O
7	detrusor	O
8	contractility	O
9	in	O
10	a	O
11	dose	O
12	-	O
13	dependent	O
14	manner	O
15	in	O
16	both	O
17	control	O
18	and	O
19	obstructed	O
20	bladders	O
21	.	O

1	Because	O
2	of	O
3	serious	O
4	infections	O
5	(	O
6	fever	O
7	larger	O
8	than	O
9	or	O
10	equal	O
11	to	O
12	101	O
13	degrees	O
14	F	O
15	.	O
16	granulocytes	O
17	less	O
18	than	O
19	1	O
20	,	O
21	000	O
22	/	O
23	mm	O
24	,	O
25	3	O
26	and	O
27	hospitalization	O
28	)	O
29	and	O
30	1	O
31	drug	O
32	death	O
33	in	O
34	the	O
35	first	O
36	4	O
37	patients	O
38	,	O
39	oral	O
40	calcium	O
41	leucovorin	O
42	,	O
43	20	O
44	to	O
45	30	O
46	mg	O
47	/	O
48	m2	O
49	orally	O
50	,	O
51	was	O
52	given	O
53	2	O
54	days	O
55	after	O
56	methotrexate	O
57	in	O
58	subsequent	O
59	treatment	O
60	cycles	O
61	.	O

1	To	O
2	study	O
3	the	O
4	retinal	O
5	surface	O
6	in	O
7	the	O
8	human	O
9	eye	O
10	in	O
11	normal	O
12	and	O
13	diseased	O
14	states	O
15	we	O
16	used	O
17	laser	O
18	scanning	O
19	tomography	O
20	.	O

1	To	O
2	establish	O
3	a	O
4	possible	O
5	association	O
6	between	O
7	familial	O
8	dysfibrinogenemia	O
9	and	O
10	thrombophilia	O
11	,	O
12	data	O
13	on	O
14	cases	O
15	with	O
16	both	O
17	affections	O
18	were	O
19	collected	O
20	in	O
21	a	O
22	study	O
23	within	O
24	the	O
25	framework	O
26	of	O
27	the	O
28	SSC	O
29	Subcommittee	O
30	on	O
31	Fibrinogen	O
32	of	O
33	the	O
34	International	O
35	Society	O
36	on	O
37	Thrombosis	O
38	and	O
39	Haemostasis	O
40	.	O

1	By	O
2	contrast	O
3	,	O
4	deletion	O
5	of	O
6	this	O
7	Ras	B
8	-	I
9	binding	I
10	site	I
11	did	O
12	not	O
13	diminish	O
14	activation	O
15	of	O
16	Raf	B
17	-	I
18	1	I
19	kinase	I
20	by	O
21	Src	B
22	,	O
23	implying	O
24	that	O
25	Src	B
26	and	O
27	Ras	B
28	can	O
29	activate	O
30	Raf	B
31	-	I
32	1	I
33	through	O
34	independent	O
35	mechanisms	O
36	.	O

1	Ion	O
2	injection	O
3	.	O

1	EBNA	B
2	-	I
3	2	I
4	and	O
5	the	O
6	cis	O
7	-	O
8	acting	O
9	CD23	B
10	element	I
11	increased	O
12	TK	B
13	-	I
14	promoted	I
15	mRNA	I
16	and	O
17	did	O
18	not	O
19	alter	O
20	the	O
21	herpes	O
22	simplex	O
23	virus	O
24	TK	B
25	promoter	I
26	transcription	O
27	start	O
28	site	O
29	.	O

1	Appropriate	O
2	restriction	O
3	sites	O
4	allow	O
5	one	O
6	to	O
7	insert	O
8	virtually	O
9	any	O
10	desired	O
11	cDNA	O
12	fragment	O
13	directly	O
14	behind	O
15	the	O
16	epitope	O
17	-	O
18	specific	O
19	sequence	O
20	and	O
21	before	O
22	a	O
23	long	O
24	poly	O
25	(	O
26	A	O
27	)	O
28	tail	O
29	.	O

1	Dissipation	O
2	of	O
3	claudication	O
4	pain	O
5	after	O
6	walking	O
7	:	O
8	implications	O
9	for	O
10	endurance	O
11	training	O
12	.	O

1	Ultrasound	O
2	effect	O
3	on	O
4	the	O
5	cytochrome	B
6	oxidase	I
7	activity	O

1	The	O
2	negative	O
3	calcium	O
4	balance	O
5	with	O
6	hyperparathyroidemia	O
7	occurred	O
8	after	O
9	continuous	O
10	oral	O
11	administration	O
12	of	O
13	Cd	O
14	and	O
15	developed	O
16	via	O
17	increased	O
18	urinary	O
19	excretion	O
20	of	O
21	calcium	O
22	.	O

1	The	O
2	por	O
3	gene	O
4	has	O
5	been	O
6	expressed	O
7	,	O
8	for	O
9	the	O
10	first	O
11	time	O
12	,	O
13	in	O
14	anaerobically	O
15	grown	O
16	Escherichia	O
17	coli	O
18	behind	O
19	the	O
20	isopropyl	B
21	-	I
22	beta	I
23	-	I
24	D	I
25	-	I
26	thiogalactopyranoside	I
27	-	I
28	inducible	I
29	tac	I
30	promoter	I
31	,	O
32	resulting	O
33	in	O
34	the	O
35	production	O
36	of	O
37	POR	O
38	in	O
39	its	O
40	active	O
41	form	O
42	.	O

1	A	O
2	list	O
3	of	O
4	12	O
5	names	O
6	for	O
7	the	O
8	disease	O
9	and	O
10	37	O
11	diagnostic	O
12	criteria	O
13	were	O
14	proposed	O
15	to	O
16	a	O
17	Consensus	O
18	Panel	O
19	of	O
20	12	O
21	Italian	O
22	experts	O
23	who	O
24	ranked	O
25	them	O
26	in	O
27	order	O
28	so	O
29	as	O
30	to	O
31	identify	O
32	a	O
33	core	O
34	set	O
35	of	O
36	criteria	O
37	.	O

1	Fufang	O
2	wuzi	O
3	yanzong	O
4	pills	O
5	have	O
6	strong	O
7	leukogenic	O
8	effect	O
9	on	O
10	cyclophosphamide	O
11	induced	O
12	leukopenia	O
13	in	O
14	mice	O
15	.	O

1	Thus	O
2	,	O
3	prostacyclin	O
4	enhanced	O
5	the	O
6	autoregulative	O
7	property	O
8	of	O
9	the	O
10	inner	O
11	ear	O
12	vessels	O
13	.	O

1	The	O
2	calcium	O
3	ratio	O
4	(	O
5	mean	O
6	ratio	O
7	of	O
8	the	O
9	predicted	O
10	to	O
11	measured	O
12	TBCa	O
13	)	O
14	in	O
15	men	O
16	was	O
17	1	O
18	.	O
19	000	O
20	+/-	O
21	7	O
22	.	O
23	8	O
24	%	O
25	and	O
26	in	O
27	women	O
28	0	O
29	.	O
30	996	O
31	+/-	O
32	7	O
33	.	O
34	1	O
35	%.	O

1	A	O
2	key	O
3	event	O
4	in	O
5	this	O
6	process	O
7	is	O
8	the	O
9	selective	O
10	recognition	O
11	of	O
12	the	O
13	target	O
14	membrane	O
15	by	O
16	the	O
17	vesicle	O
18	and	O
19	the	O
20	current	O
21	view	O
22	is	O
23	that	O
24	SNARE	O
25	protein	O
26	interactions	O
27	likely	O
28	play	O
29	a	O
30	central	O
31	role	O
32	in	O
33	vesicle	O
34	-	O
35	target	O
36	recognition	O
37	and	O
38	or	O
39	membrane	O
40	fusion	O
41	.	O

1	It	O
2	brings	O
3	about	O
4	fatigue	O
5	,	O
6	negative	O
7	moods	O
8	,	O
9	and	O
10	impaired	O
11	health	O
12	,	O
13	sleep	O
14	,	O
15	safety	O
16	,	O
17	and	O
18	working	O
19	capacity	O
20	.	O

1	Arnt3	O
2	mRNA	O
3	was	O
4	expressed	O
5	in	O
6	brain	O
7	,	O
8	skeletal	O
9	muscle	O
10	,	O
11	13	O
12	.	O
13	5	O
14	-	O
15	day	O
16	embryos	O
17	,	O
18	and	O
19	P19	O
20	cells	O
21	treated	O
22	with	O
23	retinoic	O
24	acid	O
25	.	O

1	The	O
2	role	O
3	of	O
4	intraoperative	O
5	echocardiography	O
6	in	O
7	surgery	O
8	of	O
9	the	O
10	heart	O
11	and	O
12	large	O
13	vessels	O

1	Immunoglobulin	O
2	light	O
3	chain	O
4	(	O
5	IgL	O
6	)	O
7	diversity	O
8	is	O
9	generated	O
10	in	O
11	the	O
12	chicken	O
13	by	O
14	recombination	O
15	between	O
16	the	O
17	single	O
18	functional	O
19	variable	O
20	(	O
21	VL	O
22	)	O
23	and	O
24	joining	O
25	(	O
26	JL	O
27	)	O
28	gene	O
29	segments	O
30	and	O
31	subsequent	O
32	somatic	O
33	diversification	O
34	of	O
35	the	O
36	rearranged	O
37	VL	O
38	region	O
39	.	O

1	Glycogen	O
2	synthesis	O
3	and	O
4	catabolism	O
5	,	O
6	gluconeogenesis	O
7	,	O
8	glycolysis	O
9	,	O
10	motility	O
11	,	O
12	cell	O
13	surface	O
14	properties	O
15	and	O
16	adherence	O
17	are	O
18	modulated	O
19	by	O
20	csrA	O
21	in	O
22	Escherichia	O
23	coli	O
24	,	O
25	while	O
26	the	O
27	production	O
28	of	O
29	several	O
30	secreted	O
31	virulence	O
32	factors	O
33	,	O
34	the	O
35	plant	O
36	hypersensitive	O
37	response	O
38	elicitor	O
39	HrpN	O
40	(	O
41	Ecc	O
42	)	O
43	and	O
44	,	O
45	potentially	O
46	,	O
47	other	O
48	secondary	O
49	metabolites	O
50	are	O
51	regulated	O
52	by	O
53	rsmA	O
54	in	O
55	Erwinia	B
56	carotovora	I
57	.	O

1	Sequence	O
2	comparison	O
3	indicates	O
4	that	O
5	exons	O
6	5	O
7	'/	O
8	L	O
9	and	O
10	L	O
11	/	O
12	N	O
13	in	O
14	PSG12	O
15	and	O
16	PSG12	O
17	psi	O
18	are	O
19	99	O
20	%	O
21	identical	O
22	,	O
23	except	O
24	that	O
25	the	O
26	L	O
27	/	O
28	N	O
29	exon	O
30	in	O
31	the	O
32	PSG12	O
33	psi	B
34	gene	I
35	contains	O
36	a	O
37	stop	O
38	codon	O
39	.	O

1	A	O
2	subsequent	O
3	screen	O
4	for	O
5	the	O
6	loss	O
7	of	O
8	the	O
9	positively	O
10	selectable	O
11	target	O
12	locus	O
13	marker	O
14	detects	O
15	the	O
16	desired	O
17	replacement	O
18	at	O
19	modest	O
20	frequency	O
21	(>	O
22	2	O
23	%).	O

1	RESULTS	O
2	:	O
3	We	O
4	identified	O
5	a	O
6	full	O
7	-	O
8	length	O
9	cDNA	O
10	with	O
11	an	O
12	open	O
13	reading	O
14	frame	O
15	of	O
16	2883	O
17	bp	O
18	corresponding	O
19	to	O
20	a	O
21	predicted	O
22	protein	O
23	of	O
24	961	O
25	amino	O
26	acids	O
27	that	O
28	shares	O
29	greater	O
30	than	O
31	95	O
32	%	O
33	homology	O
34	with	O
35	the	O
36	rat	B
37	gamma	I
38	-	I
39	aminobutyric	I
40	acid	I
41	B	I
42	(	O
43	GABAB	O
44	)	O
45	receptor	O
46	.	O

1	Characterization	O
2	of	O
3	the	O
4	transcription	O
5	factor	O
6	MTF	O
7	-	O
8	1	O
9	from	O
10	the	O
11	Japanese	O
12	pufferfish	O
13	(	O
14	Fugu	O
15	rubripes	O
16	)	O
17	reveals	O
18	evolutionary	O
19	conservation	O
20	of	O
21	heavy	O
22	metal	O
23	stress	O
24	response	O
25	.	O

1	The	O
2	DAP5	O
3	/	O
4	p86	O
5	apoptotic	O
6	form	O
7	was	O
8	more	O
9	potent	O
10	than	O
11	DAP5	O
12	/	O
13	p97	O
14	in	O
15	these	O
16	functional	O
17	assays	O
18	.	O

1	Biol	O
2	.	O

1	These	O
2	cell	O
3	lines	O
4	,	O
5	selected	O
6	for	O
7	the	O
8	ability	O
9	to	O
10	support	O
11	the	O
12	replication	O
13	of	O
14	a	O
15	temperature	O
16	-	O
17	sensitive	O
18	VP5	B
19	mutant	I
20	,	O
21	were	O
22	used	O
23	to	O
24	isolate	O
25	VP5	O
26	and	O
27	VP23	O
28	null	O
29	mutants	O
30	.	O

1	The	O
2	zona	O
3	pellucida	O
4	(	O
5	ZP	O
6	),	O
7	the	O
8	extracellular	O
9	glycocalyx	O
10	that	O
11	surrounds	O
12	the	O
13	oocyte	O
14	,	O
15	is	O
16	well	O
17	known	O
18	to	O
19	mediate	O
20	homologous	O
21	gamete	O
22	interaction	O
23	.	O

1	Clinicopathologic	O
2	studies	O
3	in	O
4	feminizing	O
5	tumors	O
6	of	O
7	the	O
8	ovary	O
9	.	O

1	False	O
2	positive	O
3	amniotic	O
4	fluid	O
5	alpha	B
6	fetoprotein	I
7	levels	O
8	resulting	O
9	from	O
10	contamination	O
11	with	O
12	fetal	O
13	blood	O
14	:	O
15	results	O
16	of	O
17	an	O
18	experiment	O
19	.	O

1	Studies	O
2	on	O
3	the	O
4	organic	O
5	matrix	O
6	of	O
7	human	O
8	ear	O
9	ossicles	O

1	Our	O
2	results	O
3	demonstrate	O
4	that	O
5	distinct	O
6	cytoplasmic	O
7	domains	O
8	of	O
9	these	O
10	cytokine	O
11	receptors	O
12	elicit	O
13	convergent	O
14	signaling	O
15	pathways	O
16	and	O
17	provide	O
18	evidence	O
19	that	O
20	beta	O
21	c	O
22	and	O
23	IL	B
24	-	I
25	2R	I
26	beta	I
27	function	O
28	as	O
29	a	O
30	complete	O
31	signal	O
32	transducer	O
33	.	O

1	We	O
2	have	O
3	identified	O
4	three	O
5	binding	O
6	sites	O
7	for	O
8	protein	O
9	complexes	O
10	:	O
11	a	O
12	palindrome	O
13	,	O
14	a	O
15	direct	O
16	repeat	O
17	,	O
18	and	O
19	a	O
20	C	O
21	+	O
22	T	O
23	sequence	O
24	that	O
25	corresponds	O
26	to	O
27	seven	O
28	GAGA	O
29	motifs	O
30	on	O
31	the	O
32	transcribed	O
33	strand	O
34	.	O

1	This	O
2	indicates	O
3	that	O
4	under	O
5	certain	O
6	experimental	O
7	conditions	O
8	cdc2	B
9	/	I
10	p58	I
11	and	O
12	cdc2	B
13	/	I
14	p62	I
15	may	O
16	express	O
17	some	O
18	differences	O
19	in	O
20	their	O
21	catalytic	O
22	activity	O
23	.	O

1	Drugs	O
2	suppressed	O
3	>	O
4	or	O
5	=	O
6	75	O
7	%	O
8	of	O
9	the	O
10	total	O
11	premature	O
12	ventricular	O
13	contractions	O
14	in	O
15	all	O
16	patients	O
17	who	O
18	had	O
19	both	O
20	use	O
21	-	O
22	dependent	O
23	QRS	O
24	prolongation	O
25	and	O
26	reverse	O
27	use	O
28	-	O
29	dependent	O
30	QT	O
31	prolongation	O
32	,	O
33	in	O
34	79	O
35	%	O
36	of	O
37	patients	O
38	with	O
39	use	O
40	-	O
41	dependent	O
42	QRS	O
43	prolongation	O
44	alone	O
45	,	O
46	in	O
47	70	O
48	%	O
49	with	O
50	reverse	O
51	use	O
52	-	O
53	dependent	O
54	QT	O
55	prolongation	O
56	alone	O
57	,	O
58	and	O
59	in	O
60	11	O
61	%	O
62	with	O
63	neither	O
64	use	O
65	-	O
66	dependent	O
67	QRS	O
68	prolongation	O
69	nor	O
70	reverse	O
71	use	O
72	-	O
73	dependent	O
74	QT	O
75	prolongation	O
76	.	O

1	Vasopressin	O
2	(	O
3	AVP	O
4	),	O
5	the	O
6	antidiuretic	O
7	hormone	O
8	,	O
9	is	O
10	a	O
11	cyclic	O
12	nonapeptide	O
13	that	O
14	acts	O
15	through	O
16	binding	O
17	to	O
18	G	B
19	protein	I
20	-	I
21	coupled	I
22	specific	I
23	membrane	I
24	receptors	I
25	pharmacologically	O
26	divided	O
27	into	O
28	three	O
29	subtypes	O
30	(	O
31	V1a	O
32	,	O
33	V1b	O
34	,	O
35	and	O
36	V2	O
37	)	O
38	linked	O
39	to	O
40	distinct	O
41	second	O
42	messengers	O
43	.	O

1	The	O
2	promoter	O
3	was	O
4	stimulated	O
5	8	O
6	-	O
7	20	O
8	-	O
9	fold	O
10	by	O
11	phorbol	O
12	esters	O
13	accounting	O
14	for	O
15	the	O
16	previously	O
17	observed	O
18	transcriptional	O
19	activation	O
20	of	O
21	protein	B
22	kinase	I
23	C	I
24	beta	I
25	.	O

1	MPO	O
2	was	O
3	labeled	O
4	with	O
5	1	O
6	mCi	O
7	125I	O
8	by	O
9	a	O
10	technique	O
11	of	O
12	self	O
13	-	O
14	labeling	O
15	in	O
16	the	O
17	presence	O
18	of	O
19	10	O
20	(-	O
21	4	O
22	)	O
23	M	O
24	hydrogen	O
25	peroxide	O
26	.	O

1	Sequence	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	5	O
7	'-	O
8	flanking	O
9	region	O
10	upstream	O
11	to	O
12	the	O
13	ATG	O
14	codon	O
15	did	O
16	not	O
17	contain	O
18	a	O
19	conventional	O
20	TATA	O
21	box	O
22	.	O

1	Induction	O
2	of	O
3	CD86	O
4	expression	O
5	by	O
6	stimulation	O
7	of	O
8	U937	O
9	cells	O
10	with	O
11	IFN	B
12	-	I
13	gamma	I
14	revealed	O
15	the	O
16	presence	O
17	of	O
18	two	O
19	functional	O
20	GAS	B
21	(	I
22	gamma	I
23	-	I
24	interferon	I
25	activation	O
26	site	O
27	)	O
28	elements	O
29	.	O

1	Trial	O
2	3	O
3	broiler	O
4	chickens	O
5	were	O
6	maintained	O
7	on	O
8	control	O
9	feed	O
10	until	O
11	they	O
12	reached	O
13	3	O
14	weeks	O
15	of	O
16	age	O
17	at	O
18	which	O
19	time	O
20	they	O
21	were	O
22	taken	O
23	off	O
24	of	O
25	feed	O
26	for	O
27	2	O
28	.	O
29	5	O
30	hr	O
31	and	O
32	then	O
33	placed	O
34	on	O
35	either	O
36	control	O
37	feed	O
38	or	O
39	feed	O
40	containing	O
41	4	O
42	.	O
43	0	O
44	ppm	O
45	ochratoxin	O
46	A	O
47	,	O
48	and	O
49	heart	O
50	rate	O
51	and	O
52	blood	O
53	pressure	O
54	were	O
55	measured	O
56	every	O
57	half	O
58	hour	O
59	through	O
60	7	O
61	hr	O
62	.	O

1	However	O
2	,	O
3	five	O
4	new	O
5	mutation	O
6	sites	O
7	(	O
8	S61	O
9	,	O
10	SL1	O
11	,	O
12	S29	O
13	,	O
14	SL11	O
15	,	O
16	SL196	O
17	and	O
18	SL126	O
19	)	O
20	are	O
21	unique	O
22	to	O
23	the	O
24	nrdB	O
25	intron	O
26	and	O
27	disrupt	O
28	self	O
29	-	O
30	splicing	O
31	.	O

1	Our	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	expression	O
7	of	O
8	Cktsf1b1	O
9	,	O
10	a	O
11	gene	O
12	associated	O
13	with	O
14	early	O
15	development	O
16	and	O
17	cell	O
18	transformation	O
19	,	O
20	is	O
21	sensitive	O
22	to	O
23	MKK	O
24	levels	O
25	and	O
26	may	O
27	be	O
28	regulated	O
29	via	O
30	multiple	O
31	transcription	O
32	factor	O
33	complexes	O
34	.	O

1	We	O
2	report	O
3	here	O
4	the	O
5	cloning	O
6	of	O
7	the	O
8	murine	O
9	p44	B
10	MAP	I
11	kinase	I
12	(	I
13	extracellular	I
14	signal	I
15	-	I
16	regulated	I
17	kinase	I
18	1	I
19	)	I
20	gene	I
21	,	O
22	the	O
23	determination	O
24	of	O
25	its	O
26	intron	O
27	/	O
28	exon	O
29	boundaries	O
30	,	O
31	and	O
32	the	O
33	characterization	O
34	of	O
35	its	O
36	promoter	O
37	.	O

1	RT	O
2	-	O
3	PCR	O
4	and	O
5	in	O
6	situ	O
7	hybridization	O
8	analyses	O
9	of	O
10	a	O
11	time	O
12	course	O
13	of	O
14	juvenile	O
15	testis	O
16	development	O
17	indicate	O
18	that	O
19	Spo11	O
20	expression	O
21	begins	O
22	in	O
23	early	O
24	meiotic	O
25	Prophase	O
26	I	O
27	,	O
28	prior	O
29	to	O
30	the	O
31	pachytene	O
32	stage	O
33	,	O
34	with	O
35	increasing	O
36	accumulation	O
37	of	O
38	mRNA	O
39	through	O
40	the	O
41	pachytene	O
42	stage	O
43	.	O

1	Silicosis	O
2	mortality	O

1	Comparison	O
2	of	O
3	the	O
4	p50	B
5	sequence	O
6	to	O
7	other	O
8	cloned	O
9	proteins	O
10	revealed	O
11	89	O
12	%	O
13	homology	O
14	with	O
15	a	O
16	glycosaminoglycan	O
17	-	O
18	binding	O
19	protein	O
20	and	O
21	54	O
22	%	O
23	homology	O
24	with	O
25	Drosophila	O
26	cell	O
27	cycle	O
28	control	O
29	protein	O
30	(	O
31	cdc	O
32	)	O
33	37	O
34	.	O

1	Further	O
2	,	O
3	the	O
4	ability	O
5	of	O
6	recombinant	O
7	beta	O
8	and	O
9	/	O
10	or	O
11	gamma	O
12	chains	O
13	to	O
14	function	O
15	in	O
16	defined	O
17	biochemical	O
18	assays	O
19	of	O
20	beta	B
21	gamma	I
22	activity	O
23	was	O
24	assessed	O
25	for	O
26	membrane	O
27	extracts	O
28	and	O
29	supernatant	O
30	fractions	O
31	from	O
32	infected	O
33	Sf9	O
34	cells	O
35	.	O

1	One	O
2	unit	O
3	encodes	O
4	traA	O
5	,	O
6	traF	O
7	,	O
8	and	O
9	traB	O
10	,	O
11	while	O
12	the	O
13	second	O
14	encodes	O
15	traC	O
16	,	O
17	traD	O
18	,	O
19	and	O
20	traG	O
21	.	O

1	Corticosteroid	O
2	therapy	O
3	is	O
4	known	O
5	to	O
6	be	O
7	hazardous	O
8	in	O
9	patients	O
10	with	O
11	occult	O
12	infection	O
13	but	O
14	the	O
15	mechanism	O
16	by	O
17	which	O
18	the	O
19	host	O
20	parasite	O
21	relationship	O
22	is	O
23	altered	O
24	by	O
25	steroids	O
26	is	O
27	not	O
28	known	O
29	.	O
30	We	O
31	have	O
32	used	O
33	an	O
34	intestinal	O
35	protozoal	O
36	parasite	O
37	,	O
38	Giardia	O
39	muris	O
40	,	O
41	to	O
42	examine	O
43	the	O
44	effects	O
45	of	O
46	corticosteroids	O
47	on	O
48	the	O
49	number	O
50	of	O
51	parasites	O
52	in	O
53	the	O
54	intestine	O
55	in	O
56	the	O
57	course	O
58	of	O
59	a	O
60	primary	O
61	infection	O
62	.	O

1	The	O
2	proteins	O
3	differ	O
4	in	O
5	the	O
6	presence	O
7	or	O
8	absence	O
9	of	O
10	a	O
11	21	O
12	-	O
13	amino	O
14	-	O
15	acid	O
16	sequence	O
17	located	O
18	24	O
19	amino	O
20	acids	O
21	C	O
22	terminal	O
23	of	O
24	the	O
25	translational	O
26	initiation	O
27	codon	O
28	.	O

1	W	O
2	.	O

1	Both	O
2	receptors	O
3	utilize	B
4	protein	I
5	tyrosine	I
6	kinases	I
7	(	O
8	PTKs	O
9	)	O
10	for	O
11	the	O
12	phosphorylation	O
13	of	O
14	various	O
15	signaling	O
16	molecules	O
17	,	O
18	a	O
19	process	O
20	that	O
21	is	O
22	critical	O
23	for	O
24	the	O
25	function	O
26	of	O
27	both	O
28	receptors	O
29	.	O

1	DESIGN	O
2	:	O
3	Comparison	O
4	of	O
5	number	O
6	of	O
7	women	O
8	with	O
9	PKU	O
10	aged	O
11	15	O
12	-	O
13	44	O
14	years	O
15	on	O
16	the	O
17	NSW	O
18	PKU	O
19	database	O
20	(	O
21	observed	O
22	number	O
23	)	O
24	with	O
25	expected	O
26	number	O
27	derived	O
28	from	O
29	population	O
30	data	O
31	.	O

1	Except	O
2	for	O
3	nonperfusion	O
4	of	O
5	neurosensory	O
6	retinal	O
7	vessels	O
8	at	O
9	a	O
10	light	O
11	dose	O
12	of	O
13	150	O
14	J	O
15	/	O
16	cm2	O
17	,	O
18	no	O
19	other	O
20	adverse	O
21	events	O
22	were	O
23	of	O
24	concern	O
25	.	O

1	In	O
2	addition	O
3	,	O
4	mapping	O
5	of	O
6	the	O
7	promoter	O
8	region	O
9	and	O
10	the	O
11	identification	O
12	of	O
13	putative	O
14	promoter	O
15	regulatory	O
16	sequences	O
17	should	O
18	give	O
19	insight	O
20	into	O
21	the	O
22	transcriptional	O
23	regulation	O
24	of	O
25	UCP2	O
26	expression	O
27	--	O
28	in	O
29	particular	O
30	by	O
31	anyone	O
32	of	O
33	the	O
34	above	O
35	mentioned	O
36	factors	O
37	--	O
38	in	O
39	vitro	O
40	and	O
41	in	O
42	vivo	O
43	.	O

1	His	O
2	HC	B
3	II	I
4	activity	O
5	and	O
6	antigen	O
7	levels	O
8	were	O
9	49	O
10	%	O
11	and	O
12	50	O
13	%,	O
14	respectively	O
15	,	O
16	and	O
17	his	O
18	daughter	O
19	also	O
20	showed	O
21	similar	O
22	low	O
23	levels	O
24	.	O

1	Intermediate	O
2	levels	O
3	of	O
4	gene	O
5	activity	O
6	were	O
7	observed	O
8	for	O
9	TnI	B
10	enhancers	I
11	containing	O
12	E	O
13	-	O
14	boxes	O
15	derived	O
16	from	O
17	the	O
18	MCK	O
19	left	O
20	E	O
21	-	O
22	box	O
23	site	O
24	or	O
25	from	O
26	the	O
27	Ig	B
28	kappa	I
29	E2	I
30	E	I
31	-	I
32	box	I
33	.	O

1	Next	O
2	,	O
3	we	O
4	stably	O
5	overexpressed	O
6	wild	B
7	-	I
8	type	I
9	Shc	I
10	or	O
11	Y317F	B
12	mutant	I
13	Shc	I
14	into	O
15	HIRc	O
16	cells	O
17	.	O

1	PNRC	O
2	:	O
3	a	O
4	proline	O
5	-	O
6	rich	O
7	nuclear	O
8	receptor	O
9	coregulatory	O
10	protein	O
11	that	O
12	modulates	O
13	transcriptional	O
14	activation	O
15	of	O
16	multiple	O
17	nuclear	O
18	receptors	O
19	including	O
20	orphan	B
21	receptors	I
22	SF1	I
23	(	I
24	steroidogenic	I
25	factor	I
26	1	I
27	)	O
28	and	O
29	ERRalpha1	O
30	(	O
31	estrogen	B
32	related	I
33	receptor	I
34	alpha	I
35	-	I
36	1	I
37	).	O

1	National	O
2	certification	O
3	:	O
4	a	O
5	vital	O
6	component	O
7	of	O
8	quality	O
9	assurance	O
10	.	O

1	Quantitative	O
2	analysis	O
3	of	O
4	plasmid	O
5	loss	O
6	rates	O
7	in	O
8	cdc28	O
9	-	O
10	1N	O
11	strains	O
12	carrying	O
13	plasmids	O
14	with	O
15	multiple	O
16	replication	O
17	origins	O
18	suggests	O
19	that	O
20	a	O
21	defect	O
22	in	O
23	initiating	O
24	DNA	O
25	replication	O
26	probably	O
27	causes	O
28	this	O
29	plasmid	O
30	loss	O
31	phenotype	O
32	.	O

1	We	O
2	have	O
3	therefore	O
4	evaluated	O
5	the	O
6	efficacy	O
7	and	O
8	safety	O
9	of	O
10	doxazosin	O
11	,	O
12	a	O
13	new	O
14	orally	O
15	active	O
16	selective	O
17	alpha	O
18	1	O
19	blocker	O
20	,	O
21	in	O
22	patients	O
23	with	O
24	systemic	O
25	hypertension	O
26	with	O
27	concomitant	O
28	airflow	O
29	limitation	O
30	.	O

1	Crohn	O
2	'	O
3	s	O
4	disease	O
5	in	O
6	prolonged	O
7	remission	O
8	:	O
9	should	O
10	one	O
11	augment	O
12	protein	O
13	-	O
14	calorie	O
15	intake	O
16	as	O
17	compared	O
18	to	O
19	healthy	O
20	subjects	O
21	?]	O
22	The	O
23	aim	O
24	of	O
25	our	O
26	two	O
27	year	O
28	prospective	O
29	study	O
30	was	O
31	to	O
32	evaluate	O
33	whether	O
34	adult	O
35	Crohn	O
36	'	O
37	s	O
38	disease	O
39	patients	O
40	in	O
41	prolonged	O
42	remission	O
43	(	O
44	CDAI	O
45	<	O
46	150	O
47	),	O
48	in	O
49	order	O
50	to	O
51	maintain	O
52	their	O
53	body	O
54	weight	O
55	as	O
56	close	O
57	as	O
58	possible	O
59	to	O
60	the	O
61	ideal	O
62	one	O
63	,	O
64	need	O
65	a	O
66	protein	O
67	-	O
68	calorie	O
69	intake	O
70	higher	O
71	than	O
72	the	O
73	predicted	O
74	one	O
75	and	O
76	that	O
77	of	O
78	healthy	O
79	controls	O
80	.	O

1	The	O
2	approach	O
3	derives	O
4	from	O
5	a	O
6	recently	O
7	described	O
8	strategy	O
9	for	O
10	making	O
11	recombinants	O
12	from	O
13	five	O
14	overlapping	O
15	EBV	O
16	cosmid	O
17	-	O
18	cloned	O
19	DNAs	O
20	(	O
21	B	O
22	.	O

1	This	O
2	suggests	O
3	that	O
4	cardiovascular	O
5	magnetic	O
6	resonance	O
7	is	O
8	the	O
9	preferred	O
10	technique	O
11	for	O
12	volume	O
13	and	O
14	ejection	O
15	fraction	O
16	estimation	O
17	in	O
18	heart	O
19	failure	O
20	patients	O
21	,	O
22	because	O
23	of	O
24	its	O
25	3D	O
26	approach	O
27	for	O
28	non	O
29	-	O
30	symmetric	O
31	ventricles	O
32	and	O
33	superior	O
34	image	O
35	quality	O
36	.	O

1	The	O
2	structural	O
3	analysis	O
4	also	O
5	demonstrated	O
6	that	O
7	the	O
8	heterogeneity	O
9	of	O
10	the	O
11	HDC	O
12	mRNA	O
13	is	O
14	caused	O
15	by	O
16	an	O
17	insertion	O
18	of	O
19	the	O
20	seventh	O
21	intron	O
22	sequence	O
23	and	O
24	alternative	O
25	use	O
26	of	O
27	the	O
28	splicing	O
29	acceptor	O
30	site	O
31	at	O
32	the	O
33	12th	O
34	exon	O
35	.	O

1	Optical	O
2	-	O
3	absorption	O
4	spectra	O
5	,	O
6	crystal	O
7	-	O
8	field	O
9	energy	O
10	levels	O
11	,	O
12	and	O
13	transition	O
14	line	O
15	strengths	O
16	of	O
17	holmium	O
18	in	O
19	trigonal	O
20	Na3	O

1	Transfection	O
2	of	O
3	cDNAs	O
4	for	O
5	three	O
6	mutant	O
7	enzymes	O
8	into	O
9	FPGS	O
10	-	O
11	null	O
12	Chinese	O
13	hamster	O
14	ovary	O
15	cells	O
16	restored	O
17	a	O
18	reduced	O
19	level	O
20	of	O
21	clonal	O
22	growth	O
23	,	O
24	whereas	O
25	a	O
26	T339I	O
27	mutant	O
28	supported	O
29	growth	O
30	at	O
31	a	O
32	level	O
33	comparable	O
34	to	O
35	that	O
36	of	O
37	the	O
38	wild	O
39	-	O
40	type	O
41	enzyme	O
42	.	O

1	These	O
2	data	O
3	indicate	O
4	that	O
5	the	O
6	third	O
7	intracellular	O
8	loop	O
9	of	O
10	the	O
11	rat	O
12	GnRH	B
13	-	I
14	R	I
15	is	O
16	involved	O
17	in	O
18	receptor	O
19	G	O
20	(	O
21	q	O
22	/	O
23	11	O
24	)	O
25	protein	O
26	coupling	O
27	and	O
28	/	O
29	or	O
30	selectivity	O
31	,	O
32	and	O
33	in	O
34	the	O
35	GGH	O
36	(	O
37	3	O
38	)	O
39	1	O
40	'	O
41	cell	O
42	line	O
43	,	O
44	this	O
45	loop	O
46	is	O
47	also	O
48	involved	O
49	in	O
50	signal	O
51	transduction	O
52	mediated	O
53	through	O
54	the	O
55	Gs	O
56	protein	O
57	pathway	O
58	.	O

1	These	O
2	striations	O
3	were	O
4	caused	O
5	by	O
6	contact	O
7	between	O
8	the	O
9	sharp	O
10	edge	O
11	of	O
12	the	O
13	upper	O
14	canine	O
15	and	O
16	the	O
17	P3	O
18	during	O
19	honing	O
20	(	O
21	canine	O
22	/	O
23	premolar	O
24	complex	O
25	).	O

1	In	O
2	the	O
3	first	O
4	,	O
5	homologous	O
6	sequences	O
7	were	O
8	deleted	O
9	from	O
10	a	O
11	mouse	O
12	enhancer	O
13	,	O
14	resulting	O
15	in	O
16	a	O
17	tissue	O
18	-	O
19	specific	O
20	loss	O
21	of	O
22	activity	O
23	when	O
24	assayed	O
25	in	O
26	transgenic	O
27	mice	O
28	.	O

1	Binding	O
2	activity	O
3	in	O
4	rat	O
5	liver	O
6	nuclear	O
7	extracts	O
8	includes	O
9	these	O
10	orphan	B
11	receptors	I
12	as	O
13	judged	O
14	from	O
15	electromobility	O
16	supershift	O
17	experiments	O
18	and	O
19	from	O
20	results	O
21	obtained	O
22	with	O
23	expressed	O
24	receptors	O
25	,	O
26	although	O
27	the	O
28	element	O
29	in	O
30	CYP2C11	O
31	did	O
32	not	O
33	bind	O
34	HNF	B
35	-	I
36	4	O
37	.	O

1	Our	O
2	findings	O
3	demonstrate	O
4	a	O
5	dose	O
6	-	O
7	dependent	O
8	blockade	O
9	of	O
10	the	O
11	mechanical	O
12	sensitivity	O
13	caused	O
14	by	O
15	a	O
16	mild	O
17	thermal	O
18	injury	O
19	by	O
20	both	O
21	GBP	O
22	and	O
23	IBG	O
24	.	O

1	Northern	O
2	blotting	O
3	with	O
4	a	O
5	unique	O
6	17	O
7	-	O
8	mer	O
9	oligonucleotide	O
10	demonstrated	O
11	the	O
12	absence	O
13	of	O
14	the	O
15	mutant	O
16	sequence	O
17	in	O
18	the	O
19	mRNA	O
20	from	O
21	which	O
22	the	O
23	cDNA	O
24	library	O
25	giving	O
26	rise	O
27	to	O
28	the	O
29	mutant	O
30	cDNA	O
31	was	O
32	constructed	O
33	.	O

1	Investigation	O
2	of	O
3	the	O
4	structural	O
5	basis	O
6	of	O
7	the	O
8	interaction	O
9	between	O
10	human	O
11	Igs	O
12	and	O
13	gp120	O
14	shows	O
15	that	O
16	the	O
17	viral	O
18	gp120	O
19	SAg	O
20	can	O
21	interact	O
22	only	O
23	with	O
24	a	O
25	subset	O
26	of	O
27	human	O
28	V	O
29	(	O
30	H	O
31	)	O
32	3	O
33	+	O
34	Igs	O
35	.	O

1	In	O
2	this	O
3	study	O
4	the	O
5	splenectomized	O
6	captive	O
7	born	O
8	cynomolgus	O
9	appeared	O
10	to	O
11	be	O
12	capable	O
13	of	O
14	supplementing	O
15	rhesus	O
16	as	O
17	an	O
18	antimalarial	O
19	drug	O
20	testing	O
21	model	O
22	.	O

1	Extracellular	O
2	fibril	O
3	formation	O
4	by	O
5	neuroglial	O
6	cells	O
7	at	O
8	the	O
9	vitreoretinal	O
10	junction	O
11	of	O
12	the	O
13	human	O
14	eye	O
15	.	O

1	Reactivities	O
2	to	O
3	horse	O
4	anti	B
5	-	I
6	lymphocyte	I
7	globulin	I
8	.	O

1	Intravenous	O
2	amine	O
3	pressor	O
4	tests	O
5	in	O
6	healthy	O
7	volunteers	O
8	.	O

1	Our	O
2	study	O
3	was	O
4	designed	O
5	to	O
6	investigate	O
7	the	O
8	effect	O
9	of	O
10	MMF	O
11	on	O
12	in	O
13	vivo	O
14	bone	O
15	mineral	O
16	metabolism	O
17	.	O

1	Confirmatory	O
2	statistics	O
3	included	O
4	item	O
5	2	O
6	of	O
7	the	O
8	Clinical	O
9	Global	O
10	Impression	O
11	(	O
12	CGI	O
13	),	O
14	the	O
15	total	O
16	score	O
17	of	O
18	the	O
19	Sandoz	O
20	Clinical	O
21	Assessment	O
22	Geriatric	O
23	(	O
24	SCAG	O
25	)	O
26	scale	O
27	,	O
28	the	O
29	subscale	O
30	'	O
31	need	O
32	for	O
33	help	O
34	'	O
35	of	O
36	the	O
37	nurse	O
38	'	O
39	s	O
40	rating	O
41	of	O
42	geriatric	O
43	patients	O
44	(	O
45	Beurteilungsskala	O
46	fur	O
47	geriatrische	O
48	Patienten	O
49	;	O
50	BGP	O
51	)	O
52	and	O
53	the	O
54	total	O
55	score	O
56	of	O
57	the	O
58	Short	O
59	Cognitive	O
60	Performance	O
61	Test	O
62	(	O
63	Syndrom	O
64	-	O
65	Kurztest	O
66	;	O
67	SKT	O
68	).	O

1	Analysis	O
2	of	O
3	hematopoietic	O
4	growth	O
5	factor	O
6	prescriptions	O
7	in	O
8	19	O
9	french	O
10	cancer	O
11	centers	O

1	Intraoperatively	O
2	the	O
3	complement	O
4	factor	O
5	C3c	O
6	decreased	O
7	by	O
8	20	O
9	%,	O
10	while	O
11	alpha	B
12	1	I
13	-	I
14	antitrypsin	I
15	showed	O
16	postoperatively	O
17	an	O
18	increase	O
19	by	O
20	30	O
21	%.	O

1	Mechanisms	O
2	of	O
3	visible	O
4	-	O
5	light	O
6	emission	O
7	from	O
8	electro	O
9	-	O
10	oxidized	O
11	porous	O
12	silicon	O
13	.	O

1	Because	O
2	the	O
3	number	O
4	of	O
5	parameters	O
6	required	O
7	by	O
8	a	O
9	Volterra	O
10	series	O
11	grows	O
12	rapidly	O
13	with	O
14	both	O
15	the	O
16	length	O
17	of	O
18	its	O
19	memory	O
20	and	O
21	the	O
22	order	O
23	of	O
24	its	O
25	nonlinearity	O
26	,	O
27	methods	O
28	for	O
29	identifying	O
30	these	O
31	models	O
32	from	O
33	measurements	O
34	of	O
35	input	O
36	/	O
37	output	O
38	data	O
39	are	O
40	limited	O
41	to	O
42	low	O
43	-	O
44	order	O
45	systems	O
46	with	O
47	relatively	O
48	short	O
49	memories	O
50	.	O

1	The	O
2	cellular	O
3	rate	O
4	of	O
5	anticoagulant	O
6	heparan	O
7	sulfate	O
8	proteoglycan	O
9	(	O
10	HSPGact	O
11	)	O
12	generation	O
13	is	O
14	determined	O
15	by	O
16	the	O
17	level	O
18	of	O
19	a	O
20	kinetically	O
21	limiting	O
22	microsomal	O
23	activity	O
24	,	O
25	HSact	O
26	conversion	O
27	activity	O
28	,	O
29	which	O
30	is	O
31	predominantly	O
32	composed	O
33	of	O
34	the	O
35	long	O
36	sought	O
37	heparan	O
38	sulfate	O
39	D	O
40	-	O
41	glucosaminyl	O
42	3	O
43	-	O
44	O	O
45	-	O
46	sulfotransferase	O
47	(	O
48	3	O
49	-	O
50	OST	O
51	)	O
52	(	O
53	Shworak	O
54	,	O
55	N	O
56	.	O

1	Relatively	O
2	little	O
3	is	O
4	known	O
5	regarding	O
6	the	O
7	role	O
8	of	O
9	5	B
10	-	I
11	HT2	I
12	receptor	I
13	activity	O
14	in	O
15	male	O
16	rat	O
17	sexual	O
18	behavior	O
19	.	O

1	Immunelectrophoretic	O
2	pattern	O
3	of	O
4	Wassermann	O
5	reagin	O
6	and	O
7	comparison	O
8	of	O
9	the	O
10	appearance	O
11	time	O
12	between	O
13	RPCF	O
14	and	O
15	FTA	O
16	antibodies	O

1	A	O
2	second	O
3	promoter	O
4	activity	O
5	was	O
6	identified	O
7	in	O
8	the	O
9	region	O
10	between	O
11	the	O
12	two	O
13	major	O
14	transcriptional	O
15	start	O
16	sites	O
17	.	O

1	Recessive	O
2	lethal	O
3	mutations	O
4	were	O
5	isolated	O
6	based	O
7	upon	O
8	failure	O
9	to	O
10	complement	O
11	the	O
12	recessive	O
13	lethality	O
14	of	O
15	Df	O
16	(	O
17	3L	O
18	)	O
19	RR2	O
20	,	O
21	a	O
22	deletion	O
23	of	O
24	the	O
25	DRE	O
26	region	O
27	that	O
28	removes	O
29	16	O
30	-	O
31	18	O
32	polytene	O
33	chromosome	O
34	bands	O
35	.	O

1	Total	O
2	cholesterol	O
3	was	O
4	measured	O
5	in	O
6	amniotic	O
7	fluids	O
8	collected	O
9	at	O
10	different	O
11	stages	O
12	of	O
13	gestation	O
14	.	O

1	Unitary	O
2	-	O
3	group	O
4	approach	O
5	to	O
6	spin	O
7	-	O
8	dependent	O
9	operators	O
10	.	O

1	The	O
2	peptide	O
3	sequence	O
4	contains	O
5	a	O
6	region	O
7	of	O
8	80	O
9	amino	O
10	acids	O
11	that	O
12	shows	O
13	similarity	O
14	to	O
15	bcl	B
16	-	I
17	2	I
18	and	O
19	to	O
20	the	O
21	recently	O
22	described	O
23	bcl	B
24	-	I
25	2	I
26	-	I
27	related	I
28	gene	I
29	,	O
30	MCL1	O
31	.	O

1	This	O
2	and	O
3	previous	O
4	results	O
5	suggest	O
6	that	O
7	the	O
8	CRE	O
9	and	O
10	Sp1	B
11	site	I
12	may	O
13	synergistically	O
14	activate	O
15	TH	O
16	transcription	O
17	in	O
18	a	O
19	promoter	O
20	context	O
21	-	O
22	dependent	O
23	manner	O
24	.	O

1	Nocodazole	O
2	arrest	O
3	of	O
4	DU249	O
5	cells	O
6	was	O
7	exploited	O
8	for	O
9	the	O
10	detection	O
11	of	O
12	an	O
13	M	O
14	-	O
15	phase	O
16	-	O
17	activated	O
18	MBP	B
19	kinase	I
20	that	O
21	was	O
22	resolved	O
23	from	O
24	p41	O
25	MAP	B
26	kinase	I
27	by	O
28	phenyl	O
29	-	O
30	Superose	O
31	chromatography	O
32	.	O

1	Echinostomiasis	O
2	is	O
3	aggravated	O
4	by	O
5	socioeconomic	O
6	factors	O
7	such	O
8	as	O
9	poverty	O
10	,	O
11	malnutrition	O
12	,	O
13	an	O
14	explosively	O
15	growing	O
16	free	O
17	-	O
18	food	O
19	market	O
20	,	O
21	a	O
22	lack	O
23	of	O
24	supervised	O
25	food	O
26	inspection	O
27	,	O
28	poor	O
29	or	O
30	insufficient	O
31	sanitation	O
32	,	O
33	other	O
34	helminthiases	O
35	,	O
36	and	O
37	declining	O
38	economic	O
39	conditions	O
40	.	O

1	Morphogenesis	O
2	of	O
3	the	O
4	trochanter	O
5	produced	O
6	by	O
7	femoral	O
8	regeneration	O
9	in	O
10	the	O
11	phasmid	O
12	Carausius	O
13	morosus	O
14	Br	O

1	Mutating	O
2	a	O
3	potential	O
4	cleavage	O
5	site	O
6	located	O
7	N	O
8	-	O
9	terminal	O
10	to	O
11	the	O
12	protease	O
13	domain	O
14	,	O
15	Gln2526	O
16	-	O
17	Asp2527	O
18	,	O
19	diminished	O
20	processing	O
21	.	O

1	Dopaminergic	O
2	modulation	O
3	of	O
4	transcallosal	O
5	activity	O
6	of	O
7	cat	O
8	motor	O
9	cortical	O
10	neurons	O
11	.	O

1	That	O
2	of	O
3	the	O
4	T2	O
5	gene	O
6	contains	O
7	numerous	O
8	potential	O
9	sites	O
10	for	O
11	binding	O
12	the	O
13	mammalian	B
14	transcription	I
15	factor	I
16	SP1	I
17	,	O
18	but	O
19	no	O
20	TATA	O
21	or	O
22	CCAAT	O
23	sequences	O
24	are	O
25	evident	O
26	near	O
27	to	O
28	its	O
29	5	O
30	'	O
31	end	O
32	,	O
33	although	O
34	these	O
35	latter	O
36	features	O
37	are	O
38	associated	O
39	with	O
40	the	O
41	human	O
42	T1	O
43	gene	O
44	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	effect	O
7	of	O
8	the	O
9	isomers	O
10	of	O
11	pentobarbital	O
12	and	O
13	secobarbital	O
14	on	O
15	mult	O
16	FR30	O
17	FI600	O
18	responding	O
19	and	O
20	on	O
21	suppressed	O
22	responding	O
23	are	O
24	qualitatively	O
25	similar	O
26	.(	O
27	ABSTRACT	O
28	TRUNCATED	O
29	AT	O
30	250	O
31	WORDS	O
32	)	O

1	We	O
2	previously	O
3	delineated	O
4	a	O
5	region	O
6	in	O
7	the	O
8	fatty	B
9	-	I
10	acid	I
11	synthase	I
12	promoter	I
13	,	O
14	which	O
15	was	O
16	responsible	O
17	for	O
18	obesity	O
19	-	O
20	related	O
21	overexpression	O
22	of	O
23	the	O
24	fatty	B
25	-	I
26	acid	I
27	synthase	I
28	(	I
29	FAS	I
30	)	I
31	gene	I
32	,	O
33	by	O
34	negatively	O
35	regulating	O
36	the	O
37	activity	O
38	of	O
39	the	O
40	downstream	O
41	promoter	O
42	in	O
43	lean	O
44	but	O
45	not	O
46	obese	O
47	rat	O
48	fat	O
49	cells	O
50	.	O

1	The	O
2	case	O
3	for	O
4	completing	O
5	the	O
6	lymphadenectomy	O
7	when	O
8	positive	O
9	lymph	O
10	nodes	O
11	are	O
12	found	O
13	during	O
14	radical	O
15	hysterectomy	O
16	for	O
17	cervical	O
18	carcinoma	O
19	.	O

1	Indirect	O
2	plasma	O
3	parameters	O
4	such	O
5	as	O
6	vitamin	O
7	E	O
8	,	O
9	thiol	O
10	and	O
11	uric	O
12	acid	O
13	levels	O
14	were	O
15	also	O
16	quantified	O
17	.	O

1	At	O
2	the	O
3	very	O
4	high	O
5	dose	O
6	levels	O
7	used	O
8	,	O
9	sodium	O
10	saccharin	O
11	and	O
12	sodium	O
13	cyclamate	O
14	were	O
15	weak	O
16	solitary	O
17	carcinogens	O
18	producing	O
19	4	O
20	/	O
21	253	O
22	and	O
23	3	O
24	/	O
25	228	O
26	bladder	O
27	tumours	O
28	respectively	O
29	,	O
30	and	O
31	the	O
32	first	O
33	of	O
34	these	O
35	tumours	O
36	did	O
37	not	O
38	appear	O
39	for	O
40	more	O
41	than	O
42	80	O
43	weeks	O
44	.	O

1	Purification	O
2	and	O
3	cloning	O
4	of	O
5	a	O
6	novel	O
7	serine	O
8	protease	O
9	,	O
10	RNK	B
11	-	I
12	Met	I
13	-	I
14	1	I
15	,	O
16	from	O
17	the	O
18	granules	O
19	of	O
20	a	O
21	rat	O
22	natural	O
23	killer	O
24	cell	O
25	leukemia	O
26	.	O

1	5	O
2	-(	O
3	Dimethylaminopropyl	O
4	)-	O
5	19	O
6	,	O
7	11	O
8	-	O
9	dihydro	O
10	-	O
11	5H	O
12	-	O
13	benzo	O
14	[	O
15	2	O
16	,	O
17	3	O
18	]	O
19	pyrido	O
20	[	O
21	6	O
22	,	O
23	7	O
24	-	O
25	b	O
26	]	O
27	azepine	O
28	.	O

1	A	O
2	bovine	O
3	abomasum	O
4	lambda	O
5	gt11	O
6	cDNA	O
7	library	O
8	was	O
9	screened	O
10	with	O
11	a	O
12	monoclonal	O
13	antibody	O
14	raised	O
15	against	O
16	the	O
17	rabbit	O
18	H	O
19	,	O
20	K	B
21	-	I
22	ATPase	I
23	beta	I
24	subunit	I
25	.	O

1	A	O
2	recombinant	O
3	vector	O
4	,	O
5	p410	O
6	+,	O
7	was	O
8	constructed	O
9	which	O
10	carried	O
11	the	O
12	BamHI	O
13	-	O
14	K	O
15	fragment	O
16	(	O
17	nucleotides	O
18	107565	O
19	to	O
20	112625	O
21	of	O
22	the	O
23	B95	O
24	-	O
25	8	O
26	strain	O
27	,	O
28	encoding	O
29	the	O
30	EBV	B
31	-	I
32	associated	I
33	nuclear	I
34	antigen	I
35	EBNA	I
36	-	I
37	1	I
38	),	O
39	the	O
40	cis	O
41	-	O
42	acting	O
43	sequence	O
44	from	O
45	the	O
46	BamHI	B
47	-	I
48	C	I
49	fragment	I
50	,	O
51	and	O
52	a	O
53	dominant	O
54	selectable	O
55	marker	O
56	gene	O
57	encoding	O
58	G	O
59	-	O
60	418	O
61	resistance	O
62	in	O
63	animal	O
64	cells	O
65	.	O

1	Previous	O
2	studies	O
3	have	O
4	demonstrated	O
5	that	O
6	tissue	O
7	-	O
8	restricted	O
9	transcription	O
10	factors	O
11	including	O
12	PU	O
13	.	O
14	1	O
15	and	O
16	PU	O
17	.	O
18	1	O
19	interaction	O
20	partner	O
21	(	O
22	PIP	O
23	)	O
24	function	O
25	synergistically	O
26	with	O
27	c	B
28	-	I
29	Fos	I
30	plus	O
31	c	B
32	-	I
33	Jun	I
34	to	O
35	stimulate	O
36	the	O
37	kappaE3	O
38	'-	O
39	enhancer	O
40	in	O
41	3T3	O
42	cells	O
43	.	O

1	All	O
2	patients	O
3	received	O
4	VCR	O
5	1	O
6	.	O
7	0	O
8	mg	O
9	/	O
10	m2	O
11	weekly	O
12	for	O
13	6	O
14	weeks	O
15	with	O
16	dose	O
17	modification	O
18	for	O
19	neurotoxicity	O
20	.	O

1	Yeast	O
2	Gal11	O
3	protein	O
4	mediates	O
5	the	O
6	transcriptional	O
7	activation	O
8	signal	O
9	of	O
10	two	O
11	different	O
12	transacting	O
13	factors	O
14	,	O
15	Gal4	B
16	and	O
17	general	B
18	regulatory	I
19	factor	I
20	I	I
21	/	I
22	repressor	I
23	/	I
24	activator	I
25	site	I
26	binding	I
27	protein	I
28	1	I
29	/	O
30	translation	O
31	upstream	O
32	factor	O
33	.	O

1	Evidence	O
2	for	O
3	a	O
4	role	O
5	of	O
6	endogenous	B
7	corticotropin	I
8	-	I
9	releasing	I
10	factor	I
11	in	O
12	cold	O
13	,	O
14	ether	O
15	,	O
16	immobilization	O
17	,	O
18	and	O
19	traumatic	O
20	stress	O
21	.	O

1	Cowpox	O
2	virus	O
3	contains	O
4	two	O
5	copies	O
6	of	O
7	an	O
8	early	O
9	gene	O
10	encoding	O
11	a	O
12	soluble	O
13	secreted	O
14	form	O
15	of	O
16	the	O
17	type	O
18	II	O
19	TNF	B
20	receptor	I
21	.	O

1	Mucolipidosis	O
2	type	O
3	IV	O
4	:	O
5	clinical	O
6	spectrum	O
7	and	O
8	natural	O
9	history	O
10	.	O

1	These	O
2	results	O
3	illustrate	O
4	an	O
5	important	O
6	role	O
7	for	O
8	La	O
9	in	O
10	RNA	O
11	production	O
12	by	O
13	demonstrating	O
14	its	O
15	ability	O
16	to	O
17	clear	O
18	the	O
19	termination	O
20	sites	O
21	of	O
22	class	O
23	III	O
24	templates	O
25	,	O
26	thereby	O
27	promoting	O
28	efficient	O
29	use	O
30	of	O
31	transcription	O
32	complexes	O
33	by	O
34	pol	B
35	III	I
36	.	O

1	Human	O
2	T	O
3	-	O
4	cell	O
5	leukemia	O
6	virus	O
7	type	O
8	I	O
9	(	O
10	HTLV	O
11	-	O
12	I	O
13	)	O
14	encodes	O
15	a	O
16	40	O
17	-	O
18	kDa	O
19	nuclear	O
20	protein	O
21	,	O
22	Tax	B
23	,	O
24	which	O
25	stimulates	O
26	transcription	O
27	from	O
28	three	O
29	21	O
30	-	O
31	base	O
32	pair	O
33	(	O
34	bp	O
35	)	O
36	repeats	O
37	in	O
38	its	O
39	U3	O
40	region	O
41	.	O

1	Movement	O
2	time	O
3	and	O
4	kinematic	O
5	characteristics	O
6	were	O
7	analyzed	O
8	together	O
9	with	O
10	the	O
11	magnitude	O
12	of	O
13	cerebral	O
14	blood	O
15	flow	O
16	to	O
17	identify	O
18	areas	O
19	of	O
20	brain	O
21	activity	O
22	proportionate	O
23	to	O
24	task	O
25	and	O
26	movement	O
27	variables	O
28	.	O

1	However	O
2	,	O
3	the	O
4	elderly	O
5	group	O
6	showed	O
7	significantly	O
8	longer	O
9	mean	O
10	residence	O
11	times	O
12	(	O
13	MRTs	O
14	)	O
15	and	O
16	lower	O
17	plasma	O
18	clearance	O
19	of	O
20	lidocaine	O
21	during	O
22	the	O
23	period	O
24	compared	O
25	with	O
26	the	O
27	adult	O
28	group	O
29	(	O
30	P	O
31	<	O
32	.	O
33	05	O
34	).	O

1	A	O
2	total	O
3	of	O
4	112	O
5	patients	O
6	received	O
7	anistreplase	O
8	and	O
9	119	O
10	received	O
11	heparin	O
12	within	O
13	a	O
14	mean	O
15	period	O
16	of	O
17	188	O
18	+/-	O
19	62	O
20	min	O
21	following	O
22	the	O
23	onset	O
24	of	O
25	symptoms	O
26	.	O

1	High	O
2	levels	O
3	of	O
4	C	O
5	subunits	O
6	are	O
7	observed	O
8	in	O
9	several	O
10	subsequent	O
11	larval	O
12	and	O
13	adult	O
14	stages	O
15	of	O
16	development	O
17	.	O

1	Nucleotide	O
2	sequence	O
3	of	O
4	DNA	O
5	controlling	O
6	expression	O
7	of	O
8	genes	O
9	for	O
10	maltosaccharide	O
11	utilization	O
12	in	O
13	Streptococcus	O
14	pneumoniae	O
15	.	O

1	The	O
2	Saccharomyces	O
3	cerevisiae	O
4	RAD30	O
5	gene	O
6	,	O
7	a	O
8	homologue	O
9	of	O
10	Escherichia	O
11	coli	O
12	dinB	O
13	and	O
14	umuC	O
15	,	O
16	is	O
17	DNA	O
18	damage	O
19	inducible	O
20	and	O
21	functions	O
22	in	O
23	a	O
24	novel	O
25	error	O
26	-	O
27	free	O
28	postreplication	O
29	repair	O
30	mechanism	O
31	.	O

1	Identification	O
2	of	O
3	five	O
4	new	O
5	genes	O
6	,	O
7	closely	O
8	related	O
9	to	O
10	the	O
11	interleukin	B
12	-	I
13	1beta	I
14	converting	I
15	enzyme	I
16	gene	I
17	,	O
18	that	O
19	do	O
20	not	O
21	encode	O
22	functional	O
23	proteases	O
24	.	O

1	The	O
2	statistical	O
3	significance	O
4	of	O
5	the	O
6	prognosis	O
7	factors	O
8	was	O
9	studied	O
10	by	O
11	uni	O
12	-	O
13	and	O
14	multivariative	O
15	methods	O
16	,	O
17	according	O
18	to	O
19	the	O
20	model	O
21	of	O
22	Cox	O
23	,	O
24	with	O
25	the	O
26	help	O
27	of	O
28	an	O
29	IMB	O
30	computer	O
31	.	O

1	GTPase	B
2	activating	I
3	specificity	O
4	of	O
5	RGS12	O
6	and	O
7	binding	O
8	specificity	O
9	of	O
10	an	O
11	alternatively	O
12	spliced	O
13	PDZ	B
14	(	I
15	PSD	I
16	-	I
17	95	O
18	/	O
19	Dlg	O
20	/	O
21	ZO	B
22	-	I
23	1	I
24	)	O
25	domain	O
26	.	O

1	B	O
2	cell	O
3	-	O
4	specific	O
5	mb	B
6	-	I
7	1	I
8	and	O
9	B29	O
10	genes	O
11	encode	O
12	the	O
13	alpha	O
14	/	O
15	beta	O
16	components	O
17	of	O
18	the	O
19	BCR	B
20	-	I
21	associated	O
22	complex	O
23	in	O
24	mature	O
25	sIgM	O
26	+	O
27	B	O
28	cells	O
29	.	O

1	Deletion	O
2	of	O
3	the	O
4	NF	B
5	-	I
6	IL6	I
7	beta	I
8	leucine	I
9	zipper	I
10	domain	I
11	also	O
12	greatly	O
13	diminished	O
14	the	O
15	interaction	O
16	between	O
17	these	O
18	two	O
19	proteins	O
20	.	O

1	Of	O
2	the	O
3	21	O
4	quadrants	O
5	positive	O
6	in	O
7	the	O
8	controls	O
9	,	O
10	17	O
11	were	O
12	correlated	O
13	with	O
14	previously	O
15	detected	O
16	jaw	O
17	pathoses	O
18	.	O

1	Sequence	O
2	and	O
3	genetic	O
4	organization	O
5	of	O
6	a	O
7	Zymomonas	O
8	mobilis	O
9	gene	O
10	cluster	O
11	that	O
12	encodes	O
13	several	O
14	enzymes	O
15	of	O
16	glucose	O
17	metabolism	O
18	.	O

1	Each	O
2	individual	O
3	shot	O
4	25	O
5	bullets	O
6	in	O
7	about	O
8	5	O
9	minutes	O
10	,	O
11	at	O
12	an	O
13	intensity	O
14	level	O
15	calculated	O
16	at	O
17	163	O
18	dB	O
19	.	O

1	Copyright	O
2	2000	O
3	Academic	O
4	Press	O
5	.	O

1	Prevention	O
2	,	O
3	differential	O
4	diagnosis	O
5	and	O
6	therapy	O
7	of	O
8	travel	O
9	diarrhea	O

1	Mammalian	O
2	M	O
3	-	O
4	Ras	B
5	and	O
6	a	O
7	Caenorhabditis	O
8	elegans	O
9	orthologue	O
10	exhibit	O
11	conserved	O
12	structural	O
13	features	O
14	,	O
15	and	O
16	these	O
17	are	O
18	likely	O
19	to	O
20	mediate	O
21	activation	O
22	of	O
23	distinctive	O
24	signaling	O
25	paths	O
26	that	O
27	function	O
28	in	O
29	parallel	O
30	to	O
31	those	O
32	downstream	O
33	of	O
34	p21	B
35	Ras	I
36	.	O

1	How	O
2	does	O
3	a	O
4	nurse	O
5	go	O
6	about	O
7	maintaining	O
8	her	O
9	level	O
10	of	O
11	competence	O
12	when	O
13	she	O
14	is	O
15	one	O
16	of	O
17	the	O
18	few	O
19	local	O
20	practitioners	O
21	in	O
22	her	O
23	field	O
24	?	O
25	Vancouver	O
26	sex	O
27	therapist	O
28	Bianca	O
29	Rucker	O
30	is	O
31	doing	O
32	it	O
33	by	O
34	cultivating	O
35	a	O
36	network	O
37	of	O
38	colleagues	O
39	and	O
40	mentors	O
41	in	O
42	related	O
43	fields	O
44	both	O
45	at	O
46	home	O
47	and	O
48	across	O
49	the	O
50	continent	O
51	.	O

1	Videonystagmoscopy	O
2	has	O
3	been	O
4	used	O
5	to	O
6	subjectively	O
7	observe	O
8	the	O
9	responses	O
10	of	O
11	the	O
12	vestibular	O
13	system	O
14	in	O
15	a	O
16	population	O
17	of	O
18	patients	O
19	with	O
20	vestibular	O
21	deficits	O
22	.	O

1	Furthermore	O
2	,	O
3	the	O
4	deletion	O
5	of	O
6	bcp	O
7	from	O
8	the	O
9	chromosome	O
10	had	O
11	no	O
12	effect	O
13	on	O
14	gcv	O
15	-	O
16	lacZ	B
17	expression	O
18	.	O

1	Late	O
2	mRNA	O
3	selected	O
4	by	O
5	a	O
6	cDNA	O
7	homologous	O
8	to	O
9	the	O
10	HindIII	B
11	-	I
12	P	I
13	/	I
14	EcoRI	I
15	-	I
16	B	I
17	region	O
18	of	O
19	the	O
20	AcNPV	O
21	map	O
22	directed	O
23	the	O
24	synthesis	O
25	of	O
26	31K	O
27	and	O
28	30K	O
29	proteins	O
30	which	O
31	comigrated	O
32	with	O
33	the	O
34	31K	O
35	and	O
36	30K	O
37	proteins	O
38	translated	O
39	from	O
40	RNA	O
41	selected	O
42	by	O
43	the	O
44	HindIII	B
45	-	I
46	A	I
47	/	I
48	EcoRI	I
49	-	I
50	C	I
51	/	I
52	SstI	I
53	-	I
54	G	I
55	cDNA	I
56	.	O

1	The	O
2	present	O
3	study	O
4	shows	O
5	that	O
6	phosphatidylinositol	B
7	3	I
8	-	I
9	kinase	I
10	-	I
11	dependent	I
12	p38	I
13	kinase	I
14	activation	O
15	regulates	O
16	Akt	B
17	phosphorylation	O
18	and	O
19	activity	O
20	in	O
21	human	O
22	neutrophils	O
23	.	O

1	Two	O
2	hundred	O
3	sixty	O
4	-	O
5	four	O
6	patients	O
7	scheduled	O
8	for	O
9	DCBM	O
10	were	O
11	randomized	O
12	to	O
13	receive	O
14	intravenously	O
15	geG	O
16	0	O
17	.	O
18	25	O
19	mg	O
20	(	O
21	geG	O
22	-	O
23	25	O
24	),	O
25	or	O
26	geG	O
27	0	O
28	.	O
29	5	O
30	mg	O
31	(	O
32	geG	O
33	-	O
34	50	O
35	),	O
36	or	O
37	HBB	O
38	20	O
39	mg	O
40	as	O
41	hypotonic	O
42	agent	O
43	.	O

1	The	O
2	major	O
3	transcription	O
4	factors	O
5	controlling	O
6	arginine	O
7	metabolism	O
8	in	O
9	Escherichia	O
10	coli	O
11	and	O
12	Bacillus	O
13	subtilis	O
14	,	O
15	ArgR	O
16	and	O
17	AhrC	O
18	,	O
19	respectively	O
20	,	O
21	are	O
22	homologous	O
23	multimeric	O
24	proteins	O
25	that	O
26	form	O
27	l	O
28	-	O
29	arginine	O
30	-	O
31	dependent	O
32	DNA	O
33	-	O
34	binding	O
35	complexes	O
36	capable	O
37	of	O
38	repressing	O
39	transcription	O
40	of	O
41	the	O
42	biosynthetic	O
43	genes	O
44	(	O
45	both	O
46	),	O
47	activating	O
48	transcription	O
49	of	O
50	catabolic	O
51	genes	O
52	(	O
53	AhrC	O
54	only	O
55	)	O
56	or	O
57	facilitating	O
58	plasmid	O
59	dimer	O
60	resolution	O
61	(	O
62	both	O
63	).	O

1	Nursing	O
2	home	O
3	discharges	O
4	in	O
5	clinical	O
6	practice	O
7	.	O

1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	sequences	O
6	in	O
7	the	O
8	SH2	B
9	/	I
10	SH3	I
11	/	I
12	SH2	I
13	region	O
14	of	O
15	p120	B
16	GAP	I
17	are	O
18	required	O
19	for	O
20	full	O
21	catalytic	O
22	activity	O
23	toward	O
24	Ras	B
25	.	O

1	In	O
2	recent	O
3	years	O
4	,	O
5	successful	O
6	physiological	O
7	models	O
8	have	O
9	been	O
10	developed	O
11	for	O
12	a	O
13	variety	O
14	of	O
15	volatile	O
16	and	O
17	nonvolatile	O
18	chemicals	O
19	,	O
20	and	O
21	their	O
22	ability	O
23	to	O
24	perform	O
25	the	O
26	extrapolations	O
27	needed	O
28	in	O
29	risk	O
30	assessment	O
31	has	O
32	been	O
33	demonstrated	O
34	.	O

1	Analysis	O
2	of	O
3	this	O
4	sequence	O
5	combined	O
6	with	O
7	that	O
8	previously	O
9	reported	O
10	for	O
11	the	O
12	5	O
13	'-	O
14	flanking	O
15	region	O
16	directly	O
17	proximal	O
18	to	O
19	the	O
20	start	O
21	of	O
22	transcription	O
23	revealed	O
24	several	O
25	putative	O
26	regulatory	O
27	sequences	O
28	.	O

1	By	O
2	contrast	O
3	,	O
4	secretory	O
5	HI	O
6	antibodies	O
7	were	O
8	not	O
9	demonstrated	O
10	at	O
11	the	O
12	onset	O
13	of	O
14	illness	O
15	in	O
16	any	O
17	of	O
18	the	O
19	patients	O
20	,	O
21	but	O
22	their	O
23	formation	O
24	started	O
25	early	O
26	and	O
27	the	O
28	antibodies	O
29	reached	O
30	maximal	O
31	levels	O
32	about	O
33	10	O
34	days	O
35	after	O
36	onset	O
37	of	O
38	illness	O
39	.	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	the	O
6	increase	O
7	in	O
8	V	O
9	O2	O
10	may	O
11	have	O
12	been	O
13	a	O
14	consequence	O
15	of	O
16	the	O
17	increase	O
18	in	O
19	Q	O
20	O2	O
21	rather	O
22	than	O
23	a	O
24	response	O
25	to	O
26	the	O
27	procedure	O
28	itself	O
29	.	O

1	Stability	O
2	of	O
3	pyrimethamine	O
4	in	O
5	a	O
6	liquid	O
7	dosage	O
8	formulation	O
9	stored	O
10	for	O
11	three	O
12	months	O
13	.	O

1	In	O
2	wild	O
3	-	O
4	type	O
5	cells	O
6	,	O
7	SSM1b	O
8	transcripts	O
9	accumulate	O
10	to	O
11	twice	O
12	the	O
13	level	O
14	of	O
15	SSM1a	O
16	transcripts	O
17	,	O
18	suggesting	O
19	that	O
20	SSM1b	O
21	is	O
22	responsible	O
23	for	O
24	the	O
25	majority	O
26	of	O
27	the	O
28	Ssm1p	O
29	pool	O
30	.	O

1	A	O
2	genomic	O
3	clone	O
4	was	O
5	isolated	O
6	that	O
7	contained	O
8	12	O
9	.	O
10	5	O
11	kb	O
12	of	O
13	the	O
14	5	O
15	'-	O
16	flanking	O
17	region	O
18	and	O
19	the	O
20	first	O
21	exon	O
22	of	O
23	the	O
24	p69	O
25	/	O
26	71	B
27	2	I
28	-	I
29	5A	I
30	synthetase	I
31	gene	I
32	.	O

1	Since	O
2	AP	B
3	-	I
4	1	I
5	is	O
6	an	O
7	important	O
8	mediator	O
9	of	O
10	tumor	O
11	promoter	O
12	action	O
13	,	O
14	these	O
15	findings	O
16	may	O
17	explain	O
18	the	O
19	anti	O
20	-	O
21	tumor	O
22	-	O
23	promoting	O
24	activity	O
25	of	O
26	phenolic	O
27	antioxidants	O
28	.	O

1	This	O
2	study	O
3	indicates	O
4	that	O
5	the	O
6	phenotype	O
7	of	O
8	myofibrillar	O
9	disarray	O
10	seen	O
11	in	O
12	HCM	O
13	patients	O
14	which	O
15	harbor	O
16	either	O
17	of	O
18	these	O
19	two	O
20	mutations	O
21	may	O
22	not	O
23	be	O
24	directly	O
25	due	O
26	to	O
27	the	O
28	failure	O
29	of	O
30	the	O
31	mutant	O
32	myosin	B
33	heavy	I
34	chain	I
35	protein	I
36	to	O
37	assemble	O
38	and	O
39	form	O
40	normal	O
41	sarcomeres	O
42	,	O
43	but	O
44	may	O
45	rather	O
46	be	O
47	a	O
48	secondary	O
49	effect	O
50	possibly	O
51	resulting	O
52	from	O
53	the	O
54	chronic	O
55	stress	O
56	of	O
57	decreased	O
58	beta	B
59	MHC	I
60	function	O
61	.	O

1	A	O
2	highly	O
3	significant	O
4	correlation	O
5	was	O
6	found	O
7	between	O
8	the	O
9	presence	O
10	of	O
11	fibrinolytic	O
12	degradation	O
13	products	O
14	(	O
15	FDP	O
16	)	O
17	and	O
18	the	O
19	incidence	O
20	of	O
21	nephropathy	O
22	and	O
23	renal	O
24	insufficiency	O
25	,	O
26	as	O
27	well	O
28	as	O
29	between	O
30	the	O
31	presence	O
32	of	O
33	fibrin	B
34	monomers	I
35	(	O
36	Godal	O
37	'	O
38	s	O
39	ethanol	O
40	-	O
41	gelification	O
42	test	O
43	)	O
44	and	O
45	the	O
46	evolutive	O
47	signs	O
48	of	O
49	the	O
50	primary	O
51	disease	O
52	(	O
53	fever	O
54	,	O
55	accelerated	O
56	ESR	O
57	).	O

1	The	O
2	promoter	O
3	of	O
4	the	O
5	rat	B
6	PGS	I
7	-	I
8	2	I
9	gene	I
10	contains	O
11	a	O
12	CAAT	B
13	enhancer	I
14	-	I
15	binding	I
16	protein	I
17	consensus	O
18	site	O
19	(	O
20	CAAT	O
21	box	O
22	)	O
23	which	O
24	can	O
25	confer	O
26	hormone	O
27	inducibility	O
28	to	O
29	a	O
30	PGS	O
31	-	O
32	2	O
33	.	O
34	CAT	B
35	reporter	I
36	gene	I
37	,	O
38	as	O
39	well	O
40	as	O
41	a	O
42	putative	O
43	E	O
44	-	O
45	box	O
46	region	O
47	.	O

1	The	O
2	effect	O
3	of	O
4	iron	O
5	intake	O
6	on	O
7	59Fe	O
8	absorption	O
9	throughout	O
10	pregnancy	O
11	,	O
12	and	O
13	on	O
14	maternal	O
15	and	O
16	fetal	O
17	Fe	O
18	status	O
19	towards	O
20	the	O
21	end	O
22	of	O
23	pregnancy	O
24	,	O
25	was	O
26	investigated	O
27	in	O
28	rats	O
29	.	O

1	These	O
2	activities	O
3	are	O
4	all	O
5	required	O
6	for	O
7	stimulation	O
8	of	O
9	cell	O
10	growth	O
11	by	O
12	middle	O
13	-	O
14	T	O
15	and	O
16	activate	O
17	members	O
18	of	O
19	the	O
20	MAP	B
21	kinase	I
22	family	I
23	.	O

1	The	O
2	partial	O
3	ORF	O
4	was	O
5	found	O
6	to	O
7	be	O
8	identical	O
9	to	O
10	the	O
11	C	O
12	terminus	O
13	of	O
14	HrpJ2	O
15	.	O

1	LD50	O
2	values	O
3	of	O
4	terms	O
5	of	O
6	KP	O
7	were	O
8	84	O
9	mg	O
10	/	O
11	kg	O
12	in	O
13	male	O
14	rats	O
15	and	O
16	122	O
17	mg	O
18	/	O
19	kg	O
20	in	O
21	female	O
22	rats	O
23	when	O
24	KP	O
25	-	O
26	CMC	O
27	was	O
28	administered	O
29	intrarectally	O
30	,	O
31	and	O
32	117	O
33	mg	O
34	/	O
35	kg	O
36	in	O
37	male	O
38	and	O
39	92	O
40	mg	O
41	/	O
42	kg	O
43	in	O
44	female	O
45	when	O
46	KP	O
47	-	O
48	T10	O
49	was	O
50	administered	O
51	intrarectally	O
52	.,	O
53	while	O
54	peroral	O
55	administration	O
56	of	O
57	KP	O
58	-	O
59	CMC	O
60	showed	O
61	LD50	O
62	values	O
63	of	O
64	68	O
65	mg	O
66	/	O
67	kg	O
68	in	O
69	males	O
70	and	O
71	78	O
72	mg	O
73	/	O
74	kg	O
75	in	O
76	females	O
77	in	O
78	terms	O
79	of	O
80	KP	O
81	.	O

1	Human	B
2	T	I
3	-	I
4	cell	I
5	leukemia	I
6	virus	I
7	type	I
8	I	I
9	Tax	I
10	activation	O
11	of	O
12	NF	B
13	-	I
14	kappa	I
15	B	I
16	/	I
17	Rel	I
18	involves	O
19	phosphorylation	O
20	and	O
21	degradation	O
22	of	O
23	I	B
24	kappa	I
25	B	I
26	alpha	I
27	and	O
28	RelA	O
29	(	O
30	p65	B
31	)-	I
32	mediated	O
33	induction	O
34	of	O
35	the	O
36	c	B
37	-	I
38	rel	I
39	gene	I
40	.	O

1	Nodular	O
2	involvement	O
3	of	O
4	the	O
5	left	O
6	lung	O
7	and	O
8	infiltration	O
9	of	O
10	the	O
11	mucosa	O
12	of	O
13	the	O
14	left	O
15	lower	O
16	lobe	O
17	bronchus	O
18	followed	O
19	very	O
20	gradually	O
21	and	O
22	a	O
23	monoclonal	O
24	gammopathy	O
25	(	O
26	IgA	B
27	--	O
28	Type	O
29	Kappa	O
30	)	O
31	was	O
32	demonstrated	O
33	.	O

1	The	O
2	combination	O
3	of	O
4	F1	O
5	and	O
6	F2	O
7	which	O
8	was	O
9	the	O
10	best	O
11	predictor	O
12	of	O
13	CHD	O
14	in	O
15	this	O
16	population	O
17	(	O
18	G1	O
19	)	O
20	might	O
21	be	O
22	interpreted	O
23	as	O
24	reflecting	O
25	trunk	O
26	adiposity	O
27	mainly	O
28	abdominal	O
29	.	O

1	The	O
2	abundance	O
3	of	O
4	transcripts	O
5	from	O
6	several	O
7	unrelated	O
8	genes	O
9	is	O
10	decreased	O
11	in	O
12	cdc68	O
13	-	O
14	1	O
15	mutant	O
16	cells	O
17	after	O
18	transfer	O
19	to	O
20	the	O
21	restrictive	O
22	temperature	O
23	,	O
24	while	O
25	at	O
26	least	O
27	one	O
28	transcript	O
29	,	O
30	from	O
31	the	O
32	HSP82	B
33	gene	I
34	,	O
35	persists	O
36	in	O
37	an	O
38	aberrant	O
39	fashion	O
40	.	O

1	The	O
2	pulmonary	O
3	effects	O
4	observed	O
5	,	O
6	became	O
7	more	O
8	pronounced	O
9	with	O
10	increasing	O
11	NO2	O
12	concentrations	O
13	(	O
14	0	O
15	,	O
16	25	O
17	,	O
18	75	O
19	,	O
20	125	O
21	,	O
22	175	O
23	or	O
24	200	O
25	ppm	O
26	,	O
27	1	O
28	ppm	O
29	NO2	O
30	=	O
31	1	O
32	.	O
33	88	O
34	mg	O
35	m	O
36	-	O
37	3	O
38	NO2	O
39	)	O
40	and	O
41	exposure	O
42	times	O
43	(	O
44	5	O
45	,	O
46	10	O
47	,	O
48	20	O
49	or	O
50	30	O
51	min	O
52	).	O

1	Reproducing	O
2	populations	O
3	of	O
4	this	O
5	aphid	O
6	were	O
7	first	O
8	detected	O
9	in	O
10	Puerto	O
11	Rico	O
12	in	O
13	April	O
14	1992	O
15	.	O

1	REV	B
2	I	I
3	:	O
4	All	O
5	vessels	O
6	up	O
7	to	O
8	50	O
9	%	O
10	stenosed	O
11	have	O
12	a	O
13	patent	O
14	graft	O
15	.	O

1	We	O
2	also	O
3	examined	O
4	the	O
5	effect	O
6	of	O
7	proteolytic	O
8	processing	O
9	in	O
10	the	O
11	MVE	O
12	nonstructural	O
13	polyprotein	O
14	segment	O
15	mediated	O
16	by	O
17	the	O
18	viral	O
19	proteinase	O
20	NS3	O
21	on	O
22	antigen	O
23	processing	O
24	and	O
25	presentation	O
26	of	O
27	the	O
28	MVE	O
29	H	O
30	-	O
31	2Kk	O
32	-	O
33	restricted	O
34	T	O
35	cell	O
36	determinant	O
37	.	O

1	In	O
2	Rat	O
3	1a	O
4	cells	O
5	,	O
6	m1R	O
7	stimulation	O
8	of	O
9	phospholipase	B
10	C	I
11	beta	I
12	and	O
13	the	O
14	marked	O
15	rise	O
16	in	O
17	intracellular	O
18	calcium	O
19	stimulated	O
20	cyclic	O
21	AMP	O
22	(	O
23	cAMP	O
24	)	O
25	synthesis	O
26	,	O
27	resulting	O
28	in	O
29	the	O
30	activation	O
31	of	O
32	protein	O
33	kinase	O
34	A	O
35	.	O

1	Deletion	O
2	analysis	O
3	showed	O
4	that	O
5	the	O
6	-	O
7	321	O
8	/+	O
9	41	O
10	sequence	O
11	was	O
12	sufficient	O
13	for	O
14	both	O
15	the	O
16	constitutive	O
17	promoter	O
18	activity	O
19	and	O
20	auto	O
21	-	O
22	activation	O
23	and	O
24	electrophoretic	O
25	mobility	O
26	shift	O
27	assays	O
28	identified	O
29	the	O
30	interaction	O
31	of	O
32	C	O
33	/	O
34	EBPs	O
35	and	O
36	Sp1	B
37	to	O
38	this	O
39	region	O
40	.	O

1	Using	O
2	a	O
3	battery	O
4	of	O
5	I	B
6	kappa	I
7	B	I
8	alpha	I
9	mutants	I
10	,	O
11	we	O
12	show	O
13	that	O
14	(	O
15	i	O
16	)	O
17	a	O
18	dimer	O
19	binds	O
20	a	O
21	single	B
22	I	I
23	kappa	I
24	B	I
25	alpha	I
26	molecule	I
27	,	O
28	(	O
29	ii	O
30	)	O
31	the	O
32	acidic	O
33	C	O
34	-	O
35	terminal	O
36	region	O
37	of	O
38	I	B
39	kappa	I
40	B	I
41	alpha	I
42	is	O
43	not	O
44	required	O
45	for	O
46	protein	O
47	-	O
48	protein	O
49	binding	O
50	and	O
51	does	O
52	not	O
53	mask	O
54	the	O
55	nuclear	O
56	localization	O
57	signal	O
58	of	O
59	the	O
60	dimer	O
61	,	O
62	(	O
63	iii	O
64	)	O
65	the	O
66	same	O
67	C	O
68	-	O
69	terminal	O
70	region	O
71	is	O
72	required	O
73	for	O
74	inhibition	O
75	of	O
76	DNA	O
77	binding	O
78	,	O
79	and	O
80	(	O
81	iv	O
82	)	O
83	this	O
84	inhibition	O
85	may	O
86	be	O
87	accomplished	O
88	by	O
89	direct	O
90	interaction	O
91	between	O
92	the	O
93	PEST	O
94	-	O
95	like	O
96	region	O
97	and	O
98	the	O
99	DNA	O
100	-	O
101	binding	O
102	region	O
103	of	O
104	one	O
105	of	O
106	the	O
107	subunits	O
108	of	O
109	the	O
110	dimer	O
111	.	O

1	Supershift	O
2	assays	O
3	,	O
4	using	O
5	Jun	B
6	and	I
7	Fos	I
8	family	I
9	member	I
10	-	I
11	specific	I
12	antibodies	I
13	,	O
14	showed	O
15	that	O
16	protein	O
17	complexes	O
18	formed	O
19	by	O
20	AtT	O
21	-	O
22	20	O
23	cell	O
24	nuclear	O
25	extracts	O
26	bound	O
27	to	O
28	the	O
29	c	B
30	-	I
31	jun	I
32	AP	I
33	-	I
34	1	I
35	site	I
36	were	O
37	comprised	O
38	of	O
39	Jun	B
40	family	I
41	members	O
42	,	O
43	JunD	O
44	,	O
45	JunB	O
46	,	O
47	and	O
48	cJun	O
49	.	O

1	The	O
2	SH3	B
3	domains	O
4	of	O
5	Grb2	B
6	bound	O
7	in	O
8	vitro	O
9	to	O
10	specific	O
11	proline	O
12	-	O
13	rich	O
14	motifs	O
15	in	O
16	the	O
17	HPK1	O
18	tail	O
19	and	O
20	functioned	O
21	synergistically	O
22	to	O
23	direct	O
24	the	O
25	stable	O
26	binding	O
27	of	O
28	Grb2	B
29	to	O
30	HPK1	O
31	in	O
32	transfected	O
33	Cos1	O
34	cells	O
35	.	O

1	Although	O
2	L	O
3	-	O
4	threo	O
5	-	O
6	dihydroxyphenylserine	O
7	(	O
8	DOPS	O
9	),	O
10	an	O
11	artificial	O
12	norepinephrine	O
13	(	O
14	NE	O
15	)	O
16	precursor	O
17	,	O
18	did	O
19	not	O
20	change	O
21	immobility	O
22	in	O
23	intact	O
24	mice	O
25	,	O
26	DOPS	O
27	significantly	O
28	reduced	O
29	immobility	O
30	in	O
31	mice	O
32	pretreated	O
33	with	O
34	the	O
35	selective	O
36	NE	O
37	neurotoxin	O
38	DSP4	O
39	.	O

1	All	O
2	of	O
3	the	O
4	basal	O
5	TPN	O
6	solutions	O
7	were	O
8	isonitrogenous	O
9	and	O
10	identical	O
11	in	O
12	nutrient	O
13	composition	O
14	,	O
15	except	O
16	for	O
17	the	O
18	difference	O
19	in	O
20	energy	O
21	level	O
22	,	O
23	which	O
24	was	O
25	adjusted	O
26	with	O
27	glucose	O
28	.	O

1	Specifically	O
2	,	O
3	the	O
4	deduced	O
5	FR	O
6	-	O
7	19	O
8	amino	O
9	acid	O
10	sequence	O
11	has	O
12	approximately89	O
13	,	O
14	77	O
15	,	O
16	and	O
17	68	O
18	%	O
19	overall	O
20	identity	O
21	to	O
22	chicken	O
23	TEF	B
24	-	I
25	1A	I
26	,	O
27	mouse	O
28	TEF	B
29	-	I
30	1	I
31	,	O
32	and	O
33	mouse	O
34	embryonic	O
35	TEA	O
36	domain	O
37	-	O
38	containing	O
39	factor	O
40	,	O
41	respectively	O
42	.	O

1	The	O
2	data	O
3	indicate	O
4	that	O
5	the	O
6	five	O
7	different	O
8	(	O
9	and	O
10	partially	O
11	overlapping	O
12	)	O
13	sry	O
14	messenger	O
15	RNAs	O
16	detectable	O
17	in	O
18	early	O
19	embryos	O
20	are	O
21	initiated	O
22	at	O
23	three	O
24	separate	O
25	sites	O
26	,	O
27	each	O
28	directly	O
29	upstream	O
30	from	O
31	one	O
32	of	O
33	the	O
34	three	O
35	protein	O
36	-	O
37	coding	O
38	regions	O
39	,	O
40	designated	O
41	(	O
42	in	O
43	5	O
44	'	O
45	to	O
46	3	O
47	'	O
48	order	O
49	)	O
50	beta	O
51	,	O
52	alpha	O
53	and	O
54	delta	O
55	.	O

1	EGV	O
2	had	O
3	no	O
4	detectable	O
5	effect	O
6	on	O
7	PP	O
8	secretion	O
9	under	O
10	basal	O
11	or	O
12	stimulated	O
13	conditions	O
14	.	O

1	The	O
2	aspirate	O
3	from	O
4	a	O
5	parathyroid	O
6	cyst	O
7	was	O
8	watery	O
9	clear	O
10	and	O
11	contained	O
12	high	O
13	amount	O
14	of	O
15	parathyroid	B
16	hormone	I
17	.	O

1	The	O
2	protein	O
3	is	O
4	composed	O
5	of	O
6	a	O
7	central	O
8	alpha	O
9	-	O
10	helical	O
11	portion	O
12	with	O
13	globular	O
14	domains	O
15	at	O
16	both	O
17	NH2	O
18	and	O
19	COOH	O
20	termini	O
21	,	O
22	and	O
23	the	O
24	epitope	O
25	to	O
26	the	O
27	monoclonal	O
28	antibody	O
29	resides	O
30	in	O
31	the	O
32	central	O
33	alpha	O
34	-	O
35	helical	O
36	stalk	O
37	.	O

1	Heterodimers	O
2	of	O
3	myogenin	O
4	and	O
5	E12	B
6	(	O
7	or	O
8	MyoD	B
9	and	O
10	E12	B
11	)	O
12	specifically	O
13	bound	O
14	a	O
15	restriction	O
16	fragment	O
17	extending	O
18	from	O
19	-	O
20	200	O
21	to	O
22	-	O
23	103	O
24	relative	O
25	to	O
26	the	O
27	start	O
28	of	O
29	cardiac	B
30	alpha	I
31	-	I
32	actin	I
33	transcription	O
34	.	O

1	The	O
2	C	O
3	-	O
4	terminal	O
5	approximately	O
6	50	O
7	amino	O
8	acids	O
9	of	O
10	Bel	O
11	-	O
12	1	O
13	are	O
14	shown	O
15	to	O
16	be	O
17	essential	O
18	for	O
19	Bel	O
20	-	O
21	1	O
22	activity	O
23	but	O
24	can	O
25	be	O
26	effectively	O
27	substituted	O
28	by	O
29	the	O
30	C	O
31	-	O
32	terminal	O
33	activation	O
34	domain	O
35	of	O
36	VP16	B
37	.	O

1	Microvessels	O
2	were	O
3	counted	O
4	in	O
5	a	O
6	x200	O
7	field	O
8	(	O
9	0	O
10	.	O
11	754	O
12	mm2	O
13	)	O
14	in	O
15	the	O
16	area	O
17	of	O
18	maximal	O
19	angiogenesis	O
20	.	O

1	The	O
2	TEA1	O
3	(	O
4	Ty	O
5	enhancer	O
6	activator	O
7	)	O
8	gene	O
9	sequence	O
10	predicts	O
11	a	O
12	protein	O
13	of	O
14	86	O
15	.	O
16	9	O
17	kDa	O
18	whose	O
19	N	O
20	terminus	O
21	contains	O
22	a	O
23	zinc	O
24	cluster	O
25	and	O
26	dimerization	O
27	motif	O
28	typical	O
29	of	O
30	the	O
31	Gal4	B
32	-	I
33	type	I
34	family	I
35	of	O
36	DNA	O
37	-	O
38	binding	O
39	proteins	O
40	.	O

1	In	O
2	vitro	O
3	expression	O
4	of	O
5	four	O
6	different	O
7	naturally	O
8	occurring	O
9	nonsense	O
10	and	O
11	missense	O
12	mutations	O
13	revealed	O
14	a	O
15	dramatically	O
16	altered	O
17	subcellular	O
18	location	O
19	of	O
20	the	O
21	protein	O
22	in	O
23	cultured	O
24	cells	O
25	.	O

1	Developmental	O
2	follow	O
3	-	O
4	up	O
5	at	O
6	age	O
7	2	O
8	years	O
9	was	O
10	performed	O
11	.	O

1	Removal	O
2	of	O
3	PDMP	O
4	from	O
5	the	O
6	cell	O
7	medium	O
8	resulted	O
9	in	O
10	reversal	O
11	of	O
12	the	O
13	cell	O
14	cycle	O
15	changes	O
16	,	O
17	with	O
18	cells	O
19	re	O
20	-	O
21	entering	O
22	the	O
23	S	O
24	phase	O
25	.	O

1	Campomelic	O
2	dysplasia	O
3	translocation	O
4	breakpoints	O
5	are	O
6	scattered	O
7	over	O
8	1	O
9	Mb	O
10	proximal	O
11	to	O
12	SOX9	O
13	:	O
14	evidence	O
15	for	O
16	an	O
17	extended	O
18	control	O
19	region	O
20	.	O

1	The	O
2	present	O
3	investigation	O
4	conducted	O
5	in	O
6	a	O
7	population	O
8	of	O
9	258	O
10	dentally	O
11	aware	O
12	individuals	O
13	in	O
14	the	O
15	age	O
16	range	O
17	20	O
18	-	O
19	69	O
20	years	O
21	,	O
22	was	O
23	initiated	O
24	to	O
25	elucidate	O
26	the	O
27	relationship	O
28	between	O
29	tobacco	O
30	smoking	O
31	and	O
32	supragingival	O
33	calculus	O
34	,	O
35	taking	O
36	into	O
37	account	O
38	possible	O
39	confounding	O
40	factors	O
41	such	O
42	as	O
43	age	O
44	,	O
45	gender	O
46	,	O
47	oral	O
48	hygiene	O
49	and	O
50	gingival	O
51	inflammation	O
52	.	O

1	At	O
2	the	O
3	same	O
4	time	O
5	we	O
6	obtained	O
7	easily	O
8	understandable	O
9	EEG	O
10	-	O
11	information	O
12	which	O
13	has	O
14	never	O
15	previously	O
16	been	O
17	available	O
18	to	O
19	us	O
20	.	O

1	Three	O
2	-	O
3	dimensional	O
4	structural	O
5	studies	O
6	using	O
7	electron	O
8	cryomicroscopy	O
9	showed	O
10	that	O
11	the	O
12	binding	O
13	of	O
14	one	O
15	Fab	O
16	(	O
17	8H2	O
18	/	O
19	G5	O
20	)	O
21	does	O
22	not	O
23	affect	O
24	the	O
25	conformation	O
26	of	O
27	the	O
28	capsid	O
29	,	O
30	and	O
31	the	O
32	efficiency	O
33	of	O
34	mRNA	O
35	production	O
36	is	O
37	similar	O
38	to	O
39	that	O
40	of	O
41	the	O
42	native	O
43	subviral	O
44	particle	O
45	.	O

1	Expression	O
2	of	O
3	Msp	O
4	was	O
5	toxic	O
6	to	O
7	E	O
8	.	O
9	coli	O
10	when	O
11	the	O
12	entire	O
13	msp	O
14	gene	O
15	was	O
16	present	O
17	.	O

1	A	O
2	reduced	O
3	matrix	O
4	distribution	O
5	and	O
6	enhanced	O
7	cell	O
8	density	O
9	were	O
10	observed	O
11	as	O
12	the	O
13	biofilm	O
14	aged	O
15	.	O

1	Large	O
2	strain	O
3	differences	O
4	were	O
5	found	O
6	for	O
7	all	O
8	variables	O
9	recorded	O
10	,	O
11	i	O
12	.	O
13	e	O
14	.,	O
15	the	O
16	proportion	O
17	of	O
18	attacking	O
19	males	O
20	,	O
21	the	O
22	time	O
23	spent	O
24	in	O
25	the	O
26	brightly	O
27	lit	O
28	box	O
29	,	O
30	and	O
31	the	O
32	number	O
33	of	O
34	transitions	O
35	between	O
36	the	O
37	lit	O
38	and	O
39	the	O
40	dark	O
41	boxes	O
42	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	identified	O
7	Sp1	B
8	and	O
9	Sp3	B
10	as	O
11	major	O
12	factors	O
13	binding	O
14	to	O
15	the	O
16	Sp1	B
17	sites	I
18	of	O
19	the	O
20	p21	B
21	/	I
22	WAF1	I
23	/	I
24	Cip1	I
25	promoter	I
26	in	O
27	MG63	O
28	cells	O
29	through	O
30	electrophoretic	O
31	mobility	O
32	shift	O
33	assays	O
34	and	O
35	showed	O
36	that	O
37	TSA	O
38	treatment	O
39	did	O
40	not	O
41	change	O
42	their	O
43	binding	O
44	activities	O
45	.	O

1	Eight	O
2	-	O
3	four	O
4	ACOAs	O
5	were	O
6	tested	O
7	in	O
8	order	O
9	to	O
10	examine	O
11	the	O
12	fit	O
13	of	O
14	the	O
15	model	O
16	to	O
17	the	O
18	data	O
19	by	O
20	path	O
21	analysis	O
22	with	O
23	LISREL	O
24	VII	O
25	.	O

1	The	O
2	murine	O
3	mutation	O
4	dominant	O
5	white	O
6	spotting	O
7	(	O
8	W	O
9	)	O
10	is	O
11	in	O
12	the	O
13	proto	B
14	-	I
15	oncogene	I
16	,	O
17	c	B
18	-	I
19	kit	I
20	.	O

1	The	O
2	dopamine	O
3	D4	O
4	receptor	O
5	as	O
6	well	O
7	as	O
8	many	O
9	other	O
10	catecholaminergic	O
11	receptors	O
12	contain	O
13	several	O
14	putative	O
15	SH3	B
16	binding	I
17	domains	I
18	.	O

1	11	O
2	-	O
3	Aminoundecanoyl	O
4	-	O
5	SK	O
6	-	O
7	NH2	O
8	and	O
9	11	O
10	-	O
11	aminoundecanoyl	O
12	-	O
13	SH	O
14	-	O
15	NH2	O
16	establish	O
17	that	O
18	a	O
19	simple	O
20	alkyl	O
21	backbone	O
22	can	O
23	maintain	O
24	an	O
25	appropriate	O
26	distance	O
27	between	O
28	three	O
29	elements	O
30	critical	O
31	for	O
32	recognition	O
33	by	O
34	the	O
35	fungal	O
36	enzyme	O
37	'	O
38	s	O
39	peptide	O
40	-	O
41	binding	O
42	site	O
43	:	O
44	a	O
45	simple	O
46	omega	O
47	-	O
48	terminal	O
49	amino	O
50	group	O
51	,	O
52	a	O
53	beta	O
54	-	O
55	hydroxyl	O
56	,	O
57	and	O
58	an	O
59	epsilon	O
60	-	O
61	amino	O
62	group	O
63	or	O
64	an	O
65	imidazole	O
66	.	O

1	By	O
2	DNase	B
3	I	I
4	footprint	O
5	analysis	O
6	of	O
7	the	O
8	PNR	O
9	element	O
10	,	O
11	a	O
12	palindrome	O
13	of	O
14	two	O
15	high	O
16	-	O
17	affinity	O
18	Ets	B
19	-	I
20	binding	I
21	sites	I
22	(	O
23	CTTCCCTGGAAG	O
24	)	O
25	was	O
26	identified	O
27	.	O

1	A	O
2	more	O
3	complete	O
4	analysis	O
5	of	O
6	dose	O
7	response	O
8	,	O
9	time	O
10	and	O
11	mode	O
12	of	O
13	Ga	O
14	administration	O
15	(	O
16	preinjury	O
17	or	O
18	postinjury	O
19	),	O
20	and	O
21	availability	O
22	of	O
23	Ga	O
24	across	O
25	the	O
26	blood	O
27	-	O
28	brain	O
29	barrier	O
30	is	O
31	needed	O
32	to	O
33	further	O
34	evaluate	O
35	the	O
36	efficacy	O
37	of	O
38	this	O
39	compound	O
40	.	O

1	Only	O
2	seven	O
3	patients	O
4	,	O
5	five	O
6	of	O
7	whom	O
8	have	O
9	metastatic	O
10	disease	O
11	,	O
12	survive	O
13	more	O
14	than	O
15	10	O
16	years	O
17	after	O
18	first	O
19	presentation	O
20	;	O
21	nine	O
22	patients	O
23	,	O
24	one	O
25	of	O
26	whom	O
27	has	O
28	secondaries	O
29	,	O
30	survive	O
31	for	O
32	5	O
33	years	O
34	or	O
35	less	O
36	.	O

1	We	O
2	used	O
3	the	O
4	Toshiba	O
5	IIDR	O
6	system	O
7	,	O
8	which	O
9	is	O
10	composed	O
11	of	O
12	an	O
13	X	O
14	-	O
15	ray	O
16	TV	O
17	system	O
18	and	O
19	a	O
20	digital	O
21	image	O
22	managing	O
23	circuit	O
24	.	O

1	The	O
2	majority	O
3	of	O
4	MRF	O
5	units	O
6	were	O
7	behaviorally	O
8	incongruent	O
9	;	O
10	in	O
11	the	O
12	most	O
13	frequently	O
14	observed	O
15	case	O
16	,	O
17	their	O
18	activity	O
19	failed	O
20	to	O
21	change	O
22	reliably	O
23	when	O
24	behavior	O
25	habituated	O
26	.	O

1	When	O
2	considered	O
3	with	O
4	the	O
5	known	O
6	neurotoxic	O
7	effects	O
8	on	O
9	children	O
10	of	O
11	"	O
12	low	O
13	levels	O
14	"	O
15	of	O
16	exposure	O
17	to	O
18	lead	O
19	,	O
20	these	O
21	results	O
22	also	O
23	suggest	O
24	that	O
25	either	O
26	an	O
27	excessively	O
28	narrow	O
29	margin	O
30	of	O
31	safety	O
32	or	O
33	insufficient	O
34	safety	O
35	is	O
36	provided	O
37	by	O
38	present	O
39	U	O
40	.	O
41	S	O
42	.	O
43	guidelines	O
44	,	O
45	which	O
46	classify	O
47	an	O
48	elevated	O
49	blood	O
50	lead	O
51	concentration	O
52	as	O
53	25	O
54	micrograms	O
55	/	O
56	dl	O
57	or	O
58	greater	O
59	.	O

1	Little	O
2	is	O
3	known	O
4	about	O
5	the	O
6	mechanism	O
7	,	O
8	but	O
9	the	O
10	availability	O
11	of	O
12	rapid	O
13	facile	O
14	assays	O
15	for	O
16	monitoring	O
17	immunoglobulin	B
18	hypermutation	O
19	would	O
20	greatly	O
21	aid	O
22	the	O
23	development	O
24	of	O
25	culture	O
26	systems	O
27	for	O
28	hypermutating	O
29	B	O
30	cells	O
31	as	O
32	well	O
33	as	O
34	the	O
35	screening	O
36	for	O
37	individuals	O
38	deficient	O
39	in	O
40	the	O
41	process	O
42	.	O

1	The	O
2	number	O
3	of	O
4	lactotropes	O
5	,	O
6	somatotropes	O
7	,	O
8	thyrotropes	O
9	,	O
10	and	O
11	gonadotropes	O
12	was	O
13	not	O
14	altered	O
15	compared	O
16	with	O
17	controls	O
18	,	O
19	indicating	O
20	that	O
21	in	O
22	the	O
23	adult	O
24	pituitary	O
25	,	O
26	POMC	O
27	products	O
28	are	O
29	not	O
30	required	O
31	to	O
32	maintain	O
33	the	O
34	distribution	O
35	of	O
36	cell	O
37	types	O
38	.	O

1	The	O
2	effects	O
3	of	O
4	antithrombotic	O
5	drugs	O
6	in	O
7	patients	O
8	with	O
9	left	O
10	ventricular	O
11	thrombi	O
12	:	O
13	assessment	O
14	with	O
15	indium	O
16	-	O
17	111	O
18	platelet	O
19	imaging	O
20	and	O
21	two	O
22	-	O
23	dimensional	O
24	echocardiography	O
25	.	O

1	The	O
2	data	O
3	indicate	O
4	that	O
5	etr	O
6	-	O
7	1	O
8	is	O
9	essential	O
10	for	O
11	muscle	O
12	development	O
13	in	O
14	C	O
15	.	O
16	elegans	O
17	,	O
18	perhaps	O
19	by	O
20	playing	O
21	a	O
22	role	O
23	in	O
24	post	O
25	-	O
26	transcriptional	O
27	processing	O
28	of	O
29	some	O
30	muscle	O
31	component	O
32	,	O
33	and	O
34	thus	O
35	suggesting	O
36	a	O
37	possible	O
38	conservation	O
39	of	O
40	gene	O
41	function	O
42	with	O
43	human	O
44	CUG	O
45	-	O
46	bp	O
47	.	O

1	In	O
2	group	O
3	B	O
4	37	O
5	MBq	O
6	in	O
7	150	O
8	microL	O
9	of	O
10	99mTc	O
11	-	O
12	HSA	O
13	nanocolloid	O
14	was	O
15	additionally	O
16	injected	O
17	intradermally	O
18	18	O
19	h	O
20	before	O
21	surgery	O
22	(	O
23	3	O
24	-	O
25	6	O
26	aliquots	O
27	injected	O
28	perilesionally	O
29	).	O

1	This	O
2	makes	O
3	these	O
4	compounds	O
5	attractive	O
6	as	O
7	vehicles	O
8	for	O
9	these	O
10	and	O
11	other	O
12	gases	O
13	in	O
14	-	O
15	vivo	O
16	and	O
17	in	O
18	-	O
19	vitro	O
20	.	O

1	A	O
2	careful	O
3	,	O
4	radiolabelled	O
5	tissue	O
6	-	O
7	distribution	O
8	study	O
9	is	O
10	warranted	O
11	to	O
12	elucidate	O
13	the	O
14	complicated	O
15	metabolic	O
16	fate	O
17	of	O
18	perhexiline	O
19	.	O

1	GRP78	O
2	,	O
3	a	O
4	molecular	O
5	chaperone	O
6	expressed	O
7	in	O
8	the	O
9	endoplasmic	O
10	reticulum	O
11	,	O
12	is	O
13	a	O
14	"	O
15	glucose	O
16	-	O
17	regulated	O
18	protein	O
19	"	O
20	induced	O
21	by	O
22	stress	O
23	responses	O
24	that	O
25	deplete	O
26	glucose	O
27	or	O
28	intracisternal	O
29	calcium	O
30	or	O
31	otherwise	O
32	disrupt	O
33	glycoprotein	O
34	trafficking	O
35	.	O

1	3	O
2	'	O
3	RNA	O
4	boundary	O
5	experiments	O
6	indicate	O
7	that	O
8	the	O
9	5	O
10	'	O
11	structure	O
12	reduces	O
13	the	O
14	number	O
15	of	O
16	(	O
17	G	O
18	/	O
19	U	O
20	)	O
21	AG	O
22	repeats	O
23	required	O
24	for	O
25	stable	O
26	TRAP	B
27	-	I
28	trp	I
29	leader	O
30	RNA	O
31	association	O
32	.	O

1	Bone	O
2	marrow	O
3	abnormalities	O
4	in	O
5	Hodgkin	O
6	'	O
7	s	O
8	disease	O
9	are	O
10	reviewed	O
11	and	O
12	the	O
13	current	O
14	understanding	O
15	of	O
16	the	O
17	pathological	O
18	mechanisms	O
19	leading	O
20	to	O
21	aplastic	O
22	anemia	O
23	is	O
24	discussed	O
25	.	O

1	Determination	O
2	of	O
3	transaminases	O
4	with	O
5	an	O
6	autoanalyzer	O

1	Interestingly	O
2	,	O
3	a	O
4	portion	O
5	of	O
6	the	O
7	tail	O
8	domain	O
9	(	O
10	aa	O
11	,	O
12	1	O
13	,	O
14	094	O
15	-	O
16	1	O
17	,	O
18	830	O
19	)	O
20	shares	O
21	58	O
22	%	O
23	amino	O
24	acid	O
25	sequence	O
26	identity	O
27	with	O
28	a	O
29	723	O
30	-	O
31	aa	O
32	protein	O
33	from	O
34	mouse	O
35	brain	O
36	reported	O
37	to	O
38	be	O
39	a	O
40	glutamic	B
41	acid	I
42	decarboxylase	I
43	.	O

1	Copyright	O
2	1999	O
3	Academic	O
4	Press	O
5	.	O

1	Chicken	O
2	sterol	B
3	carrier	I
4	protein	I
5	2	I
6	/	I
7	sterol	I
8	carrier	I
9	protein	I
10	x	O
11	:	O
12	cDNA	O
13	cloning	O
14	reveals	O
15	evolutionary	O
16	conservation	O
17	of	O
18	structure	O
19	and	O
20	regulated	O
21	expression	O
22	.	O

1	Standard	O
2	reference	O
3	sources	O
4	indicate	O
5	that	O
6	an	O
7	able	O
8	-	O
9	bodied	O
10	11	O
11	-	O
12	year	O
13	-	O
14	old	O
15	child	O
16	of	O
17	comparable	O
18	height	O
19	requires	O
20	1	O
21	,	O
22	493	O
23	kcal	O
24	/	O
25	d	O
26	for	O
27	support	O
28	of	O
29	basal	O
30	metabolic	O
31	functions	O
32	.	O

1	In	O
2	vitro	O
3	transcription	O
4	results	O
5	indicate	O
6	that	O
7	this	O
8	5	O
9	'	O
10	structure	O
11	functions	O
12	in	O
13	the	O
14	attenuation	O
15	mechanism	O
16	,	O
17	since	O
18	deletion	O
19	of	O
20	the	O
21	stem	O
22	-	O
23	loop	O
24	caused	O
25	an	O
26	increase	O
27	in	O
28	transcription	O
29	readthrough	O
30	.	O

1	Mutations	O
2	at	O
3	the	O
4	suf12	B
5	locus	I
6	were	O
7	isolated	O
8	in	O
9	Saccharomyces	O
10	cerevisiae	O
11	as	O
12	extragenic	O
13	suppressors	O
14	of	O
15	+	O
16	1	O
17	frameshift	O
18	mutations	O
19	in	O
20	glycine	O
21	(	O
22	GGX	O
23	)	O
24	and	O
25	proline	O
26	(	O
27	CCX	O
28	)	O
29	codons	O
30	,	O
31	as	O
32	well	O
33	as	O
34	UGA	O
35	and	O
36	UAG	O
37	nonsense	O
38	mutations	O
39	.	O

1	Northern	O
2	blot	O
3	hybridization	O
4	demonstrated	O
5	that	O
6	HEP	O
7	-	O
8	COP	O
9	was	O
10	expressed	O
11	in	O
12	a	O
13	wide	O
14	range	O
15	of	O
16	human	O
17	adult	O
18	and	O
19	fetal	O
20	tissues	O
21	.	O

1	From	O
2	transient	O
3	expression	O
4	studies	O
5	,	O
6	we	O
7	could	O
8	demonstrate	O
9	that	O
10	the	O
11	SH3	B
12	domain	I
13	of	O
14	PLC	B
15	-	I
16	gamma1	I
17	is	O
18	necessary	O
19	for	O
20	the	O
21	association	O
22	with	O
23	SOS1	O
24	in	O
25	vivo	O
26	.	O

1	Despite	O
2	the	O
3	small	O
4	number	O
5	of	O
6	patients	O
7	,	O
8	on	O
9	the	O
10	basis	O
11	of	O
12	this	O
13	report	O
14	,	O
15	we	O
16	can	O
17	confirm	O
18	that	O
19	1	O
20	.	O
21	5	O
22	MU	O
23	/	O
24	day	O
25	of	O
26	alpha	B
27	-	I
28	IFN	I
29	is	O
30	an	O
31	adequate	O
32	treatment	O
33	for	O
34	patients	O
35	with	O
36	hairy	O
37	cell	O
38	leukemia	O
39	.	O

1	Fusion	O
2	of	O
3	ubiquitin	B
4	to	O
5	pADPRP	O
6	increased	O
7	the	O
8	yield	O
9	of	O
10	pADPRP	O
11	approximately	O
12	10	O
13	-	O
14	fold	O
15	compared	O
16	to	O
17	that	O
18	of	O
19	the	O
20	unfused	O
21	enzyme	O
22	.	O

1	The	O
2	Functional	O
3	Independence	O
4	Measure	O
5	:	O
6	a	O
7	comparative	O
8	study	O
9	of	O
10	clinician	O
11	and	O
12	self	O
13	ratings	O
14	.	O

1	LA	O
2	-	O
3	3848	O
4	-	O
5	MS	O
6	.	O

1	A	O
2	cDNA	O
3	clone	O
4	pCZ1	O
5	,	O
6	with	O
7	a	O
8	1	O
9	.	O
10	1	O
11	kb	O
12	insert	O
13	,	O
14	was	O
15	isolated	O
16	from	O
17	a	O
18	NaCl	O
19	-	O
20	adapted	O
21	tobacco	O
22	cell	O
23	cDNA	O
24	library	O
25	that	O
26	encodes	O
27	an	O
28	apparently	O
29	full	O
30	-	O
31	length	O
32	29	O
33	kDa	O
34	protein	O
35	(	O
36	251	O
37	amino	O
38	acids	O
39	)	O
40	with	O
41	a	O
42	calculated	O
43	pI	O
44	of	O
45	5	O
46	.	O
47	7	O
48	.	O

1	TPTA	O
2	produced	O
3	brain	O
4	congestion	O
5	,	O
6	and	O
7	hepatic	O
8	and	O
9	pulmonary	O
10	petechial	O
11	and	O
12	generalized	O
13	hemorrhages	O
14	.	O

1	In	O
2	support	O
3	of	O
4	clinical	O
5	antianginal	O
6	studies	O
7	,	O
8	the	O
9	vasodilator	O
10	nicorandil	O
11	(	O
12	NIC	O
13	)	O
14	was	O
15	combined	O
16	with	O
17	the	O
18	beta	B
19	-	I
20	adrenergic	I
21	receptor	I
22	antagonists	O
23	propranolol	O
24	(	O
25	PRO	O
26	)	O
27	and	O
28	atenolol	O
29	(	O
30	ATN	O
31	)	O
32	and	O
33	with	O
34	the	O
35	calcium	O
36	channel	O
37	blocker	O
38	diltiazem	O
39	(	O
40	DTZ	O
41	)	O
42	to	O
43	determine	O
44	their	O
45	cardiovascular	O
46	and	O
47	pharmacokinetic	O
48	interactions	O
49	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	both	O
6	naturally	O
7	acquired	O
8	and	O
9	passive	O
10	(	O
11	modified	O
12	immune	O
13	serum	B
14	globulin	I
15	)	O
16	antibodies	O
17	to	O
18	type	O
19	III	O
20	group	O
21	B	O
22	Streptococcus	O
23	antigen	O
24	are	O
25	partially	O
26	protective	O
27	against	O
28	intra	O
29	-	O
30	amniotic	O
31	infection	O
32	.	O

1	The	O
2	Nostoc	O
3	petBD	O
4	genes	O
5	are	O
6	not	O
7	closely	O
8	linked	O
9	to	O
10	the	O
11	psbB	B
12	gene	I
13	(	O
14	encoding	O
15	the	O
16	51	O
17	-	O
18	kDa	O
19	photosystem	O
20	II	O
21	polypeptide	O
22	)	O
23	and	O
24	do	O
25	not	O
26	contain	O
27	introns	O
28	as	O
29	do	O
30	the	O
31	closely	O
32	related	O
33	chloroplast	O
34	genes	O
35	.	O

1	CONCLUSIONS	O
2	.	O

1	Transient	O
2	co	O
3	-	O
4	transfection	O
5	assays	O
6	involving	O
7	NFKB2	O
8	expression	O
9	vectors	O
10	and	O
11	kappa	B
12	B	I
13	-	I
14	driven	I
15	reporter	I
16	plasmids	O
17	indicate	O
18	that	O
19	NFKB2	O
20	p85	B
21	has	O
22	lost	O
23	the	O
24	transcriptional	O
25	repressor	O
26	functions	O
27	typical	O
28	of	O
29	normal	O
30	NFKB2	B
31	p52	I
32	.	O

1	The	O
2	results	O
3	obtained	O
4	tend	O
5	to	O
6	prove	O
7	that	O
8	the	O
9	reticuloendothelial	O
10	system	O
11	mainly	O
12	participated	O
13	in	O
14	beryllium	O
15	retention	O
16	.	O

1	Fragments	O
2	and	O
3	analogs	O
4	of	O
5	the	O
6	hormone	O
7	ACTH	B
8	were	O
9	previously	O
10	shown	O
11	to	O
12	have	O
13	beneficial	O
14	effect	O
15	on	O
16	the	O
17	outcome	O
18	of	O
19	head	O
20	injury	O
21	,	O
22	while	O
23	elevated	O
24	levels	O
25	of	O
26	corticosterone	O
27	(	O
28	CS	O
29	)	O
30	exacerbate	O
31	it	O
32	.	O

1	Members	O
2	of	O
3	the	O
4	mitogen	B
5	activated	I
6	protein	I
7	(	I
8	MAP	I
9	)	I
10	kinase	I
11	family	I
12	,	O
13	extracellular	O
14	signal	O
15	-	O
16	regulated	O
17	kinase	O
18	,	O
19	stress	B
20	-	I
21	activated	I
22	protein	I
23	kinase	I
24	-	I
25	1	I
26	/	I
27	c	I
28	-	I
29	Jun	I
30	NH2	I
31	-	I
32	terminal	I
33	kinase	I
34	,	O
35	and	O
36	p38	B
37	,	O
38	are	O
39	central	O
40	elements	O
41	that	O
42	transduce	O
43	the	O
44	signal	O
45	generated	O
46	by	O
47	growth	O
48	factors	O
49	,	O
50	cytokines	O
51	,	O
52	and	O
53	stressing	O
54	agents	O
55	.	O

1	When	O
2	nifA	B
3	mRNA	I
4	5	O
5	'	O
6	start	O
7	points	O
8	were	O
9	mapped	O
10	by	O
11	primer	O
12	extension	O
13	,	O
14	both	O
15	a	O
16	minor	O
17	upstream	O
18	transcript	O
19	(	O
20	s	O
21	)	O
22	starting	O
23	45	O
24	bp	O
25	distal	O
26	to	O
27	the	O
28	anaerobox	O
29	and	O
30	a	O
31	major	O
32	downstream	O
33	transcript	O
34	starting	O
35	10	O
36	bp	O
37	distal	O
38	to	O
39	the	O
40	sigma	B
41	54	I
42	box	I
43	were	O
44	observed	O
45	.	O

1	Cocaine	O
2	-	O
3	treated	O
4	rats	O
5	acquired	O
6	a	O
7	preference	O
8	for	O
9	cocaine	O
10	-	O
11	associated	O
12	contextual	O
13	stimuli	O
14	(	O
15	CS	O
16	)	O
17	relative	O
18	to	O
19	saline	O
20	-	O
21	injected	O
22	control	O
23	rats	O
24	.	O

1	Canadian	O
2	survey	O
3	reveals	O
4	widespread	O
5	dissatisfaction	O
6	among	O
7	physicians	O
8	.	O

1	Transcription	O
2	of	O
3	the	O
4	gene	O
5	for	O
6	ivanolysin	O
7	O	O
8	and	O
9	expression	O
10	of	O
11	other	O
12	genes	O
13	of	O
14	the	O
15	virulence	O
16	gene	O
17	cluster	O
18	in	O
19	L	O
20	.	O
21	ivanovii	O
22	were	O
23	dependent	O
24	on	O
25	PrfA	O
26	.	O

1	USA	O
2	80	O
3	,	O
4	3618	O
5	-	O
6	3622	O
7	)	O
8	The	O
9	two	O
10	proteins	O
11	show	O
12	36	O
13	%	O
14	identities	O
15	in	O
16	their	O
17	amino	O
18	acid	O
19	sequence	O
20	,	O
21	in	O
22	an	O
23	alignment	O
24	requiring	O
25	six	O
26	gaps	O
27	.	O

1	Multiple	O
2	mitogen	B
3	-	I
4	activated	I
5	protein	I
6	kinase	I
7	signaling	O
8	pathways	O
9	connect	O
10	the	O
11	cot	O
12	oncoprotein	O
13	to	O
14	the	O
15	c	B
16	-	I
17	jun	I
18	promoter	I
19	and	O
20	to	O
21	cellular	O
22	transformation	O
23	.	O

1	Among	O
2	known	O
3	flea	O
4	larvae	O
5	,	O
6	the	O
7	genus	O
8	Anomiopsyllus	O
9	(	O
10	Anomiopsyllinae	O
11	,	O
12	Anomiopsyllini	O
13	)	O
14	is	O
15	as	O
16	distinctive	O
17	in	O
18	larval	O
19	form	O
20	as	O
21	are	O
22	the	O
23	adults	O
24	.	O

1	Inhibition	O
2	of	O
3	the	O
4	Mek	O
5	/	O
6	Erk	O
7	pathway	O
8	in	O
9	Rat1	O
10	/	O
11	ras	B
12	cells	O
13	,	O
14	using	O
15	the	O
16	Mek	O
17	inhibitor	O
18	,	O
19	PD98059	O
20	,	O
21	resulted	O
22	in	O
23	complete	O
24	cytoskeletal	O
25	recovery	O
26	,	O
27	indistinguishable	O
28	from	O
29	that	O
30	induced	O
31	by	O
32	HR12	O
33	.	O

1	The	O
2	3ASubE	O
3	cells	O
4	expressing	O
5	CXCR2	O
6	with	O
7	mutation	O
8	of	O
9	Ser	O
10	-	O
11	346	O
12	,	O
13	-	O
14	347	O
15	,	O
16	and	O
17	-	O
18	348	O
19	to	O
20	alanine	O
21	,	O
22	or	O
23	with	O
24	mutation	O
25	of	O
26	only	O
27	one	O
28	serine	O
29	in	O
30	this	O
31	domain	O
32	,	O
33	continue	O
34	to	O
35	be	O
36	phosphorylated	O
37	in	O
38	response	O
39	to	O
40	ligand	O
41	and	O
42	are	O
43	60	O
44	-	O
45	70	O
46	%	O
47	desensitized	O
48	following	O
49	the	O
50	initial	O
51	ligand	O
52	challenge	O
53	.	O

1	Altogether	O
2	46	O
3	phase	O
4	III	O
5	activities	O
6	were	O
7	recorded	O
8	.	O

1	Two	O
2	of	O
3	these	O
4	six	O
5	cases	O
6	showed	O
7	mucosal	O
8	spread	O
9	without	O
10	stromal	O
11	invasion	O
12	(	O
13	type	O
14	A	O
15	);	O
16	the	O
17	remaining	O
18	four	O
19	cases	O
20	presented	O
21	a	O
22	direct	O
23	extension	O
24	(	O
25	type	O
26	B	O
27	)	O
28	from	O
29	muscle	O
30	-	O
31	invasive	O
32	carcinomas	O
33	of	O
34	the	O
35	bladder	O
36	.	O

1	This	O
2	may	O
3	explain	O
4	in	O
5	part	O
6	a	O
7	secular	O
8	trend	O
9	towards	O
10	reduced	O
11	birthweight	O
12	for	O
13	gestation	O
14	in	O
15	preterm	O
16	infants	O
17	.	O

1	In	O
2	this	O
3	report	O
4	we	O
5	studied	O
6	the	O
7	role	O
8	of	O
9	protein	B
10	-	I
11	tyrosine	I
12	phosphatase	I
13	SHP	I
14	-	I
15	2	I
16	in	O
17	ErbB	B
18	-	I
19	mediated	O
20	activation	O
21	of	O
22	mitogen	B
23	-	I
24	activated	I
25	protein	I
26	kinase	I
27	(	O
28	MAPK	O
29	)	O
30	by	O
31	overexpressing	O
32	SHP	B
33	-	I
34	2	I
35	mutants	I
36	in	O
37	COS	O
38	-	O
39	7	O
40	cells	O
41	.	O

1	Overexpression	O
2	of	O
3	either	O
4	DAP	O
5	-	O
6	1	O
7	or	O
8	sentrin	O
9	causes	O
10	apoptosis	O
11	of	O
12	TNF	B
13	-	I
14	sensitive	O
15	L929	O
16	fibroblast	O
17	cell	O
18	line	O
19	,	O
20	as	O
21	well	O
22	as	O
23	TNF	B
24	-	I
25	resistant	O
26	osteosarcoma	O
27	cell	O
28	line	O
29	,	O
30	U2OS	O
31	.	O

1	The	O
2	human	B
3	immunodeficiency	I
4	virus	I
5	type	I
6	-	I
7	1	I
8	(	I
9	HIV	I
10	-	I
11	1	I
12	)	I
13	Tat	I
14	protein	I
15	regulates	O
16	transcription	O
17	by	O
18	stimulating	O
19	RNA	B
20	polymerase	I
21	processivity	I
22	.	O

1	Canine	O
2	reproduction	O
3	:	O
4	effects	O
5	of	O
6	a	O
7	single	O
8	injection	O
9	of	O
10	medroxyprogesterone	O
11	acetate	O
12	on	O
13	the	O
14	reproductive	O
15	organs	O
16	of	O
17	the	O
18	bitch	O
19	.	O

1	Recombinant	B
2	HRMT1L2	I
3	protein	I
4	encoded	O
5	by	O
6	the	O
7	most	O
8	common	O
9	5	O
10	'-	O
11	variant	O
12	exhibited	O
13	methyltransferase	O
14	activity	O
15	in	O
16	vitro	O
17	.	O

1	In	O
2	contrast	O
3	to	O
4	previously	O
5	characterized	O
6	proteophosphoglycans	O
7	,	O
8	the	O
9	ppg1	O
10	gene	O
11	product	O
12	is	O
13	predominantly	O
14	membrane	O
15	-	O
16	associated	O
17	and	O
18	it	O
19	is	O
20	expressed	O
21	on	O
22	the	O
23	promastigote	O
24	cell	O
25	surface	O
26	.	O

1	The	O
2	mean	O
3	marginal	O
4	discrepancy	O
5	of	O
6	provisional	O
7	restorations	O
8	was	O
9	compared	O
10	for	O
11	restorations	O
12	fabricated	O
13	from	O
14	stone	O
15	,	O
16	low	O
17	-	O
18	viscosity	O
19	poly	O
20	(	O
21	vinyl	O
22	siloxane	O
23	),	O
24	and	O
25	medium	O
26	-	O
27	viscosity	O
28	poly	O
29	(	O
30	vinyl	O
31	siloxane	O
32	).	O

1	Growth	O
2	factor	O
3	stimulation	O
4	of	O
5	cells	O
6	causes	O
7	the	O
8	phosphorylation	O
9	of	O
10	the	O
11	c	B
12	-	I
13	Myc	I
14	transcriptional	O
15	activation	O
16	domain	O
17	at	O
18	Ser62	O
19	within	O
20	a	O
21	proline	O
22	-	O
23	rich	O
24	region	O
25	that	O
26	is	O
27	highly	O
28	conserved	O
29	among	O
30	members	O
31	of	O
32	the	O
33	Myc	B
34	family	I
35	(	O
36	Alvarez	O
37	,	O
38	E	O
39	.,	O
40	Northwood	O
41	,	O
42	I	O
43	.	O
44	C	O
45	.,	O
46	Gonzalez	O
47	,	O
48	F	O
49	.	O

1	However	O
2	,	O
3	unlike	O
4	the	O
5	SIN3	O
6	gene	O
7	of	O
8	Saccharomyces	O
9	cerevisiae	O
10	,	O
11	pst1	O
12	(+)	O
13	is	O
14	essential	O
15	for	O
16	cell	O
17	viability	O
18	.	O

1	Toxicity	O
2	was	O
3	very	O
4	mild	O
5	with	O
6	both	O
7	regimens	O
8	,	O
9	although	O
10	sedation	O
11	was	O
12	significantly	O
13	higher	O
14	in	O
15	arm	O
16	B	O
17	(	O
18	p	O
19	less	O
20	than	O
21	0	O
22	.	O
23	001	O
24	).	O

1	Mutation	O
2	of	O
3	the	O
4	Sp1	B
5	element	I
6	,	O
7	which	O
8	abolishes	O
9	Sp1	B
10	binding	I
11	,	O
12	results	O
13	in	O
14	a	O
15	6	O
16	-	O
17	10	O
18	-	O
19	fold	O
20	reduction	O
21	in	O
22	reporter	O
23	activity	O
24	.	O

1	Although	O
2	olfactory	O
3	associative	O
4	conditioning	O
5	in	O
6	newborn	O
7	rats	O
8	produces	O
9	marked	O
10	structural	O
11	and	O
12	functional	O
13	changes	O
14	in	O
15	the	O
16	olfactory	O
17	bulb	O
18	,	O
19	recent	O
20	evidence	O
21	suggests	O
22	that	O
23	extrabulbar	O
24	circuits	O
25	must	O
26	be	O
27	involved	O
28	in	O
29	storing	O
30	these	O
31	early	O
32	memories	O
33	.	O

1	A	O
2	method	O
3	for	O
4	determining	O
5	optimal	O
6	development	O
7	conditions	O
8	by	O
9	summary	O
10	oxygen	O
11	consumption	O

1	The	O
2	effect	O
3	of	O
4	acute	O
5	,	O
6	mid	O
7	-	O
8	cervical	O
9	spinal	O
10	cord	O
11	lesions	O
12	on	O
13	neuronal	O
14	and	O
15	reflex	O
16	activity	O
17	evoked	O
18	by	O
19	the	O
20	noxious	O
21	visceral	O
22	stimulus	O
23	,	O
24	colorectal	O
25	distension	O
26	(	O
27	CRD	O
28	;	O
29	80	O
30	mmHg	O
31	,	O
32	20	O
33	s	O
34	),	O
35	was	O
36	determined	O
37	in	O
38	halothane	O
39	-	O
40	anesthetized	O
41	rats	O
42	.	O

1	This	O
2	observation	O
3	calls	O
4	for	O
5	careful	O
6	monitoring	O
7	of	O
8	calcium	O
9	and	O
10	alkaline	B
11	phosphatase	I
12	values	O
13	and	O
14	possible	O
15	adjustments	O
16	of	O
17	vitamin	O
18	D	O
19	intake	O
20	when	O
21	fortifiers	O
22	are	O
23	used	O
24	for	O
25	extended	O
26	periods	O
27	.	O

1	We	O
2	have	O
3	mutated	O
4	to	O
5	cysteine	O
6	,	O
7	one	O
8	at	O
9	a	O
10	time	O
11	,	O
12	21	O
13	consecutive	O
14	residues	O
15	in	O
16	the	O
17	fourth	O
18	TMS	O
19	(	O
20	TM4	O
21	).	O

1	There	O
2	was	O
3	also	O
4	a	O
5	highly	O
6	significant	O
7	correlation	O
8	between	O
9	total	O
10	selenium	O
11	intake	O
12	and	O
13	liver	O
14	selenium	O
15	concentration	O
16	(	O
17	r	O
18	=	O
19	0	O
20	.	O
21	99	O
22	,	O
23	p	O
24	<	O
25	0	O
26	.	O
27	01	O
28	)	O
29	after	O
30	1	O
31	mo	O
32	of	O
33	treatment	O
34	,	O
35	but	O
36	this	O
37	time	O
38	liver	O
39	selenium	O
40	did	O
41	not	O
42	change	O
43	with	O
44	time	O
45	,	O
46	and	O
47	the	O
48	correlation	O
49	remained	O
50	highly	O
51	significant	O
52	throughout	O
53	the	O
54	investigation	O
55	.	O

1	UAS1	O
2	is	O
3	the	O
4	binding	O
5	site	O
6	for	O
7	the	O
8	transcriptional	O
9	regulator	O
10	Adr1p	O
11	.	O

1	Experimental	O
2	pancreatitis	O
3	in	O
4	pigs	O
5	.	O

1	Echo	O
2	modulation	O
3	in	O
4	Pr3	O
5	+:	O
6	YAlO3	O
7	.	O

1	MK	O
2	-	O
3	801	O
4	administration	O
5	resulted	O
6	in	O
7	a	O
8	biphasic	O
9	response	O
10	in	O
11	seizure	O
12	latency	O
13	.	O

1	Both	O
2	mu	O
3	and	O
4	gamma	B
5	2b	I
6	heavy	I
7	chain	I
8	genes	I
9	cause	O
10	this	O
11	feedback	O
12	inhibition	O
13	of	O
14	heavy	O
15	chain	O
16	gene	O
17	rearrangement	O
18	.	O

1	Effects	O
2	of	O
3	negative	O
4	pleural	O
5	pressure	O
6	on	O
7	left	O
8	ventricular	O
9	hemodynamics	O
10	.	O

1	This	O
2	is	O
3	particularly	O
4	intriguing	O
5	because	O
6	SKUT	O
7	-	O
8	1B	O
9	-	O
10	20	O
11	cells	O
12	lack	O
13	the	O
14	transcription	O
15	factor	O
16	Pit	B
17	-	I
18	1	I
19	.	O

1	Tonsillectomy	O
2	is	O
3	an	O
4	effective	O
5	means	O
6	of	O
7	prophylaxis	O
8	for	O
9	upper	O
10	respiratory	O
11	infection	O
12	in	O
13	habitual	O
14	angina	O
15	patients	O
16	.	O

1	Fibrin	O
2	cloaking	O
3	along	O
4	the	O
5	catheter	O
6	was	O
7	found	O
8	in	O
9	20	O
10	patients	O
11	studied	O
12	by	O
13	pull	O
14	-	O
15	out	O
16	arteriography	O
17	and	O
18	was	O
19	unassociated	O
20	with	O
21	clinical	O
22	symptoms	O
23	.	O

1	In	O
2	an	O
3	earlier	O
4	study	O
5	(	O
6	Kimura	O
7	,	O
8	Y	O
9	.,	O
10	Kurzydlowski	O
11	,	O
12	K	O
13	.,	O
14	Tada	O
15	,	O
16	M	O
17	.,	O
18	and	O
19	MacLennan	O
20	,	O
21	D	O
22	.	O

1	We	O
2	cloned	O
3	and	O
4	sequenced	O
5	the	O
6	cDNAs	O
7	against	O
8	genomic	O
9	RNA	O
10	and	O
11	mRNA	O
12	for	O
13	phosphoprotein	O
14	(	O
15	P	O
16	)	O
17	of	O
18	human	O
19	parainfluenza	O
20	type	O
21	2	O
22	virus	O
23	(	O
24	PIV	O
25	-	O
26	2	O
27	).	O
28	cDNA	O
29	clone	O
30	from	O
31	genomic	O
32	RNA	O
33	was	O
34	1439	O
35	nucleotides	O
36	in	O
37	length	O
38	excluding	O
39	poly	O
40	(	O
41	A	O
42	)	O
43	and	O
44	was	O
45	found	O
46	to	O
47	have	O
48	two	O
49	small	O
50	open	O
51	reading	O
52	frames	O
53	encoding	O
54	proteins	O
55	of	O
56	233	O
57	and	O
58	249	O
59	amino	O
60	acids	O
61	.	O

1	These	O
2	data	O
3	confirm	O
4	the	O
5	existence	O
6	of	O
7	hyperlipemic	O
8	abdominal	O
9	crisis	O
10	as	O
11	a	O
12	distinct	O
13	entity	O
14	and	O
15	testify	O
16	to	O
17	the	O
18	importance	O
19	of	O
20	recognizing	O
21	this	O
22	syndrome	O
23	in	O
24	order	O
25	to	O
26	avoid	O
27	the	O
28	occurrence	O
29	of	O
30	acute	O
31	pancreatitis	O
32	and	O
33	the	O
34	performance	O
35	of	O
36	unnecessary	O
37	and	O
38	potentially	O
39	harmful	O
40	surgery	O
41	.	O

1	Identical	O
2	results	O
3	were	O
4	obtained	O
5	when	O
6	transfections	O
7	and	O
8	mobility	O
9	shift	O
10	assays	O
11	were	O
12	performed	O
13	in	O
14	primary	O
15	rat	O
16	hepatocytes	O
17	in	O
18	which	O
19	the	O
20	endogenous	O
21	ALS	O
22	gene	O
23	is	O
24	expressed	O
25	.	O

1	Comparison	O
2	of	O
3	the	O
4	amino	O
5	acid	O
6	sequences	O
7	of	O
8	the	O
9	RPO1	O
10	polypeptides	O
11	of	O
12	IIV6	O
13	,	O
14	LCDV	O
15	,	O
16	and	O
17	MCV	O
18	-	O
19	1	O
20	with	O
21	the	O
22	corresponding	O
23	prokaryotic	O
24	,	O
25	eukaryotic	O
26	,	O
27	and	O
28	viral	O
29	proteins	O
30	revealed	O
31	differences	O
32	in	O
33	amino	O
34	acid	O
35	similarity	O
36	and	O
37	phylogenetic	O
38	relationships	O
39	.	O

1	Using	O
2	an	O
3	opsonophagocytic	O
4	bacterial	O
5	assay	O
6	and	O
7	a	O
8	suckling	O
9	rat	O
10	model	O
11	of	O
12	GBS	O
13	sepsis	O
14	,	O
15	we	O
16	analyzed	O
17	a	O
18	modified	O
19	human	B
20	immunoglobulin	I
21	for	O
22	opsonic	O
23	and	O
24	protective	O
25	antibody	O
26	.	O

1	The	O
2	subjects	O
3	received	O
4	a	O
5	single	O
6	500	O
7	mg	O
8	dose	O
9	of	O
10	acetaminophen	O
11	i	O
12	.	O
13	v	O
14	.	O
15	and	O
16	concentrations	O
17	in	O
18	plasma	O
19	were	O
20	measured	O
21	for	O
22	360	O
23	minutes	O
24	and	O
25	in	O
26	urine	O
27	for	O
28	24	O
29	h	O
30	in	O
31	order	O
32	to	O
33	estimate	O
34	the	O
35	production	O
36	of	O
37	metabolites	O
38	.	O

1	Involvement	O
2	of	O
3	AP1	B
4	and	O
5	PEA3	B
6	binding	I
7	sites	I
8	in	O
9	the	O
10	regulation	O
11	of	O
12	murine	O
13	tissue	O
14	inhibitor	O
15	of	O
16	metalloproteinases	O
17	-	O
18	1	O
19	(	O
20	TIMP	B
21	-	I
22	1	I
23	)	O
24	transcription	O
25	.	O

1	Advances	O
2	in	O
3	the	O
4	management	O
5	of	O
6	gynecologic	O
7	cancer	O
8	--	O
9	radiation	O
10	therapy	O
11	.	O

1	The	O
2	relationships	O
3	among	O
4	four	O
5	descriptors	O
6	of	O
7	lactate	O
8	increase	O
9	:	O
10	lactate	O
11	threshold	O
12	(	O
13	LT	O
14	)	O
15	(	O
16	the	O
17	VO2	O
18	at	O
19	which	O
20	blood	O
21	lactate	O
22	concentration	O
23	begins	O
24	to	O
25	increase	O
26	above	O
27	the	O
28	resting	O
29	level	O
30	during	O
31	an	O
32	incremental	O
33	exercise	O
34	test	O
35	),	O
36	LT1	O
37	(	O
38	the	O
39	VO2	O
40	at	O
41	which	O
42	blood	O
43	lactate	O
44	increases	O
45	1	O
46	mM	O
47	above	O
48	the	O
49	resting	O
50	level	O
51	),	O
52	LT2	O
53	(	O
54	the	O
55	VO2	O
56	at	O
57	which	O
58	blood	O
59	lactate	O
60	concentration	O
61	reaches	O
62	a	O
63	fixed	O
64	value	O
65	of	O
66	2	O
67	mM	O
68	),	O
69	onset	O
70	of	O
71	blood	O
72	lactate	O
73	accumulation	O
74	(	O
75	OBLA	O
76	;	O
77	the	O
78	VO2	O
79	at	O
80	which	O
81	blood	O
82	lactate	O
83	reaches	O
84	a	O
85	concentration	O
86	of	O
87	4	O
88	mM	O
89	),	O
90	were	O
91	compared	O
92	with	O
93	aerobic	O
94	capacity	O
95	(	O
96	VO2max	O
97	)	O
98	and	O
99	12	O
100	min	O
101	running	O
102	performance	O
103	in	O
104	19	O
105	untrained	O
106	female	O
107	students	O
108	.	O

1	These	O
2	IgG	B
3	antibodies	I
4	in	O
5	the	O
6	babies	O
7	diminished	O
8	rapidly	O
9	after	O
10	delivery	O
11	,	O
12	and	O
13	were	O
14	detectable	O
15	only	O
16	in	O
17	3	O
18	cases	O
19	at	O
20	2	O
21	,	O
22	3	O
23	,	O
24	and	O
25	5	O
26	months	O
27	of	O
28	ages	O
29	out	O
30	of	O
31	38	O
32	babies	O
33	up	O
34	to	O
35	21	O
36	months	O
37	.	O

1	Nonsynonymous	O
2	substitution	O
3	in	O
4	abalone	O
5	sperm	O
6	fertilization	O
7	genes	O
8	exceeds	O
9	substitution	O
10	in	O
11	introns	O
12	and	O
13	mitochondrial	O
14	DNA	O
15	.	O

1	From	O
2	the	O
3	15	O
4	-	O
5	kb	O
6	clone	O
7	a	O
8	4	O
9	-	O
10	kb	O
11	EcoRI	O
12	fragment	O
13	containing	O
14	the	O
15	first	O
16	two	O
17	exons	O
18	and	O
19	2	O
20	.	O
21	6	O
22	kb	O
23	of	O
24	the	O
25	5	O
26	'	O
27	flanking	O
28	region	O
29	of	O
30	the	O
31	opn	O
32	gene	O
33	was	O
34	sequenced	O
35	,	O
36	and	O
37	the	O
38	transcriptional	O
39	start	O
40	site	O
41	determined	O
42	by	O
43	primer	O
44	extension	O
45	analysis	O
46	and	O
47	S1	B
48	nuclease	I
49	mapping	O
50	.	O

1	Maximum	O
2	number	O
3	of	O
4	strains	O
5	(	O
6	39	O
7	.	O
8	1	O
9	%)	O
10	were	O
11	resistant	O
12	in	O
13	S	O
14	.	O
15	bareilly	O
16	serotype	O
17	,	O
18	followed	O
19	by	O
20	S	O
21	.	O
22	typhimurium	O
23	(	O
24	21	O
25	.	O
26	7	O
27	%)	O
28	and	O
29	least	O
30	in	O
31	S	O
32	.	O
33	typhi	O
34	(	O
35	17	O
36	.	O
37	4	O
38	%).	O

1	S	O
2	.,	O
3	and	O
4	Walter	O
5	,	O
6	P	O
7	.	O

1	Patch	O
2	test	O
3	results	O
4	obtained	O
5	with	O
6	corticosteroid	O
7	allergic	O
8	patients	O
9	tested	O
10	with	O
11	a	O
12	large	O
13	corticosteroid	O
14	series	O
15	validated	O
16	the	O
17	earlier	O
18	classification	O
19	of	O
20	corticosteroid	O
21	molecules	O
22	in	O
23	four	O
24	groups	O
25	of	O
26	cross	O
27	-	O
28	reacting	O
29	molecules	O
30	:	O
31	i	O
32	.	O
33	e	O
34	.,	O
35	group	O
36	A	O
37	(	O
38	hydrocortisone	O
39	type	O
40	),	O
41	group	O
42	B	O
43	(	O
44	acetonides	O
45	),	O
46	group	O
47	C	O
48	(	O
49	betamethasone	O
50	type	O
51	-	O
52	non	O
53	esterified	O
54	)	O
55	and	O
56	group	O
57	D	O
58	(	O
59	esters	O
60	).	O

1	We	O
2	studied	O
3	the	O
4	GR	B
5	in	O
6	DMS	O
7	-	O
8	79	O
9	cells	O
10	derived	O
11	from	O
12	a	O
13	human	O
14	ACTH	B
15	-	I
16	secreting	O
17	small	O
18	cell	O
19	lung	O
20	cancer	O
21	.	O

1	PURPOSE	O
2	:	O
3	To	O
4	introduce	O
5	an	O
6	image	O
7	analysis	O
8	of	O
9	the	O
10	cornea	O
11	in	O
12	photorefractive	O
13	keratectomy	O
14	(	O
15	PRK	O
16	)	O
17	for	O
18	preoperative	O
19	and	O
20	early	O
21	postoperative	O
22	determination	O
23	of	O
24	changes	O
25	in	O
26	the	O
27	condition	O
28	of	O
29	the	O
30	cornea	O
31	.	O

1	All	O
2	Cu	O
3	values	O
4	obtained	O
5	from	O
6	the	O
7	organs	O
8	investigated	O
9	had	O
10	reached	O
11	a	O
12	saturation	O
13	level	O
14	at	O
15	8	O
16	mug	O
17	Cu	O
18	/	O
19	g	O
20	diet	O
21	with	O
22	the	O
23	exception	O
24	of	O
25	the	O
26	values	O
27	for	O
28	body	O
29	Cu	O
30	found	O
31	in	O
32	the	O
33	dams	O
34	that	O
35	were	O
36	killed	O
37	on	O
38	the	O
39	day	O
40	of	O
41	delivery	O
42	.	O

1	Comparison	O
2	of	O
3	Tc	O
4	-	O
5	99m	O
6	sestamibi	O
7	perfusion	O
8	imaging	O
9	and	O
10	echocardiography	O
11	using	O
12	an	O
13	arbutamine	O
14	infusion	O
15	for	O
16	the	O
17	detection	O
18	of	O
19	coronary	O
20	artery	O
21	disease	O
22	.	O

1	Diagnosis	O
2	of	O
3	primary	O
4	sclerosing	O
5	cholangitis	O
6	in	O
7	a	O
8	blood	O
9	donor	O
10	with	O
11	elevated	O
12	serum	B
13	alanine	I
14	aminotransferase	I
15	.	O

1	In	O
2	this	O
3	paper	O
4	,	O
5	we	O
6	have	O
7	analyzed	O
8	the	O
9	structure	O
10	of	O
11	human	O
12	gene	O
13	for	O
14	Gx	O
15	alpha	O
16	,	O
17	which	O
18	spans	O
19	more	O
20	than	O
21	60	O
22	kilobases	O
23	.	O

1	Tl	O
2	-	O
3	201	O
4	uptake	O
5	ratio	O
6	of	O
7	the	O
8	right	O
9	ventricle	O
10	,	O
11	which	O
12	represents	O
13	the	O
14	ratio	O
15	of	O
16	total	O
17	counts	O
18	of	O
19	the	O
20	right	O
21	ventricle	O
22	to	O
23	counts	O
24	of	O
25	the	O
26	administered	O
27	dose	O
28	of	O
29	Tl	O
30	-	O
31	201	O
32	,	O
33	was	O
34	higher	O
35	in	O
36	COPD	O
37	,	O
38	especially	O
39	in	O
40	pulmonary	O
41	emphysema	O
42	and	O
43	B	O
44	type	O
45	COPD	O
46	by	O
47	Burrows	O
48	classification	O
49	than	O
50	in	O
51	controls	O
52	.	O

1	However	O
2	,	O
3	there	O
4	were	O
5	some	O
6	properties	O
7	of	O
8	Rak	O
9	that	O
10	are	O
11	distinct	O
12	from	O
13	Src	B
14	-	I
15	like	I
16	kinases	I
17	:	O
18	(	O
19	a	O
20	)	O
21	expression	O
22	of	O
23	Rak	O
24	was	O
25	predominantly	O
26	in	O
27	epithelial	O
28	-	O
29	derived	O
30	cell	O
31	lines	O
32	and	O
33	tissues	O
34	,	O
35	especially	O
36	normal	O
37	liver	O
38	and	O
39	kidney	O
40	,	O
41	and	O
42	cell	O
43	lines	O
44	of	O
45	breast	O
46	and	O
47	colon	O
48	origin	O
49	;	O
50	(	O
51	b	O
52	)	O
53	Rak	O
54	does	O
55	not	O
56	harbor	O
57	the	O
58	NH2	O
59	-	O
60	terminal	O
61	glycine	O
62	essential	O
63	for	O
64	myristylation	O
65	and	O
66	membrane	O
67	localization	O
68	;	O
69	and	O
70	(	O
71	c	O
72	)	O
73	Rak	O
74	possesses	O
75	a	O
76	putative	O
77	bipartite	O
78	nuclear	O
79	localization	O
80	signal	O
81	in	O
82	the	O
83	SH2	B
84	domain	I
85	,	O
86	and	O
87	subcellular	O
88	fractionation	O
89	studies	O
90	revealed	O
91	that	O
92	p54rak	O
93	resides	O
94	predominantly	O
95	in	O
96	the	O
97	nucleus	O
98	.	O

1	The	O
2	efficacy	O
3	and	O
4	safety	O
5	of	O
6	a	O
7	novel	O
8	percutaneous	O
9	anaesthetic	O
10	preparation	O
11	based	O
12	on	O
13	amethocaine	O
14	has	O
15	been	O
16	investigated	O
17	in	O
18	the	O
19	paediatric	O
20	clinical	O
21	environment	O
22	.	O

1	Children	O
2	'	O
3	s	O
4	temperament	O
5	and	O
6	maternal	O
7	socialization	O
8	at	O
9	Time	O
10	1	O
11	(	O
12	n	O
13	=	O
14	103	O
15	,	O
16	aged	O
17	2	O
18	-	O
19	3	O
20	years	O
21	)	O
22	were	O
23	considered	O
24	predictors	O
25	of	O
26	future	O
27	conscience	O
28	,	O
29	assessed	O
30	using	O
31	new	O
32	observational	O
33	and	O
34	narrative	O
35	measures	O
36	.	O

1	XYL1	O
2	was	O
3	isolated	O
4	as	O
5	a	O
6	highly	O
7	expressed	O
8	fusion	O
9	clone	O
10	from	O
11	a	O
12	'	O
13	lacZ	B
14	translational	O
15	fusion	O
16	library	O
17	.	O

1	We	O
2	sought	O
3	to	O
4	determine	O
5	whether	O
6	such	O
7	differences	O
8	in	O
9	polyadenylation	O
10	affect	O
11	the	O
12	steady	O
13	-	O
14	state	O
15	levels	O
16	of	O
17	DHFR	O
18	and	O
19	mRNAs	O
20	expressed	O
21	from	O
22	either	O
23	allele	O
24	and	O
25	,	O
26	in	O
27	a	O
28	more	O
29	general	O
30	sense	O
31	,	O
32	to	O
33	ask	O
34	whether	O
35	differences	O
36	in	O
37	3	O
38	'	O
39	end	O
40	RNA	O
41	processing	O
42	in	O
43	a	O
44	gene	O
45	containing	O
46	multiple	O
47	poly	O
48	(	O
49	A	O
50	)	O
51	sites	O
52	affects	O
53	the	O
54	final	O
55	level	O
56	of	O
57	gene	O
58	expression	O
59	.	O

1	A	O
2	rise	O
3	of	O
4	hemoglobin	B
5	concentration	O
6	accompanied	O
7	by	O
8	an	O
9	increase	O
10	of	O
11	the	O
12	total	O
13	iron	O
14	in	O
15	the	O
16	blood	O
17	serum	O
18	of	O
19	white	O
20	mice	O
21	was	O
22	found	O
23	under	O
24	oxygen	O
25	pressure	O
26	of	O
27	4	O
28	atm	O
29	for	O
30	an	O
31	hour	O
32	(	O
33	preconvulsive	O
34	state	O
35	)	O
36	and	O
37	6	O
38	atm	O
39	(	O
40	convulsive	O
41	state	O
42	).	O

1	A	O
2	Y	O
3	.	O
4	lipolytica	O
5	Kar2p	O
6	mutant	O
7	was	O
8	isolated	O
9	that	O
10	restored	O
11	interaction	O
12	with	O
13	an	O
14	Sls1p	O
15	mutant	O
16	,	O
17	suggesting	O
18	that	O
19	the	O
20	interaction	O
21	with	O
22	Sls1p	O
23	could	O
24	be	O
25	nucleotide	O
26	and	O
27	/	O
28	or	O
29	conformation	O
30	dependent	O
31	.	O

1	Human	O
2	Duo	O
3	contains	O
4	a	O
5	guanine	B
6	nucleotide	I
7	exchange	I
8	factor	I
9	(	I
10	GEF	I
11	)	O
12	domain	O
13	that	O
14	is	O
15	likely	O
16	to	O
17	be	O
18	rac1	O
19	-	O
20	specific	O
21	,	O
22	a	O
23	pleckstrin	B
24	homology	O
25	(	O
26	PH	B
27	)	I
28	domain	I
29	and	I
30	spectrin	I
31	-	I
32	like	I
33	repeat	O
34	units	O
35	.	O

1	Mean	O
2	ROI	O
3	-	O
4	A	O
5	/	O
6	B	O
7	ratio	O
8	was	O
9	49	O
10	.	O
11	6	O
12	+/-	O
13	1	O
14	.	O
15	7	O
16	%	O
17	in	O
18	the	O
19	diabetic	O
20	group	O
21	,	O
22	significantly	O
23	lower	O
24	than	O
25	the	O
26	57	O
27	.	O
28	9	O
29	+/-	O
30	1	O
31	.	O
32	6	O
33	%	O
34	at	O
35	the	O
36	nondiabetic	O
37	group	O
38	(	O
39	p	O
40	less	O
41	than	O
42	0	O
43	.	O
44	005	O
45	).	O

1	The	O
2	vaccine	O
3	used	O
4	was	O
5	known	O
6	to	O
7	be	O
8	immunogenic	O
9	for	O
10	older	O
11	children	O
12	and	O
13	adults	O
14	.	O

1	Raf	B
2	is	O
3	a	O
4	key	O
5	serine	B
6	-	I
7	threonine	I
8	protein	I
9	kinase	I
10	which	O
11	participates	O
12	in	O
13	the	O
14	transmission	O
15	of	O
16	growth	O
17	,	O
18	anti	O
19	-	O
20	apoptotic	O
21	and	O
22	differentiation	O
23	messages	O
24	.	O

1	In	O
2	marked	O
3	contrast	O
4	to	O
5	AgfA	O
6	,	O
7	none	O
8	of	O
9	the	O
10	chimeric	O
11	SefA	O
12	proteins	O
13	were	O
14	expressed	O
15	or	O
16	assembled	O
17	into	O
18	fimbriae	O
19	.	O

1	Elimination	O
2	of	O
3	gamma	O
4	-	O
5	irradiation	O
6	induced	O
7	oxidation	O
8	in	O
9	aqueous	O
10	drug	O
11	preparations	O

1	Propranolol	O
2	also	O
3	effectively	O
4	controlled	O
5	her	O
6	familial	O
7	tremor	O
8	.	O

1	The	O
2	used	O
3	expression	O
4	system	O
5	could	O
6	allow	O
7	to	O
8	produce	O
9	mutated	O
10	forms	O
11	of	O
12	SsEF	O
13	-	O
14	2	O
15	obtained	O
16	by	O
17	mutagenesis	O
18	of	O
19	the	O
20	corresponding	O
21	gene	O
22	.	O

1	It	O
2	was	O
3	concluded	O
4	,	O
5	that	O
6	on	O
7	a	O
8	given	O
9	section	O
10	,	O
11	75	O
12	,	O
13	7	O
14	per	O
15	cent	O
16	of	O
17	the	O
18	trabeculae	O
19	were	O
20	in	O
21	contact	O
22	with	O
23	vascular	O
24	cavities	O
25	.	O

1	PCR	O
2	analysis	O
3	indicates	O
4	that	O
5	this	O
6	new	O
7	beta	B
8	-	I
9	adducin	I
10	isoform	I
11	is	O
12	expressed	O
13	in	O
14	fetal	O
15	brain	O
16	and	O
17	liver	O
18	,	O
19	bone	O
20	marrow	O
21	,	O
22	and	O
23	NT	O
24	-	O
25	2	O
26	(	O
27	neuroepithelial	O
28	)	O
29	cells	O
30	,	O
31	but	O
32	is	O
33	not	O
34	detected	O
35	in	O
36	several	O
37	other	O
38	tissues	O
39	.	O

1	In	O
2	addition	O
3	to	O
4	the	O
5	nine	O
6	and	O
7	51	O
8	terminal	O
9	amino	O
10	acid	O
11	forms	O
12	already	O
13	known	O
14	,	O
15	we	O
16	identified	O
17	a	O
18	third	O
19	with	O
20	43	O
21	terminal	O
22	amino	O
23	acids	O
24	predicted	O
25	to	O
26	encode	O
27	a	O
28	novel	O
29	RET	B
30	protein	I
31	isoform	I
32	.	O

1	The	O
2	amino	O
3	acid	O
4	sequence	O
5	of	O
6	the	O
7	S	O
8	.	O
9	aureus	O
10	peptide	O
11	carrying	O
12	the	O
13	phosphoryl	O
14	group	O
15	was	O
16	found	O
17	to	O
18	be	O
19	Gln	B
20	-	I
21	Val	I
22	-	I
23	Val	I
24	-	I
25	Ser	I
26	-	I
27	Thr	I
28	-	I
29	Phe	I
30	-	I
31	Met	I
32	-	I
33	Gly	I
34	-	I
35	Asn	I
36	-	I
37	Gly	I
38	-	I
39	Leu	I
40	-	I
41	Ala	I
42	-	I
43	Ile	I
44	-	I
45	Pro	I
46	-	I
47	His	I
48	-	I
49	Gly	I
50	-	I
51	Thr	I
52	-	I
53	Asp	I
54	-	I
55	Asp	I
56	.	O

1	In	O
2	turn	O
3	,	O
4	assembly	O
5	of	O
6	this	O
7	complex	O
8	mediates	O
9	the	O
10	enzymatic	O
11	activation	O
12	of	O
13	the	O
14	p21	B
15	-	I
16	activated	I
17	protein	I
18	kinase	I
19	1	I
20	and	O
21	facilitates	O
22	actin	B
23	polymerization	O
24	.	O

1	Spontaneous	O
2	degradation	O
3	of	O
4	atracurium	O
5	in	O
6	plasma	O
7	is	O
8	the	O
9	major	O
10	route	O
11	of	O
12	elimination	O
13	in	O
14	man	O
15	and	O
16	contributes	O
17	to	O
18	a	O
19	short	O
20	elimination	O
21	half	O
22	-	O
23	life	O
24	(	O
25	approximatively	O
26	20	O
27	min	O
28	).	O

1	Binding	O
2	to	O
3	sulphatides	O
4	and	O
5	the	O
6	alpha	B
7	-	I
8	dystroglycan	I
9	receptor	I
10	was	O
11	much	O
12	stronger	O
13	and	O
14	required	O
15	at	O
16	least	O
17	two	O
18	LG	O
19	modules	O
20	.	O

1	After	O
2	surgery	O
3	,	O
4	patients	O
5	self	O
6	administered	O
7	one	O
8	of	O
9	three	O
10	possible	O
11	postsurgical	O
12	medications	O
13	,	O
14	which	O
15	included	O
16	placebo	O
17	,	O
18	codeine	O
19	60	O
20	mg	O
21	,	O
22	and	O
23	ibuprofen	O
24	400	O
25	mg	O
26	,	O
27	when	O
28	their	O
29	pain	O
30	reached	O
31	a	O
32	moderate	O
33	or	O
34	severe	O
35	intensity	O
36	.	O

1	Genomic	O
2	DNA	O
3	sequencing	O
4	in	O
5	the	O
6	vicinity	O
7	of	O
8	methylmalonyl	B
9	-	I
10	CoA	I
11	mutase	I
12	gene	I
13	(	O
14	mutAB	O
15	)	O
16	from	O
17	a	O
18	rifamycin	O
19	SV	O
20	-	O
21	producing	O
22	Amycolatopsis	O
23	mediterranei	O
24	U32	O
25	allowed	O
26	us	O
27	to	O
28	clone	O
29	,	O
30	sequence	O
31	,	O
32	and	O
33	identify	O
34	a	O
35	gene	O
36	encoding	O
37	a	O
38	novel	O
39	serine	B
40	/	I
41	threonine	I
42	protein	I
43	kinase	I
44	(	O
45	amk	O
46	).	O

1	The	O
2	MAP	B
3	kinase	I
4	cascade	O
5	is	O
6	highly	O
7	conserved	O
8	in	O
9	all	O
10	eukaryotes	O
11	and	O
12	involved	O
13	in	O
14	numerous	O
15	cellular	O
16	responses	O
17	.	O

1	Bacteriostatic	O
2	and	O
3	bacteriacidal	O
4	activity	O
5	of	O
6	hydroxy	O
7	-	O
8	9	O
9	ellipticine	O
10	in	O
11	vitro	O

1	EsaR	O
2	can	O
3	repress	O
4	its	O
5	own	O
6	expression	O
7	but	O
8	seems	O
9	not	O
10	to	O
11	regulate	O
12	the	O
13	expression	O
14	of	O
15	esaI	O
16	.	O

1	In	O
2	both	O
3	experiments	O
4	,	O
5	average	O
6	daily	O
7	gain	O
8	and	O
9	gain	O
10	-	O
11	to	O
12	-	O
13	feed	O
14	ratio	O
15	were	O
16	similar	O
17	for	O
18	TR	O
19	and	O
20	CR	O
21	.	O

1	Changes	O
2	of	O
3	thirtynine	O
4	serum	O
5	protein	O
6	components	O
7	following	O
8	surgical	O
9	stress	O
10	.	O

1	Among	O
2	blood	O
3	donors	O
4	in	O
5	the	O
6	Republic	O
7	of	O
8	Serbia	O
9	,	O
10	regardless	O
11	the	O
12	number	O
13	of	O
14	blood	O
15	donations	O
16	,	O
17	the	O
18	percentage	O
19	of	O
20	female	O
21	donors	O
22	is	O
23	significantly	O
24	lower	O
25	compared	O
26	to	O
27	the	O
28	percentage	O
29	of	O
30	male	O
31	blood	O
32	donors	O
33	.	O

1	Importantly	O
2	,	O
3	in	O
4	HeLa	O
5	and	O
6	293	O
7	cells	O
8	,	O
9	endogenous	O
10	and	O
11	transfected	O
12	I	B
13	kappaB	I
14	alpha	I
15	coimmunoprecipitated	I
16	with	O
17	Myc	B
18	-	I
19	tagged	O
20	or	O
21	endogenous	O
22	Dlc	O
23	-	O
24	1	O
25	.	O

1	The	O
2	presence	O
3	of	O
4	unidentified	O
5	macroscopic	O
6	or	O
7	microscopic	O
8	clusters	O
9	of	O
10	neoplastic	O
11	cells	O
12	,	O
13	lying	O
14	around	O
15	,	O
16	more	O
17	or	O
18	less	O
19	close	O
20	to	O
21	,	O
22	the	O
23	line	O
24	of	O
25	insertion	O
26	of	O
27	lesion	O
28	,	O
29	could	O
30	render	O
31	any	O
32	attempt	O
33	to	O
34	gain	O
35	a	O
36	"	O
37	radical	O
38	"	O
39	excision	O
40	useless	O
41	.	O

1	Furthermore	O
2	,	O
3	phosphatidylinositol	O
4	(	O
5	3	O
6	,	O
7	4	O
8	,	O
9	5	O
10	)	O
11	trisphosphate	O
12	specifically	O
13	stimulates	O
14	the	O
15	activity	O
16	of	O
17	ILK	O
18	in	O
19	vitro	O
20	,	O
21	and	O
22	in	O
23	addition	O
24	,	O
25	membrane	O
26	targetted	O
27	constitutively	O
28	active	O
29	Pi	O
30	(	O
31	3	O
32	)	O
33	K	O
34	activates	O
35	ILK	O
36	in	O
37	vivo	O
38	.	O

1	Our	O
2	results	O
3	favor	O
4	the	O
5	possibility	O
6	that	O
7	the	O
8	Drosophila	O
9	EGF	B
10	receptor	I
11	DER	I
12	/	O
13	Egfr	O
14	expressed	O
15	by	O
16	the	O
17	EMA	O
18	cells	O
19	functions	O
20	as	O
21	a	O
22	receptor	O
23	for	O
24	Vein	O
25	.	O

1	A	O
2	raised	O
3	amplitude	O
4	of	O
5	the	O
6	aggregation	O
7	of	O
8	plates	O
9	and	O
10	a	O
11	decrease	O
12	in	O
13	the	O
14	threshold	O
15	of	O
16	their	O
17	sensitivity	O
18	to	O
19	ADP	O
20	were	O
21	established	O
22	in	O
23	the	O
24	persons	O
25	with	O
26	types	O
27	IIa	O
28	and	O
29	IIb	O
30	HLP	O
31	and	O
32	in	O
33	CHD	O
34	without	O
35	HLP	O
36	.	O

1	After	O
2	determining	O
3	isoflurane	O
4	MAC	O
5	in	O
6	triplicate	O
7	,	O
8	birds	O
9	were	O
10	given	O
11	a	O
12	mu	O
13	-	O
14	opioid	O
15	agonist	O
16	(	O
17	morphine	O
18	,	O
19	n	O
20	=	O
21	9	O
22	)	O
23	or	O
24	a	O
25	kappa	B
26	-	I
27	opioid	I
28	agonist	O
29	(	O
30	U50488H	O
31	,	O
32	n	O
33	=	O
34	9	O
35	).	O

1	In	O
2	analyses	O
3	with	O
4	control	O
5	for	O
6	multiple	O
7	variables	O
8	,	O
9	relative	O
10	risk	O
11	for	O
12	microalbuminuria	O
13	(	O
14	urinary	O
15	albumin	B
16	excretion	O
17	,	O
18	20	O
19	-	O
20	199	O
21	microg	O
22	/	O
23	min	O
24	)	O
25	in	O
26	men	O
27	and	O
28	women	O
29	was	O
30	2	O
31	.	O
32	51	O
33	and	O
34	1	O
35	.	O
36	62	O
37	,	O
38	respectively	O
39	,	O
40	with	O
41	18	O
42	mm	O
43	Hg	O
44	higher	O
45	(	O
46	1	O
47	SD	O
48	)	O
49	systolic	O
50	blood	O
51	pressure	O
52	;	O
53	2	O
54	.	O
55	25	O
56	and	O
57	2	O
58	.	O
59	10	O
60	,	O
61	respectively	O
62	,	O
63	with	O
64	1	O
65	.	O
66	0	O
67	-	O
68	mmol	O
69	/	O
70	L	O
71	(	O
72	40	O
73	mg	O
74	/	O
75	dL	O
76	)	O
77	higher	O
78	plasma	O
79	cholesterol	O
80	level	O
81	;	O
82	1	O
83	.	O
84	99	O
85	and	O
86	1	O
87	.	O
88	91	O
89	,	O
90	respectively	O
91	,	O
92	for	O
93	smokers	O
94	vs	O
95	nonsmokers	O
96	;	O
97	and	O
98	1	O
99	.	O
100	83	O
101	and	O
102	1	O
103	.	O
104	33	O
105	,	O
106	respectively	O
107	,	O
108	with	O
109	4	O
110	kg	O
111	/	O
112	m2	O
113	higher	O
114	body	O
115	mass	O
116	index	O
117	.	O

1	Weight	O
2	and	O
3	height	O
4	z	O
5	-	O
6	scores	O
7	were	O
8	significantly	O
9	associated	O
10	with	O
11	BMD	O
12	z	O
13	-	O
14	scores	O
15	.	O

1	Four	O
2	p53	B
3	DNA	I
4	-	I
5	binding	I
6	domain	I
7	peptides	I
8	bind	O
9	natural	O
10	p53	B
11	-	I
12	response	O
13	elements	O
14	and	O
15	bend	O
16	the	O
17	DNA	O
18	.	O

1	O2	O
2	and	O
3	CO2	O
4	in	O
5	the	O
6	tracheostomy	O
7	tube	O
8	were	O
9	continuously	O
10	monitored	O
11	by	O
12	mass	O
13	spectrometry	O
14	using	O
15	a	O
16	special	O
17	sample	O
18	-	O
19	hold	O
20	phase	O
21	-	O
22	locked	O
23	sampling	O
24	technique	O
25	.	O

1	Coronary	O
2	vasoconstriction	O
3	caused	O
4	by	O
5	endothelin	B
6	-	I
7	1	I
8	is	O
9	enhanced	O
10	by	O
11	ischemia	O
12	-	O
13	reperfusion	O
14	and	O
15	by	O
16	norepinephrine	O
17	present	O
18	in	O
19	concentrations	O
20	typically	O
21	observed	O
22	after	O
23	neonatal	O
24	cardiopulmonary	O
25	bypass	O
26	.	O

1	Although	O
2	no	O
3	Rh	O
4	-	O
5	antibodies	O
6	were	O
7	demonstrable	O
8	,	O
9	a	O
10	similar	O
11	mechanism	O
12	can	O
13	be	O
14	postulated	O
15	for	O
16	the	O
17	Rh	O
18	-	O
19	system	O
20	.	O

1	The	O
2	assay	O
3	exhibits	O
4	a	O
5	dynamic	O
6	range	O
7	of	O
8	0	O
9	.	O
10	1	O
11	-	O
12	100	O
13	micrograms	O
14	l	O
15	-	O
16	1	O
17	using	O
18	a	O
19	monoclonal	O
20	antibody	O
21	or	O
22	alternatively	O
23	10	O
24	micrograms	O
25	l	O
26	-	O
27	1	O
28	to	O
29	10	O
30	mg	O
31	l	O
32	-	O
33	1	O
34	using	O
35	commercially	O
36	available	O
37	antiserum	O
38	.	O

1	Reverse	O
2	transcription	O
3	-	O
4	PCR	O
5	was	O
6	then	O
7	used	O
8	to	O
9	clone	O
10	from	O
11	human	O
12	poly	O
13	(	O
14	A	O
15	)+	O
16	RNA	O
17	the	O
18	cDNA	O
19	corresponding	O
20	to	O
21	the	O
22	expressed	O
23	homolog	O
24	of	O
25	psi	O
26	ARF	B
27	4	O
28	,	O
29	referred	O
30	to	O
31	as	O
32	human	O
33	ARF	B
34	4	O
35	.	O

1	In	O
2	nondiabetics	O
3	the	O
4	response	O
5	of	O
6	tcPO2	O
7	but	O
8	not	O
9	of	O
10	LDF	O
11	was	O
12	influenced	O
13	by	O
14	the	O
15	values	O
16	at	O
17	rest	O
18	.	O

1	The	O
2	clinical	O
3	and	O
4	laboratory	O
5	features	O
6	of	O
7	72	O
8	children	O
9	with	O
10	Henoch	O
11	-	O
12	Schonlein	O
13	purpura	O
14	(	O
15	HSP	O
16	)	O
17	were	O
18	examined	O
19	to	O
20	determine	O
21	if	O
22	there	O
23	were	O
24	associations	O
25	between	O
26	the	O
27	laboratory	O
28	indices	O
29	--	O
30	including	O
31	white	O
32	blood	O
33	cell	O
34	(	O
35	WBC	O
36	)	O
37	counts	O
38	,	O
39	serum	B
40	C	I
41	-	I
42	reactive	I
43	protein	I
44	(	I
45	CRP	I
46	)	O
47	levels	O
48	,	O
49	platelet	O
50	(	O
51	PLT	O
52	)	O
53	counts	O
54	--	O
55	and	O
56	the	O
57	clinical	O
58	manifestations	O
59	of	O
60	acute	O
61	HSP	O
62	.	O

1	Characterization	O
2	of	O
3	the	O
4	5	O
5	'-	O
6	flanking	O
7	region	O
8	of	O
9	the	O
10	human	O
11	multidrug	O
12	resistance	O
13	protein	O
14	2	O
15	(	O
16	MRP2	O
17	)	O
18	gene	O
19	and	O
20	its	O
21	regulation	O
22	in	O
23	comparison	O
24	withthe	O
25	multidrug	O
26	resistance	O
27	protein	O
28	3	O
29	(	O
30	MRP3	O
31	)	O
32	gene	O
33	.	O

1	The	O
2	pilE	B
3	gene	I
4	product	I
5	of	O
6	Pseudomonas	O
7	aeruginosa	O
8	,	O
9	required	O
10	for	O
11	pilus	O
12	biogenesis	O
13	,	O
14	shares	O
15	amino	O
16	acid	O
17	sequence	O
18	identity	O
19	with	O
20	the	O
21	N	O
22	-	O
23	termini	O
24	of	O
25	type	O
26	4	O
27	prepilin	O
28	proteins	O
29	.	O

1	We	O
2	have	O
3	cloned	O
4	the	O
5	single	O
6	-	O
7	copy	O
8	gene	O
9	for	O
10	the	O
11	trans	O
12	-	O
13	spliceosomal	O
14	U5	B
15	snRNA	I
16	from	O
17	the	O
18	trypanosomatid	O
19	species	O
20	Leptomonas	O
21	seymouri	O
22	,	O
23	using	O
24	U5	O
25	RNA	O
26	affinity	O
27	selection	O
28	and	O
29	cDNA	O
30	cloning	O
31	.	O

1	METHODS	O
2	:	O
3	In	O
4	the	O
5	current	O
6	study	O
7	the	O
8	authors	O
9	reported	O
10	on	O
11	PPB	O
12	cases	O
13	from	O
14	a	O
15	national	O
16	retrospective	O
17	search	O
18	performed	O
19	in	O
20	18	O
21	Italian	O
22	Associations	O
23	for	O
24	Pediatric	O
25	Hematology	O
26	and	O
27	Oncology	O
28	centers	O
29	.	O

1	The	O
2	uteroglobin	B
3	promoter	I
4	contains	O
5	a	O
6	noncanonical	O
7	estrogen	O
8	responsive	O
9	element	O
10	.	O

1	In	O
2	7	O
3	of	O
4	9	O
5	cases	O
6	,	O
7	the	O
8	enhancer	O
9	is	O
10	fused	O
11	to	O
12	the	O
13	c	B
14	-	I
15	myc	I
16	bearing	O
17	sequences	O
18	of	O
19	chromosome	O
20	8	O
21	.	O

1	In	O
2	this	O
3	report	O
4	,	O
5	we	O
6	demonstrate	O
7	that	O
8	hGCN5	O
9	is	O
10	also	O
11	an	O
12	HAT	O
13	and	O
14	has	O
15	the	O
16	same	O
17	substrate	O
18	specificity	O
19	as	O
20	yGCN5	O
21	.	O

1	An	O
2	increase	O
3	in	O
4	the	O
5	level	O
6	of	O
7	serum	O
8	enzymes	O
9	,	O
10	such	O
11	as	O
12	aspartate	O
13	transaminase	O
14	,	O
15	alkaline	B
16	phosphatase	I
17	,	O
18	creatine	B
19	phosphokinase	I
20	,	O
21	lactate	B
22	dehydrogenase	I
23	after	O
24	D	O
25	.	O
26	russelli	O
27	venom	O
28	injection	O
29	in	O
30	albino	O
31	rats	O
32	is	O
33	indicative	O
34	of	O
35	cell	O
36	or	O
37	tissue	O
38	damage	O
39	.	O

1	A	O
2	synergistic	O
3	effect	O
4	on	O
5	HCK	O
6	promoter	O
7	activity	O
8	was	O
9	observed	O
10	at	O
11	high	O
12	concentrations	O
13	of	O
14	Sp1	B
15	.	O

1	The	O
2	degree	O
3	of	O
4	lung	O
5	destruction	O
6	,	O
7	reflected	O
8	by	O
9	interstitial	O
10	hemorrhage	O
11	was	O
12	assessed	O
13	by	O
14	measuring	O
15	hemoglobin	B
16	content	O
17	in	O
18	the	O
19	fluid	O
20	of	O
21	the	O
22	lavaged	O
23	lungs	O
24	.	O

1	Clone	O
2	pSRc200	O
3	hybrid	O
4	selected	O
5	an	O
6	mRNA	O
7	that	O
8	on	O
9	cell	O
10	-	O
11	free	O
12	translation	O
13	produced	O
14	a	O
15	38	O
16	-	O
17	kDa	O
18	polypeptide	O
19	.	O

1	135	O
2	students	O
3	had	O
4	a	O
5	count	O
6	of	O
7	less	O
8	than	O
9	50	O
10	eggs	O
11	/	O
12	10	O
13	ml	O
14	.	O
15	urine	O
16	and	O
17	56	O
18	had	O
19	more	O
20	than	O
21	50	O
22	eggs	O
23	/	O
24	10ml	O
25	.	O

1	The	O
2	colony	B
3	-	I
4	stimulating	I
5	factors	I
6	(	O
7	CSFs	O
8	)	O
9	principally	O
10	involved	O
11	in	O
12	the	O
13	production	O
14	of	O
15	neutrophils	O
16	and	O
17	monocytes	O
18	are	O
19	granulocyte	B
20	CSF	I
21	,	O
22	granulocyte	B
23	-	I
24	macrophage	I
25	CSF	I
26	,	I
27	macrophage	I
28	CSF	I
29	,	O
30	and	O
31	interleukin	B
32	3	I
33	(	I
34	sometimes	I
35	called	I
36	multi	I
37	-	I
38	CSF	I
39	).	O

1	A	O
2	possible	O
3	decrease	O
4	in	O
5	theophylline	O
6	'	O
7	s	O
8	volume	O
9	of	O
10	distribution	O
11	at	O
12	4	O
13	days	O
14	,	O
15	but	O
16	not	O
17	immediately	O
18	,	O
19	after	O
20	administration	O
21	of	O
22	chloroquine	O
23	was	O
24	suggested	O
25	,	O
26	although	O
27	this	O
28	just	O
29	failed	O
30	to	O
31	achieve	O
32	statistical	O
33	significance	O
34	(	O
35	p	O
36	=	O
37	0	O
38	.	O
39	055	O
40	).	O

1	A	O
2	prospectively	O
3	gated	O
4	2D	O
5	axial	O
6	sequence	O
7	with	O
8	velocity	O
9	encoding	O
10	in	O
11	the	O
12	craniocaudal	O
13	direction	O
14	in	O
15	the	O
16	cervical	O
17	region	O
18	was	O
19	set	O
20	at	O
21	a	O
22	velocity	O
23	of	O
24	+/-	O
25	10	O
26	cm	O
27	/	O
28	s	O
29	.	O

1	The	O
2	most	O
3	frequent	O
4	risk	O
5	factor	O
6	for	O
7	ischaemic	O
8	was	O
9	hypertension	O
10	.	O

1	The	O
2	Authors	O
3	have	O
4	proposed	O
5	to	O
6	develop	O
7	this	O
8	research	O
9	employing	O
10	a	O
11	preparation	O
12	containing	O
13	exclusively	O
14	a	O
15	cortisonic	O
16	,	O
17	the	O
18	desametazone	O
19	,	O
20	in	O
21	order	O
22	to	O
23	evaluate	O
24	the	O
25	alterations	O
26	of	O
27	the	O
28	dentinogenesis	O
29	to	O
30	be	O
31	attributed	O
32	to	O
33	such	O
34	component	O
35	.	O

1	These	O
2	changes	O
3	in	O
4	virus	O
5	entry	O
6	features	O
7	may	O
8	result	O
9	in	O
10	coronaviruses	O
11	with	O
12	novel	O
13	pathogenic	O
14	properties	O
15	.	O

1	We	O
2	conclude	O
3	that	O
4	at	O
5	these	O
6	low	O
7	levels	O
8	studied	O
9	,	O
10	aluminum	O
11	accumulates	O
12	in	O
13	intestinal	O
14	tissue	O
15	,	O
16	and	O
17	that	O
18	this	O
19	accumulation	O
20	is	O
21	enhanced	O
22	by	O
23	citrate	O
24	ligand	O
25	.	O

1	Allergic	O
2	reaction	O
3	to	O
4	Patent	O
5	Blue	O
6	Violet	O
7	during	O
8	lymphography	O
9	.	O

1	Six	O
2	of	O
3	them	O
4	,	O
5	NUC1	O
6	,	O
7	PRP21	O
8	(	O
9	also	O
10	called	O
11	SPP91	O
12	),	O
13	CDC6	O
14	,	O
15	CRY2	O
16	,	O
17	the	O
18	gene	O
19	encoding	O
20	the	O
21	ribosomal	O
22	protein	O
23	S24	O
24	and	O
25	the	O
26	gene	O
27	coding	O
28	for	O
29	a	O
30	hypothetical	O
31	protein	O
32	of	O
33	599	O
34	amino	O
35	acids	O
36	,	O
37	have	O
38	been	O
39	sequenced	O
40	previously	O
41	.	O

1	Improvement	O
2	of	O
3	the	O
4	CRT	O
5	display	O
6	of	O
7	an	O
8	averager	O
9	.	O

1	Biol	O
2	.	O

1	It	O
2	is	O
3	related	O
4	to	O
5	a	O
6	variety	O
7	of	O
8	mammalian	O
9	Golgi	O
10	-	O
11	associated	O
12	proteins	O
13	and	O
14	to	O
15	the	O
16	yeast	O
17	Uso1p	O
18	,	O
19	an	O
20	essential	O
21	protein	O
22	involved	O
23	in	O
24	docking	O
25	of	O
26	endoplasmic	O
27	reticulum	O
28	-	O
29	derived	O
30	vesicles	O
31	to	O
32	the	O
33	cis	O
34	-	O
35	Golgi	O
36	.	O

1	MEASUREMENTS	O
2	AND	O
3	MAIN	O
4	RESULTS	O
5	:	O
6	Lung	O
7	elastance	O
8	(	O
9	EL	O
10	)	O
11	and	O
12	resistance	O
13	(	O
14	RL	O
15	)	O
16	were	O
17	calculated	O
18	from	O
19	measurements	O
20	of	O
21	airway	O
22	pressure	O
23	,	O
24	esophageal	O
25	pressure	O
26	,	O
27	and	O
28	airway	O
29	flow	O
30	in	O
31	five	O
32	anesthetized	O
33	,	O
34	paralyzed	O
35	dogs	O
36	during	O
37	sinusoidal	O
38	forcing	O
39	at	O
40	a	O
41	constant	O
42	mean	O
43	airway	O
44	pressure	O
45	of	O
46	10	O
47	cmH2O	O
48	in	O
49	a	O
50	wide	O
51	range	O
52	of	O
53	breathing	O
54	frequencies	O
55	(	O
56	0	O
57	.	O
58	2	O
59	to	O
60	1	O
61	.	O
62	0	O
63	Hz	O
64	in	O
65	intervals	O
66	of	O
67	0	O
68	.	O
69	2	O
70	)	O
71	and	O
72	tidal	O
73	volumes	O
74	(	O
75	50	O
76	,	O
77	100	O
78	,	O
79	200	O
80	,	O
81	and	O
82	to	O
83	300	O
84	mL	O
85	).	O

1	GATA	B
2	-	I
3	1	I
4	mRNA	I
5	was	O
6	present	O
7	in	O
8	equivalent	O
9	levels	O
10	in	O
11	both	O
12	erythroid	O
13	cell	O
14	lines	O
15	,	O
16	but	O
17	at	O
18	a	O
19	low	O
20	level	O
21	in	O
22	FDC	O
23	-	O
24	P1	O
25	cells	O
26	.	O

1	Solving	O
2	an	O
3	age	O
4	old	O
5	problem	O
6	.	O

1	Observations	O
2	on	O
3	the	O
4	flight	O
5	activities	O
6	of	O
7	Chrysops	O
8	caecutiens	O
9	L	O
10	.	O

1	(	O
2	1991	O
3	).	O

1	Plots	O
2	of	O
3	RV	O
4	,	O
5	LV	O
6	+	O
7	S	O
8	and	O
9	2A	O
10	weight	O
11	vs	O
12	real	O
13	hematocrit	O
14	showed	O
15	sharp	O
16	upward	O
17	inflections	O
18	at	O
19	real	O
20	hematocrit	O
21	65	O
22	%,	O
23	suggesting	O
24	a	O
25	possible	O
26	role	O
27	of	O
28	increased	O
29	viscosity	O
30	in	O
31	CO	O
32	cardiomegaly	O
33	at	O
34	the	O
35	higher	O
36	hematocrit	O
37	.	O

1	Mild	O
2	orbital	O
3	discomfort	O
4	occurred	O
5	in	O
6	some	O
7	patients	O
8	.	O

1	In	O
2	contrast	O
3	to	O
4	hemodynamic	O
5	and	O
6	histopathological	O
7	predictors	O
8	of	O
9	survival	O
10	,	O
11	vWF	O
12	:	O
13	Ag	O
14	does	O
15	not	O
16	require	O
17	invasive	O
18	techniques	O
19	to	O
20	be	O
21	determined	O
22	.	O

1	A	O
2	method	O
3	for	O
4	determining	O
5	cumulative	O
6	behavioral	O
7	toxicity	O
8	after	O
9	chronic	O
10	oral	O
11	administration	O
12	of	O
13	l	O
14	-	O
15	alpha	O
16	-	O
17	acetylmethadol	O
18	to	O
19	female	O
20	rats	O
21	.	O

1	Localization	O
2	of	O
3	the	O
4	cytokine	O
5	response	O
6	element	O
7	by	O
8	5	O
9	'-	O
10	deletion	O
11	analysis	O
12	and	O
13	site	O
14	-	O
15	directed	O
16	mutagenesis	O
17	revealed	O
18	a	O
19	cis	O
20	-	O
21	acting	O
22	binding	O
23	site	O
24	for	O
25	activated	O
26	STAT	B
27	complexes	O
28	.	O

1	Within	O
2	the	O
3	Strep	O
4	.	O
5	mutans	O
6	group	O
7	there	O
8	was	O
9	a	O
10	highly	O
11	-	O
12	significant	O
13	difference	O
14	between	O
15	Strep	O
16	.	O
17	mutans	O
18	/	O
19	Strep	O
20	.	O
21	cricetus	O
22	(	O
23	p	O
24	less	O
25	than	O
26	0	O
27	.	O
28	01	O
29	)	O
30	with	O
31	respect	O
32	to	O
33	mean	O
34	clump	O
35	size	O
36	.	O

1	The	O
2	protein	O
3	product	O
4	of	O
5	orfD	O
6	,	O
7	which	O
8	is	O
9	probably	O
10	a	O
11	new	O
12	tra	O
13	gene	O
14	(	O
15	named	O
16	traX	O
17	),	O
18	contains	O
19	65	O
20	%	O
21	hydrophobic	O
22	amino	O
23	acids	O
24	,	O
25	especially	O
26	rich	O
27	in	O
28	alanine	O
29	and	O
30	leucine	O
31	.	O

1	BYV	O
2	,	O
3	citrus	O
4	tristeza	O
5	virus	O
6	(	O
7	CTV	O
8	),	O
9	beet	O
10	yellow	O
11	stunt	O
12	virus	O
13	(	O
14	BYSV	O
15	)	O
16	and	O
17	carnation	O
18	necrotic	O
19	fleck	O
20	virus	O
21	templates	O
22	produced	O
23	1	O
24	kb	O
25	amplification	O
26	products	O
27	,	O
28	which	O
29	were	O
30	shown	O
31	by	O
32	sequencing	O
33	to	O
34	represent	O
35	fragments	O
36	of	O
37	the	O
38	respective	O
39	HSP70	B
40	genes	I
41	.	O

1	However	O
2	,	O
3	the	O
4	history	O
5	of	O
6	acute	O
7	severe	O
8	complications	O
9	from	O
10	otitis	O
11	media	O
12	revealed	O
13	a	O
14	higher	O
15	frequency	O
16	in	O
17	those	O
18	individuals	O
19	with	O
20	alpha	B
21	1	I
22	-	I
23	antitrypsin	I
24	deficiency	O
25	as	O
26	compared	O
27	to	O
28	normals	O
29	.	O

1	The	O
2	effect	O
3	of	O
4	antilymphocyte	O
5	sera	O
6	on	O
7	formation	O
8	of	O
9	transplantation	O
10	and	O
11	anti	O
12	-	O
13	infection	O
14	immunity	O
15	in	O
16	mice	O

1	Evaluating	O
2	dietary	O
3	department	O
4	management	O
5	.	O

1	The	O
2	initial	O
3	translation	O
4	protein	O
5	encoded	O
6	by	O
7	the	O
8	cDNA	O
9	is	O
10	53	O
11	,	O
12	932	O
13	kDa	O
14	and	O
15	possesses	O
16	a	O
17	hydrophilic	O
18	amino	O
19	acid	O
20	composition	O
21	with	O
22	glutamic	O
23	acid	O
24	comprising	O
25	22	O
26	%	O
27	of	O
28	the	O
29	total	O
30	amino	O
31	acid	O
32	residues	O
33	.	O

1	With	O
2	regard	O
3	to	O
4	the	O
5	characteristic	O
6	expression	O
7	pattern	O
8	of	O
9	DJ	O
10	protein	O
11	and	O
12	its	O
13	conspicuous	O
14	repeat	O
15	units	O
16	possible	O
17	functional	O
18	roles	O
19	are	O
20	discussed	O
21	.	O

1	The	O
2	incidence	O
3	of	O
4	fetal	O
5	breathing	O
6	movements	O
7	(	O
8	06	O
9	.	O
10	00	O
11	-	O
12	10	O
13	.	O
14	00	O
15	h	O
16	)	O
17	decreased	O
18	with	O
19	increasing	O
20	gestational	O
21	age	O
22	while	O
23	fetal	O
24	arterial	O
25	concentrations	O
26	of	O
27	plasma	O
28	PGE	O
29	increased	O
30	significantly	O
31	over	O
32	the	O
33	same	O
34	period	O
35	of	O
36	gestation	O
37	.	O

1	To	O
2	examine	O
3	the	O
4	role	O
5	of	O
6	this	O
7	CE2	O
8	element	O
9	in	O
10	regulating	O
11	Hoxa1	O
12	expression	O
13	in	O
14	vivo	O
15	,	O
16	transgenic	O
17	mice	O
18	were	O
19	generated	O
20	which	O
21	express	O
22	a	O
23	Hoxa1	B
24	beta	I
25	-	I
26	galactosidase	I
27	reporter	I
28	gene	I
29	that	O
30	contains	O
31	a	O
32	mutation	O
33	in	O
34	the	O
35	CE2	O
36	element	O
37	.	O

1	A	O
2	cDNA	O
3	library	O
4	of	O
5	tumour	O
6	cells	O
7	was	O
8	screened	O
9	with	O
10	an	O
11	interleukin	B
12	2	I
13	gene	I
14	-	I
15	specific	O
16	probe	O
17	.	O

1	Dosimetric	O
2	estimates	O
3	for	O
4	these	O
5	organs	O
6	were	O
7	2	O
8	.	O
9	3	O
10	+/-	O
11	1	O
12	.	O
13	1	O
14	and	O
15	2	O
16	.	O
17	3	O
18	+/-	O
19	1	O
20	.	O
21	4	O
22	rad	O
23	(.	O
24	02	O
25	+/-	O
26	.	O
27	01	O
28	Gy	O
29	),	O
30	respectively	O
31	,	O
32	with	O
33	a	O
34	whole	O
35	-	O
36	body	O
37	estimate	O
38	of	O
39	0	O
40	.	O
41	28	O
42	rad	O
43	(.	O
44	003	O
45	Gy	O
46	).	O

1	Fas	B
2	-	I
3	resistant	O
4	DT	O
5	-	O
6	40	O
7	lymphoma	O
8	B	O
9	-	O
10	cells	O
11	rendered	O
12	BTK	O
13	-	O
14	deficient	O
15	through	O
16	targeted	O
17	disruption	O
18	of	O
19	the	O
20	btk	B
21	gene	I
22	by	O
23	homologous	O
24	recombination	O
25	knockout	O
26	underwent	O
27	apoptosis	O
28	after	O
29	Fas	O
30	ligation	O
31	,	O
32	but	O
33	wild	O
34	-	O
35	type	O
36	DT	O
37	-	O
38	40	O
39	cells	O
40	or	O
41	BTK	O
42	-	O
43	deficient	O
44	DT	O
45	-	O
46	40	O
47	cells	O
48	reconstituted	O
49	with	O
50	wild	O
51	-	O
52	type	O
53	human	B
54	btk	I
55	gene	I
56	did	O
57	not	O
58	.	O

1	Recently	O
2	,	O
3	extremely	O
4	high	O
5	levels	O
6	of	O
7	endothelin	B
8	-	I
9	1	I
10	(	I
11	ET	I
12	-	I
13	1	I
14	)	O
15	were	O
16	detected	O
17	in	O
18	the	O
19	pericardial	O
20	fluid	O
21	of	O
22	patients	O
23	undergoing	O
24	cardiac	O
25	surgery	O
26	.	O

1	Injection	O
2	of	O
3	double	O
4	-	O
5	stranded	O
6	RNA	O
7	into	O
8	C	O
9	.	O
10	elegans	O
11	results	O
12	in	O
13	embryonic	O
14	lethality	O
15	;	O
16	thus	O
17	,	O
18	the	O
19	SF1	O
20	gene	O
21	is	O
22	essential	O
23	not	O
24	only	O
25	in	O
26	yeast	O
27	but	O
28	also	O
29	in	O
30	at	O
31	least	O
32	one	O
33	metazoan	O
34	.	O

1	A	O
2	mutant	O
3	areA	B
4	product	I
5	truncated	I
6	immediately	O
7	after	O
8	the	O
9	last	O
10	residue	O
11	of	O
12	the	O
13	highly	O
14	conserved	O
15	GATA	B
16	(	O
17	DNA	O
18	-	O
19	binding	O
20	)	O
21	domain	O
22	retains	O
23	partial	O
24	function	O
25	.	O

1	However	O
2	,	O
3	there	O
4	has	O
5	not	O
6	been	O
7	any	O
8	evidence	O
9	of	O
10	A	O
11	.	O
12	salmonicida	O
13	infections	O
14	,	O
15	specifically	O
16	furunculosis	O
17	,	O
18	associated	O
19	with	O
20	the	O
21	fish	O
22	in	O
23	this	O
24	loch	O
25	.	O

1	Amino	O
2	acid	O
3	sequence	O
4	comparison	O
5	revealed	O
6	significant	O
7	homology	O
8	between	O
9	the	O
10	yeast	O
11	and	O
12	Escherichia	B
13	coli	I
14	gamma	I
15	-	I
16	glutamyl	I
17	kinases	I
18	throughout	O
19	their	O
20	lengths	O
21	.	O

1	Taken	O
2	together	O
3	,	O
4	these	O
5	findings	O
6	show	O
7	that	O
8	16K	O
9	hPRL	O
10	inhibits	O
11	the	O
12	VEGF	B
13	-	I
14	induced	O
15	Ras	B
16	activation	O
17	;	O
18	this	O
19	antagonism	O
20	represents	O
21	a	O
22	novel	O
23	and	O
24	potentially	O
25	important	O
26	mechanism	O
27	for	O
28	the	O
29	control	O
30	of	O
31	angiogenesis	O
32	.	O

1	Therefore	O
2	more	O
3	active	O
4	and	O
5	tolerable	O
6	salvage	O
7	regimens	O
8	are	O
9	needed	O
10	.	O

1	The	O
2	translation	O
3	products	O
4	of	O
5	both	O
6	clones	O
7	are	O
8	highly	O
9	homologous	O
10	to	O
11	APS1	O
12	(	O
13	66	O
14	and	O
15	86	O
16	%	O
17	identity	O
18	,	O
19	respectively	O
20	)	O
21	over	O
22	their	O
23	entire	O
24	lengths	O
25	,	O
26	including	O
27	amino	O
28	terminal	O
29	sequences	O
30	resembling	O
31	transit	O
32	peptides	O
33	for	O
34	plastid	O
35	localization	O
36	.	O

1	The	O
2	sequence	O
3	data	O
4	now	O
5	permit	O
6	a	O
7	detailed	O
8	interpretation	O
9	of	O
10	the	O
11	X	O
12	-	O
13	ray	O
14	crystallographic	O
15	structure	O
16	of	O
17	the	O
18	enzyme	O
19	and	O
20	the	O
21	cloning	O
22	and	O
23	expression	O
24	of	O
25	the	O
26	clostridial	O
27	gene	O
28	will	O
29	facilitate	O
30	site	O
31	-	O
32	directed	O
33	mutagenesis	O
34	.	O

1	There	O
2	were	O
3	122	O
4	cases	O
5	of	O
6	tuberculosis	O
7	over	O
8	an	O
9	average	O
10	10	O
11	.	O
12	3	O
13	yr	O
14	of	O
15	follow	O
16	-	O
17	up	O
18	(	O
19	crude	O
20	annual	O
21	incidence	O
22	,	O
23	76	O
24	.	O
25	2	O
26	/	O
27	100	O
28	,	O
29	000	O
30	).	O

1	The	O
2	infected	O
3	cell	O
4	protein	O
5	no	O
6	.	O
7	0	O
8	(	O
9	ICP0	O
10	)	O
11	of	O
12	herpes	O
13	simplex	O
14	virus	O
15	1	O
16	is	O
17	a	O
18	promiscuous	O
19	transactivator	O
20	shown	O
21	to	O
22	enhance	O
23	the	O
24	expression	O
25	of	O
26	genes	O
27	introducted	O
28	into	O
29	cells	O
30	by	O
31	infection	O
32	or	O
33	transfection	O
34	.	O

1	The	O
2	same	O
3	-	O
4	sized	O
5	EBNA	B
6	protein	I
7	(	O
8	approximately	O
9	78	O
10	,	O
11	000	O
12	)	O
13	was	O
14	made	O
15	after	O
16	transfection	O
17	with	O
18	BamHI	O
19	-	O
20	K	O
21	(	O
22	5	O
23	.	O
24	2	O
25	kilobase	O
26	pairs	O
27	[	O
28	kbp	O
29	])	O
30	or	O
31	the	O
32	I1f	O
33	subfragment	O
34	(	O
35	2	O
36	.	O
37	9	O
38	kbp	O
39	).	O

1	The	O
2	5	O
3	'	O
4	ends	O
5	of	O
6	F3R	O
7	late	O
8	transcripts	O
9	were	O
10	located	O
11	to	O
12	an	O
13	A	O
14	within	O
15	the	O
16	sequence	O
17	5	O
18	'-	O
19	TAAAG	O
20	,	O
21	41	O
22	nt	O
23	downstream	O
24	from	O
25	the	O
26	early	O
27	promoter	O
28	and	O
29	17	O
30	nt	O
31	upstream	O
32	from	O
33	the	O
34	initiation	O
35	codon	O
36	.	O

1	Coenzyme	O
2	Q10	O
3	:	O
4	blood	O
5	levels	O
6	and	O
7	metabolic	O
8	demand	O
9	.	O

1	The	O
2	hydropathy	O
3	plot	O
4	revealed	O
5	a	O
6	rather	O
7	hydrophilic	O
8	N	O
9	-	O
10	terminal	O
11	region	O
12	and	O
13	the	O
14	absence	O
15	of	O
16	a	O
17	hydrophobic	O
18	signal	O
19	peptide	O
20	.	O

1	This	O
2	emancipation	O
3	of	O
4	the	O
5	ability	O
6	to	O
7	copulate	O
8	from	O
9	hormonal	O
10	influence	O
11	makes	O
12	female	O
13	sexual	O
14	motivation	O
15	the	O
16	primary	O
17	regulator	O
18	of	O
19	mating	O
20	in	O
21	primates	O
22	.	O

1	The	O
2	results	O
3	of	O
4	the	O
5	ISIS	O
6	-	O
7	2	O
8	trial	O
9	and	O
10	the	O
11	data	O
12	from	O
13	the	O
14	Antiplatelet	O
15	Trialists	O
16	'	O
17	Collaboration	O
18	indicated	O
19	that	O
20	aspirin	O
21	is	O
22	mandatory	O
23	in	O
24	patients	O
25	with	O
26	acute	O
27	myocardial	O
28	infarction	O
29	and	O
30	for	O
31	secondary	O
32	prevention	O
33	.	O

1	Experimental	O
2	reproduction	O
3	of	O
4	malignant	O
5	catarrhal	O
6	fever	O
7	in	O
8	Bali	O
9	cattle	O

1	The	O
2	study	O
3	made	O
4	to	O
5	define	O
6	the	O
7	ability	O
8	of	O
9	lipid	O
10	A	O
11	monoclonal	O
12	antibodies	O
13	to	O
14	correct	O
15	hemodynamic	O
16	disturbances	O
17	due	O
18	to	O
19	endotoxemia	O
20	in	O
21	dog	O
22	experiments	O
23	showed	O
24	the	O
25	efficacy	O
26	of	O
27	the	O
28	antibodies	O
29	administration	O
30	.	O

1	In	O
2	an	O
3	effort	O
4	to	O
5	separate	O
6	domains	O
7	of	O
8	FadR	O
9	required	O
10	for	O
11	DNA	O
12	binding	O
13	,	O
14	dimerization	O
15	,	O
16	and	O
17	ligand	O
18	binding	O
19	,	O
20	chimeric	O
21	protein	O
22	fusions	O
23	between	O
24	the	O
25	DNA	O
26	binding	O
27	domain	O
28	of	O
29	LexA	O
30	and	O
31	different	O
32	regions	O
33	of	O
34	FadR	O
35	were	O
36	constructed	O
37	.	O

1	195mPt	O
2	-	O
3	labeled	O
4	cisplatin	O
5	was	O
6	administered	O
7	iv	O
8	and	O
9	ip	O
10	to	O
11	control	O
12	mice	O
13	and	O
14	to	O
15	mice	O
16	bearing	O
17	Sarcoma	O
18	180	O
19	.	O

1	Identification	O
2	of	O
3	an	O
4	AfsA	O
5	homologue	O
6	(	O
7	BarX	O
8	)	O
9	from	O
10	Streptomyces	O
11	virginiae	O
12	as	O
13	a	O
14	pleiotropic	O
15	regulator	O
16	controlling	O
17	autoregulator	O
18	biosynthesis	O
19	,	O
20	virginiamycin	O
21	biosynthesis	O
22	and	O
23	virginiamycin	O
24	M1	O
25	resistance	O
26	.	O

1	Simultaneous	O
2	right	O
3	and	O
4	left	O
5	adrenal	O
6	and	O
7	peripheral	O
8	blood	O
9	samples	O
10	were	O
11	collected	O
12	for	O
13	determination	O
14	of	O
15	oestrone	O
16	(	O
17	E1	O
18	)	O
19	and	O
20	oestradiol	O
21	(	O
22	E2	O
23	).	O

1	Where	O
2	UMDNJ	O
3	is	O
4	headed	O
5	.	O

1	Immunoprecipitation	O
2	experiments	O
3	using	O
4	DokR	O
5	-	O
6	specific	O
7	antibodies	O
8	revealed	O
9	an	O
10	interaction	O
11	between	O
12	endogenous	O
13	DokR	O
14	and	O
15	a	O
16	150	O
17	-	O
18	kDa	O
19	protein	O
20	that	O
21	is	O
22	tyrosine	O
23	-	O
24	phosphorylated	O
25	in	O
26	EGF	B
27	-	I
28	stimulated	O
29	BaF	O
30	/	O
31	3	O
32	cells	O
33	.	O

1	If	O
2	this	O
3	is	O
4	the	O
5	case	O
6	,	O
7	identification	O
8	and	O
9	characterization	O
10	of	O
11	transcripts	O
12	from	O
13	the	O
14	Ig	B
15	loci	I
16	should	O
17	permit	O
18	a	O
19	better	O
20	understanding	O
21	of	O
22	the	O
23	gene	O
24	rearrangement	O
25	process	O
26	.	O

1	Ligation	O
2	of	O
3	CD40	B
4	rescues	I
5	Ramos	I
6	-	I
7	Burkitt	I
8	lymphoma	O
9	B	O
10	cells	O
11	from	O
12	calcium	O
13	ionophore	B
14	-	I
15	and	I
16	antigen	I
17	receptor	I
18	-	I
19	triggered	O
20	apoptosis	O
21	by	O
22	inhibiting	O
23	activation	O
24	of	O
25	the	O
26	cysteine	O
27	protease	O
28	CPP32	O
29	/	O
30	Yama	O
31	and	O
32	cleavage	O
33	of	O
34	its	O
35	substrate	O
36	PARP	O
37	.	O

1	However	O
2	,	O
3	multiple	O
4	alanine	O
5	substitutions	O
6	or	O
7	proline	O
8	(	O
9	helix	O
10	-	O
11	destabilizing	O
12	)	O
13	substitutions	O
14	disrupted	O
15	both	O
16	oligomerization	O
17	and	O
18	transport	O
19	of	O
20	GP64	O
21	EFP	O
22	.	O

1	The	O
2	hypBFCDE	O
3	operon	O
4	from	O
5	Rhizobium	O
6	leguminosarum	O
7	biovar	O
8	viciae	O
9	is	O
10	expressed	O
11	from	O
12	an	O
13	Fnr	O
14	-	O
15	type	O
16	promoter	O
17	that	O
18	escapes	O
19	mutagenesis	O
20	of	O
21	the	O
22	fnrN	O
23	gene	O
24	.	O

1	Finally	O
2	,	O
3	we	O
4	determined	O
5	the	O
6	genomic	O
7	organization	O
8	of	O
9	the	O
10	human	O
11	TrxR2	O
12	gene	O
13	,	O
14	which	O
15	consists	O
16	of	O
17	18	O
18	exons	O
19	spanning	O
20	about	O
21	67	O
22	kb	O
23	,	O
24	and	O
25	its	O
26	chromosomal	O
27	localization	O
28	at	O
29	position	O
30	22q11	O
31	.	O
32	2	O
33	.	O

1	L	O
2	-	O
3	735	O
4	,	O
5	524	O
6	free	O
7	base	O
8	or	O
9	sulfate	O
10	salt	O
11	was	O
12	administered	O
13	orally	O
14	as	O
15	suspension	O
16	,	O
17	solution	O
18	or	O
19	in	O
20	solid	O
21	dosage	O
22	forms	O
23	to	O
24	fasted	O
25	or	O
26	fed	O
27	Beagle	O
28	dogs	O
29	.	O

1	The	O
2	number	O
3	of	O
4	muricidal	O
5	rats	O
6	increased	O
7	with	O
8	increase	O
9	in	O
10	the	O
11	duration	O
12	of	O
13	Cd	O
14	administration	O
15	in	O
16	association	O
17	with	O
18	greater	O
19	accumulation	O
20	of	O
21	Cd	O
22	in	O
23	the	O
24	olfactory	O
25	bulb	O
26	than	O
27	in	O
28	any	O
29	other	O
30	region	O
31	of	O
32	the	O
33	brain	O
34	.	O

1	Comparison	O
2	of	O
3	genomic	O
4	sequence	O
5	shows	O
6	that	O
7	the	O
8	ph	O
9	locus	O
10	has	O
11	been	O
12	duplicated	O
13	,	O
14	and	O
15	that	O
16	it	O
17	contains	O
18	proximal	O
19	and	O
20	distal	O
21	transcription	O
22	units	O
23	.	O

1	TPA	O
2	and	O
3	TGF	B
4	-	I
5	beta	I
6	1	I
7	did	O
8	not	O
9	markedly	O
10	affect	O
11	the	O
12	activities	O
13	of	O
14	the	O
15	72	O
16	-	O
17	kDa	O
18	enzyme	O
19	.	O

1	Intravenous	O
2	antibiotic	O
3	therapy	O
4	in	O
5	cystic	O
6	fibrosis	O
7	:	O
8	in	O
9	hospital	O
10	or	O
11	at	O
12	home	O
13	?	O

1	Small	B
2	Maf	I
3	proteins	I
4	heterodimerize	I
5	with	O
6	Fos	B
7	and	O
8	may	O
9	act	O
10	as	O
11	competitive	O
12	repressors	O
13	of	O
14	the	O
15	NF	B
16	-	I
17	E2	I
18	transcription	I
19	factor	I
20	.	O

1	Just	O
2	before	O
3	inserting	O
4	on	O
5	the	O
6	anterior	O
7	margin	O
8	and	O
9	apex	O
10	of	O
11	the	O
12	iliac	O
13	crest	O
14	it	O
15	widens	O
16	,	O
17	assuming	O
18	the	O
19	aspect	O
20	of	O
21	a	O
22	small	O
23	cone	O
24	.	O

1	We	O
2	compared	O
3	the	O
4	inhibitory	O
5	effect	O
6	of	O
7	naturally	O
8	occurring	O
9	mutant	O
10	hTR	O
11	beta	O
12	1	O
13	,	O
14	artificially	O
15	created	O
16	hTR	B
17	alpha	I
18	1	I
19	mutants	I
20	,	O
21	c	B
22	-	I
23	erbA	I
24	alpha	I
25	2	I
26	and	O
27	the	O
28	human	B
29	peroxisome	I
30	proliferator	I
31	-	I
32	activated	I
33	receptor	I
34	(	O
35	hPPAR	O
36	)	O
37	on	O
38	three	O
39	prototypic	O
40	T3	O
41	-	O
42	response	O
43	elements	O
44	(	O
45	TREs	O
46	),	O
47	TRE	O
48	-	O
49	PAL	O
50	,	O
51	DR	O
52	+	O
53	4	O
54	and	O
55	TRE	O
56	-	O
57	LAP	O
58	.	O

1	DNase	B
2	I	I
3	footprinting	O
4	and	O
5	electrophoretic	O
6	mobility	O
7	shift	O
8	analyses	O
9	revealed	O
10	two	O
11	hepatocyte	B
12	nuclear	I
13	factor	I
14	-	I
15	1	I
16	(	O
17	HNF1	O
18	),	O
19	three	O
20	CCAAT	B
21	/	I
22	enhancer	I
23	-	I
24	binding	I
25	protein	I
26	(	I
27	C	I
28	/	I
29	EBP	I
30	),	O
31	and	O
32	one	O
33	consensus	O
34	palindromic	O
35	thyroid	O
36	hormone	O
37	response	O
38	elements	O
39	within	O
40	the	O
41	first	O
42	215	O
43	base	O
44	pairs	O
45	(	O
46	bp	O
47	)	O
48	of	O
49	the	O
50	promoter	O
51	sequence	O
52	of	O
53	rat	O
54	Std	O
55	.	O

1	Two	O
2	other	O
3	peptides	O
4	,	O
5	either	O
6	partially	O
7	or	O
8	totally	O
9	lacking	O
10	the	O
11	basic	O
12	region	O
13	,	O
14	but	O
15	containing	O
16	the	O
17	intact	O
18	leucine	O
19	zipper	O
20	domain	O
21	,	O
22	readily	O
23	form	O
24	dimers	O
25	but	O
26	do	O
27	not	O
28	bind	O
29	to	O
30	the	O
31	CRE	O
32	.	O

1	To	O
2	characterize	O
3	the	O
4	expression	O
5	of	O
6	this	O
7	DNA	O
8	repair	O
9	enzyme	O
10	,	O
11	we	O
12	have	O
13	isolated	O
14	the	O
15	corresponding	O
16	genomic	O
17	clone	O
18	.	O

1	The	O
2	second	O
3	method	O
4	,	O
5	the	O
6	"	O
7	macro	O
8	"	O
9	assay	O
10	,	O
11	has	O
12	a	O
13	sensitivity	O
14	range	O
15	of	O
16	0	O
17	.	O
18	03	O
19	-	O
20	5	O
21	.	O
22	0	O
23	micrograms	O
24	phosphorus	O
25	with	O
26	100	O
27	-	O
28	500	O
29	microliters	O
30	HClO4	O
31	.	O

1	Bacteriologic	O
2	culture	O
3	of	O
4	pancreatic	O
5	tissue	O
6	was	O
7	positive	O
8	in	O
9	6	O
10	/	O
11	8	O
12	IB	O
13	and	O
14	3	O
15	/	O
16	17	O
17	NIB	O
18	rats	O
19	(	O
20	p	O
21	less	O
22	than	O
23	0	O
24	.	O
25	01	O
26	).	O

1	We	O
2	are	O
3	reporting	O
4	an	O
5	autopsy	O
6	case	O
7	of	O
8	so	O
9	-	O
10	called	O
11	"	O
12	acute	O
13	multiple	O
14	sclerosis	O
15	"	O
16	that	O
17	was	O
18	difficult	O
19	to	O
20	differentiate	O
21	from	O
22	a	O
23	brain	O
24	tumor	O
25	on	O
26	MRI	O
27	findings	O
28	.	O

1	This	O
2	specific	O
3	methylation	O
4	pattern	O
5	caused	O
6	inactivation	O
7	of	O
8	the	O
9	HSV	B
10	tk	I
11	gene	I
12	,	O
13	while	O
14	methylation	O
15	of	O
16	the	O
17	cytosine	O
18	residues	O
19	within	O
20	the	O
21	nucleotide	O
22	sequence	O
23	from	O
24	+	O
25	811	O
26	to	O
27	+	O
28	1309	O
29	had	O
30	no	O
31	effect	O
32	on	O
33	HSV	B
34	tk	I
35	gene	I
36	activity	O
37	.	O

1	Animal	O
2	studies	O
3	showed	O
4	that	O
5	beam	O
6	equalization	O
7	significantly	O
8	improved	O
9	fluoroscopic	O
10	and	O
11	angiographic	O
12	image	O
13	quality	O
14	.	O

1	The	O
2	recombinant	O
3	vaccinia	O
4	virus	O
5	-	O
6	expressed	O
7	mutant	O
8	P1	O
9	polyproteins	O
10	were	O
11	analyzed	O
12	for	O
13	proteolytic	O
14	processing	O
15	defects	O
16	in	O
17	cells	O
18	coinfected	O
19	with	O
20	a	O
21	recombinant	O
22	vaccinia	O
23	virus	O
24	(	O
25	VVP3	O
26	)	O
27	that	O
28	expresses	O
29	the	O
30	poliovirus	O
31	3CD	O
32	protease	O
33	and	O
34	for	O
35	processing	O
36	and	O
37	assembly	O
38	defects	O
39	by	O
40	using	O
41	a	O
42	trans	O
43	complementation	O
44	system	O
45	in	O
46	which	O
47	P1	O
48	-	O
49	expressing	O
50	recombinant	O
51	vaccinia	O
52	viruses	O
53	provide	O
54	capsid	O
55	precursor	O
56	to	O
57	a	O
58	defective	O
59	poliovirus	O
60	genome	O
61	that	O
62	does	O
63	not	O
64	express	O
65	functional	O
66	capsid	O
67	proteins	O
68	(	O
69	D	O
70	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	contact	O
6	allergy	O
7	to	O
8	K	O
9	-	O
10	CG	O
11	is	O
12	common	O
13	.	O

1	DATA	O
2	SOURCES	O
3	:	O
4	Epidemiologic	O
5	studies	O
6	,	O
7	research	O
8	studies	O
9	,	O
10	review	O
11	articles	O
12	,	O
13	and	O
14	government	O
15	reports	O
16	pertaining	O
17	to	O
18	epidemiology	O
19	of	O
20	lung	O
21	cancer	O
22	.	O

1	A	B
2	receptor	I
3	-	I
4	like	I
5	protein	I
6	kinase	I
7	,	O
8	OsPK10	O
9	,	O
10	has	O
11	been	O
12	cloned	O
13	from	O
14	rice	O
15	(	O
16	Oryza	O
17	sativa	O
18	).	O

1	We	O
2	consider	O
3	that	O
4	DIL	O
5	-	O
6	CP	O
7	is	O
8	a	O
9	safe	O
10	and	O
11	excellent	O
12	CP	O
13	in	O
14	CABG	O
15	surgery	O
16	and	O
17	we	O
18	are	O
19	now	O
20	utilizing	O
21	this	O
22	CP	O
23	in	O
24	all	O
25	patients	O
26	requiring	O
27	CABG	O
28	surgery	O
29	.	O

1	17	O
2	.	O
3	5	O
4	%	O
5	of	O
6	cycles	O
7	).	O

1	Gamma	B
2	glutamyl	I
3	transpeptidase	I
4	(	O
5	GGTP	O
6	)	O
7	activity	O
8	in	O
9	the	O
10	seminal	O
11	fluid	O

1	These	O
2	data	O
3	provide	O
4	strong	O
5	evidence	O
6	that	O
7	E2F	B
8	or	O
9	an	O
10	E2F	B
11	-	I
12	related	I
13	transcription	I
14	factor	I
15	is	O
16	involved	O
17	in	O
18	the	O
19	regulation	O
20	of	O
21	nonmuscle	O
22	myosin	B
23	expression	O
24	.	O

1	Group	O
2	psychometric	O
3	functions	O
4	for	O
5	listeners	O
6	with	O
7	hearing	O
8	loss	O
9	do	O
10	not	O
11	show	O
12	a	O
13	decrease	O
14	in	O
15	performance	O
16	at	O
17	the	O
18	largest	O
19	values	O
20	of	O
21	delta	O
22	f	O
23	included	O
24	in	O
25	this	O
26	study	O
27	.	O

1	Depending	O
2	on	O
3	treatment	O
4	exposures	O
5	,	O
6	this	O
7	at	O
8	-	O
9	risk	O
10	population	O
11	may	O
12	experience	O
13	life	O
14	-	O
15	threatening	O
16	late	O
17	effects	O
18	,	O
19	such	O
20	as	O
21	cirrhosis	O
22	secondary	O
23	to	O
24	hepatitis	O
25	C	O
26	or	O
27	late	O
28	-	O
29	onset	O
30	anthracycline	O
31	-	O
32	induced	O
33	cardiomyopathy	O
34	,	O
35	or	O
36	life	O
37	-	O
38	changing	O
39	late	O
40	effects	O
41	,	O
42	such	O
43	as	O
44	cognitive	O
45	dysfunction	O
46	.	O

1	Consistent	O
2	with	O
3	this	O
4	finding	O
5	,	O
6	wild	O
7	-	O
8	type	O
9	SAGA	O
10	inhibits	O
11	TBP	B
12	binding	I
13	to	O
14	the	O
15	HIS3	B
16	promoter	I
17	in	O
18	vitro	O
19	,	O
20	while	O
21	SAGA	O
22	lacking	O
23	Spt3	O
24	or	O
25	Spt8	O
26	is	O
27	not	O
28	inhibitory	O
29	.	O

1	Triumph	O
2	of	O
3	Leninist	O
4	national	O
5	policy	O

1	Interferon	B
2	-	I
3	alpha	I
4	treatment	O
5	of	O
6	posttransplant	O
7	lymphoproliferative	O
8	disorder	O
9	in	O
10	recipients	O
11	of	O
12	solid	O
13	organ	O
14	transplants	O
15	.	O

1	CONCLUSIONS	O
2	:	O
3	Significant	O
4	elevations	O
5	of	O
6	IL	B
7	-	I
8	1alpha	I
9	and	O
10	IL	B
11	-	I
12	1beta	I
13	occur	O
14	in	O
15	patients	O
16	with	O
17	bacterial	O
18	cystitis	O
19	and	O
20	microscopic	O
21	hematuria	O
22	.	O

1	We	O
2	have	O
3	developed	O
4	a	O
5	rAAV	O
6	-	O
7	mediated	O
8	gene	O
9	transfer	O
10	system	O
11	for	O
12	the	O
13	rat	B
14	preproinsulin	I
15	II	I
16	gene	I
17	.	O

1	USA	O
2	80	O
3	,	O
4	802	O
5	-	O
6	806	O
7	]	O
8	was	O
9	used	O
10	to	O
11	isolate	O
12	a	O
13	genomic	O
14	clone	O
15	lambda	O
16	PGK	B
17	-	I
18	1	I
19	containing	O
20	a	O
21	portion	O
22	of	O
23	an	O
24	autosomal	O
25	locus	O
26	for	O
27	phosphoglycerate	B
28	kinase	I
29	(	O
30	PGK	O
31	).	O

1	The	O
2	role	O
3	of	O
4	calcitonin	B
5	,	O
6	and	O
7	other	O
8	agonists	O
9	which	O
10	activate	O
11	the	O
12	cAMP	O
13	pathway	O
14	,	O
15	in	O
16	regulating	O
17	transcription	O
18	of	O
19	the	O
20	human	B
21	parathyroid	I
22	hormone	I
23	-	I
24	related	I
25	protein	I
26	(	I
27	PTHrP	I
28	)	I
29	gene	I
30	was	O
31	investigated	O
32	in	O
33	a	O
34	human	O
35	lung	O
36	cancer	O
37	cell	O
38	line	O
39	(	O
40	BEN	O
41	).	O

1	Mutations	O
2	in	O
3	the	O
4	alpha	O
5	and	O
6	sigma	B
7	-	I
8	70	I
9	subunits	I
10	of	O
11	RNA	O
12	polymerase	O
13	affect	O
14	expression	O
15	of	O
16	the	O
17	mer	O
18	operon	O
19	.	O

1	These	O
2	characteristics	O
3	indicated	O
4	the	O
5	pronounced	O
6	activity	O
7	of	O
8	collagenous	O
9	fiber	O
10	synthesis	O
11	and	O
12	the	O
13	matrix	O
14	of	O
15	the	O
16	osteoid	O
17	tissue	O
18	.	O

1	The	O
2	potential	O
3	for	O
4	highly	O
5	reactive	O
6	nanoparticles	O
7	(	O
8	RNP	O
9	)	O
10	to	O
11	absorb	O
12	destructively	O
13	,	O
14	i	O
15	.	O
16	e	O
17	.	O
18	to	O
19	neutralize	O
20	highly	O
21	toxic	O
22	substances	O
23	such	O
24	as	O
25	the	O
26	warfare	O
27	agents	O
28	GA	O
29	,	O
30	GB	O
31	,	O
32	HD	O
33	and	O
34	VX	O
35	,	O
36	has	O
37	been	O
38	demonstrated	O
39	in	O
40	the	O
41	laboratory	O
42	.	O

1	Leukemia	O
2	-	O
3	inhibitory	O
4	factor	O
5	(	O
6	LIF	O
7	)	O
8	is	O
9	a	O
10	neuropoietin	O
11	able	O
12	to	O
13	regulate	O
14	the	O
15	differentiation	O
16	and	O
17	the	O
18	survival	O
19	of	O
20	many	O
21	cell	O
22	types	O
23	,	O
24	which	O
25	include	O
26	some	O
27	neuronal	O
28	populations	O
29	.	O

1	METHODS	O
2	:	O
3	Out	O
4	of	O
5	171	O
6	patients	O
7	receiving	O
8	anticoagulation	O
9	between	O
10	July	O
11	1992	O
12	and	O
13	December	O
14	1993	O
15	,	O
16	83	O
17	patients	O
18	with	O
19	hemispheric	O
20	embolisms	O
21	received	O
22	heparin	O
23	within	O
24	72	O
25	hours	O
26	from	O
27	onset	O
28	(	O
29	activated	O
30	partial	O
31	thromboplastin	B
32	time	O
33	[	O
34	aPTT	O
35	]	O
36	1	O
37	.	O
38	5	O
39	times	O
40	control	O
41	value	O
42	).	O

1	Structural	O
2	analysis	O
3	of	O
4	the	O
5	5	O
6	'-	O
7	regulatory	O
8	region	O
9	reveals	O
10	that	O
11	the	O
12	c	B
13	-	I
14	met	I
15	promoter	I
16	lacks	O
17	TATA	O
18	or	O
19	CAAT	O
20	elements	O
21	but	O
22	has	O
23	an	O
24	extremely	O
25	high	O
26	G	O
27	-	O
28	C	O
29	content	O
30	and	O
31	multiple	O
32	Sp1	B
33	binding	I
34	sites	I
35	.	O

1	Early	O
2	-	O
3	onset	O
4	scleral	O
5	necrosis	O
6	after	O
7	iodine	O
8	I	O
9	125	O
10	plaque	O
11	radiotherapy	O
12	for	O
13	ciliochoroidal	O
14	melanoma	O
15	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	acetyltransferase	O
6	activity	O
7	of	O
8	p300	B
9	was	O
10	observed	O
11	to	O
12	be	O
13	distinct	O
14	from	O
15	the	O
16	broadly	O
17	essential	O
18	activation	O
19	function	O
20	of	O
21	the	O
22	CH3	O
23	domain	O
24	/	O
25	E1A	B
26	-	I
27	binding	I
28	region	O
29	.	O

1	The	O
2	relative	O
3	abundance	O
4	of	O
5	each	O
6	alternatively	O
7	spliced	O
8	mRNA	O
9	was	O
10	determined	O
11	by	O
12	reverse	B
13	transcription	I
14	-	I
15	polymerase	I
16	chain	I
17	reaction	O
18	in	O
19	various	O
20	human	O
21	tissues	O
22	and	O
23	cell	O
24	lines	O
25	.	O

1	There	O
2	were	O
3	no	O
4	instances	O
5	of	O
6	major	O
7	flap	O
8	necrosis	O
9	although	O
10	two	O
11	flaps	O
12	showed	O
13	tip	O
14	ischaemia	O
15	.	O

1	In	O
2	protocol	O
3	2	O
4	,	O
5	eight	O
6	different	O
7	subjects	O
8	performed	O
9	Con	O
10	and	O
11	Ecc	O
12	arm	O
13	curls	O
14	to	O
15	fatigue	O
16	,	O
17	followed	O
18	by	O
19	postexercise	O
20	muscle	O
21	ischemia	O
22	,	O
23	by	O
24	using	O
25	the	O
26	same	O
27	resistance	O
28	as	O
29	in	O
30	protocol	O
31	1	O
32	.	O

1	Secretory	O
2	IgA	B
3	and	O
4	serum	B
5	immunoglobulins	I
6	as	O
7	indices	O
8	of	O
9	the	O
10	local	O
11	immunity	O
12	of	O
13	the	O
14	intestinal	O
15	mucosa	O
16	in	O
17	acute	O
18	leukemias	O

1	This	O
2	region	O
3	binds	O
4	two	O
5	ubiquitous	O
6	nuclear	O
7	factors	O
8	,	O
9	USF	B
10	/	I
11	MLTF	I
12	and	O
13	the	O
14	CAAT	B
15	-	I
16	binding	I
17	transcription	I
18	factor	I
19	/	I
20	nuclear	I
21	factor	I
22	1	I
23	(	I
24	CTF	I
25	/	I
26	NF1	I
27	).	O

1	Physiol	O
2	.	O

1	Its	O
2	hydropathy	O
3	profile	O
4	predicts	O
5	seven	O
6	transmembrane	O
7	spans	O
8	and	O
9	a	O
10	hydrophilic	O
11	amino	O
12	terminus	O
13	of	O
14	approximately	O
15	100	O
16	residues	O
17	,	O
18	and	O
19	it	O
20	suggests	O
21	the	O
22	presence	O
23	of	O
24	an	O
25	amphiphilic	B
26	alpha	I
27	-	I
28	helix	I
29	(	O
30	L	O
31	-	O
32	61	O
33	to	O
34	F	O
35	-	O
36	97	O
37	)	O
38	in	O
39	close	O
40	proximity	O
41	to	O
42	the	O
43	first	O
44	strongly	O
45	hydrophobic	O
46	segment	O
47	of	O
48	ProW	O
49	.	O

1	At	O
2	baseline	O
3	,	O
4	serum	O
5	levels	O
6	of	O
7	lycopene	O
8	and	O
9	FLOP	O
10	were	O
11	abnormally	O
12	high	O
13	and	O
14	serum	O
15	FLOP	O
16	was	O
17	correlated	O
18	significantly	O
19	with	O
20	plasma	O
21	cyclosporine	O
22	levels	O
23	(	O
24	r	O
25	=	O
26	0	O
27	.	O
28	646	O
29	,	O
30	p	O
31	=	O
32	0	O
33	.	O
34	016	O
35	).	O

1	The	O
2	first	O
3	transfusion	O
4	resulted	O
5	in	O
6	a	O
7	platelet	O
8	increment	O
9	to	O
10	32	O
11	Gpt	O
12	/	O
13	l	O
14	(	O
15	CCI	O
16	11	O
17	).	O

1	Surprisingly	O
2	,	O
3	the	O
4	COOH	O
5	-	O
6	terminal	O
7	domain	O
8	of	O
9	RanGAP1	O
10	was	O
11	also	O
12	found	O
13	to	O
14	harbor	O
15	a	O
16	nuclear	O
17	localization	O
18	signal	O
19	.	O

1	This	O
2	article	O
3	will	O
4	briefly	O
5	review	O
6	the	O
7	published	O
8	data	O
9	on	O
10	the	O
11	morphology	O
12	,	O
13	function	O
14	,	O
15	and	O
16	biochemistry	O
17	of	O
18	the	O
19	normal	O
20	renal	O
21	medulla	O
22	and	O
23	the	O
24	pathology	O
25	associated	O
26	with	O
27	RPN	O
28	,	O
29	together	O
30	with	O
31	the	O
32	secondary	O
33	changes	O
34	which	O
35	give	O
36	rise	O
37	to	O
38	cortical	O
39	degeneration	O
40	or	O
41	epithelial	O
42	carcinoma	O
43	.	O

1	Metabolic	O
2	labeling	O
3	studies	O
4	in	O
5	S	O
6	.	O
7	cerevisiae	O
8	and	O
9	co	O
10	-	O
11	expression	O
12	of	O
13	nmt72p	O
14	with	O
15	several	O
16	protein	O
17	substrates	O
18	of	O
19	Nmt1p	O
20	in	O
21	Escherichia	O
22	coli	O
23	indicate	O
24	that	O
25	the	O
26	Leu99	O
27	-->	O
28	Pro	O
29	substitution	O
30	causes	O
31	a	O
32	reduction	O
33	in	O
34	the	O
35	acylation	O
36	of	O
37	some	O
38	but	O
39	not	O
40	all	O
41	protein	O
42	substrates	O
43	.	O

1	Merr	O
2	.)	O
3	embryo	O
4	library	O
5	.	O

1	Ten	O
2	days	O
3	of	O
4	cefadroxil	O
5	therapy	O
6	was	O
7	used	O
8	to	O
9	treat	O
10	44	O
11	children	O
12	with	O
13	urinary	O
14	tract	O
15	infection	O
16	and	O
17	CRP	B
18	values	O
19	greater	O
20	than	O
21	or	O
22	equal	O
23	to	O
24	28	O
25	microgram	O
26	/	O
27	ml	O
28	(	O
29	CRP	B
30	-	I
31	positive	O
32	group	O
33	).	O

1	During	O
2	both	O
3	encephalopathy	O
4	episodes	O
5	,	O
6	CSF	B
7	protein	I
8	and	O
9	immunoglobulin	B
10	G	I
11	(	I
12	IgG	I
13	)	O
14	levels	O
15	were	O
16	elevated	O
17	without	O
18	an	O
19	increased	O
20	IgG	B
21	index	O
22	or	O
23	IgG	B
24	synthesis	O
25	rate	O
26	.	O

1	Recurrent	O
2	arterial	O
3	thrombotic	O
4	disease	O
5	on	O
6	young	O
7	onset	O
8	and	O
9	protein	O
10	S	O
11	deficiency	O
12	.	O

1	Northern	O
2	blot	O
3	analysis	O
4	revealed	O
5	the	O
6	expression	O
7	of	O
8	LIMK	O
9	-	O
10	1	O
11	mRNA	O
12	predominantly	O
13	in	O
14	the	O
15	brain	O
16	and	O
17	the	O
18	expression	O
19	of	O
20	LIMK	O
21	-	O
22	2	O
23	mRNA	O
24	in	O
25	various	O
26	tissues	O
27	in	O
28	the	O
29	rat	O
30	.	O

1	Moreover	O
2	,	O
3	the	O
4	ability	O
5	to	O
6	selectivity	O
7	arrest	O
8	elongation	O
9	by	O
10	polIII	O
11	at	O
12	defined	O
13	positions	O
14	within	O
15	the	O
16	tRNA	B
17	gene	I
18	transcription	O
19	unit	O
20	has	O
21	permitted	O
22	the	O
23	identification	O
24	of	O
25	discrete	O
26	functional	O
27	properties	O
28	of	O
29	paused	O
30	mammalian	O
31	polIII	O
32	ternary	O
33	complexes	O
34	.	O

1	We	O
2	studied	O
3	the	O
4	role	O
5	of	O
6	prostaglandins	O
7	in	O
8	acid	O
9	-	O
10	induced	O
11	esophagitis	O
12	and	O
13	the	O
14	associated	O
15	LES	O
16	hypotension	O
17	by	O
18	simultaneous	O
19	treatment	O
20	of	O
21	some	O
22	animals	O
23	with	O
24	indomethacin	O
25	(	O
26	150	O
27	micrograms	O
28	/	O
29	kg	O
30	intravenous	O
31	),	O
32	a	O
33	specific	O
34	inhibitor	O
35	of	O
36	prostaglandin	O
37	synthesis	O
38	,	O
39	either	O
40	during	O
41	production	O
42	of	O
43	esophagitis	O
44	or	O
45	during	O
46	recovery	O
47	.	O

1	The	O
2	lacS	O
3	gene	O
4	was	O
5	cloned	O
6	in	O
7	an	O
8	E	O
9	.	O
10	coli	O
11	-	O
12	Streptococcus	O
13	shuttle	O
14	vector	O
15	and	O
16	was	O
17	expressed	O
18	both	O
19	in	O
20	a	O
21	lacS	O
22	deletion	O
23	derivative	O
24	of	O
25	S	O
26	.	O
27	thermophilus	O
28	and	O
29	in	O
30	a	O
31	pNZ63	O
32	-	O
33	cured	O
34	strain	O
35	,	O
36	L	O
37	.	O
38	lactis	O
39	NZ6091	O
40	.	O

1	Sweet	O
2	oranges	O
3	,	O
4	mandarin	O
5	,	O
6	grapefruit	O
7	,	O
8	lemon	O
9	,	O
10	and	O
11	lime	O
12	are	O
13	generally	O
14	used	O
15	for	O
16	processing	O
17	.	O

1	We	O
2	also	O
3	discovered	O
4	a	O
5	V	O
6	lambda	O
7	pseudogene	O
8	,	O
9	called	O
10	psi	O
11	V	O
12	lambda	O
13	1	O
14	,	O
15	3	O
16	kb	O
17	upstream	O
18	of	O
19	the	O
20	U266	O
21	lambda	O
22	gene	O
23	.	O

1	The	O
2	mean	O
3	change	O
4	in	O
5	HbA1	O
6	,	O
7	adjusted	O
8	for	O
9	the	O
10	initial	O
11	value	O
12	,	O
13	was	O
14	-	O
15	0	O
16	.	O
17	4	O
18	%	O
19	in	O
20	the	O
21	experimental	O
22	and	O
23	+	O
24	0	O
25	.	O
26	5	O
27	%	O
28	in	O
29	the	O
30	control	O
31	group	O
32	(	O
33	p	O
34	less	O
35	than	O
36	0	O
37	.	O
38	05	O
39	).	O

1	No	O
2	patient	O
3	had	O
4	a	O
5	history	O
6	of	O
7	excess	O
8	alcohol	O
9	intake	O
10	,	O
11	or	O
12	prolonged	O
13	intake	O
14	of	O
15	hepatotoxic	O
16	drugs	O
17	and	O
18	steroids	O
19	,	O
20	and	O
21	were	O
22	not	O
23	obese	O
24	or	O
25	malnourished	O
26	.	O

1	1972	O
2	.	O

1	Renin	O
2	studies	O
3	performed	O
4	in	O
5	34	O
6	hypertensive	O
7	patients	O
8	and	O
9	in	O
10	a	O
11	control	O
12	group	O
13	of	O
14	11	O
15	recipients	O
16	showed	O
17	that	O
18	elevation	O
19	of	O
20	plasma	O
21	renin	B
22	activity	O
23	and	O
24	of	O
25	plasma	O
26	aldosterone	O
27	level	O
28	is	O
29	frequent	O
30	but	O
31	difficult	O
32	to	O
33	interpret	O
34	,	O
35	particularly	O
36	when	O
37	a	O
38	renal	O
39	artery	O
40	stenosis	O
41	is	O
42	observed	O
43	.	O

1	It	O
2	is	O
3	transparent	O
4	,	O
5	cheap	O
6	to	O
7	be	O
8	made	O
9	,	O
10	and	O
11	easy	O
12	to	O
13	empty	O
14	and	O
15	was	O
16	tested	O
17	in	O
18	118	O
19	animals	O
20	for	O
21	two	O
22	and	O
23	four	O
24	weeks	O
25	.	O

1	Control	O
2	Tmuscle	O
3	was	O
4	35	O
5	.	O
6	8	O
7	+/-	O
8	0	O
9	.	O
10	7	O
11	degrees	O
12	C	O
13	,	O
14	with	O
15	control	O
16	Wi	O
17	,	O
18	max	O
19	being	O
20	51	O
21	.	O
22	6	O
23	(	O
24	SD	O
25	8	O
26	.	O
27	7	O
28	)	O
29	W	O
30	.	O
31	kg	O
32	-	O
33	1	O
34	.	O

1	Induced	O
2	expression	O
3	of	O
4	c	B
5	-	I
6	myc	I
7	is	O
8	likely	O
9	to	O
10	contribute	O
11	to	O
12	the	O
13	proliferation	O
14	of	O
15	Stat1	O
16	-	O
17	null	O
18	cells	O
19	in	O
20	response	O
21	to	O
22	IFNs	O
23	.	O

1	Acute	O
2	type	O
3	A	O
4	hepatitis	O
5	in	O
6	three	O
7	patients	O
8	with	O
9	chronic	O
10	HBV	O
11	infection	O
12	.	O

1	Here	O
2	we	O
3	have	O
4	tested	O
5	the	O
6	hypothesis	O
7	that	O
8	the	O
9	short	O
10	transcripts	O
11	,	O
12	or	O
13	proteins	O
14	translated	O
15	from	O
16	the	O
17	short	O
18	transcripts	O
19	,	O
20	are	O
21	also	O
22	required	O
23	for	O
24	respiration	O
25	.	O

1	Antituberculosis	O
2	agents	O
3	.	O

1	These	O
2	sites	O
3	are	O
4	also	O
5	potential	O
6	keratan	O
7	sulfate	O
8	attachment	O
9	sites	O
10	.	O

1	Cell	O
2	survival	O
3	by	O
4	Epo	B
5	did	O
6	not	O
7	require	O
8	activation	O
9	of	O
10	other	O
11	known	O
12	signaling	O
13	pathways	O
14	including	O
15	PI	B
16	-	I
17	3	I
18	kinase	I
19	,	O
20	PLC	B
21	-	I
22	gamma	I
23	,	O
24	Ras	B
25	or	O
26	Stats	O
27	.	O

1	BACKGROUND	O
2	:	O
3	Delineation	O
4	of	O
5	the	O
6	morphologic	O
7	aspects	O
8	of	O
9	age	O
10	-	O
11	related	O
12	macular	O
13	degeneration	O
14	(	O
15	ARMD	O
16	)	O
17	is	O
18	helpful	O
19	in	O
20	correlation	O
21	with	O
22	the	O
23	clinical	O
24	features	O
25	and	O
26	may	O
27	contribute	O
28	to	O
29	understanding	O
30	the	O
31	pathogenesis	O
32	.	O

1	Suppressive	O
2	therapy	O
3	for	O
4	thyroid	O
5	nodules	O
6	.	O

1	Although	O
2	ANP	O
3	induced	O
4	systemic	O
5	capillary	O
6	filtration	O
7	,	O
8	in	O
9	the	O
10	calf	O
11	,	O
12	filtration	O
13	was	O
14	reduced	O
15	with	O
16	ANP	O
17	.	O

1	SPP	O
2	also	O
3	induced	O
4	transient	O
5	tyrosine	O
6	phosphorylation	O
7	of	O
8	focal	O
9	adhesion	O
10	kinase	O
11	(	O
12	p125	O
13	(	O
14	FAK	B
15	)),	I
16	a	O
17	cytosolic	B
18	tyrosine	I
19	kinase	I
20	that	O
21	localizes	O
22	in	O
23	focal	O
24	adhesions	O
25	,	O
26	and	O
27	of	O
28	the	O
29	cytoskeleton	O
30	-	O
31	associated	O
32	protein	O
33	paxillin	B
34	.	O

1	MSMS	O
2	Council	O
3	hears	O
4	new	O
5	public	O
6	health	O
7	director	O
8	.	O

1	The	O
2	NR2	O
3	hybrid	O
4	is	O
5	a	O
6	powerful	O
7	tool	O
8	for	O
9	the	O
10	mapping	O
11	of	O
12	new	O
13	probes	O
14	of	O
15	this	O
16	region	O
17	,	O
18	as	O
19	well	O
20	as	O
21	for	O
22	obtaining	O
23	new	O
24	informative	O
25	probes	O
26	specific	O
27	for	O
28	the	O
29	deletion	O
30	by	O
31	subtractive	O
32	cloning	O
33	of	O
34	the	O
35	region	O
36	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	sMtCK	O
6	genomic	O
7	upstream	O
8	sequences	O
9	reveals	O
10	a	O
11	typical	O
12	TATAA	O
13	box	O
14	within	O
15	the	O
16	80	O
17	base	O
18	pairs	O
19	(	O
20	bp	O
21	)	O
22	that	O
23	,	O
24	by	O
25	transfection	O
26	experiments	O
27	,	O
28	are	O
29	sufficient	O
30	to	O
31	promote	O
32	expression	O
33	of	O
34	chimeric	O
35	plasmids	O
36	with	O
37	the	O
38	chloramphenicol	B
39	acetyltransferase	I
40	reporter	I
41	.	O

1	Phase	O
2	II	O
3	study	O
4	of	O
5	VP	O
6	-	O
7	16	O
8	(	O
9	capsule	O
10	)	O
11	in	O
12	solid	O
13	tumors	O
14	.	O

1	Although	O
2	Grice	O
3	'	O
4	s	O
5	operation	O
6	has	O
7	been	O
8	used	O
9	all	O
10	over	O
11	the	O
12	world	O
13	,	O
14	no	O
15	systematic	O
16	account	O
17	of	O
18	it	O
19	has	O
20	been	O
21	found	O
22	in	O
23	the	O
24	literature	O
25	(	O
26	including	O
27	publications	O
28	dealing	O
29	with	O
30	technique	O
31	),	O
32	which	O
33	presents	O
34	it	O
35	in	O
36	terms	O
37	related	O
38	to	O
39	the	O
40	basic	O
41	"	O
42	classical	O
43	"	O
44	principles	O
45	on	O
46	which	O
47	the	O
48	operation	O
49	was	O
50	conceived	O
51	.	O

1	One	O
2	site	O
3	,	O
4	PAL	O
5	,	O
6	occurs	O
7	within	O
8	the	O
9	10	O
10	bp	O
11	sequence	O
12	GGGGAGGAGG	O
13	.	O

1	However	O
2	,	O
3	mean	O
4	food	O
5	intake	O
6	in	O
7	the	O
8	40	O
9	%	O
10	group	O
11	was	O
12	half	O
13	that	O
14	of	O
15	the	O
16	ACT	O
17	group	O
18	(	O
19	p	O
20	<	O
21	0	O
22	.	O
23	001	O
24	)	O
25	and	O
26	significantly	O
27	less	O
28	(	O
29	p	O
30	<	O
31	0	O
32	.	O
33	01	O
34	)	O
35	than	O
36	the	O
37	SEP	O
38	group	O
39	,	O
40	which	O
41	consumed	O
42	amounts	O
43	equivalent	O
44	to	O
45	65	O
46	%	O
47	of	O
48	daily	O
49	requirement	O
50	.	O

1	Mutations	O
2	in	O
3	the	O
4	VPS45	O
5	gene	O
6	,	O
7	a	O
8	SEC1	O
9	homologue	O
10	,	O
11	result	O
12	in	O
13	vacuolar	O
14	protein	O
15	sorting	O
16	defects	O
17	and	O
18	accumulation	O
19	of	O
20	membrane	O
21	vesicles	O
22	.	O

1	The	O
2	statistical	O
3	analysis	O
4	of	O
5	data	O
6	of	O
7	TRH	O
8	test	O
9	on	O
10	a	O
11	sample	O
12	of	O
13	57	O
14	healthy	O
15	volunteers	O
16	has	O
17	permitted	O
18	an	O
19	evaluation	O
20	of	O
21	the	O
22	upper	O
23	limits	O
24	of	O
25	the	O
26	normal	O
27	thyrotropin	O
28	response	O
29	;	O
30	the	O
31	secretory	O
32	area	O
33	(	O
34	As	O
35	)	O
36	was	O
37	shown	O
38	to	O
39	be	O
40	more	O
41	discriminating	O
42	.	O

1	Furthermore	O
2	,	O
3	using	O
4	transgenic	O
5	mouse	O
6	technology	O
7	we	O
8	localized	O
9	independent	O
10	cis	O
11	-	O
12	regulatory	O
13	elements	O
14	controlling	O
15	the	O
16	tissue	O
17	-	O
18	specific	O
19	expression	O
20	of	O
21	Pax6	O
22	.	O

1	Constitutive	O
2	phosphorylation	O
3	of	O
4	the	O
5	CD30v	B
6	protein	I
7	was	O
8	demonstrated	O
9	by	O
10	in	O
11	vitro	O
12	labeling	O
13	with	O
14	[	O
15	32P	O
16	].	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	anthraquinone	O
6	sennoside	O
7	B	O
8	and	O
9	rhein	O
10	are	O
11	weakly	O
12	genotoxic	O
13	.	O

1	Remarkably	O
2	,	O
3	U21	O
4	contains	O
5	a	O
6	long	O
7	stretch	O
8	(	O
9	13	O
10	nt	O
11	.)	O
12	of	O
13	complementarity	O
14	to	O
15	a	O
16	highly	O
17	conserved	O
18	sequence	O
19	in	O
20	28S	B
21	rRNA	I
22	.	O

1	BACKGROUND	O
2	:	O
3	The	O
4	aim	O
5	of	O
6	this	O
7	study	O
8	was	O
9	to	O
10	determine	O
11	and	O
12	compare	O
13	interleukin	B
14	-	I
15	6	I
16	(	I
17	IL	I
18	-	I
19	6	O
20	)	O
21	levels	O
22	in	O
23	gingival	O
24	crevicular	O
25	fluid	O
26	(	O
27	GCF	O
28	)	O
29	and	O
30	clinical	O
31	periodontal	O
32	findings	O
33	in	O
34	patients	O
35	with	O
36	rheumatoid	O
37	arthritis	O
38	(	O
39	RA	O
40	)	O
41	and	O
42	adult	O
43	periodontitis	O
44	(	O
45	AP	B
46	).	O

1	Effect	O
2	of	O
3	variations	O
4	in	O
5	time	O
6	interval	O
7	between	O
8	treatment	O
9	with	O
10	BCG	O
11	and	O
12	quartz	O
13	dust	O
14	on	O
15	translocation	O
16	of	O
17	quartz	O
18	dust	O
19	from	O
20	the	O
21	lungs	O
22	to	O
23	their	O
24	regional	O
25	lymph	O
26	nodes	O
27	.	O

1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	of	O
6	the	O
7	R2	O
8	protein	O
9	was	O
10	used	O
11	to	O
12	provide	O
13	evidence	O
14	that	O
15	this	O
16	motif	O
17	is	O
18	also	O
19	part	O
20	of	O
21	the	O
22	active	O
23	site	O
24	of	O
25	the	O
26	endonuclease	O
27	encoded	O
28	by	O
29	this	O
30	element	O
31	.	O

1	Anoxia	O
2	was	O
3	introduced	O
4	by	O
5	perfusing	O
6	the	O
7	gill	O
8	with	O
9	water	O
10	deprived	O
11	of	O
12	oxygen	O
13	or	O
14	by	O
15	halting	O
16	the	O
17	water	O
18	flow	O
19	to	O
20	the	O
21	gill	O
22	.	O

1	The	O
2	properties	O
3	of	O
4	the	O
5	phi	O
6	29	O
7	SSB	O
8	-	O
9	ssDNA	O
10	complex	O
11	are	O
12	described	O
13	.	O

1	We	O
2	have	O
3	cloned	O
4	and	O
5	sequenced	O
6	the	O
7	mouse	O
8	NMO1	O
9	cDNA	O
10	,	O
11	which	O
12	encodes	O
13	the	O
14	NAD	O
15	(	O
16	P	O
17	)	O
18	H	O
19	:	O
20	menadione	O
21	oxidoreductase	O
22	[	O
23	also	O
24	called	O
25	NAD	O
26	(	O
27	P	O
28	)	O
29	H	B
30	:(	I
31	quinone	I
32	acceptor	I
33	)	I
34	oxidoreductase	I
35	;	I
36	quinone	I
37	reductase	I
38	;	I
39	azo	I
40	dye	I
41	reductase	I
42	;	O
43	DT	O
44	diaphorase	O
45	;	O
46	EC	O
47	1	O
48	.	O
49	6	O
50	.	O
51	99	O
52	.	O
53	2	O
54	].	O

1	Infectious	O
2	mutant	O
3	virus	O
4	progeny	O
5	was	O
6	obtained	O
7	only	O
8	on	O
9	complementing	O
10	gK	O
11	-	O
12	expressing	O
13	cells	O
14	,	O
15	suggesting	O
16	that	O
17	gK	O
18	has	O
19	an	O
20	important	O
21	function	O
22	in	O
23	the	O
24	replication	O
25	cycle	O
26	.	O

1	In	O
2	cells	O
3	limited	O
4	for	O
5	His	O
6	,	O
7	increased	O
8	expression	O
9	of	O
10	arg	O
11	-	O
12	2	O
13	and	O
14	cpc	B
15	-	I
16	1	I
17	,	O
18	and	O
19	decreased	O
20	expression	O
21	of	O
22	cox	O
23	-	O
24	5	O
25	,	O
26	also	O
27	had	O
28	translational	O
29	and	O
30	transcriptional	O
31	components	O
32	.	O

1	The	O
2	rear	O
3	silver	O
4	liquid	O
5	chamber	O
6	was	O
7	threefold	O
8	thick	O
9	to	O
10	17	O
11	MeV	O
12	protons	O
13	in	O
14	water	O
15	and	O
16	it	O
17	efficiently	O
18	produced	O
19	either	O
20	13N	O
21	by	O
22	the	O
23	16O	O
24	(	O
25	p	O
26	,	O
27	alpha	O
28	)	O
29	13N	O
30	reaction	O
31	or	O
32	[	O
33	18F	O
34	]	O
35	fluoride	O
36	ion	O
37	by	O
38	the	O
39	18O	O
40	(	O
41	p	O
42	,	O
43	n	O
44	)	O
45	18F	O
46	reaction	O
47	.	O

1	The	O
2	coding	O
3	region	O
4	of	O
5	2385	O
6	nucleotides	O
7	corresponds	O
8	to	O
9	a	O
10	polypeptide	O
11	chain	O
12	of	O
13	795	O
14	amino	O
15	acids	O
16	,	O
17	giving	O
18	a	O
19	molecular	O
20	weight	O
21	of	O
22	91	O
23	,	O
24	555	O
25	for	O
26	the	O
27	hsp108	O
28	protein	O
29	.	O

1	Considering	O
2	these	O
3	sources	O
4	of	O
5	error	O
6	some	O
7	of	O
8	the	O
9	variability	O
10	in	O
11	the	O
12	present	O
13	investigation	O
14	might	O
15	be	O
16	avoided	O
17	by	O
18	systematic	O
19	instructions	O
20	.	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequence	O
6	exhibited	O
7	98	O
8	%	O
9	identity	O
10	to	O
11	the	O
12	human	O
13	cellular	O
14	transglutaminase	O
15	sequence	O
16	.	O

1	Mutagenesis	O
2	of	O
3	the	O
4	pecT	O
5	regulatory	O
6	region	O
7	revealed	O
8	the	O
9	presence	O
10	of	O
11	two	O
12	sites	O
13	in	O
14	which	O
15	insertions	O
16	reproduced	O
17	the	O
18	pec	O
19	-	O
20	1	O
21	phenotype	O
22	.	O

1	Wnt	B
2	-	I
3	1	I
4	overexpression	O
5	in	O
6	mammary	O
7	epithelial	O
8	cells	O
9	induced	O
10	cyclin	B
11	D1	I
12	mRNA	I
13	and	O
14	targeted	O
15	overexpression	O
16	of	O
17	Wnt	B
18	-	I
19	1	I
20	in	O
21	the	O
22	mammary	O
23	gland	O
24	of	O
25	transgenic	O
26	mice	O
27	increased	O
28	both	O
29	ILK	O
30	activity	O
31	and	O
32	cyclin	B
33	D1	I
34	levels	O
35	.	O

1	These	O
2	results	O
3	support	O
4	the	O
5	hypothesis	O
6	that	O
7	in	O
8	the	O
9	presence	O
10	of	O
11	tryptophan	O
12	the	O
13	ribosome	O
14	translating	O
15	tnaC	O
16	blocks	O
17	Rho	B
18	'	O
19	s	O
20	access	O
21	to	O
22	the	O
23	boxA	O
24	and	O
25	rut	O
26	sites	O
27	,	O
28	thereby	O
29	preventing	O
30	transcription	O
31	termination	O
32	.	O

1	High	O
2	plasma	O
3	concentrations	O
4	of	O
5	soluble	O
6	E	B
7	-	I
8	selectin	I
9	were	O
10	closely	O
11	associated	O
12	with	O
13	multiple	O
14	-	O
15	organ	O
16	dysfunction	O
17	and	O
18	death	O
19	.	O

1	In	O
2	the	O
3	control	O
4	group	O
5	,	O
6	platelet	O
7	markers	O
8	increased	O
9	1	O
10	h	O
11	after	O
12	surgery	O
13	.	O

1	The	O
2	second	O
3	functional	O
4	pair	O
5	of	O
6	CreA	O
7	sites	O
8	is	O
9	located	O
10	between	O
11	the	O
12	two	O
13	transcription	O
14	initiation	O
15	sites	O
16	.	O

1	Gastric	O
2	CO2	O
3	/	O
4	HCO3	O
5	was	O
6	determined	O
7	in	O
8	absence	O
9	of	O
10	simultaneous	O
11	inhibition	O
12	of	O
13	acid	O
14	secretion	O
15	by	O
16	intra	O
17	-	O
18	and	O
19	extragastric	O
20	pCO2	O
21	/	O
22	pH	O
23	measurements	O
24	in	O
25	23	O
26	persons	O
27	and	O
28	calculated	O
29	using	O
30	the	O
31	equation	O
32	of	O
33	Henderson	O
34	-	O
35	Hasselbalch	O
36	.	O
37	pCO2	O
38	was	O
39	measured	O
40	with	O
41	use	O
42	of	O
43	a	O
44	new	O
45	electrode	O
46	.	O

1	Characterization	O
2	of	O
3	polymorphic	O
4	TNRs	O
5	in	O
6	novel	O
7	and	O
8	even	O
9	known	O
10	genes	O
11	expressed	O
12	in	O
13	human	O
14	spinal	O
15	cord	O
16	is	O
17	likely	O
18	to	O
19	help	O
20	in	O
21	the	O
22	identification	O
23	of	O
24	new	O
25	candidates	O
26	for	O
27	genes	O
28	involved	O
29	in	O
30	neurodegenerative	O
31	disorders	O
32	.	O

1	The	O
2	levels	O
3	of	O
4	galactosyltransferase	O
5	activity	O
6	in	O
7	sera	O
8	from	O
9	normal	O
10	children	O
11	and	O
12	patients	O
13	with	O
14	cystic	O
15	fibrosis	O
16	.	O

1	These	O
2	results	O
3	provide	O
4	direct	O
5	evidence	O
6	for	O
7	differential	O
8	susceptibility	O
9	to	O
10	endonuclease	O
11	-	O
12	mediated	O
13	mRNA	O
14	decay	O
15	resulting	O
16	from	O
17	the	O
18	differential	O
19	affinity	O
20	of	O
21	a	O
22	RNA	O
23	-	O
24	binding	O
25	protein	O
26	for	O
27	cis	O
28	-	O
29	acting	O
30	stability	O
31	determinants	O
32	.	O

1	Chem	O
2	.	O

1	Twenty	O
2	-	O
3	one	O
4	ELISA	O
5	-	O
6	positive	O
7	sera	O
8	were	O
9	tested	O
10	and	O
11	confirmed	O
12	positive	O
13	by	O
14	plaque	O
15	reduction	O
16	neutralization	O
17	testing	O
18	.	O

1	We	O
2	studied	O
3	the	O
4	effect	O
5	of	O
6	skinfold	O
7	thickness	O
8	on	O
9	the	O
10	correlation	O
11	between	O
12	serum	O
13	total	O
14	bilirubin	O
15	level	O
16	and	O
17	transcutaneous	O
18	bilirubin	O
19	(	O
20	TcB	O
21	)	O
22	readings	O
23	.	O

1	The	O
2	genome	O
3	of	O
4	all	O
5	retroviruses	O
6	consists	O
7	of	O
8	two	O
9	identical	O
10	RNAs	O
11	noncovalently	O
12	linked	O
13	near	O
14	their	O
15	5	O
16	'	O
17	end	O
18	.	O

1	Mycotoxins	O
2	in	O
3	feeds	O
4	and	O
5	foods	O
6	.	O

1	The	O
2	diagnosis	O
3	of	O
4	amyloidosis	O
5	was	O
6	determined	O
7	from	O
8	a	O
9	labial	O
10	salivary	O
11	gland	O
12	biopsy	O
13	.	O

1	A	O
2	protocol	O
3	is	O
4	elaborated	O
5	for	O
6	the	O
7	preparation	O
8	and	O
9	characterization	O
10	of	O
11	a	O
12	quality	O
13	control	O
14	material	O
15	(	O
16	QCM	O
17	)	O
18	containing	O
19	intrinsic	O
20	concentration	O
21	of	O
22	cadmium	O
23	(	O
24	Cd	O
25	)	O
26	(	O
27	0	O
28	.	O
29	8	O
30	microgram	O
31	/	O
32	L	O
33	)	O
34	and	O
35	lead	O
36	(	O
37	Pb	O
38	)	O
39	(	O
40	13	O
41	.	O
42	4	O
43	micrograms	O
44	/	O
45	dL	O
46	)	O
47	from	O
48	bovine	O
49	blood	O
50	and	O
51	an	O
52	elevated	O
53	QCM	O
54	containing	O
55	Cd	O
56	(	O
57	5	O
58	.	O
59	0	O
60	micrograms	O
61	/	O
62	L	O
63	),	O
64	mercury	O
65	(	O
66	Hg	O
67	)	O
68	(	O
69	11	O
70	.	O
71	2	O
72	micrograms	O
73	/	O
74	L	O
75	),	O
76	and	O
77	Pb	O
78	(	O
79	34	O
80	.	O
81	5	O
82	micrograms	O
83	/	O
84	dL	O
85	)	O
86	from	O
87	bovine	O
88	blood	O
89	spiked	O
90	with	O
91	aqueous	O
92	spiking	O
93	-	O
94	solutions	O
95	prepared	O
96	with	O
97	salts	O
98	of	O
99	Cd	O
100	,	O
101	Hg	O
102	,	O
103	and	O
104	Pb	O
105	.	O

1	In	O
2	patients	O
3	resistant	O
4	to	O
5	VAD	O
6	,	O
7	high	O
8	-	O
9	dose	O
10	therapies	O
11	with	O
12	intravenous	O
13	melphalan	O
14	,	O
15	a	O
16	CBV	O
17	combination	O
18	(	O
19	cyclophosphamide	O
20	-	O
21	BCNU	O
22	-	O
23	VP	O
24	-	O
25	16	O
26	)	O
27	or	O
28	an	O
29	EDAP	O
30	regimen	O
31	(	O
32	VP	O
33	-	O
34	16	O
35	-	O
36	platinum	O
37	)	O
38	produced	O
39	responses	O
40	in	O
41	about	O
42	40	O
43	%	O
44	of	O
45	patients	O
46	.	O

1	In	O
2	human	O
3	brain	O
4	,	O
5	contactin	O
6	was	O
7	first	O
8	identified	O
9	by	O
10	amino	O
11	terminal	O
12	and	O
13	peptide	O
14	sequencing	O
15	of	O
16	the	O
17	lentil	B
18	-	I
19	lectin	I
20	-	I
21	binding	I
22	glycoprotein	I
23	Gp135	O
24	.	O

1	Symposium	O
2	on	O
3	presenile	O
4	spongy	O
5	encephalopathies	O
6	.	O

1	The	O
2	tissue	O
3	-	O
4	specific	O
5	expression	O
6	of	O
7	DP	B
8	family	I
9	members	O
10	suggests	O
11	that	O
12	the	O
13	combination	O
14	of	O
15	DP	O
16	/	O
17	E2F	B
18	heterodimers	O
19	that	O
20	constitute	O
21	DRTF1	O
22	/	O
23	E2F	B
24	is	O
25	influenced	O
26	by	O
27	the	O
28	phenotype	O
29	of	O
30	the	O
31	cell	O
32	.	O

1	Myocardial	O
2	interstitial	O
3	edema	O
4	is	O
5	more	O
6	likely	O
7	a	O
8	potential	O
9	mechanism	O
10	of	O
11	diastolic	O
12	dysfunction	O
13	after	O
14	DC	O
15	shocks	O
16	.	O

1	Heterogeneous	B
2	nuclear	I
3	ribonucleoprotein	I
4	A1	I
5	binds	O
6	to	O
7	the	O
8	transcription	O
9	-	O
10	regulatory	O
11	region	O
12	of	O
13	mouse	O
14	hepatitis	O
15	virus	O
16	RNA	O
17	.	O

1	The	O
2	amino	O
3	-	O
4	terminal	O
5	DNA	O
6	-	O
7	binding	O
8	domain	O
9	of	O
10	Pip	O
11	exhibits	O
12	a	O
13	high	O
14	degree	O
15	of	O
16	homology	O
17	to	O
18	the	O
19	DNA	O
20	-	O
21	binding	O
22	domains	O
23	of	O
24	members	O
25	of	O
26	the	O
27	interferon	B
28	regulatory	I
29	factor	I
30	(	I
31	IRF	I
32	)	I
33	family	I
34	,	O
35	which	O
36	includes	O
37	IRF	B
38	-	I
39	1	I
40	,	O
41	IRF	B
42	-	I
43	2	I
44	,	O
45	ICSBP	O
46	,	O
47	and	O
48	ISGF3	B
49	gamma	I
50	.	O

1	This	O
2	paper	O
3	reviews	O
4	the	O
5	middleware	O
6	-	O
7	based	O
8	approach	O
9	adopted	O
10	by	O
11	CEN	B
12	ENV	I
13	12967	I
14	-	I
15	1	I
16	and	O
17	the	O
18	specialisation	O
19	necessary	O
20	for	O
21	the	O
22	healthcare	O
23	record	O
24	based	O
25	on	O
26	CEN	O
27	ENV	O
28	12265	O
29	'	O
30	Electronic	O
31	Healthcare	O
32	Record	O
33	Architecture	O
34	'.	O

1	Microdetermination	O
2	of	O
3	adrenocortical	O
4	steroids	O
5	by	O
6	double	O
7	isotope	O
8	method	O
9	.	O

1	Northern	O
2	(	O
3	RNA	O
4	)	O
5	blot	O
6	analyses	O
7	indicated	O
8	that	O
9	the	O
10	cdh	O
11	genes	O
12	encoding	O
13	the	O
14	five	O
15	subunits	O
16	and	O
17	an	O
18	open	O
19	reading	O
20	frame	O
21	(	O
22	ORF1	O
23	)	O
24	with	O
25	unknown	O
26	function	O
27	are	O
28	cotranscribed	O
29	during	O
30	growth	O
31	on	O
32	acetate	O
33	.	O

1	AIMS	O
2	/	O
3	METHODS	O
4	:	O
5	Reticuloendothelial	O
6	system	O
7	function	O
8	,	O
9	as	O
10	assessed	O
11	by	O
12	clearance	O
13	of	O
14	radiolabelled	O
15	bacteria	O
16	,	O
17	was	O
18	evaluated	O
19	in	O
20	acute	O
21	liver	O
22	injury	O
23	induced	O
24	by	O
25	D	O
26	-	O
27	galactosamine	O
28	in	O
29	rats	O
30	,	O
31	and	O
32	compared	O
33	with	O
34	that	O
35	after	O
36	70	O
37	%	O
38	liver	O
39	resection	O
40	model	O
41	.	O

1	Intron	O
2	K1	O
3	cox1	O
4	.	O
5	2	O
6	is	O
7	not	O
8	found	O
9	in	O
10	S	O
11	.	O
12	cerevisiae	O
13	and	O
14	appears	O
15	at	O
16	an	O
17	unique	O
18	location	O
19	in	O
20	K	O
21	.	O
22	lactis	O
23	.	O

1	All	O
2	ABFI	B
3	-	I
4	binding	I
5	sites	I
6	,	O
7	regardless	O
8	of	O
9	origin	O
10	,	O
11	provided	O
12	weak	O
13	UAS	O
14	function	O
15	in	O
16	vivo	O
17	when	O
18	examined	O
19	in	O
20	test	O
21	plasmids	O
22	.	O

1	C	B
2	/	I
3	EBP	I
4	alpha	I
5	also	O
6	activates	O
7	the	O
8	promoter	O
9	of	O
10	the	O
11	rat	B
12	class	I
13	-	I
14	I	I
15	ADH	I
16	gene	I
17	in	O
18	a	O
19	sequence	O
20	-	O
21	specific	O
22	manner	O
23	[	O
24	Potter	O
25	et	O
26	al	O
27	.,	O
28	Arch	O
29	.	O

1	Little	O
2	or	O
3	no	O
4	protection	O
5	was	O
6	detected	O
7	using	O
8	adrenal	O
9	cortex	O
10	,	O
11	adrenal	O
12	medulla	O
13	,	O
14	liver	O
15	,	O
16	kidney	O
17	cortex	O
18	,	O
19	spleen	O
20	,	O
21	or	O
22	T	O
23	-	O
24	lymphocyte	O
25	total	O
26	RNA	O
27	.	O

1	Effect	O
2	of	O
3	Azadirachta	O
4	indica	O
5	hydroalcoholic	O
6	leaf	O
7	extract	O
8	on	O
9	the	O
10	cardiovascular	O
11	system	O
12	.	O

1	Radiative	O
2	corrections	O
3	to	O
4	beta	O
5	decay	O
6	and	O
7	the	O
8	possibility	O
9	of	O
10	a	O
11	fourth	O
12	generation	O
13	.	O

1	For	O
2	oral	O
3	administration	O
4	,	O
5	AUC0	O
6	-	O
7	infinity	O
8	was	O
9	58	O
10	.	O
11	47	O
12	+/-	O
13	16	O
14	.	O
15	37	O
16	microg	O
17	x	O
18	h	O
19	/	O
20	ml	O
21	,	O
22	t1	O
23	/	O
24	2beta	O
25	was	O
26	18	O
27	.	O
28	39	O
29	+/-	O
30	0	O
31	.	O
32	06	O
33	hours	O
34	,	O
35	maximum	O
36	concentration	O
37	(	O
38	Cmax	O
39	)	O
40	was	O
41	2	O
42	.	O
43	12	O
44	+/-	O
45	00	O
46	.	O
47	51	O
48	microg	O
49	/	O
50	ml	O
51	,	O
52	time	O
53	to	O
54	Cmax	O
55	was	O
56	2	O
57	.	O
58	20	O
59	+/-	O
60	2	O
61	.	O
62	17	O
63	hours	O
64	,	O
65	mean	O
66	absorption	O
67	time	O
68	was	O
69	2	O
70	.	O
71	09	O
72	+/-	O
73	0	O
74	.	O
75	51	O
76	hours	O
77	,	O
78	and	O
79	bioavailability	O
80	was	O
81	42	O
82	+/-	O
83	0	O
84	.	O
85	42	O
86	%.	O

1	This	O
2	brief	O
3	review	O
4	analyses	O
5	these	O
6	interactions	O
7	and	O
8	defines	O
9	clinical	O
10	settings	O
11	where	O
12	antibiotic	O
13	-	O
14	induced	O
15	endotoxin	O
16	release	O
17	may	O
18	prove	O
19	to	O
20	be	O
21	clinically	O
22	relevant	O
23	.	O

1	The	O
2	galactose	O
3	transporter	O
4	shows	O
5	both	O
6	sequence	O
7	and	O
8	structural	O
9	homology	O
10	with	O
11	a	O
12	superfamily	O
13	of	O
14	sugar	O
15	transporters	O
16	which	O
17	includes	O
18	the	O
19	human	O
20	HepG2	O
21	-	O
22	erythrocyte	O
23	and	O
24	fetal	O
25	muscle	O
26	glucose	O
27	transporters	O
28	,	O
29	the	O
30	rat	O
31	brain	O
32	and	O
33	liver	O
34	glucose	O
35	transporters	O
36	,	O
37	the	O
38	Escherichia	O
39	coli	O
40	xylose	O
41	and	O
42	arabinose	O
43	permeases	O
44	,	O
45	and	O
46	the	O
47	S	O
48	.	O
49	cerevisiae	O
50	glucose	O
51	,	O
52	maltose	O
53	,	O
54	and	O
55	galactose	O
56	transporters	O
57	.	O

1	TBPf	O
2	is	O
3	defined	O
4	as	O
5	a	O
6	quotient	O
7	of	O
8	the	O
9	difference	O
10	of	O
11	the	O
12	first	O
13	and	O
14	the	O
15	second	O
16	measurement	O
17	:	O
18	TBPf	O
19	=	O
20	(	O
21	P1	B
22	-	I
23	P2	I
24	)/(	I
25	A1	I
26	-	I
27	A2	I
28	).	O

1	If	O
2	no	O
3	reply	O
4	was	O
5	received	O
6	,	O
7	telephone	O
8	contact	O
9	or	O
10	home	O
11	visits	O
12	were	O
13	made	O
14	.	O

1	A	O
2	point	O
3	mutation	O
4	in	O
5	Galphao	O
6	and	O
7	Galphai1	O
8	blocks	O
9	interaction	O
10	with	O
11	regulator	O
12	of	O
13	G	O
14	protein	O
15	signaling	O
16	proteins	O
17	.	O

1	The	O
2	C	O
3	/	O
4	D	O
5	ratio	O
6	was	O
7	equal	O
8	to	O
9	or	O
10	over	O
11	0	O
12	.	O
13	6	O
14	in	O
15	9	O
16	cases	O
17	(	O
18	16	O
19	eyes	O
20	),	O
21	and	O
22	the	O
23	values	O
24	were	O
25	inconsistent	O
26	between	O
27	both	O
28	eyes	O
29	in	O
30	55	O
31	%	O
32	of	O
33	the	O
34	patients	O
35	.	O

1	The	O
2	present	O
3	study	O
4	was	O
5	designed	O
6	to	O
7	evaluate	O
8	the	O
9	sensitivity	O
10	and	O
11	specificity	O
12	of	O
13	AMP	O
14	CT	O
15	(	O
16	Gen	O
17	-	O
18	Probe	O
19	Incorporated	O
20	,	O
21	San	O
22	Diego	O
23	,	O
24	CA	O
25	,	O
26	USA	O
27	)	O
28	on	O
29	urogenital	O
30	specimens	O
31	taken	O
32	from	O
33	symptomatic	O
34	patients	O
35	and	O
36	on	O
37	first	O
38	void	O
39	urine	O
40	(	O
41	FVU	O
42	)	O
43	specimens	O
44	from	O
45	asymptomatic	O
46	patients	O
47	.	O

1	A	O
2	striking	O
3	finding	O
4	in	O
5	all	O
6	of	O
7	the	O
8	studies	O
9	was	O
10	a	O
11	positive	O
12	correlation	O
13	between	O
14	PI	O
15	ACTH	B
16	and	O
17	MSH	O
18	contents	O
19	.	O

1	These	O
2	observations	O
3	provide	O
4	strong	O
5	support	O
6	for	O
7	the	O
8	idea	O
9	that	O
10	expression	O
11	of	O
12	mutant	O
13	tRNA	O
14	can	O
15	confer	O
16	a	O
17	mutator	O
18	phenotype	O
19	,	O
20	including	O
21	the	O
22	UVM	O
23	-	O
24	constitutive	O
25	phenotype	O
26	observed	O
27	in	O
28	mutA	O
29	and	O
30	mutC	O
31	cells	O
32	.	O

1	We	O
2	suggest	O
3	that	O
4	this	O
5	gene	O
6	cluster	O
7	codes	O
8	for	O
9	(	O
10	parts	O
11	of	O
12	)	O
13	a	O
14	multisubunit	B
15	cytochrome	I
16	c	I
17	haem	I
18	lyase	I
19	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	overall	O
6	chance	O
7	that	O
8	a	O
9	patient	O
10	would	O
11	undergo	O
12	ET	O
13	was	O
14	greater	O
15	in	O
16	a	O
17	cycle	O
18	in	O
19	which	O
20	more	O
21	than	O
22	one	O
23	follicle	O
24	20	O
25	mm	O
26	or	O
27	larger	O
28	was	O
29	developing	O
30	than	O
31	in	O
32	a	O
33	cycle	O
34	in	O
35	which	O
36	a	O
37	single	O
38	large	O
39	follicle	O
40	was	O
41	developing	O
42	.	O

1	Serum	O
2	gamma	O
3	glutamyltransferase	O
4	in	O
5	the	O
6	diagnosis	O
7	of	O
8	liver	O
9	disease	O
10	in	O
11	cattle	O
12	.	O

1	To	O
2	study	O
3	the	O
4	role	O
5	of	O
6	heavy	O
7	chain	O
8	motifs	O
9	in	O
10	substrate	O
11	recognition	O
12	,	O
13	secreted	O
14	variants	O
15	of	O
16	recombinant	O
17	bovine	O
18	proenteropeptidase	O
19	were	O
20	constructed	O
21	by	O
22	replacing	O
23	the	O
24	transmembrane	O
25	domain	O
26	with	O
27	a	O
28	signal	O
29	peptide	O
30	.	O

1	A	O
2	new	O
3	instrument	O
4	has	O
5	been	O
6	designed	O
7	for	O
8	freeze	O
9	-	O
10	fracturing	O
11	of	O
12	biological	O
13	material	O
14	in	O
15	ultra	O
16	high	O
17	vacuum	O
18	.	O

1	The	O
2	HSD3B1	O
3	and	O
4	HSD3B2	O
5	genes	O
6	encoding	O
7	the	O
8	types	O
9	I	O
10	and	O
11	II	O
12	3	O
13	beta	O
14	-	O
15	HSD	O
16	isoenzymes	O
17	,	O
18	respectively	O
19	,	O
20	have	O
21	been	O
22	previously	O
23	assigned	O
24	by	O
25	in	O
26	situ	O
27	hybridization	O
28	to	O
29	the	O
30	chromosome	O
31	1p13	O
32	.	O
33	1	O
34	region	O
35	.	O

1	The	O
2	cases	O
3	included	O
4	35	O
5	de	O
6	novo	O
7	diffuse	O
8	aggressive	O
9	lymphomas	O
10	(	O
11	DAL	O
12	;	O
13	19	O
14	large	O
15	-	O
16	cell	O
17	,	O
18	4	O
19	mixed	O
20	-	O
21	cell	O
22	,	O
23	and	O
24	12	O
25	large	O
26	-	O
27	cell	O
28	immunoblastic	O
29	),	O
30	52	O
31	transformed	O
32	aggressive	O
33	lymphomas	O
34	derived	O
35	from	O
36	follicular	O
37	lymphomas	O
38	(	O
39	TFL	O
40	),	O
41	42	O
42	indolent	O
43	follicular	O
44	lymphomas	O
45	(	O
46	FL	O
47	),	O
48	14	O
49	mantle	O
50	cell	O
51	lymphomas	O
52	(	O
53	MCL	O
54	),	O
55	and	O
56	27	O
57	small	O
58	noncleaved	O
59	cell	O
60	lymphomas	O
61	(	O
62	SNCL	O
63	).	O

1	Molecular	O
2	analysis	O
3	of	O
4	a	O
5	novel	O
6	schizosaccharomyces	O
7	pombe	O
8	gene	O
9	containing	O
10	two	O
11	RNP	O
12	consensus	O
13	-	O
14	sequence	O
15	RNA	O
16	-	O
17	binding	O
18	domains	O
19	.	O

1	CONCLUSION	O
2	:	O
3	The	O
4	alpha2	B
5	-	I
6	adrenergic	I
7	antagonist	O
8	idazoxan	O
9	increases	O
10	glucose	O
11	-	O
12	induced	O
13	sympathetic	O
14	activity	O
15	but	O
16	not	O
17	energy	O
18	expenditure	O
19	in	O
20	obese	O
21	subjects	O
22	.	O

1	Furthermore	O
2	,	O
3	the	O
4	NH2	O
5	-	O
6	terminal	O
7	portion	O
8	of	O
9	the	O
10	homologue	O
11	was	O
12	not	O
13	translocated	O
14	into	O
15	the	O
16	outer	O
17	membrane	O
18	without	O
19	its	O
20	COOH	O
21	-	O
22	terminal	O
23	part	O
24	.	O

1	Serial	O
2	followup	O
3	strength	O
4	data	O
5	for	O
6	2	O
7	patients	O
8	were	O
9	compared	O
10	to	O
11	change	O
12	in	O
13	creatinine	O
14	kinase	O
15	(	O
16	CK	O
17	)	O
18	levels	O
19	.	O

1	Cold	O
2	cardioplegia	O
3	was	O
4	administered	O
5	at	O
6	45	O
7	mm	O
8	Hg	O
9	every	O
10	20	O
11	minutes	O
12	for	O
13	2	O
14	hours	O
15	.	O

1	It	O
2	applies	O
3	Udry	O
4	'	O
5	s	O
6	biosocial	O
7	perspective	O
8	,	O
9	which	O
10	attempts	O
11	to	O
12	reconcile	O
13	the	O
14	biological	O
15	and	O
16	sociological	O
17	models	O
18	of	O
19	premarital	O
20	sexual	O
21	and	O
22	reproductive	O
23	behaviour	O
24	.	O

1	The	O
2	authors	O
3	evaluate	O
4	the	O
5	clinical	O
6	efficacy	O
7	of	O
8	EMB	O
9	AZS	O
10	in	O
11	recurrent	O
12	ulcer	O
13	after	O
14	operation	O
15	on	O
16	the	O
17	stomach	O
18	caused	O
19	by	O
20	a	O
21	high	O
22	level	O
23	of	O
24	acid	O
25	production	O
26	and	O
27	ulcerative	O
28	gastroduodenal	O
29	bleeding	O
30	.	O

1	T	O
2	antigen	O
3	contains	O
4	four	O
5	H	O
6	-	O
7	2Db	O
8	-	O
9	restricted	O
10	cytotoxic	O
11	T	O
12	lymphocyte	O
13	(	O
14	CTL	O
15	)	O
16	recognition	O
17	epitopes	O
18	that	O
19	are	O
20	targets	O
21	for	O
22	CTL	O
23	clones	O
24	Y	O
25	-	O
26	1	O
27	,	O
28	Y	O
29	-	O
30	2	O
31	,	O
32	Y	O
33	-	O
34	3	O
35	,	O
36	and	O
37	Y	O
38	-	O
39	5	O
40	.	O

1	Surgical	O
2	treatment	O
3	of	O
4	pulmonary	O
5	metastases	O
6	.	O

1	The	O
2	gene	O
3	was	O
4	uniquely	O
5	mapped	O
6	with	O
7	odds	O
8	>	O
9	1	O
10	,	O
11	000	O
12	:	O
13	1	O
14	on	O
15	chromosome	O
16	3p	O
17	in	O
18	Centre	O
19	d	O
20	'	O
21	Etude	O
22	du	O
23	Polymorphisme	O
24	Humain	O
25	pedigrees	O
26	.	O

1	Hepatitis	O
2	B	O
3	vaccine	O
4	:	O
5	still	O
6	has	O
7	its	O
8	problems	O
9	.	O

1	However	O
2	,	O
3	little	O
4	is	O
5	known	O
6	regarding	O
7	the	O
8	genomic	O
9	organization	O
10	and	O
11	developmental	O
12	expression	O
13	of	O
14	the	O
15	caveolin	B
16	gene	I
17	family	I
18	.	O

1	This	O
2	may	O
3	account	O
4	,	O
5	at	O
6	least	O
7	in	O
8	part	O
9	,	O
10	for	O
11	the	O
12	ability	O
13	of	O
14	excess	O
15	wt	O
16	p53	B
17	to	O
18	inhibit	O
19	cell	O
20	proliferation	O
21	and	O
22	to	O
23	interfere	O
24	with	O
25	neoplastic	O
26	processes	O
27	.	O

1	In	O
2	conclusion	O
3	,	O
4	these	O
5	observations	O
6	demonstrated	O
7	that	O
8	stratification	O
9	of	O
10	acute	O
11	MI	O
12	patients	O
13	by	O
14	plasma	O
15	ANF	O
16	level	O
17	is	O
18	a	O
19	useful	O
20	non	O
21	-	O
22	invasive	O
23	method	O
24	for	O
25	predicting	O
26	prognosis	O
27	and	O
28	for	O
29	identifying	O
30	individuals	O
31	at	O
32	high	O
33	risk	O
34	of	O
35	cardiac	O
36	death	O
37	.	O

1	Primer	O
2	extension	O
3	analysis	O
4	and	O
5	RNA	O
6	sequencing	O
7	demonstrates	O
8	that	O
9	the	O
10	transcription	O
11	start	O
12	point	O
13	of	O
14	rat	O
15	ODC	O
16	mRNA	O
17	is	O
18	located	O
19	303	O
20	nt	O
21	upstream	O
22	from	O
23	the	O
24	A	O
25	residue	O
26	in	O
27	the	O
28	start	O
29	codon	O
30	.	O

1	Additionally	O
2	,	O
3	putative	O
4	CF1	O
5	/	O
6	USP	O
7	and	O
8	Broad	O
9	Complex	B
10	Z2	I
11	transcription	I
12	factor	I
13	elements	O
14	were	O
15	found	O
16	in	O
17	the	O
18	upstream	O
19	regions	O
20	of	O
21	MIH	O
22	and	O
23	MO	O
24	-	O
25	IH	O
26	genes	O
27	respectively	O
28	.	O

1	The	O
2	linear	O
3	plasmid	O
4	pDHL1	O
5	from	O
6	Debaryomyces	O
7	hansenii	O
8	encodes	O
9	a	O
10	protein	O
11	highly	O
12	homologous	O
13	to	O
14	the	O
15	pGKL1	O
16	-	O
17	plasmid	O
18	DNA	O
19	polymerase	O
20	.	O

1	This	O
2	negative	O
3	regulatory	O
4	pathway	O
5	may	O
6	be	O
7	important	O
8	for	O
9	determining	O
10	cell	O
11	fate	O
12	or	O
13	maintaining	O
14	an	O
15	inducible	O
16	state	O
17	in	O
18	the	O
19	ventroposterior	O
20	region	O
21	of	O
22	the	O
23	embryo	O
24	.	O

1	Biochemical	O
2	analysis	O
3	reveals	O
4	that	O
5	KS1	O
6	is	O
7	a	O
8	nuclear	O
9	protein	O
10	containing	O
11	two	O
12	transcriptional	O
13	repressor	O
14	domains	O
15	,	O
16	R1	O
17	and	O
18	R2	O
19	.	O

1	When	O
2	the	O
3	downstream	O
4	operator	O
5	was	O
6	altered	O
7	,	O
8	there	O
9	was	O
10	a	O
11	fourfold	O
12	reduction	O
13	in	O
14	reporter	O
15	enzyme	O
16	levels	O
17	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	report	O
7	the	O
8	isolation	O
9	and	O
10	characterization	O
11	of	O
12	the	O
13	entire	O
14	rat	O
15	GSTA3	O
16	(	O
17	rGST	O
18	Yc1	O
19	)	O
20	subunit	O
21	gene	O
22	.	O

1	These	O
2	observations	O
3	link	B
4	actin	I
5	plaque	O
6	assembly	O
7	to	O
8	increased	O
9	cell	O
10	substrate	O
11	adhesion	O
12	.	O

1	Interestingly	O
2	,	O
3	the	O
4	IR5	O
5	ORF	O
6	of	O
7	EHV	B
8	-	I
9	1	I
10	possesses	O
11	a	O
12	sequence	O
13	of	O
14	13	O
15	amino	O
16	acids	O
17	(	O
18	CAYWCCLGHAFAC	O
19	)	O
20	that	O
21	is	O
22	a	O
23	perfect	O
24	match	O
25	to	O
26	the	O
27	consensus	O
28	zinc	O
29	finger	O
30	motif	O
31	(	O
32	C	B
33	-	I
34	X2	I
35	-	I
36	4	I
37	-	I
38	C	I
39	-	I
40	X2	I
41	-	I
42	15	O
43	-	O
44	C	O
45	/	O
46	H	O
47	-	O
48	X2	O
49	-	O
50	4	O
51	-	O
52	C	O
53	/	O
54	H	O
55	).	O

1	Several	O
2	highly	O
3	conserved	O
4	regions	O
5	were	O
6	identified	O
7	at	O
8	the	O
9	near	O
10	N	O
11	terminus	O
12	,	O
13	middle	O
14	and	O
15	C	O
16	terminus	O
17	.	O

1	The	O
2	1	O
3	.	O
4	9	O
5	-	O
6	kb	O
7	C	O
8	mu	O
9	RNA	O
10	contains	O
11	the	O
12	3	O
13	'	O
14	sequence	O
15	characteristic	O
16	of	O
17	secreted	O
18	mu	O
19	chain	O
20	,	O
21	whereas	O
22	the	O
23	longer	O
24	species	O
25	bear	O
26	that	O
27	of	O
28	membrane	O
29	-	O
30	bound	O
31	mu	O
32	chin	O
33	.	O

1	A	O
2	reduction	O
3	of	O
4	the	O
5	aspartate	B
6	aminotransferase	I
7	activity	O
8	was	O
9	observed	O
10	from	O
11	800	O
12	mg	O
13	/	O
14	kg	O
15	b	O
16	.	O
17	w	O
18	./	O
19	d	O
20	onwards	O
21	.	O

1	Menstrual	O
2	-	O
3	cycle	O
4	phase	O
5	did	O
6	not	O
7	significantly	O
8	affect	O
9	personality	O
10	variables	O
11	in	O
12	either	O
13	group	O
14	.	O

1	In	O
2	DNase	B
3	I	I
4	footprinting	O
5	protection	O
6	analysis	O
7	,	O
8	both	O
9	SFRE	O
10	and	O
11	ERE	O
12	regions	O
13	were	O
14	protected	O
15	by	O
16	glutathione	B
17	S	I
18	-	I
19	transferase	I
20	-	I
21	ERRalpha1	I
22	fusion	I
23	protein	I
24	.	O

1	Hops	O
2	,	O
3	and	O
4	L	O
5	.	O

1	This	O
2	study	O
3	was	O
4	designed	O
5	to	O
6	assess	O
7	and	O
8	compare	O
9	the	O
10	ability	O
11	of	O
12	three	O
13	different	O
14	forms	O
15	of	O
16	DSG	O
17	to	O
18	block	O
19	EIB	O
20	.	O

1	If	O
2	hnRNP	O
3	K	O
4	is	O
5	a	O
6	transcription	O
7	factor	O
8	,	O
9	then	O
10	interactions	O
11	with	O
12	the	O
13	RNA	B
14	polymerase	I
15	II	I
16	transcription	O
17	apparatus	O
18	are	O
19	predicted	O
20	.	O

1	A	O
2	long	O
3	follow	O
4	-	O
5	up	O
6	study	O
7	revealed	O
8	that	O
9	convalescent	O
10	stage	O
11	children	O
12	still	O
13	have	O
14	the	O
15	potency	O
16	to	O
17	have	O
18	an	O
19	immediate	O
20	type	O
21	hypersensitivity	O
22	reaction	O
23	on	O
24	exposure	O
25	to	O
26	mite	O
27	antigen	O
28	,	O
29	with	O
30	a	O
31	high	O
32	titer	O
33	of	O
34	mite	O
35	specific	O
36	IgE	B
37	in	O
38	their	O
39	sera	O
40	,	O
41	but	O
42	they	O
43	are	O
44	free	O
45	from	O
46	asthmatic	O
47	attacks	O
48	because	O
49	of	O
50	the	O
51	reduction	O
52	in	O
53	the	O
54	amount	O
55	of	O
56	mite	O
57	antigen	O
58	in	O
59	the	O
60	body	O
61	,	O
62	as	O
63	shown	O
64	by	O
65	the	O
66	reduction	O
67	in	O
68	the	O
69	amount	O
70	of	O
71	mite	O
72	specific	O
73	IgG	B
74	.	O

1	A	O
2	stochastic	O
3	version	O
4	of	O
5	Kernell	O
6	'	O
7	s	O
8	(	O
9	1968	O
10	,	O
11	1972	O
12	)	O
13	model	O
14	with	O
15	cumulative	O
16	afterhyperpolarization	O
17	(	O
18	AHP	O
19	)	O
20	was	O
21	simulated	O
22	.	O

1	Mutating	O
2	the	O
3	Fcp1p	O
4	-	O
5	binding	O
6	motif	O
7	KEFGK	O
8	in	O
9	the	O
10	RAP74	O
11	(	O
12	Tfg1p	O
13	)	O
14	subunit	O
15	of	O
16	TFIIF	O
17	to	O
18	EEFGE	O
19	led	O
20	to	O
21	both	O
22	synthetic	O
23	phenotypes	O
24	in	O
25	certain	O
26	fcp1	O
27	tfg1	O
28	double	O
29	mutants	O
30	and	O
31	a	O
32	reduced	O
33	ability	O
34	of	O
35	Fcp1p	O
36	to	O
37	activate	O
38	transcription	O
39	when	O
40	it	O
41	is	O
42	artificially	O
43	tethered	O
44	to	O
45	a	O
46	promoter	O
47	.	O

1	Therefore	O
2	,	O
3	in	O
4	our	O
5	in	O
6	vitro	O
7	model	O
8	,	O
9	the	O
10	localization	O
11	of	O
12	the	O
13	mutation	O
14	in	O
15	the	O
16	K	B
17	-	I
18	ras	I
19	gene	I
20	predisposes	O
21	to	O
22	a	O
23	different	O
24	level	O
25	of	O
26	aggressiveness	O
27	in	O
28	the	O
29	transforming	O
30	phenotype	O
31	.	O

1	Induced	O
2	expression	O
3	of	O
4	Rnd3	O
5	is	O
6	associated	O
7	with	O
8	transformation	O
9	of	O
10	polarized	O
11	epithelial	O
12	cells	O
13	by	O
14	the	O
15	Raf	B
16	-	I
17	MEK	I
18	-	I
19	extracellular	I
20	signal	I
21	-	I
22	regulated	I
23	kinase	I
24	pathway	O
25	.	O

1	Using	O
2	GST	B
3	-	I
4	PKR	I
5	fusion	O
6	chromatography	O
7	,	O
8	direct	O
9	physical	O
10	interaction	O
11	between	O
12	the	O
13	mouse	O
14	and	O
15	human	O
16	PKR	B
17	homologs	I
18	was	O
19	established	O
20	.	O

1	Adjustment	O
2	for	O
3	age	O
4	,	O
5	total	O
6	cholesterol	O
7	,	O
8	HDL	B
9	cholesterol	I
10	,	O
11	triglycerides	O
12	,	O
13	current	O
14	smoking	O
15	,	O
16	and	O
17	systolic	O
18	pressure	O
19	slightly	O
20	reduced	O
21	the	O
22	association	O
23	between	O
24	fibrinogen	B
25	and	O
26	atherosclerosis	O
27	.	O

1	The	O
2	27	O
3	-	O
4	base	O
5	element	O
6	interacts	O
7	with	O
8	a	O
9	PDGF	B
10	-	I
11	activated	I
12	serine	I
13	/	I
14	threonine	I
15	phosphoprotein	I
16	that	O
17	is	O
18	detected	O
19	only	O
20	within	O
21	the	O
22	nucleus	O
23	of	O
24	PDGF	B
25	-	I
26	treated	O
27	3T3	O
28	cells	O
29	.	O

1	Batch	O
2	cultures	O
3	of	O
4	S	O
5	.	O
6	mutans	O
7	serotype	O
8	a	O
9	demonstrated	O
10	no	O
11	growth	O
12	on	O
13	MSB	O
14	agar	O
15	.	O

1	Sudomoina	O
2	,	O
3	A	O
4	.	O

1	Intron	O
2	8	O
3	harbored	O
4	a	O
5	strong	O
6	erythroid	O
7	-	O
8	specific	O
9	enhancer	O
10	activity	O
11	which	O
12	was	O
13	orientation	O
14	-	O
15	dependent	O
16	.	O

1	The	O
2	gene	O
3	structure	O
4	of	O
5	Elk1	O
6	spans	O
7	15	O
8	.	O
9	2	O
10	kb	O
11	and	O
12	consists	O
13	of	O
14	seven	O
15	exons	O
16	and	O
17	six	O
18	introns	O
19	.	O

1	D5	O
2	/	O
3	D1	O
4	(	O
5	CT	O
6	)	O
7	or	O
8	D5	O
9	/	O
10	D1D	O
11	(	O
12	CT	O
13	)	O
14	tail	O
15	substitution	O
16	mutants	O
17	displayed	O
18	a	O
19	rank	O
20	order	O
21	of	O
22	potency	O
23	and	O
24	agonist	O
25	affinities	O
26	virtually	O
27	mimicking	O
28	wild	O
29	-	O
30	type	O
31	(	O
32	wt	B
33	)	I
34	D1	I
35	receptors	I
36	,	O
37	as	O
38	indexed	O
39	by	O
40	both	O
41	ligand	O
42	binding	O
43	and	O
44	dopamine	O
45	-	O
46	stimulated	O
47	cAMP	O
48	accumulation	O
49	assays	O
50	,	O
51	and	O
52	,	O
53	similar	O
54	to	O
55	wt	B
56	D1	I
57	receptors	I
58	,	O
59	did	O
60	not	O
61	exhibit	O
62	receptor	O
63	constitutive	O
64	activity	O
65	or	O
66	responsiveness	O
67	to	O
68	inverse	O
69	agonists	O
70	.	O

1	Specifically	O
2	,	O
3	I	O
4	use	O
5	molecular	O
6	markers	O
7	that	O
8	identify	O
9	particular	O
10	neuroectodermal	O
11	domains	O
12	,	O
13	all	O
14	neuroblasts	O
15	or	O
16	individual	O
17	neuroblasts	O
18	,	O
19	to	O
20	show	O
21	that	O
22	in	O
23	DER	B
24	mutant	I
25	embryos	O
26	(	O
27	1	O
28	)	O
29	intermediate	O
30	column	O
31	neuroblasts	O
32	do	O
33	not	O
34	form	O
35	,	O
36	(	O
37	2	O
38	)	O
39	medial	O
40	column	O
41	neuroblasts	O
42	often	O
43	acquire	O
44	identities	O
45	inappropriate	O
46	for	O
47	their	O
48	position	O
49	,	O
50	while	O
51	(	O
52	3	O
53	)	O
54	lateral	O
55	neuroblasts	O
56	develop	O
57	normally	O
58	.	O

1	Both	O
2	factors	O
3	demonstrated	O
4	significant	O
5	correlations	O
6	with	O
7	rCBF	O
8	in	O
9	the	O
10	medial	O
11	prefrontal	O
12	cortex	O
13	and	O
14	frontal	O
15	polar	O
16	cortex	O
17	while	O
18	for	O
19	each	O
20	factor	O
21	there	O
22	were	O
23	also	O
24	unique	O
25	patterns	O
26	of	O
27	correlations	O
28	with	O
29	posterior	O
30	brain	O
31	regions	O
32	.	O

1	We	O
2	propose	O
3	that	O
4	Mnt	O
5	:	O
6	Max	B
7	:	O
8	Sin3	O
9	complexes	O
10	normally	O
11	function	O
12	to	O
13	restrict	B
14	Myc	I
15	:	O
16	Max	B
17	activities	O
18	associated	O
19	with	O
20	cell	O
21	proliferation	O
22	.	O

1	The	O
2	obtained	O
3	results	O
4	were	O
5	compared	O
6	with	O
7	control	O
8	group	O
9	(	O
10	10	O
11	female	O
12	volunteers	O
13	).	O

1	We	O
2	screened	O
3	a	O
4	K562	O
5	cDNA	O
6	library	O
7	and	O
8	identified	O
9	novel	O
10	transcripts	O
11	,	O
12	MZF1B	O
13	and	O
14	MZF1C	O
15	.	O

1	A	O
2	consensus	O
3	binding	O
4	site	O
5	for	O
6	the	O
7	transcription	O
8	factor	O
9	SP1	O
10	was	O
11	identified	O
12	in	O
13	intron	O
14	As	O
15	downstream	O
16	of	O
17	the	O
18	proenkephalin	O
19	germ	O
20	cell	O
21	cap	O
22	site	O
23	region	O
24	.	O

1	According	O
2	to	O
3	the	O
4	results	O
5	of	O
6	assays	O
7	obtained	O
8	with	O
9	the	O
10	use	O
11	of	O
12	assay	O
13	systems	O
14	ORTHO	O
15	ELISA	O
16	and	O
17	ABBOTT	O
18	HCV	O
19	EIA	O
20	(	O
21	USA	O
22	),	O
23	the	O
24	detection	O
25	rate	O
26	of	O
27	anti	B
28	-	I
29	HCV	I
30	-	I
31	C100	I
32	-	I
33	3	O
34	among	O
35	primary	O
36	blood	O
37	donors	O
38	in	O
39	Moscow	O
40	was	O
41	1	O
42	.	O
43	37	O
44	%	O
45	and	O
46	was	O
47	not	O
48	different	O
49	from	O
50	that	O
51	among	O
52	HBsAg	O
53	carriers	O
54	(	O
55	1	O
56	.	O
57	8	O
58	%)	O
59	and	O
60	among	O
61	donors	O
62	with	O
63	anti	B
64	-	I
65	HCV	I
66	-	I
67	C100	I
68	-	I
69	3	O
70	in	O
71	the	O
72	blood	O
73	(	O
74	1	O
75	.	O
76	6	O
77	%)	O
78	(	O
79	p	O
80	<	O
81	0	O
82	.	O
83	01	O
84	).	O

1	With	O
2	constructs	O
3	containing	O
4	the	O
5	binding	O
6	site	O
7	of	O
8	one	O
9	gene	O
10	fused	O
11	to	O
12	the	O
13	promoter	O
14	of	O
15	the	O
16	other	O
17	,	O
18	we	O
19	demonstrated	O
20	that	O
21	the	O
22	positional	O
23	requirements	O
24	are	O
25	a	O
26	function	O
27	of	O
28	the	O
29	specific	O
30	binding	O
31	site	O
32	,	O
33	not	O
34	the	O
35	promoter	O
36	.	O

1	In	O
2	an	O
3	attempt	O
4	to	O
5	investigate	O
6	whether	O
7	the	O
8	intergenic	O
9	region	O
10	between	O
11	the	O
12	oleosin	O
13	and	O
14	a	O
15	second	O
16	open	O
17	reading	O
18	frame	O
19	(	O
20	ORFII	O
21	)	O
22	in	O
23	Brassica	O
24	napus	O
25	(	O
26	L	O
27	.)	O
28	is	O
29	a	O
30	divergent	O
31	promoter	O
32	,	O
33	and	O
34	also	O
35	to	O
36	characterize	O
37	the	O
38	ORFII	O
39	,	O
40	cDNA	O
41	clones	O
42	homologous	O
43	to	O
44	ORFII	O
45	were	O
46	isolated	O
47	from	O
48	a	O
49	leaf	O
50	cDNA	O
51	library	O
52	.	O

1	At	O
2	the	O
3	C	O
4	-	O
5	terminus	O
6	of	O
7	the	O
8	protein	O
9	is	O
10	a	O
11	domain	O
12	that	O
13	contains	O
14	sequences	O
15	very	O
16	similar	O
17	to	O
18	those	O
19	found	O
20	in	O
21	the	O
22	breakpoint	O
23	cluster	O
24	region	O
25	gene	O
26	product	O
27	,	O
28	n	O
29	-	O
30	chimerin	O
31	,	O
32	and	O
33	rho	O
34	GAP	O
35	,	O
36	all	O
37	of	O
38	which	O
39	have	O
40	been	O
41	shown	O
42	to	O
43	possess	O
44	intrinsic	O
45	GAP	O
46	activity	O
47	on	O
48	small	O
49	GTPases	O
50	.	O

1	Antibodies	O
2	raised	O
3	to	O
4	the	O
5	expressed	O
6	NS3	O
7	by	O
8	immunization	O
9	of	O
10	mice	O
11	detected	O
12	both	O
13	NS3	O
14	and	O
15	NS3A	O
16	in	O
17	BTV	O
18	-	O
19	10	O
20	-	O
21	infected	O
22	BHK	O
23	cells	O
24	but	O
25	not	O
26	in	O
27	purified	O
28	BTV	O
29	-	O
30	10	O
31	virus	O
32	particles	O
33	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	open	O
7	-	O
8	section	O
9	effect	O
10	decreases	O
11	the	O
12	torsional	O
13	stiffness	O
14	and	O
15	stress	O
16	concentration	O
17	effects	O
18	decrease	O
19	the	O
20	torsional	O
21	strength	O
22	of	O
23	a	O
24	long	O
25	bone	O
26	with	O
27	a	O
28	longitudinal	O
29	defect	O
30	.	O

1	The	O
2	sensitivity	O
3	of	O
4	the	O
5	vas	O
6	deferens	O
7	to	O
8	adrenaline	O
9	was	O
10	also	O
11	reduced	O
12	in	O
13	scorbutic	O
14	guinea	O
15	pigs	O
16	,	O
17	thus	O
18	decreasing	O
19	their	O
20	fertility	O
21	rate	O
22	.	O

1	In	O
2	the	O
3	local	O
4	geomagnetic	O
5	field	O
6	,	O
7	the	O
8	animals	O
9	preferred	O
10	the	O
11	SE	O
12	-	O
13	sector	O
14	.	O

1	The	O
2	present	O
3	investigation	O
4	has	O
5	revealed	O
6	that	O
7	the	O
8	distribution	O
9	of	O
10	the	O
11	main	O
12	fatty	O
13	acids	O
14	in	O
15	Leptospira	O
16	phospholipids	O
17	is	O
18	similar	O
19	to	O
20	their	O
21	distribution	O
22	in	O
23	Leptospira	O
24	neutral	O
25	lipids	O
26	with	O
27	the	O
28	exception	O
29	of	O
30	unsaturated	O
31	fatty	O
32	acid	O
33	with	O
34	14	O
35	carbon	O
36	atoms	O
37	,	O
38	occurring	O
39	mainly	O
40	in	O
41	phospholipids	O
42	.	O

1	We	O
2	have	O
3	explored	O
4	the	O
5	mechanism	O
6	of	O
7	action	O
8	of	O
9	the	O
10	fibronectin	B
11	splicing	O
12	enhancer	O
13	and	O
14	found	O
15	that	O
16	the	O
17	SE	O
18	element	O
19	is	O
20	required	O
21	for	O
22	efficient	O
23	assembly	O
24	of	O
25	early	O
26	splicing	O
27	complexes	O
28	,	O
29	allowing	O
30	a	O
31	more	O
32	efficient	O
33	interaction	O
34	of	O
35	the	O
36	U2	B
37	snRNP	I
38	with	O
39	branch	O
40	site	O
41	sequences	O
42	.	O

1	We	O
2	suggest	O
3	that	O
4	sensitivity	O
5	to	O
6	photoperiod	O
7	in	O
8	pallid	O
9	bats	O
10	,	O
11	as	O
12	in	O
13	several	O
14	other	O
15	mammals	O
16	,	O
17	is	O
18	mediated	O
19	by	O
20	the	O
21	pineal	O
22	gland	O
23	.	O

1	In	O
2	the	O
3	IA	O
4	task	O
5	,	O
6	post	O
7	-	O
8	training	O
9	intraperitoneal	O
10	injections	O
11	of	O
12	picrotoxin	O
13	and	O
14	bicuculline	O
15	induced	O
16	a	O
17	dose	O
18	-	O
19	dependent	O
20	enhancement	O
21	of	O
22	retention	O
23	measured	O
24	24	O
25	h	O
26	after	O
27	the	O
28	training	O
29	,	O
30	while	O
31	retention	O
32	was	O
33	not	O
34	affected	O
35	by	O
36	bicuculline	O
37	methiodide	O
38	(	O
39	a	O
40	GABA	O
41	receptor	O
42	antagonist	O
43	that	O
44	does	O
45	not	O
46	readily	O
47	cross	O
48	the	O
49	blood	O
50	-	O
51	brain	O
52	barrier	O
53	).	O

1	To	O
2	confirm	O
3	the	O
4	binding	O
5	of	O
6	protein	O
7	to	O
8	these	O
9	sites	O
10	in	O
11	cells	O
12	,	O
13	we	O
14	carried	O
15	out	O
16	an	O
17	in	O
18	vivo	O
19	genomic	O
20	footprinting	O
21	analysis	O
22	of	O
23	this	O
24	portion	O
25	of	O
26	the	O
27	TGF	B
28	alpha	I
29	promoter	I
30	in	O
31	normal	O
32	and	O
33	transformed	O
34	rat	O
35	liver	O
36	epithelial	O
37	cell	O
38	lines	O
39	that	O
40	express	O
41	the	O
42	endogenous	O
43	gene	O
44	at	O
45	varying	O
46	levels	O
47	.	O

1	An	O
2	extensive	O
3	inverted	O
4	repeat	O
5	is	O
6	present	O
7	3	O
8	'	O
9	of	O
10	rpeA	O
11	;	O
12	inverted	O
13	repeats	O
14	are	O
15	found	O
16	downstream	O
17	of	O
18	all	O
19	PE	O
20	operons	O
21	sequenced	O
22	to	O
23	date	O
24	,	O
25	although	O
26	the	O
27	sequence	O
28	is	O
29	not	O
30	conserved	O
31	.	O

1	A	O
2	second	O
3	peptide	O
4	(	O
5	amino	O
6	acids	O
7	58	O
8	-	O
9	77	O
10	)	O
11	also	O
12	antagonized	O
13	p21	B
14	-	I
15	activity	O
16	,	O
17	but	O
18	this	O
19	peptide	O
20	did	O
21	not	O
22	affect	O
23	the	O
24	ability	O
25	of	O
26	p21	B
27	to	O
28	interact	O
29	with	O
30	cyclin	B
31	E	I
32	/	I
33	Cdk2	I
34	.	O

1	Combination	O
2	of	O
3	3	O
4	multiple	O
5	primary	O
6	malignant	O
7	and	O
8	benign	O
9	tumors	O
10	of	O
11	the	O
12	breasts	O
13	and	O
14	uterus	O

1	Hepatocellular	O
2	injury	O
3	during	O
4	preservation	O
5	of	O
6	human	O
7	livers	O
8	with	O
9	UW	O
10	and	O
11	HTK	O
12	solution	O
13	.	O

1	In	O
2	the	O
3	absence	O
4	of	O
5	enhancer	O
6	sequences	O
7	,	O
8	the	O
9	adenovirus	B
10	E1A	I
11	gene	I
12	can	O
13	not	O
14	stimulate	O
15	CATase	O
16	synthesis	O
17	.	O

1	Pit	B
2	-	I
3	1	I
4	is	O
5	a	O
6	tissue	O
7	-	O
8	specific	O
9	POU	B
10	domain	I
11	factor	I
12	obligatory	O
13	for	O
14	the	O
15	appearance	O
16	of	O
17	three	O
18	cell	O
19	phenotypes	O
20	in	O
21	the	O
22	anterior	O
23	pituitary	O
24	gland	O
25	.	O

1	By	O
2	contrast	O
3	,	O
4	all	O
5	proteins	O
6	initiated	O
7	with	O
8	a	O
9	methionine	O
10	placed	O
11	one	O
12	residue	O
13	upstream	O
14	of	O
15	the	O
16	natural	O
17	N	O
18	terminus	O
19	of	O
20	PR	O
21	failed	O
22	to	O
23	show	O
24	specific	O
25	proteolysis	O
26	.	O

1	A	O
2	study	O
3	was	O
4	performed	O
5	to	O
6	compare	O
7	the	O
8	ONLINE	O
9	and	O
10	EMIT	O
11	II	O
12	immunoassays	O
13	with	O
14	gas	O
15	chromatographic	O
16	/	O
17	mass	O
18	spectrometric	O
19	(	O
20	GC	O
21	/	O
22	MS	O
23	)	O
24	analysis	O
25	of	O
26	methaqualone	O
27	metabolites	O
28	on	O
29	urine	O
30	using	O
31	samples	O
32	obtained	O
33	from	O
34	a	O
35	clinical	O
36	study	O
37	.	O

1	To	O
2	define	O
3	the	O
4	number	O
5	and	O
6	nature	O
7	of	O
8	the	O
9	E6	O
10	and	O
11	E7	B
12	gene	I
13	products	O
14	expressed	O
15	in	O
16	BPV	O
17	-	O
18	1	O
19	-	O
20	transformed	O
21	cells	O
22	,	O
23	we	O
24	performed	O
25	immunoprecipitation	O
26	experiments	O
27	with	O
28	antisera	O
29	raised	O
30	to	O
31	bacterially	O
32	expressed	O
33	BPV	B
34	-	I
35	1	I
36	E6	I
37	and	O
38	E7	B
39	fusion	I
40	proteins	I
41	.	O

1	These	O
2	data	O
3	provide	O
4	the	O
5	molecular	O
6	tools	O
7	for	O
8	the	O
9	final	O
10	identification	O
11	of	O
12	the	O
13	MKS	O
14	and	O
15	the	O
16	MUL	O
17	genes	O
18	.	O

1	In	O
2	the	O
3	context	O
4	of	O
5	the	O
6	ADH2	O
7	upstream	O
8	regulatory	O
9	region	O
10	,	O
11	including	O
12	UAS1	O
13	,	O
14	working	O
15	in	O
16	concert	O
17	with	O
18	the	O
19	ADH2	O
20	basal	O
21	promoter	O
22	elements	O
23	,	O
24	UAS2	O
25	-	O
26	dependent	O
27	gene	O
28	activation	O
29	was	O
30	dependent	O
31	on	O
32	orientation	O
33	,	O
34	copy	O
35	number	O
36	,	O
37	and	O
38	helix	O
39	phase	O
40	.	O

1	Value	O
2	of	O
3	determination	O
4	of	O
5	alkaline	B
6	phosphatase	I
7	isoenzymes	I
8	for	O
9	differential	O
10	diagnosis	O
11	of	O
12	obstructive	O
13	jaundice	O
14	and	O
15	biliary	O
16	liver	O
17	cirrhosis	O

1	NH3	O
2	and	O
3	NO	O
4	interaction	O
5	with	O
6	Si	O
7	(	O
8	100	O
9	)-(	O
10	2	O
11	x	O
12	1	O
13	)	O
14	surfaces	O
15	.	O

1	Epigenetic	O
2	switching	O
3	of	O
4	transcriptional	O
5	states	O
6	:	O
7	cis	O
8	-	O
9	and	O
10	trans	O
11	-	O
12	acting	O
13	factors	O
14	affecting	O
15	establishment	O
16	of	O
17	silencing	O
18	at	O
19	the	O
20	HMR	B
21	locus	I
22	in	O
23	Saccharomyces	O
24	cerevisiae	O
25	.	O

1	The	O
2	sequence	O
3	of	O
4	the	O
5	putative	O
6	RBP1	O
7	protein	O
8	contains	O
9	two	O
10	copies	O
11	of	O
12	an	O
13	RNA	O
14	recognition	O
15	motif	O
16	,	O
17	two	O
18	glutamine	O
19	stretches	O
20	,	O
21	an	O
22	asparagine	O
23	-	O
24	rich	O
25	region	O
26	,	O
27	a	O
28	methionine	O
29	-	O
30	rich	O
31	region	O
32	,	O
33	and	O
34	two	O
35	long	O
36	potential	O
37	alpha	O
38	-	O
39	helixes	O
40	.	O

1	Oxygen	O
2	tension	O
3	of	O
4	the	O
5	small	O
6	lymph	O
7	vessels	O
8	(	O
9	PLO2	O
10	)	O
11	of	O
12	the	O
13	rabbit	O
14	hind	O
15	limb	O
16	was	O
17	measured	O
18	with	O
19	both	O
20	a	O
21	flow	O
22	-	O
23	through	O
24	micro	O
25	chamber	O
26	and	O
27	a	O
28	polarographic	O
29	catheter	O
30	-	O
31	tip	O
32	oxygen	O
33	electrode	O
34	to	O
35	obtain	O
36	experimental	O
37	data	O
38	on	O
39	the	O
40	source	O
41	of	O
42	oxygen	O
43	in	O
44	the	O
45	lymph	O
46	.	O

1	As	O
2	assessed	O
3	by	O
4	a	O
5	genetic	O
6	assay	O
7	that	O
8	measures	O
9	AAI	O
10	-	O
11	dependent	O
12	DNA	O
13	binding	O
14	,	O
15	TraM	O
16	inhibited	O
17	TraR	O
18	function	O
19	before	O
20	and	O
21	after	O
22	the	O
23	transcription	O
24	factor	O
25	had	O
26	bound	O
27	to	O
28	its	O
29	DNA	O
30	recognition	O
31	site	O
32	.	O

1	Fifty	O
2	min	O
3	after	O
4	release	O
5	from	O
6	stress	O
7	,	O
8	increases	O
9	in	O
10	plasma	O
11	corticosterone	O
12	levels	O
13	induced	O
14	by	O
15	stress	O
16	recovered	O
17	in	O
18	the	O
19	biting	O
20	group	O
21	but	O
22	remained	O
23	high	O
24	in	O
25	the	O
26	non	O
27	-	O
28	biting	O
29	group	O
30	.	O

1	Fluid	O
2	(	O
3	AVLF	O
4	)	O
5	31	O
6	.	O

1	The	O
2	centromedial	O
3	amygdala	O
4	and	O
5	gastric	O
6	pathology	O
7	in	O
8	rats	O
9	.	O

1	Nitrogen	O
2	balance	O
3	was	O
4	compared	O
5	,	O
6	and	O
7	metabolic	O
8	complications	O
9	were	O
10	monitored	O
11	by	O
12	evaluating	O
13	BUN	O
14	,	O
15	serum	O
16	creatinine	O
17	,	O
18	creatinine	O
19	clearance	O
20	,	O
21	serum	O
22	CO2	O
23	,	O
24	SGOT	O
25	,	O
26	SGPT	O
27	,	O
28	serum	O
29	LDH	O
30	,	O
31	and	O
32	serum	B
33	alkaline	I
34	phosphatase	I
35	.	O

1	Cryoglobulinemia	O
2	in	O
3	Raynaud	O
4	'	O
5	s	O
6	syndrome	O

1	Transfecting	O
2	the	O
3	cloned	O
4	bovine	O
5	PBR	O
6	/	O
7	IBP	O
8	cDNA	O
9	into	O
10	COS	O
11	-	O
12	7	O
13	cells	O
14	resulted	O
15	in	O
16	an	O
17	11	O
18	-	O
19	fold	O
20	increase	O
21	in	O
22	the	O
23	density	O
24	of	O
25	high	O
26	affinity	O
27	[	O
28	3H	O
29	]	O
30	PK	O
31	11195	O
32	binding	O
33	sites	O
34	which	O
35	had	O
36	only	O
37	low	O
38	affinity	O
39	for	O
40	Ro5	O
41	-	O
42	4864	O
43	.	O

1	These	O
2	results	O
3	confirmed	O
4	that	O
5	cleavage	O
6	of	O
7	the	O
8	leader	O
9	peptide	O
10	is	O
11	the	O
12	last	O
13	step	O
14	in	O
15	nisin	O
16	maturation	O
17	and	O
18	is	O
19	necessary	O
20	to	O
21	generate	O
22	a	O
23	biologically	O
24	active	O
25	peptide	O
26	.	O

1	Thyreoliberin	O
2	VUFB	O
3	in	O
4	thyroid	O
5	gammagraphy	O

1	Venkatesan	O
2	,	O
3	and	O
4	D	O
5	.	O

1	The	O
2	preferences	O
3	were	O
4	for	O
5	intact	O
6	vis	O
7	-	O
8	a	O
9	-	O
10	vis	O
11	castrated	O
12	males	O
13	,	O
14	though	O
15	injections	O
16	of	O
17	TP	O
18	restored	O
19	the	O
20	castrates	O
21	'	O
22	attractiveness	O
23	to	O
24	the	O
25	females	O
26	.	O

1	The	O
2	synergistic	O
3	effect	O
4	due	O
5	to	O
6	the	O
7	5	O
8	'-	O
9	3	O
10	'	O
11	cooperation	O
12	was	O
13	at	O
14	least	O
15	fourfold	O
16	greater	O
17	than	O
18	the	O
19	sum	O
20	of	O
21	the	O
22	contributions	O
23	of	O
24	the	O
25	individual	O
26	UTRs	O
27	.	O

1	Cyclin	B
2	-	I
3	dependent	I
4	kinase	I
5	-	I
6	2	I
7	(	O
8	Cdk2	B
9	)	O
10	forms	O
11	an	O
12	inactive	O
13	complex	O
14	with	O
15	cyclin	B
16	D1	I
17	since	O
18	Cdk2	B
19	associated	O
20	with	O
21	cyclin	B
22	D1	I
23	is	O
24	not	O
25	phosphorylated	O
26	by	O
27	Cdk7	B
28	-	I
29	cyclin	I
30	-	I
31	H	I
32	.	O

1	An	O
2	ELISA	O
3	procedure	O
4	was	O
5	developed	O
6	for	O
7	monitoring	O
8	the	O
9	specific	O
10	IgE	B
11	response	O
12	in	O
13	dogs	O
14	to	O
15	Dirofilaria	O
16	immitis	O
17	infection	O
18	.	O

1	Copyright	O
2	2000	O
3	Academic	O
4	Press	O
5	.	O

1	We	O
2	have	O
3	previously	O
4	mapped	O
5	the	O
6	defect	O
7	in	O
8	RIIIS	O
9	/	O
10	J	O
11	to	O
12	distal	O
13	mouse	O
14	Chr	O
15	11	O
16	,	O
17	distinct	O
18	from	O
19	the	O
20	Vwf	O
21	locus	O
22	on	O
23	Chr	O
24	6	O
25	.	O

1	Serum	O
2	HBV	O
3	-	O
4	DNA	O
5	,	O
6	viral	O
7	serology	O
8	,	O
9	and	O
10	liver	O
11	enzymes	O
12	were	O
13	measured	O
14	sequentially	O
15	;	O
16	liver	O
17	histology	O
18	was	O
19	taken	O
20	before	O
21	and	O
22	during	O
23	treatment	O
24	in	O
25	12	O
26	patients	O
27	.	O

1	This	O
2	association	O
3	was	O
4	independently	O
5	significant	O
6	for	O
7	patients	O
8	treated	O
9	primarily	O
10	(	O
11	not	O
12	for	O
13	recurrence	O
14	).	O

1	Abstracts	O
2	.	O

1	The	O
2	present	O
3	investigation	O
4	sought	O
5	to	O
6	identify	O
7	the	O
8	principal	O
9	dimensions	O
10	of	O
11	the	O
12	Framingham	O
13	Type	O
14	A	O
15	scale	O
16	(	O
17	FTAS	O
18	)	O
19	and	O
20	then	O
21	to	O
22	examine	O
23	their	O
24	physiological	O
25	and	O
26	psychological	O
27	correlates	O
28	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	,	O
6	lesions	O
7	of	O
8	the	O
9	OPT	O
10	complex	O
11	(	O
12	the	O
13	thalamic	O
14	source	O
15	of	O
16	afferents	O
17	to	O
18	IHA	O
19	and	O
20	HD	O
21	)	O
22	were	O
23	found	O
24	to	O
25	have	O
26	no	O
27	effect	O
28	on	O
29	color	O
30	-	O
31	reversal	O
32	learning	O
33	performance	O
34	.	O

1	Resistance	O
2	to	O
3	thyroid	O
4	hormone	O
5	:	O
6	implications	O
7	for	O
8	neurodevelopmental	O
9	research	O
10	on	O
11	the	O
12	effects	O
13	of	O
14	thyroid	O
15	hormone	O
16	disruptors	O
17	.	O

1	Results	O
2	confirmed	O
3	that	O
4	stress	O
5	produced	O
6	CA3	O
7	dendritic	O
8	atrophy	O
9	and	O
10	tianeptine	O
11	prevented	O
12	it	O
13	.	O

1	Stat	B
2	activation	O
3	in	O
4	response	O
5	to	O
6	GH	B
7	and	O
8	IL	B
9	-	I
10	6	O
11	was	O
12	determined	O
13	by	O
14	reporter	O
15	gene	O
16	induction	O
17	.	O

1	Alignment	O
2	of	O
3	the	O
4	amino	O
5	acid	O
6	sequences	O
7	surrounding	O
8	Tyr	O
9	-	O
10	766	O
11	with	O
12	corresponding	O
13	regions	O
14	of	O
15	other	O
16	FGFRs	O
17	revealed	O
18	conserved	O
19	tyrosine	O
20	residues	O
21	in	O
22	all	O
23	known	O
24	members	O
25	of	O
26	the	O
27	FGFR	B
28	family	I
29	.	O

1	RESULTS	O
2	:	O
3	In	O
4	the	O
5	pregnant	O
6	group	O
7	,	O
8	serum	O
9	PP14	O
10	concentrations	O
11	were	O
12	markedly	O
13	increased	O
14	after	O
15	ET	O
16	,	O
17	and	O
18	a	O
19	significant	O
20	difference	O
21	between	O
22	the	O
23	pregnant	O
24	group	O
25	and	O
26	the	O
27	nonpregnant	O
28	group	O
29	was	O
30	observed	O
31	8	O
32	days	O
33	following	O
34	ET	O
35	(	O
36	p	O
37	<	O
38	0	O
39	.	O
40	01	O
41	).	O

1	Overlapping	O
2	cDNA	O
3	clones	O
4	were	O
5	isolated	O
6	and	O
7	sequenced	O
8	.	O

1	The	O
2	mRNA	O
3	expression	O
4	of	O
5	RFX1	O
6	,	O
7	RFX2	O
8	,	O
9	and	O
10	RFX3	O
11	was	O
12	detected	O
13	ubiquitously	O
14	,	O
15	but	O
16	in	O
17	transient	O
18	-	O
19	transfection	O
20	assays	O
21	,	O
22	multimerized	O
23	RFX	O
24	binding	O
25	sites	O
26	in	O
27	front	O
28	of	O
29	a	O
30	basal	O
31	promoter	O
32	efficiently	O
33	functioned	O
34	in	O
35	a	O
36	tissue	O
37	-	O
38	and	O
39	lineage	O
40	-	O
41	specific	O
42	manner	O
43	.	O

1	To	O
2	study	O
3	a	O
4	possible	O
5	functional	O
6	role	O
7	of	O
8	this	O
9	putative	O
10	chicken	O
11	ICS	O
12	,	O
13	an	O
14	oligonucleotide	O
15	spanning	O
16	the	O
17	upstream	O
18	sequences	O
19	of	O
20	the	O
21	BF	O
22	-	O
23	IV	O
24	gene	O
25	(-	O
26	174	O
27	/-	O
28	194	O
29	)	O
30	was	O
31	cloned	O
32	singly	O
33	or	O
34	in	O
35	multiple	O
36	copies	O
37	before	O
38	the	O
39	herpes	O
40	TK	B
41	promoter	I
42	controlling	O
43	the	O
44	chloramphenicol	B
45	acetyl	I
46	transferase	I
47	(	O
48	CAT	B
49	)	I
50	gene	I
51	(	O
52	pBLCAT2	O
53	).	O

1	Neither	O
2	gene	O
3	possesses	O
4	a	O
5	distinct	O
6	transcriptional	O
7	start	O
8	site	O
9	as	O
10	shown	O
11	by	O
12	nuclease	O
13	S1	O
14	analysis	O
15	.	O

1	The	O
2	absence	O
3	of	O
4	H4PteGlun	O
5	bound	O
6	to	O
7	the	O
8	T	O
9	protein	O
10	in	O
11	our	O
12	experimental	O
13	conditions	O
14	demonstrates	O
15	that	O
16	H4PteGlun	O
17	is	O
18	not	O
19	covalently	O
20	linked	O
21	to	O
22	the	O
23	T	O
24	protein	O
25	.	O

1	Nucleotide	O
2	sequencing	O
3	indicates	O
4	that	O
5	this	O
6	E1	B
7	alpha	I
8	cDNA	I
9	clone	O
10	is	O
11	1821	O
12	base	O
13	pairs	O
14	(	O
15	bp	O
16	)	O
17	in	O
18	length	O
19	with	O
20	an	O
21	open	O
22	reading	O
23	frame	O
24	of	O
25	1365	O
26	bp	O
27	and	O
28	a	O
29	3	O
30	'-	O
31	untranslated	O
32	region	O
33	of	O
34	356	O
35	bp	O
36	.	O

1	Survival	O
2	after	O
3	development	O
4	of	O
5	symptomatic	O
6	infection	O
7	(	O
8	P	O
9	-	O
10	2	O
11	)	O
12	did	O
13	not	O
14	differ	O
15	by	O
16	transmission	O
17	mode	O
18	.	O

1	Based	O
2	on	O
3	AUC	O
4	infinity	O
5	analyses	O
6	,	O
7	the	O
8	pharmacokinetics	O
9	of	O
10	buflomedil	O
11	were	O
12	found	O
13	to	O
14	be	O
15	linear	O
16	within	O
17	the	O
18	dose	O
19	ranges	O
20	studied	O
21	(	O
22	50	O
23	to	O
24	200	O
25	mg	O
26	for	O
27	i	O
28	.	O
29	v	O
30	.	O
31	injection	O
32	and	O
33	150	O
34	to	O
35	450	O
36	mg	O
37	for	O
38	oral	O
39	administration	O
40	).	O

1	Inhibition	O
2	of	O
3	erythromycin	O
4	synthesis	O
5	by	O
6	disruption	O
7	of	O
8	malonyl	B
9	-	I
10	coenzyme	I
11	A	I
12	decarboxylase	I
13	gene	I
14	eryM	O
15	in	O
16	Saccharopolyspora	O
17	erythraea	O
18	.	O

1	Specific	O
2	hyperimmune	O
3	globulins	O
4	to	O
5	pathogens	O
6	such	O
7	as	O
8	Haemophilus	O
9	influenzae	O
10	and	O
11	Streptococcus	O
12	pneumoniae	O
13	have	O
14	also	O
15	been	O
16	studied	O
17	.	O

1	Indeed	O
2	,	O
3	ERM	O
4	and	O
5	c	B
6	-	I
7	Jun	I
8	synergistically	I
9	activated	I
10	the	O
11	EBS	O
12	-	O
13	CRE	O
14	without	O
15	making	O
16	an	O
17	apparent	O
18	ternary	O
19	complex	O
20	.	O

1	DESIGN	O
2	--	O
3	A	O
4	randomised	O
5	study	O
6	was	O
7	conducted	O
8	in	O
9	all	O
10	women	O
11	aged	O
12	50	O
13	-	O
14	70	O
15	years	O
16	who	O
17	were	O
18	eligible	O
19	for	O
20	breast	O
21	cancer	O
22	screening	O
23	and	O
24	living	O
25	in	O
26	the	O
27	city	O
28	of	O
29	Utrecht	O
30	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	evaluate	O
5	the	O
6	accuracy	O
7	of	O
8	working	O
9	casts	O
10	for	O
11	crown	O
12	and	O
13	bridge	O
14	restorations	O
15	made	O
16	from	O
17	twin	O
18	mix	O
19	putty	O
20	/	O
21	wash	O
22	silicone	O
23	elastomeric	O
24	impression	O
25	materials	O
26	using	O
27	different	O
28	types	O
29	of	O
30	stock	O
31	tray	O
32	.	O

1	Dosage	O
2	in	O
3	both	O
4	cases	O
5	was	O
6	0	O
7	.	O
8	2	O
9	g	O
10	/	O
11	m2	O
12	.	O

1	These	O
2	results	O
3	strongly	O
4	suggest	O
5	that	O
6	locally	O
7	-	O
8	applied	O
9	TTC	O
10	in	O
11	combination	O
12	with	O
13	FDBA	O
14	enhances	O
15	new	O
16	bone	O
17	formation	O
18	in	O
19	experimental	O
20	alveolar	O
21	bone	O
22	defects	O
23	.	O

1	Interestingly	O
2	,	O
3	the	O
4	RNA	O
5	sequences	O
6	selected	O
7	by	O
8	the	O
9	mutated	O
10	zinc	O
11	knuckle	O
12	9G8	O
13	variant	O
14	are	O
15	efficiently	O
16	recognized	O
17	by	O
18	SRp20	O
19	,	O
20	in	O
21	agreement	O
22	with	O
23	the	O
24	fact	O
25	that	O
26	the	O
27	RBD	O
28	of	O
29	9G8	O
30	and	O
31	SRp20	O
32	are	O
33	similar	O
34	.	O

1	No	O
2	differences	O
3	in	O
4	fixation	O
5	quality	O
6	were	O
7	observed	O
8	between	O
9	cochleas	O
10	fixed	O
11	by	O
12	intravascular	O
13	perfusion	O
14	and	O
15	cochleas	O
16	fixed	O
17	by	O
18	intralabyrinthine	O
19	perfusion	O
20	.	O

1	The	O
2	signalling	O
3	molecules	O
4	Wnt1	O
5	and	O
6	Sonic	O
7	hedgehog	O
8	,	O
9	implicated	O
10	in	O
11	the	O
12	activation	O
13	of	O
14	Myf5	O
15	in	O
16	myogenic	O
17	progenitor	O
18	cells	O
19	in	O
20	the	O
21	somite	O
22	,	O
23	are	O
24	also	O
25	produced	O
26	in	O
27	the	O
28	viscinity	O
29	of	O
30	the	O
31	Myf5	O
32	expression	O
33	domain	O
34	in	O
35	the	O
36	mesencephalon	O
37	.	O

1	Maximum	O
2	induction	O
3	of	O
4	AP	B
5	-	I
6	1	I
7	was	O
8	reached	O
9	at	O
10	a	O
11	concentration	O
12	of	O
13	250	O
14	nmol	O
15	/	O
16	L	O
17	of	O
18	CalC	O
19	.	O

1	Src	B
2	activation	O
3	induced	O
4	by	O
5	FGF1	O
6	was	O
7	blocked	O
8	by	O
9	the	O
10	SH2	B
11	domain	I
12	of	O
13	Src	B
14	and	O
15	PP2	O
16	,	O
17	a	O
18	specific	O
19	inhibitor	O
20	of	O
21	Src	B
22	.	O

1	BACKGROUND	O
2	:	O
3	Mitosis	O
4	is	O
5	regulated	O
6	by	O
7	MPF	O
8	(	O
9	maturation	O
10	promoting	O
11	factor	O
12	),	O
13	the	O
14	active	O
15	form	O
16	of	O
17	Cdc2	B
18	/	O
19	28	O
20	-	O
21	cyclin	B
22	B	I
23	complexes	I
24	.	O

1	Transient	O
2	overexpression	O
3	of	O
4	c	B
5	-	I
6	Jun	I
7	induced	O
8	tenascin	O
9	-	O
10	C	O
11	expression	O
12	in	O
13	primary	O
14	REF	O
15	and	O
16	in	O
17	FR3T3	O
18	,	O
19	an	O
20	established	O
21	fibroblast	O
22	cell	O
23	line	O
24	.	O

1	The	O
2	carboxyl	O
3	-	O
4	terminal	O
5	portion	O
6	of	O
7	UKLF	O
8	contains	O
9	three	O
10	zinc	O
11	fingers	O
12	of	O
13	the	O
14	Cys2	O
15	-	O
16	His2	O
17	type	O
18	and	O
19	binds	O
20	in	O
21	vitro	O
22	to	O
23	the	O
24	CACCC	O
25	motif	O
26	of	O
27	the	O
28	beta	B
29	-	I
30	globin	I
31	promoter	I
32	and	O
33	to	O
34	the	O
35	Sp1	B
36	recognition	I
37	sequence	O
38	.	O

1	Of	O
2	the	O
3	117	O
4	patients	O
5	(	O
6	out	O
7	of	O
8	the	O
9	136	O
10	)	O
11	with	O
12	serologic	O
13	evidence	O
14	of	O
15	chronic	O
16	thyroiditis	O
17	who	O
18	could	O
19	be	O
20	studied	O
21	,	O
22	eight	O
23	(	O
24	7	O
25	%)	O
26	had	O
27	hyperthyroidism	O
28	and	O
29	45	O
30	(	O
31	38	O
32	%)	O
33	were	O
34	hypothyroid	O
35	.	O

1	The	O
2	recovery	O
3	index	O
4	(	O
5	T25	O
6	-	O
7	T75	O
8	)	O
9	after	O
10	the	O
11	infusion	O
12	stopped	O
13	was	O
14	similar	O
15	in	O
16	patients	O
17	who	O
18	received	O
19	mivacurium	O
20	and	O
21	those	O
22	who	O
23	received	O
24	suxamethonium	O
25	.	O

1	Carbohydrates	O
2	and	O
3	glycoconjugates	O
4	biophysical	O
5	methods	O
6	.	O

1	Since	O
2	electrical	O
3	stimulation	O
4	of	O
5	neurones	O
6	may	O
7	activate	O
8	not	O
9	only	O
10	cell	O
11	bodies	O
12	but	O
13	also	O
14	neuronal	O
15	fibres	O
16	,	O
17	this	O
18	study	O
19	aimed	O
20	to	O
21	test	O
22	a	O
23	selectively	O
24	cholinergic	O
25	neurochemical	O
26	stimulation	O
27	of	O
28	the	O
29	rat	O
30	substantia	O
31	innominata	O
32	(	O
33	SI	O
34	)	O
35	by	O
36	the	O
37	local	O
38	microinjection	O
39	of	O
40	carbachol	O
41	;	O
42	the	O
43	effects	O
44	of	O
45	this	O
46	acetylcholine	O
47	agonist	O
48	were	O
49	compared	O
50	with	O
51	glutamate	O
52	.	O

1	The	O
2	gene	O
3	lac	B
4	-	I
5	1	I
6	,	O
7	encoding	O
8	the	O
9	enzyme	O
10	laccase	O
11	,	O
12	is	O
13	the	O
14	best	O
15	characterized	O
16	of	O
17	a	O
18	number	O
19	of	O
20	genes	O
21	in	O
22	the	O
23	chestnut	O
24	blight	O
25	fungus	O
26	,	O
27	Cryphonectria	O
28	parasitica	O
29	,	O
30	that	O
31	are	O
32	repressed	O
33	by	O
34	hypoviruses	O
35	,	O
36	a	O
37	group	O
38	of	O
39	virulence	O
40	-	O
41	attenuating	O
42	mycoviruses	O
43	.	O
44	lac	B
45	-	I
46	1	I
47	has	O
48	also	O
49	been	O
50	shown	O
51	to	O
52	be	O
53	transcriptionally	O
54	activated	O
55	by	O
56	low	O
57	concentrations	O
58	of	O
59	the	O
60	translational	O
61	inhibitor	O
62	cycloheximide	O
63	(	O
64	CHX	O
65	)	O
66	and	O
67	by	O
68	the	O
69	immunosuppressant	O
70	cyclosporin	O
71	A	O
72	.	O

1	Recent	O
2	target	O
3	BP	O
4	goals	O
5	promulgated	O
6	by	O
7	the	O
8	Sixth	O
9	Report	O
10	from	O
11	the	O
12	Joint	O
13	National	O
14	Committee	O
15	(	O
16	JNC	O
17	VI	O
18	)	O
19	are	O
20	based	O
21	on	O
22	the	O
23	premise	O
24	that	O
25	the	O
26	intensity	O
27	of	O
28	treatment	O
29	directly	O
30	corresponds	O
31	to	O
32	the	O
33	magnitude	O
34	of	O
35	pretreatment	O
36	risk	O
37	.	O

1	Like	O
2	the	O
3	Tob	O
4	protein	O
5	,	O
6	Tob2	O
7	inhibited	O
8	cell	O
9	cycle	O
10	progression	O
11	from	O
12	the	O
13	G0	O
14	/	O
15	G1	O
16	to	O
17	S	O
18	phases	O
19	.	O

1	Developmental	O
2	toxicity	O
3	of	O
4	the	O
5	class	O
6	III	O
7	antiarrhythmic	O
8	agent	O
9	almokalant	O
10	in	O
11	mice	O
12	.	O

1	The	O
2	diagnosis	O
3	of	O
4	miliary	O
5	tuberculosis	O
6	should	O
7	be	O
8	systematically	O
9	considered	O
10	in	O
11	ARDS	O
12	of	O
13	unknown	O
14	origin	O
15	.	O

1	A	O
2	short	O
3	open	O
4	reading	O
5	frame	O
6	(	O
7	ORF2	O
8	),	O
9	of	O
10	unknown	O
11	function	O
12	,	O
13	is	O
14	present	O
15	in	O
16	all	O
17	FIV	O
18	isolates	O
19	.	O

1	Previous	O
2	experience	O
3	and	O
4	contextual	O
5	cues	O
6	are	O
7	essential	O
8	elements	O
9	in	O
10	the	O
11	generation	O
12	of	O
13	a	O
14	subjective	O
15	prediction	O
16	.	O

1	Malignant	O
2	lymphoma	O
3	is	O
4	very	O
5	heterogeneous	O
6	in	O
7	terms	O
8	of	O
9	its	O
10	biological	O
11	behavior	O
12	.	O

1	In	O
2	a	O
3	prospective	O
4	,	O
5	randomized	O
6	clinical	O
7	trial	O
8	we	O
9	compared	O
10	the	O
11	efficacy	O
12	of	O
13	subcutaneously	O
14	(	O
15	SC	O
16	)	O
17	administered	O
18	(	O
19	every	O
20	8	O
21	h	O
22	)	O
23	calcium	O
24	heparin	O
25	to	O
26	intravenous	O
27	(	O
28	IV	O
29	)	O
30	sodium	O
31	heparin	O
32	in	O
33	the	O
34	treatment	O
35	of	O
36	proximal	O
37	deep	O
38	-	O
39	vein	O
40	thrombosis	O
41	(	O
42	DVT	O
43	).	O

1	Covalent	O
2	modification	O
3	of	O
4	the	O
5	transactivator	B
6	protein	I
7	IE2	I
8	-	I
9	p86	O
10	of	O
11	human	O
12	cytomegalovirus	O
13	by	O
14	conjugation	O
15	to	O
16	the	O
17	ubiquitin	B
18	-	I
19	homologous	I
20	proteins	I
21	SUMO	I
22	-	I
23	1	I
24	and	O
25	hSMT3b	O
26	.	O

1	These	O
2	well	O
3	-	O
4	characterized	O
5	brain	O
6	regions	O
7	may	O
8	provide	O
9	a	O
10	basis	O
11	for	O
12	future	O
13	studies	O
14	of	O
15	RPTP	B
16	-	I
17	kappa	I
18	function	O
19	.	O

1	Vasoactive	O
2	intestinal	O
3	peptide	O
4	and	O
5	pituitary	O
6	adenylate	B
7	cyclase	I
8	-	I
9	activating	I
10	polypeptide	I
11	inhibit	I
12	nuclear	I
13	factor	I
14	-	I
15	kappa	I
16	B	I
17	-	I
18	dependent	I
19	gene	I
20	activation	O
21	at	O
22	multiple	O
23	levels	O
24	in	O
25	the	O
26	human	O
27	monocytic	O
28	cell	O
29	line	O
30	THP	O
31	-	O
32	1	O
33	.	O

1	Removal	O
2	of	O
3	beta	B
4	2	I
5	-	I
6	microglobulin	I
7	by	O
8	hemodialysis	O
9	and	O
10	hemofiltration	O
11	:	O
12	a	O
13	four	O
14	year	O
15	follow	O
16	up	O
17	.	O

1	The	O
2	real	O
3	challenge	O
4	for	O
5	the	O
6	future	O
7	will	O
8	be	O
9	the	O
10	management	O
11	of	O
12	patients	O
13	who	O
14	do	O
15	not	O
16	respond	O
17	to	O
18	first	O
19	-	O
20	line	O
21	treatment	O
22	.	O

1	In	O
2	support	O
3	of	O
4	this	O
5	interpretation	O
6	we	O
7	demonstrate	O
8	that	O
9	MQ9b	O
10	binds	O
11	strongly	O
12	5	O
13	of	O
14	17	O
15	motif	O
16	-	O
17	positive	O
18	,	O
19	pathogen	O
20	-	O
21	derived	O
22	synthetic	O
23	peptides	O
24	.	O

1	The	O
2	amino	O
3	acid	O
4	sequences	O
5	of	O
6	the	O
7	yeast	O
8	and	O
9	mammalian	O
10	mitochondrial	O
11	targeting	O
12	sequences	O
13	are	O
14	similar	O
15	but	O
16	less	O
17	related	O
18	than	O
19	the	O
20	mature	O
21	polypeptides	O
22	.	O

1	Two	O
2	members	O
3	of	O
4	the	O
5	Cbl	B
6	family	I
7	have	O
8	since	O
9	been	O
10	defined	O
11	in	O
12	mammals	O
13	(	O
14	c	B
15	-	I
16	Cbl	I
17	and	I
18	Cbl	I
19	-	I
20	b	O
21	),	O
22	one	O
23	in	O
24	C	O
25	.	O
26	elegans	O
27	(	O
28	Sli	O
29	-	O
30	1	O
31	)	O
32	and	O
33	one	O
34	in	O
35	Drosophila	B
36	(	I
37	D	I
38	-	I
39	Cbl	I
40	).	O

1	D	O
2	.	O

1	Genotoxic	O
2	activity	O
3	of	O
4	a	O
5	tobacco	O
6	-	O
7	specific	O
8	nitrosamine	O
9	.	O

1	Twenty	O
2	-	O
3	eight	O
4	(	O
5	7	O
6	.	O
7	0	O
8	%)	O
9	infants	O
10	without	O
11	periventricular	O
12	hemorrhage	O
13	were	O
14	revealed	O
15	as	O
16	having	O
17	spastic	O
18	cerebral	O
19	palsy	O
20	by	O
21	neurodevelopmental	O
22	evaluation	O
23	in	O
24	later	O
25	infancy	O
26	.	O

1	The	O
2	tumor	B
3	-	I
4	suppressor	I
5	protein	I
6	p53	I
7	is	O
8	involved	O
9	in	O
10	maintaining	O
11	genomic	O
12	stability	O
13	.	O

1	A	O
2	position	O
3	-	O
4	independent	O
5	activation	O
6	domain	O
7	which	O
8	contained	O
9	conserved	O
10	regions	O
11	II	O
12	and	O
13	III	O
14	was	O
15	identified	O
16	at	O
17	the	O
18	carboxyl	O
19	terminus	O
20	of	O
21	the	O
22	HNF	B
23	-	I
24	3	I
25	beta	I
26	protein	I
27	(	O
28	amino	O
29	acids	O
30	361	O
31	to	O
32	458	O
33	).	O

1	Molecular	O
2	cloning	O
3	of	O
4	Elk	B
5	-	I
6	3	O
7	,	O
8	a	O
9	new	O
10	member	O
11	of	O
12	the	O
13	Ets	B
14	family	I
15	expressed	O
16	during	O
17	mouse	O
18	embryogenesis	O
19	and	O
20	analysis	O
21	of	O
22	its	O
23	transcriptional	O
24	repression	O
25	activity	O
26	.	O

1	Tyrosine	O
2	1356	O
3	forms	O
4	a	O
5	multisubstrate	O
6	binding	O
7	site	O
8	for	O
9	the	O
10	Grb2	B
11	and	O
12	Shc	B
13	adaptor	I
14	proteins	I
15	,	O
16	the	O
17	p85	B
18	subunit	I
19	of	O
20	phosphatidylinositol	B
21	3	I
22	'-	I
23	kinase	I
24	,	O
25	phospholipase	B
26	Cgamma	O
27	,	O
28	and	O
29	a	O
30	phosphatase	O
31	,	O
32	SHP2	O
33	.	O

1	Seventeen	O
2	of	O
3	the	O
4	35	O
5	patients	O
6	were	O
7	randomly	O
8	chosen	O
9	to	O
10	receive	O
11	a	O
12	training	O
13	program	O
14	(	O
15	lasting	O
16	approximately	O
17	1	O
18	month	O
19	)	O
20	designed	O
21	to	O
22	establish	O
23	a	O
24	systematic	O
25	strategy	O
26	of	O
27	organizing	O
28	complex	O
29	visual	O
30	material	O
31	.	O

1	Second	O
2	,	O
3	the	O
4	membrane	O
5	expression	O
6	of	O
7	alpha	O
8	and	O
9	beta	O
10	subunits	O
11	was	O
12	mimicked	O
13	by	O
14	cholesterol	O
15	and	O
16	17	O
17	-	O
18	ketocholesterol	O
19	,	O
20	both	O
21	of	O
22	which	O
23	inhibit	O
24	HMG	B
25	-	I
26	CoA	I
27	reductase	I
28	.	O

1	RESULTS	O
2	:	O
3	We	O
4	isolated	O
5	a	O
6	C	O
7	.	O
8	elegans	O
9	cDNA	O
10	that	O
11	encoded	O
12	a	O
13	protein	O
14	which	O
15	was	O
16	similar	O
17	to	O
18	,	O
19	but	O
20	not	O
21	exactly	O
22	homologous	O
23	with	O
24	mammalian	B
25	p120	I
26	Ras	I
27	-	I
28	GAP	I
29	.	O

1	This	O
2	growth	O
3	arrest	O
4	is	O
5	partly	O
6	suppressed	O
7	on	O
8	minimal	O
9	medium	O
10	or	O
11	under	O
12	conditions	O
13	in	O
14	which	O
15	the	O
16	cells	O
17	are	O
18	less	O
19	dependent	O
20	on	O
21	mitochondrial	O
22	metabolism	O
23	.	O

1	The	O
2	Jem	O
3	peptide	O
4	sequence	O
5	shows	O
6	a	O
7	'	O
8	leucine	O
9	-	O
10	zipper	O
11	'	O
12	dimerisation	O
13	motif	O
14	with	O
15	limited	O
16	homology	O
17	to	O
18	Fos	B
19	/	I
20	Jun	I
21	and	O
22	ATF	B
23	/	I
24	CREB	I
25	proteins	I
26	and	O
27	several	O
28	putative	O
29	phosphorylation	O
30	sites	O
31	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	zebrafish	O
6	egr1	O
7	coding	O
8	region	O
9	revealed	O
10	a	O
11	high	O
12	level	O
13	of	O
14	homology	O
15	to	O
16	the	O
17	mouse	O
18	,	O
19	rat	O
20	,	O
21	and	O
22	human	B
23	Egr1	I
24	genes	I
25	with	O
26	the	O
27	notable	O
28	exception	O
29	of	O
30	a	O
31	polymorphic	O
32	,	O
33	triplet	O
34	nucleotide	O
35	repeat	O
36	sequence	O
37	in	O
38	the	O
39	region	O
40	coding	O
41	for	O
42	the	O
43	amino	O
44	terminus	O
45	of	O
46	the	O
47	Egr1	B
48	protein	I
49	.	O

1	The	O
2	psychological	O
3	tests	O
4	consisted	O
5	of	O
6	a	O
7	free	O
8	-	O
9	recall	O
10	task	O
11	,	O
12	a	O
13	test	O
14	for	O
15	visuomotor	O
16	coordination	O
17	and	O
18	a	O
19	recognition	O
20	task	O
21	.	O

1	As	O
2	well	O
3	,	O
4	further	O
5	deletion	O
6	of	O
7	the	O
8	promoter	O
9	region	O
10	to	O
11	nucleotide	O
12	-	O
13	110	O
14	,	O
15	which	O
16	contains	O
17	only	O
18	one	O
19	SF	B
20	-	I
21	1	I
22	binding	I
23	site	I
24	,	O
25	still	O
26	retained	O
27	the	O
28	ability	O
29	to	O
30	respond	O
31	to	O
32	exogenous	O
33	SF	B
34	-	I
35	1	I
36	.	O

1	Examination	O
2	of	O
3	DNA	O
4	:	O
5	protein	O
6	binding	O
7	complexes	O
8	by	O
9	gel	O
10	-	O
11	shift	O
12	analysis	O
13	indicated	O
14	that	O
15	nuclear	O
16	factors	O
17	from	O
18	both	O
19	proliferative	O
20	and	O
21	growth	O
22	-	O
23	arrested	O
24	cells	O
25	bound	O
26	to	O
27	the	O
28	DNA	O
29	fragment	O
30	spanning	O
31	-	O
32	949	O
33	-	O
34	-	O
35	722	O
36	bp	O
37	.	O

1	We	O
2	have	O
3	identified	O
4	and	O
5	characterized	O
6	a	O
7	vitamin	O
8	D	O
9	response	O
10	element	O
11	(	O
12	VDRE	O
13	)	O
14	in	O
15	the	O
16	promoter	O
17	of	O
18	c	B
19	-	I
20	fos	I
21	.	O

1	The	O
2	function	O
3	of	O
4	the	O
5	C	O
6	-	O
7	terminal	O
8	tail	O
9	in	O
10	telomere	O
11	maintenance	O
12	is	O
13	not	O
14	mediated	O
15	through	O
16	the	O
17	RAP1	B
18	interacting	I
19	factor	I
20	RIF1	O
21	:	O
22	rap1	O
23	alleles	O
24	defective	O
25	in	O
26	both	O
27	the	O
28	C	O
29	-	O
30	terminal	O
31	tail	O
32	and	O
33	RIF1	O
34	interaction	O
35	domains	O
36	have	O
37	additive	O
38	effects	O
39	on	O
40	telomere	O
41	length	O
42	.	O

1	Change	O
2	in	O
3	plasma	O
4	cystyl	O
5	aminopeptidase	O
6	(	O
7	oxytocinase	O
8	)	O
9	between	O
10	30	O
11	-	O
12	34	O
13	weeks	O
14	'	O
15	gestation	O
16	as	O
17	a	O
18	predictor	O
19	of	O
20	pregnancy	O
21	-	O
22	induced	O
23	hypertension	O
24	.	O

1	Electromagnetic	O
2	blood	O
3	flow	O
4	(	O
5	BF	O
6	)	O
7	probe	O
8	was	O
9	applied	O
10	on	O
11	the	O
12	left	O
13	anterior	O
14	descending	O
15	artery	O
16	(	O
17	LAD	O
18	).	O

1	Type	O
2	II	O
3	could	O
4	be	O
5	divided	O
6	further	O
7	into	O
8	two	O
9	forms	O
10	(	O
11	IIA	O
12	and	O
13	IIB	O
14	)	O
15	that	O
16	may	O
17	represent	O
18	two	O
19	underscribed	O
20	species	O
21	or	O
22	developmental	O
23	stages	O
24	of	O
25	the	O
26	same	O
27	species	O
28	.	O

1	Expression	O
2	of	O
3	this	O
4	protein	O
5	in	O
6	E	O
7	.	O
8	coli	O
9	demonstrated	O
10	that	O
11	tyrosine	O
12	was	O
13	incorporated	O
14	during	O
15	suppression	O
16	and	O
17	that	O
18	yeast	O
19	cytoplasmic	O
20	TyrRS	O
21	activity	O
22	was	O
23	produced	O
24	.	O

1	Here	O
2	,	O
3	we	O
4	evidence	O
5	that	O
6	the	O
7	developmental	O
8	functions	O
9	of	O
10	the	O
11	family	O
12	of	O
13	transcription	O
14	factors	O
15	characterized	O
16	by	O
17	the	O
18	POU	B
19	DNA	O
20	binding	O
21	motif	O
22	exerts	O
23	roles	O
24	in	O
25	mammalian	O
26	development	O
27	.	O

1	We	O
2	discuss	O
3	the	O
4	results	O
5	in	O
6	relation	O
7	to	O
8	previous	O
9	systems	O
10	for	O
11	parcellating	O
12	the	O
13	posterior	O
14	ectosylvian	O
15	gyrus	O
16	of	O
17	the	O
18	cat	O
19	and	O
20	consider	O
21	the	O
22	possibility	O
23	that	O
24	divisions	O
25	of	O
26	the	O
27	feline	O
28	posterior	O
29	ectosylvian	O
30	gyrus	O
31	correspond	O
32	directly	O
33	to	O
34	areas	O
35	making	O
36	up	O
37	the	O
38	superior	O
39	temporal	O
40	gyrus	O
41	in	O
42	primates	O
43	.	O

1	Regionalization	O
2	of	O
3	drug	O
4	delivery	O
5	is	O
6	a	O
7	potential	O
8	method	O
9	to	O
10	avoid	O
11	this	O
12	problem	O
13	.	O

1	This	O
2	loss	O
3	was	O
4	independent	O
5	of	O
6	drug	O
7	concentration	O
8	and	O
9	a	O
10	correction	O
11	factor	O
12	was	O
13	employed	O
14	to	O
15	calculate	O
16	the	O
17	true	O
18	free	O
19	diazepam	O
20	concentration	O
21	.	O

1	In	O
2	addition	O
3	to	O
4	the	O
5	protein	B
6	-	I
7	tyrosine	I
8	kinase	I
9	domain	I
10	,	O
11	p56lck	B
12	possesses	I
13	Src	I
14	homology	I
15	2	I
16	and	O
17	3	O
18	(	O
19	SH2	B
20	and	O
21	SH3	B
22	)	O
23	domains	O
24	as	O
25	well	O
26	as	O
27	a	O
28	unique	O
29	N	O
30	-	O
31	terminal	O
32	region	O
33	.	O

1	The	O
2	patient	O
3	'	O
4	s	O
5	role	O
6	,	O
7	organized	O
8	by	O
9	the	O
10	prerequisites	O
11	of	O
12	expressive	O
13	freedom	O
14	,	O
15	is	O
16	counter	O
17	posed	O
18	with	O
19	the	O
20	psychoanalyst	O
21	'	O
22	s	O
23	,	O
24	which	O
25	is	O
26	structured	O
27	to	O
28	empower	O
29	listening	O
30	and	O
31	understanding	O
32	.	O

1	Within	O
2	the	O
3	span	O
4	of	O
5	attenuator	O
6	region	O
7	encoding	O
8	the	O
9	three	O
10	stem	O
11	-	O
12	loop	O
13	structures	O
14	of	O
15	mRNA	O
16	secondary	O
17	configuration	O
18	,	O
19	hot	O
20	spots	O
21	of	O
22	base	O
23	-	O
24	residue	O
25	divergence	O
26	were	O
27	localized	O
28	to	O
29	looped	O
30	-	O
31	out	O
32	regions	O
33	.	O

1	The	O
2	splice	O
3	acceptor	O
4	site	O
5	is	O
6	ca	O
7	.	O

1	Homologous	O
2	recombination	O
3	between	O
4	the	O
5	Autographa	O
6	californica	O
7	nuclear	O
8	polyhedrosis	O
9	virus	O
10	(	O
11	AcNPV	O
12	)	O
13	genome	O
14	and	O
15	a	O
16	0	O
17	.	O
18	6	O
19	-	O
20	kbp	O
21	-	O
22	long	O
23	DNA	O
24	fragment	O
25	derived	O
26	from	O
27	the	O
28	putative	O
29	DNA	O
30	helicase	B
31	gene	I
32	of	O
33	Bombyx	O
34	mori	O
35	nuclear	O
36	polyhedrosis	O
37	virus	O
38	generates	O
39	eh2	O
40	-	O
41	AcNPV	O
42	,	O
43	an	O
44	expanded	O
45	-	O
46	host	O
47	-	O
48	range	O
49	AcNPV	O
50	mutant	O
51	(	O
52	S	O
53	.	O

1	Involvement	O
2	of	O
3	AP	B
4	-	I
5	2	I
6	in	O
7	regulation	O
8	of	O
9	the	O
10	R	B
11	-	I
12	FABP	I
13	gene	I
14	in	O
15	the	O
16	developing	O
17	chick	O
18	retina	O
19	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	follow	O
5	-	O
6	up	O
7	prospectively	O
8	patients	O
9	with	O
10	arthritis	O
11	after	O
12	infection	O
13	with	O
14	beta	B
15	-	I
16	haemolytic	I
17	streptococci	I
18	of	O
19	Lancefield	O
20	group	O
21	A	O
22	(	O
23	beta	O
24	HSA	O
25	),	O
26	with	O
27	emphasis	O
28	on	O
29	clinical	O
30	characteristics	O
31	and	O
32	serological	O
33	features	O
34	.	O

1	We	O
2	recommend	O
3	that	O
4	ovarian	O
5	stimulation	O
6	is	O
7	done	O
8	only	O
9	if	O
10	there	O
11	is	O
12	a	O
13	valid	O
14	indication	O
15	after	O
16	proper	O
17	assessment	O
18	of	O
19	the	O
20	ovaries	O
21	,	O
22	and	O
23	that	O
24	women	O
25	who	O
26	have	O
27	had	O
28	ovarian	O
29	stimulation	O
30	are	O
31	followed	O
32	for	O
33	longer	O
34	than	O
35	at	O
36	present	O
37	.	O

1	High	O
2	-	O
3	resolution	O
4	structure	O
5	of	O
6	the	O
7	diphtheria	B
8	toxin	I
9	repressor	I
10	complexed	O
11	with	O
12	cobalt	O
13	and	O
14	manganese	O
15	reveals	O
16	an	O
17	SH3	B
18	-	I
19	like	I
20	third	O
21	domain	O
22	and	O
23	suggests	O
24	a	O
25	possible	O
26	role	O
27	of	O
28	phosphate	O
29	as	O
30	co	O
31	-	O
32	corepressor	O
33	.	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	compare	O
5	pregnancy	O
6	complications	O
7	in	O
8	women	O
9	having	O
10	genetic	O
11	amniocentesis	O
12	at	O
13	11	O
14	-	O
15	14	O
16	weeks	O
17	versus	O
18	those	O
19	undergoing	O
20	amniocentesis	O
21	at	O
22	16	O
23	-	O
24	19	O
25	weeks	O
26	'	O
27	gestation	O
28	.	O

1	The	O
2	tissue	O
3	specificity	O
4	of	O
5	gene	O
6	expression	O
7	was	O
8	identical	O
9	to	O
10	that	O
11	described	O
12	previously	O
13	for	O
14	the	O
15	CaMV	B
16	35S	I
17	domain	I
18	B	I
19	enhancer	I
20	element	I
21	.	O

1	Addition	O
2	of	O
3	synthetic	O
4	tyrosine	O
5	-	O
6	phosphorylated	O
7	peptides	O
8	derived	O
9	from	O
10	betac	O
11	cytoplasmic	O
12	tyrosines	O
13	prior	O
14	to	O
15	GM	B
16	-	I
17	CSF	I
18	stimulation	O
19	inhibited	O
20	the	O
21	in	O
22	vitro	O
23	activation	O
24	of	O
25	STAT5	O
26	.	O

1	The	O
2	effect	O
3	of	O
4	dietary	O
5	zinc	O
6	deficiency	O
7	on	O
8	the	O
9	mossy	O
10	fiber	O
11	zinc	O
12	content	O
13	of	O
14	the	O
15	rat	O
16	hippocampus	O
17	.	O

1	Congruent	O
2	with	O
3	empirical	O
4	predictions	O
5	,	O
6	the	O
7	most	O
8	homesick	O
9	children	O
10	perceived	O
11	low	O
12	control	O
13	over	O
14	homesickness	O
15	and	O
16	separation	O
17	,	O
18	and	O
19	coped	O
20	by	O
21	relinquishing	O
22	control	O
23	.	O

1	The	O
2	data	O
3	suggest	O
4	that	O
5	plasminogen	B
6	,	I
7	alpha	I
8	2AP	I
9	,	O
10	and	O
11	C1	B
12	-	I
13	INH	I
14	,	O
15	should	O
16	be	O
17	considered	O
18	equine	O
19	acute	O
20	-	O
21	phase	O
22	proteins	O
23	.	O

1	The	O
2	previously	O
3	described	O
4	enhanced	O
5	translation	O
6	of	O
7	spinach	O
8	L12	O
9	mRNA	O
10	from	O
11	its	O
12	two	O
13	tandem	O
14	AUG	O
15	codons	O
16	and	O
17	the	O
18	two	O
19	functional	O
20	rpl12	O
21	genes	O
22	in	O
23	Arabidopsis	O
24	probably	O
25	provide	O
26	two	O
27	mechanisms	O
28	for	O
29	generating	O
30	the	O
31	four	O
32	copies	O
33	of	O
34	L12	O
35	/	O
36	chloroplast	O
37	ribosome	O
38	,	O
39	qualitatively	O
40	different	O
41	from	O
42	those	O
43	attempted	O
44	in	O
45	eubacteria	O
46	.	O

1	Demographic	O
2	characteristics	O
3	and	O
4	risk	O
5	factor	O
6	data	O
7	for	O
8	76	O
9	,	O
10	672	O
11	clients	O
12	were	O
13	studied	O
14	to	O
15	characterize	O
16	the	O
17	distribution	O
18	of	O
19	infection	O
20	with	O
21	human	O
22	immunodeficiency	O
23	virus	O
24	(	O
25	HIV	O
26	)	O
27	and	O
28	the	O
29	use	O
30	of	O
31	counseling	O
32	and	O
33	testing	O
34	facilities	O
35	in	O
36	Houston	O
37	,	O
38	Tex	O
39	.	O

1	The	O
2	protein	O
3	expressed	O
4	by	O
5	F2771	O
6	cDNA	O
7	in	O
8	transfected	O
9	COS	O
10	cells	O
11	is	O
12	localized	O
13	in	O
14	the	O
15	cytoplasm	O
16	.	O

1	Schnell	O
2	,	O
3	J	O
4	.	O

1	(	O
2	1986	O
3	)	O
4	method	O
5	of	O
6	separation	O
7	of	O
8	Cryptosporidium	O
9	spp	O
10	.	O
11	oocysts	O
12	from	O
13	feces	O
14	by	O
15	using	O
16	a	O
17	percoll	O
18	discontinuous	O
19	density	O
20	gradient	O
21	appeared	O
22	a	O
23	method	O
24	of	O
25	choice	O
26	for	O
27	obtaining	O
28	large	O
29	numbers	O
30	of	O
31	oocysts	O
32	of	O
33	C	O
34	.	O
35	parvum	O
36	free	O
37	of	O
38	fecal	O
39	contamination	O
40	.	O

1	Cyclosporine	O
2	treatment	O
3	for	O
4	intractable	O
5	polymyositis	O
6	.	O

1	Animals	O
2	received	O
3	a	O
4	dose	O
5	of	O
6	dexamethasone	O
7	(	O
8	10	O
9	mg	O
10	/	O
11	kg	O
12	i	O
13	.	O
14	p	O
15	.)	O
16	prior	O
17	to	O
18	the	O
19	protein	O
20	-	O
21	free	O
22	surfactant	O
23	preparation	O
24	Exosurf	O
25	(	O
26	pure	O
27	phospholipids	O
28	containing	O
29	surfactant	O
30	,	O
31	Wellcome	O
32	GmbH	O
33	,	O
34	Burgwedel	O
35	,	O
36	Germany	O
37	)	O
38	and	O
39	a	O
40	rSP	O
41	-	O
42	C	O
43	based	O
44	surfactant	O
45	,	O
46	respectively	O
47	.	O

1	In	O
2	addition	O
3	,	O
4	expected	O
5	decreases	O
6	in	O
7	ATIC	O
8	enzymatic	O
9	function	O
10	in	O
11	ATIC	O
12	-	O
13	ALK	O
14	-	O
15	containing	O
16	lymphomas	O
17	may	O
18	render	O
19	these	O
20	tumors	O
21	more	O
22	sensitive	O
23	to	O
24	antifolate	O
25	drugs	O
26	such	O
27	as	O
28	methotrexate	O
29	.	O

1	Studies	O
2	of	O
3	lipoproteins	O
4	should	O
5	,	O
6	however	O
7	,	O
8	be	O
9	made	O
10	in	O
11	children	O
12	from	O
13	families	O
14	known	O
15	to	O
16	have	O
17	FH	O
18	or	O
19	early	O
20	coronary	O
21	heart	O
22	disease	O
23	.	O

1	This	O
2	report	O
3	describes	O
4	a	O
5	patient	O
6	with	O
7	a	O
8	previous	O
9	inferior	O
10	acute	O
11	myocardial	O
12	infarction	O
13	who	O
14	developed	O
15	right	O
16	ventricular	O
17	infarction	O
18	with	O
19	significant	O
20	anterior	O
21	lead	O
22	ST	O
23	segment	O
24	elevation	O
25	(	O
26	V1	O
27	-	O
28	V4	O
29	)	O
30	caused	O
31	by	O
32	the	O
33	loss	O
34	of	O
35	two	O
36	large	O
37	right	O
38	ventricular	O
39	branches	O
40	during	O
41	a	O
42	coronary	O
43	angioplasty	O
44	of	O
45	the	O
46	right	O
47	coronary	O
48	artery	O
49	.	O

1	Feeding	O
2	behavior	O
3	,	O
4	circannual	O
5	body	O
6	weight	O
7	and	O
8	hibernation	O
9	rhythms	O
10	in	O
11	European	O
12	hamsters	O
13	lesioned	O
14	in	O
15	the	O
16	noradrenergic	O
17	ascending	O
18	bundles	O

1	Carboxy	O
2	-	O
3	terminal	O
4	Spc110p	O
5	truncations	O
6	lacking	O
7	the	O
8	calmodulin	B
9	binding	I
10	site	I
11	can	O
12	support	O
13	growth	O
14	and	O
15	are	O
16	also	O
17	phosphorylated	O
18	in	O
19	a	O
20	cell	O
21	cycle	O
22	-	O
23	specific	O
24	manner	O
25	.	O

1	After	O
2	4	O
3	h	O
4	,	O
5	lesions	O
6	in	O
7	the	O
8	secretory	O
9	part	O
10	of	O
11	the	O
12	stomach	O
13	were	O
14	scored	O
15	and	O
16	mucosal	O
17	prostaglandin	O
18	E2	O
19	synthesis	O
20	was	O
21	determined	O
22	by	O
23	the	O
24	ex	O
25	vivo	O
26	prostaglandin	O
27	generation	O
28	technique	O
29	.	O

1	Changes	O
2	in	O
3	immunologic	O
4	reactivity	O
5	in	O
6	subjects	O
7	receiving	O
8	transfer	O
9	factor	O
10	could	O
11	not	O
12	be	O
13	distinguished	O
14	from	O
15	those	O
16	in	O
17	subjects	O
18	receiving	O
19	placebo	O
20	.	O

1	A	O
2	full	O
3	-	O
4	length	O
5	human	B
6	pim	I
7	-	I
8	1	I
9	cDNA	I
10	was	O
11	subcloned	O
12	into	O
13	the	O
14	bacterial	O
15	vector	O
16	pGEX	O
17	-	O
18	2T	O
19	and	O
20	the	O
21	Pim	B
22	-	I
23	1	I
24	protein	I
25	expressed	O
26	as	O
27	a	O
28	fusion	O
29	product	O
30	with	O
31	bacterial	O
32	glutathione	B
33	S	I
34	-	I
35	transferase	I
36	(	O
37	GST	B
38	).	O

1	CONCLUSIONS	O
2	:	O
3	Free	O
4	protein	O
5	S	O
6	deficiency	O
7	is	O
8	common	O
9	among	O
10	hospitalized	O
11	patients	O
12	,	O
13	even	O
14	in	O
15	the	O
16	absence	O
17	of	O
18	a	O
19	recognized	O
20	predisposing	O
21	condition	O
22	.	O

1	Down	O
2	-	O
3	regulation	O
4	of	O
5	IRS	B
6	-	I
7	1	I
8	is	O
9	linked	O
10	to	O
11	its	O
12	serine	O
13	phosphorylation	O
14	dependent	O
15	on	O
16	PI	B
17	3	I
18	-	I
19	kinase	I
20	activity	O
21	and	O
22	appears	O
23	required	O
24	for	O
25	differentiation	O
26	to	O
27	occur	O
28	,	O
29	as	O
30	IRS	B
31	-	I
32	1	I
33	is	O
34	not	O
35	modified	O
36	and	O
37	continues	O
38	to	O
39	accumulate	O
40	in	O
41	a	O
42	nondifferentiating	O
43	myoblast	O
44	cell	O
45	line	O
46	.	O

1	AMDA	O
2	white	O
3	paper	O
4	identifies	O
5	ways	O
6	to	O
7	improve	O
8	pharmaceutical	O
9	care	O
10	in	O
11	SNFs	O
12	.	O

1	Consistent	O
2	with	O
3	previous	O
4	reports	O
5	,	O
6	addition	O
7	of	O
8	a	O
9	myristoylation	O
10	signal	O
11	to	O
12	mSos1	O
13	(	O
14	MyrSos1	O
15	)	O
16	rendered	O
17	it	O
18	transforming	O
19	for	O
20	NIH	O
21	3T3	O
22	cells	O
23	and	O
24	deletion	O
25	of	O
26	the	O
27	mSos	O
28	C	O
29	terminus	O
30	(	O
31	MyrSos1	O
32	-	O
33	deltaC	O
34	)	O
35	did	O
36	not	O
37	interfere	O
38	with	O
39	this	O
40	activity	O
41	.	O

1	FISH	O
2	using	O
3	a	O
4	whole	O
5	chromosome	O
6	4	O
7	paint	O
8	demonstrated	O
9	multiple	O
10	rearrangements	O
11	involving	O
12	chromosome	O
13	4	O
14	in	O
15	MCF	O
16	-	O
17	7	O
18	AdVp3000	O
19	and	O
20	MCF	O
21	-	O
22	7	O
23	MX	O
24	,	O
25	while	O
26	S1	B
27	-	I
28	M1	I
29	-	I
30	80	O
31	contained	O
32	only	O
33	a	O
34	simple	O
35	reciprocal	O
36	translocation	O
37	.	O

1	Sp1	B
2	binds	O
3	two	O
4	sites	O
5	in	O
6	the	O
7	CD11c	O
8	promoter	O
9	in	O
10	vivo	O
11	specifically	O
12	in	O
13	myeloid	O
14	cells	O
15	and	O
16	cooperates	O
17	with	O
18	AP1	B
19	to	O
20	activate	O
21	transcription	O
22	.	O

1	Because	O
2	the	O
3	mutant	O
4	defective	O
5	in	O
6	DNA	O
7	binding	O
8	also	O
9	fails	O
10	to	O
11	stimulate	O
12	Abf1	O
13	ARS1	O
14	DNA	O
15	-	O
16	binding	O
17	activity	O
18	,	O
19	our	O
20	results	O
21	suggest	O
22	that	O
23	Cdc6	O
24	DNA	O
25	-	O
26	binding	O
27	activity	O
28	may	O
29	play	O
30	a	O
31	pivotal	O
32	role	O
33	in	O
34	the	O
35	initiation	O
36	of	O
37	DNA	O
38	replication	O
39	.	O

1	Gel	O
2	filtration	O
3	,	O
4	sedimentation	O
5	velocity	O
6	,	O
7	and	O
8	immunoprecipitation	O
9	experiments	O
10	revealed	O
11	that	O
12	beta4	O
13	is	O
14	a	O
15	component	O
16	of	O
17	a	O
18	multisubunit	O
19	complex	O
20	(	O
21	AP	B
22	-	I
23	4	O
24	)	O
25	that	O
26	also	O
27	contains	O
28	the	O
29	sigma4	O
30	polypeptide	O
31	and	O
32	two	O
33	additional	O
34	adaptor	O
35	subunit	O
36	homologs	O
37	named	O
38	mu4	O
39	(	O
40	mu	O
41	-	O
42	ARP2	O
43	)	O
44	and	O
45	epsilon	O
46	.	O

1	With	O
2	a	O
3	view	O
4	to	O
5	identifying	O
6	other	O
7	important	O
8	U14	O
9	interactions	O
10	,	O
11	a	O
12	stem	O
13	-	O
14	loop	O
15	domain	O
16	required	O
17	for	O
18	activity	O
19	of	O
20	Saccharomyces	O
21	cerevisiae	O
22	U14	O
23	RNAs	O
24	(	O
25	the	O
26	Y	O
27	domain	O
28	)	O
29	was	O
30	first	O
31	subjected	O
32	to	O
33	detailed	O
34	mutational	O
35	analysis	O
36	.	O

1	However	O
2	,	O
3	L	O
4	-	O
5	plastin	O
6	has	O
7	been	O
8	found	O
9	in	O
10	many	O
11	types	O
12	of	O
13	malignant	O
14	human	O
15	cells	O
16	of	O
17	non	O
18	-	O
19	hemopoietic	O
20	origin	O
21	suggesting	O
22	that	O
23	its	O
24	expression	O
25	is	O
26	induced	O
27	accompanying	O
28	tumorigenesis	O
29	in	O
30	solid	O
31	tissues	O
32	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	DNA	O
6	-	O
7	binding	O
8	experiments	O
9	show	O
10	that	O
11	either	O
12	one	O
13	of	O
14	the	O
15	two	O
16	MADS	B
17	domains	O
18	of	O
19	a	O
20	dimer	O
21	can	O
22	be	O
23	sufficient	O
24	to	O
25	confer	O
26	a	O
27	particular	O
28	DNA	O
29	-	O
30	binding	O
31	specificity	O
32	to	O
33	the	O
34	complex	O
35	and	O
36	that	O
37	sequences	O
38	outside	O
39	the	O
40	amino	O
41	-	O
42	terminal	O
43	basic	O
44	region	O
45	of	O
46	the	O
47	MADS	B
48	domain	I
49	can	O
50	,	O
51	in	O
52	some	O
53	cases	O
54	,	O
55	contribute	O
56	to	O
57	the	O
58	DNA	O
59	-	O
60	binding	O
61	specificity	O
62	of	O
63	the	O
64	proteins	O
65	.	O

1	Transvenous	O
2	serial	O
3	xeroradiography	O
4	.	O

1	Three	O
2	mutants	O
3	were	O
4	isolated	O
5	from	O
6	the	O
7	widely	O
8	used	O
9	strain	O
10	,	O
11	PAO1	O
12	.	O

1	Substitution	O
2	of	O
3	the	O
4	Ser	O
5	-	O
6	Thr	O
7	sites	O
8	with	O
9	the	O
10	phosphomimetic	O
11	Asp	O
12	generated	O
13	a	O
14	constitutively	O
15	active	O
16	form	O
17	of	O
18	IRF	B
19	-	I
20	3	O
21	that	O
22	functioned	O
23	as	O
24	a	O
25	very	O
26	strong	O
27	activator	O
28	of	O
29	promoters	O
30	containing	O
31	PRDI	O
32	-	O
33	PRDIII	O
34	or	O
35	ISRE	O
36	regulatory	O
37	elements	O
38	.	O

1	The	O
2	IE0	O
3	gene	O
4	product	O
5	also	O
6	transactivated	O
7	the	O
8	IE1	B
9	promoter	I
10	but	O
11	did	O
12	not	O
13	affect	O
14	expression	O
15	from	O
16	its	O
17	own	O
18	promoter	O
19	.	O

1	Samples	O
2	obtained	O
3	from	O
4	normal	O
5	volunteers	O
6	and	O
7	from	O
8	the	O
9	great	O
10	majority	O
11	of	O
12	the	O
13	patients	O
14	,	O
15	excluding	O
16	those	O
17	with	O
18	asthma	O
19	,	O
20	had	O
21	no	O
22	effect	O
23	on	O
24	ciliary	O
25	beating	O
26	.	O

1	The	O
2	emerging	O
3	complexity	O
4	of	O
5	the	O
6	5	O
7	'	O
8	regulatory	O
9	region	O
10	of	O
11	the	O
12	GH	B
13	receptor	I
14	gene	I
15	was	O
16	emphasised	O
17	by	O
18	the	O
19	observation	O
20	that	O
21	probes	O
22	derived	O
23	from	O
24	exon	O
25	1B	O
26	and	O
27	the	O
28	distal	O
29	3	O
30	'	O
31	intron	O
32	boundary	O
33	do	O
34	not	O
35	hybridise	O
36	with	O
37	previously	O
38	cloned	O
39	genomic	O
40	sequences	O
41	that	O
42	span	O
43	the	O
44	liver	O
45	-	O
46	specific	O
47	P1	O
48	promoter	O
49	and	O
50	exon	O
51	2	O
52	.	O

1	The	O
2	predicted	O
3	DNA	O
4	-	O
5	binding	O
6	,	O
7	zinc	O
8	finger	O
9	domain	O
10	protein	O
11	sequence	O
12	was	O
13	strictly	O
14	conserved	O
15	.	O

1	A	O
2	4	O
3	.	O
4	8	O
5	-	O
6	kilobase	O
7	BamHI	B
8	-	I
9	HindIII	I
10	fragment	I
11	encoding	O
12	the	O
13	entire	O
14	Neurospora	B
15	crassa	I
16	CuZn	I
17	superoxide	I
18	dismutase	I
19	gene	I
20	(	O
21	herein	O
22	designated	O
23	sod	O
24	-	O
25	1	O
26	)	O
27	was	O
28	isolated	O
29	from	O
30	a	O
31	genomic	O
32	library	O
33	using	O
34	two	O
35	60	O
36	-	O
37	base	O
38	deoxyoligonucleotide	O
39	probes	O
40	corresponding	O
41	to	O
42	the	O
43	published	O
44	N	O
45	.	O
46	crassa	O
47	amino	O
48	acid	O
49	sequence	O
50	.	O

1	Specific	O
2	and	O
3	heritable	O
4	genetic	O
5	interference	O
6	by	O
7	double	O
8	-	O
9	stranded	O
10	RNA	O
11	in	O
12	Arabidopsis	O
13	thaliana	O
14	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	members	O
6	of	O
7	the	O
8	ATF	B
9	family	I
10	are	O
11	involved	O
12	in	O
13	mediating	O
14	the	O
15	transcriptional	O
16	regulation	O
17	of	O
18	the	O
19	KGF	O
20	gene	O
21	in	O
22	response	O
23	to	O
24	extracellular	O
25	stimuli	O
26	via	O
27	a	O
28	novel	O
29	CRE	O
30	regulatory	O
31	element	O
32	.	O

1	Because	O
2	of	O
3	the	O
4	operon	O
5	structure	O
6	of	O
7	this	O
8	organism	O
9	,	O
10	traditional	O
11	methods	O
12	such	O
13	as	O
14	insertional	O
15	mutagenesis	O
16	run	O
17	the	O
18	risk	O
19	of	O
20	introducing	O
21	polar	O
22	effects	O
23	on	O
24	downstream	O
25	genes	O
26	or	O
27	creating	O
28	secondary	O
29	mutations	O
30	elsewhere	O
31	in	O
32	the	O
33	genome	O
34	.	O

1	The	O
2	physical	O
3	and	O
4	chemical	O
5	stability	O
6	of	O
7	a	O
8	combination	O
9	of	O
10	drugs	O
11	commonly	O
12	administered	O
13	into	O
14	the	O
15	epidural	O
16	or	O
17	intrathecal	O
18	space	O
19	for	O
20	the	O
21	treatment	O
22	of	O
23	chronic	O
24	pain	O
25	was	O
26	investigated	O
27	.	O

1	Once	O
2	the	O
3	proliferation	O
4	of	O
5	fibroblasts	O
6	and	O
7	collagen	B
8	synthesis	O
9	had	O
10	led	O
11	to	O
12	an	O
13	increase	O
14	of	O
15	mechanical	O
16	strength	O
17	,	O
18	no	O
19	negative	O
20	effect	O
21	on	O
22	wound	O
23	healing	O
24	could	O
25	be	O
26	detected	O
27	applying	O
28	the	O
29	same	O
30	chemotherapeutic	O
31	agents	O
32	.	O

1	Extensive	O
2	DNA	O
3	rearrangement	O
4	occurs	O
5	during	O
6	the	O
7	development	O
8	of	O
9	the	O
10	somatic	O
11	macronucleus	O
12	from	O
13	the	O
14	germ	O
15	line	O
16	micronucleus	O
17	in	O
18	ciliated	O
19	protozoans	O
20	.	O

1	Xylose	O
2	-	O
3	and	O
4	arabinose	O
5	-	O
6	containing	O
7	polymers	O
8	were	O
9	better	O
10	digested	O
11	than	O
12	was	O
13	cellulose	O
14	for	O
15	both	O
16	breads	O
17	.	O

1	The	O
2	implications	O
3	for	O
4	estimates	O
5	of	O
6	cortical	O
7	magnification	O
8	and	O
9	possible	O
10	differences	O
11	in	O
12	the	O
13	specializations	O
14	of	O
15	foveal	O
16	and	O
17	peripheral	O
18	vision	O
19	are	O
20	discussed	O
21	.	O

1	Termination	O
2	of	O
3	induced	O
4	VT	O
5	on	O
6	the	O
7	first	O
8	attempt	O
9	was	O
10	comparable	O
11	with	O
12	BV	O
13	pacing	O
14	(	O
15	87	O
16	.	O
17	4	O
18	%)	O
19	versus	O
20	RV	O
21	pacing	O
22	(	O
23	89	O
24	.	O
25	6	O
26	%).	O

1	Endocytosis	O
2	and	O
3	vacuolar	O
4	degradation	O
5	of	O
6	the	O
7	plasma	O
8	membrane	O
9	-	O
10	localized	O
11	Pdr5	O
12	ATP	B
13	-	I
14	binding	I
15	cassette	I
16	multidrug	I
17	transporter	I
18	in	O
19	Saccharomyces	O
20	cerevisiae	O
21	.	O

1	The	O
2	methylation	O
3	of	O
4	nuclear	O
5	and	O
6	chloroplast	O
7	DNAs	O
8	has	O
9	been	O
10	examined	O
11	in	O
12	relation	O
13	to	O
14	the	O
15	known	O
16	differential	O
17	expression	O
18	of	O
19	C4	O
20	photosynthesis	O
21	genes	O
22	in	O
23	the	O
24	bundle	O
25	sheath	O
26	and	O
27	mesophyll	O
28	cells	O
29	of	O
30	etiolated	O
31	,	O
32	greening	O
33	,	O
34	and	O
35	fully	O
36	green	O
37	maize	O
38	leaves	O
39	.	O

1	Nucleotide	O
2	sequence	O
3	analysis	O
4	of	O
5	the	O
6	HA	B
7	gene	I
8	in	O
9	these	O
10	two	O
11	mutants	O
12	confirmed	O
13	the	O
14	HA	O
15	-	O
16	phenotype	O
17	.	O

1	Prevalence	O
2	of	O
3	rheumatoid	O
4	arthritis	O
5	and	O
6	rheumatoid	O
7	factor	O
8	in	O
9	women	O
10	:	O
11	evidence	O
12	for	O
13	a	O
14	secular	O
15	decline	O
16	.	O

1	The	O
2	MVV	O
3	-	O
4	value	O
5	is	O
6	under	O
7	the	O
8	predicted	O
9	level	O
10	in	O
11	the	O
12	case	O
13	of	O
14	67	O
15	-	O
16	76	O
17	percent	O
18	.	O

1	The	O
2	abscess	O
3	was	O
4	debrided	O
5	and	O
6	the	O
7	septum	O
8	was	O
9	patched	O
10	with	O
11	a	O
12	single	O
13	layer	O
14	of	O
15	autologous	O
16	pericardium	O
17	.	O

1	Use	O
2	of	O
3	serum	O
4	thyroglobulin	O
5	determination	O
6	in	O
7	the	O
8	follow	O
9	-	O
10	up	O
11	of	O
12	differentiated	O
13	carcinomas	O
14	of	O
15	the	O
16	thyroid	O

1	Research	O
2	was	O
3	carried	O
4	out	O
5	on	O
6	the	O
7	rheumatoid	O
8	factors	O
9	in	O
10	the	O
11	serum	O
12	of	O
13	917	O
14	patients	O
15	by	O
16	means	O
17	of	O
18	two	O
19	tests	O
20	(	O
21	one	O
22	using	O
23	polystyrene	O
24	and	O
25	one	O
26	with	O
27	erythrocytes	O
28	)	O
29	and	O
30	the	O
31	results	O
32	obtained	O
33	were	O
34	compared	O
35	using	O
36	a	O
37	method	O
38	of	O
39	reference	O
40	.	O

1	Detection	O
2	of	O
3	airborne	O
4	Mycobacterium	O
5	tuberculosis	O
6	by	O
7	air	O
8	filtration	O
9	and	O
10	polymerase	O
11	chain	O
12	reaction	O
13	.	O

1	The	O
2	invasive	O
3	pattern	O
4	of	O
5	squamous	O
6	cell	O
7	carcinoma	O
8	in	O
9	the	O
10	mandibular	O
11	gingiva	O

1	Protein	O
2	films	O
3	are	O
4	distinctly	O
5	different	O
6	in	O
7	mechanical	O
8	profiles	O
9	from	O
10	those	O
11	films	O
12	made	O
13	of	O
14	other	O
15	materials	O
16	.	O

1	Angiography	O
2	of	O
3	aneurysmal	O
4	bone	O
5	cyst	O
6	.	O

1	The	O
2	expression	O
3	of	O
4	the	O
5	gene	O
6	encoding	O
7	the	O
8	enzyme	O
9	(	O
10	CYP19	O
11	)	O
12	is	O
13	regulated	O
14	,	O
15	in	O
16	part	O
17	,	O
18	by	O
19	tissue	O
20	-	O
21	specific	O
22	promoters	O
23	through	O
24	the	O
25	use	O
26	of	O
27	alternative	O
28	-	O
29	splicing	O
30	mechanisms	O
31	.	O

1	These	O
2	mutant	O
3	proteins	O
4	retained	O
5	the	O
6	ability	O
7	to	O
8	competitively	O
9	inhibit	O
10	kappa	B
11	B	I
12	-	I
13	mediated	O
14	transcriptional	O
15	activation	O
16	of	O
17	the	O
18	human	O
19	immunodeficiency	O
20	virus	O
21	long	O
22	terminal	O
23	repeat	O
24	but	O
25	failed	O
26	to	O
27	efficiently	O
28	transform	O
29	chicken	O
30	lymphoid	O
31	cells	O
32	both	O
33	in	O
34	vitro	O
35	and	O
36	in	O
37	vivo	O
38	.	O

1	Individual	O
2	mutations	O
3	in	O
4	motifs	O
5	III	O
6	,	O
7	IV	O
8	,	O
9	and	O
10	V	O
11	had	O
12	distinctive	O
13	effects	O
14	on	O
15	the	O
16	affinity	O
17	of	O
18	enzyme	O
19	for	O
20	GTP	O
21	,	O
22	the	O
23	rate	O
24	of	O
25	covalent	O
26	catalysis	O
27	(	O
28	EpG	O
29	formation	O
30	),	O
31	or	O
32	the	O
33	transfer	O
34	of	O
35	GMP	O
36	from	O
37	enzyme	O
38	to	O
39	RNA	O
40	.	O

1	62	O
2	:	O
3	2491	O
4	-	O
5	2499	O
6	,	O
7	1987	O
8	).	O

1	Histone	O
2	acetylation	O
3	levels	O
4	in	O
5	cells	O
6	result	O
7	from	O
8	a	O
9	dynamic	O
10	equilibrium	O
11	between	O
12	competing	O
13	histone	B
14	acetylases	O
15	and	O
16	deacetylases	O
17	.	O

1	Furthermore	O
2	,	O
3	binding	O
4	of	O
5	recombinant	B
6	Myb	I
7	and	O
8	Ets	B
9	-	I
10	2	I
11	protein	I
12	to	O
13	these	O
14	fragments	O
15	could	O
16	be	O
17	competed	O
18	with	O
19	an	O
20	excess	O
21	of	O
22	double	O
23	stranded	O
24	oligodeoxynucleotides	O
25	containing	O
26	canonical	O
27	,	O
28	but	O
29	not	O
30	mutated	O
31	,	O
32	Myb	B
33	-	I
34	or	O
35	Ets	B
36	-	I
37	binding	I
38	sites	I
39	.	O

1	The	O
2	MPS1	O
3	open	O
4	reading	O
5	frame	O
6	has	O
7	been	O
8	fused	O
9	to	O
10	those	O
11	that	O
12	encode	O
13	the	O
14	LexA	B
15	protein	I
16	or	O
17	the	O
18	GST	B
19	protein	I
20	and	O
21	both	O
22	of	O
23	these	O
24	constructs	O
25	function	O
26	in	O
27	yeast	O
28	.	O

1	SL1	O
2	trans	O
3	-	O
4	splicing	O
5	specified	O
6	by	O
7	AU	O
8	-	O
9	rich	O
10	synthetic	O
11	RNA	O
12	inserted	O
13	at	O
14	the	O
15	5	O
16	'	O
17	end	O
18	of	O
19	Caenorhabditis	O
20	elegans	O
21	pre	O
22	-	O
23	mRNA	O
24	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	T	O
6	.	O
7	C	O
8	.,	O
9	LDL	B
10	-	I
11	C	I
12	.,	O
13	HDL	B
14	-	I
15	C	I
16	.,	O
17	HDL2	B
18	-	I
19	C	I
20	.,	O
21	apo	O
22	B	O
23	,	O
24	apo	B
25	A	I
26	-	I
27	I	I
28	/	I
29	B	I
30	ratio	O
31	and	O
32	apo	B
33	A	I
34	-	I
35	II	I
36	/	I
37	B	I
38	ratio	O
39	are	O
40	predictive	O
41	risk	O
42	factors	O
43	of	O
44	the	O
45	coronary	O
46	heart	O
47	disease	O
48	.	O

1	Analysis	O
2	of	O
3	Standard	O
4	Reference	O
5	Material	O
6	1846	O
7	,	O
8	Infant	O
9	Formula	O
10	,	O
11	gave	O
12	a	O
13	mean	O
14	value	O
15	of	O
16	0	O
17	.	O
18	95	O
19	+/-	O
20	0	O
21	.	O
22	088	O
23	mg	O
24	vitamin	O
25	K	O
26	/	O
27	kg	O
28	(	O
29	K	O
30	or	O
31	K1	O
32	?)	O
33	(	O
34	n	O
35	=	O
36	31	O
37	)	O
38	with	O
39	a	O
40	coefficient	O
41	of	O
42	variation	O
43	of	O
44	9	O
45	.	O
46	26	O
47	.	O

1	Demispan	O
2	is	O
3	a	O
4	reliable	O
5	and	O
6	reproducible	O
7	measure	O
8	of	O
9	stature	O
10	in	O
11	the	O
12	elderly	O
13	.	O

1	Armed	O
2	with	O
3	a	O
4	clear	O
5	understanding	O
6	of	O
7	the	O
8	pathophysiologic	O
9	pathways	O
10	that	O
11	may	O
12	cause	O
13	and	O
14	/	O
15	or	O
16	contribute	O
17	to	O
18	the	O
19	development	O
20	of	O
21	unconjugated	O
22	hyperbilirubinemia	O
23	and	O
24	the	O
25	associated	O
26	jaundice	O
27	,	O
28	the	O
29	practitioner	O
30	will	O
31	be	O
32	successful	O
33	in	O
34	helping	O
35	the	O
36	family	O
37	understand	O
38	their	O
39	child	O
40	'	O
41	s	O
42	illness	O
43	.	O

1	The	O
2	3	O
3	.	O
4	3	O
5	-	O
6	fold	O
7	higher	O
8	expression	O
9	in	O
10	the	O
11	fetal	O
12	heart	O
13	than	O
14	in	O
15	the	O
16	adult	O
17	heart	O
18	suggests	O
19	that	O
20	HFHZ	O
21	mRNA	O
22	is	O
23	downregulated	O
24	in	O
25	the	O
26	process	O
27	of	O
28	development	O
29	.	O

1	Furthermore	O
2	,	O
3	the	O
4	wide	O
5	distribution	O
6	of	O
7	the	O
8	GFP	O
9	-	O
10	POLO	O
11	protein	O
12	to	O
13	all	O
14	compartments	O
15	of	O
16	the	O
17	mitotic	O
18	apparatus	O
19	provides	O
20	a	O
21	valuable	O
22	tool	O
23	for	O
24	future	O
25	studies	O
26	on	O
27	cell	O
28	cycle	O
29	during	O
30	development	O
31	.	O

1	Recurrent	O
2	G	O
3	-	O
4	to	O
5	-	O
6	A	O
7	substitution	O
8	in	O
9	a	O
10	single	O
11	codon	O
12	of	O
13	SREBP	B
14	cleavage	I
15	-	I
16	activating	I
17	protein	I
18	causes	O
19	sterol	O
20	resistance	O
21	in	O
22	three	O
23	mutant	O
24	Chinese	O
25	hamster	O
26	ovary	O
27	cell	O
28	lines	O
29	.	O

1	To	O
2	test	O
3	whether	O
4	or	O
5	not	O
6	SOCS	O
7	-	O
8	3	O
9	also	O
10	binds	O
11	to	O
12	the	O
13	IGFIR	O
14	,	O
15	we	O
16	cloned	O
17	human	O
18	SOCS	O
19	-	O
20	3	O
21	by	O
22	reverse	B
23	transcription	I
24	-	I
25	polymerase	I
26	chain	I
27	reaction	O
28	from	O
29	human	O
30	skeletal	O
31	muscle	O
32	mRNA	O
33	.	O

1	CO2	O
2	assimilation	O
3	by	O
4	chloroplasts	O
5	illuminated	O
6	on	O
7	filter	O
8	paper	O
9	.	O

1	CONCLUSIONS	O
2	:	O
3	These	O
4	routinely	O
5	collected	O
6	data	O
7	provided	O
8	quantitative	O
9	estimates	O
10	of	O
11	changes	O
12	in	O
13	CBZ	O
14	Cl	O
15	/	O
16	F	O
17	due	O
18	to	O
19	comedication	O
20	and	O
21	an	O
22	age	O
23	-	O
24	related	O
25	decrease	O
26	in	O
27	Cl	O
28	/	O
29	F	O
30	The	O
31	derived	O
32	regression	O
33	equations	O
34	reasonably	O
35	predicted	O
36	concentrations	O
37	in	O
38	a	O
39	separate	O
40	validation	O
41	set	O
42	.	O

1	The	O
2	M	O
3	reading	O
4	frame	O
5	differed	O
6	from	O
7	the	O
8	reported	O
9	sequence	O
10	by	O
11	a	O
12	single	O
13	nucleotide	O
14	corresponding	O
15	to	O
16	a	O
17	conservative	O
18	lysine	O
19	to	O
20	arginine	O
21	amino	O
22	acid	O
23	substitution	O
24	near	O
25	the	O
26	carboxy	O
27	-	O
28	terminus	O
29	conserved	O
30	among	O
31	the	O
32	M	O
33	proteins	O
34	of	O
35	paramyxoviruses	O
36	.	O

1	Glycogen	O
2	utilization	O
3	was	O
4	increased	O
5	,	O
6	but	O
7	tissue	O
8	levels	O
9	of	O
10	creatine	B
11	phosphate	I
12	,	O
13	ATP	O
14	,	O
15	and	O
16	lactate	O
17	were	O
18	similar	O
19	to	O
20	those	O
21	in	O
22	hearts	O
23	receiving	O
24	normal	O
25	flow	O
26	.	O

1	Evidence	O
2	forthe	O
3	electroosmosis	O
4	theory	O
5	of	O
6	transport	O
7	in	O
8	the	O
9	phloem	O
10	.	O

1	Effect	O
2	of	O
3	a	O
4	high	O
5	-	O
6	intensity	O
7	SHF	O
8	field	O
9	on	O
10	the	O
11	blood	O
12	coagulation	O
13	system	O

1	Mapping	O
2	of	O
3	the	O
4	mouse	B
5	ornithine	I
6	decarboxylase	I
7	-	I
8	related	I
9	sequence	I
10	family	I
11	.	O

1	In	O
2	Malmo	O
3	,	O
4	Sweden	O
5	,	O
6	17	O
7	,	O
8	181	O
9	school	O
10	children	O
11	born	O
12	in	O
13	the	O
14	years	O
15	1961	O
16	-	O
17	1965	O
18	were	O
19	screened	O
20	for	O
21	scoliosis	O
22	once	O
23	a	O
24	year	O
25	between	O
26	the	O
27	ages	O
28	of	O
29	7	O
30	and	O
31	16	O
32	years	O
33	,	O
34	during	O
35	1971	O
36	-	O
37	1980	O
38	.	O

1	Patulin	O
2	is	O
3	extracted	O
4	from	O
5	apple	O
6	butter	O
7	samples	O
8	with	O
9	ethyl	O
10	acetate	O
11	and	O
12	the	O
13	extract	O
14	is	O
15	cleaned	O
16	up	O
17	on	O
18	a	O
19	silica	O
20	gel	O
21	column	O
22	,	O
23	using	O
24	benzene	O
25	-	O
26	ethyl	O
27	acetate	O
28	(	O
29	75	O
30	+	O
31	25	O
32	)	O
33	as	O
34	the	O
35	eluant	O
36	.	O

1	The	O
2	promoter	O
3	activity	O
4	of	O
5	the	O
6	gene	O
7	encoding	O
8	Alzheimer	B
9	beta	I
10	-	I
11	amyloid	I
12	precursor	I
13	protein	I
14	(	I
15	APP	I
16	)	O
17	is	O
18	regulated	O
19	by	O
20	two	O
21	blocks	O
22	of	O
23	upstream	O
24	sequences	O
25	.	O

1	Synthesis	O
2	of	O
3	(+)-	O
4	lysergic	O
5	acid	O
6	diethylamide	O
7	tartrate	O

1	The	O
2	mean	O
3	values	O
4	of	O
5	protease	O
6	activity	O
7	were	O
8	significantly	O
9	higher	O
10	in	O
11	the	O
12	test	O
13	groups	O
14	than	O
15	in	O
16	the	O
17	control	O
18	group	O
19	at	O
20	baseline	O
21	.	O

1	Pregnant	O
2	women	O
3	at	O
4	term	O
5	had	O
6	the	O
7	lowest	O
8	levels	O
9	of	O
10	antithrombin	B
11	III	I
12	.	O

1	Identification	O
2	and	O
3	characterization	O
4	of	O
5	the	O
6	promoter	O
7	for	O
8	the	O
9	cytotactin	O
10	gene	O
11	.	O

1	Aneurysmal	O
2	bone	O
3	cyst	O
4	of	O
5	the	O
6	jaws	O
7	:	O
8	analysis	O
9	of	O
10	11	O
11	cases	O
12	.	O

1	Initially	O
2	,	O
3	we	O
4	observed	O
5	that	O
6	unmutated	O
7	p53	B
8	is	O
9	strongly	O
10	expressed	O
11	in	O
12	premalignant	O
13	mammary	O
14	glands	O
15	and	O
16	in	O
17	mammary	O
18	tumors	O
19	derived	O
20	from	O
21	the	O
22	MMTV	B
23	-	I
24	c	I
25	-	I
26	myc	I
27	strain	O
28	.	O

1	We	O
2	used	O
3	oligonucleotide	O
4	-	O
5	directed	O
6	mutagenesis	O
7	to	O
8	alter	O
9	a	O
10	site	O
11	in	O
12	MucA	O
13	homologous	O
14	to	O
15	the	O
16	Ala	O
17	-	O
18	Gly	O
19	cleavage	O
20	site	O
21	of	O
22	LexA	O
23	.	O

1	The	O
2	skp1	O
3	+	O
4	gene	O
5	is	O
6	not	O
7	essential	O
8	.	O

1	The	O
2	elm1	O
3	kinase	O
4	functions	O
5	in	O
6	a	O
7	mitotic	O
8	signaling	O
9	network	O
10	in	O
11	budding	O
12	yeast	O
13	.	O

1	DAF16	O
2	is	O
3	known	O
4	to	O
5	be	O
6	a	O
7	component	O
8	of	O
9	a	O
10	signaling	O
11	pathway	O
12	that	O
13	has	O
14	been	O
15	partially	O
16	dissected	O
17	genetically	O
18	and	O
19	includes	O
20	homologues	O
21	of	O
22	the	O
23	insulin	B
24	/	I
25	IGF	I
26	-	I
27	1	I
28	receptor	I
29	,	O
30	PtdIns	B
31	3	I
32	-	I
33	kinase	I
34	and	O
35	PKB	B
36	.	O

1	Deletion	O
2	mapping	O
3	of	O
4	the	O
5	human	O
6	presenilin	O
7	-	O
8	1	O
9	(	O
10	PS1	O
11	)	O
12	promoter	O
13	delineated	O
14	the	O
15	most	O
16	active	O
17	fragment	O
18	from	O
19	-	O
20	118	O
21	to	O
22	+	O
23	178	O
24	in	O
25	relation	O
26	to	O
27	the	O
28	transcription	O
29	start	O
30	site	O
31	mapped	O
32	in	O
33	this	O
34	study	O
35	,	O
36	in	O
37	both	O
38	human	O
39	neuroblastoma	O
40	SK	O
41	-	O
42	N	O
43	-	O
44	SH	O
45	and	O
46	hepatoma	O
47	HepG2	O
48	cells	O
49	.	O

1	The	O
2	O2	O
3	deficit	O
4	was	O
5	not	O
6	related	O
7	to	O
8	blood	O
9	lactate	O
10	during	O
11	submaximal	O
12	exercise	O
13	,	O
14	muscle	O
15	enzyme	O
16	activity	O
17	(	O
18	citrate	B
19	synthase	I
20	,	I
21	3	I
22	-	I
23	hydroxyacyl	I
24	-	I
25	CoA	I
26	-	I
27	dehydrogenase	I
28	,	O
29	lactate	B
30	dehydrogenase	I
31	),	O
32	number	O
33	of	O
34	muscle	O
35	capillaries	O
36	,	O
37	%	O
38	ST	O
39	fibres	O
40	or	O
41	muscle	O
42	buffer	O
43	capacity	O
44	.	O

1	Brain	O
2	cholinesterase	O
3	activity	O
4	of	O
5	nestling	O
6	great	O
7	egrets	O
8	,	O
9	snowy	O
10	egrets	O
11	and	O
12	black	O
13	-	O
14	crowned	O
15	night	O
16	-	O
17	herons	O
18	.	O
19	inhibition	O
20	of	O
21	brain	O
22	cholinesterase	O
23	(	O
24	ChE	O
25	)	O
26	activity	O
27	in	O
28	birds	O
29	is	O
30	often	O
31	used	O
32	to	O
33	diagnose	O
34	exposure	O
35	or	O
36	death	O
37	from	O
38	organophosphorus	O
39	or	O
40	carbamate	O
41	pesticides	O
42	.	O

1	During	O
2	the	O
3	febrile	O
4	period	O
5	,	O
6	pleocytosis	O
7	was	O
8	associated	O
9	with	O
10	high	O
11	levels	O
12	of	O
13	IgG	B
14	,	O
15	IL	B
16	-	I
17	6	O
18	,	O
19	TNF	B
20	-	I
21	alpha	I
22	,	O
23	and	O
24	PGE2	O
25	in	O
26	the	O
27	cerebrospinal	O
28	fluid	O
29	.	O

1	Collectively	O
2	,	O
3	these	O
4	experiments	O
5	demonstrate	O
6	that	O
7	CFTR	O
8	'	O
9	s	O
10	NBF1	B
11	+	I
12	R	I
13	region	O
14	and	O
15	its	O
16	NBF2	O
17	domain	O
18	,	O
19	after	O
20	folding	O
21	separately	O
22	as	O
23	distinct	O
24	units	O
25	,	O
26	have	O
27	a	O
28	strong	O
29	propensity	O
30	to	O
31	interact	O
32	and	O
33	that	O
34	this	O
35	interaction	O
36	is	O
37	stable	O
38	in	O
39	the	O
40	absence	O
41	of	O
42	added	O
43	nucleotides	O
44	or	O
45	exogenously	O
46	induced	O
47	phosphorylation	O
48	.	O

1	The	O
2	lytic	O
3	cycle	O
4	of	O
5	KSHV	O
6	,	O
7	probably	O
8	under	O
9	the	O
10	initial	O
11	control	O
12	of	O
13	the	O
14	KSHV	O
15	/	O
16	Rta	O
17	gene	O
18	,	O
19	may	O
20	directly	O
21	contribute	O
22	to	O
23	tumor	O
24	pathogenesis	O
25	.	O

1	This	O
2	sequence	O
3	similarity	O
4	raises	O
5	the	O
6	possibility	O
7	that	O
8	GCN1	O
9	interacts	O
10	with	O
11	ribosomes	O
12	or	O
13	tRNA	O
14	molecules	O
15	and	O
16	functions	O
17	in	O
18	conjunction	O
19	with	O
20	GCN2	O
21	in	O
22	monitoring	O
23	uncharged	O
24	tRNA	O
25	levels	O
26	during	O
27	the	O
28	process	O
29	of	O
30	translation	O
31	elongation	O
32	.	O

1	The	O
2	effects	O
3	of	O
4	dominant	O
5	interfering	O
6	forms	O
7	of	O
8	the	O
9	JNK	B
10	/	O
11	p38	B
12	signaling	O
13	pathway	O
14	demonstrate	O
15	that	O
16	activation	O
17	of	O
18	these	O
19	kinases	O
20	is	O
21	critical	O
22	for	O
23	cytokine	O
24	-	O
25	induced	O
26	E	B
27	-	I
28	selectin	I
29	gene	I
30	expression	O
31	.	O

1	Resistance	O
2	ratios	O
3	for	O
4	the	O
5	other	O
6	field	O
7	strains	O
8	obtained	O
9	by	O
10	comparison	O
11	with	O
12	the	O
13	R5	O
14	strain	O
15	ranged	O
16	from	O
17	24	O
18	.	O
19	5	O
20	to	O
21	239	O
22	for	O
23	topical	O
24	application	O
25	and	O
26	from	O
27	1	O
28	.	O
29	2	O
30	to	O
31	9	O
32	.	O
33	8	O
34	for	O
35	the	O
36	glass	O
37	jar	O
38	method	O
39	.	O

1	Propranolol	O
2	(	O
3	Inderal	O
4	)	O
5	administered	O
6	in	O
7	a	O
8	dose	O
9	which	O
10	blocks	O
11	the	O
12	beta	O
13	-	O
14	adrenergic	O
15	apparatus	O
16	of	O
17	the	O
18	heart	O
19	prevents	O
20	the	O
21	development	O
22	of	O
23	the	O
24	positive	O
25	inotropic	O
26	effect	O
27	of	O
28	therapeutic	O
29	doses	O
30	of	O
31	strophanthin	O
32	K	O
33	on	O
34	a	O
35	hypodynamic	O
36	left	O
37	ventricular	O
38	myocardium	O
39	.	O

1	We	O
2	further	O
3	demonstrate	O
4	that	O
5	the	O
6	Stress	B
7	-	I
8	Activated	I
9	-	I
10	Protein	I
11	-	I
12	Kinase	I
13	(	O
14	SAPK	B
15	)	O
16	target	O
17	sites	O
18	of	O
19	ATF2	O
20	,	O
21	Thr69	O
22	and	O
23	Thr71	O
24	are	O
25	not	O
26	required	O
27	for	O
28	the	O
29	formation	O
30	of	O
31	the	O
32	p300	B
33	/	I
34	CBP	I
35	-	I
36	ATF2	I
37	multiprotein	I
38	complex	I
39	.	O

1	Chronic	O
2	administration	O
3	of	O
4	sodium	O
5	cyanate	O
6	decreases	O
7	O2	O
8	extraction	O
9	ratio	O
10	in	O
11	dogs	O
12	.	O

1	Transcript	O
2	analysis	O
3	reveals	O
4	that	O
5	lethal	O
6	B	O
7	block	O
8	substitutions	O
9	reduce	O
10	U6	B
11	RNA	I
12	synthesis	O
13	at	O
14	least	O
15	10	O
16	-	O
17	fold	O
18	in	O
19	vivo	O
20	and	O
21	20	O
22	-	O
23	fold	O
24	in	O
25	vitro	O
26	.	O

1	Key	O
2	areas	O
3	of	O
4	the	O
5	selection	O
6	process	O
7	including	O
8	medical	O
9	and	O
10	surgical	O
11	alternatives	O
12	to	O
13	transplantation	O
14	,	O
15	the	O
16	composition	O
17	of	O
18	the	O
19	transplant	O
20	work	O
21	-	O
22	up	O
23	,	O
24	specific	O
25	inclusion	O
26	criteria	O
27	as	O
28	well	O
29	as	O
30	specific	O
31	psychosocial	O
32	factors	O
33	and	O
34	specific	O
35	disease	O
36	etiologies	O
37	and	O
38	co	O
39	-	O
40	morbidities	O
41	that	O
42	might	O
43	represent	O
44	contraindications	O
45	were	O
46	extensively	O
47	reviewed	O
48	.	O

1	3	O
2	.	O

1	The	O
2	second	O
3	part	O
4	of	O
5	this	O
6	paper	O
7	shows	O
8	some	O
9	medical	O
10	applications	O
11	of	O
12	these	O
13	two	O
14	aspects	O
15	of	O
16	NMR	O
17	,	O
18	with	O
19	help	O
20	of	O
21	some	O
22	examples	O
23	,	O
24	taken	O
25	from	O
26	the	O
27	literature	O
28	,	O
29	according	O
30	to	O
31	what	O
32	is	O
33	concerned	O
34	with	O
35	endocrinology	O
36	.	O

1	The	O
2	enteric	O
3	route	O
4	is	O
5	the	O
6	principal	O
7	mode	O
8	of	O
9	transmission	O
10	for	O
11	hepatitis	O
12	A	O
13	,	O
14	but	O
15	maximal	O
16	levels	O
17	of	O
18	hepatitis	O
19	A	O
20	virus	O
21	excretion	O
22	occur	O
23	before	O
24	the	O
25	onset	O
26	of	O
27	jaundice	O
28	.	O

1	Morphological	O
2	and	O
3	functional	O
4	alterations	O
5	noted	O
6	after	O
7	baboon	O
8	renal	O
9	allotransplantation	O
10	.	O

1	RESULTS	O
2	:	O
3	Among	O
4	women	O
5	,	O
6	the	O
7	age	O
8	-	O
9	related	O
10	decline	O
11	in	O
12	BMD	O
13	at	O
14	all	O
15	non	O
16	-	O
17	spine	O
18	skeletal	O
19	sites	O
20	was	O
21	significantly	O
22	different	O
23	from	O
24	zero	O
25	,	O
26	with	O
27	the	O
28	largest	O
29	decline	O
30	seen	O
31	at	O
32	the	O
33	femoral	O
34	neck	O
35	(-.	O
36	0038	O
37	g	O
38	/	O
39	cm2	O
40	/	O
41	y	O
42	,	O
43	p	O
44	<	O
45	.	O
46	001	O
47	)	O
48	and	O
49	the	O
50	smallest	O
51	at	O
52	the	O
53	trochanter	O
54	of	O
55	the	O
56	hip	O
57	(-.	O
58	0023	O
59	g	O
60	/	O
61	cm2	O
62	/	O
63	y	O
64	,	O
65	p	O
66	=	O
67	.	O
68	03	O
69	).	O

1	Both	O
2	4	O
3	,	O
4	8	O
5	-	O
6	DiMeIQx	O
7	and	O
8	A	O
9	alpha	O
10	C	O
11	were	O
12	found	O
13	at	O
14	<	O
15	1	O
16	p	O
17	.	O
18	p	O
19	.	O
20	b	O
21	.	O

1	These	O
2	results	O
3	establish	O
4	that	O
5	hydroquinones	O
6	lead	O
7	to	O
8	mutagenicity	O
9	and	O
10	carcinogenicity	O
11	.	O

1	Insulin	B
2	-	I
3	stimulated	O
4	glucose	O
5	transport	O
6	in	O
7	adipocytes	O
8	is	O
9	mediated	O
10	by	O
11	the	O
12	insulin	B
13	receptor	I
14	.	O

1	Colorectal	O
2	carcinoma	O
3	:	O
4	therapeutic	O
5	approach	O
6	in	O
7	patients	O
8	already	O
9	treated	O
10	with	O
11	metastasis	O
12	resection	O

1	Martin	O
2	Luther	O
3	and	O
4	his	O
5	physicians	O
6	.	O

1	Both	O
2	normal	O
3	and	O
4	transforming	O
5	PCPH	O
6	proteins	O
7	have	O
8	guanosine	O
9	diphosphatase	O
10	activity	O
11	but	O
12	only	O
13	the	O
14	oncoprotein	O
15	cooperates	O
16	with	O
17	Ras	B
18	in	O
19	activating	O
20	extracellular	B
21	signal	I
22	-	I
23	regulated	I
24	kinase	I
25	ERK1	I
26	.	O

1	Salient	O
2	applications	O
3	of	O
4	PB	B
5	-	I
6	PK	I
7	modeling	O
8	to	O
9	toxicological	O
10	problems	O
11	are	O
12	illustrated	O
13	with	O
14	examples	O
15	.	O

1	Serological	O
2	studies	O
3	of	O
4	antibodies	O
5	to	O
6	Epstein	B
7	-	I
8	Barr	I
9	virus	O
10	in	O
11	infectious	O
12	mononucleosis	O

1	The	O
2	deduced	O
3	bovine	B
4	EFIA	I
5	#	I
6	1	I
7	amino	O
8	acid	O
9	(	O
10	aa	O
11	)	O
12	sequence	O
13	is	O
14	98	O
15	%	O
16	identical	O
17	to	O
18	rat	O
19	EFIA	O
20	and	O
21	100	O
22	%	O
23	identical	O
24	to	O
25	human	B
26	EFIA	I
27	/	I
28	DbpB	I
29	/	I
30	YB	I
31	-	I
32	1	I
33	family	I
34	member	I
35	DNA	I
36	-	I
37	binding	I
38	protein	I
39	B	I
40	(	O
41	DbpB	O
42	).	O

1	CyIIa	O
2	transcription	O
3	follows	O
4	,	O
5	and	O
6	is	O
7	therefore	O
8	downstream	O
9	of	O
10	,	O
11	the	O
12	initial	O
13	specification	O
14	of	O
15	these	O
16	embryonic	O
17	domains	O
18	.	O

1	Theory	O
2	and	O
3	applications	O
4	of	O
5	pulse	O
6	dosing	O
7	:	O
8	a	O
9	summary	O
10	of	O
11	the	O
12	symposium	O
13	.	O

1	Moreover	O
2	,	O
3	glucan	B
4	synthase	I
5	activity	O
6	,	O
7	which	O
8	is	O
9	activated	O
10	by	O
11	Rho1p	O
12	,	O
13	was	O
14	significantly	O
15	reduced	O
16	in	O
17	the	O
18	deltabem4	O
19	mutant	O
20	.	O

1	All	O
2	pigs	O
3	had	O
4	significant	O
5	regional	O
6	LV	O
7	dysfunction	O
8	and	O
9	reduced	O
10	LV	O
11	ejection	O
12	fraction	O
13	(	O
14	41	O
15	+/-	O
16	11	O
17	%).	O

1	Infect	O
2	.	O

1	A	O
2	pre	O
3	-	O
4	boutonniere	O
5	deformity	O
6	was	O
7	simulated	O
8	by	O
9	dividing	O
10	the	O
11	central	O
12	slip	O
13	.	O

1	Our	O
2	data	O
3	show	O
4	also	O
5	that	O
6	phagocytic	O
7	killing	O
8	of	O
9	meningococci	O
10	is	O
11	probably	O
12	a	O
13	more	O
14	consistent	O
15	assay	O
16	than	O
17	antibody	O
18	titer	O
19	levels	O
20	for	O
21	antimeningococcal	O
22	immunity	O
23	,	O
24	especially	O
25	in	O
26	LCC	O
27	-	O
28	deficient	O
29	patients	O
30	.	O

1	1	O
2	,	O
3	among	O
4	which	O
5	nine	O
6	have	O
7	been	O
8	cloned	O
9	and	O
10	two	O
11	(	O
12	potentially	O
13	functional	O
14	)	O
15	sequenced	O
16	.	O

1	Although	O
2	the	O
3	E	O
4	-	O
5	box	O
6	consensus	O
7	is	O
8	minimally	O
9	defined	O
10	as	O
11	CANNTG	O
12	,	O
13	the	O
14	adjacent	O
15	nucleotides	O
16	of	O
17	functional	O
18	E	O
19	-	O
20	boxes	O
21	are	O
22	variable	O
23	for	O
24	genes	O
25	regulated	O
26	by	O
27	the	O
28	bHLH	O
29	proteins	O
30	.	O

1	And	O
2	the	O
3	natural	O
4	barriers	O
5	?	O

1	Of	O
2	these	O
3	carriers	O
4	149	O
5	were	O
6	diagnosed	O
7	to	O
8	be	O
9	asymptomatic	O
10	clinically	O
11	,	O
12	biochemically	O
13	and	O
14	echographically	O
15	.	O

1	Analysis	O
2	of	O
3	1	O
4	Mb	O
5	of	O
6	published	O
7	sequence	O
8	from	O
9	the	O
10	region	O
11	of	O
12	conserved	O
13	synteny	O
14	on	O
15	human	O
16	chromosome	O
17	5q31	O
18	-	O
19	q33	O
20	identified	O
21	45	O
22	gene	O
23	candidates	O
24	,	O
25	including	O
26	35	O
27	expressed	O
28	genes	O
29	in	O
30	the	O
31	human	O
32	IL	B
33	-	I
34	4	I
35	cytokine	I
36	gene	I
37	cluster	I
38	.	O

1	The	O
2	construction	O
3	of	O
4	a	O
5	small	O
6	library	O
7	of	O
8	mouse	O
9	repetitive	O
10	DNA	O
11	has	O
12	been	O
13	previously	O
14	reported	O
15	(	O
16	Pietras	O
17	et	O
18	al	O
19	.,	O
20	Nucleic	O
21	Acids	O
22	Res	O
23	.	O

1	Male	B
2	-	I
3	enhanced	I
4	antigen	I
5	gene	I
6	is	O
7	phylogenetically	O
8	conserved	O
9	and	O
10	expressed	O
11	at	O
12	late	O
13	stages	O
14	of	O
15	spermatogenesis	O
16	.	O

1	Both	O
2	mutant	O
3	receptors	O
4	were	O
5	expressed	O
6	on	O
7	the	O
8	cell	O
9	surface	O
10	and	O
11	bound	O
12	insulin	B
13	normally	O
14	,	O
15	but	O
16	showed	O
17	markedly	O
18	impaired	O
19	autophosphorylation	O
20	in	O
21	response	O
22	to	O
23	insulin	B
24	.	O

1	Studies	O
2	using	O
3	a	O
4	reporter	O
5	plasmid	O
6	with	O
7	a	O
8	functionally	O
9	disrupted	O
10	sterol	O
11	-	O
12	responsive	O
13	element	O
14	(	O
15	SRE	O
16	)-	O
17	1	O
18	revealed	O
19	a	O
20	reduced	O
21	stimulatory	O
22	response	O
23	to	O
24	IL	B
25	-	I
26	6	O
27	.	O

1	An	O
2	amino	O
3	-	O
4	acid	O
5	sequence	O
6	comparison	O
7	revealed	O
8	that	O
9	Bacillus	O
10	YM55	O
11	-	O
12	1	O
13	aspartase	O
14	shared	O
15	71	O
16	%	O
17	homology	O
18	with	O
19	Bacillus	O
20	subtilis	O
21	aspartase	O
22	and	O
23	49	O
24	%	O
25	with	O
26	Escherichia	O
27	coli	O
28	and	O
29	Pseudomonas	O
30	fluorescens	O
31	aspartases	O
32	.	O

1	Certain	O
2	transcript	O
3	patterns	O
4	in	O
5	Epifagus	O
6	plastids	O
7	are	O
8	highly	O
9	complex	O
10	and	O
11	similar	O
12	to	O
13	those	O
14	of	O
15	tobacco	O
16	operons	O
17	.	O

1	No	O
2	difference	O
3	in	O
4	elastin	O
5	peptide	O
6	concentration	O
7	was	O
8	observed	O
9	between	O
10	emphysematous	O
11	patients	O
12	and	O
13	control	O
14	subjects	O
15	(	O
16	mean	O
17	+/-	O
18	SD	O
19	=	O
20	2	O
21	.	O
22	39	O
23	+/-	O
24	1	O
25	.	O
26	18	O
27	micrograms	O
28	/	O
29	ml	O
30	in	O
31	patients	O
32	versus	O
33	2	O
34	.	O
35	55	O
36	+/-	O
37	1	O
38	.	O
39	34	O
40	micrograms	O
41	/	O
42	ml	O
43	in	O
44	policemen	O
45	and	O
46	2	O
47	.	O
48	59	O
49	+/-	O
50	1	O
51	.	O
52	20	O
53	micrograms	O
54	/	O
55	ml	O
56	in	O
57	coal	O
58	miners	O
59	).	O

1	1993	O
2	.	O

1	Many	O
2	studies	O
3	have	O
4	pointed	O
5	out	O
6	the	O
7	possibility	O
8	of	O
9	"	O
10	masked	O
11	"	O
12	organic	O
13	factors	O
14	in	O
15	erectile	O
16	impotence	O
17	,	O
18	detectable	O
19	only	O
20	by	O
21	means	O
22	of	O
23	laboratory	O
24	investigations	O
25	:	O
26	mild	O
27	hypogonadism	O
28	,	O
29	hyperprolactinemia	O
30	,	O
31	occlusions	O
32	selectively	O
33	located	O
34	at	O
35	the	O
36	site	O
37	of	O
38	the	O
39	sexual	O
40	arteries	O
41	,	O
42	venous	O
43	incompetence	O
44	,	O
45	subclinical	O
46	neuropathies	O
47	.	O

1	We	O
2	failed	O
3	to	O
4	find	O
5	these	O
6	data	O
7	to	O
8	be	O
9	useful	O
10	in	O
11	predicting	O
12	the	O
13	time	O
14	of	O
15	onset	O
16	of	O
17	initial	O
18	seizures	O
19	after	O
20	acute	O
21	ischemic	O
22	stroke	O
23	and	O
24	recurrence	O
25	.	O

1	Increased	O
2	levels	O
3	of	O
4	anticardiolipin	B
5	immunoglobulin	I
6	G	I
7	may	O
8	also	O
9	cause	O
10	bleeding	O
11	.	O

1	Immunostaining	O
2	of	O
3	cells	O
4	transfected	O
5	with	O
6	these	O
7	constructs	O
8	revealed	O
9	that	O
10	both	O
11	the	O
12	myristoylated	O
13	and	O
14	nonmyristoylated	O
15	mutants	O
16	were	O
17	localized	O
18	in	O
19	nuclei	O
20	,	O
21	whereas	O
22	wild	B
23	-	I
24	type	I
25	PKC	I
26	alpha	I
27	was	O
28	primarily	O
29	cytoplasmic	O
30	and	O
31	perinuclear	O
32	.	O

1	TG	O
2	-	O
3	day	O
4	and	O
5	TG	O
6	-	O
7	night	O
8	were	O
9	19	O
10	.	O
11	4	O
12	+/-	O
13	6	O
14	.	O
15	1	O
16	%,	O
17	26	O
18	.	O
19	6	O
20	+/-	O
21	5	O
22	.	O
23	3	O
24	%,	O
25	(	O
26	750	O
27	mm3	O
28	<	O
29	T	O
30	.	O

1	However	O
2	,	O
3	in	O
4	a	O
5	multivariate	O
6	analysis	O
7	considering	O
8	age	O
9	,	O
10	gender	O
11	,	O
12	and	O
13	a	O
14	previous	O
15	history	O
16	of	O
17	cardiovascular	O
18	diseases	O
19	,	O
20	female	O
21	gender	O
22	was	O
23	not	O
24	independently	O
25	associated	O
26	with	O
27	death	O
28	.	O

1	Results	O
2	of	O
3	this	O
4	study	O
5	indicate	O
6	that	O
7	GLC	O
8	of	O
9	short	O
10	chain	O
11	fatty	O
12	acids	O
13	produced	O
14	on	O
15	agar	O
16	medium	O
17	by	O
18	anaerobes	O
19	,	O
20	combined	O
21	with	O
22	simple	O
23	tests	O
24	such	O
25	as	O
26	Gram	O
27	'	O
28	s	O
29	stain	O
30	and	O
31	colonial	O
32	morphology	O
33	,	O
34	may	O
35	allow	O
36	fir	O
37	direct	O
38	presumptive	O
39	genus	O
40	identification	O
41	from	O
42	an	O
43	initial	O
44	pure	O
45	agar	O
46	culture	O
47	.	O

1	This	O
2	study	O
3	examines	O
4	the	O
5	cooperative	O
6	effects	O
7	of	O
8	a	O
9	human	B
10	estrogen	I
11	receptor	I
12	-	I
13	alpha	I
14	(	O
15	ERalpha	O
16	)	O
17	isoform	O
18	on	O
19	estrogen	O
20	(	O
21	E2	O
22	)-	O
23	mediated	O
24	gene	O
25	activation	O
26	in	O
27	U2	B
28	-	I
29	OS	I
30	osteosarcoma	I
31	cells	O
32	.	O

1	Expression	O
2	was	O
3	cell	O
4	cycle	O
5	controlled	O
6	,	O
7	with	O
8	steady	O
9	-	O
10	state	O
11	RNA	O
12	levels	O
13	significantly	O
14	higher	O
15	in	O
16	growth	O
17	-	O
18	arrested	O
19	than	O
20	in	O
21	growth	O
22	-	O
23	stimulated	O
24	cells	O
25	.	O

1	8	O
2	%	O
3	(	O
4	95	O
5	%	O
6	CI	O
7	,	O
8	21	O
9	.	O
10	3	O
11	-	O
12	44	O
13	.	O
14	3	O
15	%).	O

1	Truncated	O
2	ICSBP	O
3	lacking	O
4	the	O
5	first	O
6	33	O
7	amino	O
8	-	O
9	terminal	O
10	amino	O
11	acids	O
12	fails	O
13	to	O
14	bind	O
15	to	O
16	the	O
17	ICS	O
18	,	O
19	indicating	O
20	that	O
21	at	O
22	least	O
23	part	O
24	of	O
25	the	O
26	DNA	O
27	binding	O
28	domain	O
29	is	O
30	located	O
31	within	O
32	the	O
33	well	O
34	conserved	O
35	amino	O
36	terminus	O
37	.	O

1	There	O
2	was	O
3	evidence	O
4	of	O
5	attenuated	O
6	regression	O
7	slopes	O
8	relating	O
9	recalled	O
10	to	O
11	observed	O
12	portion	O
13	sizes	O
14	for	O
15	4	O
16	of	O
17	the	O
18	10	O
19	food	O
20	groups	O
21	;	O
22	adjusted	O
23	r2	O
24	values	O
25	for	O
26	the	O
27	recalled	O
28	portion	O
29	sizes	O
30	ranged	O
31	from	O
32	0	O
33	.	O
34	02	O
35	to	O
36	0	O
37	.	O
38	94	O
39	.	O

1	Glutamyl	B
2	-	I
3	tRNA	I
4	synthetase	I
5	and	I
6	prolyl	I
7	-	I
8	tRNA	I
9	synthetase	I
10	belong	O
11	to	O
12	different	O
13	classes	O
14	of	O
15	aminoacyl	B
16	-	I
17	tRNA	I
18	synthetases	I
19	that	O
20	are	O
21	thought	O
22	to	O
23	have	O
24	evolved	O
25	along	O
26	independent	O
27	evolutionary	O
28	pathways	O
29	.	O

1	The	O
2	loss	O
3	of	O
4	avirulence	O
5	activity	O
6	because	O
7	of	O
8	mutations	O
9	in	O
10	the	O
11	acidic	O
12	transcriptional	O
13	activation	O
14	domain	O
15	was	O
16	restored	O
17	by	O
18	addition	O
19	of	O
20	the	O
21	activation	O
22	domain	O
23	from	O
24	the	O
25	herpes	O
26	simplex	O
27	viral	O
28	protein	O
29	VP16	B
30	.	O

1	Thus	O
2	,	O
3	the	O
4	human	O
5	D1A	O
6	gene	O
7	belongs	O
8	to	O
9	the	O
10	category	O
11	of	O
12	tissue	O
13	-	O
14	specific	O
15	,	O
16	regulated	O
17	genes	O
18	that	O
19	have	O
20	housekeeping	O
21	-	O
22	type	O
23	promoters	O
24	.	O

1	No	O
2	patient	O
3	in	O
4	group	O
5	2	O
6	developed	O
7	HAT	O
8	(	O
9	P	O
10	=	O
11	0	O
12	.	O
13	006	O
14	versus	O
15	group	O
16	1	O
17	).	O

1	Furthermore	O
2	,	O
3	a	O
4	mutant	O
5	receptor	O
6	(	O
7	Y977F	O
8	/	O
9	Y989F	O
10	[	O
11	PLC	B
12	gamma	I
13	-	I
14	binding	I
15	sites	I
16	])	O
17	could	O
18	fully	O
19	activate	O
20	Ras	B
21	,	O
22	and	O
23	the	O
24	direct	O
25	activation	O
26	of	O
27	protein	O
28	kinase	O
29	C	O
30	and	O
31	calcium	O
32	mobilization	O
33	had	O
34	almost	O
35	no	O
36	effect	O
37	on	O
38	the	O
39	GDP	O
40	/	O
41	GTP	O
42	state	O
43	of	O
44	Ras	B
45	in	O
46	this	O
47	cell	O
48	line	O
49	.	O

1	Southwestern	O
2	blot	O
3	analysis	O
4	demonstrated	O
5	that	O
6	this	O
7	phosphoprotein	O
8	can	O
9	bind	O
10	the	O
11	kappa	B
12	B	I
13	element	I
14	directly	O
15	and	O
16	specifically	O
17	.	O

1	With	O
2	0	O
3	.	O
4	5	O
5	vol	O
6	.-%,	O
7	the	O
8	corresponding	O
9	values	O
10	were	O
11	345	O
12	mumol	O
13	/	O
14	1	O
15	(	O
16	5	O
17	.	O
18	72	O
19	mg	O
20	/	O
21	100	O
22	ml	O
23	)	O
24	and	O
25	137	O
26	mumol	O
27	/	O
28	1	O
29	(	O
30	2	O
31	.	O
32	25	O
33	mg	O
34	/	O
35	100	O
36	ml	O
37	)	O
38	respectively	O
39	.	O

1	Tobramycin	O
2	-	O
3	loaded	O
4	SLN	O
5	administered	O
6	i	O
7	.	O
8	v	O
9	.	O
10	showed	O
11	a	O
12	prolonged	O
13	circulation	O
14	time	O
15	compared	O
16	to	O
17	the	O
18	i	O
19	.	O
20	v	O
21	.	O
22	administered	O
23	tobramycin	O
24	solution	O
25	.	O

1	Osteoadherin	O
2	is	O
3	a	O
4	recently	O
5	described	O
6	bone	O
7	proteoglycan	O
8	containing	O
9	keratan	O
10	sulfate	O
11	.	O

1	Recombinant	O
2	BRI1	O
3	-	O
4	KD	O
5	autophosphorylated	O
6	on	O
7	serine	O
8	(	O
9	Ser	O
10	)	O
11	and	O
12	threonine	O
13	(	O
14	Thr	O
15	)	O
16	residues	O
17	with	O
18	p	O
19	-	O
20	Ser	O
21	predominating	O
22	.	O

1	SM	O
2	is	O
3	also	O
4	shown	O
5	to	O
6	be	O
7	associated	O
8	in	O
9	vivo	O
10	with	O
11	other	O
12	components	O
13	of	O
14	the	O
15	CRM	O
16	1	O
17	export	O
18	pathway	O
19	,	O
20	including	O
21	the	O
22	small	O
23	GTPase	B
24	Ran	I
25	and	O
26	the	O
27	nucleoporin	O
28	CAN	O
29	/	O
30	Nup214	O
31	.	O

1	Histological	O
2	changes	O
3	,	O
4	including	O
5	cortical	O
6	cell	O
7	involution	O
8	and	O
9	hemorrhage	O
10	occurring	O
11	during	O
12	the	O
13	neonatal	O
14	period	O
15	,	O
16	would	O
17	seem	O
18	to	O
19	have	O
20	crucial	O
21	relevance	O
22	to	O
23	the	O
24	remodeling	O
25	of	O
26	the	O
27	adrenal	O
28	vasculature	O
29	.	O

1	Experience	O
2	with	O
3	the	O
4	tensor	O
5	fasciae	O
6	latae	O
7	free	O
8	flap	O
9	.	O

1	Analysis	O
2	of	O
3	mig	O
4	/	O
5	CAT	B
6	chimeric	O
7	constructs	O
8	transiently	O
9	transfected	O
10	into	O
11	the	O
12	RAW	O
13	264	O
14	.	O
15	7	O
16	mouse	O
17	monocytic	O
18	cell	O
19	line	O
20	revealed	O
21	a	O
22	unique	O
23	IFN	B
24	-	I
25	gamma	I
26	-	I
27	responsive	I
28	element	I
29	(	I
30	gamma	I
31	RE	I
32	-	I
33	1	I
34	).	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	both	O
6	PKC	B
7	alpha	I
8	(	O
9	calcium	O
10	dependent	O
11	)	O
12	and	O
13	PKC	B
14	delta	I
15	(	O
16	calcium	O
17	independent	O
18	)	O
19	may	O
20	mediate	O
21	the	O
22	transcription	O
23	of	O
24	TPA	O
25	-	O
26	inducible	O
27	genes	O
28	through	O
29	both	O
30	AP	B
31	-	I
32	1	I
33	and	O
34	non	O
35	-	O
36	AP	B
37	-	I
38	1	I
39	sequences	O
40	.	O

1	The	O
2	content	O
3	of	O
4	glucosamine	O
5	and	O
6	galactosamine	O
7	in	O
8	tartar	O

1	Mean	O
2	growth	O
3	changes	O
4	in	O
5	this	O
6	Class	O
7	II	O
8	sample	O
9	were	O
10	comparable	O
11	to	O
12	those	O
13	previously	O
14	reported	O
15	for	O
16	male	O
17	subjects	O
18	with	O
19	Class	O
20	I	O
21	malocclusions	O
22	over	O
23	the	O
24	same	O
25	age	O
26	period	O
27	,	O
28	suggesting	O
29	a	O
30	similarity	O
31	in	O
32	postpubertal	O
33	development	O
34	between	O
35	these	O
36	two	O
37	groups	O
38	.	O

1	We	O
2	have	O
3	investigated	O
4	the	O
5	contribution	O
6	of	O
7	specific	O
8	TATA	O
9	-	O
10	binding	O
11	protein	O
12	(	O
13	TBP	B
14	)-	I
15	TATA	O
16	interactions	O
17	to	O
18	the	O
19	promoter	O
20	activity	O
21	of	O
22	a	O
23	constitutively	O
24	expressed	O
25	silkworm	O
26	tRNA	O
27	(	O
28	C	O
29	)(	O
30	Ala	O
31	)	O
32	gene	O
33	and	O
34	have	O
35	also	O
36	asked	O
37	whether	O
38	the	O
39	lack	O
40	of	O
41	similar	O
42	interactions	O
43	accounts	O
44	for	O
45	the	O
46	low	O
47	promoter	O
48	activity	O
49	of	O
50	a	O
51	silk	O
52	gland	O
53	-	O
54	specific	O
55	tRNA	O
56	(	O
57	SG	O
58	)(	O
59	Ala	O
60	)	O
61	gene	O
62	.	O

1	Determination	O
2	of	O
3	aortic	O
4	distensibility	O
5	and	O
6	its	O
7	variations	O
8	in	O
9	arterial	O
10	hypertension	O
11	.	O

1	Ten	O
2	males	O
3	performed	O
4	both	O
5	test	O
6	conditions	O
7	and	O
8	oxygen	O
9	uptake	O
10	VO2	O
11	,	O
12	heart	O
13	rate	O
14	,	O
15	minute	O
16	ventilation	O
17	VE	O
18	,	O
19	perceived	O
20	exertion	O
21	and	O
22	spinal	O
23	shrinkage	O
24	were	O
25	recorded	O
26	.	O

1	We	O
2	and	O
3	others	O
4	have	O
5	demonstrated	O
6	that	O
7	the	O
8	c	B
9	-	I
10	cbl	I
11	proto	I
12	-	I
13	oncogene	I
14	product	I
15	is	O
16	one	O
17	of	O
18	the	O
19	earliest	O
20	targets	O
21	of	O
22	tyrosine	O
23	phosphorylation	O
24	upon	O
25	T	O
26	cell	O
27	receptor	O
28	stimulation	O
29	.	O

1	The	O
2	nit	O
3	-	O
4	3	O
5	gene	O
6	of	O
7	the	O
8	filamentous	O
9	fungus	O
10	Neurospora	O
11	crassa	O
12	encodes	O
13	nitrate	B
14	reductase	I
15	,	O
16	the	O
17	enzyme	O
18	which	O
19	catalyzes	O
20	the	O
21	first	O
22	step	O
23	in	O
24	nitrate	O
25	assimilation	O
26	.	O

1	Pulmonary	O
2	vascular	O
3	resistance	O
4	was	O
5	not	O
6	altered	O
7	,	O
8	ejection	O
9	fraction	O
10	remained	O
11	unchanged	O
12	and	O
13	isovolumic	O
14	relaxation	O
15	period	O
16	was	O
17	lengthened	O
18	(	O
19	119	O
20	+/-	O
21	20	O
22	.	O
23	1	O
24	to	O
25	147	O
26	.	O
27	39	O
28	+/-	O
29	21	O
30	.	O
31	15	O
32	,	O
33	P	O
34	less	O
35	than	O
36	0	O
37	.	O
38	05	O
39	).	O

1	Various	O
2	companies	O
3	produce	O
4	this	O
5	type	O
6	of	O
7	lens	O
8	.	O

1	Immunohistochemical	O
2	studies	O
3	revealed	O
4	positive	O
5	staining	O
6	for	O
7	S100	B
8	protein	I
9	in	O
10	all	O
11	the	O
12	granular	O
13	cell	O
14	tumors	O
15	of	O
16	the	O
17	adult	O
18	but	O
19	in	O
20	none	O
21	of	O
22	the	O
23	congenital	O
24	granular	O
25	cell	O
26	epulides	O
27	.	O

1	Myocardial	O
2	perfusion	O
3	was	O
4	evaluated	O
5	using	O
6	the	O
7	enhanced	O
8	gray	O
9	level	O
10	after	O
11	contrast	O
12	injection	O
13	,	O
14	and	O
15	the	O
16	level	O
17	was	O
18	compared	O
19	with	O
20	the	O
21	morphology	O
22	and	O
23	degree	O
24	of	O
25	collateral	O
26	development	O
27	.	O

1	Antidromic	O
2	invasion	O
3	of	O
4	impulses	O
5	and	O
6	recurrent	O
7	collateral	O
8	inhibition	O
9	in	O
10	pyramidal	O
11	tract	O
12	neurones	O
13	.	O

1	Review	O
2	of	O
3	the	O
4	literature	O
5	and	O
6	report	O
7	of	O
8	a	O
9	case	O
10	of	O
11	a	O
12	dermoid	O
13	cyst	O
14	.	O

1	A	O
2	5	O
3	.	O
4	3	O
5	-	O
6	kb	O
7	DNA	O
8	fragment	O
9	,	O
10	which	O
11	included	O
12	the	O
13	entire	O
14	structural	O
15	porin	O
16	gene	O
17	(	O
18	named	O
19	porCa	O
20	)	O
21	and	O
22	its	O
23	flanking	O
24	regions	O
25	,	O
26	was	O
27	identified	O
28	.	O

